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Abstract 
 
The overall aims of this PhD were (1) to evaluate the mechanisms controlling functional 
expression of neonatal Nav1.5 (nNav1.5), the predominant voltage-gated sodium 
channel (VGSC) subtype expressed in metastatic human breast cancer (BCa) cells, and 
(2) to characterize the electrophysiological and pharmacological properties of nNav1.5 
compared with the adult Nav1.5 (aNav1.5) counterpart. Experiments were carried out 
under normoxic and hypoxic conditions. 
The Results chapter-1 demonstrates the hypoxic upregulation of functional 
VGSC (nNav1.5) expression in MDA-MB-231 human BCa cells, proposed to occur via 
positive feedback involving Na+ influx and activation of protein kinase A. Upregulation 
of nNav1.5, evident at mRNA, protein and signalling levels, led to significant 
augmentation of Matrigel invasion. The hypoxia-sensitive persistent Na+ current (INaP) 
played a significant role in the increased invasiveness. 
The Results chapter-2 shows that, compared to aNav1.5, nNav1.5 (i) exhibited 
depolarized activation, (ii) had slower activation/inactivation kinetics, (iii) allowed 
greater transient charge (Na+) influx, (iv) recovered from inactivation significantly more 
slowly, (v) exhibited greater use-dependent attenuation, and (vi) expressed larger INaP. 
Mutagenesis studies revealed the charge-reversing Asp211 (aNav1.5) to Lys211 (nNav1.5) 
switch to be predominantly responsible for these differences. Surprisingly, however, 
challenging the two splice variants with mono-, di- and trivalent cations generated only 
subtle differential effects in channel gating.  
The Results chapter-3 determines the sensitivities of nNav1.5 and aNav1.5 to 
various VGSC blockers. The effects of small-molecule drugs lidocaine, phenytoin, 
mexiletine, procaine, ranolazine and riluzole were similar. NESOpAb, a polyclonal 
  
 
 6 
antibody targeting nNav1.5, exhibited ~200-fold lower threshold and ~5-fold lower IC50 
for inhibiting nNav1.5 vs. aNav1.5; the Lys/Asp211 residue was crucial to this 
difference. Spider toxins ProTx-II and HaTx were found to share a binding site in the 
nNav1.5/aNav1.5 splicing region, exhibiting ~25- and 5-fold selectivity for aNav1.5. 
Each Results chapter ends with a discussion and highlighting of clinical 
implications.  
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This Introduction is subdivided into four sections. Sections 1 and 2 summarize the 
structure, function and regulation of voltage-gated sodium channels (VGSCs). The third 
section deals with metastatic disease including the proposed involvement of VGSCs. 
The last section covers the pharmacology of VGSCs and possible targeting of metastatic 
breast cancer (BCa). Unless specified otherwise, the examples given are from human. 
 
1.1 Voltage-gated sodium channels 
VGSCs play an essential role in cellular (mainly neuronal and muscular) excitability, 
opening briefly upon membrane depolarization and generating the transient Na+ current 
(INa) necessary for the initiation and propagation of action potentials (APs) (Hille, 2001; 
Waxman, 2007). VGSC dysfunctioning, either through mutation or altered expression 
levels, leads to numerous, life-limiting pathologies, including epilepsies, cardiac 
arrhythmias (e.g. long QT and Brugada syndromes), paralyses, and chronic pain 
(Viswanathan and Balser, 2004; George, 2005; Momin and Wood, 2008; Cannon and 
Bean, 2010).  
VGSCs are also present, and functional, in traditionally ‘non-excitable’ cells 
such as microglia, lymphocytes, macrophages, endothelial cells, and cancer cells of 
epithelial origin, where their role(s) is less well defined (Diss et al., 2004). Thus, for 
example, in vascular endothelial cells, VGSC-mediated Na+ influx was suggested to 
increase the cytosolic Ca2+ level (via reversed or slowed Na+/Ca2+ exchange), which in 
turn could activate downstream signalling and contribute to angiogenesis (Sage et al., 
1991; Gosling et al., 1998). In metastatic BCa cells, VGSC activity was shown to 
induce peri-membrane acidification, which favoured cathepsin activity, thereby 
enhancing invasiveness (Brackenbury et al., 2007; Gillet et al., 2009). 
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1.1.1 Basic structure of VGSCs 
VGSCs are heteromultimeric membrane-bound proteins composed of a large α-subunit 
(VGSCα) and one or more associated smaller auxillary β-subunit (VGSCβ) (Catterall, 
2000). Basic channel functionality is achieved by VGSCα that forms the ionopore (Yu 
and Catterall, 2003).  
 
1.1.1.1 VGSCα 
The VGSCα is 220-260 kilodaltons (kDa) in molecular weight, and has four structurally 
homologous domains (D1-D4), each with six α-helical transmembrane segments (S1-
S6) (Figure 1.1A). Each S4 segment contains positively-charged arginine or lysine at 
every third residue, which enable the channel to sense changes in membrane potential, 
thus triggering activation followed by fast inactivation (Catterall, 2000; Swartz, 2008). 
However, voltage-sensing also requires S1-S3, which contain negatively-charged acidic 
residues acting as countercharges for the positive S4 residues (Section 1.1.5; Tombola 
et al., 2006; DeCaen et al., 2009; Catterall, 2010). The S6 segments form the wide inner 
lining of the channel pore, whereas the membrane re-entrant loops between S5 and S6 
(i.e. P-loops or short-segments SS1-SS2) form the ion selective narrower outer lining of 
the pore (Section 1.1.3) (Catterall, 2000). Essentially, therefore, the transmembrane 
regions of VGSCαs consist of two-functional domains repeated four times: a voltage-
sensing domain (comprising S1-S4) and a pore-forming domain (comprising S5 and S6) 
(Swartz, 2008; Catterall, 2010).  
The N- and C-terminal and inter-domain (ID) cytoplasmic linkers contribute to 
channel function, localization and membrane stability by providing sites for channel 
modulation by factors including protein kinases/phosphatases and protein-protein 
interactions (Section 1.2; Abriel and Kass, 2005; Chahine et al., 2005). Importantly,  
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   B     (i)                (ii) 
Figure 1.1 Structure of voltage-gated Na+ channels 
(A) Cartoon illustrating the VGSC α-subunit together with the β1-subunit. VGSCα has 
four domains (D1-4), each with six α-helical transmembrane segments (S1-6). S5-6 
(pink) are the pore-lining segments; the S4 helices (yellow) form the voltage-sensors; h 
in blue circle represents the fast inactivation particle (‘IFM’ motif: Ile-Phe-Met); blue 
circles are the sites implicated in forming the inactivation gate receptor; ψ shows the 
sites of probable N-linked glycosylation; red circles and diamonds represent the sites 
for PKA and PKC phosphorylation, respectively; white circles in the re-entrant S5-S6 
loops represent the outer (EEDD) and inner (DEKA) rings that form the ion selectivity 
filter. The extracellular domain of the β1 is shown as an immunoglobulin-like fold, 
which interacts non-covalently with the α-subunit as shown. (B) (i) The bell-shaped 3D 
structure of the VGSCα from Sato et al. (2001)’s electron micrograph reconstructions 
at 19 Å resolution. Modified from Catterall (2001). (ii) Cartoon illustrating VGSCα 
structure, at the cross-section indicated with a dashed line in part (i) (top view); a, 
central ion permeation pore; b, gating pores. Modified from Ogatha and Ogishi (2002).  
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however, the ID3-4 linker plays a vital role in fast inactivation, essentially forming the 
inactivating ‘particle’ that blocks the intracellular ion pore typically within milliseconds 
of channel activation (Section 1.1.6; Goldin, 2003). 
The 3-dimensional (3D) structure of the VGSCα was elucidated using helium-
cooled cyro electron microscopy and single-particle image analysis (Sato et al., 2001). 
These revealed four transmembrane masses (i.e. D1-D4) arrayed symmetrically around 
a central hydrophilic pore (Figure 1.1B). This was consistent with the high-resolution 
structure of the Kv1.2 voltage-gated potassium channel (VGPC) obtained by X-ray 
crystallography (Long et al., 2005a, 2007). Viewed parallel to the membrane surface, 
the VGSCα protein appeared bell-shaped, with 47% of its mass on the intracellular side 
of the membrane and 24% on the extracellular side (Catterall, 2001). Most of the 
intracellular mass was attributed to the large N- and C-termini and the large intracellular 
linkers connecting D1, D2 and D3 (Figure 1.1.A; Catterall, 2001). Sato et al. (2001) 
also found that the central ion permeation pore did not connect directly to the 
intracellular and extracellular spaces; rather, it branched into four ‘inlets’ and ‘outlets’ 
on both sides of the membrane (Figure 1.1B) (Sato et al., 2001; Catterall, 2001). In 
addition, four peripherally located transmembrane pores were found, which were 
presumed to be the gating pores for voltage-sensor movement during channel activation 
(Section 1.1.5) (Yu and Catterall, 2003; Tombola et al., 2006).  
  
1.1.1.2 VGSCβ 
To date, four β-subunit isoforms (β1- β4) and a splice variant of the β1 subunit (β1A) 
have been identified (Isom et al., 1992, 1995; Kazen-Gillespie et al., 2000; Morgan et 
al., 2000; Yu et al., 2003). All VGSCβs (33-45 kDa) contain a single transmembrane 
segment, a short intracellular C-terminal tail, and a long, heavily glycosylated 
 Chapter 1                                                                                                         General Introduction  
 
 36 
extracellular N-terminal domain (Figure 1.2; Isom, 2001). The β1/β1A- and β3-subunits 
associate non-covalently with VGSCα (e.g. via D1:S5/6 and D4:S5/6 linkers of VGSCα 
and multiple acidic N-terminal residues and C-terminal domain of VGSCβ1) (Figure 
1.2; Isom et al., 1992; Makita et al., 1996; McCormick et al., 1998; Kazen-Gillespie et 
al., 2000; Morgan et al., 2000; Spampanato et al., 2004). The β2 and β4 subunits are 
disulfide-linked to the α-subunit (Isom et al., 1995; Yu et al., 2003). 
 VGSCβs can modify VGSCα gating in an α/β isoform-specific manner and 
regulate the level of functional channel expression by promoting the intracellular 
trafficking of the mature VGSCα protein or by enhancing its cell surface stability (Isom, 
2001; Chahine et al., 2005; Meadows and Isom, 2005). In addition, all four VGSCβs 
contain a well-conserved extracellular immunoglobulin (Ig)-like domain, with cell 
adhesion molecule (CAM)-like motifs (Isom, 2001; Brackenbury et al., 2008). This 
property was first discovered for β2 (whose Ig-like fold was shown to have 45% 
sequence similarity with one of the six Ig motifs in the extracellular domain of neuronal 
CAM contactin; Isom et al., 1995). Further experiments revealed that VGSCβs can 
function as members of the Ig superfamily CAMs (IGSF-CAMs) (Brackenbury et al., 
2008). Thus, both β1 and β2 can interact trans-homophilically, resulting in cellular 
aggregation and ankyrin recruitment to cell-to-cell contacts (Malhotra et al., 2000, 
2002). Heterophilically, β1 was found to interact with other CAMs including contactin, 
N-cadherin, NrCAM, neurofascin-155, neurofascin-186 and VGSCβ2, and could thus 
result in increased functional VGSC expression in plasma membrane (Kazarinova-
Noyes et al., 2001; Malhotra et al., 2004; McEwen and Isom, 2004; McEwen et al., 
2004). Both β1 and β2 were also shown to interact with (and repelled from) the 
extracellular matrix (ECM) molecules tenascin-C and tenascin-R, thereby influencing 
cell migration (Srinivasan et al., 1998; Xiao et al., 1999).  
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Figure 1.2 Basic functional architecture of VGSCβ1 
N-terminal amino acid residues responsible for interaction with the α-subunit 
(McCormick et al., 1998), putative N-linked glycosylation sites (Ψ; McCormick et al., 
1998), site of intron retention generating the β1A splice variant (Kazen-Gillespie et al., 
2000), the single transmembrane segment, the C-terminal intracellular domain, and the 
extracellular Ig-like domain are shown. Interaction of the intracellular C-terminal tail 
with the α-subunit has also been reported (Spampanato et al., 2004). Modified from 
Brackenbury et al. (2008). 
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1.1.2 Molecular diversity and tissue distribution 
Higher vertebrates possess nine different VGSCα genes (Nav1.1-1.9), sited at 
chromosomes 2, 3, 12 and 17, as well as a related but functionally distinct non-voltage-
gated sodium-sensing Nax channel (Table 1.1; Goldin et al., 2000). VGSCαs all 
typically possess very similar amino acid sequences in both transmembrane and ID3-4 
regions (Plummer and Meisler, 1999). In contrast, VGSCαs differ significantly in the 
length of the modulatory cytoplasmic regions (e.g. ID1-2, C-terminus). For example, 
VGSCαs located at the chromosome-2 cluster (Nav1.1, 1.2, 1.3 and 1.7) and Nav1.6 all 
have significantly longer ID1-2 linkers than the others; VGSCαs located at the 
chromosome-3 cluster (Nav1.5, 1.8, and 1.9) have significantly longer ID2-3 linkers; in 
contrast, both these regions are exceptionally short in Nav1.4 (Diss et al., 2004). As a 
result of these extensive interdomain differences (and the generally more subtle amino 
acid differences in the transmembrane regions), channels derived from different VGSCα 
genes exhibit markedly different electrophysiological and regulatory characteristics, 
imparting a unique ‘physiological signature’ upon each VGSCα (Chahine et al., 2005). 
These allow the different channels to either (i) respond to different types of stimuli, 
and/or (ii) respond with slightly different kinetics, giving rise to a range of electrical 
signals (Catterall et al., 2005; Rush et al., 2007). For instance, in rat cortical neurons, 
low-threshold Nav1.6 and higher-threshold Nav1.2 channels localize to distal and 
proximal ends of the axon initial segment (AIS), mediating forward-propagating and 
backpropagating APs, respectively (Hu et al., 2009). Specifically, upon reaching the 
AIS, synaptic depolarization bypasses the proximal Nav1.2 channels but activates the 
distal, lower-threshold Nav1.6. In turn, Nav1.6-mediated depolarization initiates the 
forward-propagating AP, and also activates the higher-threshold Nav1.2 channels, 
resulting in a backpropagating AP to the soma that may be important for synaptic 
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Table 1.1 The VGSC α-subunit gene family  
 
Abbreviations: CNS, central nervous system; DRG, dorsal root ganglion; ND, not determined; PNS, peripheral nervous system; TTX IC50, concentration 
of tetrodotoxin giving half-maximal current block. Modified from England (2008) and Clare (2010).  
Isoform Former names Gene symbol Chromosomal location Primary tissue location TTX IC50 (nM) 
Nav1.1 rat I, HBSCI, GPBI, Scn1a SCN1A 2q24 CNS 6 
Nav1.2 rat II, HBSCII, HBA SCN2A 2q23 CNS 12 
Nav1.3 rat III  SCN3A 2q24 CNS, DRG 4 
Nav1.4 SkM1, µ1 SCN4A 17q23 Skeletal muscle 5 
Nav1.5 SkM2 SCN5A 3p21 Heart 2000 
Nav1.6 NaCh6, PN4, Scn8, CerIII SCN8A 12q13 CNS 1 
Nav1.7 NaS, hNE-Na, PN1 SCN9A 2q24 PNS 4 
Nav1.8 SNS, PN3, NaNG SCN10A 3p21 DRG 60000 
Nav1.9 NaN, SNS2, PN5, NaT, SCN12A SCN11A 3p21 DRG 40000 
Nax Nav2.2, NaG, Nav2.3, SCN6A SCN7A 2q21 Heart, uterus, glia ND 
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plasticity (Dulla and Huguenard, 2009; Hu et al., 2009). In addition to the presence of 
multiple VGSCα subtypes, diversity in VGSCα function can also be generated by 
numerous pre- and post-translational mechanisms, such as association with activity-
modulating β-subunits (or other interacting proteins), phosphorylation, glycosylation 
and alternative splicing (Section 1.2) (Chahine et al., 2005; Shao et al., 2009). 
VGSCα subtypes can broadly be classified by their sensitivity to the highly 
specific guanidine-based neurotoxin, tetrodotoxin (TTX) (Fozzard and Lipkind, 2010). 
Thus, ‘TTX-sensitive’ (TTX-S) VGSCαs (Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6, 
and Nav1.7) are inhibited by low nanomolar concentrations of TTX and generally have 
fast inactivation kinetics (Goldin, 2001). In contrast, ‘TTX-resistant’ (TTX-R) VGSCαs 
(Nav1.5, Nav1.8, Nav1.9) are sensitive to TTX only at micromolar concentrations and 
exhibit relatively slower inactivation kinetics (Plummer and Meisler, 1999). Sensitivity 
to TTX is determined by an aromatic residue (phenylalanine or tyrosine) in the pore 
lining SS2 region of D1:S5/S6; TTX-R VGSCαs have a polar residue (cysteine or 
serine) at this position (e.g. Cys373 in Nav1.5) (Satin et al., 1992; Heinemann et al., 
1992; Fozzard and Lipkind, 2010). This is illustrated for Nav1.2 (TTX-S) and three 
TTX-R channels (Nav1.5, Nav1.8, Nav1.9) in the following scheme. 
 
 
 
 
 
 
 
 
SS1 SS2 
Nav1.2 RLMTQDFWENLYQ 
Nav1.5  RLMTQDCWERLYQ 
Nav1.8  RLMTQDSWERLYQ 
Nav1.9  RVMTQDSWERLYR 
 
F: Phe → TTX-S 
C: Cys → TTX-R   
S: Ser → TTX-R    
  
Sequences of pore loop (SS1-SS2) regions of various TTX-S and TTX-R VGSCαs. The SS1 
and SS2 regions are as described by Guy and Conti (1990). TTX-sensitivity-determining amino 
acids are shaded; TTX-S channels (e.g. Nav1.2) have an aromatic phenylalanine or tyrosine at 
this position, whilst TTX-R channels have a polar cysteine (Nav1.5) or serine (Nav1.8, Nav.1.9). 
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Expression of different VGSCαs is tissue-specific and can be developmentally 
regulated (Table 1.1; Plummer and Meisler 1999; Catterall 2000). Thus, Nav1.1, Nav1.2 
and Nav1.6 are primarily expressed in CNS neurons; Nav1.6 is mainly found in axon 
initial segments (AIS), nodes of Ranvier, and somata; Nav1.2 is expressed in 
unmyelinated axons and AIS in myelinated axons; and Nav1.1 is localized mainly in the 
neuronal somata (Trimmer and Rhodes, 2004; Ragsdale, 2008; Hu et al., 2009; 
Mantegazza et al., 2010). Nav1.3 expression occurs mainly in the CNS (Chen et al., 
2000a; Whitaker et al., 2001), and also in DRG neurons following peripheral nerve 
damage (Waxman et al., 1994; Black et al., 1999). Nav1.4 is the major VGSCα in adult 
skeletal muscle (Cooperman et al., 1987; Kraner et al., 1989), whilst Nav1.5 is 
expressed in the heart, where it is predominantly responsible for the generation of the 
cardiac AP (Gellens et al., 1992; Herfst et al., 2004). Finally, Nav1.7, Nav1.8 and 
Nav1.9 are prominent in the peripheral nervous system (PNS), and are critical for the 
transmission of nociceptive signals by peripheral primary sensory afferents (Akopian et 
al., 1996; Toledo-Aral et al., 1997; Dib-Hajj et al., 1998; England, 2008). 
Expression of multiple functional VGSCαs can occur in single cells, and such 
multiplicity of VGSCα expression is thought to be due to different VGSCαs fulfilling 
distinct roles in given cells (Diss et al., 2004). Thus, for example, in mouse ventricular 
cardiomyoctes, the predominant Nav1.5 channel is mainly localized in intercalated 
discs, where it mediates the rapid conduction of the cardiac AP from one cell to the next 
along the cardiac muscle fiber (intercalated discs contain gap junctions that electrically 
connect adjacent cardiomyocytes) (Maier et al., 2004). In contrast, the neuronal 
VGSCαs (e.g. Nav1.1, Nav1.3, Nav1.6) are mainly localized in the transverse tubules 
(T-tubules), which suggests that these channels are important for electrical excitation to 
contraction coupling in cardiac muscle (T-tubules are sarcolemmal invaginations that 
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allow membrane depolarization to reach cell interior and activate contractile machinery) 
(Maier et al., 2002, 2004; Haufe et al., 2005).  
Molecular / functional diversity among VGSCβs is also achieved by 
anatomically and developmentally regulated differential expression (Table 1.2) 
(Meadows and Isom, 2005). For instance, in situ hybridization studies showed that 
VGSCβ1 and VGSCβ3 mRNA expression occurs in a complementary fashion in adult 
rat CNS (Morgan et al., 2000). Additional diversity is achieved among β1-subunits 
through alternative splicing; a developmentally regulated intron retention event 
generates the β1A splice variant, which (i) has little or no amino acid homology with β1 
apart from the shared N-terminal Ig domain, and (ii) is down-regulated (and replaced 
by) β1 in developing rat brain. Finally, as with VGSCαs, multiple VGSCβ isoforms are 
expressed in given cell types, where each isoform may again have a distinct subcellular 
role (Table 1.2) (Isom, 2001; Chahine et al., 2005; Brackenbury et al., 2008). Indeed, 
Maier et al. (2004) showed that β1 and β3 are localized in T-tubules in ventricular 
cardiomyocytes (as are Nav1.1, Nav1.2 and Nav1.6), whereas β2 and β4 are mainly 
expressed in intercalated discs with Nav1.5. Thus, structurally similar β1/β3 and β2/β4 
may be functionally similar as well, modifying specifically the VGSCα subtypes that 
are involved in excitation-contraction coupling and AP conduction in cardiac muscle, 
respectively (Isom, 2001; Maier et al., 2004; Kaufmann et al., 2010).  
 
1.1.3 The ion pore of VGSCαs: permeability and selectivity  
VGSCαs are permeable to several monovalent cations in the order: Na+ ~ Li+ > Tl+ > K+ 
> Rb+ > Cs+, the K+/Na+ permeability ratio being ~ 0.08 (Hille, 1972, 2001; Townsend 
et al., 1997). VGSCαs are also permeable to a number of non-metallic cations including 
hydroxylamine and guanidinium (suggesting a minimum pore size of 3.2 x 5.2 Å) but  
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Table 1.2 VGSC β-subunit isoforms 
 
Abbreviations: CNS, central nervous system; DRG, dorsal root ganglion; PNS, peripheral 
nervous system. Modified from Brackenbury et al. (2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isoform MW (kDa) Gene symbol Chromosomal location Tissue location 
β1 36 SCN1B 19q13 Heart, skeletal muscle, CNS, glia, PNS 
β1A 45 SCN1B 19q13 Heart, skeletal muscle, 
adrenal gland, PNS 
β2 33 SCN2B 11q22 CNS, PNS, heart, glia 
β3 36 SCN3B 11q23 CNS, adrenal gland, kidney, heart, PNS 
β4 38 SCN4B 11q23 Heart, skeletal muscle, CNS, PNS 
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impermeable to organic cations such as choline and imidazole (Hille, 1971). Residues 
forming the ion selectivity filter in the outer vestibule of the pore include an inner ring 
(DEKA) and outer ring (EEDD) ring of mostly negatively charged amino acids (Terlau 
et al., 1991; Chiamvimonvat et al., 1996; Favre et al., 1996). The outer ring 
carboxylates (EEDD) are presumed to assist dehydration of Na+, whereas the inner 
DEKA ring is responsible for the Na+-selective permeation (Sun et al., 1997; Khan et 
al., 2002; Yu and Catterall, 2003). Indeed, mutation of the DEKA motif to EEEE in 
Nav1.2 changed selectivity from Na+ to Ca2+ (Heinemann et al., 1992). The SS2 
segments in each of the four domains contributes two amino acids to the selectivity 
filter (one each for the inner and outer rings), as illustrated in the following scheme. It is 
to this outer pore region of the channel that the highly specific VGSC blockers TTX and 
saxitoxin (STX) bind (see Section 1.4.2) (Terlau et al., 1991; Catterall et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
The wider inner-pore of VGSCαs is formed mainly by the four S6 segments (Catterall, 
2000), and various drugs, including local anaesthetics, antiarrhythmics and 
SS1 SS2 
Domain 1   365  LFRLMTQDCWERLYQQTLRS 384 
Domain 2   891  IFRILCGEWIETMWDCMEVS 910 
Domain 3   1412 LLQVATFKGWMDINYAAVDS 1431 
Domain 4   1703 LFQITTSAGWDELLSPILNT 1722 
 
TTX 
The VGSCα (Nav1.5) ion selectivity filter. The SS1 and SS2 regions are as described by Guy 
and Conti (1990). Nav1.5 residues that form the inner (DEKA) and outer (EEDD) rings of the 
selectivity filter are shown in red and shaded (sequence from Gellens et al., 1992). Cys373, 
adjacent to the D1 selectivity filter Asp372, makes Nav1.5 resistant to TTX (indicated with arrow).  
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anticonvulsants, inhibit Na+ conductance by binding to multiple sites within D1:S6, 
D3:S6 and D4:S6 (Section 1.4.1) (Ragsdale et al., 1994, 1996; Clare, 2010). 
 
1.1.4 Functional states  
Basically, VGSCs cycle between ‘closed’, ‘open/activated’ and ‘inactivated’ states 
depending on the value of the membrane potential (Vm) and time (Figure 1.3A) (Hille, 
2001). Functionally, the channel has two gates, the activation gate (A gate) and the 
inactivation gate (I gate), both of which must be open to allow Na+ permeation. Upon 
membrane depolarization, opening of the A gate (through conformational changes in the 
pore-lining S6 segments) is caused by the outward movement of the positively charged 
S4 segments in all four domains (Section 1.1.5) (Armstrong, 2006). The I gate is formed 
by the cytoplasmically located inactivation particle in the ID3-4 linker and a receptor 
for it located in proximity to the inner mouth of the channel pore (Section 1.1.6). 
Closing of the I gate (which inactivates the channel by physically blocking Na+ 
permeation) is coupled to S4 activation (mainly D4:S4), and thus occurs typically 
within couple milliseconds of the opening of the A gate. This generates only a brief 
influx of Na+ (Figure 1.3B), which characterizes the initial phase of the AP in excitable 
cells (George, 2005). Upon repolarization of the Vm (e.g. due to VGPC activity), the 
VGSC ‘recovers’ from inactivation and returns to the initial resting/closed state, i.e. the 
A gate closes (S4 segments move inward) and the I gate opens (the inactivation particle 
is released from its receptor) (Catterall, 2000; Armstrong, 2006) .  
In reality, however, VGSC gating is more complex than described above, since 
each of the S4 voltage-sensors (i) contain a different number of charged residues (4, 5, 6 
and 8 in D1, D2, D3 and D4, respectively), (ii) exhibit slightly different voltage-
dependence and kinetics of activation, and (iii) play unique roles in VGSC gating  
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Figure 1.3 Voltage gated Na+ channel functional states  
(A) Schematic representation of a VGSC undergoing the major gating transitions. At 
rest (hyperpolarized Vm), VGSC is in closed state. Upon membrane depolarization, 
channel activates and then rapidly inactivates (i.e. open-state inactivation, Osi). 
Alternatively, the channel may transit directly to the inactivated state (i.e. closed-state 
inactivation, Csi). From the inactivated state, VGSC deactivates (recovers) to closed 
state upon membrane repolarization. (B) Cartoon representing a typical whole-cell 
voltage clamp recording of VGSC activity in response to membrane depolarization. 
Downward deflection of the current trace (red) represent the brief inward flow of Na+ 
(INa) upon membrane depolarization. Modified from George (2005). 
 
 
Recovery Csi 
1 ms 
INa 
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(Kontis and Goldin, 1997; Horn et al., 2000; Bosmans et al., 2008; Swartz, 2008). Such 
differences in S4 behaviour have been determined mainly by measuring ‘gating 
currents’ (Ig), which are small capacitative currents associated with the movement of 
positively charged S4 residues (mostly arginines) across the membrane electrical field 
(Section 1.1.5; Tombola et al., 2006). Moreover, most current knowledge regarding the 
precise gating modules of VGSCs (e.g. S4 location/ movement, activation-inactivation 
coupling) came from studies combining Ig measurements with (i) mutagenesis of the 
charged S4 residues, (ii) substituted cysteine accessibility assays, (iii) use of 
neurotoxins that target S3-S4 linkers (e.g. α-scorpion toxins bind to D4:S3/S4; Section 
1.4.2), and (iv) attachment of fluorescent probes to specific channel sites (e.g. S3-S4 
linkers), whose movement is detected as a change in the emission/absorption spectra or 
the quantum yield of the attached probe (reviewed in: Bezanilla, 2000; Tombola et al., 
2006; Catterall, 2010).  
Collectively, such advanced studies revealed, for example, (i) that concerted 
activation of all four voltage-sensors is required for channel opening, (ii) that S4 
segments in D1-D3 move faster compared to the D4:S4, (iii) that activation of S4 
segments in D3 and D4 is sufficient for channel inactivation (i.e. closing of the I gate), 
and (iv) that channel inactivation is voltage-independent per se but derives voltage-
dependence by coupling to activation (i.e. the outward movement of S4 voltage-sensors) 
(Cota and Armstrong, 1989; Cha et al., 1999; Horn et al., 2000; Chanda and Bezanilla, 
2002). In particular, the specific role played by D4:S4 in activation-inactivation 
coupling is well-evidenced; (i) mutations of charged D4:S4 residues resulted in channel 
inactivation with slowed kinetics and reduced voltage-dependence (Chen et al., 1996), 
and (ii) neurotoxins targeting specifically the D4:S3/S4 linker (and trapping it in closed 
state) impared inactivation without much effect on channel activation (Catterall, 2007; 
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Bosmans and Swartz, 2010). Importantly, given that activation of all four voltage-
sensors is required for channel opening, neurotoxin studies also indicated that D4:S4 
activation may occur in ‘multiple stages’ such that D4:S4 moves into a partially 
activated state upon depolarization (enough for the A gate to open), whereas its 
complete outward movement is necessary for channel activation-inactivation coupling 
(Horn et al., 2000). Incorporating these findings into a previous model provided by 
Armstrong and Gilly (1979), Armstrong (2006) proposed an updated scheme for the 
overall gating states of a VGSC, which is described as follows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A0I 
q1 
A1I A2I 
q3 
A3I 
q2 q4 
A4I 
q5 
AI 
A4I AI 
qni 
Csi Recovery λ      κ   Osi 
Deactivation 
Activation gate closed Activation gate open 
Inactivation  
gate closed 
Inactivation  
gate open 
State diagram for activation and inactivation of VGSCs from Armstrong (2006). ‘A’ 
represents activation gate; ‘I’ represents inactivation gate; red signifies a closed gate; green 
signifies an open gate; ‘q’ represents the gating charge associated for each state transition. At rest 
(i.e. hyperpolarized Vm), VGSC is closed and fully deactivated (A0I). When the Vm is depolarized, 
VGSC transits through multiple non-conducting, partially-activated states before becoming fully 
activated (AI) (i.e. all four S4 sensors are activated). Majority of channels then rapidly inactivate 
to AI (i.e. open-state inactivation, Osi) since the rate constant κ is larger than λ. Osi is not voltage-
dependent, does not generate any gating current, and immobilizes ⅔rds of the activation gating 
charge (i.e. charged S4 residues in D3 and D4). Upon repolarization, ⅓rd of the gating charge that 
was not immobilized (qni: charge not immobilized) is released, closing the activation gate (A4I) 
(i.e. S4 in D1 and D2 deactivates, moving inward). Channels then recover to the resting A0I state 
(via A4I → A4I →→ A0I) by releasing the remaining ⅔rds of the gating charge that was 
immobilized by inactivation (i.e. S4 in D3 and D4 deactivates). This pathway bypasses AI → AI 
because λ is small, thus preventing Na+ conductance during repolarization. Closed-state 
inactivation (Csi) (i.e. A4I → A4I) occurs if the channel dwells in partially activated states for a 
significant period of time (i.e. in case of slow or weak depolarisations). Deactivation from open to 
closed state (AI → A4I) occurs if the Vm repolarises before the inactivation gate is closed. 
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1.1.5 Activation 
In order for VGSC activation to occur depolarization of the membrane must be detected 
by a voltage-sensitive channel region and this ‘voltage-sensing’ mechanism must be 
coupled to the movement of the channel’s activation gate (A gate), allowing opening of 
the ion conducting pore. A plethora of evidence from mutagenesis studies, substituted 
cysteine accessibility assays and Ig measurements show that the transmembrane S4 
segments act as the ‘voltage-sensors’ in VGSCs (e.g. Stuhmer et al., 1989; Yang and 
Horn, 1995; Yang et al., 1996; Kontis et al., 1997). As predicted originally by Hodgkin 
and Huxley (1952), the ability of S4 segments to sense changes in the Vm is due to their 
possession of a large number of positively charged amino acids, which act as gating 
charges that change position in response to a change in the transmembrane electric field 
(Tombola et al., 2006). The resulting conformational changes associated with such 
charge translocation in turn trigger the opening of the VGSC pore, resulting in increased 
Na+ conductance (Swartz, 2008; Catterall, 2010). 
Each of the four S4 segments in VGSCαs contains four to eight positively 
charged amino acid residues (mostly arginines) located at three amino acid intervals 
(there are respectively 4, 5, 6 and 8 positive residues in the S4 of D1, D2, D3 and D4) 
(Noda et al., 1984; Catterall, 2000). Under resting conditions, the negative internal 
transmembrane potential would exert an inward pulling force on the positive S4 
charges, whereas membrane depolarization would have the opposite effect, repelling the 
positive residues and thereby inducing S4 movement (Swartz, 2008). Ig measurements 
have consistently shown that 12-16 positive charges are transferred outward across the 
electric field during VGSC activation (Bezanilla, 2000; Kuzmenkin et al., 2004); 
however, the precise way in which the S4 segments move to accommodate such charge 
translocation remains debated. Three models exist, as described briefly below:  
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i. Sliding helix (Catterall et al., 1986) or helical screw (Guy and Seetharamulu, 
1986) model. This proposes that S4 is in a transmembrane orientation in both 
resting and activated states, and its movements occur through a hydrophilic 
gating pore, which surrounds and insulates it from lipid (Figure 1.4A). Under 
resting conditions, the positively charged S4 residues are drawn inward by the 
negative internal transmembrane potential and they are stabilized by pairing with 
negative residues on the neighbouring S1, S2 and/or S3 helices (DaCaen et al., 
2008, 2009). A sudden membrane depolarization relieves the inward pulling 
force on the S4 charges and disrupts their ion pairs with the negative S1-S3 
residues. The S4 segments become free to rotate and slide outwards such that 
each positive S4 residue makes a series of new ion pairs with the neighbouring 
negative residues (DaCaen et al., 2008, 2009). This shifts charge across the 
membrane, from an inner to an outer vestibule that surrounds the S4 segment 
(Figure 1.4A). The resulting conformational changes in all four domains of the 
channel open it to Na+ influx (Tombola et al., 2006; Catterall, 2010). 
ii. Transporter model (Bezanilla, 2000, 2005). This is based on the crystal structure 
of the bacterial K+ channel KcsA (Doyle et al., 1998) and is similar to the 
sliding helix model except that the S4 segments translocate their gating charges 
mainly by rotating (twisting) along their axis without much vertical sliding. 
Under resting conditions, the positively charged S4 residues are exposed to the 
intracellular environment by means of a water-filled crevice that is formed by 
the tilted orientation of the transmembrane segments (Figure 1.4B). Upon 
depolarization, the positive S4 residues are forced outwards but due to physical 
constraints the S4 segments do not move vertically but rotate ~ 180° on a tilt 
(Starace and Bezanilla, 2004; Chanda et al., 2005). As a result, the positive S4  
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Figure 1.4 Conceptual models of voltage-sensing in VGSCs 
Orange cylinders represent the positively charges S4 segments. Protein surrounding is 
colored in gray; lipid is shown in green. The four outermost arginines in S4 segments 
are shown as blue spheres when in foreground and as empty blue circles when in the 
background. For each model, the resting state of the S4 segment is shown on the left 
and the activated state on the right: (A) The sliding helix or helical screw model; (B) 
The transporter model; (C) The paddle model. Modified from Tombola et al. (2006). 
 
 
Transporter model 
Sliding helix model 
Paddle model  
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residues move into another crevice, this time filled with the extracellular 
solution, completing their transmembrane translocation (Figure 1.4B).  
iii. Paddle model (Jiang et al., 2003). This was inspired by the crystal structures of 
the bacterial K+ channel KvAP. Accordingly, S1, S2 and S4 segments form long 
uninterrupted helices, whereas S3 contains two shorter helices. The extracellular 
helix in S3 (S3b) and S4 forms a helical hairpin (i.e. a helix-turn-helix motif), 
called the voltage-sensor paddle, which was proposed to move (i.e. paddle) as a 
unit upon membrane depolarization. In the resting state, the S4 segment is 
located deep within the membrane, with its positive charges exposed to lipid, 
and the S3b segment resides on top of S4. Upon membrane depolarization, S3b-
S4 paddle moves together to the extracellular surface, which initiates the 
conformational change that opens the channel pore (Ruta et al., 2005; Swartz, 
2008). In the mammalian K+ channel Kv1.2, whose crystal structure was 
obtained by Long et al. (2005a), the entire S3 helix was proposed to be part a 
part of the S3-S4 voltage-sensor paddle (Long et al., 2005b, 2007).  
 
Whether via spiral sliding (sliding helix model), rotation (transporter model) or 
paddling (paddle model), the net outcome of S4 movement upon depolarization is 
opening of the VGSC activation gate. As regards the coupling between voltage-sensing 
and pore opening, it is presently accepted that the movement of the S4 segments upon 
depolarization results in a pulling force on the intracellular S4-S5 linker, which in turn 
leads to bending of the inner S6 segments and pore opening (Tombola et al., 2006; 
Swartz, 2008; Catterall, 2010).  
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1.1.6 Inactivation  
The transient open state of VGSCs is ended by the process of ‘fast’ inactivation. This 
occurs by a ‘hinged-lid’ or ‘ball-and-chain’ mechanism, in which an inactivation 
particle in the short intracellular loop between D3 and D4 (ID3-4) physically occludes 
the inner mouth of the pore by docking to its receptor positioned nearby (Figure 1.5A; 
Goldin, 2003). Mutagenesis studies revealed that the hydrophobic amino acid triad 
isoleucine-phenylalanine-methionine (the ‘IFM’ motif) is essential for fast inactivation 
(West et al., 1992), and peptides containing this motif (e.g. KIFMK) can mimic the 
endogenous inactivation particle, restoring fast inactivation to VGSCs with a mutated 
inactivated gate (Eaholtz et al., 1994). In agreement with these findings, the 3D 
structure of the inactivation particle, obtained using multidimensional NMR, revealed 
(1) that the IFM motif is located critically in the N-terminal end of a rigid α-helix, and 
(2) Phe1489 of the IFM and the nearby Thr1491 (another important residue for 
inactivation; Kellenberger et al., 1997) are exposed to solvent away from the core of the 
inactivation particle, i.e. they are positioned ideally for a direct interaction with an 
inner-pore docking site (Figure 1.5B; Rohl et al., 1999). Taken together, the rigid α-
helix was predicted to act as a ‘scaffold’, presenting the hydrophobic IFM triad and the 
adjacent Thr1491 to the inner-pore docking site as the inactivation gate closes (Figure 
1.5A; Catterall, 2000).  
As discussed in Section 1.1.4, closing of the inactivation gate has no intrinsic 
voltage-dependence, and derives its apparent voltage-dependence through coupling to 
the outward movement of D4:S4 during activation (Armstrong, 2006). This implies that 
the receptor for the inactivation particle becomes available only if the activation gate is 
activated (i.e. S4 segments have moved outward). Indeed, scanning mutagenesis 
experiments revealed that the docking site for the inactivation particle consists of  
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Figure 1.5 Mechanism of fast inactivation  
(A) The intracellular linker between domains 3 and 4 (ID3-4) forms a ‘hinged lid’ that is 
responsible for fast inactivation of the VGSC; the critical Phe1489 (Nav1.2 numbering) 
within the hydrophobic IFM motif (Ile1488-Phe1489-Met1490) occludes the intracellular 
mouth of the pore during the inactivation process (right). (B) 3D structure of the central 
portion of the inactivation particle in ID3-4 of rat Nav1.2, as determined by 
multidimensional NMR (Rohl et al., 1999). Side chains of the core IFM motif residues 
are shown in yellow. Thr1491, which is also important for inactivation, is shown in green. 
Ser1506, which is a protein kinase C (PKC) phosphorylation site, is also indicated in 
green. Acidic residues are shown in red, basic residues in blue, polar residues in green 
and non-polar residues in white. Adapted from Yu and Catterall (2003). 
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multiple amino acid residues in the inner mouth of the pore (Figure 1.1.A, blue circles), 
including couple hydrophobic residues in the intracellular end of D4:S6 (McPhee et al., 
1995) and various amino acid residues in the cytoplasmic linkers D3:S4/S5 (Smith and 
Goldin, 1997a) and D4:S4/S5 (Lerche et al., 1997; McPhee et al., 1998; Filatov et al., 
1998). The outward movement of S4 segments during activation is thus presumed to 
expose the critical receptor residues in D3:S4/S5, D4:S4/S5 and D4:S6 such that they 
can interact directly with the inactivation particle (Goldin, 2003).  
VGSC inactivation is often referred to as a single process, i.e. fast inactivation; 
however, prolonged membrane depolarization or high-frequency stimulation can induce 
several ‘non-fast’ modes of inactivation, which have been termed ‘intermediate’, ‘slow’, 
and ‘ultraslow’, defined by the time they leave a VGSC refractory during repolarization 
(Ulbricht, 2005). Recovery from fast inactivation typically occurs with a time constant 
in the low millisecond range, whereas recovery from intermediate, slow and ultraslow 
inactivation has a time constant in the range of hundreds of milliseconds, seconds, and 
10-100s, respectively (Hilber et al., 2001; Goldin, 2003). Therefore, whilst VGSC fast 
inactivation is important for rapid repolarisation of the AP in excitable cells, the slower 
inactivation modes may regulate overall excitability, such as by modulating the rate of 
high-frequency (i.e. burst) firing of neurons (Ruff et al., 1988).  
Mechanistically, intermediate/slow/ultraslow inactivation do not involve the fast 
inactivation gate in ID3-4 (Featherstone et al., 1996; Townsend and Horn, 1997; 
Vedentham and Cannon, 1998), and are often grouped as “slow inactivation” (Vilin and 
Ruben, 2001). Slow inactivation generally is thought to result from structural 
rearrangement of the channel pore (analogous to the C-type inactivation in VGPCs), 
although the precise mechanism(s) preventing ion flow is still unknown (Goldin, 2003; 
Tikhonov and Zhorov, 2007). Several studies have shown that various P-loop (SS1-
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SS2) residues, in particular those at and around the inner DEKA and outer EEDD ion 
selectivity rings, can affect development of slow inactivation (Balser et al., 1996; Hilber 
et al., 2001; Zhang et al., 2003). Various other regions of the channel have also been 
implicated in regulating slow inactivation; these include the inner-pore-lining S6 
segments in D1 and D3 (Chen et al., 2006), cytoplasmic S4-S5 linkers in D1 and D2 
(Bendahhou et al., 2002; Lampert et al., 2006) and the S4 voltage-sensor in D4 
(Mitrovic et al., 2000). Interestingly, slow inactivation was also shown be affected by 
the ionic microenvironent such that a reduction in the extracellular Na+ concentration 
enhanced entry into slow inactivated states in both Nav1.4 and Nav1.5 (Townsend and 
Horn, 1997; Chen et al., 2000b). This was later modelled to occur due to enhanced 
electrostatic repulsion between the EEDD carboxylates (i.e. in the presence of reduced 
Na+), which was predicted to disrupt the “permeable configuration of the ion pore” 
(Tikhonov and Zhorov, 2007). Further work is needed to determine the precise 
mechanism(s) of slow inactivation and to identify the structural differences between the 
intermediate-, slow- and ultraslow-inactivated states. 
 
1.1.7 Persistent activity 
Upon membrane depolarization, majority of VGSCs activate and rapidly inactivate, 
after which they remain closed/non-conducting until repolarization occurs (Section 
1.1.4). However, a small percentage of VGSCs may not inactivate, or inactivate and re-
open during sustained depolarisations (e.g. the plateau phase of the cardiac AP), 
generating a small persistent Na+ current (INaP), which has been detected in the 
membranes of various types of neurons and cardiomyocytes (Saint et al., 1992; Maltsev 
et al., 1998, 2008a; Magistretti et al., 1999; Taddese and Bean, 2002; Maltsev and 
Undrovinas, 2006; reviewed in Crill, 1996; Saint, 2008). INaP could also be recorded in 
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heterologous systems expressing a single VGSCα subtype (e.g. for Nav1.1, Nav1.2 and 
Nav1.5; Aman et al., 2009; Qu et al., 2001; Maltsev and Undrovinas, 2006), suggesting 
(1) that multiple VGSCα subtypes are capable of expressing INaP and (2) that transient 
INa and INaP can be carried by the same molecular entity, i.e. the same VGSCα subtype 
(Zaza et al., 2008).  
Biophysically, the mechanism responsible for INaP is not fully understood; 
however, in human ventricular and rabbit Purkinje myocytes, spontaneous modal 
changes in VGSC gating were shown to result in (i) scattered late openings and (ii) 
burst openings, which collectively reflected as an inactivation-resistant Na+ current (i.e. 
INaP) at the macroscopic level (Patlak and Ortiz, 1985; Zilberter et al., 1994; Maltsev et 
al., 1998; 2008a; Bohle et al., 2002; Undrovinas et al., 2002; Maltsev and Undrovinas, 
2006). Studies on cardiac cells also found that the unitary events producing the transient 
INa and INaP shared similar characteristics (e.g. same ionic selectivity, unitary 
conductance, activation voltage-dependence, reversal potential, TTX-sensitivity), except 
that the late scattered and burst openings (responsible for INaP) were resistant to 
inactivation even at very depolarized potentials (e.g. positive to -10 mV) (Maltsev et al., 
1998; Undrovinas et al., 2002; Maltsev and Undrovinas, 2006). These findings 
indicated that INaP was distinct from (i) the background/leak Na+ current, which is TTX-
insensitive and voltage-independent (Lu et al., 2007, 2009) and (ii) the time-
independent/equilibrium ‘window’ INa, which occurs at restricted potentials where the 
VGSC steady-state activation and inactivation curves overlap (Attwell et al., 1979; 
Colatsky, 1982). 
In cardiomyocytes, INaP is usually very small, < 1% of transient peak INa (e.g. 
Saint et al., 1992; Maltsev et al., 1998; Zygmunt et al., 2001). However, because INaP is 
non-inactivating (or very-slowly inactivating), it can carry a significant amount of 
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charge (Na+). Maltsev and Undrovinas (2006) recorded and modelled INaP activity in 
human ventricular and mid-myocardial cardiomyocytes where INaP is ~ x1000 smaller 
than the transient peak INa, but it lasts ~ x1000 longer (2 s vs. 2 ms). It was thus 
concluded that transient INa and INaP contributed equally to the total Na+ influx, in 
agreement with other studies on human, rat, guinea-pig and dog ventricular myocytes 
(e.g. Kiyosue and Arita, 1989; Saint et al., 1992; Zygmunt et al., 2001; Undrovinas et 
al., 2002; Makielski and Farley, 2007). 
A number of physiological, pathophysiological and experimental conditions 
were reported to significantly enhance INaP in cardiomyocytes (and some also in 
neurons); these include inactivation-slowing neurotoxins (e.g. sea anemone toxin ATX-
II; Schreibmayer et al., 1987; Chahine et al., 1996), hypoxia (Ju et al., 1996; 
Hammarstrom and Gage, 2000), ischemic metabolites (e.g. lysophosphatidycholine and 
palmitoyl-L-carnitine; Burnashev et al., 1991; Wu and Corr, 1994), reactive oxygen 
species (e.g. H2O2; Song et al., 2006; Wang et al., 2007), Nav1.5 mutations associated 
with the long QT-3 syndrome (Bennett et al., 1995; Fredj et al., 2006), and heart failure 
associated with ischemia and myocardial infarction (Maltsev et al., 1998; Huang et al., 
2001; Valvidia et al., 2005).  
In cardiomyocytes, enhancement of INaP was shown to be sufficient to prolong 
the cardiac AP plateau/duration, inducing ‘temporal’ AP heterogeneity and early after 
depolarizations (EADs) (Ward and Giles, 1997; Maltsev et al., 1998, 2007; 
Antzelevitch et al., 1999; Undrovinas et al., 1999; Tian et al., 2004; Wu et al., 2006; 
Belardinelli et al., 2006; Zaza et al., 2008). In addition, in ischemic/hypoxic 
cardiomyocytes, excess Na+ entry via INaP was found to result in Ca2+ over-loading 
through reduced or reversed Na+/Ca2+ exchange (NCX), thereby further contributing to 
progression of cardiac arrhythmias (Haigney et al., 1994; Eigel and Hadley, 1999; Xiao 
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and Allen, 1999; Baartscheer et al., 2003; Pieske and Houser, 2003; Bers et al., 2006; 
O’Rourke and Maack, 2007; Maltsev and Undrovinas, 2008). In central neurons, INaP 
was shown to modulate the subthreshold membrane potential, thereby regulating 
dendritic depolarizations, repetitive firing and synaptic transmission (Crill, 1996; 
Taddese and Bean, 2002; Huang and Trussell, 2008). 
 
1.2 Regulation of VGSC expression/activity 
Regulation of VGSC functional expression is complex and occurs at multiple levels, 
which can be grouped into three, as follows (Figure 1.6): 
i. Transcriptional; 
ii. Post-transcriptional/pre-translational (mRNA splicing, degradation); and 
iii. Post-translational (glycosylation, phosphorylation, trafficking, protein-protein 
interactions). 
 
1.2.1 Transcription and mRNA degradation 
VGSC gene transcription has been shown to be affected by a variety of stimuli, 
including electrical activity (e.g. Sherman and Catterall, 1984; Sashiaha et al., 1994; 
Brackenbury and Djamgoz, 2006), injury (e.g. Iwahashi et al., 1994; Black et al., 1999), 
hypoxia (Xia and Haddad, 1999; Xia et al., 2000; Cacenas et al., 2007), growth factors 
such as the nerve growth factor (NGF) (e.g. Black et al., 1997), and steroid hormones 
such as androgen (e.g. Tabb et al., 1994; Zakon, 1998, Diss et al., 2008). Control of 
VGSCα expression involves interaction of multiple positive and negative transcriptional 
regulators with promoter regions, and can occur in an isoform- and/or tissue-specific 
manner (reviewed in Diss et al., 2004; Herfst et al., 2004). As regards isoform-specific 
regulation, the core promoter of Nav1.2 was shown to contain multiple transcription  
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Post-translational processing 
Trafficking to plasma membrane 
Functional VGSC 
Transcriptional 
regulators 
Recycled VGSC 
Phosphorylation 
β-subunits 
Protein-protein 
interactions 
Figure 1.6 Key mechanisms regulating VGSCα functional expression  
Regulation of VGSCα expression can occur at the transcriptional level, followed by 
mRNA splicing/trafficking/degradation. After translation, the VGSCα protein is 
processed and then trafficked to the plasma membrane, where it is subject to modulation 
by phosphorylation and interaction with other proteins, including VGSCβs.  
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factor consensus sites, including a GC box, TATA element, glucocorticoid response 
element and a neuron-specific POU-family transactivator (Brn-2) element (Schade and 
Brown, 2000). The Nav1.5 promoter, on the other hand, contains cytosine-rich motifs, a 
muscle-restrictive enhancer element (MRSE), and myogenic determination factor 
(MyoD) binding sites (Sheng et al., 1994). As regards tissue-specific control, (i) the 
Nav1.5 promoter was found to drive reporter expression in L6 myotubes, but not in 
NIH3T3 fibroblasts (Zhang H et al., 1999), and similarly (ii) the Nav1.2 promoter was 
shown to cause reporter expression in SH-SY5Y neuroblastoma cells, but not in HeLa 
epithelial cell line (Schade and Brown, 2000). Taken together, therefore, a ‘primary’ 
chemical stimulus (e.g. a growth factor) can induce differential transcriptional effects on 
different VGSCαs, and the effects may also vary depending on the cell/tissue 
background. Accordingly, for example, NGF was found to increase Nav1.7 expression 
in PC12 cells, whilst enhancing Nav1.8 but reducing Nav1.3 mRNA level in DRG 
neurons (Toledo-Aral et al., 1995; Black et al., 1997).  
At least one transcriptional factor has been described so far that regulates the 
specific expression of a single VGSCα isoform, i.e. Nav1.2. Thus, the repressor element 
1 (RE1) binding silencer protein (REST), which is expressed only in non-neuronal cells, 
was shown to bind to the RE1 element in the Nav1.2 promoter, inhibiting transcription 
of this VGSCα isoform and thereby restricting its expression to neuronal cells (Chong et 
al., 1995). Consistently, over-expression of REST in cultured neurones significantly 
reduced functional VGSC activity, an effect that could be prevented or reversed by 
raising intracellular cyclic adenosine monophosphate (cAMP) levels (Nadeau and 
Lester, 2002). It is worthwhile to note that REST functions as a part of a repressor 
‘complex’, its activity being dependent on binding of corepressor proteins, CoREST and 
mSin3A (Andres et al., 1999; Grimes et al., 2000).  
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The steady-state VGSCα mRNA level is determined not only by gene 
transcription but also mRNA stability (Wada et al., 2004). For instance, in bovine 
adrenal chromaffin (BAC) cells, activation of Ca2+-independent protein kinase C (PKC-
ε) by the phorbol ester 12-O-tetra-decanolylphorbol 13-acetate (TPA) decreased the 
Nav1.7 mRNA level; using RNA synthesis inhibitor actinomycin D, this effect was 
shown to be due to accelerated mRNA degradation (Yanagita et al., 1999; Kobayashi et 
al., 2002). Similarly, treatment of BAC cells with the extracellular signal-regulated 
kinase (ERK) inhibitors (PD98059 and U0126) reduced constitutive phosphorylation of 
ERK1 and ERK2, and increased the half-life of Nav1.7 mRNA from ~ 18 to 26 h, 
without affecting transcription, suggesting that activated ERK can induce acceleration 
of Nav1.7 mRNA degradation (Yanagita et al., 2003). 
Other studies have shown that functional VGSC activity, cAMP/PKA-dependent 
pathways and intracellular Ca2+ can also modulate α-subunit mRNA levels, despite the 
mechanism underlying these effects (i.e. altered transcription vs. mRNA degradation) 
was unresolved. Thus, in rat cardiomyocytes, chronic administration of class I anti-
arrhythmic drugs was found to upregulate the Nav1.5 mRNA level, suggesting a 
negative auto-regulatory role for functional VGSC activity (Sherman and Catterall, 
1984; Taouis et al., 1991; Duff et al., 1992; Kang et al., 1997). Treatment of developing 
rat muscle with 8-Br-cyclic AMP for 8 days increased VGSCα mRNA expression 
(Offord and Catterall, 1989), and similar cAMP-dependent effects were observed in 
denervated skeletal muscle, bovine adrenal chromaffin cells and spinal cord astrocytes 
(Sherman et al., 1985; Oh and Waxman, 1998; Wada et al., 2004). Finally, in rat 
cardiac myocytes, application of the Ca2+ ionophore A23187 resulted in an ~ 5-fold 
decrease in the VGSCα mRNA level, whereas Ca2+ chelator BAPTA-AM had the 
opposite effect (Taouis et al., 1991; Duff et al., 1992; Chiamvimonvat et al., 1995). 
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Such effect of Ca2+ was later shown to be cell- and isoform-specific: in rat pituitary GH3 
cells, expression of Nav1.2 and Nav1.3 mRNAs decreased but Nav1.1 and Nav1.6 
mRNA levels stayed unchanged upon application of Ca2+ channel agonist Bay K 8644 
(Vega et al., 2003). 
 
1.2.2 Alternative splicing 
Alternative splicing (AS), the process by which introns and exons of the primary RNA 
transcript (pre-mRNA) are recognized and processed in different ways, leads to the 
production of two or more different mRNAs from a single gene (Blencowe, 2006). 
Accordingly, AS is widely recognized as a primary mechanism by which highly 
complex, dynamic regulation of mRNA expression is achieved, and a large proteome 
(of > 90,000 proteins) is generated from only ~ 26,000 human genes (Wang ET et al., 
2008; Chen and Manley, 2009).  
The functional diversity of VGSC α-subunits, in particular, is increased 
considerably by AS of important functional domains, permitting fine-tuning of channel 
activity (Diss et al., 2004). To date five different sites in VGSCα genes have been found 
to be modulated by AS (Figure 1.7A), and eight of the nine functional VGSCα isoforms 
have been shown to be alternatively spliced at one or several of the five sites: only 
Nav1.4 has not yet been found to be expressed in more than one mRNA isoform (Table 
1.3). Alternative splicing of VGSCαs gives rise to two different types of variant 
transcripts: those that encode modified channel proteins (with either extra/fewer amino 
acids or amino acid substitutions; e.g. Schaller et al., 1992) and those that possess 
premature termination codons that, if translated, would give rise to highly truncated 
channels missing part of transmembrane domain/domains (e.g. Plummer et al., 1997) 
(Table 1.3). The functional importance of the truncated channel-encoding-transcripts is  
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Figure 1.7 Alternative splicing of VGSCαs and molecular differences between D1:S3 
neonatal and adult splice variants of Nav1.5 
(A) Basic molecular structure of a VGSCα showing the five major alternative splicing (AS) 
sites (shown in black). Conserved exon boundary positions are indicated with thin black 
lines and exons are numbered (for Nav1.5). Figure was prepared in collaboration with J.K.J. 
Diss. (B) (i) Schematic diagram of SCN5A (gene encoding Nav1.5), showing the relative 
positions of the mutually exclusive 5’- (neonatal, shaded) and 3’- (adult, black) exon 6. (ii) 
Deduced amino acid sequences of Nav1.5 exon 6 alternatives, with changed amino acids 
underlined / in bold. (iii) SCN5A exon 6 encodes parts of S3 and S4 in D1 and the 
extracellular S3/S4 linker (shaded). The predicted locations of the amino acids different in 
the two D1:S3 splice isoforms (red) are located mainly in the C-terminal end of D1:S3 and 
in the S3-S4 linker region. ‘K211D’ indicates the ‘charge-reversing’ amino acid change at 
position 211: negative aspartate in adult Nav1.5 (aNav1.5) and positive lysine in neonatal 
Nav1.5 (nNav1.5). From Onkal and Djamgoz (2009). 
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Table 1.3 VGSC α-subunit mRNA splicing 
 
 
 
Site1 VGSCα Splicing event Functional consequence Reference 
(1) D1:S3-S4 1.1, 1.2, 1.3, 1.5, 1.6, 1.7 
Mutually exclusive exon 6: 
substitution of aspartate in 
adult to a neutral/positive 
residue in neonate 
Modify voltage-dependence and 
kinetics of channel gating 
Copley et al. (2004); Sarao et al. (1991); 
Gustafson et al. (1993); Chioni et al. (2005); 
Plummer et al. (1998); Belcher et al. (1995); 
Chatelier et al. (2008). 
(2) ID1-2 1.1., 1.3, 1.6, 1.7 
Alternative exon 12 donors: 
multiple splice forms with 
different ID1-2 regions 
Modify (add/remove) 
phosphorylation sites 
Schaller et al. (1992); Dietrich et al. (1998); 
Thimmapaya et al. (2005); Plummer et al. 
(1998); Toledo-Aral et al. (1997); Raymond et 
al. (2004). 
(3) ID2-3 1.5, 1.8 
Skipping of parts of exon 17 
or exon18 or both: isoforms 
with shortened ID2-3 linker 
Modify voltage-dependence of 
activation/inactivation, produce 
non-functional proteins 
Gersdorff-Korsgaard et al. (2001); Zimmer et al. 
(2002b); Camacho et al. (2006); Makielski et al. 
(2003). 
(4) D3:S3-S5 1.1, 1.6 
Mutually exclusive exon 21 
(for Nav1.6) or  skipping of 
parts of exon 21 or exon 22 
(for Nav1.1) 
Predominantly non-functional 
‘fail-safe’ proteins 
Plummer et al. (1997); Oh and Waxman (1998); 
Schaller et al. (1995); Carrithers et al. (2009). 
(5) D4:S3-COOH 1.5, 1.9 
Multiple final exon (exon 
27) variants (for Nav1.9) or 
alternative exon 26 donors 
(for Nav1.5)  
Truncated protein at D4:S3, if 
translated Gellens et al. (1992); Jeong et al. (2000). 
Abbreviations: D, domain; S, segment; ID, interdomain linker. 1The number in parenthesis indicates the alternative splice site as numbered in Figure 1.7A.  
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presently unresolved but it has been postulated that these mRNAs may give rise to 
truncated proteins that are able to associate with other truncated VGSCαs and/or act as a 
“fail-safe” mechanism preventing the synthesis/activity of full-length VGSCα protein 
(Plummer et al., 1997; Diss et al., 2004).  
AS events that result in modified but functional VGSCαs, on the other hand, 
contributes significantly to functional VGSC diversity by generating splice variants 
with differing electrophysiological, pharmacological and/or modulatory characteristics 
(Table 1.3) (Schroeter et al., 2010). As shown in Figure 1.7A, the five major VGSCα 
AS sites bring about changes in the resultant mRNA encoding two distinct functional 
parts of the channel protein: (i) Sites 1, 4 and 5 alter the resultant mRNA at exons 
encoding regions that include transmembrane S3-S4 segments, and (ii) Sites 2 and 3 
bring about changes to parts of the mRNA encoding intracellular ID loops (Diss et al., 
2004). Given the importance of cytoplasmic ID regions for channel modulation (e.g. via 
PKA phosphorylation), splicing events in ID1-2 and ID2-3 could result in VGSCα 
variants with differing modulatory properties. Indeed, in mouse DRG neurons, an 
alternative splice form of Nav1.5 (termed Nav1.5c) encoded an additional glutamate 
residue (Q1077) within the ID2-3 linker region (AS site 3), which disrupted a putative 
casein kinase 2 (CK2) phosphorylation site (Figure 1.7A) (Kerr et al., 2004). In 
addition, splicing in the ID1-2 region (AS site 2) produced variants of Nav1.1, Nav1.3, 
Nav1.6 and Nav1.7, which possessed a shortened ID1-2 linker with multiple PKA and 
PKC phosphorylation sites removed (Figure 1.1A and Table 1.3) (Diss et al., 2004). 
Such ID1-2 splice variants of Nav1.3 expressed in Xenopus oocytes were found to 
exhibit slightly different (3-5 mV) half-activation and inactivation voltages, although 
the ultimate functional significance of these changes was unclear (Thimmapaya et al., 
2005).  
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Alternative splicing within VGSCα transmembrane regions has been shown to 
generate splice isoforms with greater electrophysiological distinction. A particularly 
important AS site in this regard is D1:S3-S4 (AS site 1), and given its central 
importance to this PhD project, the molecular basis and functional consequences of 
D1:S3 splicing is discussed at length as follows. Splicing at D1:S3-S4 region involves 
the inclusion of one or other of two mutually exclusive alternative exons (exon 6: 
5’genomic and 3’genomic) encoding part of D1:S3, most of D1:S4, and the D1:S3-S4 
extracellular linker (shown for Nav1.5 in Figure 1.7AB) (Plummer and Meisler, 1999). 
D1:S3 splicing, which was first described for Nav1.2 and Nav1.3 in rat brain, was 
deemed to be developmentally regulated since the transcripts containing the 5’-exon 
were abundant at birth, but were quickly replaced by the 3’-exon containing transcripts 
within a few days (Sarao et al., 1991; Gustafson et al., 1993). Hence, channels with the 
5’-variant were termed ‘neonatal’ and their 3’-variant counterparts, ‘adult’. Similar 
D1:S3 splicing has since been reported for Nav1.1 (Copley, 2004), Nav1.5 (Fraser et 
al., 2005, Ou et al., 2005), Nav1.6 (Plummer et al., 1998) and Nav1.7 (Belcher et al., 
1995; Klugbauer et al., 1995), although the developmental regulation of D1:S3 splicing 
was only confirmed for Nav1.5 in mouse heart (Chioni et al., 2005).  
Except for Nav1.5, the ‘adult’ and ‘neonatal’ exon 6 variants are very similar, 
typically differing at 19-21 nucleotides resulting in 1-3 amino acids changes, whereby a 
single amino acid at position 7 in the extracellular S3-S4 linker differs consistently: this 
is a negatively-charged aspartate in the ‘adult’ variants but a neutral amino acid in the 
‘neonatal’ counterparts (Plummer and Meisler, 1999; Diss et al., 2004). Nav1.5 exon 6 
splice variants differ from each other to a greater extent however (31 nucleotides / 7 
amino acids), and importantly the key amino acid (position 7) of the ‘neonatal’ variant 
is a positively charged lysine rather than a neutral residue, i.e. Lys211 → Asp211 charge 
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reversal during development (Figure 1.7B; Fraser et al., 2005; Ou et al., 2005). Because 
six of the seven amino acids different between Nav1.5 D1:S3 variants are located in the 
extracellular D1:S3/S4 linker region, Chioni et al. (2005) succeeded in generating a 
polyclonal antibody (NESOpAb) which selectively recognized and blocked ‘neonatal’ 
vs. ‘adult’ Nav1.5 expressed stably in EBNA-293 cells. By using NESOpAb in 
immunohistochemical studies, Chioni et al. (2005) confirmed the developmental 
regulation of Nav1.5 D1:S3 splicing in mouse heart (Chioni et al., 2005). 
A number of recent studies have elucidated the differences in the 
electrophysiological properties of VGSCs encoded by D1:S3 ‘adult’ and ‘neonatal’ 
mRNAs (Xu et al., 2007; Chatelier et al., 2008; Jarecki et al., 2009). Thus, ‘adult’ 
Nav1.2, which differs from its ‘neonatal’ counterpart by a single amino acid (N209D; 
neonatal → adult), exhibited significantly depolarized voltage dependence of steady-
state inactivation, slower activation kinetics and quicker recovery from inactivation (Xu 
et al., 2007). Consequently, compared to ‘neonatal’, ‘adult’ Nav1.2 was more excitable, 
i.e. more likely to fire, both in response to a given depolarizing stimulus and to 
repetitive stimuli. This was consistent with the studies of Chatelier et al. (2008) and 
Jarecki et al. (2009) in which the only reported difference between Nav1.7 D1:S3 
isoforms was the slower development of closed-state inactivation of ‘adult’ channels 
compared to ‘neonatal’ counterparts; the result of this being that the ‘adult’ channels 
were again more excitable than ‘neonatal’ channels, since they were more likely to 
generate large ‘ramp’ currents in response to gradually increasing depolarizing stimuli 
that eventually reached threshold (Nav1.7 D1:S3 variants differ by two amino acids: 
L201V and N206D, neonatal → adult). Finally, as regards D1:S3 splicing in Nav1.5, 
functional expression of ‘neonatal’ Nav1.5 variant (nNav1.5) has been identified in both 
human metastatic BCa and neuroblastoma cells; however, a direct electrophysiological 
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comparison with ‘adult’ Nav1.5 was not made (Fraser et al., 2005; Ou et al., 2005). 
Importantly, in MDA-MB-231 BCa cells, nNav1.5 activity was associated with 
promotion of metastatic cell behaviour in vitro (Fraser et al., 2005; Brackenbury et al., 
2007; Gillet et al., 2009), and ‘oncofoetal’ profile of nNav1.5 expression in BCa was 
suggested to endow this channel with a possible clinical potential against metastatic 
BCa (Section 1.3.9; Roger et al., 2006; Onkal and Djamgoz, 2009). In this regard, 
characterization of the electrophysiological and pharmacological properties of nNav1.5, 
with respect to aNav1.5, is among the aims of the present PhD. 
The cellular/subcellular mechanisms controlling VGSCα splicing are poorly 
understood and a variety of affectors have been found. For example, axotomy was 
shown to decrease levels of a Nav1.5 isoform with an in-frame deletion of exon 18 
(Kerr et al., 2007). In adult rat DRG neurons, NGF increased the level of a splice 
variant of Nav1.8 (termed SNS-A) that contained a partial repeat of D2 by a form of 
trans-splicing (Akopian et al., 1999). In spinal cord astrocytes, expression of Nav1.6 
D3:S3-S5 splice variants was upregulated by 48 h exposure to the membrane-permeant 
dibutyryl cAMP (dbcAMP), whereas dbcAMP had no such effect in cerebral astrocytes 
or B50 and B104 neuroblastoma cell lines (Oh and Waxman, 1998). In other ion 
channels, membrane depolarization is also known to affect AS patterns. For example, in 
GH3 pituitary cells, depolarizing the membrane by KCl (6 h) repressed splicing of 
‘STREX’, an exon that confers Ca2+ sensitivity in large-conductance K+ (BK) channel 
mRNAs (Xie and Black, 2001).  
 
1.2.3 Post-translational processing 
VGSCαs contain numerous potential extracellular glycosylation sites located mainly in 
the pore lining S5-S6 loops of D1 and D3 (Bennett, 2002). Five of these sites are 
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universally conserved, suggestive of an essential role (Stocker and Bennett, 2006). 
Indeed, a wealth of evidence suggests that addition of negatively charged carbohydrate 
molecules (mainly sialic acids) significantly hyperpolarizes voltage-dependence of 
VGSC gating through an electrostatic mechanism, i.e. by contributing to the negative 
surface potential sensed by the channel S4 voltage sensors (Bennett et al., 1997; Marban 
et al., 1998; Bennett, 2002; Cronin et al., 2005). 
The extent of VGSCα glycosylation is subtype-specific, e.g. Nav1.1-Nav1.4 are 
15-30% carbohydrate, whereas Nav1.5 and Nav1.9 are only 5% glycosylated (Zhang Y 
et al., 1999; Tyrell et al., 2001). Interestingly, the effect of glycosylation on VGSC 
function may also be subtype-specific, e.g. in transfected Chinese hamster ovary (CHO) 
cells, reduced sialylation depolarized activation gating of Nav1.4, but not Nav1.5 
(Bennett, 2002). This study also found that replacing the D1:S5-S6 region of Nav1.4 
with that of Nav1.5 abrogates the effect of sialylation, indicating that modulation of 
Nav1.4 by sialic acid occurs in the D1:S5-S6 loop. However, other studies in 
cardiomyoctes and HEK-293 cells showed that Nav1.5 gating may also be sensitive to 
sialylation, suggesting that the functional effect of glycosylation on given VGSCα 
isoforms can be cell-type specific (Zhang Y et al., 1999; Stocker and Bennett, 2006).  
 Apart from the α-subunit, the VGSCβ1 and β2 subunits were also found to be 
heavily glycosylated, by up to 40% (Isom et al., 1992; Marban et al., 1998). 
Importantly, it has been shown that fully sialylated β1 hyperpolarized the voltage-
dependence of Nav1.2, Nav1.5 and Nav1.7 expressed in CHO cells, whereas non-
sialylated β1 had no such effect (Johnson et al., 2004). Finally, in addition to 
glycosylation, palmitylation and sulphation of Nav1.2 was found to occur early in 
biosynthesis in neonatal rat brain neurons, although the functional consequence(s) of 
these modifications was not clear (Schmidt and Catterall, 1987).  
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1.2.4 Protein trafficking and degradation 
The level of functional VGSC expression relies on a fine balance between protein 
recycling (externalization-internalization) and degradation. Intracellular trafficking of 
VGSCs is a tightly regulated process and occurs via vesicular endo/exocytosis (Herfst et 
al., 2004), controlled by PKA activity (Muniz et al., 1996, 1997; Zhou et al., 2000; 
2002), Ca2+ signaling (Shiraishi et al., 2001a), and protein-protein interactions (e.g. with 
scaffolding proteins or CAMs; Okuse et al., 2002; Shah et al., 2004). For instance, in 
Nav1.5-expressing Xenopus oocytes, activation of PKA through cytosolic injection of 
cAMP rapidly upregulated functional VGSC expression within 1 h (Frohnwieser et al., 
1997); confocal immunomicroscopy of living HEK-293 cells revealed that PKA 
induced externalization of Nav1.5 channels from intracellular storage pools, e.g. 
endoplasmic reticulum (Hallaq et al., 2006). Consistently, Zhou et al. (2000) showed 
that the PKA-dependent upregulation of functional Nav1.5 expression in Xenopus 
oocytes was abolished in the presence of monensin and chloroquine, which both disrupt 
intracellular protein trafficking (Tietze et al., 1980; Tartakoff, 1983; Mollenhauer et al., 
1990). Notably, removal of phosphorylation sites (Ser525 and Ser528; Nav1.5 numbering) 
or RXR endoplasmic reticulum (ER) retention motifs in the ID1-2 loop of Nav1.5 
(479RKR481, 533RRR535 and 659RQR661) abolished the PKA-mediated increase in 
Nav1.5 current amplitude, indicating that PKA may mask these motifs to prevent 
interaction with as yet unidentified protein(s) (Zhou et al., 2002).  
 VGSC trafficking has been shown also to be regulated by Ca2+ signalling. Thus, 
in BAC cells, inhibitors of calcineurin (a Ca2+- and calmodulin-dependent protein 
phosphatase 2B) enhanced [3H]STX binding of cell-surface VGSCs, an effect that could 
be attenuated by co-application of brefeldin A (BFA; an inhibitor of trans-Golgi 
network transport), suggesting that calcineurin reduced externalization of newly 
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synthesized VGSC protein (Shiraishi et al., 2001b). In addition, A23187-induced 
elevation of [Ca2+]i significantly reduced [3H]STX binding in BAC cells, an effect that 
could be prevented by the inhibition of Ca2+-dependent PKC (PKC-α) (Shiraishi et al., 
2001a). Other studies in BAC cells have also found (i) that activation of PKC-α with 
thymeleatoxin (TMX) reduced [3H]STX binding, and (ii) that this effect was preserved 
in the presence of BFA, suggesting that PKC-α reduced cell surface VGSC expression 
via promotion of endocytic internalisation (Yanagita et al., 2000; Kobayashi et al., 
2002). Finally, in BAC cells, calpastatin-induced inhibition of the Ca2+-dependent 
cysteine protease calpain (which stimulates budding of clathrin-coated vesicles; 
Shimkets et al., 1997) abrogated the A23187-induced reduction in [3H]STX binding, 
suggesting that Ca2+-dependent VGSC internalization also involves calpain activity 
(Shiraishi et al., 2001a). Overall, therefore, Ca2+-dependent downregulation of VGSC 
functional expression in BAC cells is likely to involve co-operative activities of PKC-α, 
calpain and calcineurin, resulting in reduced externalization and/or enhanced 
internalisation of VGSC protein (Wada et al., 2004). 
 Interactions of VGSCs with various scaffolding proteins and CAMs have been 
also shown to modulate channel trafficking and site-specific membrane targeting. For 
instance, in DRG neurons, N-terminus of Nav1.8 was found to interact with the light 
chain (p11) of the cytoskeletal (F-actin) binding protein annexin II (Figure 1.8); in 
stably transfected CHO cells, confocal immunocytochemistry revealed that p11-Nav1.8 
interaction promoted Nav1.8 trafficking to the plasma membrane (Okuse et al., 2002). 
Contactin, a CAM, is also involved in VGSC trafficking, e.g. when co-expressed in 
CHO cells, contactin directly interacted with C-terminus of Nav1.9, enhancing cell 
surface expression of this VGSCα isoform (Liu et al., 2001). Similarly, in neonatal rat 
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Figure 1.8 Regulatory sites of VGSCs 
Numbered serine residues (S) phosphorylated by PKA or PKC (Nav1.2 numbering); arrows indicate possible interaction sites between the 
VGSC α- and β-subunits. Abbreviations: An II, annexin II; AnkG, ankyrin G; CaM, calmodulin; Gβγ, G-protein β-γ complex; Ub, ubiquitin. 
Modified from Chahine et al. (2005). 
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brain, contactin co-immunoprecipitated with Nav1.3, and enhanced cell surface VGSC 
expression when co-expressed with Nav1.3 in HEK-293 cells (Shah et al., 2004).  
The membrane skeletal protein ankyrin G (AnkG) binds directly to a conserved 
motif {[V/A]P[I/L]AxxE[S/D]D} in the ID2-3 linker of VGSCαs (Figure 1.8), and 
plays an essential role in site-specific targeting of (i) Nav1.2 and Nav1.6 to AIS and 
nodes of Ranvier in CNS neurons and (ii) Nav1.5 to intercalated discs in 
cardiomyocytes (Bennett and Chen, 2001; Lemaillet et al., 2003; Herfst et al., 2004; 
Cusdin et al., 2008). Thus, AnkG was shown by regional knockout in mouse cerebellum 
to be essential for VGSC clustering to AIS, along with the ankyrin-binding L1 CAMs, 
neurofascin-186 and NrCAM (Zhou D et al., 1998; Leterrier et al., 2010). In 
cardiomyocytes, a Brugada syndrome-causing mutation (E1053K) in the AnkG binding 
site of Nav1.5 was found to eliminate AnkG-Nav1.5 interaction, thereby resulting in 
reduced and disorganized Nav1.5 expression in the sarcolemma, intercalated discs and 
T-tubules (Mohler et al., 2004).  
Increasing evidence suggests that the level of functional VGSC expression can 
also be modified by (i) VGSC activity (i.e. auto-regulation) and (ii) the β-subunits. As 
regards (i), chronic treatment of fetal rat brain neurons with VGSC ‘openers’ 
veratridine, batrachotoxin and α-scorpion toxin (α-ScTX) reduced the surface 
expression of VGSCs determined by 3[H]STX binding, indicating a negative feedback 
auto-regulation of VGSC expression (Dargent and Couraud, 1990). This effect was later 
shown to occur due to increased channel internalisation to endosomes, using [125I]α-
ScTX as both VGSC activator and probe (Dargent et al., 1994; Paillart et al., 1996). 
Interestingly, in the highly metastatic Mat-LyLu rat prostate cancer (PCa) and MDA-
MB-231 human BCa cells, the auto-regulatory effect of VGSC activity was a positive 
one, i.e. long-term blockage of VGSC activity using TTX resulted in reduced trafficking 
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of VGSCs to the plasma membrane, determined using patch-clamp electrophysiology 
and confocal immunocytochemistry (Brackenbury and Djamgoz, 2006; Chioni et al., 
2010). In both cancer cell lines, auto-regulation of VGSC expression was shown to 
involve Na+-dependent stimulation of PKA activity, which in turn enhanced VGSC 
externalization, increasing the level of cell surface VGSCs (Shao et al., 2009). 
Regarding the effect of β-subunits on VGSC functional expression, green 
fluorescent protein (GFP) chimeras expressed in HEK-293 cells revealed that Nav1.5 / 
VGSCβ1 (but not VGSCβ2) complex exists already in ER, indicating that β1 may assist 
trafficking of the Nav1.5 to the plasma membrane (Zimmer et al., 2002a). Other studies 
have shown β1 to increase the cell surface expression of Nav1.2 through β1-contactin 
and β1-ankyrin interactions (Kazarinova-Noyes et al., 2001; McEwen et al., 2004). 
Notably, measurements of [3H]STX  binding revealed that VGSC expression was 
significantly reduced in plasma membrane of DRG neurons from β2-knockout mice, 
indicating that the β2 subunit plays an important role in trafficking and/or surface 
stability of VGSCαs (Chen et al., 2002). Also, plasma membrane expression of Nav1.8 
was found to be facilitated by coexpression with the β3 subunit in Xenopus oocytes or 
ND7/23 cells (Shah et al., 2000; John et al., 2004). Using chimaeric constructs, Zhang 
et al. (2008) showed that a highly efficient ER retention signal in the ID1-2 region of 
Nav1.8 was masked by an interaction between Nav1.8 and the C-terminus of the β3 
subunit, resulting in enhanced Nav1.8 externalization. 
 Finally, Nedd4 family of ubiquitin-protein ligases were found to bind to the C-
terminal PY motifs of VGSCs, inducing targeted degradation via ubiquitination (Figure 
1.8) (Herfst et al., 2004; Ingham et al., 2004). Coexpression of Nedd4 with Nav1.5 in 
Xenopus oocytes reduced peak current density without affecting channel gating 
properties, indicating promotion of VGSC removal from the plasma membrane (Abriel 
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et al., 2000a). Consistently, in HEK-293 cells, cell surface expression of Nav1.5 was 
reduced upon coexpression with Nedd4-2 (van Bemmelen et al., 2004). Similarly, 
Nedd4-2 was shown to reduce the peak current amplitude of Nav1.2, Nav1.7 and 
Nav1.8 expressed in Xenopus oocytes (Fotia et al., 2004) and Nav1.2 and Nav1.3 
expressed in HEK-293 cells (van Bemmelen et al., 2004; Rougier et al., 2005). Nedd4-
dependent ubiquitination is thus likely to be a general mechanism for VGSCα 
internalisation and degradation (Shao et al., 2009). 
 
1.2.5 Phosphorylation 
VGSC activity can be modulated via phosphorylation by serine/threonine protein 
kinases PKA and PKC (Figure 1.9) and tyrosine kinases (Cantrell and Catterall, 2001; 
Chahine et al., 2005). Phosphorylation can modulate VGSCα (i) gating and/or (ii) 
intracellular trafficking, in a VGSCα subtype-dependent manner. 
 
1.2.5.1 Protein kinase A 
Neuronal VGSCα isoforms (e.g. Nav1.1, Nav1.2, Nav1.7) contain five consensus sites 
in their cytoplasmic ID1-2 linkers for phosphorylation by PKA (Figure 1.8; Marban et 
al., 1998). Phosphopeptide analysis revealed that four of the ‘consensus’ serine residues 
in the ID1-2 linker of Nav1.2 (Ser573, Ser610, Ser623 and Ser687) were phosphorylated by 
PKA (Figure 1.8) (Murphy et al., 1993). Notably, A kinase anchoring protein (AKAP-
15) has also been shown to bind to the cytoplasmic ID1-2 linker region, targeting PKA 
to its phosphorylation sites and thereby allowing rapid channel neuromodulation 
(Cantrell et al., 2002; Few et al., 2007). In transfected CHO cells and Xenopus oocytes, 
activation of PKA with 8-Br-cAMP or forskolin reduced Nav1.2 peak currents, without 
affecting the voltage-dependence of activation or inactivation (Li et al., 1992; Smith and  
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Figure 1.9 Modulation of VGSCs by PKA and PKC 
(A) Regulation by PKA. Receptor activation (e.g. D1-like dopamine receptors) leads to 
stimulation of adenylyl cyclase (AC), which in turn activates PKA which promotes 
VGSC trafficking and phosphorylates VGSCs. (B) Regulation by PKC. Activation of a 
G-protein coupled receptor leads to phospholipase C (PLC) activation and production of 
diacylglycerol (DAG) and inositol triphosphate. The latter stimulates Ca2+ release from 
internal stores. Ca2+ and DAG both activate PKC, which in turn phosphorylates VGSCs. 
Activated PKC associates with its RACK (receptor for activated C-kinase). Modified 
from Chahine et al. (2005). 
 
 
 Chapter 1                                                                                                         General Introduction  
 
 78 
Goldin, 1996, 1998). This effect involved phosphorylation of Ser573 (Smith and Goldin, 
1997b; Cantrell et al., 1997) and reduction in (i) number of channels expressed in 
plasma membrane and (ii) peak single-channel conductance (Li et al., 1992). A similar 
inhibitory effect of PKA was reported for Nav1.1 and Nav1.7 channels expressed in 
Xenopus oocytes (Smith and Goldin, 1998; Vijayaragavan et al., 2004). In addition, 
activation of dopamine D1 receptors in acutely dissociated hippocampal neurons 
reduced peak Na+ current amplitude in a PKA-dependent manner (Cantrell et al., 1997).  
In contrast, PKA activators dose-dependently enhanced TTX-R Nav1.8 currents 
expressed in rat sensory neurons, COS-7 cells or Xenopus oocytes, and in each case, 
there were accompanying changes in channel gating including hyperpolarization of 
activation voltage-range and acceleration of activation and inactivation kinetics 
(England et al., 1996; Gold et al., 1996, 1998; Fitzgerald et al., 1999; Vijayaragavan et 
al., 2004). Similar effects of PKA were also obtained for Nav1.5 expressed in Xenopus 
oocytes, and this was shown to be due to phosphorylation Ser525 and Ser528, which 
increased externalization of channels to the cell surface (Zhou et al., 2000, 2002). 
 The contrasting effects of PKA phosphorylation on TTX-S (Nav1.1, Nav1.2, 
Nav1.7; reduction in current amplitude) vs. TTX-R VGSCαs (Nav1.5, Nav1.8; increase 
in current amplitude) may in part be due to differential dual effects of PKA: (i) ‘direct’ 
phosphorylation of the serine residues in the channel ID1-2 linker, and (ii) ‘indirect’ 
modulation of VGSC trafficking (Figure 1.9). Regarding (ii), for example, upon 
removal of the PKA phosphorylation sites in the ID1-2 linker of Nav1.2, the peak 
current amplitude in Nav1.2-expressing Xenopus oocytes was enhanced by PKA 
activation (Smith and Goldin, 2000). This suggested that potentiation by PKA was an 
‘indirect’ process, i.e. PKA possibly phosphorylated some intermediate protein(s) that 
were involved in Nav1.2 trafficking (Smith and Goldin, 2000; Chahine et al., 2005). In 
 Chapter 1                                                                                                         General Introduction  
 
 79 
principle, therefore, PKA phosphorylation may activate a ‘trafficking-modifier’ 
accessory protein that associates preferentially with only some VGSCαs, facilitating 
trafficking of these to the plasma membrane, whilst having no effect on the other 
VGSCα isoforms (Chahine et al., 2005). 
  
1.2.5.2 Protein kinase C 
Activation of PKC with phorbol esters [(phorbol 12-myristate, 13-acetate (PMA) and 
phorbol 12,13-dibutyrate (PDBu)] reduced peak currents of several heterologously 
expressed VGSCαs including Nav1.2, Nav1.4, Nav1.5, Nav1.7 and Nav1.8 
(Schreibmayer et al., 1991; Bendahhou et al., 1995; Murray et al., 1997; Tateyama et 
al., 2003; Vijayaragavan et al., 2004). Consistently, PKC activation with carbachol 
(through muscarinic receptors) suppressed the peak VGSC current in isolated 
hippocampal neurons, and this effect could be blocked by the PKC pseudosubstrate 
inhibitor PKCI19-36 (Cantrell et al., 1996). In such studies, inhibition of VGSCαs by 
PKC phosphorylation was shown to involve (i) reduced open-channel probability, (ii) 
slowed open-state inactivation, (iii) hyperpolarized steady-state availability, and/or (iii) 
enhanced intrinsic slow-inactivation (Godoy and Cukierman 1994; Qu et al. 1994; Carr 
et al., 2003; Chen et al., 2006). On the other hand, in isolated rat DRG neurons, 
activation of PKC with PMA or PDBu resulted in a dose-dependent increase in the peak 
amplitude of TTX-R Na+ currents, an effect that was associated with increased channel 
conductance and acceleration of the rates of activation and inactivation (Gold et al. 
1996, 1998; Baker, 2005b). Such contrasting effect of PKC on DRG neurons was 
suggested to be due to the presence of multiple VGSCαs (at least Nav1.7, Nav1.8 and 
Nav1.9) that may be modulated differentially by PKC (Chahine et al., 2005). 
Consistently, Thio and Sontheimer (1993) showed using two distinct subpopulations of 
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rat spinal cord astrocytes that PKC increased TTX-R currents, but reduced TTX-S 
currents, although the specific VGSCα isoforms involved were not known.  
 Mutational analysis revealed that PKC can phosphorylate VGSCαs at multiple 
sites. One key site in Nav1.2 was found to be Ser1506 (Ser1503 for Nav1.5) in the ID3-4 
linker close to the ‘IFM’ fast inactivation particle (Figure 1.5B and 1.8) (West et al., 
1991; Qu et al. 1996). However, Murray et al. (2007) reported that mutating Ser1503 to 
alanine in Nav1.5 expressed in Xenopus oocytes reduced but did not abolish the effect 
of PKC on channel function, suggesting that additional PKC phosphorylation site(s) 
may exist. Consistently, mutagenesis studies in Nav1.2 revealed that maximal reduction 
of current amplitude required PKC phosphorylation of Ser554 and Ser573 in ID1-2 linker 
as well as Ser1506 in ID3-4 linker (Cantrell et al., 2002).  
 
1.2.5.3 Interaction of protein kinases A and C 
A number of studies have indicated that PKA and PKC may co-operate in modulating 
VGSC activity (Cantrell and Catterall, 2001). For instance, in rat DRG neurons, PKA-
induced increase in VGSC current (by forskolin) was attenuated in the presence of the 
PKC inhibitor peptide PKCI19-36, suggesting convergence of PKA and PKC effects 
(Gold et al., 1998). Consistent with this, mutagenesis experiments revealed that the 
inhibitory effect of PKA on Nav1.2 expressed in CHO cells was enhanced by PKC-
dependent phosphorylation of Ser576 in the ID1-2 and/or Ser1506 in the ID3-4 linkers (Li 
et al., 1993; Cantrell et al., 2002). Moreover, such interaction between the effects of 
PKA and PKC was shown to be dependent on the membrane potential: (i) at 
hyperpolarized voltages (e.g. -110 mV), PKA induced minimal effect on Nav1.2 
activity per se, whereas concurrent activation of PKC restored the inhibitory effect of 
PKA on Nav1.2 (Li et al., 1993); (ii) at more depolarized voltages (e.g. -70 mV), 
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substantial PKA-modulation of Nav1.2 occurred without the requirement for PKC 
activation (Cantrell et al., 2002).  
 
1.2.5.4 Tyrosine kinase 
VGSCs may also be modulated by tyrosine phosphorylation (Diss et al., 2004). In rat 
pheochromocytoma PC12 cells, activation of receptor tyrosine kinases (RTKs) by acute 
application of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) or 
epidermal growth factor (EGF) reduced peak Nav1.7 current amplitude, which was 
shown to occur due to hyperpolarization of the voltage-dependence of steady-state 
inactivation (Hilborn et al., 1998). Consistently, (i) in brain neurons, VGSCαs 
coimmunoprecipitated with the receptor protein tyrosine phosphatase β (RPTPβ), and 
(ii) in HEK-293 cells, RPTPβ dephosphorylated the basally phosphorylated VGSCαs, 
depolarizing their voltage-dependence of inactivation (Ratcliffe et al., 2000). 
 
1.2.6 Protein-protein interactions 
Cell surface VGSCαs form macro-molecular complexes with a number of adhesion 
molecules and cytoskeletal adaptors, the underlying protein-protein interactions being 
important for their functional properties, intracellular trafficking, cell-surface stability, 
and/or site-specific membrane targeting (Cusdin et al., 2008; Leterrier et al., 2010). The 
modulatory proteins that have been shown to interact with VGSCαs include annexin II, 
ubiquitin, contactin, AnkG (these have been described in Section 1.2.4), VGSC β-
subunits, Ca2+-dependent calmodulin (CaM), and G-proteins (Figure 1.8).  
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1.2.6.1 VGSC β-subunits 
In addition to their involvement in VGSCα trafficking (Section 1.2.4), VGSC β-subunits 
can directly modulate the electrophysiological properties of VGSCαs, in a α/β subtype-
dependent manner (Meadows and Isom, 2005). Isom et al. (1992) showed that co-
expression of the β1-subunit with Nav1.2 in Xenopus oocytes increased peak current 
amplitude, hyperpolarized voltage-dependence of steady-state inactivation, and 
increased the rate of activation and inactivation. Patton et al. (1994) extended these 
findings to Nav1.3 and Nav1.4, and suggested that association with the β1-subunit 
switches VGSCα gating to a faster mode. Consistently, Nuss et al. (1995) and Fahmi et 
al. (2001) showed that coexpression of β1 with Nav1.5 in Xenopus oocytes enhances 
peak current amplitude and increases the rate of inactivation; Qu et al. (1995) found 
similar results except that there was no effect of β1 on Nav1.5 inactivation. In 
mammalian cells, however, the effects of β1 on Nav1.5 gating were somewhat different: 
(i) in HEK-293 and tsA-201 cells, β1 enhanced Nav1.5 current density, but depolarized 
voltage-dependence of activation and inactivation, and slowed the rate of recovery from 
inactivation (Xiao et al., 2000; Qu et al., 2001); (ii) in CHO cells, β1 did not affect peak 
Nav1.5 current density, hyperpolarized voltage dependence of activation and 
inactivation, accelerated inactivation kinetics and did not affect recovery from 
inactivation (Ko et al., 2005). Thus, despite β1 generally enhances the peak current 
amplitude and accelerates gating in Nav1.2-Nav1.5, its functional effects may vary with 
the VGSCα isoform as well as the cell background. 
 β2- and β3-subunits were also shown to accelerate Nav1.2 inactivation in 
Xenopus oocytes, in a similar manner but to a lesser extent than β1 (Isom et al., 1995; 
Morgan et al., 2000). These findings were in agreement with Shah et al. (2001), Stevens 
et al. (2001) and Fahmi et al. (2001), who respectively showed that β3-coexpression 
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shifts Nav1.3, Nav1.4 and Nav1.5 gating to a faster mode in Xenopus oocytes (as 
judged from the proportional amplitudes of fast and slow time constants of inactivation 
and/or recovery from inactivation). In addition to its effect on gating kinetics, the β3-
subunit also hyperpolarized the voltage-dependence of steady-state inactivation in 
Nav1.2 and Nav1.3, despite having a depolarising effect in Nav1.5 (Morgan et al., 
2000; Fahmi et al., 2001; Shah et al., 2001; Stevens et al., 2001). As in the case of β1, 
some of the functional effects of β3 coexpression was different in mammalian cells than 
in oocytes: (i) in CHO cells, Nav1.5 availability was hyperpolarized and recovery from 
inactivation slowed (Ko et al., 2005), and (ii) in tsA-201 cells, Nav1.2 availability was 
depolarized (Qu et al., 2001). 
When coexpressed with Nav1.2 or Nav1.4 in tsA-201 cells, the β4-subunit 
hyperpolarized voltage-dependence of activation, without affecting inactivation (Yu et 
al., 2003). Yu et al. (2003) also showed that, in Nav1.2-expressing cells, such effects of 
β4 overrode the opposite effects of β1 ad β3, when they were also co-expressed, 
indicating a ‘governing’ role of β4 in the presence of other VGSCβ subunits. Similar to 
its effect on Nav1.2 and Nav1.4, β4 hyperpolarized voltage-dependence of activation of 
Nav1.1 expressed in HEK-293 cells (Aman et al., 2009). In addition, β4 coexpression 
was found to enhance INaP expressed by the Nav1.1 channels; this effect was 
antagonized when β1 was also present (Aman et al., 2009). Similar enhancement of INaP 
by β4 was recently reported to occur also in cultured cerebellar granule neurons (Bant 
and Raman, 2010). 
 
1.2.6.2 Calmodulin 
Intracellular Ca2+ can modify VGSC gating (i) by directly binding to the EF hand found 
in the C-termini of VGSCαs (Wingo et al., 2004) and/or (ii) by activating calmodulin 
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(CaM) that binds to VGSCαs via a highly conserved C-terminal IQ motif (Figure 1.8) 
(Deschenes et al., 2002). Studies in heterologous systems showed that CaM binds to C-
termini of both Nav1.4 and Nav1.5, causing a hyperpolarizing shift in steady-state 
inactivation of Nav1.4, but not Nav1.5 (Deschenes et al., 2002). In contrast, inhibition 
of the Ca2+/CaM-dependent kinase (CaMK) with KN-93 showed no effect on Nav1.4, 
but depolarized activation of Nav1.5, suggesting that Nav1.4 may be modulated directly 
by CaM and Nav1.5 by CaMK (Deschenes et al., 2002; Young and Caldwell, 2005).  
In native cardiomyoctes, Ca2+/CaM/CaMK-modulation of VGSC activity 
appeared complex and species-dependent. In rabbit and mouse ventricular 
cardiomyoctes, over-expression of CaMK hyperpolarised steady-state VGSC 
inactivation, enhanced ‘intermediate’ inactivation, slowed recovery from inactivation, 
and upregulated INaP that in turn resulted in increased [Na]i as determined using sodium-
binding benzofuran isophthalate (SBFI) (these effects could be prevented by CaMK 
inhibitor KN-93) (Wagner et al., 2006). In guinea pig and rat ventricular 
cardiomyocytes, on the other hand, CaMK activity resulted in depolarization of steady-
state inactivation, decreased entry into intermediate inactivation and accelerated 
recovery from inactivation, although the enhancement of INaP was again observed (Yoon 
et al., 2009; Aiba et al., 2010). Similarly, increased Ca2+ concentration was found to 
enhance INaP in normal and failing dog ventricular myocytes, and this effect was 
blocked by CaMK inhibitors (Maltsev et al., 2008b). Despite species-dependent 
differences in other parameters, therefore, Ca2+/CaM/CaMK signalling in 
cardiomyocytes appeared to consistently favour persistent VGSC activity, which in turn 
indicated altered (i.e. unstable) functioning of the channel inactivation gate (Kim et al., 
2004; Chagot et al., 2009). 
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1.2.6.3 G-proteins 
G-proteins have also been shown to directly interact with and modulate the activity of 
VGSCαs. In Nav1.2-expressing CHO cells and rat hippocampal neurons, activation of 
G-proteins with guanosine 5’[γ-thio]triphosphate (GTP[γS]) enhanced peak VGSC 
current density and negatively shifted voltage-dependence of activation and steady-state 
inactivation (Ma et al., 1994). Similarly, GTP[γS] application rapidly (within 5 minutes) 
increased the amplitude of persistent TTX-R Nav1.9 currents in small-diameter rat 
DRG neurons, suggesting that modulation of VGSC function by G-proteins may be 
important for nociception (Baker et al., 2003; Ostman et al., 2008). Furthermore, 
coexpression of G-protein βγ subunits (Gβγ) with Nav1.2 in tsA-201 cells resulted in 
depolarization of steady-state inactivation and upregulated a slowly-inactivating 
persistent current; these effects were reversed by synthetic peptides containing the Gβγ-
binding motif (QXXER) found in the C-termini of VGSCαs, suggesting that Gβγ binds 
directly to the Nav1.2 channel (Ma et al., 1997). In a separate study, Gβγ subunits were 
shown to directly interact with and upregulate INaP of Nav1.1 in tsA-201 cells, whilst 
having no such effect on Nav1.4 or Nav1.5 (Mantegazza et al., 2005). In rat ventricular 
cardiomyocytes, activation of β-adrenergic receptors with isoprenaline (ISO) enhanced 
peak Na+ current amplitude via increasing the number of cell surface VGSCs; this effect 
was blocked by an anti-G protein stimulatory α-subunit (Gsα) IgG, but not by the PKA 
inhibitor peptide PKI14-22, indicating that Gsα-induced upregulation of VGSC activity 
was not through PKA (Lu et al., 1999).  
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1.3 Metastatic disease 
Cancer is expected to become the leading cause of death by the year 2012, overtaking 
cardiovascular disease (Edwards et al., 2005; Jemal et al., 2010). Primary 
tumourigenesis is thought to arise from heterogeneous accumulation of genetic 
alterations (e.g. mutations in proto-oncogenes or tumour suppressor genes) and/or 
epigenetic changes (e.g. hypo/hyper-methylation of DNA), resulting in dysregulation of 
gene expression levels and/or patterns that ultimately gives rise to a group of hyper-
proliferating cells (Hanahan and Weinberg, 2000; Gibbs, 2003; Bild et al., 2006). Most 
current therapeutic strategies against early-stage cancers include excision of the primary 
tumour followed by adjuvant therapy (e.g. chemo-and/or radio-therapy) to destroy any 
remaining tumour cells. However, although this approach can be effective for some 
years, re-emergence of tumours is not uncommon (Vaidya and Welch, 2007). More 
importantly, metastasis – spread of cells from the primary neoplasm ultimately to form 
secondary tumours – is what causes the majority (> 90%) of cancer-related mortality 
(Nyugen and Massague, 2007; Hunter et al., 2008).  
Metastasis is a complex, multi-stage process in which cancer cells disassociate 
from each other, invade through basement membrane, enter blood or lymph circulation, 
re-attach at a distant site, and form secondary tumours after proliferation and induction 
of angiogenesis (Section 1.3.2) (Fidler, 2003). Despite its inherent complexity, a 
reductionist approach can be adopted initially to describe metastasis as an interrelated 
series of basic cellular behaviours, including directional motility, secretion, adhesion 
and invasion (Bacac and Stamenkovic, 2008). Accordingly, considerable effort has been 
made to determine the genes → proteins → signaling mechanisms involved in each of 
these cellular processes, with the ultimate goal to develop accurate and efficient 
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prognostic/diagnostic markers and long-lasting therapies against metastatic disease 
(Schwirzke et al., 1999; Weigelt et al., 2005).  
At present, there still remains a significant unmet need for novel anti-metastatic 
‘targets’ in various major cancers. The latter include the most common carcinomas, 
breast cancer (BCa) in women and prostate cancer (PCa) in men (Ramirez et al., 2008; 
Ventura and Merajver, 2008; Jemal et al., 2010). In this regard, an emerging and 
promising new field of investigation is centered around functional expression of 
voltage-sensitive ion channels in metastatic carcinomas (Fiske et al., 2006; Prevarskaya 
et al., 2007; Fraser and Pardo, 2008; Arcangeli et al., 2009). VGSCs in particular 
appear to be strongly associated with metastatic potential, as evinced by their high level 
expression in aggressive carcinomas and role in controlling various steps of the 
metastatic cascade (Sections 1.3.4 – 1.3.6) (Grimes et al., 1995; Roger et al., 2003; 
Fraser et al., 2005; Brackenbury et al., 2007; Gillet et al., 2009). Accordingly, VGSCs 
are becoming an exciting new class of targets for selective identification of metastatic 
potential and/or blockage of its progression (Roger et al., 2006; Onkal and Djamgoz, 
2009). In the following, we aim to (i) to introduce briefly the ‘VGSC and cancer’ field, 
with emphasis upon metastatic progression, and (ii) to reveal the specific molecular 
characteristics of VGSC expression in breast cancer that would make it a promising 
anti-metastatic target. 
 
1.3.1 The case of breast cancer 
Worldwide, BCa is the most commonly diagnosed cancer in women, with a leading 
mortality rate second only to lung cancer (Jemal et al., 2010). Similar to other 
carcinomas, BCa is a complex and heterogeneous disease, e.g. features including 
aetiology, histology, proliferation rates, metastatic aggression, sites of secondary 
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metastases and sensitivity to different treatments may vary not only between different 
patients, but also within tumors (Kirsch and Loeffler, 2005; Weigelt et al., 2005). Risk 
factors of the disease include family history, age, pregnancy- and hormone-related 
factors, dietary factors, anthropometric indices and physical activity, and environmental 
factors (e.g. radiation) (Veronesi et al. 2005; Nicolini et al., 2006). Mutations in two 
particular genes BRCA1 and BRCA2, for instance, are thought to account for the 
‘inherited’ cases of BCa, which accounts for ~ 10% of all BCa cases (Wooster et al., 
1995; Rahman and Stratton, 1998; Ingvarsson, 2004).  
Among the major diagnostic/prognostic markers for metastatic BCa tumors are: 
(1) location (i.e. epithelial vs. stromal origin and/or breast duct vs. lobule), (2) size, (3) 
lymph node status, (4) estrogen/progesterone receptor status, and (5) HER2/neu 
(encoding the epidermal growth factor receptor EGFR2) status (Menard et al., 2003; Ali 
and Coombes, 2005; Veronesi et al., 2005; Nicolini et al., 2006). Notably, BCa cells 
with invasive potential metastasize predominantly to bone, liver, lung and brain, where 
it is presumed that the local microenvironment provides chemotactic agents and growth 
factors that are favourable for secondary tumor formation (Veronesi et al., 2005). In 
particular, estrogen receptor (ER) positive tumors (~ 70% of all cases) spread 
preferentially to bone, whereas ER-negative tumors metastasize more aggressively to 
visceral organs; additional complexity is brought by the fact that the ER-status of 
tumors may change over the progression of the disease (Nicolini et al., 2006; Nyugen 
and Massague, 2007). 
 
1.3.2 Stages in metastasis 
Metastasis is a complex process involving a series of interacting steps, failure to 
complete one of which can prevent secondary tumour formation (Figure 1.10).  
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Figure 1.10 The metastatic cascade 
Transformation of normal epithelial cells results in carcinoma in situ. Reduced 
adhesiveness and enhanced migratory behaviour of tumour cells progresses the disease 
to an invasive stage. After degradation of the basement membrane, tumour cells invade 
the surrounding stroma, migrate and intravasate into lymph or blood circulation. 
Surviving cells arrest in the capillaries of a distant organ. Formation of secondary 
tumours occurs after proliferation, induction of angiogenesis and microenvironment 
activation. VGSCs have been shown in vitro to be involved in controlling various 
components of the metastatic cascade, as indicated. Modified from Bacac and 
Stamenkovic (2007). 
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Accordingly, Fidler (2003) described a ‘winner’ metastatic cell as, “…a decathlon 
champion who must be proficient in all events (steps of metastasis), rather than just a 
few”. The essential steps of metastatis can be summarized as follows (Figure 1.10) 
(Bacac and Stamenkovic, 2008): 
1. Detachment of single cells or cell aggregates from primary tumor site. Loss of 
adherent junctions occurs mainly due to reduced E-cadherin expression/function. 
Other major players include integrins and CD44, both of which bind to 
extracellular matrix (ECM) components. 
2. Local migration and invasion through basement membrane, host stroma and 
endothelium into vascular and/or lymphatic systems (i.e. intravasation). 
Membrane bound or secreted matrix metalloproteinases (MMPs) and cathepsins 
play a central role in degradation of ECM including the basement membrane.  
3. Transport in circulation. After entering vascular and/or lymphatic circulation, 
tumor cells are subject to mechanical stress and immune defences. They often 
aggregate with other cancer cells or platelets, which is thought to help their 
survival. Only a minority (~ 0.01%) of circulating tumor cells survive. 
4. Arrest in capillary beds of distant organ(s) (secondary sites) and re-attachment to 
endothelial cells and/or basement membrane. 
5. Extravasation and invasion into organ parenchyma, followed by migration to 
sites close to arterioles where cell growth is favoured. 
6. Proliferation within the organ parenchyma and formation of secondary tumors. 
Initially formed micrometastases can remain ‘dormant’ in the absence of 
angiogenesis and/or unfavourable microenvironment. 
7. Angiogenesis. In order to exceed a diameter of 0.5-1 mm, secondary metastases 
require development of a new vascular network. The initiating signal for 
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angiogenesis comes from the O2-deprived (hypoxic) tumor cells; these produce 
and secrete excess vascular endothelial growth factor (VEGF-A), which binds to 
transmembrane tyrosine kinase receptors of endothelial cells initiating vessel 
sprouting. Angiogenesis facilitates (i) tumor growth by supplying O2 and survival 
factors and removing waste products, and also (ii) re-entry of tumor cells into 
circulation to produce additional metastases.  
  
1.3.3 Metastasis – progressive or pre-programmed? 
Primary tumorigenesis and metastasis have been shown to be two distinct processes, 
each depending on a separate set of molecular/cellular determinants: the most direct 
proof of this is the existence of at least 11 metastasis suppressor genes that can inhibit 
metastasis without affecting primary tumorigenicity (e.g. histidine kinase Nm23 and 
mitogen-activated protein kinase kinase (MAPKK) MKK4) (Steeg, 2003; Welsh et al., 
2000, 2004, 2006; Berger et al., 2004; Weigelt et al., 2005; Vaidya and Welsh, 2007). 
However, conflicting theories exist as regards how and when a sup-group of primary 
tumor cells gain the ability (i.e. the molecular makeup) over others to metastasize and 
initiate formation of secondary tumors (Bacac and Stamenkovic, 2008). 
The classical ‘progression’ model proposes that a series of stochastic genetic 
events in the primary tumor endows a small subpopulation of cells with the ability to 
complete all steps of the metastasis to ultimately form tumours at a secondary site 
(Fidler and Kripke, 1977; Hunter, 2004). This model receives strong support from the 
existence of metastasis suppressor genes, and suggests (i) that it is a functional loss of 
these pro-metastatic genes that allows development of metastatic disease from an 
initially confined primary tumour, and hence (ii) that these genes present the major 
therapeutic targets for anti-cancer treatment (Shevde and Welch, 2003; Steeg, 2003). 
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Recent evidence, however, challenges the ‘progression’ model, suggesting that 
metastatic potential may be ‘pre-programmed’ in primary tumors (Bernards and 
Weinberg, 2002; Bacac and Stamenkovic, 2008). In particular, gene expression profile 
of a subset of primary adenocarcinoma tumors was found to resemble that of metastatic 
tumors, and correlated with poor clinical outcome, suggesting that metastatic potential 
is encoded within the bulk tumor tissue (Ramaswamy et al., 2003). Similarly, 
microarray expression profiling of breast carcinomas indicated that primary tumors 
without lymph node metastases (LNM) can exhibit a poor “genetic prognosis 
signature”, indicating that the metastatic phenotype already exists within the primary 
tumor (van’t Veer et al., 2002). In addition, ~ 5% of metastatic disease cases have no 
clinically detectable primary tumor, in further support of the ‘pre-programmed’ 
hypothesis (Hunter, 2004).  
A third ‘integrative’ model that reconciles the two conflicting theories of 
metastasis has also been proposed (Hynes, 2003; Bacac and Stamenkovic, 2008). Thus, 
primary tumors can be distinguished according to their metastatic potential, but rare 
subpopulations of variant cells, which are capable of forming metastases, are found 
within the primary tumors (Weigelt et al., 2005). The ‘integrative’ model encompasses 
three principles, which sufficiently explain the reasons that account for the failure to 
diagnose/treat metastasis with the current conventional methods and therapies.  
1. Tumor cells constitute a very heterogeneous population with regards to their 
metastatic potential (Fidler, 2003; Nguyen and Massague, 2007). Thus, for 
example, genes/proteins associated with different sub-processes of metastasis (e.g. 
adhesion, motility and invasion) can vary among different regions of primary 
neoplasms (Poste and Fidler, 1980; Simone et al., 1998).  
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2. During the progression of the disease, variant (metastatic) tumor cells, which 
preexist in the heterogeneous tumor population, acquire further genetic variations 
due to their high genetic instability that may result in additional changes in their 
metastatic potential (Fidler, 2002, 2003; Schmidt-Kittler, 2003; Gupta et al., 2007; 
Vecchi et al., 2007).  
3. The cross-talk between the variant, metastasizing cells and the homeostatic 
mechanisms of the surrounding microenvironment can also influence disease 
progression (Hunter, 2004). For example, hypoxia, a major tumor 
microenvironmental stress condition, has been associated with increased risk of 
metastatic dissemination in vivo (Pouyseggur et al., 2006; Bertout et al., 2008) and 
was shown to enhance invasiveness of multiple cancer lines in vitro (e.g. via 
upregulating expression/activity of various MMPs and cathepsins) (Canning et al., 
2001; Burke et al., 2003; Brat et al., 2004; Ridgway et al., 2005).  
These points reinforce the view that new therapies and prognostic markers of metastasis 
should be targeted against not only the metastatic cells but also their microenvironmet 
(Fidler, 2002).  
 
1.3.4 VGSC expression in cancer in vitro and in vivo  
Funtional VGSC expression was first detected in the Dunning rat model of prostate 
cancer (PCa): strongly metastatic Mat-LyLu cells expressed TTX-S VGSCs, whereas 
the corresponding weakly metastatic AT-2 cells did not (Grimes et al., 1995). A similar 
difference was later found between the analogous human PCa cell lines, strongly 
metastatic PC-3 and weakly metastatic LNCaP cells (Laniado et al., 1997). As regards 
BCa, TTX-R VGSCs were found in strongly metastatic MDA-MB-231 BCa cells, but 
not in weakly metastatic MCF-7 or MDA-MB-268 cell lines (Roger et al., 2003; Fraser 
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et al., 2005). Importantly, functional VGSC expression has also been detected in 
metastatic cell lines of other cancers including, lymphoma (Fraser et al., 2004), small 
cell lung cancer (SCLC) (Blandino et al., 1995; Onganer and Djamgoz, 2005; Onganer 
et al., 2005), non-small cell lung cancer (NSCLC) (Roger et al., 2007), mesothelioma 
(Fulgenzi et al., 2006), neuroblastoma (Ou et al., 2005), melanoma (Allen et al., 1997), 
cervical cancer (Diaz et al., 2007), colon cancer (House et al., 2010) and ovarian cancer 
(Gao et al., 2010) (Table 1.4). It is highly likely, therefore, that functional VGSCα 
expression / upregulation is a general property of metastatic carcinomas (Table 1.4). 
Indeed, House et al. (2010) stated that VGSC “…is a key regulator of a gene 
transcriptional network that controls cancer invasion”. 
 The predominant VGSCαs expressed in metastatic PCa and BCa were Nav1.7 
and Nav1.5, respectively, with lower expression of various other VGSCα subtypes 
(Table 1.4; Diss et al., 2001; Fraser et al., 2005). Nav1.7 mRNA was upregulated ~ 
1000-fold in strongly metastatic Mat-LyLu and PC-3 cell lines, compared with the 
corresponding weakly metastatic cells (Diss et al., 2001). Similarly, Nav1.5 mRNA was 
upregulated ~ 1800-fold in metastatic MDA-MB-231 cells, compared with MCF-7 cells 
(Table 1.4; Fraser et al, 2005). Importantly, in both Mat-LyLu and MDA-MB-231 cells, 
Nav1.7 and Nav1.5 were found primarily in their ‘neonatal’ (5’-exon 6) D1:S3 splice-
forms (Diss et al., 2001; Chioni et al., 2005; Fraser et al., 2005). In particular, exon 6 of 
‘neonatal’ Nav1.5 (nNav1.5) differs from the counterpart exon 6 of aNav1.5 by 31 of its 
92 nucleotides, resulting in 7 amino acid differences in D1:S3/S4 region (Figure 1.7 and 
Section 1.2.2) (Chioni et al., 2005). A novel nNav1.5 selective polyclonal antibody, 
NESOpAb, was used to confirm that nNav1.5 protein was also more highly expressed in 
plasma membranes of MDA-MB-231 compared with MCF-7 cells (Chioni et al., 2005; 
Fraser et al., 2005). nNav1.5 mRNA has also been found to be highly expressed in 
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Table 1.4 VGSCα expression and potentiation of metastatic cell behaviours (MCBs) in cancer cells 
 
 
Cancer (cell line) Major VGSC(s)1 MCB(s) Reference(s) 
BCa (MDA-MB-231) nNav1.5 (1800x), Nav1.6, Nav1.7 
Transwell migration, Matrigel invasion, 
lateral motility, galvanotaxis, endocytic 
membrane activity 
Fraser et al. (2005); Roger et al. (2003); Brackenbury 
et al. (2007); Gillet et al. (2009); Chioni et al. (2010) 
PCa (PC-3M, LNCaP, Mat-LyLu) nNav1.7 (1100x), Nav1.2, Nav1.3, Nav1.6 
Process extention, galvanotaxis, lateral 
motility, endocytosis; detachment, gene 
expression, Matrigel invasion 
Fraser et al. (1999, 2003); Djamgoz et al. (2001); 
Mycielska et al. (2003, 2005); Palmer et al. (2008); 
Grimes et al. (1995); Laniado et al. (1997); Bennett et 
al. (2004); Nakajima et al. (2009) 
SCLC (H69, H209, H510) TTX-R
2
, Nav1.3, Nav1.5, 
Nav1.6, Nav1.9 Endocytic membrane activity Blandino et al. (1995) ; Onganer and Djamgoz (2005)  
NSCLC (H23, H460, Calu-1) Nav1.5, Nav1.6, Nav1.7 Matrigel invasion Roger et al. (2007) 
Lymphoma (Jurkat) Nav1.5, Nav1.6, Nav1.7, Nav1.9 Matrigel invasion Fraser et al. (2004) 
Mesothelioma (MPM)  Nav1.2, Nav1.6, Nav1.7 Lateral motility Fulgenzi et al. (2006) 
Colon cancer Nav1.5 Matrigel invasion House et al. (2010) 
Ovarian cancer (Caov-3, SKOV-3) Nav1.5, Nav1.2, Nav1.4, Nav1.7 Matrigel invasion, Transwell migration Gao et al. (2010) 
Neuroblastoma (nB1) nNav1.5 ND Ou et al. (2005) 
Cervical cancer (JP, 085, 354)  Nav1.2, Nav1.7 Nav1.4, Nav1.6  ND Diaz et al. (2007) 
Melanoma  (C8161, C8146) ND ND Allen et al. (1997) 
Abbreviations: BCa, breast cancer, MCB, metastatic cell behaviour; ND, not determined; nNav1.5, neonatal Nav1.5; NSCLC, non-small cell lung cancer; PCa, prostate 
cancer; SCLC, small cell lung cancer; VGSC, voltage-gated sodium channel. 1 Pre-dominant isoforms are denoted in bold. Number in brackets indicates fold upregulation 
compared with corresponding weakly metastatic cells. 2 Predominant isoform unknown, but IC50 for TTX was 215 nM (Blandino et al., 1995).  
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human neuroblastoma cell line, nB1 (Ou et al., 2005). Occurrence of embryonic forms 
of VGSCs in cancer cells is in general agreement with “oncofoetal” gene expression 
(Ariel et al., 1997; Monk and Holding, 2001). 
In vivo, Fraser et al. (2005) detected upregulation of nNav1.5 in metastatic BCa 
biopsy samples using immunohistochemistry with the NESOpAb antibody. Fraser et al. 
(2005) also reported (i) that nNav1.5 mRNA expression in primary breast tumours 
correlated strongly with LNM, (ii) that there was no case of LNM without nNav1.5 
mRNA expression in the corresponding primary tumour, and (iii) that in 25-30% of 
cases, nNav1.5 mRNA was present without evident LNM. The latter observation raised 
the possibility that VGSC expression could be an early event in metastatic progression 
and patients of this group could develop metastases later, consistent with the 
pathobiology of VGSC expression in metastatic disease. In human PCa biopsies, real-
time PCR data revealed that Nav1.7 mRNA levels were significantly upregulated in 
metastatic carcinomas compared with normal epithelium and benign hyperplasia (Diss 
et al., 2005). Analysis of “Receiver Operator Characteristics” (ROC) suggested Nav1.7 
to have sufficient selectivity and sensitivity to be an effective marker for PCa metastasis 
(Diss et al., 2005). At protein level also, using tissue microarrays, Abdul and Hoosein 
(2002a) showed upregulation of VGSC expression in a subset of human PCa biopsies. 
Upregulation of VGSCs was also found in SCLC biopsies using immunohistochemistry 
with a pan-VGSC antibody (Onganer et al., 2005). Also, multiple VGSCα isoforms 
(Nav1.2, 1.4, 1.6, 1.7) have been identified both in primary cultures and biopsy samples 
of cervical cancer (CaC) (Diaz et al., 2007). More recently, (i) real-time PCR showed 
Nav1.5 and Nav1.4 expression to be upregulated in cancerous vs. normal ovarian tissue, 
and (ii) immunohistochemistry showed VGSC expression to correlate with grade and 
metastatis of ovarian cancer (Gao et al., 2010). Similarly, immunohistochemistry of 
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patient biopsies revealed strong Nav1.5 protein staining in colon cancer specimens but 
not in matched-paired normal colon tissues (House et al., 2010). 
 
1.3.5 Cellular excitability (CELEX) hypothesis of metastasis 
Where examined, the VGSC upregulation in metastatic cells/tissues was found to be 
accompanied by concomitant down-regulation of VGPC expression and/or activity in 
vitro and/or in vivo, as in BCa (Fraser et al., 2005), NSCLC (Roger et al., 2007), rat 
PCa (Grimes et al., 1995; Fraser et al., 2003), and human PCa (Laniado et al., 2001; 
Abdul and Hoosein, 2002b; Ohya et al., 2009). This is illustrated for human BCa cells 
in Figure 1.11. Thus, the outward (VGPC) current is down-regulated in parallel with 
increased metastatic potential, the inward (VGSC) current appearing only in the 
strongly metastatic MDA-MB-231 cells where very little outward current is observed. It 
would follow from such pairing of channel activities that the reduced VGPC activity 
would depolarize the resting membrane potential, as observed, favouring VGSC 
‘activation’ (Onganer and Djamgoz, 2005; Fraser et al., 2005; Prevarskaya et al., 2007). 
These observations have led to the proposal of the “cellular excitability” (CELEX) 
hypothesis of cancer metastasis (Djamgoz and Isbilen, 2006), which agrees favorably 
with the well-evidenced ‘neuronal’ phenotype of aggressive cancer cells (Liotta and 
Clair, 2000; Onganer and Djamgoz, 2005; Hagel and Stavrou, 2007; Brackenbury et al., 
2008). Accordingly, metastatic cell membranes are potentially ‘excitable’, in line with 
their hyperactive behaviour (Hoang et al., 2007ab). Indeed, APs have been recorded 
from strongly metastatic cell lines, e.g. H146 small cell lung cancer cells (Blandino et 
al., 1995) and MDA-MB-231 BCa cells (R. Onkal and M.B.A. Djamgoz, unpublished 
observations).   
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Figure 1.11 Voltage-activated whole-cell membrane currents recorded from 
human BCa cell lines of varying metastatic potential 
Recordings from a human breast epithelial cell line (MCF-10A) and BCa cells with 
increasing metastatic potential are shown. The currents were generated by pulsing the 
membrane potential from a holding voltage of -100 mV, in 5 mV steps, from -60 to 
+60 mV for 200 ms. Voltage pulses were applied with a repeat interval of 20 seconds. 
For clarity, every second current trace generated is displayed. Inward and outward 
currents were carried by VGSCs and VGPCs, i.e. they were eliminated by external 
TTX and internal Cs+ application, respectively. With increasing metastatic potential, 
outward (K+) currents are reduced, and inward (Na+) currents appear only in the 
strongly metastatic MDA-MB-231 cells. Data from Fraser et al. (2005) and S. P. 
Fraser, unpublished observations. 
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1.3.6 VGSC involvement in metastatic cell behaviour 
There is substantial evidence, obtained using various independent techniques, for 
VGSC-mediated control (enhancement) of a range of metastatic cell behaviours 
(MCBs), as follows (Table 1.4): 
 
1.3.6.1 Tetrodotoxin 
The highly selective VGSC blocker, tetrodotoxin (TTX), suppressed various in vitro 
MCBs in human and rodent cell lines of breast, prostate, lung, colon and ovarian 
cancers. These VGSC-potentiated cellular behaviours included invasion (Grimes et al., 
1995; Laniado et al., 1997; Smith et al., 1998; Roger et al., 2003; Bennett et al., 2004; 
Brackenbury et al., 2007; Gillet et al., 2009; Chioni et al., 2010; Gao et al., 2010; 
House et al., 2010), colony formation in Matrigel composed 3-D matrices (Gillet et al., 
2009), cell morphology and process extension (Fraser et al., 1999), galvanotaxis 
(Djamgoz et al., 2001; Fraser et al., 2005), lateral motility (Fraser et al., 2003), 
transverse (“Transwell”) migration (Roger et al., 2003; Fraser et al., 2005; Brackenbury 
and Djamgoz, 2006; Chioni et al., 2010; Gao et al., 2010), adhesion (Palmer et al., 
2008; Chioni et al., 2009), gene expression (Mycielska et al., 2005; House et al., 2010), 
endocytic membrane activity (Mycielska et al., 2003; Onganer and Djamgoz, 2005; 
Nakajima et al., 2009), vesicular patterning (Krasowska et al., 2004), and nitric oxide 
production (Williams and Djamgoz, 2005). Comparable experiments showed that TTX 
had no effect on weakly metastatic cell lines, consistent with the absence of functional 
VGSCs in these cells. Interestingly, proliferation of metastatic PCa, BCa and ovarian 
cancer cells was not affected by TTX (Fraser et al., 2003, 2005; Gao et al., 2010), 
implying that VGSCs are involved mainly in metastatic progression, rather than in 
primary tumourigenesis. This is a clear example of primary and secondary 
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tumourigenesis being governed by separate sets of molecular determinants (Welch, 
2004, 2006). Another example can be seen in rat PCa cell lines, where functional VGPC 
(Kv1.3) expression is upregulated and controls proliferation only in weakly metastatic 
AT-2 cells (Fraser et al., 2003). In contrast, Kv1.3 is downregulated in metastatic Mat-
LyLu cells and plays no role in proliferation; instead VGPCs are reduced more to 
promote VGSC activity, as proposed by the CELEX hypothesis (Section 1.3.5).  
 
1.3.6.2 Gene silencing 
Downregulating specifically functional nNav1.5 expression using small interfering 
RNAs (siRNA) suppressed VGSC-dependent migration and invasion in MDA-MB-231 
human BCa cells in vitro (Brackenbury et al., 2007). Comparable results were obtained 
in a separate study (Gillet et al., 2009). Similarly, inhibition of VGSC activity with 
siRNAs specific for Nav1.5 suppressed the invasive potential of colon cancer cells in 
vitro (House et al., 2010). Moreover, in PC-3 human metastatic PCa cells, siRNA 
targeting the pre-dominant VGSCαs, Nav1.7 (SCN9A) and Nav1.6 (SCN8A), inhibited 
endocytosis and invasiveness (Nakajima et al., 2009). Nakajima et al. (2009) also 
reported that suppression of VGSC activity by RNAi failed to affect proliferation in PC-
3 cells, again consistent with the lack of effect of TTX in primary tumourigenesis 
(Fraser et al., 2003, 2005). These results further support the notion that the mechanisms 
controlling primary and secondary tumour formation are different. Another aspect of 
VGSC expression that emerged from the siRNA work on BCa is that silencing nNav1.5 
protein level by only ~ 30% was sufficient to eliminate its role in promoting 
invasiveness, i.e. in ‘all-or-none’ fashion (Brackenbury et al., 2007). This raised the 
possibility that functional VGSC expression acts like a ‘switch’ promoting metastatic 
behaviour to a higher gear.  
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1.3.6.3 Transfection studies 
Over-expression of Nav1.4 in a weakly metastatic human PCa cell line (LNCaP) 
significantly increased invasion and this effect was reversed by TTX (Bennett et al., 
2004). Hence, Bennett et al. (2004) suggested that VGSC activity is “necessary and 
sufficient” for the invasive behavior of PCa cells. An important implication of this study 
was that the identity of the VGSCα subtype expressed in cancer cells may not be 
relevant. Thus, although the ‘culprit’ VGSCα expressed in metastatic human PCa cells 
is Nav1.7, over-expression of Nav1.4 was adequate to enhance invasiveness. This raises 
the important question of whether the subtype of VGSC expressed is important to 
invasiveness or whether any VGSC (e.g. simply to allow Na+ influx into cells) would 
suffice. In the case of the latter possibility, expression of the different VGSC subtypes 
in different cancers would just be a matter of tissue origin (given the basic tissue-
specific distribution of VGSC subtypes), rather than a strict functional 
(pathophysiological) prerequisite. However, further studies are required to address this 
intriguing question. 
 
1.3.6.4 Other pharmaceutical agents 
Experiments involving mainstream small-molecule VGSC blockers and openers also 
suggested a role for VGSCs in the metastatic process, despite possible non-specific 
side-effects of such pharmacological agents. Local anaesthetic lidocaine and 
anticonvulsant phenytoin both inhibited the VGSC-dependent enhancement of 
endocytic membrane activity in SCLC cell lines (Onganer and Djamgoz, 2005). 
Phenytoin also significantly reduced the lateral motility of Mat-LyLu rat PCa cells 
(Fraser et al., 2003; Sikes et al., 2003). Eicosapentaenoic acid (EPA), an omega-3 
polyunsaturated fatty acid and a known blocker of VGSC activity, reduced mRNA and 
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functional protein levels of Nav1.6 and Nav1.7, and suppressed VGSC-dependent 
invasion and endocytosis in human and rat PCa (PC-3 and Mat-LyLu) cell lines 
(Nakajima et al., 2009). Similarly, docosahexaenoic acid (DHA), an EPA derivative, 
blocked VGSC (mainly Nav1.5) activity and VGSC-dependent migration in MDA-MB-
231 human BCa cells (Isbilen et al., 2006). On the other hand, VGSC openers promoted 
MCBs; veratridine enhanced galvanotaxis, whilst aconitine and anemone toxin (ATX-
II) increased motility of Mat-LyLu cells (Djamgoz et al., 2001; Fraser et al., 2003). 
However, the effects of the ‘openers’ were minimal, consistent with the view that 
VGSCs, when functionally expressed, already make a ‘maximal’ contribution to 
enhancement of MCBs, i.e. in all-or-none (‘switching’) fashion (Section 1.3.6.2).    
 
1.3.7 Association of VGSC activity with ‘mainstream’ cancer mechanisms 
Mechanism(s) regulating VGSC expression in metastatic cancer cells are relatively 
poorly understood. Since prostate and breast cancers are both highly hormone sensitive, 
a starting point in elucidating the regulatory mechanisms would be serum factors. 
Indeed, such factors have been shown to affect VGSC expression and activity in 
strongly metastatic rat prostate cancer Mat-LyLu cells (Ding and Djamgoz, 2004). As 
regards steroid hormones, it is already apparent from cells’ resting state that there is a 
direct association with hormone sensitivity and VGSC expression. Thus, strongly 
metastatic PC-3M and MBA-MB-231 cells are both devoid of classic receptors for 
androgen and estrogen, respectively, and both express functional VGSCs. The converse 
is also true for corresponding hormone-sensitive, weakly/non-metastatic cells that do 
not express functional VGSCs. Interestingly, steroid hormones can have non-
transcriptional (non-genomic) roles (Leung et al., 2007; Prossnitz et al., 2008), and such 
an effect was recently demonstrated for the potentiating action of estrogen on VGSC 
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activity in MBA-MD-231 cells, involving GPR30 as a cell-surface receptor and 
decreased adhesion as a functional output (Fraser et al., 2010). Moreover, when cancer 
cells become hormone insensitive, they frequently become dependent on growth factors 
(Santen et al., 2005, 2008), which are well-known modulators of VGSC 
expression/function. In particular, epidermal growth factor (EGF) increased VGSC 
activity and enhanced migration of Mat-LyLu cells (Ding et al., 2008). Similarly, in the 
strongly metastatic human PC-3M cells, EGF enhanced migration, endocytosis and 
invasion via mainly functional Nav1.7 upregulation (Onganer and Djamgoz, 2007). 
Although nerve growth factor (NGF) also upregulated functional VGSC density in 
plasma membrane of Mat-Ly-Lu cells, via PKA activity, there was no subsequent effect 
on cellular migration (Brackenbury and Djamgoz, 2007). These results suggested that 
there are multiple growth factors regulating VGSCs in cancer cells and that the latter 
may be ‘compartmentilised’ subcellularly such that different VGSC pools control 
different MCBs.    
Interestingly, VGSC expression may also be under activity-dependent 
regulation. For example, in Mat-LyLu rat PCa cells, activity-dependent regulation kept 
Nav1.7 expression upregulated via a positive feedback mechanism involving both 
increased SCN9A transcription and PKA-mediated VGSC protein trafficking to plasma 
membrane (Brackenbury and Djamgoz, 2006). A similar positive auto-regulatory loop 
was also reported for functional VGSC (nNav1.5) expression in MDA-MB-231 
metastatic human BCa cells (Chioni et al., 2010). Autoregulation of VGSCs by positive 
feedback is unusual and would imply that blocking VGSC activity would lead to 
suppression of functional VGSC activity and expression in both short and long term. 
Such a characteristic would add to VGSCs being an ideal target for inducing regression 
as well as suppression of metastasis. 
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VGSC β-subunits specifically are also associated with mainstream cancer 
mechanisms (Brackenbury et al., 2008). Thus, upregulation of β3 in mouse fibroblasts 
and human cancer cell lines was shown to be dependent on p53, a major tumour 
suppressor (Adachi et al., 2004). VGSCβ3 is conspicuous by its absence in PCa (Diss et 
al., 2008) and BCa cells (Chioni et al., 2009), i.e. the absence of β3 expression may be 
an indicator of oncogenesis (Brackenbury et al., 2008). As regards hormonal control, 
VGSCβ1 expression was found to be downregulated following treatment with an 
androgen analogue (Diss et al., 2008). Interestingly, VGSCβ1 has been suggested to 
function as a CAM in human BCa (see Section 1.3.8.2; Chioni et al., 2009), and results 
indicated that the interaction between cell adhesion and VGSC activity may be 
reciprocal, whereby VGSCα expression is upregulated transcriptionally when BCa cells 
are in a state of weak adhesion (Brackenbury et al., 2008; Chioni et al., 2009). 
In overall conclusion, VGSC expression in carcinomas is not an isolated 
phenomenon but a part of the overall cancer process in close association with the 
mainstream mechanisms.  
 
1.3.8. Mechanism(s) of VGSC activity in the control of metastatic cell behaviours 
Overall, there are two main possible mechanisms through which VGSC activity, non-
exclusively, may enhance MCBs, as follows: 
 
1.3.8.1 Conductance (Na+ influx) mechanisms 
Most simply, Na+ influx through VGSC may be responsible for the enhancement of 
MCBs. In MDA-MB-231 BCa cell line, analysis of INa activation/inactivation curves 
revealed a small ‘window current’ between potentials -60 and -30 mV, which would 
imply that INa was tonically active around the resting membrane potential of these cells 
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(~ -40-60 mV; Roger et al., 2003; Fraser et al., 2005). Similar results were obtained in 
H460 non-small cell lung cancer cell line and using a Na+-specific fluorescent probe 
(SBFI), H460 cells were shown to have a significantly larger (~ 2-fold) intracellular 
sodium concentration ([Na+]i) compared to the normal NL-20 cells (Roger et al., 2007). 
This also agrees with the maintained increase in the sodium content of malignant BCa 
tissue in vivo (Ouwerkerk et al., 2007). Furthermore, inhibition of various basal MCBs 
by the pore-blocker TTX strongly suggests that a percentage of VGSCs are tonically 
active (i.e. open) at any given time in ‘resting’ metastatic cancer cells. The ‘Na+ influx’ 
hypothesis receives further support from a recent study by Gillet et al. (2009), who 
showed that (i) reduction of Na+ concentration in the culture medium decreases whilst 
(ii) veratridine, a VGSC ‘opener’ (i.e. giving larger Na+ influx), enhances invasiveness 
of MDA-MB-231 cells. On the other hand, the major criticism of the ‘Na+ influx’ 
hypothesis is that the transient INa through VGSCs may have negligible effect on the 
global [Na+]i in these cells and any downstream effect is not likely. Nonetheless, 
generation of local Na+ gradients cannot be ruled out (e.g. Nikolaeva et al., 2005; 
Bennay et al., 2008). Indeed, VGSC activity-dependent local changes in [Na+]i has 
recently been demonstrated by fluorescence imaging with Na+-indicator dyes (e.g. 
Medvedeva et al., 2009). Furthermore, tumour cells experience moderate (~ 3% O2) to 
severe (< 0.5% O2) hypoxia in vivo, a condition which has been shown to significantly 
upregulate the ‘persistent’ component of INa (INaP) (Ju et al., 1996; Hammarstrom and 
Gage, 2000, 2002; Saint, 2008). As described earlier (Section 1.1.7), unlike the rapid 
and complete inactivation of the ‘transient’ INa (within few milliseconds), INaP is 
resistant to inactivation for seconds (at depolarized potentials), and consequently, can 
cause significant increase in global [Na+]i levels (Xiao and Allen, 1999; Saint, 2006; O’ 
Rourke and Maack, 2007). 
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Whether local or global, any change in [Na+]i due to VGSC activity may alter 
membrane potential, Ca2+ homeostasis (e.g. via Na+/Ca2+ exchanger), pH balance (e.g. 
via Na+/H+ exchanger), and activity of Na+-dependent enzymes (e.g. PKA, cathepsins) 
in metastatic tumour cells, potentially resulting in the enhancement of various MCBs. 
For example, VGSC (Nav1.5) activity was shown to acidify the ‘perimembrane’ pH, 
thus enhancing the proteolytic activity of secreted cysteine cathepsins towards the 
surrounding extracellular matrix, ultimately resulting in the invasive phenotype of 
MDA-MB-231 BCa cells (Gillet et al., 2009). Similarly, in macrophages, VGSCs 
(predominantly Nav1.5 and Nav1.6) were shown to regulate intraendosomal pH levels, 
thereby modulating phagocytosis (Carrithers et al., 2007; 2009). Furthermore, 
alterations of ion homeostasis (Na+, Ca2+ and H+) could subsequently activate key 
kinases (e.g. PKA, PKC, CaMK), which can in turn modulate the actin cytoskeleton 
thereby enhancing vesicular transport, secretion, migration, and invasion in metastatic 
breast and prostate cancer cells (Djamgoz et al., 2001; Mycielska and Djamgoz, 2004; 
Roger et al., 2003, 2006, Brackenbury et al., 2007).  
 
1.3.8.2 Non-conductance mechanisms 
Alternatively, the role of VGSCs in metastasis could involve a ‘non-conducting’ 
function via direct interactions of VGSCαs or VGSCβs with other plasma membrane 
and/or intracellular proteins (Diss et al., 2004; Kaczmarek, 2006; Shao et al., 2009). For 
instance, VGSC β1 and β2 has been shown to associate with tenascin-C and tenascin-R 
(thereby influencing cell migration) and participate in homophilic cell adhesion, 
resulting in cellular aggregation and ankyrin recruitment (Brackenbury et al., 2008). 
Importantly, VGSCβs (β1, β2 and β4) are expressed in human BCa cell lines, where β1 
mRNA and protein levels are significantly higher in the weakly metastatic MCF-7 cell 
 Chapter 1                                                                                                         General Introduction  
 
 107 
line compared to the highly metastatic MDA-MB-231 cells, consistent with the higher 
adhesiveness of MCF-7 cells (Palmer et al., 2008; Chioni et al., 2009). Chioni et al. 
(2009) also showed that down-regulation of VGSCβ1 with siRNA increased migration 
(via reduced adhesion) of weakly metastatic MCF-7 human BCa cells. Furthermore, 
stable over-expression of β1 in MDA-MB-231 cells concomitantly upregulated INa, yet 
reduced cellular motility, suggesting that the cell adhesive effects of β1 may be 
independent of changes in cellular excitability (Chioni et al., 2009). This supports the 
notion that VGSCβs can function autonomously as CAMs, independent of the ion-
conducting VGSCαs (Isom, 2002). In addition, in human PCa cells, VGSCβs are more 
highly expressed in strongly metastatic PC-3 cell line relative to the weakly metastatic 
LNCaP cells, implying that VGSCβs can serve different functions in different cells 
(Diss et al., 2008). Further work is required to elucidate the non-conducting role of 
VGSCs and the functional significance of VGSCβ expression in metastasis. These 
would be worthwhile studies since VGSCβs are themselves a drug target (Brackenbury 
et al., 2008).  
 
1.3.9 Neonatal Nav1.5 expression in metastatic BCa 
As noted earlier (Section 1.3.4), VGSC (nNav1.5) expression in metastatic BCa cells 
and tissues is oncofoetal and this provides the channel with significant advantages as a 
novel anti-BCa target, as follows (Table 1.5):  
1. nNav1.5 differs from its adult counterpart (aNav1.5) at 31 out of 92 nucleotides, 
resulting in 7 amino acid changes in the D1:S3/S4 region (Figure 1.7 and Section 
1.2.2) (Gellens et al., 1992; Fraser et al., 2005; Schroeter et al., 2010). BLAST 
analysis revealed that the amino acid sequence in the spliced region of nNav1.5 is 
unique in the human genome.  
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Table 1.5 Characteristics of nNav1.5 expression that would make it an ideal 
target for clinical management of metastatic BCa 
 
 The cellular nNav1.5 mRNA expression is up-regulated by ~ 1800-fold in strongly 
metastatic cells compared with weakly metastatic cells grown in culture, also in vivo 
 The mRNA upregulation in accompanied by increased protein and signal levels 
 nNav1.5 expression/activity enhances metastatic cell behaviours in vitro and correlates 
positively with BCa lymph node metastasis in vivo 
 nNav1.5 in BCa differs from its nearest counterpart (aNav1.5 - cardiac VGSCα) by 7 
amino acids 
 As judged by sensitivity to a specific antibody, nNav1.5 has significant structural 
difference from aNav1.5 
 nNav1.5 expression is confined to metastatic BCa and is absent in non-CNS adult 
human tissues 
 nNav1.5 in BCa is potentially targetable by (i) a monoclonal antibody, (ii) RNAi, (iii) 
small-molecule blockers of VGSCs (anticonvulsants, antiarrhythmics and local 
anaesthetics) and/or (iv) natural neurotoxins 
 VGSC expression in cancer is under control of activity dependent regulation by positive 
feedback whereby ‘short-term’ blocking of nNav1.5 activity may shut down the channel 
irreversibly in the ‘long-term’ 
 
Abbreviations: aNav1.5, adult Nav1.5; BCa, breast cancer; CNS, central nervous system; mRNA, 
messenger RNA; nNav1.5, neonatal Nav1.5; RNAi, RNA interference; VGSCα, voltage-gated 
sodium channel α-subunit. 
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2. The stretch of the 6 (out of 7) amino acid differences between aNav1.5 and 
nNav1.5 was exploited to produce a polyclonal antibody (NESOpAb) that 
selectively recognized an extracellular epitope (i.e. D1:S3/S4 linker; applicable to 
living cells) in the nNav1.5 channel (Chioni et al., 2005).  
3. In electrophysiological recordings, NESOpAb blocked nNav1.5 activity with high 
efficiency and ~ x400 more selectively compared to aNav1.5 (Chioni et al., 2005). 
Consistent with the electrophysiology, NESOpAb suppressed in vitro migration 
and invasion of metastatic BCa cells (Brackenbury et al., 2007). This also 
confirmed the specific involvement of nNav1.5 in BCa invasiveness, as shown 
independently by the siRNA experiments (Section 1.3.6.2; Brackenbury et al., 
2007). 
4. In vivo, strong immunohistochemincal staining with NESOpAb was detected only 
in human BCa tissues, but not in normal breast tissue (Fraser et al., 2005). These 
results complemented mRNA-based correlation of nNav1.5 expression in primary 
tumours and LNM (Fraser et al., 2005). The expression pattern was compatible 
with functional VGSC (nNav1.5) expression being an early event in metastasis. 
5. Wang J et al. (2008) showed that nNav1.5 mRNA expression in normal adults is 
confined to CNS, similar to findings in mouse (Chioni et al., 2005). In addition, in 
preliminary studies, immunohistochemistry with NESOpAb was employed to 
demonstrate that nNav1.5 protein is not expressed in a range of human tissues 
(post-mortem or biopsy), including skeletal muscle, oesophagus, small intestine, 
colon, stomach, bladder and prostate (R. Fahrioglu, H. Kaya and M.B.A. 
Djamgoz, unpublished observations). Therefore, given the blood-brain barrier, the 
only reachable target for a fully nNav1.5-selective drug or antibody could be the 
metastatic BCa cell in the adult patient’s body. 
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Taken together, therefore, nNav1.5 mRNA and/or protein expression can be exploited 
clinically as an early marker of metastatic breast cancer. Furthermore, since nNav1.5 
could make a significant functional contribution to metastatic progression, this target 
also has therapeutic potential (Roger et al., 2006; Onkal and Djamgoz, 2009).  
 
1.4 Pharmacology of VGSCs: selective targeting of nNav1.5 in metastatic BCa 
Several different classes of VGSC inhibitors can be considered for selective targeting of 
nNav1.5 in metastatic BCa, as follows. For each class of VGSC blockers described, first 
a general overview is given followed by a focused discussion as regards the 
pharmacological separation of nNav1.5 from aNav1.5.  
 
1.4.1 Small-molecule pharmaceuticals 
Small-molecular-weight pharmaceuticals, including anticonvulsants, antiarrhythmics, 
and local anaesthetics, constitute the main class of VGSC inhibitors in clinical use 
against pathologies such as cardiac arrhythmias, neuropathic pain and epilepsy 
(Catterall, 2000; Clare, 2010). Small-molecule drugs typically bind to VGSCαs in a 1:1 
fashion, inhibiting Na+ conductance (Nau and Wang, 2004). This may occur via (i) 
physical occlusion of the pore by the drug molecule, preventing ion flow, and/or (ii) 
accumulation of non-conducting channels upon drug binding due to stabilization of 
inactivated states and/or gating charge immobilization (Hille, 2001; Sheets and Hanck, 
2003; England, 2008; Hanck et al., 2009). Regarding physical block, molecular 
modelling studies revealed that most local anaesthetics and related small-molecule 
pharmaceuticals do not carry sufficient space-filling bulk to produce complete pore 
occlusion (Lipkind and Fozzard, 2005). Alternatively, it was suggested that the tertiary 
amine group found in most small-molecule blockers (Figure 1.12A), which is  
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Figure 1.12 Small-molecule pharmaceuticals bind to conserved S6 sites in VGSCαs 
(A) Local anaesthetics and other chemically related agents typically contain (i) a positively 
charged nitrogen moiety that interacts with Phe1760 in D4:S6 and Leu1462 in D3:S6 (Nav1.5 
numbering), and (ii) an aromatic group that interacts with Tyr1767 in D4:S6 and Asn406 in D1:S6 
(Lipkind and Fozzard, 2005). Modified from Mantegazza et al. (2010). See Figure 1.13 for 
chemical structures of the inhibitors used in the present study. (B) Comparison of the inner-pore 
S6 residues between human VGSCα subtypes. Conserved residues are in black, conservative 
differences are in grey, and non-conservative differences are in white. Red arrows indicate 
Asn406, Leu1462, Phe1760 and Tyr1767, which form the core ‘binding pocket’ for VGSC blockers; 
black arrows indicate the other implicated sites affecting drug binding. Modified from Clare 
(2010). 
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predominantly charged at physiological pH, binds to a site just intracellular to the 
channel selectivity filter, introducing extra positive charge in this region (McNulty et 
al., 2007). Such ‘electrostatic’ resistance to Na+ influx together with any ‘steric’ 
hindrance to ion flow by the presence of the drug molecule was concluded to be the 
basis of current block by local anaesthetics and other chemically related compounds 
including anticonvulsants and antiarrythmics (Lipkind and Fozzard, 2005; McNulty et 
al., 2007; Scheuer, 2007).  
Mutagenesis experiments revealed that, despite large differences in drug 
structures, local anaesthetics / antiarrhythmics (e.g. lidocaine, etidocaine) and 
anticonvulsants (e.g. phenytoin, lamotrigine) interact with a common binding site 
located within the inner-pore of various VGSCαs tested (Figure 1.12A and 1.13; 
Catterall, 2000). The core of this ‘drug pocket’ is formed by four S6 residues in D1, D2 
and D4, which correspond in Nav1.5 to Asn406 (D1), Leu1462 (D3), and Phe1760 and 
Tyr1767 (D4) (Figure 1.12A; Ragsdale et al., 1994; 1996; Wang et al., 1998; Yarov-
Yarovoy et al., 2001; 2002; Liu et al., 2003; Nau and Wang, 2004; Fredj et al., 2006; 
McNulty et al., 2007; Browne et al., 2009). Mutagenesis studies have also identified 
several other S6 residues that may modulate the interaction of small-molecule 
inhibitors with VGSCαs, including Ile397 and Leu409 in D1 (Ragsdale et al., 1994; 
Wang et al., 1998; Browne et al., 2009), Asn1463 and Ile1466 in D3 (Ragsdale et al., 
1994; Yaroy-Yarovoy et al., 2001), and, Ile1756, Ile1757, Val1763 and Asn1765 in D4 
(Figure 1.12B; Ragsdale et al., 1994). Importantly, the relative significance of these 
residues for drug-block varied for different pharmaceuticals and/or VGSCαs tested, 
indicating that the receptor sites for small-molecule inhibitors may be overlapping but 
not identical (Scholz, 2002). 
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Figure 1.13 Small-molecule VGSC inhibitors used in the present study 
Structures, chemical formulae and therapeutic application according to NCBI PubChem 
database. All drugs contain a hydrophilic nitrogen moiety and al least one hydrophobic aromatic 
group: (A) local anaesthetic and antiarrhythmic lidocaine (C14H22N2O); (B) anticonvulsant and 
antiarrhythmic phenytoin (C15H12N2O2); (C) antiarrhythmic mexiletine (C11H17NO); (D) local 
anaesthetic procaine (C13H20N2O2); (E) anti-anginal ranolazine (C24H33N3O4); (F) anticonvulsant 
riluzole (C8H5F3N2OS). 
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Consistent with their ‘inner-pore’ locations, all of abovementioned amino acid 
residues that are implicated in drug-block are completely conserved among VGSCαs 
(except Ile1466 which is a Val in Nav1.8); even the neighbouring amino acids in S6 
segments of each domain are largely similar (Figure 1.12B; Clare, 2010). Accordingly, 
standard small-molecule VGSC inhibitors exhibit low-degree subtype-selectivity, 
which, at first sight, suggests that their clinical use could result in serious side-effects 
(England, 2008). Nevertheless, this class of drugs can selectively inhibit VGSC activity 
in neurons and cardiomyocytes with (i) abnormally depolarized resting potentials and 
(ii) rapid action AP firing rates, characteristic of a range of cardiac and neuronal 
pathologies (Clare, 2010; Mantegazza et al., 2010). As regards (i), local anaesthetics, 
antiarrhythmics and anticonvulsants typically have higher affinity for the open / 
inactivated vs. resting conformation of VGSCs, i.e. drug binding is state-dependent 
(Ragsdale et al., 1991, 1996). Consequently, block by these agents is voltage-
dependent such that the extent of block becomes greater at more depolarized resting 
potentials where a larger fraction of the channel population exists in their ‘higher-
affinity’ inactivated conformation (Hille, 2001). As regards (ii), state-dependence of 
drug binding dictates that drug block is also use (frequency)-dependent, i.e. 
proportional to VGSC activity. Thus, association of the drug molecules to open and 
inactivated states upon VGSC activation combined with relatively slow drug 
dissociation from these ‘higher-affinity’ states accumulates drug-bound channels 
during episodes of high-frequency channel activity (Ragsdale et al., 1991; Hille, 2001).  
State-dependence of block by small-molecule drugs was explained by the 
‘modulated receptor hypothesis’ (Hille, 1977), which suggests that the drug receptor on 
VGSCs is in a low-affinity conformation in channels at resting hyperpolarized 
voltages, and switches to a high-affinity state at more depolarized voltages at which the 
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channels are open / inactivated (Ragsdale et al., 1996; Hille, 2001). Sheets and Hanck 
(2007) showed that stabilizing the S4 segments in D3 and D4 in their outward (open / 
inactivated) conformations would lock Nav1.5 channels into a high-affinity state for 
lidocaine, essentially verifying the modulated receptor hypothesis.  
Apart from conferring efficacy in the clinic, state-dependence of block suggests 
that VGSCαs with different biophysical characteristics (e.g. voltage-dependence of 
steady-state inactivation) may exhibit differing sensitivities to small-molecule blockers 
even if there are no intrinsic differences in the drug receptor site per se (Ragsdale et al., 
1994, 1996; Hille, 2001). Leffler et al. (2007) showed that, at a depolarized holding 
potential of -80 mV, tonic block by lidocaine was 5-fold and tricyclic antidepressant 
amitriptyline 8-fold more potent in TTX-S channels (Nav1.1, Nav1.6 and Nav1.7) than 
Nav1.8 in ND7/23 cells. The higher potency of lidocaine and amitriptyline for TTX-S 
VGSCs was explained by the significantly hyperpolarized voltage-dependence of 
steady-state inactivation in these channels compared to Nav1.8, i.e. higher percentage 
of TTX-S channels resided in the high-affinity inactivated states when the cells were 
held at -80 mV. Conversely, use-dependent block by lidocaine was greater for Nav1.8 
vs. Nav1.7 expressed in Xenopus oocytes (Chevrier et al., 2004), Nav1.8 vs. TTX-S 
channels expressed in ND7/23 cells (Leffler et al., 2007), and TTX-R vs. TTX-S 
channels expressed in native DRG neurons (Roy and Narahashi, 1992). Such subtype-
selectivity was explained by the higher tendency of Nav1.8 / TTX-R channels to enter 
high-affinity slow inactivated states upon high-frequency stimulation (Leffler et al., 
2007). Similar ‘gating-dependent’ but ‘binding-site independent’ differences in drug 
block have also been reported for other VGSCαs including Nav1.5 vs. Nav1.4 (Nuss et 
al., 1995; 2000; Wang et al., 1996; Wright et al., 1997) and Nav1.5 vs. Nav1.2 (Weiser 
et al., 1999). 
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Interestingly, a number of studies have also found significant differences in the 
interaction of various small-molecule pharmaceuticals with neonatal vs. adult VGSCs 
in various tissues including Nav1.5-expressing cardiac muscle (e.g. Galper and 
Catterall, 1978; Hering et al., 1983; Morikawa and Rosen, 1984; Yabek et al., 1987; 
Spinelli et al., 1988; Jeck and Rosen, 1990; Xu et al., 1991, 1992; Diaz et al., 1998; 
Ribeiro and Costa, 2003; Castillo et al., 2003). Of particular importance to the present 
study, VGSC currents in neonatal (1-2 day old) rat cardiomyocytes were more sensitive 
to tonic and use-dependent block by phenytoin compared to adult cardiomyocytes (Xu 
et al., 1991). Similar results were also obtained with the antiarrythmics mexiletine and 
lidocaine in neonatal vs. adult rat, canine and rabbit cardiomyocytes (Hering et al., 
1983; Jeck and Rosen, 1990; Xu et al., 1992; Wu et al., 1993). The greater sensitivity 
of neonatal VGSCs to phenytoin and lidocaine were explained by their relatively 
hyperpolarized steady-state inactivation, slower recovery from inactivation, and higher 
tendency to enter slow inactivated states (Xu et al., 1991, 1992). Overall, these results 
(i) are suggestive of significant developmental changes in Nav1.5 electrophysiology / 
pharmacology (which may involve differences between nNav1.5 vs. aNav1.5), and (ii) 
further illustrate that electrophysiological differences may result in subtype-selective 
actions of small-molecule pharmaceuticals even if there is no change in the binding 
site. However, regarding (i) above, one needs to be cautious for the following reasons: 
a) Multiple VGSCα isoforms in addition to Nav1.5 (including Nav1.1-1.4 and 
Nav1.6) are functionally expressed in cardiac myocytes contributing to the total 
Na+ conductance (Maier et al., 2004; Kaufmann et al., 2010). 
b) Developmental changes in VGSCα phosphorylation, glycosylation and/or 
interaction with accessory proteins (e.g. VGSCβs) may have also contributed 
the reported electrophysiological / pharmacological differences (Makielski et 
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al., 1996; Yang and Roden, 1996; Stocker and Bennett, 2006; David et al., 
2008; Abriel, 2009).  
c) Despite the demonstration of abundant nNav1.5 protein expression in neonatal 
mice cardiomyocytes (Chioni et al., 2005), whether nNav1.5 functionally 
contributed to the Na+ currents recorded by Xu et al. (1991 and 1992) in 
neonatal rat cardiomyocytes is not known.  
Overall, therefore, although published evidence suggests that nNav1.5 and aNav1.5 
may have differing sensitivities to various small-molecule drugs, accurate comparison 
of nNav1.5 vs. aNav1.5 in this regard would require ‘isolated’ characterization by 
heterologous expression. This is among the objectives of the present study (Chapter 5).  
 
1.4.2 Neurotoxins  
Natural neurotoxins from spider, scorpion and cone snail venoms are highly potent 
modulators of voltage-gated ion channels including VGSCs (Cestele and Catterall, 
2000; Rodriguez de la Vega et al., 2003; Catterall et al., 2007; Swartz, 2007; Bosmans 
and Swartz, 2010). Given their high specificity and wide repertoire of effects on 
channel activity, neurotoxins have been useful tools for structure-function studies to 
probe individual gating mechanisms of VGSCs and VGPCs (Alabi et al., 2007; 
Bosmans et al., 2008; Solokov et al., 2008). Neurotoxins interact with at least six 
receptor sites on VGSCαs (Table 1.6), and modify channel conductance and/or gating 
via at least three discrete modes of action: direct pore block, indirect allosteric 
modulation of gating, and voltage-sensor trapping. The following summarizes the sites 
and modes of action of the most common neurotoxins:  
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Table 1.6 Neurotoxin receptor sites on voltage-gated sodium channels 
 
 
Site no. Neurotoxin Functional effect / mechanism of action Major binding site 
1 Tetrodotoxin, saxitoxin, µ-conotoxins Inhibition of conductance due to pore occlusion D1-D4: SS1-SS2 
2 Aconitine, veratridine, batrachotoxin, grayanotoxin Persistent / enhanced activation due to hyperpolarization  
of activation and inhibition of inactivation  D1:S6,  D4:S6 
3 α-scorpion toxins, atrachotoxins, sea anemone toxins Slowed inactivation due to prevention of outward 
movement of D4:S4 (i.e. trapped in the resting state) D4:S3-S4 
4 β-scorpion toxins Enhanced activation due to trapping of D2:S4 in outward position D2:S3-S4 
5 Brevetoxins, ciguatoxins Enhanced activation due to hyperpolarization of activation 
and inhibition of inactivation  D1:S6, D4:S5 
6 δ-conotoxins Slowed inactivation due to prevention of outward 
movement of D4:S4 (i.e. trapped in the resting state) D4:S4 
Abbreviations: D, domain; S, segment; SS, short-segment. Modified from Catterall et al. (2007). 
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i. Pore-blocking neurotoxins (site 1), which include hydrophilic low-molecular-
weight toxins (e.g. TTX, saxitoxin) and large polypeptide toxins (e.g. µ-
conotoxin), physically occupy the external entrance to the channel pore, 
suppressing Na+ conductance (Table 1.6).  
ii. Hydrophobic alkaloid toxins (e.g. aconitine, veratridine; site 2) and other lipid-
soluble toxins (e.g. brevetoxin, ciguatoxin; site 5) interact with intramembrane 
sites distinct from the pore and the S4 voltage-sensors, allosterically favouring 
open vs. inactivated channel states (Table 1.6). 
iii. Polypeptide ‘gating-modifier’ toxins modulate VGSC gating through trapping 
S4 voltage-sensors in their resting (inward) or activated (outward) 
conformations by binding to extracellular receptor sites including D4:S3/S4 
linker (e.g. α-scorpion toxins; site 3), D2:S3/S4 linker (β-scorpion toxins; site 
4) and D4:S4 (δ-conotoxins; site 6) (Table 1.6). 
Unlike small-molecule pharmaceuticals, binding sites of the gating-modifier toxins 
(class iii above) in particular are located in peripheral and relatively less conserved 
parts of VGSCs (Goldin et al., 2000; England, 2008). Accordingly, there is a growing 
list of neurotoxins with subtype-selective effects on VGSCαs. For instance, α-like toxin 
OD1 (site 3), isolated from the venom of scorpion Odonthobuthus doriae, selectively 
increased peak and persistent currents of Nav1.7 and inhibited fast inactivation with > 
25-fold more potency compared to Nav.1.3, whilst having no effect on Nav1.8 
(Maertens et al., 2006). β-toxin Tz1 (site 4), isolated from the Venezuelan scorpion 
Tityus zulianus, hyperpolarized voltage-dependence of activation significantly more 
strongly in Nav1.4 compared to Nav1.2 and Nav1.6, with no effect on Nav1.5 or 
Nav1.7 (Leipold et al., 2006). Block of Nav1.7 currents by Huwentoxin-IV (site 4), 
isolated from the venom of tarantula Ornithoctonus huwena, was selective over Nav1.4 
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and 1.5 and to a lesser degree over Nav1.2 and Nav1.3 (Xiao et al., 2008). Finally, 
Jingzhaotoxin-II (site 3), isolated from Chinese tarantula Chilobrachys jingzhao, 
selectively inhibited fast inactivation of Nav1.5, with no effect on VGSCs from adult 
peripheral or central neurons (Wang M et al., 2008). 
An objective of the present study is to determine whether neurotoxins can be 
utilized to confer selectivity between nNav1.5 and aNav1.5. Ideally, such a toxin would 
have a binding site in the spliced D1:S3/S4 linker; however, this region is not among 
the six ‘classic’ neurotoxin binding sites described to date (Table 1.6; Catterall et al., 
2007). Nevertheless, the extracellular D1:S3/S4 linker constitutes a potential binding 
site for neurotoxins especially since (i) it is accessible to the hydrophilic polypeptide 
gating-modifier toxins, and (ii) S3/S4 voltage sensors of VGSCs (and other voltage-
gated ion channels) are in general ‘hot’ targets for ‘voltage-sensor trapping’ gating 
modifier neurotoxins, e.g. site 3 and site 4 toxins act on S3/S4 linkers in D4 and D2 of 
VGSCαs, respectively (Table 1.6; Swartz, 2007; Bosmans and Swartz, 2010). Indeed, 
that D1:S3/S4 may be targeted by neurotoxins was suggested by Bosmans et al. (2008), 
who re-constructed each of the four voltage-sensors (paddles) of rat Nav1.2 (rNav1.2) 
in four-fold symmetric VGPCs (i.e. Kv2.1 chimaeras) and showed that two gating-
modifier tarantula toxins Protoxin-II (ProTx-II) and Hanatoxin (HaTx) bind to the 
S3/S4 paddle in D1 as well as in D2 and D4 of rNav1.2. Through alanine-scan of the 
D1:S3/S4 region, these authors also determined that Glu206 and Phe207 (rNav1.2 
numbering) together with various other nearby residues constitute the major binding 
site for ProTx-II in D1 (Bosmans et al., 2008; Bosmans and Swartz, 2010). 
Importantly, these amino acids (shaded on rNav1.2 sequence in the scheme below) are 
fully conserved between rNav1.2 and aNav1.5, but most are different in nNav1.5. 
 
 Chapter 1                                                                                                         General Introduction  
 
 121 
 
 
 
 
 
 
 
 
 
HaTx was also shown to interact with the D1 region in rNav1.2, although the amino 
acid residues critical for toxin binding were not determined (Bosmans et al., 2008). 
Mutagenesis studies on native Kv2.1 channels revealed that HaTx interacts with S3/S4 
voltage-paddles and the most critical residues for this interaction correspond to Phe274 
and Glu277 in D1 (shaded in the scheme above; Li-Smerin and Swartz, 2000). Overall, 
therefore, ProTx-II and HaTx could potentially differentiate between aNav1.5 and 
nNav1.5, and this possibility was investigated in the present study.  
 
1.4.2.1 ProTx-II 
ProTx-II is a 30-amino acid peptide with +4 net charge purified from the tarantula 
Thrixopelma pruriens (Figure 1.14AB; Middleton et al., 2002). It contains six disulfide-
bonded cysteine residues, conforming to the inhibitory cystine knot (ICK) motif shared 
by several gating modifier neurotoxins including HaTx (ICK peptides are defined by 1-
4, 2-5 and 3-6 cystine connectivity) (Priest et al., 2007; Bosmans and Swartz, 2010). 
Similar to β-scorpion toxins, ProTx-II was shown to modify VGSC activation; 
however, in contrast to β-scorpion toxins, ProTx-II depolarized rather than  
 
nNav1.5         205 YVSENIKLGNLSALRTFRVLRALKTISVIP 234 
aNav1.5         205 YTTEFVDLGNVSALRTFRVLRALKTISVIS 234 
rNav1.2         203 YVTEFVDLGNVSALRTFRVLRALKTISVIP 232 
Kv2.1           270 YVTIFLTESNKSVLQFQNVRRVVQIFRIMR 299 
D1:S3/S4 binding site for ProTx-II and HaTx. The seven amino acids different between 
aNav1.5 and nNav1.5 are indicated in red in the nNav1.5 sequence. Shaded rNav1.2 residues 
represent amino acids critical for ProTxII block of Kv2.1 chimaeras with D1:S3/S4 paddle of 
rNav1.2 (Bosmans et al., 2008). Shaded Kv2.1 residues represent those critical for HaTx block 
(Li-Smerin and Swartz, 2000).  
 
 Chapter 1                                                                                                         General Introduction  
 
 122 
 
A 
 
              HaTx          1 ECRY L F GGCKTTSDCCK-- HLGCKFRDKYCAWDFTFS 35 
            ProTx-II     1 YCQKWMWTCDSERKCCE--GMVCR  --- LWCKKKLW 30   
 
 
     B 
 
 
 
 
 
 
 
 
 
 
 
      C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Molecular structures of ProTx-II and HaTx 
(A) Amino acid sequence for HaTx and ProTx-II are shown with backbone cysteine framework 
in grey, basic residues in blue and acidic residues in red. Hydrophobic and basic amino acids 
critical for ProTx-II interaction with Nav1.5 are indicated with black and blue arrows, 
respectively (Smith et al., 2007). (B) A molecular model of ProTx-II created by Smith et al. 
(2007). Critical residues for toxin-Nav1.5 interaction are shown in cyan and are either 
hydrophobic or basic in nature. Nonessential amino acids are shown in magenta and segregate to 
the opposite faces of the molecule than critical hydrophobic and basic residues. (C) NMR 
solution structure of HaTx (Takahashi et al., 2000; Swartz, 2007); basic residues in blue, acidic 
residues in red, Ser/Thr in pink and hydrophobic residues in green. 
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hyperpolarized voltage-dependence of channel activation (Cestele et al., 1998; Edgerton 
et al., 2008; Smith et al., 2007). Accordingly, rather than trapping D2:S3/S4 in its 
activated conformation, as suggested for β-scorpion toxins (Catterall et al., 2007), 
ProTx-II is believed to trap one or more S3/S4 linker(s) in their resting/closed-state 
conformations, thereby reducing peak conductance and depolarizing voltage-
dependence of activation (Smith et al., 2007; Bosmans et al., 2008). Evidence for this 
hypothesis was provided by Sokolov et al. (2008): (i) ProTx-II reduced gating current 
(Ig) in rNav1.2 channels, consistent with inhibition of the outward translocation of S4 
voltage-sensors, and (ii) strong positive pre-pulses reversed the inhibitory effect of 
ProTx-II on rNav1.2 and rNav1.5 channels, suggesting that the toxin can be ‘knocked 
off’ its receptor by voltage-driven movement of S4 segments into their activated 
conformations. Similar results were obtained with HaTx and various other ICK toxins 
(e.g. Huwentoxin IV), consistent with a conserved mode of action of gating modifier 
ICK peptides (Swartz and MacKinnon, 1995, 1997ab; Xiao et al., 2008; Bosmans and 
Swartz, 2010). 
Through alanine scanning mutagenesis, the bioactive surface of ProTx-II was 
found to be amphipathic, constituted mainly by hydrophobic and cationic residues 
protruding on one side of the molecule (Figure 1.14AB; Smith et al., 2007). Other 
examples of amphipathic spider toxins include HaTx (Takahashi et al., 2000), PaurTx3 
(Bosmans et al., 2006) and Huwentoxin IV (Xiao et al., 2008). An intriguing property 
of gating modifier spider toxins, including ProTx-II and HaTx, is their ability to 
partition into the lipid membrane (Smith et al., 2005; Lee and Mackinnon, 2004; 
Phillips et al., 2005; Milescu et al., 2007). The hydrophobic residues of ProTx-II were 
suggested to mediate toxin binding at the lipid-protein interface, whereas the cationic 
residues could form electrostatic interactions with acidic residues on the channel protein 
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or phospholipid head groups (Smith et al., 2007). Interestingly, mutation of the three 
negative residues on ProTx-II (Asp10, Glu12 and Glu17) did not alter toxin interaction 
with Nav1.5 channel, suggesting that the basic residues on the channel protein may not 
contribute to toxin binding (Figure 1.14A; Smith et al., 2007).  
The bioactive surface of SGTx1, another ICK spider toxin targeting VGPCs 
(and VGSCs), was also shown to be constituted mainly by hydrophobic and cationic 
residues, suggesting conserved binding determinants for gating modifier spider 
peptides, irrespective of the target channel (Wang JM et al., 2004). Consistently, most 
ICK toxins, including ProTx-II, exhibit target promiscuity, interacting with multiple 
families of voltage-gated ion channels, e.g. ProTx-II inhibited VGSCs and voltage-
gated calcium channels (VGCCs) but not VGPCs, whereas HaTx modified all three 
channel types (Middleton et al., 2002; Bosmans et al., 2008; Bosmans and Swartz, 
2010). On the other hand, given the limited sequence homology of the targetted S3/S4 
regions across different ion channels (Bosmans and Swartz, 2010), promiscuity of 
gating modifier toxins is rather unexpected. It has thus been suggested (i) that toxins 
may recognize the conserved three dimensional structure of voltage-sensor / paddle 
motifs rather than specific amino acid sequences, and/or (ii) that toxin-lipid interactions 
may constitute a major part of the total interaction mechanism, resulting in the observed 
promiscuous character of gating modifier spider toxins (Li-Smerin and Swartz, 1998; 
Swartz, 2007). 
 The four-fold asymmetric structure of VGSCs combined with the possibility of a 
‘multifaceted’ interaction between S3/S4 linkers and neurotoxins has made it difficult to 
identify the binding sites for most gating modifier peptides including ProTx-II (Catterall 
et al., 2007; Swartz, 2007; Bosmans and Swartz, 2010). Classically, gating modifier 
neurotoxins are assumed to interact with a single extracellular S3/S4 linker on VGSCs, 
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e.g. α-scorpion toxin slow channel inactivation by interacting with D4:S3/S4 (site 3) 
and β-scorpion toxins enhance activation by targeting D2:S3/S4 (site 4) (Catterall et al., 
2007). Given its modification of the activation process, ProTx-II was initially thought to 
interact with site 4; however, linker swap experiments involving mutant channels with 
D2:S3/S4 sequence in both D2 and D4 (i.e. D2:D2 mutant) or vice versa (i.e. D4:D4 
mutant) revealed that ProTx-II did not interact with either receptor site 3 or site 4 in 
human Nav1.5 (Smith et al., 2007). In contrast, Bosmans et al. (2008) showed using 
symmetric Kv2.1/rNav1.2 chimaeras that ProTx-II has binding determinants within 
S3/S4 linkers (paddles) of D1, D2 and D4 in rNav1.2. It is therefore possible that the 
conclusions reached by Smith et al. (2007) were misled by interaction of ProTx-II with 
multiple extracellular S3/S4 linkers on Nav1.5. In other words, retention of ProTx-II 
binding site after removal of D2:S3/S4 linker (D4:D4 mutant) or D4:S3/S4 linker 
(D2:D2 mutant) was not due to lack of ProTx-II interaction with site 3 or site 4 but 
rather due to interaction with both sites with similar affinity.  
However, apart from removing S3/S4 linkers in full, Smith et al. (2007) also 
mutated various individual residues in S3, S4 and S3/S4 linkers in all four domains 
(including Glu208 and Asp211 in D1) but failed to find a single amino acid residue critical 
for ProTx-II inhibition of Nav1.5. This was in contrast with mutagenesis studies on 
Kv2.1/rNav1.2 chimaeras and native rNav1.2 channels by Bosmans et al. (2008), who 
showed that Glu206 (same as Glu208 in Nav1.5 above) and Phe207 in D1, Leu835 and 
Asn842 in D2, and Glu1617 and Phe1620 in D4 were critical for the interaction of ProTx-II 
with rNav1.2 channel. It is possible that the contrasting results for the binding 
determinants of ProTx-II obtained by Smith et al. (2007) and Bosmans et al. (2008) 
were due to differences in VGSCα subtype (Nav1.2 vs. Nav1.5) or species (rat vs. 
human).  
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In the present study, ProTx-II was used primarily to test whether differences 
between D1:S3/S4 regions of aNav1.5 vs. nNav1.5 are targetable by neurotoxins; 
however, results obtained will also clarify whether D1:S3/S4 linker accommodates 
critical amino acid residues for ProTx-II binding in human Nav1.5 channel, as 
suggested by earlier studies in rNav1.2 but not in Nav1.5 (Bosmans et al., 2008; Smith 
et al., 2007). In addition, Bosmans et al. (2008) found that ProTx-II interacted most 
strongly with the S3/S4 paddle in D1 vs. D2 and D4 in rNav1.2, whereas ProTx-II was 
shown to be ~ 100-fold selective for human Nav1.7 over other VGSCαs due to a single 
amino acid change in D2:S3/S4 (Phe813 in Nav1.7 vs. Gly / Ser in other VGSCαs) 
(Schmalhofer et al., 2008). Therefore, which S3/S4 linker is most influential for ProTx-
II binding or whether multiple S3/S4 linkers with similar affinities exist is not known. 
Characterization of ProTx-II inhibition of Nav1.5 D1:S3 splice variants may also help 
resolve this issue.  
 
1.4.2.2 HaTx 
HaTx is a 35-amino acid ICK peptide (with +2 or +3 net charge) purified from the 
tarantula Grammastola spatulata (Figure 1.14AC; Swartz and MacKinnon, 1995). It 
was originally identified during a search for new Kv2.1 inhibitors but subsequent 
studies showed that HaTx also inhibits Kv4.2, VGCCs (Cav2.1) and VGSCs (rNav1.2) 
(Swartz, 2007; Bosmans et al., 2008). From NMR studies of HaTx, it was concluded, 
similar to ProTx-II, that one face the toxin molecule is formed by a cluster of 
hydrophobic residues surrounded by basic and acidic residues (Figure 1.14C; Takahashi 
et al., 2000; Swartz, 2007). As described earlier in Section 1.4.2.1, the bioactive surface 
of the structurally related SGTx1 and ProTx-II contain mainly hydrophobic and basic 
residues clustered on one face of the toxin (Wang et al., 2004; Smith et al., 2007). 
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Although mutagenesis data are not yet available for HaTx, eight of the ten most 
influential amino acids (all hydrophobic and basic) in SGTx1 are identical in HaTx, 
suggesting a conserved bioactive surface (Swartz, 2007).  
 HaTx inhibition of VGPCs (mainly studied on Kv2.1) is strikingly similar to the 
effects of ProTx-II on VGSCs, i.e. channel activation is inhibited and peak channel 
conductance is reduced due to toxin-induced trapping of S3-S4 voltage-sensors 
(paddles) in their resting states (Swartz and MacKinnon, 1997a; Lee et al., 2003; 
Phillips et al., 2005). Evidence for voltage-sensor trapping action of HaTx comes from 
(i) the toxin-induced reduction of Ig associated with the outward movement of positively 
charged S4 residues (Lee et al., 2003), (ii) mutagenesis studies locating the critical 
residues for toxin binding to S3/S4 voltage paddles (Phe274 and Glu277; see Section 
1.4.2; Swartz and Mackinnon, 1997b; Li-Smerin and Swartz, 2000; 2001; Alabi et al., 
2007), and (iii) the observation that toxin-bound channels can open and conduct ions, 
albeit the energy required for channel activation being significantly increased (as 
evident from the strongly depolarized voltage-dependence of activation) (Swartz and 
MacKinnon, 1997ab; Phillips et al., 2005).  
Of particular relevance to the current project, HaTx was shown to inhibit 
rNav1.2 channels (Bosmans et al., 2008). Re-constitution of individual rNav1.2 voltage-
sensors (paddles) in Kv2.1 chimaeras revealed that HaTx interacts with the same S3/S4 
linkers targeted by ProTx-II (i.e. D1, D2 and D4), consistent with the functional 
similarities between these two tarantula toxins (Bosmans et al., 2008). However, 
whether VGSCα isoform-dependent differences exist in HaTx inhibition, as implicated 
for ProTx-II (e.g. Nav1.7 vs. other VGSCαs), remains to be determined. Also, HaTx 
inhibition of VGSCs was not characterized in detail (Bosmans et al., 2008). Thus, it is 
not known whether the effects of HaTx on channel gating are (i) similar in VGSCs and 
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VGPCs or (ii) similar to the effects of ProTx-II on VGSCs. Comparative 
characterization of HaTx inhibition of Nav1.5 D1:S3 variants may resolve some of the 
abovementioned uncertainties about HaTx interaction with VGSCs, in addition to 
revealing whether this toxin can confer selectivity between nNav1.5 and aNav1.5. 
 
1.4.3 Polyclonal antibody specific for nNav1.5 (NESOpAb) 
One way of selectively targeting functional ion channels involves generation of 
isoform-specific ‘blocking’ antibodies that bind to extracellular epitopes on the 
channel protein (Onkal and Djamgoz, 2009; Wulff et al., 2009; Clare et al., 2010). 
Several such blocking antibodies have been reported over the years, e.g. for VGSCs 
(Meiri et al., 1986, 1989; Chioni et al., 2005; Xu et al., 2005), VGCCs (Kim and 
Neher, 1988; Morton et al., 1988; Wyatt et al., 1997; Liao et al., 2008), VGPCs (Zhou 
B et al., 1998; Lu et al., 2002; 2005; Gomez-Varela et al., 2007) and transient receptor 
potential (TRP) channels (Xu and Beech, 2001; Rosado et al., 2002; Xu et al., 2005; 
Klionsky et al., 2006; Naylor et al., 2008).  
Antibody-based targeting of ion channels was initially aimed at obtaining 
experimental tools to dissect the functional roles played by individual channel isoforms 
or by specific regions of a given ion channel; however, realization of the clinical 
potential of humanized antibodies brought even greater interest into anti-peptide 
targeting of ion channels (Baker, 2005a; Dallas et al., 2005). As regards potency, 
specificity and selectivity, antibodies have important advantages over other methods of 
ion channels targeting. For instance, most small-molecule inhibitors exhibit minimal 
subtype-selectivity and tend to have low potency (µM range) (Nau and Wang, 2004; 
Clare, 2010). Natural neurotoxins have similar or even better potency (low nM range) 
than blocker antibodies but they usually do not have the remarkable isoform-specificity 
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of antibodies (Catterall et al., 2007). Gene disruption or RNA interference methods are 
other widely used approaches to selectivity inhibit ion channels but these methods have 
intrinsic complications including compensatory gene expression (due to slow protein 
turnover rates, especially for membrane proteins), need for cell culture and efficient 
oligonucleotide delivery, non-specific interferon responses, and in the case of in vivo 
knock-out studies, restriction to a single species (i.e. mouse) (Wall and Shi, 2003; 
Dykxhoorn and Lieberman, 2005).  
Six-transmembrane domains are the building blocks of voltage-gated ion 
channels; VGPCs and transient receptor potential (TRP) channels are tetramers of 
individual six-transmembrane domains, whilst VGSCs and VGCCs are encoded from a 
single polypeptide chain as four repeat domains each with six membrane-spanning 
segments (Catterall, 2000; Catterall et al., 2005; Venkatachalam and Montell, 2007). 
Previous studies have raised blocking ion channel antibodies that target three different 
extracellular locations: (i) S3-S4 linker, which is the second extracellular loop (E2) 
(e.g. Meiri et al., 1989; Chioni et al., 2005), (ii) S5-S6 linker, which is the third 
extracellular domain (E3) immediately adjacent to the pore-loop (e.g. Zhou B et al, 
1998; Xu et al., 2005), and (iii) extracellular end of S6, i.e. between E3 and S6 segment 
(e.g. Wyatt et al., 1997). Figure 1.15 illustrates the extracellular locations of the 
blocker ion channel antibodies reported to date, and Table 1.7 summarizes the 
electrophysiological properties of these antibodies.  
The E3 region in particular appears to be an efficient region for antibody 
production, and so far, eleven E3 targeting antibodies have been reported in VGSC, 
VGPCs, VGCCs or TRP channels (Figure 1.15). Zhou B et al. (1998) provided the first 
comprehensive evidence of E3 targeting in Kv1.2 and Kv3.1 channels. These 
antibodies were found to inhibit corresponding K+ currents with IC50s of 54 and 58 nM,  
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Figure 1.15 ‘Blocking’ ion channel antibodies 
The general topology of a six-transmembrane domain of an ion channel subunit is shown. Pore-
forming S5-S6 segments are shown in purple and positively charged S4 voltage-sensor for 
voltage-gated ion channels is shown in yellow. Blocking ion channel antibodies have been 
successfully generated that target S3-S4 linker (E2), S5-S6 ‘turret’ (E3) or N-terminal end of S6; 
ion channel subtypes targeted by these antibodies are listed for each region. For VGSCs and 
VGCCs, the targeted domain is also noted. References are: nNav1.5 (Chioni et al., 2005); eel 
electroplax Nav (Meiri et al., 1989); Nav1.5 and TRPC5 (Xu et al., 2005); Kv1.2 and Kv3.1 
(Zhou B et al., 1998); Kv10.1 (Gomez-Varela et al., 2007); L-Type Cav (Morton et al., 1988); 
Cav2.1 and Cav2.2 (Liao et al., 2008); TRPC1 (Xu and Beech, 2001; Rosado et al., 2002); 
TRPM3 (Naylor et al., 2008); TRPV1 (Klionsky et al., 2006); Cav1.3 (Wyatt et al., 1997).  
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Table 1.7 Electrophysiologically characterized ‘blocking’ ion channel antibodies  
  
Antibody Target Type1 IC502 Maximal block3 Time / method4 Reference 
NESOpAb nNav1.5 D1: E2 / poly < 10 nM * 56% (< 10 nM) < 3 min / puff Chioni et al. (2005) 
Nav1.5-E3 Nav1.5 D1: E3 / poly - 60% (100 nM) 10-20 min / bath Xu et al. (2005) 
Anti-C1+ Eel electroplax Nav D1: E2 / poly - 20% (1000 nM) 10-20 min / bath Meiri et al. (1989) 
Kv1.2-BA Kv1.2        E3 / poly 54 nM # 70% (250 nM) 7-15 min / bath Zhou B et al. (1998) 
Kv3.1-BA Kv3.1        E3 / poly 58 nM # 79% (250 nM) 7-15 min / bath Zhou B et al. (1998) 
mAb56 Eag1 (Kv10.1)        E3 / mono 73 nM # 75% (200 nM) 10 min / bath Gomez-Varela et al. (2007) 
D-III IgG N-type Cav (Cav2.2) D3: E3 / poly 767 nM * 41% (20000 nM) < 2 min / puff Liao et al. (2008) 
D-III IgG P/Q type Cav (Cav2.1) D3: E3 / poly 1633 nM * 21% (20000 nM) < 2 min / puff Liao et al. (2008) 
LEMS IgG L-type Cav5          -  / poly - 40% (26667 nM) 2 hr / bath Kim & Neher (1988) 
mAb1A L-type Cav5 D3: E3 / mono - 50% (60 nM) 5-10 min / bath Morton et al. (1988) 
anti-α1D L-type Cav (Cav1.3) D4: S6 / poly - 49% (1:50 dilution) 2-4 hr / bath Wyatt et al. (1997) 
T5E3 TRPC5        E3 / poly - 50% (400 nM) 5-10 min / bath Xu et al. (2005) 
TM3E3 TRPM3        E3 / poly - 50% (1:500 dilution) 5-10 min / bath Naylor et al. (2008) 
1Epitope location / type of the antibody (polyclonal or monoclonal). E2 and E3 correspond to second (S3-S4) and third (S5-S6) extracellular linkers. For Cav1.3, the region 
targetted is top (N-terminal end) of S6. 2IC50 estimated from single-site Hill fits assuming complete block at saturation (#). Where IC50 was not estimated, concentration for 
half-maximal block is reported (*). No value is reported if only a single dose was tested. Molarity calculations assume antibody molecular weight is 150 kDa. 
3Concentration for maximal block is given in parentheses. 4Time to obtain steady-state block / method of antibody application (bath vs. puff application). 5Specific L-type 
isoform targeted by the antibody is not known. 
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respectively, within 7-15 min of antibody application (Table 1.7). The block was 
confirmed to be target-specific, e.g. there was only minimal effect of Kv1.2 antibody 
on the closely related Kv1.3, and pre-absorbing the antibody with the immunizing 
peptide or applying non-specific IgG had no effect on Kv1.2 currents (Zhou B et al., 
1998). Subsequent reports of E3 targeting in TRPC1 (Xu and Beech, 2001), Nav1.5, 
TRPC5 (Xu et al., 2005), Kv10.1 (Gomez-Varela et al., 2007), TRPM3 (Naylor et al., 
2008) and Cav2.1/2.2 (Liao et al., 2008) revealed that E3 antibodies are similar in that 
they (i) are specific for their target epitopes, (ii) induce ~ 50-70% maximal block of 
channel activity usually in the nM range, and (iii) achieve steady-state block with very 
similar time-courses, i.e. within 5-20 min when bath-applied and < 2 min when puff-
applied. For instance, the Nav1.5-E3 antibody generated by Xu et al. (2005) inhibited 
Nav1.5 currents expressed in HEK-293 cells by 60% when applied at 100 nM over a 
period of 10-20 min, whilst having no effect on Nav1.4.  
Similarities in the extent and time-course of block indicated that E3 antibodies 
may have similar modes of action. Although most immunoelectrophysiological studies 
focused on antibody potency, specificity or selectivity without revealing the precise 
mechanism of antibody action, in the light of the electrophysiological data reported, 
several non-exclusive possibilities exist for the mechanism of antibody block (Dallas et 
al., 2005; Naylor et al., 2008). First, antibodies are large molecules (IgG ~ 150 kDa) 
with ~ 140 Å overall diameter (~ 45 Å for a Fab fragment and ~ 105 Å for the open 
branches of the Fab) (Colman et al. 1987; Meiri et al., 1986; 1989). Thus, even when 
bound to a site distant from the external vestibule of the channel (e.g. E2 or E3), an 
antibody molecule can effectively block the ion permeation pathway, physically 
inhibiting channel conductance (Zhou B et al., 1998). Second, antibody binding may 
induce conformational changes that favour non-conducting channel states rather than 
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open-states, i.e. block is allosteric (Meiri et al., 1989; Naylor et al., 2008). Third, 
antibody binding may induce channel internalization, effectively reducing the number 
of functional ion channels in the plasma membrane (Kim and Neher, 1988; Zhou B et 
al., 1998). 
The factors which contributed to the success of E3 targeting included that the 
amino acid sequence of the E3 region is long (i.e. extracellularly accessible), not 
glycosylated, and not well-conserved among isoforms of a given ion channel (Xu et al., 
2005; Naylor et al., 2008). On the other hand, the other two extracellular linkers, E1 
and E2, are shorter than E3 in most ion channels including VGSCs, and hence are 
extracellularly less accessible. Moreover, E1 and E2 are possibly glycosylated in 
VGSCs, which would be antagonistic to antibody selectivity and/or efficacy (Diss et 
al., 2004; Xu et al., 2005; Stocker and Bennett, 2006). Despite these disadvantages, 
however, Meiri et al. (1989) succeeded in generating a functional antibody against the 
E2 region in D1 of the eel electroplax Nav channel (86% homology with Nav1.1 and 
Nav1.2). This antibody (1000 nM) produced minimal (15-20%) block of peak INa but 
significantly (by 30-40 mV) hyperpolarized steady-state channel availability in rat 
DRG neurons.  
As mentioned in Section 1.2.2, Chioni et al. (2005) exploited the six clustered 
amino acid differences between aNav1.5 and nNav1.5 to produce a polyclonal antibody 
(NESOpAb) that was specific for the spliced D1:S3/S4 (E2) region of nNav1.5. The 
sequence used for antibody generation was 57% (8 out 14 residues) similar in nNav1.5 
and aNav1.5 but electrophysiological recordings indicated that NESOpAb block was 
highly selective for nNav1.5 over aNav1.5 (Table 1.7). In particular, NESOpAb 
blocked nNav1.5 currents with high potency (half-maximal block < 10 nM), whilst the 
threshold concentration for block was ~ 400-fold and the concentration for half-
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maximal block was ~ 10-fold larger in aNav1.5 (Chioni et al., 2005). Also, the 
maximal block observed was only ~ 20% in aNav1.5 but 50-60% in nNav1.5, which 
was similar to the maximal block attained by E3 antibodies (Chioni et al., 2005). 
However, despite the selectivity of NESOpAb for nNav1.5, various questions 
regarding antibody block of Na+ currents were left unanswered: (i) What are the effects 
of NESOpAb on Na+ conductance and channel gating characteristics? (ii) What is the 
mechanism of action of NESOpAb in terms of channel blockade? (iii) Is Lys211 critical 
for the antibody selectivity in nNav1.5 vs. aNav1.5? (iv) Does NESOpAb have similar 
potency for recombinant nNav1.5 expressed in EBNA-293 cells and endogenous 
nNav1.5 expressed in MDA-MB-231 BCa cells? Resolving these issues is among the 
aims of the present study. 
 
1.5 Aims and scope of the present study 
The main aim of the present study was to characterize the electrophysiological, 
pharmacological and regulatory properties of the D1:S3 neonatal splice variant of 
Nav1.5 (nNav1.5), the predominant VGSCα expressed in metastatic human BCa cells. 
A multifaceted approach comprising a combination of electrophysiology, 
pharmacology, and cell and molecular biology techniques was used. The specific aims 
were as follows: 
i. To determine the effects of long-term and acute hypoxia on nNav1.5 
expression/activity in the strongly metastatic MDA-MB-231 human BCa cells. 
ii. To evaluate the role of PKA in the hypoxic regulation of nNav1.5 
expression/activity. 
iii. To investigate the functional contribution of nNav1.5 to metastatic cell 
behaviour in MDA-MB-231 BCa cells under normoxic and hypoxic conditions. 
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iv. To characterize and compare the electrophysiological properties of nNav1.5 and 
aNav1.5 heterologously expressed in EBNA-293 cells. 
v. To determine the key amino acid(s) responsible for any electrophysiological 
difference between nNav1.5 and aNav1.5. 
vi. To determine the pharmaceutical sensitivities of nNav1.5 and aNav1.5 to 
various VGSC-blocker drugs and neurotoxins, and a polyclonal antibody 
specific for nNav1.5 (NESOpAb). 
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2.1 Cell culture 
2.1.1 Cell lines and culture conditions 
All cells were seeded into 100 mm Falcon tissue culture dishes (Beckton Dickinson) 
and maintained at 37 °C, 100% relative humidity and 5% CO2. Cells were grown to 
confluence and serially passaged every 3-4 days using fresh culture medium. For the 
chronic hypoxia studies, cells were incubated in a hypoxia chamber (MicroGalaxy, RS 
Biotech) calibrated to maintain 2 or 5% O2 by continuous flow of nitrogen. All reagents 
were from Invitrogen unless stated otherwise. The cell lines used were as follows: 
 
2.1.1.1 aNav1.5 - EBNA 
This is a modified human embryonic kidney (EBNA-293) cell line stably transfected 
with D1:S3 ‘adult’ Nav1.5 (aNav1.5 / hH1) in pcDNA3.1 vector (Gellens et al., 1992; 
Chandra et al., 1998). This cell line was a kind gift from Prof. Augustus Grant. Cells 
were grown in minimum essential medium (MEM; with Earles’s salts and glutamine) 
supplemented with 10% foetal bovine serum (FBS) and 1% non-essential amino acids. 
The growth medium was also supplemented with 500 µg/ml Hygromycin B to select for 
stably transfected cells. Culture medium was the same for other EBNA-293 cell lines 
used (Section 2.1.1.2 – 2.1.1.4).  
 
2.1.1.2 nNav1.5 - EBNA 
This is an EBNA-293 cell line stably transfected with D1:S3 ‘neonatal’ Nav1.5 
(nNav1.5) (Chioni et al., 2005). The expression vector for nNav1.5 was generated by 
substituting ten key nucleotides of the aNav1.5 pcDNA3.1 using site-directed 
mutagenesis, as described previously (Chioni et al., 2005). This cell line was generated 
by Mr. Filippo Pani and Dr. Scott P. Fraser. 
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2.1.1.3 nNav1.5 K211D - EBNA 
Site-directed mutagenesis was performed on nNav1.5 pcDNA3.1, substituting two key 
nucleotides in order to generate an expression vector for the nNav1.5 K211D mutant 
(Lys211 → Asp). The mutagenesis was performed using Quickchange® XL Site-Directed 
mutagenesis Kit (QCXLM, Stratagene). PCR conditions were identical with those 
described previously for the generation of nNav1.5 vector (Chioni et al., 2005). The 
following primer pair (MWG Biotech) was used for the PCR reaction (mutated 
nucleotides in bold / underlined): Forward: 5’- CATGGCATACGTATCTGA 
AAATATAGACCTGGGCAATCTCTCAGC - 3’ and Reverse: 5’- GCTGAGAGA 
TTGCCCAGGTCTATATTTTCAGATACGTATGCC ATG - 3’. Following the PCR, 
reaction mixture was digested with DpnI (10 U at 37 oC for 1 h), and 3 µl of digested 
PCR mixture was transformed into ultra-competent XL10-Gold cells (Stratagene). 
Ampicillin-resistant clones were then picked and the plasmid DNA was purified using 
the Qiagen Midiprep Kit. Following digestion with HindIII (Promega), clones were 
sequenced (MWG Biotech) to confirm the success of the mutagenesis. This procedure 
was performed in collaboration with Dr. Dongmin Shao. 
EBNA-293 cells were stably transfected with nNav1.5 K211D pcDNA3.1 using 
Lipofectamine 2000 (Invitrogen), as described previously (Chioni et al., 2005). Briefly, 
EBNA-293 cells were plated and grown to 80% confluence in 100 mm Falcon tissue 
culture dishes 24 h prior to transfection in which 15 µg DNA and 25 µl of 
Lipofectamine 2000 were used. The cells were split (1:5) 24 h after the transfection and 
were selected using 500 µg/ml HygromycinB 24 h later. Growth medium was then 
replaced every 3-4 days. Individual colonies were picked after approximately 2 weeks 
and tested for functional VGSC expression by whole-cell patch-clamp recording.  
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2.1.1.4 Empty vector - EBNA 
This is an EBNA-293 cell line stably transfected with only the empty-vector, 
pcDNA3.1, as control (Onkal et al., 2008a). Transfection was performed using 
Lipofectamine 2000 (Invitrogen), as described in Section 2.1.1.3, by Mr. Filippo Pani 
and Dr. Scott P. Fraser. 
 
2.1.1.5 MDA-MB-231 and MCF-7 
MDA-MB-231 is a strongly metastatic breast cancer (BCa) cell line derived originally 
from the pleural effusion of a 51-year old BCa patient with widespread metastasis 
(Cailleau et al., 1974). When injected into nude mice, these cells rapidly metastasize 
mainly to lungs, lymph nodes and brain (Morini et al., 2000). MCF-7 is a weakly 
metastatic BCa cell line established from the pleural effusion a 69-year old BCa patient 
(Soule et al., 1973); when injected into nude mice, these cells only slowly metastasize 
to lungs, lymph nodes and spleen (Shafie and Liotta, 1980; Hazan et al., 2000). MDA-
MB-231 and MCF-7 cell lines were a kind gift from Prof. Ian Heart, and were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% FBS and 4 mM 
L-glutamine, as described previously (Fraser et al., 2005).  
 
2.1.1.6 Mat-LyLu 
This is a strongly metastatic Dunning rat prostate cancer (PCa) cell line originally 
derived from a spontaneously occurring prostate tumour in an inbred Copenhagen rat 
(Isaacs et al., 1986). When injected back into syngeneic Copenhagen rats, Mat-LyLu 
cells formed a rapidly growing tumour and metastasized to lymph nodes and lungs 
(Isaacs et al., 1986). This cell line was a kind gift from Prof. Chris S. Foster. Cells were 
grown in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 
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1% FBS, 2 mM L-glutamine, 250 µg/ml amphotericin B and 250 nM dexamethasone, as 
described previously (Brackenbury and Djamgoz, 2006) 
 
2.1.1.7 PC-3M 
This is a subvariant of a strongly metastatic PCa cell line (PC-3) originally derived from 
liver metastasis of human PCa (Kaighn et al., 1979; Chu et al., 2001). This cell line was 
a kind gift from Prof. Chris S. Foster. Cells were grown in RPMI 1640 medium, 
supplemented with 10% FBS, 4 mM L-glutamine, 1 mg/ml sodium bicarbonate, 4.5 
mg/ml glucose and 1 mM sodium pyruvate (Mycielska et al., 2005). 
 
2.1.1.8 Nav1.4 - HEK 
This is a HEK-293 cell line stably transfected with human Nav1.4 (Herzog et al., 2003; 
Sheets et al., 2006). This cell line was a kind gift from Prof. Stephen G. Waxman.  
Cells were grown in DMEM supplemented with 10% FBS and 4 mM L-glutamine, and 
stably transfected cells were selected using 600 µg/ml G418 (Geneticin). 
 
2.2 Pharmacology 
2.2.1 Pharmacological agents  
Stock solutions for pharmacological agents were prepared in appropriate solvents 
typically at 100x the maximum working concentration (Table 2.1), and kept at -20 °C. 
Dilutions to working concentrations were made in culture medium or mammalian 
physiological saline (MPS), as appropriate, minutes before application. For long-term 
(e.g. 24 h) treatments, pharmacological agents were added to the cell cultures 3 h post 
seeding, i.e. after the cells had settled. In all treatments that lasted longer than 24 h,  
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Table 2.1 Summary of drugs used in the present study   
  
1
 Solvent for stock solution. Dilutions to final working concentrations were made (i) in culture 
medium for long-term treatments (e.g. 24 h) and (ii) in MPS for acute application in patch-
clamp recordings. Appropriate control experiments for solvents used (e.g. for DMSO and 
peptide buffer) are described in the Results section. 
 
 
Drug Solvent1 Working concentration Supplier 
TTX Water 0.01 – 30 µM Alomone 
Forskolin Culture medium 20 – 50 µM Calbiochem 
KT5720 DMSO 500 nM Calbiochem 
Myr PKI14-22 Culture medium 20 µM Enzo Life Sciences 
Lidocaine MPS 5 – 5000 µM Sigma 
Phenytoin DMSO 1 – 200 µM Sigma 
Mexiletine MPS 1 – 5000 µM Sigma 
Procaine MPS 10 – 5000 µM Sigma 
Ranolazine MPS 10 – 5000 µM Sigma 
Riluzole DMSO (30%) in MPS 0.1 – 1000 µM Sigma 
ProTx-II Peptide buffer 10 – 10000 nM Kenneth M. Blumenthal 
HaTx Peptide buffer 20 – 5000 nM Kenton J. Swartz 
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culture medium ± pharmacological agents was refreshed daily. ProTx-II and HaTx were 
donated by Prof. Kenneth M. Blumenthal and Prof. Kenton J. Swartz, respectively 
(Table 2.1). To prevent adsorption to tubing, all toxin solutions were prepared in MPS 
supplied with 0.5 mg/ml bovine serum albumin (BSA) (termed ‘peptide buffer’).   
 
2.2.2 Toxicity test 
For long-term treatments, potential toxicity of the pharmacological agents at their 
working concentrations was determined using a trypan blue exclusion assay as 
described previously (Fraser et al., 2003). Cells (3 x 104 / ml) were seeded into 35 mm 
dishes. After pharmacological treatment, the test agent was removed and cells were 
incubated in culture medium supplied with 0.1% trypan blue (Sigma) for 10 min at 37 
°C. The trypan blue was replaced with 1 ml of normal medium and cells were viewed 
under 10x magnification. For each treatment, 30 fields of view containing at least 10 
cells were chosen at random and the percentage of dead cells (stained blue) in each field 
was recorded. The 30 percentages were averaged to represent one dish, and this 
procedure was repeated in three separate dishes.  
 
2.2.3 Morphological assessment 
Possible morphological effects of long-term hypoxic / pharmacological treatments were 
studied under an inverted microscope (Axiovert 200, Zeiss). Cells were photographed 
under 40x or 100x magnification using a digital camera (Power-Shot G5, Canon). 
 
2.3 Real-time PCR 
2.3.1 RNA extraction and cDNA synthesis 
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Total RNA was isolated from ~ 80% confluent 35 mm dishes using TRIzol reagent 
according to manufacturer’s instructions (Invitrogen). RNA samples were subjected to 
DNase I treatment (Amersham Biosciences) to remove any genomic DNA 
contamination. Approximate RNA quantity was calculated by spectrophotometric 
absorbance at 260 nm (NanoDrop 1000A, Thermo Scientific). RNA quality was 
assessed with the 260 / 280 nm absorbance ratio (ensured to be 1.8 - 2.2; Sambrook et 
al., 1989) and using agorose gel electrophoresis (Section 2.3.3; Figure 2.1).  
For each sample, 1 µg of RNA was reverse-transcribed into cDNA with 
Superscript II reverse-transcriptase (Invitrogen), as described previously (Mycielska et 
al., 2005). Each reaction was performed in a total volume of 20 µl containing 1 µg 
RNA, 250 ng random hexamer mix (Amersham Biosciences), 2 µl 0.1 M DTT, 4 µl 
Superscript II first strand buffer, 1 µl 10 mM dNTP mix (Pharmacia Biotech), 1 µl (33.8 
U) porcin RNA guard (Amersham), 1 µl (200 U) Superscript II reverse transcriptase 
(RT) and sterile distilled H20. Synthesized cDNA was diluted to 100 µl with H2O at the 
end of the reaction and stored at -20 °C. For each sample, a control (-RT) reaction was 
also performed in which H2O was substituted for Superscript II reverse transcriptase. 
 
2.3.2 PCR conditions  
Real-time polymerase chain reaction (rt-PCR) utilizing SYBR Green I technology was 
performed using the DNA Engine Opticon 2 system (MJ Research), as described 
previously (Diss et al., 2005; Mycielska et al., 2005). For each sample, amplification of 
the target gene was normalized relative to two reference (‘housekeeping’) genes, β-actin 
and cytochrome-b5 reductase (Cytb5R) (Diss et al., 2005). PCR reactions were run in 
duplicates in a total reaction volume of 20 µl, containing 5 µl cDNA, 10 µl 1x 
QuantiTech SYBR Green PCR mix (Qiagen) and 0.5 µM of sense and antisense primers 
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rRNA 28S 
rRNA 18S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.1 Visual determination of RNA quality by agarose gel electrophoresis 
Good RNA quality was characterized by greater intensity of the 28S rRNA band vs. the 18S 
rRNA band. 1 µg total RNA from EBNA-nNav1.5 cells (lane 1), EBNA-empty vector cells 
(lane 2) and EBNA-aNav1.5 cells (lane 3) were run on a 1% agarose gel. 
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 (MWG; Table 2.2). All primers were designed to flank at least one conserved intron 
and had been validated and used previously (Table 2.2).  
Each PCR was run with an initial step of 95 °C for 15 minutes to activate the 
HotStar Taq, followed by 40 cycles of 95 °C for 30 s (denaturing), annealing 
temperature for 30 s (Table 2.2) and 72 °C for 30 s (extension). Fluorescence from 
incorporation of SYBR I Green to double-stranded DNA was measured after each cycle 
(Figure 2.2A). In each PCR run, a no-template ‘H20’ control (NTC) was included to 
check for cross-contamination from other sources. Product composition was verified 
with a final melt curve in 0.3 °C steps from 65 °C to 95 °C; a high-quality single PCR 
product was characterized by one sharp drop in fluorescence over a narrow temperature 
range (Figure 2.2B). The molecular weight of the PCR product was determined by 
agarose electrophoresis (Section 2.3.3). The threshold amplification cycles (Ct) were 
determined using Opticon Monitor 2 software (MJ Research), and data were analyzed 
by the 2-∆∆Ct method (Livak and Schmittgen, 2001), using the following equation:  
 
          y = 2 – ([mean ∆Ct] – [mean ∆Ct for control])                                Equation 2.1 
 
where y is the target gene mRNA level relative to control sample, and ∆Ct is the 
difference in amplification threshold between target gene and normalizing reference 
gene. For the ∆∆Ct calculation to be valid, amplification efficiencies (i.e. primer 
efficiencies) of the target and normalizing genes must be approximately equal (Livak 
and Schmittgen, 2001). Therefore, a standard calibration curve was performed for each 
primer set using six serial dilutions of control-treated cDNA derived from MDA-MB-
231 or MCF-7 cells. For each target gene, ∆Ct was confirmed to be constant across the 
dilution range (Figure 2.3). The relative target gene mRNA level was determined from 
at least three separate experiments and expressed as mean ± standard error (SEM). 
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Table 2.2 PCR primers 
      
 
Abbreviations: Ta, annealing temperature; bp, base pair. 
1Shorter exon-skipped splice variants that, if translated, would encode highly truncated VGSCβs lacking the transmembrane domain (see Chapter 3; Diss 
et al., 2008).
Target gene Primer sequence  Ta (°C) Product size (bp) Reference 
β-actin Sense Antisense 
5’-ATGGATGATGATATCGCCGC-3’ 
5’-ATCTTCTCGCGGTTGGCCTT-3’ 59 356 
Onkal et al.  (2008a) 
Chioni et al. (2009) 
Cytb5R Sense Antisense 
5’-TATACACCCATCTCCAGCGA-3’ 
5’-CATCTCCTCATTCACGAAGC-3’ 60 511 
Diss et al. (2001) 
Brackenbury et al. (2007) 
VGSCβ1 Sense Antisense 
5’-AGAAGGGCACTGAGGAGTTT-3’ 
5’-GCAGCGATCTTCTTGTAGCA-3’ 60 379 
Diss et al. (2008) 
Chioni et al. (2009) 
VGSCβ2 Sense Antisense 
5’-GAGATGTTCCTCCAGTTCCG-3’ 
5’-TGACCACCATCAGCACCAAG-3’ 62 310 
Diss et al. (2008) 
Chioni et al. (2009) 
VGSCβ3 Sense Antisense 
5’-CTGGCTTCTCTCGTGCTTAT-3’ 
5’-TCAAACTCCCGGGACACATT-3’ 60 353, 189
1
 
Diss et al. (2008) 
Chioni et al. (2009) 
VGSCβ4 Sense Antisense 
5’-TAACCCTGTCGCTGGAGGTG-3’ 
5’-TGAGGATGAGGAGCCCGATG-3’ 64 459, 305
1
 
Diss et al. (2008) 
Chioni et al. (2009) 
nNav1.5 Sense Antisense 
5’-CTGCACGCGTTCACTTTCCT-3’ 
5’-GACAAATTGCCTAGTTTTATATTT-3’ 60 101 Brackenbury et al. (2007) 
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Figure 2.2 Sample real-time PCR amplification and melt curves 
(A) Fluorescence from SYBR green incorporation to double stranded DNA was measured after 
each PCR cycle using DNA Engine Opticon 2 system (MJ Research). Dashed line represents 
amplification threshold determined by Opticon Monitor 2 software. Samples: x1, x4, x16, x64, 
x256 and x1024 dilutions of cDNA synthesized from RNA extracted from MDA-MB-231 cells 
treated in control conditions for 24 h. Amplified gene was β-actin. (B) After PCR, product 
composition was verified by heating from 65 °C to 95 °C in 0.3 °C steps. Pure PCR products 
could be characterized by one sharp drop in fluorescence over a small temperature range, i.e. ~ 
89 °C for the β-actin amplicon. Samples as in part A. Legend shown applies to both parts. 
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Figure 2.3 Sample ∆Ct calibration curves 
To determine the efficiency of each primer set used, PCR amplification was performed on serial 
dilutions (x1, x4, x16, x64, x256, x1024) of cDNA synthesized from MDA-MB-231 or MCF-7 
cells (e.g. Figure 2.2). Four sample ∆Ct calibration curves are shown, where ∆Ct = threshold 
amplification cycle of target gene – threshold amplification cycle of the normalizing gene: (A) 
cDNA from MCF-7 cells, target gene is VGSCβ1 and normalizing gene is β-actin. (B) cDNA 
from MCF-7 cells, target gene is VGSCβ1 and normalizing gene is Cytb5R. (C) cDNA from 
MDA-MB-231 cells, target gene is nNav1.5 and normalizing gene is β-actin. (B) cDNA from 
MDA-MB-231 cells, target gene is nNav1.5 and normalizing gene is Cytb5R. Data are 
presented as mean ± SEM (n = 3) and were fitted using linear regression analysis (solid lines). 
Slopes of the ∆Ct curves were statistically similar to zero (unpaired t-test for slopes, P > 0.05), 
indicating that the efficiency of amplification of the target and normalizing genes are similar, 
validating the 2-∆∆Ct method (Livak and Schmittgen, 2001). 
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2.3.3 Agarose electrophoresis 
RNA extracts and PCR products were diluted in a loading buffer (Fisher Bioreagents) 
and separated by electrophoresis on a 1% (w/v) agarose, 1x Tris-HCl-borate-EDTA 
(TBE) gel. Samples were resolved against a 100 bp DNA ladder (Fisher Bioreagents), 
stained with SYBRSafe DNA gel stain (Invitrogen) and visualised with an ultra-violet 
(UV) imager. 
 
2.4 Immunocytochemistry 
Cells (5 x 104 /well) were plated onto glass coverslips (13 mm, BDH) in 24-well plates 
and incubated for 24 h. Non-permeabilized cells were fixed in 2% (w/v) PFA/PBS for 5 
min at room temperature, whilst permeabilized samples were fixed in 4% PFA/PBS for 
15 min (PFA, paraformaldehyde; PBS, phosphate buffered saline). Where appropriate, 
cells were (i) labelled with 20 µg/100 µl fluorescein isothiocyanate (FITC)-conjugated 
concanavalin A (Sigma) in 5% (w/v) BSA/PBS for 45 min as a plasma membrane 
marker, and then (ii) permeabilized in 0.1% (w/v) saponin/PBS for 5 min. Before and 
after the permeabilization step, cover slips were washed three times with PBS (10 min 
each). Non-specific binding sites were blocked for 1 h with 5% BSA/PBS. Cells were 
incubated with the primary antibody (pan-VGSC or VGSCβ1; Table 2.3) for 1 h, 
washed three times with PBS (10 min each), and then incubated with the appropriate 
secondary antibody (Table 2.4) for 1 h. Primary and secondary antibodies were diluted 
in 5% BSA/PBS and applied on a rocking platform. Finally, cover slips were washed 
twice in PBS and once in water, mounted in Vectashield mounting medium (Vector 
Laboratories) and stored at 4 ○C in dark overnight. The following controls were 
performed: 
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Table 2.3 Primary antibodies 
      
 
  
Abbreviations: SC, stock concentration; WC, working concentration (given as dilution factor 
from SC); ICC, immunocytochemistry; WB, Western blotting; MW, molecular weight. 
1 Pan-VGSC - a polyclonal rabbit IgG originally designed against a highly conserved 19-
amino acid sequence located within the intracellular ID3-4 linker region of VGSCαs 
(Dugandzija-Novakovic et al., 1995).  
2 Anti-actinin - a monoclonal mouse IgM produced against actin-binding protein α-actinin 
(Abd-el-Basset et al., 1991). This antibody was derived from a hybridoma produced by fusion 
of mouse myeloma cells with splenocytes from an immunized mouse.  
3 VGSCβ1 - a polyclonal rabbit IgG targeting an extracellular epitope on VGSCβ1. This 
antibody was synthesized at the Protein and Carbohydrate Structure Core Facility of 
University of Michigan, and was a kind gift from Prof. L. Isom. 
 
 
 
 
 
Table 2.4 Secondary antibodies 
 
Abbreviations: SC, stock concentration; WC, working concentration (given as dilution factor 
from SC); ICC, immunocytochemistry; WB, Western blotting. 
Primary  
Antibody Source Species  SC 
WC 
(ICC) 
WC 
(WB) 
MW 
(kDa) References 
 
Pan-VGSC1 
 
Upstate Rabbit polyclonal 1 µg/µl 1:100 1:1000 220  
Brackenbury and 
Djamgoz (2006) 
Anti-actinin2 Sigma Mouse 
monoclonal 1 µg/µl - 1:1000 100  
 
Brackenbury and 
Djamgoz (2006) 
 
VGSCβ13 L. Isom Rabbit polyclonal - 1:500 - 36  
Xiao et al. (1999) 
Malhotra et al. (2000) 
Secondary  
Antibody Source Species  SC 
WC 
(ICC) 
WC 
(WB) Application 
Anti-rabbit Alexa 568  Invitrogen Goat 2  µg/µl 1:100 - 
 
Pan-VGSC and  
VGSCβ1 (ICC)  
 
Anti-rabbit FITC Dako Swine 0.8  µg/µl 1:50 - VGSCβ1 (ICC) 
 
Anti-rabbit HRP 
 
Sigma Goat 13.1  µg/µl - 1:10000 Pan-VGSC (WB) 
Anti-mouse HRP Dako Goat 1 µg/µl - 1:1000 Anti-actinin (WB) 
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i. Autofluorescence: Cells were fixed, permeabilized and mounted without 
incubation with concanavalin A or primary / secondary antibody (cells were 
incubated with 5% BSA/PBS in corresponding steps). 
ii. No primary antibody: Immunocytochemistry was performed as above except 
that cells were incubated with 5% BSA/PBS instead of primary antibody. 
iii. Non-specific rabbit IgG: Immunocytochemistry was performed as above, except 
that cells were incubated with non-specific rabbit IgG fraction (0.01-0.02 µg/µl, 
Dako) instead of primary antibody. 
iv. Pre-absorbed primary antibody: Immunocytochemistry was performed as above, 
except that cells were incubated with primary antibody that had been pre-
absorbed with 5x (by weight) excess of the immunizing peptide for 30 min at 
room temperature. This could not be performed for VGSCβ1 antibody since the 
immunogenic peptide was not available. 
 
2.4.1 Confocal microscopy 
Cells were studied using a Leica SP5 MP microscope (63x magnification under oil 
immersion) and a Leica confocal laser scanner (Leica TCS-NT with Ar/Kr laser). FITC 
and/or Alexa568 were excited with the 488 nm and 568 nm laser lines, respectively. 
Cells were optically sectioned in the xy plane with multiple scan averaging, and images 
(1024 x 1024 pixels) were taken through the central plane of all cells simultaneously 
from two channels using a confocal pinhole of 229.96 µm. The following densitometric 
analyses were performed using the Leica LAS AF Lite software: 
i. Cell-surface protein level was determined using the “freeform line profile” 
function drawn around the cell periphery guided by concanavalin A staining 
(Brackenbury and Djamgoz, 2006). For each cell, data were assessed as total 
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staining in arbitrary units (AU) per µm. Measurements were taken from n ≥ 30 
cells (randomly chosen) per condition, for at least three independent experiments. 
ii. Internal protein level was determined using the “area histogram” function covering 
20 µm2 rectangular sections of cytoplasm (avoiding the nucleus) (Brackenbury and 
Djamgoz, 2006; Chioni et al., 2010). Measurements were taken from n ≥ 30 cells 
(randomly chosen) per condition, for at least three independent experiments. 
iii. Subcellular protein distribution was studied using the “straight-line cross-sectional 
profile” function drawn across the cytoplasm avoiding nucleus, extending the 
original methodologies of Okuse et al. (2002) and Shah et al. (2004). ‘Peripheral’ 
(i.e. plasma membrane) signal intensity was set to cover 1.5 µm inward from the 
edge of the concanavalin A staining, whilst ‘internal’ (i.e. cytoplasmic) signal 
intensity was defined as the central 30% of the line drawn. Average length of the 
cross-sections used was similar in control vs. treatment groups and hence did not 
bias any comparative analysis. Peripheral and internal protein expression was 
expressed as percentage of total cross-section staining and compared. 
Measurements were taken from n ≥ 20 cells per condition, for at least three 
independent experiments. 
 
2.5 Western blotting 
2.5.1 Extraction of total protein 
Cells were washed twice in ice-cold PBS and resuspended in ice-cold lysis buffer 
(Upstate) containing 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 
150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml 
pepstatin and 1 mM phenylmethanesulfonylfluoride (PMSF) for 15 min at 4 ○C. Lysates 
were centrifuged (Heraus, Labofuge 400R) at 13000 g, 4 ○C for 15 min and the pellet 
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was discarded. Protein yield was determined using a Bradford dye binding assay 
according to manufacturer’s instructions (Bio-Rad). Briefly, lysates were diluted in 
Coomassie Brilliant Blue G-250 dye reagent and the spectrophotometric absorbance 
was measured at 595 nm; protein yield was determined by comparison with a standard 
curve constructed using serial dilutions of BSA (Figure 2.4). 
 
2.5.2 SDS-PAGE and immunoblotting 
Equivalent amounts of protein from different lysate samples (50 µg/well) were resolved 
against a wide range coloured molecular marker (PageRuler prestained protein ladder, 
Fermantes) by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), as described previously (Brackenbury and Djamgoz, 2006). Before loading, 
lysate samples were treated with LAEMMLI 2x sample buffer (Sigma), incubated for 
10 min at 37 ○C and boiled for 5 min. Electrophoresis was performed using a 5% 
acrylamide stacking gel and a 7.5% acrylamide running gel, in a buffer containing 25 
mM Tris, 192 mM glycine and 0.1% (w/v) SDS at 100 V for 2 h. Protein was 
electroblotted onto nitrocellulose membrane at 4 ○C in a buffer containing 25 mM Tris 
and 192 mM glycine at 80 V for 2 h. Blots were (i) blocked for 1 h in 5% (w/v) non-fat 
dried milk/PBS and then 30 min in 2% (w/v) BSA/PBS at room temperature, (ii) 
incubated with primary antibodies (pan-VGSC or anti-actinin diluted in 2% BSA/PBS; 
Table 2.3) for 16 h at 4 ○C, (iii) washed three times in 0.2% Tween-20/PBS (15 min 
each), (iv) incubated with appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibodies diluted in 2% BSA/PBS (Table 2.4) for 1 h at room temperature, 
and (v) washed three times in 0.2% Tween-20/PBS (15 min each). Blots were 
developed using the ECL chemiluminescence system (Amersham) and visualized by 
exposure to Super RX100NF film (Fujifilm) at room temperature. The following 
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Figure 2.4 Standard curve for Bradford dye binding assay  
Optical density of BSA protein standard (Bio-Rad) in the range 1.25 µg to 100 µg was 
measured at 595 nm, and corrected for blank. Solid line represents linear fit to data. A 
fresh BSA standard curve was constructed for each experiment. 
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negative controls were performed: (i) Blots were probed with pan-VGSC antibody that  
had been pre-absorbed (for 30 min at room temperature) with 5x excess immunizing 
peptide. (ii) Blots were incubated with PBS only with no primary antibody added. 
Western blotting was performed in collaboration with Dr. Dongmin Shao. 
  
2.5.3 Densitometry 
Densitometric analyses were performed using ImageJ software on 600 dpi scanned 
images. Pan-VGSC band intensity was normalised to anti-actinin signal as a loading 
control / reference, for five repeat experiments. For both pan-VGSC and anti-actinin 
antibodies, a linear relationship between protein loading and signal intensity was 
confirmed using serial dilution of protein extracts (20-100 µg; Figure 2.5) (Charette et 
al., 2010). 
 
2.6 MTT assay 
In order to confirm that long-term (24 h) pharmacological and/or hypoxic treatments did 
not affect cell number during functional assays (Sections 2.7-2.8), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Alfa Aesar) assay was 
used (Grimes et al., 1995). Cells (4 x 104 /ml) were seeded in 12-well plates (Becton 
Dickinson) and incubated for 24 h to settle. This was followed by control vs. 
pharmacological / hypoxic treatment for 24 h. After the initial 24 h and at the end of 24 
h treatment period, culture medium ± pharmaceuticals were removed, and cells were 
incubated at 37 ○C for 2 h in culture media supplied with 1 mg/ml MTT. Medium was 
then replaced with 0.89 ml DMSO and 0.11 ml glycine buffer (0.1 M glycine and 0.1 M 
NaCl, pH 10.5). After 10-minute incubation at room temperature, spectrophotometric 
absorbance was measured at 570 nm using a multi-well plate reader (ELx800, BioTek 
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Figure 2.5 Effect of protein dilution on band intensity  
(A) Intensity of pan-VGSC and anti-actinin bands for serial dilution of protein extracted from 
MDA-MB-231 cells. (B, C) Band intensity, determined using ImageJ software, was plotted 
against protein concentration and fit by linear regression (solid lines). Data are presented as 
mean ± SEM (n = 4). Linear increase encompassing 50 µg/lane ensured that the system was not 
saturated at the protein quantity used in a typical SDS-PAGE loading.  
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Instruments). Absorbances (OD), within the linear range of a standard curve of serial 
dilutions of cells, were converted to cell number (Figure 2.6) and expressed relative to 
value recorded at the end of the initial 24 h incubation. All experiments were performed 
in duplicates and repeated for at least three times. For standard curves, 1000 to 512000 
cells/ml (i.e. 9 serial dilutions) were seeded in 12-well plates and incubated for 3 h to 
settle. MTT assay was then performed as describe above. This was repeated three times 
for every MTT solution prepared.  
 
2.7 Transwell migration assay 
Cells (2 x 105 /ml) were plated onto 8 µm-pore Transwell filters in a 24-well plate, 
according to manufacturer’s instructions (Becton Dickinson), and incubated in 
normoxia or hypoxia  ± 10 µM TTX for 6 h. A chemotactic gradient of 1-10% FBS was 
used. At the end of the 6 h incubation period, non-migrated cells were swabbed from the 
upper surface of the Transwell inserts. Migrated cells at the bottom of the inserts were 
fixed with 100% ice-cold methanol for 15 min and stained with 0.5% (w/v) crystal 
violet (Sigma) in 25% methanol for 15 min at room temperature. After washing with 
water, inserts were left to dry for 1 h at room temperature and subsequently viewed 
under an inverted microscope at 10x magnification (Axiovert 200, Zeiss). For each 
insert, three fields of view were photographed using a digital camera (Power-Shot G5, 
Canon), and migrated cells were counted using ImageJ software (imaging and cell 
counting were performed in a ‘blind’ fashion by Mr. Nahit Rizaner). Experiments were 
performed in duplicates, and cell counts from the total six fields of view were averaged 
to represent one repeat. Results were compiled as the mean of at least four repeats.  
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Figure 2.6 Sample standard curves for MTT assay 
Cell number in relation to absorbance at 570 nm (OD units) as determined by MTT assay is 
shown for (A) MDA-MB-231, (B) MCF-7 and (C) nNav1.5-EBNA cells. Data are presented as 
mean ± SEM (n = 3); some error bars are smaller than symbols. Standard curves spanned 1000 
cells/ml to 512000 cells/ml and were well-fit by the linear equation. Maximum absorbance 
reading of a sample observed in the present study was less than that of 512000 cells/ml, i.e. 
within the linear range.   
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2.8 Matrigel invasion assay 
Cells (2 x 105 /ml) were plated onto 8 µm-pore Transwell filters pre-coated with 1.25 
mg/ml (50 µl) Matrigel basement membrane matrix (Becton Dickinson). Cells were 
incubated in normoxia or hypoxia ± pharmacological agents (TTX or ranolazine) in a 
chemotactic gradient of 1-10% FBS for 24 h. At the end of the incubation period, non-
invaded cells were swabbed from the upper surface of the Transwell inserts. Invaded 
cells at the bottom of the inserts were fixed with 100% ice-cold methanol for 15 min 
and stained with 0.5% (w/v) crystal violet (Sigma) in 25% methanol for 15 min at room 
temperature. After washing with water, inserts were left to dry for 1 h at room 
temperature and subsequently viewed under an inverted microscope at 10x 
magnification (Axiovert 200, Zeiss). For each insert, three fields of view were 
photographed using a digital camera (Power-Shot G5, Canon), and invaded cells were 
counted using ImageJ software (imaging and cell counting were performed in a ‘blind’ 
fashion by Mr. Nahit Rizaner). Experiments were performed in duplicates, and cell 
counts from the total six fields of view were averaged to represent one repeat. Results 
were compiled as the mean of at least four repeats. 
 
2.9 Electrophysiology 
Cells (2 x 104 /ml) were seeded into 35 mm dishes in order to get a single cell spread for 
whole-cell patch clamp recording (Hamill et al., 1981). Experiments were performed at 
room temperature (22 ± 2 ºC). Cells were viewed using an inverted microscope (IM35, 
Zeiss). Prior to recording, the growth medium (± pharmacological agents) was washed 
out by perfusing the cells for ~15 minutes with the extracellular mammalian 
physiological saline (MPS) solution containing (in mM): 144 NaCl; 5.4 KCl; 1 MgCl2; 
2.5 CaCl2; 5 HEPES and 5.6 D-glucose (adjusted to pH 7.25 with CsOH). Each dish 
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was used patching for a maximum period of ~ 70 min. All chemicals were from Sigma, 
unless stated otherwise.  
 
2.9.1 Patch pipettes 
Patch-pipettes were made from borosilicate glass (GC100-F; Harvard Apparatus) using 
a two-stage vertical puller (PP830; Narashige) and were heat polished to give 
resistances of 3-5 MΩ when filled with the internal pipette solution containing (in mM): 
145 CsCl, 5 NaCl, 2 MgCl2, 11 EGTA and 10 HEPES (adjusted to pH 7.4 with CsOH). 
Cs+ was included in the internal patch solution to block K+ currents. For recording 
outward currents, equimolar KCl was substituted back for CsCl in the internal pipette 
solution and pH was adjusted using KOH. 
 
2.9.2 Solutions  
During recordings, cells were continually perfused with MPS at a rate of 1.5 ml / minute 
using a gravity fed perfusion system. The bath level was kept at a constant low volume 
of ~ 1 ml by means of a vacuum suction tube positioned above the fluid surface. After 
seal rupture, cells were left to stabilize for at least 4-5 min before recordings begun in 
order to ensure stability of dialysis by the internal pipette solution and to minimize 
background time-dependent shifts in voltage-dependent parameters (Hanck and Sheets, 
1992b; Khan et al., 2006).  
Pharmacological agents (Table 2.1) except NESOpAb, ProTx-II and HaTx were 
bath-applied by switch of the perfusion from control MPS to drug-containing MPS. 
Efficiency of solution transfer was ascertained by perfusing the cells with a Na+-free 
MPS (contained equimolar choline chloride for NaCl), which abolished Na+ currents 
within 2 s. NESOpAb, ProTx-II and HaTx were ‘puff-applied’ through low-pressure 
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ejection with a pipette located approximately 30 µm from the cell being studied (PV820 
Pneumatic PicoPump, WPI) (Chioni et al., 2005). Control experiments for potential 
mechanical side-effects of puff-application are described in Chapter 5. NESOpAb was 
originally eluted in an antibody storage buffer containing 1 ml of citrate buffer (0.01 M 
citrate, 0.2 M NaCl; pH 2.6), 0.16 ml of pH neutralizing buffer (1 M HEPES; pH 8) and 
1.4 mg/ml BSA (Chioni et al., 2005). Glycerol and sodium azide, normally added to 
antibody stocks, were not included for NESOpAb to be applicable to living cells (and 
also because sodium azide can block VGSCs) (Chioni et al., 2005). Appropriate control 
experiments for the antibody storage buffer are also described in Chapter 5. 
Acute hypoxia was induced by bubbling the perfusion medium (MPS ± 
pharmacological agent) in the flask with 100% N2 for ~ 30 min prior to application (Ju 
et al., 1996). This procedure produced no change in bath pH. The oxygen tension in the 
bath near the outlet of the perfusion tube was monitored with a dissolved O2 meter 
(ISO2, WPI). O2 tension could be reduced to ~ 20 mmHg (2.66% O2) within 2-3 min in 
the recording chamber. The O2 level at the tip of the perfusion tube was possibly lower 
and reached equilibrium more rapidly than measured by the larger O2 electrode (2 mm 
diameter) (Hammarstrom and Gage, 2000).  
For acidosis / alkalinosis experiments, control MPS was titrated with CsOH to 
the desired pH values, and MES buffer was substituted for HEPES for solutions with 
pH < 6.5. pH of each solution was confirmed to have remained within ± 0.1 pH units of 
the desired level after each experiment. CdCl2 and GdCl3 (anhydrous) were freshly 
dissolved and serially diluted in MPS to various working concentrations minutes before 
the experiment. Hydrolysis of Gd3+ possibly resulted in decreased free Gd3+ 
concentration by the formation of hydroxide complexes such as Gd(OH)2+; however, at 
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the concentrations and pH used, this reduction should be stable and < 5 % (Elinder and 
Arhem, 1994; Kuo et al. 2004).  
Test solutions (e.g. pharmacological agents, neurotoxins, NESOpAb, acute 
hypoxia, cations) were applied for at least 2 min before recordings were taken, except 
for experiments in which the time-course of effects was determined. If multiple 
concentrations of an agent were tested on the same cell, control MPS was applied 
between exposures to determine the extent of recovery, and data were accepted only if 
the pre- and post-controls were within 10%. 
 
2.9.3 Whole-cell recording  
Whole-cell recordings were performed using Axopatch 1D patch clamp amplifier (Axon 
Instruments). Patch pipettes were connected via the feed-back resistance head-stage to 
the Axopatch 1D amplifier by a Ag/AgCl electrode immersed in the pipette solution. 
Bath was grounded via a Ag/AgCl wire in agar, connected to the earth terminal of the 
amplifier. Signals were filtered at 5 kHz with a low-pass Bessel filter, digitized at 10-50 
kHz using a Digidata 1200 interface (Axon Instruments), and analysed using pCLAMP6 
software (Axon Instruments). The offset potential was zeroed before the electrode was 
touched to the cell. Linear components of leak current were subtracted online using the 
amplifier circuitry and/or offline using the pCLAMP6 software. Capacitative transients 
were cancelled and series resistance (Rs) errors were compensated by > 85 % with a 
feed-back lag of 8 µs. Junction potential errors were not corrected.  
To ensure efficient space clamping and to limit the voltage drop across Rs to < 5 
mV (for EBNA-293 transfectants), several measures were taken, as follows: 1) Only 
round, isolated cells with whole-cell capacitance of 30 pF or less were used. (2) Data 
were accepted from cells expressing peak INa < 6 nA (except when determining the 
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effects of chronic hypoxia on peak current density). (3) Only cells with activation slope 
factors > 4.5 mV were included in the analysis, since steeper slopes would indicate loss 
of efficient voltage-clamp (Stocker and Bennett, 2006; Cummins et al., 2009). (4) 
Recordings were accepted only when seal resistances were ≥ 1 GΩ and the initial 
uncorrected Rs (< 10 MΩ) changed less than 20% during the recording. To avoid 
possible bias from endogenous INa expressed in EBNA-293 or HEK-293 cells, 
recordings from these cells with INa < 500 pA were discarded (Kurejová et al., 2007; He 
and Soderlund, 2010). 
 
2.9.4 Voltage-pulse protocols 
Four main types of voltage pulse protocols, designed in pCLAMP6, were applied from 
a holding potential (Vh) of -100 mV, unless stated otherwise: 
i. Dose-response protocol: This was a single-pulse protocol used to determine dose-
response relationships, time-course of effects induced by test solutions, and use-
dependent current attenuation or block. 12 ms pulses were applied to -20 mV, -15 
mV or 0 mV at 0.1, 0.2, 1, 2, 5, 10, 20, 33 or 50 Hz, as appropriate (details are 
given in the relevant Results sections). Pulse duration was increased to 300 ms for 
studies involving persistent Na+ currents (INaP). 
ii. Current-voltage (I-V) protocol: This was used to determine peak Na+ current / 
conductance, voltage dependence and kinetics of channel activation, and kinetics 
of inactivation from open-state. Currents were generated by pulsing the membrane 
potential for 60 ms within the range -80 to +45 mV, in 5 mV increments, with an 
interpulse duration of 2 s. Pulse duration was 300 ms for INaP studies. To study 
outward currents, Vh was -90 mV, test potentials were in the range -70 to +70 mV 
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in 10 mV increments, the test pulse duration was 200 ms and interpulse duration 
was 5 s.  
iii. Steady-state inactivation protocol: This was used to study voltage dependence of 
inactivation at steady state (i.e. availability). Recordings were made using 
prepulses of 50, 250 or 1000 ms duration in the range -140 mV to -10 mV in 10 
mV increments, followed immediately by an 80 ms test pulse to -10 mV. 
Interpulse duration was 2 s.   
iv. Time course of recovery from inactivation protocol: This was used to study the 
kinetics of recovery from inactivation. Cells were treated with an 80 ms ‘control 
pulse’ to -10 mV (giving current Ic), returned to -100 mV and then an identical 
‘test pulse’ to -10 mV was applied (giving current It). Recovery interval between 
the two pulses ranged from 5 to 155 ms in 10 ms increments. In ProTx-II and 
HaTx studies, duration of control and test pulses was shorter (10 ms) to minimize 
depolarization-induced toxin unbinding (Sokolov et al., 2008). To obtain full 
recovery in the presence of lidocaine and phenytoin, a secondary recovery from 
inactivation protocol was included with identical control and test pulses (i.e. 80-
ms long), whilst the recovery interval ranged from 250-1750 ms in 250 ms 
increments (Ragsdale et al., 1991). 
Recordings were obtained from at least three separate dishes, unless stated otherwise (n 
numbers are reported in figure legends and summary tables). Data from individual 
dishes were combined to provide an overall mean and standard error (SEM).  
 
2.9.5 Curve fitting and analysis 
Where appropriate, peak INa was normalized to whole-cell capacitance (obtained from 
the automated function of the Axopatch 1D amplifier) and reported as ‘peak current 
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density’ (pA/pF). For INaP, (i) only recordings with no / minimal leakage current were 
included in the analysis, (ii) Na+ free MPS or 30 µM TTX was applied to reveal any 
background currents, which were then subtracted from the current traces (this is further 
detailed in the Results), and (iii) amplitude was determined from the average current 
measured 200-225 ms after the onset of the voltage pulse to avoid contamination from 
transient INa.  
Curve fitting and analysis were performed using Microsoft Excel 2003 and 
Origin 6.1 software, as described previously (Grimes and Djamgoz, 1998; Ding and 
Djamgoz, 2004). Data were fitted to specific functions described below using the ‘Chi-
square’ method to obtain the best fit. Current-voltage (I-V) relationships in the range -80 
to +45 mV were converted to conductance using the equation:  
 
G = I / (V-Vrev)                                                    Equation 2.2  
 
where G is conductance, I is the peak current amplitude at a voltage step, V is the test 
voltage, and Vrev is the theoretical value of the reversal potential for Na+, calculated 
from the Nernst equation to be 85 mV at room temperature (293 ○K). For each cell, 
normalized conductance and steady-state inactivation were plotted as a function of 
membrane potential and fit with a single Boltzmann function of the form:  
 
G/Gmax = 1/ [1 + exp((V1/2 – V) / k)]                   Equation 2.3 
 
where Gmax is the maximum conductance or current availability, V is the membrane 
voltage, V1/2 is the voltage at which the current is half-activated or inactivated, and k is 
the slope factor, indicating voltage-dependence of channel activation or inactivation. 
For activation data, curve fitting was performed typically in the range -80 to 0 mV since 
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conductance was noted to decline slightly at positive voltages in some cells, as reported 
previously (Grimes and Djamgoz, 1998; Cummins et al., 2009). 
Time course of current inactivation (i.e. decay of current from peak) was fitted 
with the following double exponential equation: 
 
 I = Afast exp(-t /τfast) + Aslow exp(-t /τslow) + C              Equation 2.4 
 
where I is normalized current, t is time, τfast and τslow are the time constants of the fast 
and slow current components, respectively, Afast and Aslow  are the amplitudes of the fast 
and slow current components, respectively, and C is the steady-state asymptote (i.e. 
persistent current component). Percentage in fast mode (i.e. the proportion of current 
described by τfast) was calculated by Afast / (Afast + Aslow); percentage in slow mode was 
100 – (percentage in fast mode). 
 For the time course of recovery from inactivation, It/Ic was plotted as a function 
of recovery time and fitted to the following single exponential equation:  
 
I = A exp(-t /τ) + C                                             Equation 2.5 
 
where I is normalized current, t is time, τ is the time constant, A is the amplitude of the 
normalized current, and C is the asymptote. In lidocaine and phenytoin studies, where 
longer recovery periods were tested, time course of recovery was fitted with the double 
exponential equation (Equation 2.5), and percentages of fast and slow modes were 
calculated as described for inactivation kinetics. 
 Normalized dose-response relationships were fitted with the following single-
site logistic / Hill - Langmuir equation:  
 
y = A2 + [(A1 – A2) / (1 + (C / IC50) nH)]                   Equation 2.6 
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where A1 and A2 are the maximum and the minimum, C is the test concentration, IC50 is 
concentration giving half-maximum block, and nH is the Hill coefficient. In the case of 
H+, dose-response curves were fit with the following modified version of the logistic / 
Hill equation (Khan et al., 2006):  
 
y = A1 + [(A2 – A1) / 1 + 10 (pKa – pH) nH)]                          Equation 2.7 
 
where A1 is the minimum (i.e. pH-independent fraction of current), A2 is the maximum, 
pKa is the pH at which half-maximum effect occurred, and nH is the Hill coefficient. 
Unless stated otherwise, for all dose-response fits, all parameters were initially allowed 
to vary; if nH was not statistically different from unity, it was fixed at unity in the final 
fits for consistency.  
For NESOpAb, time-course of current inhibition / recovery were fitted with the 
single exponential equation (Equation 2.6) to determine time constants (τ) for block 
onset / offset. Similarly, onset / offset time-course of INaP during acute hypoxia was 
fitted with the single exponential equation. 
 
2.10 Data analysis 
All quantitative data are presented as mean ± SEM, unless stated otherwise. Curve 
fitting and data analysis were perfomed using Microsoft Excel 2003, Origin 6.1 (Origin 
Lab) and SigmaStat 2.0 (Systat Software Inc.). Pairwise statistical significance was 
determined using paired or unpaired Student’s t-tests or Mann-Whitney rank-sum tests, 
as appropriate (detailed for given Results). For comparisons involving more than two 
groups, analysis of variance (ANOVA) followed by Newman-Keuls post hoc analysis 
was used. Comparison of slopes obtained from linear regression analysis and 
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parameters obtained from the Hill equation fits were performed using the t-test method 
for fitted parameters, as follows:  
 
  t = [(P1) – (P2)] / √ [(SEM of P1)2 + (SEM of P2)2]                          Equation 2.8 
 
where P1 and P2 are the parameter values being compared. Results were considered 
significant at P < 0.05 (*) and highly significant at P < 0.01 (**). On figures, “X” 
denotes statistical insignificance (i.e. P > 0.05), unless stated otherwise. 
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Chapter 3 
 
Hypoxic modulation of voltage-gated Na+ channel expression 
and activity in MDA-MB-231 human breast cancer cells  
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3.1 Introduction 
Voltage-gated sodium channels (VGSCs) have been detected in vitro and/or in vivo in a 
range of carcinomas, including breast cancer (BCa) and prostate cancer (PCa) (Roger et 
al., 2006; Onkal and Djamgoz, 2009). In addition, VGSC activity has been shown to 
potentiate various in vitro metastatic cell behaviours (MCBs) including, for example, 
transverse migration and Matrigel invasion, in human and rat models of breast, prostate, 
lung and colon cancers (Bennett et al., 2004; Fraser et al., 2005; Onganer et al., 2005; 
Brackenbury and Djamgoz, 2006; Brackenbury et al., 2007; Gillet et al., 2009; House et 
al., 2010). Indeed, functional VGSC expression was considered to be (i) “necessary and 
sufficient” for the invasive behaviour of human PCa cells (Bennett et al., 2004) and (ii) 
a “key regulator” of colon cancer invasion in vitro (House et al., 2010).  
In BCa, the predominant VGSC α-subunit (VGSCα) expressed is the domain 1: 
segment 3 (D1:S3) neonatal splice variant of Nav1.5 (Fraser et al., 2005). This neonatal 
Nav1.5 variant (nNav1.5) differs from the wild-type adult Nav1.5 (aNav1.5) by 7 amino 
acids in the D1:S3/S4 region; a highly conserved aspartate (Asp211) residue in the 
extracellular S3-S4 loop is switched to a positively charged lysine (Lys211) in nNav1.5 
(Chioni et al., 2005). In vitro, nNav1.5 was found to be expressed ~ 1800-fold more at 
mRNA level in the strongly metastatic MDA-MB-231 cells, compared with the weakly-
metastatic MCF-7 cells; nNav1.5 constituted ~ 80% of the total VGSCα mRNA, the 
remaining 20% being mainly Nav1.7, the only VGSCα mRNA expressed other than 
Nav1.5 that would form a non-truncated (‘functional’) channel (Fraser et al., 2005). 
Consistently, the voltage-gated Na+ current (INa) recorded from MDA-MB-231 cells 
was ~ 20% tetrodotoxin (TTX)-sensitive (TTX-S; blocked by nanomolar TTX) and ~ 
80% TTX-resistant (TTX-R); there was no functional VGSC expression in the weakly 
metastatic MCF-7 cells (Fraser et al., 2005; Brackenbury et al., 2007). In vivo, Fraser et 
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al. (2005) detected upregulation of nNav1.5 in metastatic BCa biopsy samples using 
immunohistochemistry with an antibody specific for nNav1.5 (NESOpAb; Chioni et al., 
2005). It was also reported (i) that Nav1.5 mRNA expression in primary breast tumours 
correlated strongly with lymph node metastasis (LNM) and (ii) that there was no case of 
LNM without nNav1.5 mRNA expression in the corresponding primary tumour (Fraser 
et al., 2005).  
As regards functional significance of VGSC expression in BCa, highly selective 
VGSC inhibitor, TTX, suppressed various in vitro metastatic cell behaviours in MDA-
MB-231 cells, including colony formation in Matrigel-composed 3-D matrices, 
transverse migration, Matrigel invasion, endocytic membrane activity and galvanotaxis; 
comparable experiments showed that TTX had no effect on weakly metastatic MCF-7 
cells, consistent with the absence of functional VGSC expression in this cell line (Roger 
et al., 2003; Fraser et al., 2005; Brackenbury et al., 2007; Gillet et al., 2009). 
Furthermore, downregulating specifically the functional nNav1.5 expression using RNA 
interference (RNAi) suppressed VGSC-dependent migration and invasion in MDA-MB-
231 BCa cells in vitro, suggesting that nNav1.5 was predominantly responsible for the 
VGSC-dependent potentiation of MCBs (Brackenbury et al., 2007). Similar results were 
also obtained using nNav1.5-selective blocking antibody, NESOpAb (Brackenbury et 
al., 2007). 
The precise mechanisms regulating VGSC expression in BCa are only beginning 
to be understood. In a recent study, Chioni et al. (2010) showed that functional VGSC 
(nNav1.5) expression in MDA-MB-231 cells was controlled by an activity-dependent 
positive feedback mechanism involving Na+ influx and subsequent activation of protein 
kinase A (PKA) activity. A similar mechanism has also been described in the strongly 
metastatic Mat-LyLu rat PCa cells, suggesting conserved regulation of VGSC 
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expression in BCa and PCa cells (Brackenbury and Djamgoz, 2006). As regards the 
interplay between VGSC activity and PKA signalling, it was shown that Na+ influx, 
through VGSCs, could directly activate adenylate cyclase (AC) / PKA activity (Reddy 
et al., 1995; Cooper et al., 1998; Murakami et al., 1998; Chioni et al., 2010), which can 
in turn increase the functional VGSCα level at the plasma membrane via de novo 
mRNA/protein synthesis and/or enhanced externalization of mature, intracellular 
channel protein (Yuhi et al., 1996; Frohnwieser et al., 1997; Zhou et al., 2000, 2002; 
Chioni et al., 2010). In Mat-LyLu cells, serum concentration and growth factors 
including epidermal growth factor (EGF) and nerve growth factor (NGF) were also 
found to modulate the level of functional VGSC expression, and consistently, the NGF 
effect involved PKA as a signalling intermediary (Ding and Djamgoz, 2004; 
Brackenbury and Djamgoz, 2007; Ding et al., 2008).  
To date, all studies on functional VGSC expression in cancer cell lines were 
conducted under normoxic tissue culture conditions, i.e. at ~ 20% O2 (e.g. Ding et al., 
2008; Brackenbury and Djamgoz, 2006; Chioni et al., 2010). Importantly, however, 
healthy mammalian tissue exists at mildly hypoxic 2-9% O2 in vivo (on average ~ 40 
mmHg or 5.6% O2; Brahimi-Horn and Pouyssegur, 2009), whilst tumour cells typically 
experience severe hypoxia (< 2% O2) owing to inadequate tumour vasculature (Lanzen 
et al., 2006; Vaupel and Mayer, 2007; Bertout et al., 2008). Importantly, hypoxia has 
been correlated with increased risk of metastatic spread in both rat tumour models and 
human patients, and in vitro, it has been shown to enhance the metastatic potential of 
various tumor cell lines (Brizel et al., 1996; Brown and Bicknell, 2001; Chambers et al., 
2002; Zhang and Hill, 2004; Bristow and Hill, 2008; Subarsky and Hill, 2008). 
However, whether hypoxic stress (short- or long-term) exerts any effect on VGSC 
expression / activity in cancer cells is presently unknown. Previous studies in non-
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cancer cell types (e.g. glomous cells of the carotid body, cardiomyoctes, neurons) 
showed that hypoxia can alter both the expression and function of a variety of ion 
channels including VGSCs (e.g. Stea et al., 1992, 1995; Ju et al., 1996; Fearon and 
Brown, 2004; Wang et al., 2007), Ca2+-activated K+ channels (e.g. Hartness et al., 
2003), voltage-gated K+ channels (e.g. Chouabe et al., 1997; Kamiya et al., 1999; Hool, 
2004) and L-type and T-type voltage-gated calcium channels (e.g. Fearon et al., 1997, 
2000; Smani et al., 2002; MacDonald and Hool, 2008; Pluteanu and Cribbs, 2009). 
As regards hypoxic modulation of VGSCs, earlier studies are consistent in that 
chronic hypoxia (hours to days) upregulates VGSC expression at mRNA, protein and/or 
functional levels. For instance, in glomous (type 1) cells of the carotid body, hypoxia 
(6% O2, 1-2 weeks) enhanced VGSC current density 2- to 3-fold, without altering 
voltage-dependence of activation or steady-state inactivation, suggestive of increased 
expression of VGSCαs at the plasma membrane (Stea et al., 1992, 1995; Hempleman et 
al., 1995). The percentage of glomous cells expressing functional VGSCs was also 
increased from 46% to 72% by the hypoxia pre-treatment (Hempleman et al., 1995). 
Notably, the hypoxic effect on functional VGSC expression in glomous cells was shown 
to involve (i) cAMP-dependent signalling cascades (i.e. PKA activity) and (ii) de novo 
protein synthesis (Stea et al., 1995). Consistently, Caceres et al. (2007) found that 
chronic hypoxia (10% O2, 1 week) upregulated the total VGSCα protein level by 60%, 
Nav1.1 mRNA level by 80% and Nav1.3 mRNA level by 40% in whole rat carotid 
bodies; immunocytochemical labelling of dissociated glomous cells revealed that the 
total VGSCα protein level was enhanced by 40% and the Nav1.1 protein level by 20% 
in chronically hypoxic vs. normoxic samples.  
In agreement with studies in glomous cells, in cortical and hippocampal rat 
neurons, chronic hypoxia (9.5% O2, 3 weeks) enhanced the VGSCα mRNA level by ~ 
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80%; there was a parallel increase at the protein level, determined using saxitoxin 
binding autoradiography with [3H]STX (Xia et al., 2000). Also, in homogenized 
(whole) fetal rat brains, prolonged O2 deprivation (9% O2, 4 weeks) upregulated the 
total VGSCα mRNA level by ~ 40% and protein level by ~75% (Xia and Haddad, 
1999); a follow-up study revealed that Nav1.1 and Nav1.3 mRNAs were increased by 
15% and 40%, respectively, with no effect on the Nav1.2 mRNA level (Zhang et al., 
2001). 
Apart from the effects of chronic hypoxia on VGSC expression, acute hypoxia 
(seconds to minutes) can exert profound effects on VGSC gating. Electrophysiological 
studies in neurons, cardiomyocytes and recombinant expression systems consistently 
showed that, irrespective of the VGSC α-subtype involved, acute hypoxia reduced peak 
(transient) INa while increasing a non-inactivating, persistent component of INa (INaP) 
(Cummins et al., 1993; Ju et al., 1996; O’Reilly et al., 1997; Maltsev et al., 1998; 
Fearon and Brown, 2004; Hammarstrom and Gage, 2000, 2002; Saint, 2006, 2008; 
Belardinelli et al., 2006; Wang et al., 2007).  
Unlike the rapid and complete inactivation of the transient INa (within few 
milliseconds of a depolarizing stimulus), INaP was shown to be resistant to inactivation 
for seconds even at positive potentials (Ju et al., 1996; Saint, 2008; Zaza et al., 2008). 
Thus, although its amplitude is only a small fraction of the transient INa, INaP was found 
to contribute significantly to the hypoxic elevation of [Na+]i in ventriculular 
cardiomyocytes (Haigney et al., 1994; Eigel and Hadley, 1999; Xiao and Allen, 1999; 
O’Rourke and Maack, 2007). From an electrophysiological point of view, this was 
shown to be sufficient to prolong the cardiac action potential (AP) plateau/duration, 
resulting in, for example, ‘temporal’ AP heterogeneity, early after depolarizations 
(EADs), impaired diastolic relaxation and inappropriate contraction development during 
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late repolarization (Maltsev et al., 1998, 2007; Ward and Giles, 1997; Undrovinas et al., 
1999; Tian et al., 2004; Belardinelli et al., 2006; Zaza et al., 2008). In ischemic / 
hypoxic cardiomyocytes, excess Na+ entry via INaP was also found to potentiate Ca2+ 
loading through reduced or reversed Na+/Ca2+ exchange (NCX), thereby further 
contributing to the progression of cardiac arrhythmias and mechanical dysfunction 
(Baartscheer et al., 2003; Pieske and Houser, 2003; Bers et al., 2006; Maltsev and 
Undrovinas, 2008).  
In MDA-MB-231 cells, acute hypoxia-induced INaP can potentiate functional 
VGSC expression in the long-term, given (i) that enhanced Na+ influx can activate the 
AC/PKA (Cooper et al., 1998) and (ii) that PKA, in turn, upregulates functional VGSC 
expression in this BCa cell line (Chioni et al., 2010).  
 
3.1.1 Aims and scope 
The overall aim of this study was to determine the effects of chronic (24 h) and acute 
hypoxia (minutes) on VGSC (nNav1.5) expression / activity in the strongly metastatic 
MDA-MB-231 human BCa cells. The specific aims were as follows: 
i. To elucidate the effect of chronic hypoxia on functional VGSC expression. 
ii. To determine the level (mRNA vs. protein) at which any regulation occurred, 
and to gain an insight into the underlying control mechanism. 
iii. To elucidate the effect of acute hypoxia on VGSC activity (INaP in particular), 
and to determine whether acute and chronic hypoxic effects are interrelated.  
iv. To ascertain any consequence of hypoxia on VGSC-dependent MCBs in vitro. 
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3.2 Results 
3.2.1 Effect of chronic hypoxia (24 h) on VGSC activity 
3.2.1.1 General observations 
MDA-MB-231 cells were incubated for 24 h in normoxic or hypoxic conditions (2% 
O2), 3 h post-seeding, and their voltage-activated membrane currents were studied using 
whole-cell patch-clamp subsequently. Chronic hypoxia had no noticeable effect on cell 
morphology; cells remained adherent and generally phase bright (Appendix 1). There 
was also no effect on cell viability (P = 0.73 for hypoxia vs. normoxia, n = 90; 
Appendix 2). After pre-incubation in hypoxic conditions (2% O2) for 24 h, 87.3 ± 4.5% 
of cells expressed rapidly inactivating inward currents (n = 48 / 54 from eight 
experiments), compared to 94.1 ± 2.8% for normoxic cells (n = 45 / 48 from seven 
experiments; P = 0.22) (Figure 3.1ABD). Superfusion with Na+-free mammalian 
physiological saline (MPS) perfusion solution completely eliminated the inward 
currents in both normoxic and hypoxic MDA-MB-231 cells (n = 6 each), confirming 
that all recorded currents were carried by VGSCs (Appendix 3; Fraser et al., 2005; 
Brackenbury et al., 2007). Cells that did not express inward currents were not included 
in the subsequent peak current density analysis. 
 
3.2.1.2 Peak VGSC current density 
After the initial 15-min perfusion with the mammalian physiological saline (MPS), 
measurements were typically taken from 5-6 cells per dish, at ~ 10-min intervals over ~ 
60 min. To confirm that any effect of hypoxia (2% O2, 24 h) remained stable during the 
recordings, peak VGSC current densities of normoxic and hypoxic cells were monitored 
for any change during the 60-min recording period (Figure 3.1C). The linear regression 
slopes of ‘current density vs. time post perfusion’ plots for normoxic and hypoxic cells  
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Figure 3.1 Chronic hypoxia (2% O2, 24 h) enhanced peak VGSC current density 
(A) Typical whole-cell VGSC currents in normoxic vs. hypoxic (2% O2, 24 h) MDA-MB-231 
cells, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -100 
mV; interpulse duration was 2 s. (B) Percentage of normoxic and hypoxic cells expressing 
functional VGSCs (unpaired t-test: P = 0.22; n = 7-8 dishes). (C) Peak VGSC current density of 
normoxic and hypoxic cells plotted against the time (post perfusion) (n ≥ 5). Normoxia data 
(dashed line; y = -0.04x – 11.1) and hypoxia data (solid line; y = -0.03x – 19.7) were fitted with 
the linear equation. (D) Peak current amplitudes of all recorded normoxic (bottom, n = 45) and 
hypoxic cells (top, n = 48) (shown chronologically). (E) Average peak current density in 
normoxic and hypoxic cells (unpaired t-test: (**) P < 0.01, n = 45-48). Inset, whole-cell 
capacitance in normoxic vs. hypoxic cells (unpaired t-test: P = 0.67). (F) Mean I-V relationships 
in normoxic and hypoxic cells (n = 45-48). Current density was larger in hypoxic cells in the 
voltage range -50 to +15 mV (unpaired t-test: P < 0.05). Data are mean ± SEM (except part D).    
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were not significantly different from zero (P = 0.57 and 0.69, respectively), and were 
not significantly different from each other (P = 0.91), confirming the persistence of the 
hypoxic effects for at least 75 min under normoxic conditions (Figure 3.1C). This 
allowed mean peak VGSC current densities to be complied from all cells studied during 
the recording period, irrespective of the time of the recording.  
 Peak current amplitudes recorded from forty-five normoxic and forth-eight 
hypoxic cells (from n = 7-8 dishes, respectively) are shown in Figure 3.1D (in 
chronological order). Clearly, there was no systematic difference between current sizes 
recorded on different days within the normoxic or the hypoxic group, i.e. functional 
VGSC expression of an individual batch of MDA-MB-231 cells varied only minimally 
with time in culture (Figure 3.1D). The hypoxia pre-treatment significantly enhanced 
mean peak current amplitude by ~ 42% from -301.8 ± 28.2 pA (normoxia) to -429.6 ± 
31.3 pA (P < 0.01, n = 45-48) (Figure 3.1AEF and Table 3.1). Importantly, this increase 
was not due to a change in cell size, since average whole-cell capacitance was similar in 
normoxic (21.4 ± 0.7 pF) and hypoxic cells (21.1 ± 0.7 pF, P = 0.67) (Figure 3.1E 
inset). Thus, peak current density was ~ 46% larger in hypoxic (-20.5 ± 1.4 pA/pF) 
compared to normoxic cells (-14.0 ± 1.2 pA/pF; P < 0.001) (Figure 3.1E and Table 3.1). 
Hypoxia-induced augmentation of Na+ current density was apparent at all activating test 
potentials, and was statistically significant in the voltage-range -50 mV to +15mV (P < 
0.05, n = 45-48; Figure 3.1F).  
  
3.2.1.3 VGSC gating and kinetics 
The effects of chronic hypoxia on the VGSC functional parameters in MDA-MB-231 
cells are summarized in Table 3.1. Pre-incubation in the hypoxic conditions (2% O2, 24 
h) had no effect on threshold of activation (Vthres), voltage for current peak (Vpeak), and  
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Table 3.1 Effects of hypoxia (2% O2, 24 h) on VGSC activity in MDA-MB-231 cells 
 
Parameter Normoxia Hypoxia n P-value 
Peak current (pA) -301.8 ± 28.2  -429.6 ± 31.3  45-48  0.003 ** 
Capacitance (pF) 21.4 ± 0.7 21.1 ± 0.7 45-48 0.67 
Peak current density (pA/pF) -14.0 ± 1.2 -20.5 ± 1.4  45-48 < 0.001 ** 
Vthres (mV) -47.0 ± 0.5  -47.9 ± 0.5  45-48 0.18 
Vpeak (mV) -3.9 ± 1.1  -5.3 ± 1.2  45-48 0.38 
Activation V1/2 (mV) -22.4 ± 1.1  -23.5 ± 0.9  45-48 0.41 
Activation k (mV) 7.9 ± 0.3  8.1 ± 0.2  45-48 0.61 
Inactivation V1/2 (mV) -85.7 ± 1.4  -85.1 ± 1.0  14-17 0.70 
Inactivation k (mV) -5.5 ± 0.2  -5.2 ± 0.2  14-17 0.23 
V0 (mV) 14.3 ± 1.4  15.8 ± 1.1  45-48 0.40 
Tpeak at 0 mV (ms) 1.15 ± 0.03  1.17 ± 0.04  45-48 0.69 
τfast at 0 mV (ms) 1.16 ± 0.14  1.08 ± 0.10  8-8 0.64 
τslow at 0 mV (ms) 7.53 ± 0.88  7.09 ± 0.53  8-8 0.67 
Afast at 0 mV (%) 66.5 ± 3.1   72.9 ± 2.2  8-8 0.11 
Aslow at 0 mV (%) 33.5 ± 3.1  27.1 ± 2.2  8-8 0.11 
τrecovery (ms)  19.0 ± 2.5  18.9 ± 1.7  8-11 0.98 
IC50 (µM) 4.0 ± 0.6 3.9 ± 0.9 ≥ 5 0.95 
 
 
Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant; IC50, 
concentration of TTX at which 50% of VGSC current is inhibited. Data are mean ± SEM. 
Statistical significance (P-value) was determined by unpaired t-tests: (**) P < 0.01. 
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voltage-dependence of activation or steady-state inactivation (Figure 3.1F and 3.2A). 
The window current between -60 mV and -20 mV was also unaffected by the hypoxia 
pre-treatment (Figure 3.2A inset). Similarly, kinetics of activation (Tpeak; Figure 3.2B), 
rate of recovery from inactivation (τrecovery; Figure 3.2C), and kinetics of inactivation 
from open-state (τfast, τslow and their fractional amplitudes; Figure 3.2DE) were not 
modified by chronic hypoxia. These findings suggested that the hypoxic increase in 
peak Na+ current density was not due to a change in VGSC gating, and possibly 
involved mainly increased number of functional VGSCs in the plasma membrane. 
Unchanged VGSC gating characteristics in chronically hypoxic cells also indicated that 
the proportion of VGSCαs expressed in MDA-MB-231 cells was not altered by the 
hypoxic pre-treatment, i.e. nNav1.5 remained as the pre-dominant functional VGSCα 
expressed. 
 
3.2.1.4 TTX sensitivity  
Pre-treatment under hypoxic conditions (2% O2, 24 h) had no effect on cells’ TTX-
sensitivity in the concentration range 0.01 – 30 µM (Figure 3.3 and Table 3.1). TTX 
block was studied using infrequent (0.1 Hz) single depolarisations to 0 mV, and typical 
traces illustrating dose-dependent inhibition of Na+ currents are shown in Figure 3.3A. 
At nanomolar concentrations of TTX (< 1 µM), current inhibition was similar in 
normoxic and chronically hypoxic cells, suggesting, again, that the ratio of functional 
nNav1.5 vs. TTX-S (Nav1.7) channels in MDA-MB-231 cells remained unchanged by 
the hypoxia pre-treatment (Figure 3.3BC; Brackenbury et al., 2007). In addition, Hill 
equation fits to dose-response curves yielded statistically similar IC50 values for 
normoxic (4.0 ± 0.6 µM) and hypoxic cells (3.9 ± 0.9 µM) (P = 0.95, n ≥ 5; Figure 
3.3B). Current inhibition by TTX was fully and rapidly reversible within seconds of  
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Figure 3.2 Chronic hypoxia (2% O2, 24 h) did not affect VGSC gating characteristics 
Data are presented as mean ± SEM; some error bars are smaller than symbols. Values of fitted 
parameters (obtained from cell-by-cell fits) are given in Table 3.1. (A) Normalized availability-
voltage (squares) and conductance (G/Gmax)-voltage relationships (circles) for normoxic and 
hypoxic (2% O2, 24 h) MDA-MB-231 cells. Normoxia (dashed lines) and hypoxia data (solid 
lines) were fitted with Boltzmann functions. The window current between -60 mV and -20 mV is 
magnified on the right. G/Gmax data were from the I-V recordings described in Figure 3.1AE 
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(n ≥ 45). For availability, currents were elicited with 80 ms test pulses to -10 mV after 1 s pre-
pulses in the range -140 mV to -10 mV (n ≥ 14). Holding potential was -100 mV and interpulse 
duration was 2 s. Currents (I) were normalized to the maximum current (Imax) recorded 
following the most hyperpolarized pre-pulse (-140 mV). (B) Time to peak (Tpeak) plotted as a 
function of test potential and fitted with single exponential functions in normoxic (dashed lines) 
and hypoxic cells (solid lines) (n ≥ 45). Tpeak was not affected by the hypoxic treatment 
(unpaired t-test vs. normoxia; P > 0.05 at all voltages). (C) Time-course of recovery from 
inactivation was studied with an 80 ms control pulse to -10 mV (giving current Ic), return to -
100 mV for a recovery interval ranging from 5 to 155 ms and then an identical test pulse to -10 
mV (giving current It). Holding potential was -100 mV and interpulse duration was 2 s. 
Recovered current (It /Ic) was plotted as a function of recovery interval and fitted with single 
exponential functions for normoxic (dashed lines) and hypoxic cells (solid lines) (n ≥ 8). (D) 
Time constant (τfast) and percentage amplitude (Afast) of fast inactivation (determined from 
double exponential fits to normalized Na+ current decays) plotted as a function of test potential 
(n = 8). τfast data points are connected with dashed lines for normoxic and solid lines for hypoxic 
cells. For Afast, white and black bars represent normoxic and hypoxic cells, respectively. Chronic 
hypoxia was without effect on τfast or Afast (unpaired t-tests; P > 0.05 at all voltages). (E) As in 
part D, but for the slow component of inactivation (τslow and Afast). Note that Afast + Aslow = 100% 
at each voltage. 
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Figure 3.3 Chronic hypoxia (2% O2, 24 h) had no effect on sensitivity to TTX 
(A) Typical whole-cell Na+ currents in (i) normoxic and (ii) hypoxic (2% O2, 24 h) MDA-MB-
231 cells, before and after 0.1, 1 and 7 µM TTX. Currents were elicited by 12 ms depolarizing 
steps to 0 mV at 0.1 Hz from a holding potential of -100 mV. Dashed horizontal lines indicate 
zero current. (B) Dose-response relationships for TTX block fitted with the Hill equation (nH = 
1); normoxic cells (dashed line; n ≥ 5) and hypoxic cells (solid line; n ≥ 6). Pulse protocol as in 
part A; block was monitored until a steady-state maximum was reached (< 2 min) and data were 
normalized to first control current. IC50 estimates are reported in Table 3.1. (C) Time-course of 
0.01 µM (squares) and 7 µM (circles) TTX block in normoxic (open symbols) and hypoxic cells 
(black symbols). Arrow indicates TTX application. Data were normalized to peak current 
obtained by the first control pulse (n ≥ 5). Data are presented as mean ± SEM. 
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washout and the time-course of block onset was comparable in normoxic and hypoxic 
cells at 0.01 µM and 7 µM TTX (Figure 3.3C). 
 
3.2.1.5 Outward current density  
In line with the inverse relationship between outward current density and metastatic 
potential (Onkal and Djamgoz, 2009), highly metastatic MDA-MB-231 cells were 
reported to express small (~ 100 pA) outward currents (Fraser et al., 2005). In the 
present study, hypoxia-induced increase in VGSC current density was not accompanied 
by any change in outward current expression in MDA-MB-231 cells (Figure 3.4). After 
24 h pre-incubation in hypoxic conditions (2% O2), 83.3 ± 16.7% of cells expressed 
outward currents (n = 15 / 19 from four experiments), similar to 68.3 ± 18.9% for 
normoxic cells (n = 17 / 26 from four experiments; P = 0.58) (Figure 3.4AB). Notably, 
outward currents in normoxic and hypoxic cells disappeared when Cs+ was included in 
the internal pipette solution (e.g. Figure 3.1A), suggesting that these were mediated by 
voltage-gated K+ channels (VGPCs) (Fraser et al., 2005). I-V recordings revealed that 
outward current profiles varied between cells; some currents started to decay after ~ 20 
ms, whereas others did not (Figure 3.4A). Thus, peak current measurements were taken 
at two different time points: ‘early’ (20 ms after the onset of the voltage pulse), and 
‘late’ (200 ms after the onset of the voltage pulse). Hypoxia (2% O2, 24 h) had no effect 
on early or late outward current density (Figure 3.4C).  
 
3.2.1.6 Effect of milder chronic hypoxia (5% O2, 24 h)  
Milder chronic hypoxia (5% O2, 24 h) also induced a significant increase in peak Na+ 
current density in MDA-MB-231 cells, suggesting that the threshold O2 level for this 
effect is even higher than 5% O2 (i.e. ~ average O2 level in healthy mammalian tissue in  
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Figure 3.4 Hypoxic pre-treatment (2% O2, 24 h) did not affect outward current density  
(A) Two typical sets of outward currents in MDA-MB-231 cells, elicited by 200 ms 
depolarizing pulses between -70 mV and +70 mV applied from a holding potential of -90 mV 
with interpulse duration of 5 s: (i) slow inactivating and (ii) faster decaying. (B) Percentage of 
normoxic and hypoxic (2% O2, 24 h) cells expressing outward currents (unpaired t-test: P = 
0.58; n = 4 dishes). (C) Peak ‘early’ and ‘late’ outward current densities, measured respectively 
20 ms and 200 ms post onset of the voltage pulses, in normoxic (white bars; n = 17) and 
hypoxic cells (black bars; n = 15). Unpaired t-tests revealed that chronic hypoxia had no effect 
on early or late outward current density (P = 0.24 and 0.22, respectively). Data are presented as 
mean ± SEM.   
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vivo; Brahimi-Horn and Pouyssegur, 2009). After pre-incubation in mildly hypoxic 
conditions (5% O2) for 24 h, 87.1 ± 4.9% of cells expressed Na+ currents (n = 25 / 29 
from five experiments), similar to 93.3 ± 3.1% for normoxic cells (n = 28 / 30 from five 
experiments; P = 0.43) (Figure 3.5AB). Mild hypoxia pre-treatment significantly 
enhanced mean peak current density by 67% from -15.1 ± 1.8 pA/pF to -25.2 ± 2.6 
pA/pF (P < 0.01, n = 28-25) (Figure 3.5AC and Table 3.2), even surpassing the 
corresponding 46% increase induced by more severe (2% O2) hypoxia. The increase in 
Na+ current density was statistically significant in the voltage-range -35 mV to +30mV 
(P < 0.05; Figure 3.5D). Whole-cell capacitance was unchanged between the normoxic 
(25.9 ± 1.7 pF) and hypoxic (23.7 ± 0.8 pF) cells (P = 0.23) (Figure 3.5C inset and 
Table 3.2).  
 The effect of mild hypoxia on VGSC gating characteristics is summarized in 
Table 3.2. Similar to severe hypoxia (2% O2), mild hypoxia had no effect on threshold 
of channel activation (Vthres), voltage for current peak (Vpeak), voltage-dependence of 
activation or steady-state inactivation, or the window current (Figure 3.5D and 3.6A). 
Also, there was no effect on kinetics of activation (Tpeak; Figure 3.6B) or inactivation 
(τfast, τslow and their fractional amplitudes; Figure 3.6D), or rate of recovery from 
inactivation (τrecovery; Figure 3.6C). Unchanged VGSC gating further indicated that the 
hypoxia-induced increase in Na+ current density was likely due to increased number of 
existing functional VGSCs in the plasma membrane.  
 
3.2.1.7 Effect of chronic hypoxia (2% O2, 24 h) on VGSC activity in nNav1.5-
EBNA, Mat-LyLu and MCF-7 cells 
Na+ current in MDA-MB-231 cells is ~ 20% TTX-S (mainly Nav1.7) and ~ 80% TTX-
R (mainly nNav1.5) (Figure 3.3; Fraser et al., 2005; Brackenbury et al., 2007). To  
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Figure 3.5 Less severe chronic hypoxia (5% O2, 24 h) enhanced VGSC current density 
(A) Typical whole-cell VGSC currents in (i) normoxic and (ii) hypoxic (5% O2, 24 h) MDA-
MB-231 cells, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -100 mV; interpulse duration was 2 s. (B) Percentage of normoxic and hypoxic cells 
expressing functional VGSCs (unpaired t-test: P = 0.43; n = 5 dishes). (C) Average peak current 
density in normoxic and hypoxic cells (unpaired t-test: (**) P < 0.01, n = 28-25). Inset, whole-
cell capacitance in normoxic vs. hypoxic cells (unpaired t-test: P = 0.23). (D) Mean I-V 
relationships for normoxic and hypoxic cells (n = 28-25). Current density was larger in hypoxic 
cells in the voltage range -35 to +30 mV (unpaired t-test: P < 0.05). Data are mean ± SEM.     
 
 Chapter 3                                                                        Modulation of VGSC activity by hypoxia  
 
 188 
 
Table 3.2 Effects of hypoxia (5% O2, 24 h) on VGSC activity in MDA-MB-231 cells 
 
Parameter Normoxia Hypoxia n P-value 
Peak current (pA) -413.6 ± 57.8  -600.6 ± 68.0 28-25 0.04 * 
Capacitance (pF) 25.9 ± 1.7  23.7 ± 0.8 28-25 0.23 
Peak current density (pA/pF) -15.1 ± 1.8  -25.2 ± 2.6 28-25 0.003 ** 
Vthres (mV) -45.6 ± 0.7  -45.3 ± 0.5 28-25 0.70 
Vpeak (mV) -4.3 ± 1.6  -4.8 ± 0.9 28-25 0.76 
Activation V1/2 (mV) -22.8 ± 0.9  -22.2 ± 0.6 28-25 0.55 
Activation k (mV) 7.6 ± 0.3  7.9 ± 0.2 28-25 0.37 
Inactivation V1/2 (mV) -84.7 ± 1.2  86.0 ± 1.8 19-16 0.56 
Inactivation k (mV) -5.3 ± 0.2  -5.4 ± 0.3 19-16 0.79 
V0 (mV) 15.4 ± 1.6  16.2 ± 2.3 28-25 0.74 
Tpeak at 0 mV (ms) 0.93 ± 0.06  0.84 ± 0.03 28-25 0.17 
τfast at 0 mV (ms) 1.27 ± 0.31  1.17 ± 0.14 8-8 0.77 
τslow at 0 mV (ms) 8.01 ± 0.74  7.43 ± 0.81 8-8 0.58 
Afast at 0 mV (%) 70.4 ± 4.1  73.9 ± 2.8 8-8 0.47 
Aslow at 0 mV (%) 29.6 ± 4.1  26.1 ± 2.8 8-8 0.47 
τrecovery (ms)  19.0 ± 2.5  20.9 ± 2.4 8-7 0.58 
 
 Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant. Data are mean 
± SEM. Statistical significance (P-value) was determined by unpaired t-tests: (*) P < 0.05, (**) 
P < 0.01. 
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Figure 3.6 Chronic hypoxia (5% O2, 24 h) did not affect VGSC gating characteristics  
Data are mean ± SEM. Values of fitted parameters (obtained from cell-by-cell fits) are given in 
Table 3.2. For parts A-C, dashed and solid lines represent fits to data from normoxic and 
hypoxic (5% O2, 24 h) MDA-MB-231 cells, respectively. Pulse protocols and data analysis were 
as detailed in Figure 3.2. (A) Availability-voltage (squares; n ≥ 16) and G/Gmax-voltage 
relationships (circles; n ≥ 25) fitted with Boltzmann functions. The window current is magnified 
on the right. (B) Time to peak (Tpeak) as a function of voltage fitted with single exponential 
functions (n ≥ 25). (C) Time-course of recovery from inactivation fitted with single exponential 
functions (n ≥ 7). (D) τfast (i), τslow (ii), and their percentage amplitudes (iii) from double 
exponential fits to normalized INa decays at 0 mV (n = 8). Chronic hypoxia was without effect 
on Tpeak, channel recovery (It/Ic), τfast, τslow, Afast or Aslow (unpaired t-tests: P > 0.05 at all voltages).  
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determine the effect of chronic hypoxia on nNav1.5 and Nav1.7 individually, and to test 
whether hypoxic upregulation of VGSC activity also occurs in metastatic PCa cells, 
nNav1.5-EBNA and Mat-LyLu cells (metastatic rat model of PCa, where Nav1.7 is the 
predominant functional VGSCα) were cultured in hypoxic conditions (2% O2) for 24 h 
and their membrane currents were studied.  
Effects of chronic hypoxia on nNav1.5-EBNA and Mat-LyLu (Nav1.7) Na+ 
currents were remarkably similar to the effects observed in MDA-MB-231 cells, i.e. 
peak Na+ current density was enhanced by ~ 50%, whilst there was no significant 
change in channel gating characteristics: 
i. nNav1.5-EBNA: Hypoxia pre-treatment (2% O2, 24 h) did not affect cell 
morphology (Appendix 1) or viability (Appendix 2). Na+-free MPS or 30 µM TTX 
abolished all inward currents in nNav1.5-EBNA cells, i.e. there was no ionic 
conductance other than Na+ under the recording conditions used (Appendix 3) 
(Onkal et al., 2008a). Average peak Na+ current density was 48% larger in 
chronically hypoxic (-535.8 ± 53.4 pA/pF, n = 39) vs. normoxic cells (-363.0 ± 
33.6 pA/pF; n = 37) (P < 0.01; Figure 3.7AB and Table 3.3). There was no 
significant effect on whole-cell capacitance (P = 0.07) (Figure 3.7B inset and 
Table 3.3). Increase in Na+ current density was apparent at all activating test 
potentials, and was statistically significant in the voltage-range -30 mV to +15mV 
(P < 0.05; Figure 3.7C). Chronic hypoxia was without effect on voltage-
dependence or kinetics of activation or inactivation, or rate of recovery from 
inactivation (Figure 3.8 and Table 3.3).  
ii. Mat-LyLu (Nav1.7): Hypoxia pre-treatment (2% O2, 24 h) had no noticeable 
effect on cell morphology, i.e. cells remained adherent and generally phase-bright 
(Appendix 1). Although Mat-LyLu cells tended to cluster, only round, isolated  
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Figure 3.7 Chronic hypoxia (2% O2, 24 h) enhanced nNav1.5 currents in EBNA-293 cells 
(A) Typical whole-cell VGSC currents in (i) normoxic and (ii) hypoxic (2% O2, 24 h) nNav1.5-
EBNA cells, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -100 mV; interpulse duration was 2 s. (B) Average peak current density in normoxic and 
hypoxic nNav1.5-EBNA cells (unpaired t-test: (**) P < 0.01, n = 37-39). Inset, whole-cell 
capacitance in normoxic vs. hypoxic cells (unpaired t-test: P = 0.07). (C) Mean I-V relationships 
for normoxic and hypoxic cells (n = 37-39). Current density was larger in hypoxic cells in the 
voltage range -30 to +15 mV (unpaired t-test: P < 0.05). Data are mean ± SEM.     
 
 Chapter 3                                                                        Modulation of VGSC activity by hypoxia  
 
 192 
 
Table 3.3 Effects of hypoxia (2% O2, 24 h) on functional characteristics of nNav1.5 
 
Parameter Normoxia Hypoxia n P-value 
Peak current (pA) -4567.3 ± 373.3  -6005.8 ± 588.7  37-39 0.03 * 
Capacitance (pF) 13.6 ± 0.7  11.7 ± 0.7  37-39 0.07 
Peak current density (pA/pF) -363.0 ± 33.6  -535.8 ± 53.4  37-39 0.008 ** 
Vthres (mV) -55.3 ± 0.4  -56.0 ± 0.5  37-39 0.29 
Vpeak (mV) -18.2 ± 1.8  -17.3 ± 1.7  37-39 0.70 
Activation V1/2 (mV) -33.4 ± 1.1  -32.8 ± 1.1  37-39 0.69 
Activation k (mV) 6.1 ± 0.3  6.2 ± 0.3  37-39 0.79 
Inactivation V1/2 (mV) -87.0 ± 2.3  -86.5 ± 2.2  10-8 0.88 
Inactivation k (mV) -5.7 ± 0.2  -5.9 ± 0.7  10-8 0.82 
V0 (mV) 18.7 ± 1.4  17.5 ± 1.3  37-39 0.56 
Tpeak at 0 mV (ms) 0.61 ± 0.02  0.57 ± 0.02  37-39 0.15 
τfast at 0 mV (ms) 0.94 ± 0.07  1.01 ± 0.04  10-10 0.38 
τslow at 0 mV (ms) 5.89 ± 0.59  5.81 ± 0.27  10-10 0.91 
Afast at 0 mV (%) 87.7 ± 2.6  85.9 ± 4.0  10-10 0.65 
Aslow at 0 mV (%) 12.3 ± 2.6  14.1 ± 4.0  10-10 0.65 
τrecovery (ms)  14.7 ± 1.3  14.6 ± 0.9  10-8 0.97 
 
Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant. Data are mean 
± SEM. Statistical significance (P-value) was determined by unpaired t-tests: (*) P < 0.05, (**) 
P < 0.01. 
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Figure 3.8 Chronic hypoxia (2% O2, 24 h) did not affect nNav1.5 gating characteristics  
Data are mean ± SEM. Values of fitted parameters (obtained from cell-by-cell fits) are given in 
Table 3.3. For parts A-C, dashed and solid lines represent fits to data from normoxic and 
hypoxic (2% O2, 24 h) nNav1.5-EBNA cells, respectively. Pulse protocols and data analysis 
were as detailed in Figure 3.2. (A) Availability-voltage (squares; n ≥ 8) and G/Gmax-voltage 
relationships (circles; n ≥ 37) fitted with Boltzmann functions. The window current is magnified 
on the right. (B) Time to peak (Tpeak) as a function of voltage fitted with single exponential 
functions (n ≥ 37). (C) Time-course of recovery from inactivation fitted with single exponential 
functions (n ≥ 8). (D) τfast (i), τslow (ii), and their percentage amplitudes (iii) from double 
exponential fits to normalized INa decays at 0 mV (n = 10). Chronic hypoxia was without effect 
on Tpeak, channel recovery (It/Ic), τfast, τslow, Afast or Aslow (unpaired t-tests: P > 0.05 at all voltages).  
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cells were selected for patch clamp recordings. All cells studied under normoxic 
conditions (n = 21 from four experiments) and hypoxia (n = 25 from five 
experiments) expressed rapid inward currents, which were completely eliminated 
by superfusion with a Na+-free MPS solution (n = 4 each; Appendix 3) 
(Brackenbury and Djamgoz, 2006). Average peak Na+ current density was 49% 
larger in chronically hypoxic (-32.4 ± 2.4 pA/pF, n = 25) vs. normoxic cells (-21.7 
± 2.7 pA/pF; n = 21) (P < 0.01; Figure 3.9AB and Table 3.4). Whole-cell 
capacitance was unchanged (P = 0.08) (Figure 3.9B inset). The increase in Na+ 
current density was statistically significant in the voltage-range -15 mV to +15mV 
(P < 0.05; Figure 3.9C). Chronic hypoxia was without effect on voltage-
dependence or kinetics of activation or inactivation, or rate of recovery from 
inactivation (Figure 3.10 and Table 3.4). 
We also tested whether chronic hypoxia could induce functional VGSC expression in 
weakly metastatic MCF-7 BCa cells, which normally do not express any inward 
currents (Fraser et al., 2005). However, severe hypoxia (2% O2) for 24 h or even 48 h 
was without effect, i.e. hypoxic MCF-7 cells failed to express any inward currents (n = 
16). Also, cell viability and morphology were unaffected by the hypoxic treatment 
(Appendices 1 and 2). 
 
3.2.2 Effect of shorter-term hypoxia (2% O2, 90 min) on VGSC activity 
To determine whether the hypoxic increase in VGSC current density occurred rapidly 
(i.e. within minutes), MDA-MB-231 cells were incubated in normoxic or hypoxic (2% 
O2) conditions for 90 min and their membrane currents were studied. Such hypoxic 
treatment was without effect on MDA-MB-231 Na+ current density: -16.5 ± 2.0 pA/pF 
in normoxia and -18.0 ± 1.7 pA/pF in hypoxia (P = 0.57, n = 19 each) (Figure 3.11 and  
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Figure 3.9 Chronic hypoxia (2% O2, 24 h) enhanced Na+ current density in Mat-LyLu cells 
(A) Typical whole-cell VGSC currents in (i) normoxic and (ii) hypoxic (2% O2, 24 h) Mat-LyLu 
cells, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -100 
mV; interpulse duration was 2 s. (B) Average peak current density in normoxic and hypoxic 
Mat-LyLu cells (unpaired t-test: (**) P < 0.01, n = 21-25). Inset, whole-cell capacitance in 
normoxic vs. hypoxic cells (unpaired t-test: P = 0.08). (C) Mean I-V relationships for normoxic 
and hypoxic cells (n = 21-25). Current density was larger in hypoxic cells in the voltage range -
15 to +15 mV (unpaired t-test: P < 0.05). Data are mean ± SEM.     
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Table 3.4 Effects of hypoxia (2% O2, 24 h) on VGSC activity in Mat-LyLu cells 
 
Parameter Normoxia Hypoxia n P-value 
Peak current (pA) -479.1 ± 59.1  -640.0 ± 53.4  21-25 0.04 * 
Capacitance (pF) 22.8 ± 1.5  19.7 ± 0.9  21-25 0.08 
Peak current density (pA/pF) -21.7 ± 2.7  -32.4 ± 2.4  21-25 0.004 ** 
Vthres (mV) -36.5 ± 0.8  -37.9 ± 0.7  21-25 0.20 
Vpeak (mV) -4.5 ± 1.2  -3.0 ± 1.2  21-25 0.39 
Activation V1/2 (mV) -17.6 ± 0.8  -16.1 ± 1.1  21-25 0.26 
Activation k (mV) 5.8 ± 0.4  5.4 ± 0.2  21-25 0.42 
Inactivation V1/2 (mV) -78.6 ± 1.4  -79.6 ± 1.5  10-6 0.64 
Inactivation k (mV) -6.1 ± 0.4  -6.1 ± 0.3  10-6 0.94 
V0 (mV) 10.4 ± 2.0  11.6 ± 1.8  21-25 0.65 
Tpeak at 0 mV (ms) 0.79 ± 0.04  0.73 ± 0.05  21-25 0.44 
τfast at 0 mV (ms) 0.90 ± 0.11  0.74 ± 0.08  8-8 0.26 
τslow at 0 mV (ms) 5.13 ± 0.70  5.49 ± 0.29  8-8 0.63 
Afast at 0 mV (%) 91.8 ± 2.1  94.2 ± 2.8  8-8 0.50 
Aslow at 0 mV (%) 8.2 ± 2.1  5.8 ± 2.8  8-8 0.50 
τrecovery (ms)  15.4 ± 2.6  14.8 ± 4.6  8-7 0.91 
 
 Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant. Data are mean 
± SEM. Statistical significance (P-value) was determined by unpaired t-tests: (*) P < 0.05, (**) 
P < 0.01. 
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Figure 3.10 Chronic hypoxia (2% O2, 24 h) did not affect VGSC gating in Mat-LyLu cells 
Data are mean ± SEM. Values of fitted parameters (obtained from cell-by-cell fits) are given in 
Table 3.4. For parts A-C, dashed and solid lines represent fits to data from normoxic and 
hypoxic (2% O2, 24 h) Mat-LyLu cells, respectively. Pulse protocols and data analysis were as 
detailed in Figure 3.2. (A) Availability-voltage (squares; n ≥ 6) and G/Gmax-voltage relationships 
(circles; n ≥ 21) fitted with Boltzmann functions. The window current is magnified on the right. 
(B) Time to peak (Tpeak) as a function of voltage fitted with single exponential functions (n ≥ 
21). (C) Time-course of recovery from inactivation fitted with single exponential functions (n ≥ 
7). (D) τfast (i), τslow (ii), and their percentage amplitudes (iii) from double exponential fits to 
normalized INa decays at 0 mV (n = 8). Chronic hypoxia was without effect on Tpeak, channel 
recovery (It/Ic), τfast, τslow, Afast or Aslow (unpaired t-tests: P > 0.05 at all voltages).  
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Table 3.5). Whole-cell capacitance was also unchanged (P = 0.22) (Figure 3.11B inset). 
As regards channel gating, short-term hypoxia (2% O2, 90 min) insignificantly 
depolarized activation V1/2 by 3-4 mV (P = 0.08, n = 19 each) (Figure 3.11C and 3.12A) 
and had no effect on Vthres, Vpeak or activation k (Figure 3.11C and 3.12A), inactivation 
V1/2 or k (Figure 3.12A), Tpeak (Figure 3.12B), τfast, τslow and their fractional amplitudes 
(Figure 3.12D), or τrecovery (Figure 3.12C) (Table 3.5).  
 Taken together, these results suggested that the hypoxic augmentation of Na+ 
current density (i.e. after 24 h) occurred with a time delay > 90 min. Thus, the suggested 
increase in the number of functional VGSCs in the plasma membrane likely involved de 
novo mRNA and/or protein synthesis, rather than a rapid process such as membrane 
insertion of pre-assembled channels. The subcellular level at which hypoxic 
upregulation of VGSC functional expression occurred was investigated as described 
later in Sections 3.2.6 and 3.2.7. 
 
3.2.3 Effect of acute hypoxia on VGSC activity  
We next determined the effects of acute exposure to hypoxia on peak INa and persistent 
Na+ currents (INaP) in MDA-MB-231 cells. It is well evidenced that acute hypoxia 
enhances INaP, thereby increasing [Na+]i in cardiomyoctes as well as in other cell types 
including hippocampal rat neurons and Nav1.5-expressing HEK-293 cells (Ju et al., 
1996; Hammerstrom and Gage, 2000; Fearon and Brown, 2004; Wang et al., 2007). 
Earlier, we did not determine the effects of chronic (24 h) or short-term (90 min) 
hypoxia on INaP, since patch-clamp experiments were performed in normoxic 
conditions, and the hypoxic increase in INaP is rapidly reversible upon perfusion with 
normoxic bath solution during recordings (see below; Fearon and Brown, 2004).  
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Figure 3.11 Short-term hypoxia (2% O2, 90 min) did not affect Na+ current density  
(A) Typical whole-cell VGSC currents in (i) normoxic and (ii) hypoxic (2% O2, 90 min) MDA-
MB-231 cells, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -100 mV; interpulse duration was 2 s. (B) Average peak current density in normoxic and 
hypoxic cells (unpaired t-test: P = 0.57, n = 19 each). Inset, whole-cell capacitance in normoxic 
vs. hypoxic cells (unpaired t-test: P = 0.22). (C) Mean I-V relationships for normoxic and 
hypoxic cells (n = 19 each). Current density was similar across the voltage range tested 
(unpaired t-test: P > 0.05). Inset magnifies activation in the range -60 mV to -30 mV (dotted 
square box). Data are presented as mean ± SEM.     
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Table 3.5 Effects of hypoxia (2% O2, 90 min) on VGSC activity in MDA-MB-231 
cells 
 
Parameter Normoxia Hypoxia n P-value 
Peak current (pA) -398.8 ± 49.6  -391.1 ± 36.4  19-19 0.90 
Capacitance (pF) 24.1 ± 1.2  22.0 ± 1.1  19-19 0.22 
Peak current density (pA/pF) -16.5 ± 2.0  -18.0 ± 1.7  19-19 0.57 
Vthres (mV) -46.4 ± 0.6  -45.9 ± 0.7  19-19 0.54 
Vpeak (mV) -6.3 ± 1.8  -5.5 ± 2.1  19-19 0.78 
Activation V1/2 (mV) -26.7 ± 1.4  -23.5 ± 1.2  19-19 0.08 
Activation k (mV) 6.8 ± 0.5  7.4 ± 0.4  19-19 0.38 
Inactivation V1/2 (mV) -85.6 ± 1.2  -85.9 ± 0.9  14-10 0.87 
Inactivation k (mV) -5.4 ± 0.3  -5.3 ± 0.3 14-10 0.77 
V0 (mV) 18.9 ± 3.0  18.0 ± 3.8  19-19 0.83 
Tpeak at 0 mV (ms) 0.81 ± 0.04   0.79 ± 0.03  19-19 0.62 
τfast at 0 mV (ms) 1.30 ± 0.12  1.14 ± 0.10  8-8 0.32 
τslow at 0 mV (ms) 7.91 ± 0.67  7.49 ± 0.45  8-8 0.61 
Afast at 0 mV (%) 76.0 ± 4.8  70.7 ± 3.9  8-8 0.40 
Aslow at 0 mV (%) 24.0 ± 4.8  29.3 ± 3.9  8-8 0.40 
τrecovery (ms)  16.2 ± 2.2  17.0 ± 1.5  10-8 0.77 
 
Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant. Data are mean 
± SEM. Statistical significance (P-value) was determined by unpaired t-tests: (*) P < 0.05, (**) 
P < 0.01. 
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Figure 3.12 Short-term hypoxia (2% O2, 90 min) was without effect on VGSC gating  
Data are mean ± SEM. Values of fitted parameters (obtained from cell-by-cell fits) are given in 
Table 3.5. For parts A-C, dashed and solid lines represent fits to data from normoxic and 
hypoxic (2% O2, 90 min) MDA-MB-231 cells, respectively. Pulse protocols and data analysis 
were as detailed in Figure 3.2. (A) Availability-voltage (squares; n ≥ 10) and G/Gmax-voltage 
relationships (circles; n = 19) fitted with Boltzmann functions. The window current is magnified 
on the right. (B) Time to peak (Tpeak) as a function of voltage fitted with single exponential 
functions (n = 19). (C) Time-course of recovery from inactivation fitted with single exponential 
functions (n ≥ 8). (D) τfast (i), τslow (ii), and their percentage amplitudes (iii) from double 
exponential fits to normalized INa decays at 0 mV (n = 8). Chronic hypoxia was without effect 
on Tpeak, channel recovery (It/Ic), τfast, τslow, Afast or Aslow (unpaired t-tests: P > 0.05 at all voltages).  
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3.2.3.1 Recording conditions and general observations  
Acute hypoxia (~ 20 mmHg / 2.6% O2) was induced by bubbling the MPS solution (± 
pharmaceutical agents) with 100% N2 (Ju et al., 1996). Effects on peak INa and INaP were 
characterized in MDA-MB-231 as well as nNav1.5-EBNA cells, using 300 ms single 
pulses to -20 mV (~ voltage for maximal INaP activation in Nav1.5; Ju et al., 1996; 
Saint, 2006) at 0.1 Hz frequency. For each cell, 2 initial pulses were applied under 
control (normoxic) conditions to check for basic Na+ current expression; this was 
followed by (i) 2 pulses in the presence of Na+-free MPS (to reveal any background 
ionic or leak currents), (ii) 4 pulses under control conditions (for Na+ currents to 
recover), and (iii) 30 pulses in the presence of acute hypoxia (5 min) (this protocol is 
summarized in Appendix 4). Finally, either (i) the cells were re-perfused with normoxic 
MPS (typically 1-2 min) to check for reversibility of the hypoxic effects, followed by a 
second Na+-free MPS application (e.g. Figure 3.14), or (ii) ranolazine or TTX (in 
hypoxic MPS) was applied to determine the extent of inhibition of peak and persistent 
Na+ currents, followed by the Na+-free MPS application (e.g. Figure 3.15 and 3.16). 
Recordings taken in Na+-free MPS at the beginning and end of the protocol were 
confirmed to be similar (i.e. no change in background ionic or leak current in time); 
otherwise, the recording was discarded. INaP was averaged between 200-225 ms in the 
initial Na+-free recording, and subtracted from the data points.   
 
3.2.3.2 Effects of acute hypoxia on VGSC currents in MDA-MB-231 cells 
Figures 3.13 and 3.14 illustrate the effects of acute hypoxia (5 min) on INa and INaP in 
MDA-MB-231 cells. Acute hypoxia rapidly reduced peak INa and enhanced INaP, 
consistent with earlier findings for Nav1.5-HEK cells and guinea pig ventricular 
cardiomyocytes (Fearon and Brown, 2004; Wang et al., 2007). Block of peak INa by 20- 
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Figure 3.13 Acute hypoxia enhanced INaP and slightly reduced peak INa in MDA-MB-231 cells
Example recordings from four different MDA-MB-231 cells (A, B, C, D) before (black traces) 
and after (red traces) acute hypoxia (~2.6% O2, 5 min). Currents were elicited by 300 ms single 
pulses to -20 mV from a holding potential of -100 mV at 0.1 Hz. Recordings in Na+-free MPS 
(grey traces) are also included to reveal any background current. Effects of acute hypoxia on 
peak INa are illustrated in part (i) for each cell (first 15 ms of the recordings are shown). There 
was a significant reduction in peak INa in most cells (n = 15 / 18; e.g. parts A and C) but not all 
(e.g. parts B and D). Effects on INaP are illustrated in parts (ii) with higher-gain traces (same 
traces as in corresponding part i). Acute hypoxia markedly enhanced INaP in all cells tested (n = 
18), albeit with different efficacy (e.g. part D vs. part C).  
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Figure 3.14 Acute hypoxic reduction in peak INa and enhancement of INaP 
Quantitative summary of the recordings described in Figure 3.13. (A) Time-course of the effect of acute 
hypoxia on peak INa in MDA-MB-231 cells (red circles, n = 18). Hypoxic MPS was applied after the 
fourth control pulse, and data were normalized to the first control current. To determine reversibility, 
normoxic solution was re-applied (‘wash’) after 5 min hypoxia. Peak INa was stable under control 
conditions during the recording period (black circles, n = 8). Bar diagram on the right illustrates the 
reduction in peak INa density by acute hypoxia (paired t-test vs. normoxia: (**) P < 0.01). This effect was 
fully reversible (paired t-test for wash vs. normoxia: P = 0.19). (B) Time-course of the effect of acute 
hypoxia on INaP density (average of 200-225 ms) (red circles, n = 18). Residual current in Na+-free MPS 
between 200-225 ms was averaged and subtracted from data points. INaP density was stable (~ 0 pA/pF) in 
control conditions during the recording period (black circles, n = 8). Bar diagram on the right illustrates 
the enhancement of maximal INaP density by acute hypoxia (paired t-test vs. normoxia: (**) P < 0.01). 
This effect was reversible upon re-perfusion with normoxic MPS (paired t-test for wash vs. normoxia: P = 
0.10). (C) Single exponential fit (solid red line) to the time-course of hypoxic augmentation of INaP 
revealed a τ value of 173.3 s (data from part B). (D) Heterogeneity of the time-course of hypoxic increase 
in INaP is illustrated with exemplar recordings from two MDA-MB-231 cells. Solid lines represent single 
exponential fits. Data are presented as mean ± SEM (except part D). 
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30% was observed in 15 out of 18 cells tested (e.g. Figure 3.13AC), whereas there was 
no / minimal effect in the other 3 cells (e.g. Figure 3.13BD). Increase in INaP was robust 
and occurred in all cells tested albeit with different magnitudes, e.g. in the range 10-50 
pA (e.g. Figure 3.13C vs. 3.13D). Na+-free MPS abolished both peak INa and INaP in all 
cells tested, indicating that the recorded currents were due to VGSC activity (Figure 
3.13A-D). This was confirmed further by TTX and ranolazine applications (see below).  
Time-course of the hypoxic reduction in peak INa is shown in Figure 3.14A. 
Block of INa was (i) rapid, reaching a steady-state within 20 s, and (ii) fully reversible 
upon re-perfusion with normoxic MPS (Figure 3.14A). On average, peak INa density 
was 25% smaller at the end of the 5-min acute hypoxia (-11.9 ± 1.6 pA/pF), compared 
to normoxia (-15.8 ± 1.8 pA/pF) (P < 0.01, n = 18; Figure 3.14A). Peak current density 
rapidly returned to the initial normoxic levels upon washout with normoxic MPS (-17.6 
± 3.8 pA/pF, P = 0.19 vs. normoxia, n = 18) (Figure 3.14A). Over a similar time-period 
(5 min), peak INa amplitude was confirmed to be stable under control conditions (when 
the cells were not exposed to acute hypoxia), i.e. there was no current run-down (n = 8; 
black symbols in Figure 3.14A). 
There was no detectable basal (normoxic) INaP in MDA-MB-231 cells, whereas 
acute hypoxia caused a gradual increase in INaP that reached stable levels after 4-5 min 
(Figure 3.13 and 3.14B). Average INaP densities were 0.01 ± 0.06 pA/pF under normoxic 
conditions and -0.86 ± 0.14 pA/pF during acute hypoxia (P < 0.01, n = 18; Figure 
3.14B). Thus, INaP corresponded to 0% and ~ 6% of peak INa density in normoxic and 
acutely hypoxic cells, respectively. The hypoxic increase in INaP density was reversible 
upon washout with normoxic MPS (-0.26 ± 0.15 pA/pF, P = 0.10 vs. normoxia, n = 18) 
(Figure 3.14B), consistent with earlier findings in Nav1.5-HEK cells (Fearon and 
Brown, 2004). Importantly, in 5-min control (normoxic) recordings, INaP amplitude 
 Chapter 3                                                                        Modulation of VGSC activity by hypoxia  
 
 206 
remained stable at ~ 0 pA (n = 8; black symbols in Figure 3.14B), indicating (i) that 
there was no / minimal change in the baseline current during the recording period, and 
(ii) that the observed enhancement of INaP was due to acute hypoxia. 
 Time course of the hypoxic increase in INaP occurred with an average time 
constant (τ) of 173.3 s (Figure 3.14C). However, the onset course of hypoxic INaP varied 
greatly between cells, as illustrated in Figure 3.14D. Such heterogeneity in INaP response 
times (as well as magnitudes, e.g. Figure 3.13C vs. 3.13D) was possibly due to (i) cell-
to-cell variability in onset or extent (i.e. O2 level) of hypoxia exposure and/or (ii) 
intrinsic differences in O2 sensing mechanisms between MDA-MB-231 cells 
(Hammarstrom and Gage, 2002; Saint, 2006) (this is further discussed in Section 3.3). 
 In earlier studies, TTX (10 µM) effectively blocked INaP in Nav1.5-expressing 
human and guinea pig ventricular cardiomyocytes (Maltsev et al., 2007; Wang et al., 
2007). Consistently, in MDA-MB-231 cells, hypoxic augmentation of INaP was virtually 
reversed by 10 µM TTX applied under hypoxic conditions (Figure 3.15AB). In total of 
6 cells studied, acute hypoxia reduced average peak Na+ current density by 27% from -
16.8 ± 4.8 pA/pF in normoxic conditions to -12.3 ± 4.6 pA/pF (P < 0.01; Figure 3.15C), 
whereas application of TTX (10 µM) caused a further reduction (~ 50%) in current 
density (-6.4 ± 1.6 pA/pF, P < 0.05 vs. hypoxia, n = 6) (Figure 3.15C). On the other 
hand, average INaP density was enhanced from -0.06 ± 0.13 pA/pF in normoxic 
conditions to -0.96 ± 0.28 pA/pF during acute hypoxia (P < 0.01, n = 6; Figure 3.15D), 
and 10 µM TTX reduced INaP density back to initial normoxic levels (-0.20 ± 0.10 
pA/pF) (P < 0.05 vs. hypoxia, P = 0.10 vs. normoxia, n = 6; Figure 3.15D).  Overall, 
this confirmed that the hypoxia-induced persistent current in MDA-MB-231 cells was 
due to VGSC activity. 
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Figure 3.15 TTX (10 µM) blocked hypoxic INaP in MDA-MB-231 cells 
(A, B) Example recordings from two different MDA-MB-231 cells in normoxia (black traces), 
acute hypoxia (red traces), and acute hypoxia + 10 µM TTX (blue traces). Recordings in Na+-
free MPS (grey traces) are also included to reveal any background current. Currents were 
elicited by 300 ms single pulses to -20 mV from a holding potential of -100 mV at 0.1 Hz. 
Effects on peak INa are illustrated in part (i) for each cell (first 15 ms of the recordings are 
shown). Effects on INaP are illustrated in part (ii) at higher gain. For clarity, Na+-free recording is 
not included in part (ii), but is shown in part (iii). (C) Peak INa density in normoxia and acute 
hypoxia ± 10 µM TTX (n = 6). Acute hypoxia significantly reduced peak INa (paired t-test vs. 
normoxia: (**) P < 0.01); hypoxia + 10 µM TTX caused a further reduction (paired t-test vs. 
hypoxia: (*) P < 0.05). (D) Maximal INaP density (average of 200-225 ms) in normoxia and acute 
hypoxia ± 10 µM TTX (n = 6). Residual current in Na+-free MPS was averaged between 200-
225 ms and subtracted from data points. Acute hypoxia significantly enhanced INaP density 
(paired t-test vs. normoxia: (**) P < 0.01), and TTX fully blocked this effect (paired t-test vs. 
hypoxia: (*) P < 0.05, and paired t-test vs. normoxia: P = 0.10). Data are mean ± SEM. 
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We also determined the effects of ranolazine (a selective INaP blocker) on acutely 
hypoxic MDA-MB-231 cells (Figure 3.16). A working concentration of 50 µM 
ranolazine, which blocked peak INa by only ~ 20% (under normoxic conditions) in 
MDA-MB-231 cells (Figure 3.16C), was shown previously to completely inhibit INaP in 
mice and dog ventricular cardiomyocytes (Antzelevitch et al., 2004; Fredj et al., 2006). 
Consistently, we observed that 50 µM ranolazine abolished hypoxia-induced INaP in 
MDA-MB-231 cells (Figure 3.16ABE), whilst inducing only a slight reduction in peak 
INa amplitude (Figure 3.16ABD). In total of 4 cells studied, average INaP density was 
enhanced from 0.14 ± 0.12 pA/pF in normoxia to -0.43 ± 0.04 pA/pF during acute 
hypoxia (P < 0.05; Figure 3.16E), whereas 50 µM ranolazine reduced INaP density back 
to initial normoxic levels (0.02 ± 0.05 pA/pF) (P < 0.05 vs. hypoxia, P = 0.39 vs. 
normoxia, n = 4; Figure 3.16E). On the other hand, 50 µM ranolazine minimally 
affected peak INa in three of the four cells tested (e.g. Figure 3.16B; peak INa block in the 
other cell was ~ 25% as shown in Figure 3.16A), and average peak INa density was not 
statistically different in hypoxia vs. hypoxia + 50 µM ranolazine (P = 0.53, n = 4; Figure 
3.16D). Overall, therefore, 50 µM ranolazine completely eliminated INaP in hypoxic 
MDA-MB-231 cells but only slightly reduced peak INa, consistent with its reported high 
selectivity for INaP (Undrovinas et al., 2006; Saint, 2008).  
 
3.2.3.3 Effects of acute hypoxia on nNav1.5-EBNA currents 
We next tested whether nNav1.5 alone can give rise to hypoxic INaP similar to native 
VGSCs (predominantly nNav1.5) in MDA-MB-231 cells. Figure 3.17 illustrates the 
effect of acute hypoxia (5 min) on peak INa and INaP in nNav1.5-EBNA cells. Na+-free 
MPS abolished both current components in nNav1.5-EBNA cells, indicating that these  
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Figure 3.16 Ranolazine (50 µM) inhibited hypoxic INaP with minimal effect on peak INa  
(A, B) Example recordings from two different MDA-MB-231 cells in normoxia (black traces), acute 
hypoxia (red traces), and acute hypoxia + 50 µM ranolazine (blue traces). Currents were elicited by 
300 ms single pulses to -20 mV from a holding potential of -100 mV at 0.1 Hz. Effects on peak INa 
are illustrated in part (i) for each cell (first 15 ms of the recordings are shown). Effects on INaP are 
illustrated in part (ii) at higher gain. (C) Dose-response relationship for ranolazine block of peak INa 
under control (normoxic) conditions in MDA-MB-231 cells (n ≥ 4). Data were fitted with the Hill 
equation (solid line); IC50 was 180.6 ± 6.7 µM; nH was fixed at unity (1.09 ± 0.07 initially). Pulse 
protocol was as in part A except that pulse duration was 12 ms. Block was monitored until a steady-
state maximum was reached, and data were normalized to the first control current. At 50 µM, 
ranolazine induced only ~ 20% block of peak INa in normoxic conditions (dashed lines). (D) Peak INa 
density in normoxia and acute hypoxia ± 50 µM ranolazine (n = 4). Acute hypoxia reduced peak INa 
but this effect was not quite significant (paired t-test vs. normoxia: P = 0.06). Hypoxia + 50 µM 
ranolazine caused no further reduction (paired t-test vs. hypoxia: P = 0.53). (E) Maximal INaP density 
(average of 200-225 ms) in normoxia and acute hypoxia ± 50 µM ranolazine (n = 4). For each cell, 
residual current in Na+-free MPS was averaged between 200-225 ms and subtracted from data points. 
Acute hypoxia significantly enhanced INaP density (paired t-test vs. normoxia: (*) P < 0.05), and 
ranolazine fully blocked this effect (paired t-test vs. hypoxia: (*) P < 0.05, and paired t-test vs. 
normoxia: P = 0.39). Data are mean ± SEM. 
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Figure 3.17 Acute hypoxia enhanced INaP and reduced peak INa in nNav1.5-EBNA cells 
(A, B) Example recordings from two different nNav1.5-EBNA cells before (black traces) and 
after (red traces) acute hypoxia (~2.6% O2, 5 min). Recordings in Na+-free MPS (grey traces) 
are also shown. Pulse protocol was as before (Figure 3.16). Effects on peak INa are illustrated in 
part (i); effects on INaP are illustrated in part (ii) at higher gain. (C) Time-course of the effect of 
acute hypoxia on peak INa (red circles, n = 15). Hypoxic MPS was applied after the fourth 
control pulse, and data were normalized to the first control current. To determine reversibility, 
normoxic solution was re-applied (‘wash’) after 5 min hypoxia. Peak INa was stable under 
control conditions during the recording period (black circles, n = 11). Bar diagram on the right  
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illustrates the reduction in peak INa density by acute hypoxia (paired t-test vs. normoxia: (**) P < 
0.01). (B) Time-course of the effect of acute hypoxia on INaP density (average of 200-225 ms) 
(red circles, n = 15). Residual current in Na+-free MPS between 200-225 ms was averaged and 
subtracted from data points. INaP density was stable in control conditions during the recording 
period (black circles, n = 11). A single-exponential fit (solid red line) to time-course of hypoxic 
enhancement of INaP density yielded a τ value of 198.5 s. Bar diagram on the right illustrates the 
enhancement of maximal INaP density by acute hypoxia (paired t-test vs. normoxia: (*) P < 0.05). 
Data are mean ± SEM. 
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were due to VGSC activity (Figure 3.17AB) (this is further confirmed with TTX and 
ranolazine applications later). 
Similar to MDA-MB-231 cells, acute hypoxia reduced peak INa and significantly 
enhanced INaP in nNav1.5-EBNA cells (Figure 3.17AB). Hypoxic inhibition of peak 
nNav1.5 currents by 20-30% was observed in all cells tested (n = 15; e.g. Figure 
3.17AB); the time-course of this effect is shown in Figure 3.17C. Peak current block 
reached steady-state rapidly within 10-20 s (i.e. 1st or 2nd pulse post hypoxia), and was 
fully reversible upon re-perfusion with normoxic MPS (Figure 3.17C). Average peak 
nNav1.5 current density was 23% smaller at the end of 5-min acute hypoxia (-229.6 ± 
55.3 pA/pF) vs. normoxia (-299.7 ± 61.8 pA/pF) (P < 0.01, n = 15; Figure 3.17C). 
During the 5-min recording period, nNav1.5 peak INa amplitude was stable under 
control conditions (when the cells were not exposed to acute hypoxia), i.e. there was no 
current run-down (n = 11; black symbols in Figure 3.17C). 
As regards INaP, the hypoxic enhancement of current density was fully 
reversible, and occurred similar to MDA-MB-231 cells, i.e. INaP reached stable levels 
after ~ 4 min hypoxia, with an average time-constant (τ) of 198.5 s (Figure 3.17ABD). 
Increase in INaP was evident in all acutely hypoxic nNav1.5-EBNA cells; however, as in 
the case of MDA-MB-231 cells, the magnitude of this effect was variable in the range 
10-80 pA (Figure 3.17AB and 3.18). Average INaP densities were -0.41 ± 0.33 pA/pF 
under normoxic conditions and -2.21 ± 0.58 pA/pF during acute hypoxia (P < 0.05, n = 
15; Figure 3.17D). Thus, INaP corresponded to ~ 0.2% and 1% of peak INa density in 
normoxic and acutely hypoxic nNav1.5-EBNA cells, respectively. In 5-min control 
(normoxic) recordings, INaP amplitude remained stable at ~ -0.4 pA/pF (n = 11; black 
symbols in Figure 3.17D), indicating that INaP had a small but stable value under 
normoxic conditions. 
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Figure 3.18 TTX and ranolazine blocked hypoxic INaP in nNav1.5-EBNA cells  
(A) Representative recordings from a nNav1.5-EBNA cell in normoxia (black traces), acute 
hypoxia (red traces), and acute hypoxia + 10 µM TTX (blue traces). Recording taken in Na+-free 
MPS (grey traces) is also included to reveal any background current. Currents were elicited by 
300 ms single pulses to -20 mV from a holding potential of -100 mV at 0.1 Hz. Effects on peak 
INa are illustrated in part (i). High-gain traces in parts ii-iv illustrate the modification of INaP by 
acute hypoxia (part ii), hypoxia + TTX (10 µM) (part iii), and Na+-free MPS (part iv) (these 
were plotted seperately for clarity). TTX (10 µM) abolished hypoxic INaP in nNav1.5-EBNA 
cells (n = 5). (B) Same as part A but with 50 µM ranolazine. Similar to TTX, ranolazine 
abolished hypoxic INaP in nNav1.5-EBNA cells (n = 4). 
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 Finally, we tested the effects of TTX (10 µM) and ranolazine (50 µM) on acutely 
hypoxic nNav1.5 currents (Figure 3.18). Similar to MDA-MB-231 cells, (i) 10 µM TTX 
completely eliminated INaP in hypoxic nNav1.5-EBNA cells, whilst blocking peak INa by 
> 50% (n = 5; Figure 3.18A), and (ii) 50 µM ranolazine abolished hypoxia-induced 
nNav1.5 INaP, whilst minimally inhibiting peak INa (n = 4; Figure 3.18B). Taken 
together, these findings confirmed that nNav1.5 alone can generate TTX- and 
ranolazine-sensitive INaP in response to acute hypoxia. 
 
3.2.4 Summary of effects and working hypothesis 
Chronic hypoxia (2 or 5% O2, 24 h) enhanced peak VGSC current density by ~ 50% in 
MDA-MB-231 cells, without affecting (i) voltage-dependence or kinetics of channel 
gating, (ii) TTX sensitivity, or (iii) outward current density. Similar upregulation of 
peak INa density was also observed in chronically hypoxic (2% O2, 24 h) Mat-LyLu and 
nNav1.5-EBNA cells. Shorter-term hypoxia (2% O2, 90 min) was without effect on 
peak current density in MDA-MB-231 cells. Acute hypoxia modestly reduced peak INa 
but significantly increased INaP in both MDA-MB-231 and nNav1.5-EBNA cells, 
possibly resulting in enhanced Na+ influx.  
From these data and the available evidence (Brackenbury and Djamgoz, 2006; 
Chioni et al., 2010), the following basic hypothesis for the chronic hypoxic upregulation 
of functional VGSC expression in MDA-MB-231 cells was proposed: hypoxia → 
VGSC (nNav1.5) → enhanced Na+ influx → PKA activation (Cooper et al., 1998; 
Murakami et al., 1998) → increased functional VGSC availability (Zhou et al., 2000; 
2002; Brackenbury and Djamgoz, 2006; Chioni et al., 2010). Essentially, basal 
(normoxic) positive auto-regulation of VGSCs through Na+ influx and PKA (Chioni et 
al., 2010) was suggested to be upregulated during hypoxia, due to (i) enhanced Na+ 
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influx via VGSCs (and possibly via other mechanisms including Na+/H+ exchange 
(NHE); Saint, 2006; 2008), and (ii) enhanced cAMP levels (Perez-Garcia et al., 1990; 
Delpiano and Acker, 1991; Naghshin et al., 2009). This hypothesis / scheme was tested 
systematically, focussing on the effects of various VGSC and PKA inhibitors / 
activators on peak VGSC current density in MDA-MB-231 cells (Section 3.2.5).   
 
3.2.5 Mechanism of hypoxic increase in functional VGSC expression   
3.2.5.1 Effect of TTX on VGSC functional activity 
TTX was co-applied with chronic hypoxia (2% O2, 24 h) to determine the contribution 
of Na+ influx to the hypoxic upregulation of functional VGSC expression (i.e. to 
determine the possible auto-regulatory role of Na+ influx). Inhibition of VGSCs by TTX 
reverses within seconds of washout (Section 3.2.1.4; Brackenbury and Djamgoz, 2006), 
and thus, 15-min washout prior to patch-clamp recording ensured removal of ‘acute’ 
TTX effects on channel function. Experiments were performed with two doses of TTX 
(100 nM and 10 µM) to determine the individual contributions of TTX-S and TTX-R 
currents, respectively. Since a new batch of MDA-MB-231 cells was used, normoxia 
and hypoxia (2% O2, 24 h) control data were re-collected to avoid any error due to inter-
batch variability in VGSC current density (Fraser et al., 2010). At the higher dose used 
(10 µM), 24 h TTX pre-treatment had no effect on cell viability (Appendix 2) or 
morphology (Appendix 5) under normoxic or hypoxic (2% O2) conditions. 
 Consistent with earlier findings, chronic hypoxia (2% O2, 24 h) enhanced peak 
VGSC current density by 48% from -13.6 ± 1.0 pA/pF in normoxia (n = 18) to -20.1 ± 
1.8 pA/pF (P < 0.01; n = 19) (Figure 3.19 and Table 3.6). This effect was retained when 
100 nM TTX was co-applied with chronic hypoxia (-19.6 ± 1.0 pA/pF, n = 18, P < 0.05 
vs. normoxia, P > 0.05 vs. hypoxia) (Figure 3.19ABD and Table 3.6). In contrast, 10  
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Figure 3.19 TTX abrogated the effect of chronic hypoxia on peak VGSC current density   
(A) Typical whole-cell VGSC currents in MDA-MB-231 cells pre-treated for 24 h in (i) normoxia, 
(ii) hypoxia (2% O2), (iii) hypoxia + TTX (100 nM), and (iv) hypoxia + TTX (10 µM). Currents were 
elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -100 mV; 
interpulse duration was 2 s. (B) Mean I-V relationships in normoxia, hypoxia and hypoxia + 100 nM 
TTX (n = 18-19-18, respectively). (C) Mean I-V relationship for hypoxia + 10 µM TTX (n = 19); 
normoxia and hypoxia data re-plotted from part B. (D) Average peak current density in normoxia, 
hypoxia, hypoxia + 100 nM TTX and hypoxia + 10 µM TTX. Data were compared using ANOVA 
(P < 0.05) followed by Newman-Keuls post-hoc analysis. Significance: (X) P > 0.05 for hypoxia vs. 
hypoxia + 100 nM TTX, (*) P < 0.05 for hypoxia vs. hypoxia + 10 µM TTX. Peak current density in 
hypoxia + 10 µM TTX was similar to that in normoxia (P > 0.05). Inset, whole-cell capacitance was 
unchanged between treatment groups (ANOVA: P = 0.71). Data are mean ± SEM. 
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Table 3.6 Effects of co-application of hypoxia (2% O2, 24 h) and TTX (100 nM and 10 µM) on VGSC activity in MDA-MB-231 cells 
      
 
For abbreviations, see Table 3.5. Statistical significance was determined using ANOVA followed by Newman-Keuls post-hoc analysis. Peak current 
density was significantly different between treatment groups (P < 0.05). There was no difference in other parameters (ANOVA, P > 0.05). For pairwise 
significance (P < 0.05): (a) normoxia vs. hypoxia; (b) normoxia vs. hypoxia + 100 nM TTX; (c) normoxia vs. hypoxia + 10 µM TTX; (d) hypoxia vs. 
hypoxia + 100 nM TTX; (e) hypoxia vs. hypoxia + 10 µM TTX; (f) hypoxia + 100 nM TTX vs. hypoxia + 10 µM TTX. Data are mean ± SEM.
Parameter Normoxia Hypoxia Hyp + 100 nM TTX Hyp + 10 µM TTX n Significance 
Peak current density (pA/pF)  -13.6 ± 1.0 -20.1 ± 1.8  -19.6 ± 2.4  -14.8 ± 1.5  ≥ 18 a, b, e 
Capacitance (pF) 24.5 ± 1.0  23.5 ± 0.9 25.9 ± 0.9 25.6 ± 0.8 ≥ 18 - 
Vthres (mV) -45.8 ± 0.7 -47.4 ± 0.6 -46.1 ± 0.7 -46.1 ± 0.6 ≥ 18 - 
Vpeak (mV)  -5.3 ± 1.5 -7.1 ± 1.7 -5.3 ± 1.5 -8.7 ± 1.1 ≥ 18 - 
Activation V1/2  (mV)  -24.7 ± 1.0 -24.8 ± 1.4 -24.5 ± 1.2 -25.3 ± 1.1 ≥ 18 - 
Activation k (mV) 7.7 ± 0.5 7.6 ± 0.5 7.3 ± 0.4 7.0 ± 0.5 ≥ 18 - 
Inactivation V1/2 (mV)  -84.7 ± 1.2 -85.7 ± 0.8 -86.7 ± 1.9 -84.4 ± 1.9 ≥ 10 - 
Inactivation k (mV) -5.3 ± 0.2 -5.1 ± 0.2 -5.3 ± 0.4 -5.6 ± 0.3 ≥ 10 - 
V0 (mV)  16.9 ± 3.7 15.3 ± 1.9 15.6 ± 2.2 16.1 ± 2.3 ≥ 18 - 
Tpeak at 0 mV (ms)  0.93 ± 0.06 0.89 ± 0.06 0.82 ± 0.03 0.94 ± 0.05 ≥ 18 - 
τrecovery (ms)  19.0 ± 2.5 18.9 ± 1.7 19.4 ± 2.3 19.0 ± 1.8 ≥ 8 - 
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µM TTX abrogated the effect of chronic hypoxia on VGSC peak current density (-14.8 
± 1.5 pA/pF, n = 19, P > 0.05 vs. normoxia, P < 0.05 vs. hypoxia) (Figure 3.19ACD and 
Table 3.6). Whole-cell capacitance was similar between the four treatment groups 
(Figure 3.19D inset and Table 3.6). Effects of chronic hypoxia ± TTX (100 nM or 10 
µM) on VGSC gating are summarized in Table 3.6. ANOVA comparisons among the 
four treatment groups revealed that chronic hypoxia ± TTX pre-treatments were without 
effect on Vpeak, Vthres (Figure 3.19BC), activation V1/2 or k (Figure 3.20A), inactivation 
V1/2 or k (Figure 3.20B), Tpeak (Figure 3.20C), or τrecovery (Figure 3.20D) (Table 3.6). 
These findings suggested (i) that the hypoxic increase in functional VGSC 
expression in MDA-MB-231 cells was dependent on VGSC activity / Na+ influx 
(consistent with enhancement of INaP during hypoxia), and (ii) that the Na+ influx 
fuelling this ‘auto-regulatory’ pathway was mediated primarily by the predominant 
TTX-R channel present (i.e. nNav1.5).  
 
3.2.5.2 Effect of KT5720 and Myr PKI14-22 on VGSC functional activity 
Proposed involvement of PKA in the hypoxic upregulation of functional VGSC 
expression was determined using two different PKA inhibitors, KT5720 (Kase et al., 
1987; Davies et al., 2000) and myristolated protein kinase A inhibitor peptide (Myr 
PKI14-22) (Glass et al., 1989; Dalton and Dewey, 2006; Murray, 2008). These inhibitors 
were tested in both normoxic and hypoxic (2% O2) conditions, and the corresponding 
control recordings (i.e. normoxia or hypoxia alone) were re-performed since a new 
batch of MDA-MB-231 cells was used. Incubation with 500 nM KT5720 or 20 µM Myr 
PKI14-22 for 24 h had no effect on cell viability under normoxic or hypoxic (2% O2) 
conditions (Appendix 2), and there was also no noticeable change in cell morphology 
(Appendix 5).  
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Figure 3.20 Co-application of chronic hypoxia (2% O2, 24 h) and TTX did not affect VGSC 
gating characteristics  
Data are presented as mean ± SEM; some data points are overlapping. Values of the fitted parameters 
(obtained from cell-by-cell fits) are reported in Table 3.6. Data were recorded from MDA-MB-231 
cells pre-treated (24 h) in normoxia, hypoxia (2% O2), hypoxia + 100 nM TTX, and hypoxia + 10 
µM TTX. (A) Normalized G-V relationships (G/Gmax) fitted with Boltzmann functions (n ≥ 18). Data 
from recordings described in Figure 3.19. (B) Normalized availability-voltage relationships fitted 
with Boltzmann functions (n ≥ 10). Currents were elicited with 80 ms test pulses to -10 mV after 1 s 
pre-pulses in the range -140 mV to -10 mV. Holding potential was -100 mV and interpulse duration 
was 2 s. Currents (I) were normalized to the maximum current (Imax) recorded following the most 
hyperpolarized pre-pulse (-140 mV). (C) Time to peak (Tpeak) plotted as a function of test potential 
and fitted with single exponential functions (n ≥ 18). Data from recordings described in Figure 3.19. 
(D) Time-course of recovery from inactivation was studied with an 80 ms control pulse to -10 mV 
(giving current Ic), return to -100 mV for a recovery interval ranging from 5 to 155 ms and then an 
identical test pulse to -10 mV (giving current It). Holding potential was -100 mV and interpulse 
duration was 2 s. Recovered current (It /Ic) was plotted as a function of recovery interval and fitted 
with single exponential functions (n ≥ 8). There was no significant difference (ANOVA) in any of 
the parameters between different treatment groups (Table 3.6). 
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            Chronic hypoxia (2% O2, 24 h) again increased peak VGSC current density by 
49% from -15.4 ± 1.1 pA/pF (n = 31) to -22.9 ± 1.9 pA/pF (P < 0.01; n = 40) (Figure 
3.21 and 3.22). Effects of 500 nM KT5720 or 20 µM Myr PKI14-22 pre-treatments (24 h) 
on VGSC peak current density were as follows: 
i. KT5720 (Table 3.7): Under normoxic conditions, 500 nM KT5720 was 
without effect on VGSC current density (-15.8 ± 1.6 pA/pF; n = 31, P > 0.05 
vs. normoxia) (Figure 3.21B and 3.22A). However, when co-applied with 
hypoxia (2% O2), KT5720 reduced peak current density back to normoxic 
levels, abolishing the potentiating effect of hypoxia alone (-15.1 ± 1.4 pA/pF; 
n = 28, P > 0.05 vs. normoxia, P < 0.01 vs. hypoxia) (Figure 3.21AB and 
3.22A). Notably, the mean peak current densities were similar in cells pre-
treated with hypoxia + KT5720 vs. normoxia + KT5720 (P > 0.05; Figure 
3.21B and 3.22A), suggesting that the hypoxic increase in VGSC functional 
availability occurred ‘exclusively’ through PKA. Whole-cell capacitance was 
unchanged amongst the four treatment groups (P = 0.10; Figure 3.22Aii). In 
control experiments, 24 h pre-incubation with 0.025% DMSO (1:4000 dilution 
to 500 nM KT5720 from 2 mM stock) had no effect on VGSC peak current 
density or gating in normoxic or hypoxic MDA-MB-231 cells (Appendix 6). 
ii. Myr PKI14-22 (Table 3.8): Under normoxic conditions, 20 µM Myr PKI14-22 
reduced peak VGSC current density by 47% to -8.2 ± 1.0 pA/pF (n = 23, P < 
0.01 vs. normoxia) (Figure 3.21C and 3.22B). This confirmed earlier findings 
by Chioni et al. (2010) that the basal level VGSC functional expression is 
under control of a PKA-mediated pathway (Chioni et al., 2010). Importantly, 
in hypoxic cells (2% O2), Myr PKI14-22 reduced peak current density to -8.7 ± 
1.1 pA/pF (P < 0.01 vs. hypoxia, n = 20), similar to the cells pre-treated with  
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Figure 3.21 PKA inhibitors abrogated the hypoxic increase in VGSC peak current density   
(A) Typical whole-cell VGSC currents in MDA-MB-231 cells pre-treated (24 h) in (i) normoxia, (ii) 
hypoxia (2% O2), (iii) hypoxia + 500 nM KT5720, and (iv) hypoxia + 20 µM Myr PKI14-22. Currents 
were elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -100 mV; 
interpulse duration was 2 s. Bar diagrams on the right show VGSC peak current densities of all cells 
studied (in chronological order) for each treatment group (from top to bottom): normoxia, hypoxia, 
hypoxia + KT5720, and hypoxia + Myr PKI14-22. (B) Average peak current density in normoxia / 
hypoxia ± 500 nM KT5720 (n ≥ 28). (C) Average peak current density in normoxia / hypoxia ± 20 
µM Myr PKI14-22 (n ≥ 20); normoxia and hypoxia data were re-plotted from part B. In parts B and C, 
data were compared using ANOVA (P < 0.01 for both) followed by Newman-Keuls post-hoc 
analysis; significance: (**) P < 0.01. Unless indicated otherwise, (in)significance is shown for 
KT5720 or Myr PKI14-22 treatments vs. normoxic / hypoxic controls. Data are mean ± SEM. 
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Figure 3.22 KT5720 and Myr PKI14-22 inhibited the hypoxic increase in peak current density 
Data were recorded using 60 ms pulses to between -80 mV and +45 mV from a holding 
potential of -100 mV; interpulse duration was 2 s. (A) (i) Mean current density I-V relationships 
for MDA-MB-231 cells pre-treated (24 h) in normoxia (n = 31), hypoxia (2% O2, n = 40), 
normoxia + 500 nM KT5720 (n = 31), and hypoxia + 500 nM KT5720 (n = 28). Inset magnifies 
activation in the range -60 mV to -35 mV. (ii) Whole-cell capacitance was unchanged between 
treatment groups (ANOVA: P = 0.10). (B) (i) Same as part A but for normoxia + 20 µM Myr 
PKI14-22 (n = 23) and hypoxia + 20 µM Myr PKI14-22 (n = 20); normoxia and hypoxia data were 
re-plotted from part A. (ii) Whole-cell capacitance was unchanged between treatment groups 
(ANOVA: P = 0.41). Data are mean ± SEM. 
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Table 3.7 Effect of KT5720 (500 nM, 24 h) on VGSC characteristics in normoxic and hypoxic (2% O2) MDA-MB-231 cells 
      
 
For abbreviations, see Table 3.5. Statistical significance was determined using ANOVA followed by Newman-Keuls post-hoc analysis. Peak current 
density, Vthres, and Tpeak were significantly different between treatment groups (P < 0.01); there was no difference in other parameters (ANOVA, P > 
0.05). For pairwise significance (P < 0.05): (a) normoxia vs. nor + KT5720; (b) normoxia vs. hypoxia; (c) normoxia vs. hyp + KT5720; (d) nor + 
KT5720 vs. hypoxia; (e) nor + KT5720 vs. hyp + KT5720; (f) hypoxia vs. hyp + KT5720. Data are mean ± SEM.
Parameter Normoxia Nor + KT5720 Hypoxia  Hyp + KT5720 n Significance 
Peak current density (pA/pF)  -15.4 ± 1.1  -15.8 ± 1.6  -22.9 ± 1.9  -15.1 ± 1.4  ≥ 28 b, d, f 
Capacitance (pF) 25.9 ± 0.6  26.8 ± 1.0  24.5 ± 0.8  27.0 ± 0.8  ≥ 28 - 
Vthres (mV) -45.5 ± 0.6  -43.3 ± 0.5  -46.7 ± 0.4  -43.8 ± 0.4  ≥ 28 a, c, d, f 
Vpeak (mV)  -6.9 ± 1.1  -5.8 ± 1.3  -8.3 ± 1.1  -7.5 ± 1.2  ≥ 28 - 
Activation V1/2  (mV)  -25.5 ± 0.9  -23.2 ± 0.8  -26.1 ± 0.7  -24.8 ± 0.6  ≥ 28 - 
Activation k (mV) 7.4 ± 0.3  7.0 ± 0.4  6.8 ± 0.2  7.3 ± 0.3  ≥ 28 - 
Inactivation V1/2 (mV)  -84.7 ± 1.2  -83.5 ± 0.8  -85.7 ± 0.8  -84.7 ± 0.8  ≥ 17 - 
Inactivation k (mV) -5.3 ± 0.2  -5.0 ± 0.2  -5.1 ± 0.2  -5.3 ± 0.4  ≥ 17 - 
V0 (mV)  16.2 ± 2.4  14.2 ± 1.5  16.0 ± 2.5  13.3 ± 1.4  ≥ 28 - 
Tpeak at 0 mV (ms)  0.86 ± 0.03  1.02 ± 0.04  0.88 ± 0.03  1.06 ± 0.05  ≥ 28 a, c, d, f 
τrecovery (ms)  19.0 ± 2.8  16.1 ± 3.6  18.9 ± 1.7  16.5 ± 3.3  ≥ 6 - 
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Table 3.8 Effect of Myr PKI14-22 (20 µM, 24 h) on VGSC characteristics in normoxic and hypoxic (2% O2) MDA-MB-231 cells      
 
 
For abbreviations, see Table 3.5. Statistical significance was determined using ANOVA followed by Newman-Keuls post-hoc analysis. Peak current 
density, Vthres, and Tpeak were significantly different between treatment groups (P < 0.01); there was no difference in other parameters (ANOVA, P > 
0.05). For pairwise significance (P < 0.05): (a) normoxia vs. nor + PKI; (b) normoxia vs. hypoxia; (c) normoxia vs. hyp + PKI; (d) nor + PKI vs. 
hypoxia; (e) nor + PKI vs. hyp + PKI; (f) hypoxia vs. hyp + PKI. Data are mean ± SEM; normoxia and hypoxia data are from Table 3.7.
Parameter Normoxia Nor + PKI Hypoxia  Hyp + PKI n Significance 
Peak current density (pA/pF)  -15.4 ± 1.1  -8.2 ± 1.0  -22.9 ± 1.9  -8.7 ± 1.1  ≥ 20 a, b, c, d, f 
Capacitance (pF) 25.9 ± 0.6  24.7 ± 1.0  24.5 ± 0.8  24.0 ± 0.8  ≥ 20 - 
Vthres (mV) -45.5 ± 0.6  -39.6 ± 1.0  -46.7 ± 0.4  -40.4 ± 0.8  ≥ 20 a, c, d, f 
Vpeak (mV)  -6.9 ± 1.1  -6.1 ± 1.7  -8.3 ± 1.1  -7.8 ± 1.3  ≥ 20 - 
Activation V1/2  (mV)  -25.5 ± 0.9  -24.1 ± 1.1  -26.1 ± 0.7  -23.4 ± 0.7  ≥ 20 - 
Activation k (mV) 7.4 ± 0.3  6.7 ± 0.4  6.8 ± 0.2  7.2 ± 0.4  ≥ 20 - 
Inactivation V1/2 (mV)  -84.7 ± 1.2  -85.3 ± 2.0  -85.7 ± 0.8  -85.0 ± 1.2  ≥ 10 - 
Inactivation k (mV) -5.3 ± 0.2  -5.3 ± 0.4  -5.1 ± 0.2  -5.1 ± 0.4  ≥ 10 - 
V0 (mV)  16.2 ± 2.4  16.6 ± 2.9  16.0 ± 2.5  14.1 ± 2.0  ≥ 20 - 
Tpeak at 0 mV (ms)  0.86 ± 0.03  1.07 ± 0.06  0.88 ± 0.03  1.12 ± 0.06  ≥ 20 a, c, d, f 
τrecovery (ms)  19.0 ± 2.8  16.8 ± 1.7  18.9 ± 1.7  18.5 ± 2.9  ≥ 6 - 
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normoxia + Myr PKI14-22 (P > 0.05) (Figure 3.21C and 3.22B). This supported 
the results obtained with KT5720 that the hypoxic increase in functional VGSC 
expression was primarily PKA-dependent. Whole-cell capacitance was similar 
in cells pre-treated with normoxia / hypoxia ± Myr PKI14-22 (P = 0.41; Figure 
3.22Bii). 
The effects of pre-treatment with KT5720 (500 nM) on VGSC gating characteristics are 
summarized in Table 3.7. This pre-treatment depolarized Vthres from -45.5 ± 0.6 mV to -
43.3 ± 0.5 mV in normoxia (P < 0.01, n = 31 each), and from -46.7 ± 0.4 mV to -43.8 ± 
0.4 mV in hypoxia (P < 0.01, n = 40-28, respectively) (Figure 3.22Ai inset). There was 
no significant effect on Vpeak, activation V1/2 or activation k in normoxic or hypoxic cells 
(Figure 3.22A and 3.23A). Steady-state inactivation V1/2 and k were also unaffected 
(Figure 3.23B). Pre-incubation with KT5720 significantly slowed activation (i.e. 
increased Tpeak) in the voltage-range -30 mV to 10 mV in both normoxic and hypoxic 
cells (P < 0.05 vs. corresponding normoxia / hypoxia control, n ≥ 28) (Figure 3.23C). 
On the other hand, recovery from inactivation was accelerated by the KT5720 pre-
treatment under both normoxic and hypoxic conditions, although this effect was 
significant only at recovery intervals ≤ 15 ms (n ≥ 6; Figure 3.23D) and the overall 
τrecovery was unaffected (Table 3.7). 
The effects of pre-treatment with 20 µM Myr PKI14-22 on VGSC gating 
characteristics are summarized in Table 3.8. Pre-treatment with Myr PKI14-22, as with 
KT5720, depolarized Vthres from -45.5 ± 0.6 mV to -39.6 ± 1.0 mV in normoxia (P < 
0.01, n = 31-23, respectively), and from -46.7 ± 0.4 mV to -40.4 ± 0.8 mV in hypoxia 
(P < 0.01, n = 40-20, respectively) (Figure 3.22Bi inset). There was no effect on Vpeak 
(Figure 3.22B), activation V1/2 or k (Figure 3.24A), or steady-state inactivation V1/2 or k 
(Figure 3.24B). Similar to KT5720, pre-incubation with Myr PKI14-22  significantly  
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Figure 3.23 KT5720 pre-treatment slowed Tpeak and accelerated channel recovery  
Data (mean ± SEM) were recorded from MDA-MB-231 cells pre-treated (24 h) in normoxia, 
hypoxia (2% O2), normoxia + 500 nM KT5720, and hypoxia + 500 nM KT5720. Values of the fitted 
parameters (from cell-by-cell fits) are reported in Table 3.7. (A) Normalized G-V relationships 
(G/Gmax) fitted with Boltzmann functions (n ≥ 28). Data were from recordings described in Figure 
3.21 and 3.22. (B) Normalized availability-voltage relationships fitted with Boltzmann functions (n ≥ 
17). Currents were elicited with 80 ms test pulses to -10 mV after 1 s pre-pulses in the range -140 
mV to -10 mV. Holding potential was -100 mV and interpulse duration was 2 s. Currents (I) were 
normalized to the maximum current (Imax) recorded following the most hyperpolarized pre-pulse (-
140 mV). (C) Time to peak (Tpeak) plotted as a function of test potential and fitted with single 
exponential functions (n ≥ 28). Data from recordings described in Figure 3.21 and 3.22. (D) Time-
course of recovery from inactivation was studied with a 80 ms control pulse to -10 mV (giving Ic), 
return to -100 mV for a recovery interval ranging from 5 to 155 ms and then an identical test pulse to 
-10 mV (giving It). Holding potential was -100 mV and interpulse duration was 2 s. Recovered 
current (It /Ic) was plotted as a function of recovery interval and fitted with single exponential 
functions (n ≥ 6). Tpeak and recovery from inactivation was slower in normoxic / hypoxic cells pre-
treated with 500 nM KT5720 compared to corresponding normoxic / hypoxic cells (ANOVA / 
Newman-Keuls). Significance: (*) P < 0.05, (**) P < 0.01. 
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Figure 3.24 Myr PKI14-22 pre-treatment slowed Tpeak  
Data (mean ± SEM) were recorded from MDA-MB-231 cells pre-treated (24 h) in normoxia, 
hypoxia (2% O2), normoxia + 20 µM Myr PKI14-22, and hypoxia + 20 µM Myr PKI14-22. Values of the 
fitted parameters (from cell-by-cell fits) are reported in Table 3.8. (A) Normalized G-V relationships 
(G/Gmax) fitted with Boltzmann functions (n ≥ 20). Data from recordings described in Figure 3.21 
and 3.22. (B) Normalized availability-voltage relationships fitted with Boltzmann functions (n ≥ 10). 
Currents were elicited with 80 ms test pulses to -10 mV after 1 s pre-pulses in the range -140 mV to -
10 mV. Holding potential was -100 mV and interpulse duration was 2 s. Currents (I) were 
normalized to the maximum current (Imax) recorded following the most hyperpolarized pre-pulse (-
140 mV). (C) Time to peak (Tpeak) plotted as a function of test potential and fitted with single 
exponential functions (n ≥ 20). Data from recordings described in Figure 3.21 and 3.22. (D) Time-
course of recovery from inactivation was studied with a 80 ms control pulse to -10 mV (giving Ic), 
return to -100 mV for a recovery interval ranging from 5 to 155 ms and then an identical test pulse to 
-10 mV (giving It). Holding potential was -100 mV and interpulse duration was 2 s. Recovered 
current (It /Ic) was plotted as a function of recovery interval and fitted with single exponential 
functions (n ≥ 6). Tpeak was slower in normoxic / hypoxic cells pre-treated with Myr PKI14-22 
compared to corresponding normoxic / hypoxic cells (ANOVA / Newman-Keuls). Significance: (*) 
P < 0.05, (**) P < 0.01. 
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slowed Tpeak in the voltage-range -30 mV to 10 mV in both normoxic and hypoxic cells 
(P < 0.05 vs. corresponding normoxia / hypoxia control, n ≥ 20) (Figure 3.24C). 
However, unlike KT5720, Myr PKI14-22 pre-treatment had no effect on recovery from 
inactivation (Figure 3.24D). 
Overall, these findings suggested that the hypoxic increase in functional VGSC 
expression was PKA-dependent in MDA-MB-231 cells. Given that VGSC activity / Na+ 
influx is also required for this effect (Section 3.2.5.1), it was concluded that the basal 
level (steady-state, normoxic) VGSC auto-regulation through Na+ influx and PKA 
(Chioni et al., 2010) was upregulated in the presence of hypoxia due to enhanced Na+ 
influx possibly via INaP. This is consistent with the direct potentiating effect of increased 
[Na+]i on cAMP levels / PKA activity (Cooper et al., 1998; Murakami et al., 1998; 
Brackenbury and Djamgoz, 2006; Chioni et al., 2010). This suggestion was tested 
further, using the adenylate cyclase (AC) / PKA stimulant, forskolin.  
 
3.2.5.3 Effect of forskolin on VGSC functional activity 
Incubation with forskolin (20 µM) for 24 h had no effect on cell viability in normoxic or 
hypoxic (2% O2) MDA-MB-231 cells (Appendix 2). Cells incubated in forskolin 
appeared flatter and less phase-bright than control cells (normoxia or hypoxia alone), 
and had thinner, longer processes (Appendix 5; Chioni et al., 2010). Studies with 
forskolin were performed in parallel with the PKA inhibitors (KT5720 and Myr PKI14-
22), and thus, control data (normoxia or hypoxia alone) were the same as those described 
in Section 3.2.5.2.  
Long-term (24 h) pre-incubation with forskolin, as with chronic hypoxia, but 
opposite to TTX, KT5720 and Myr PKI14-22 pre-treatments, increased VGSC peak 
current density by 59% from -15.4 ± 1.1 pA/pF in normoxia (n = 31) to -24.6 ± 2.9 
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pA/pF (n = 24, P < 0.01) (Figure 3.25ABC and Table 3.9). This potentiating effect of 
forskolin on VGSC current density was statistically similar to that of chronic hypoxia (-
22.9 ± 1.9 pA/pF; n = 40, P > 0.05 vs. normoxia + forskolin) (Figure 3.25B and Table 
3.9). Hypoxia + forskolin pre-treatment did not increase VGSC peak current density 
beyond hypoxia alone (-25.9 ± 2.2 pA/pF; n = 23, P > 0.05 vs. hypoxia) (Figure 
3.25ABC and Table 3.9), suggesting that the AC/PKA-mediated increase in VGSC 
current density in hypoxia occurred maximally, i.e. could not be augmented by further 
cAMP / PKA stimulation. Consistently, the effect of a higher dose of forskolin (50 µM) 
on peak current density in hypoxic cells was the same (data not shown). Importantly, 
mean peak current density was similar in cells pre-treated with normoxia + forskolin vs. 
cells pre-treated with hypoxia + forskolin (P > 0.05; Figure 3.25ABC and Table 3.9), 
further suggesting that the hypoxic increase in VGSC functional availability occurred 
primarily through AC/PKA. Forskolin pre-treatment also increased whole-cell 
capacitance (i.e. cell size) in both normoxic and hypoxic cells (P < 0.01 vs. normoxia / 
hypoxia alone; Figure 3.25C inset and Table 3.9), consistent with the effect on cell 
morphology (Appendix 5).  
The effects of pre-treatment with 20 µM forskolin on VGSC gating 
characteristics are summarized in Table 3.9. There was no significant effect on Vthres, 
Vpeak (Figure 3.25C), activation V1/2 or k (Figure 3.26A), or steady-state inactivation V1/2 
or k (Figure 3.26B) in normoxic or hypoxic conditions. There was also no effect on 
kinetics of activation (Tpeak; Figure 3.26C) and rate of recovery from inactivation 
(Figure 3.26D and Table 3.9). 
 Co-application (24 h) of 20 µM forskolin with 20 µM Myr PKI14-22 in normoxic 
cells (n = 19; treatment group 4 in Figure 3.27AB) reversed the potentiating effect of 
forskolin alone (n = 24; treatment group 2), reducing VGSC peak current density even  
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Figure 3.25 Forskolin enhanced peak VGSC current density in normoxic MDA-MB-231 cells 
(A) Typical whole-cell VGSC currents in MDA-MB-231 cells pre-treated for 24 h in (i) normoxia, 
(ii) hypoxia (2% O2), (iii) normoxia + forskolin (20 µM), and (iv) hypoxia + forskolin (20 µM). 
Currents were elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -
100 mV; interpulse duration was 2 s. (B) Average peak current density in normoxia (n = 31), 
hypoxia (n = 40), normoxia + 20 µM forskolin (n = 24), and hypoxia + 20 µM forskolin (n = 23). 
Normoxia and hypoxia data were from Figure 3.21. Data were compared using ANOVA (P < 0.01) 
followed by Newman-Keuls post-hoc analysis. Significance: (**) P < 0.01. Unless indicated 
otherwise, (in)significance is shown for forskolin treatments vs. respective normoxic / hypoxic 
controls. (C) Mean I-V relationships in normoxia, hypoxia, normoxia + 20 µM forskolin, and 
hypoxia + 20 µM forskolin; normoxia and hypoxia data from Figure 3.22. Inset, whole-cell 
capacitance was increased by forskolin pre-treatment in normoxia (P < 0.01) and hypoxia (P < 0.01) 
(ANOVA / Newman-Keuls). Data are presented as mean ± SEM. 
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Table 3.9 Effect of forskolin (20 µM, 24 h) on VGSC characteristics in normoxic and hypoxic (2% O2) MDA-MB-231 cells      
 
 
For abbreviations, see Table 3.5. Statistical significance was determined using ANOVA followed by Newman-Keuls post-hoc analysis. Peak current 
density and whole-cell capacitance were significantly different between treatment groups (P < 0.01); there was no difference in other parameters 
(ANOVA, P > 0.05). For pairwise significance (P < 0.01): (a) normoxia vs. nor + forsk; (b) normoxia vs. hypoxia; (c) normoxia vs. hyp + forsk; (d) nor 
+ forsk vs. hypoxia; (e) nor + forsk vs. hyp + forsk; (f) hypoxia vs. hyp + forsk. Data are mean ± SEM; normoxia and hypoxia data are from Table 3.7.
Parameter Normoxia Nor + Forskolin Hypoxia  Hyp + Forskolin n Significance 
Peak current density (pA/pF)  -15.4 ± 1.1  -24.6 ± 2.9  -22.9 ± 1.9  -25.9 ± 2.2  ≥ 23 a, b, c 
Capacitance (pF) 25.9 ± 0.6  30.0 ± 0.8  24.5 ± 0.8  32.3 ± 1.5  ≥ 23 a, c, d, f 
Vthres (mV) -45.5 ± 0.6  -46.9 ± 0.6  -46.7 ± 0.4  -46.5 ± 0.5  ≥ 23 - 
Vpeak (mV)  -6.9 ± 1.1  -10.2 ± 1.2  -8.3 ± 1.1  -8.5 ± 1.2  ≥ 23 - 
Activation V1/2  (mV)  -25.5 ± 0.9  -27.4 ± 0.7  -26.1 ± 0.7  -26.4 ± 0.7  ≥ 23 - 
Activation k (mV) 7.4 ± 0.3  6.9 ± 0.2  6.8 ± 0.2  6.7 ± 0.3  ≥ 23 - 
Inactivation V1/2 (mV)  -84.7 ± 1.2  -83.9 ± 1.0  -85.7 ± 0.8  -84.2 ± 1.6  ≥ 14 - 
Inactivation k (mV) -5.3 ± 0.2  -5.2 ± 0.1  -5.1 ± 0.2  -5.3 ± 0.3  ≥ 14 - 
V0 (mV)  16.2 ± 2.4  14.1 ± 1.7  16.0 ± 2.5  15.0 ± 4.1  ≥ 23 - 
Tpeak at 0 mV (ms)  0.86 ± 0.03  0.90 ± 0.04  0.88 ± 0.03  0.92 ± 0.03  ≥ 23 - 
τrecovery (ms)  19.0 ± 2.8  16.2 ± 2.0  18.9 ± 1.7  17.5 ± 2.1  ≥ 6 - 
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Figure 3.26 Forskolin pre-treatment had no effect on VGSC gating characteristics  
Data (mean ± SEM) were recorded from MDA-MB-231 cells pre-treated (24 h) in normoxia, 
hypoxia (2% O2), normoxia + 20 µM forskolin, and hypoxia + 20 µM forskolin. Values of the fitted 
parameters (from cell-by-cell fits) are reported in Table 3.9. (A) Normalized G-V relationships 
(G/Gmax) fitted with Boltzmann functions (n ≥ 23). Data from recordings described in Figure 3.25. 
(B) Normalized availability-voltage relationships fitted with Boltzmann functions (n ≥ 14). Currents 
were elicited with 80 ms test pulses to -10 mV after 1 s pre-pulses in the range -140 mV to -10 mV. 
Holding potential was -100 mV and interpulse duration was 2 s. Currents (I) were normalized to the 
maximum current (Imax) recorded following the most hyperpolarized pre-pulse (-140 mV). (C) Time 
to peak (Tpeak) plotted as a function of test potential and fitted with single exponential functions (n ≥ 
23). Data from recordings described in Figure 3.25. (D) Time-course of recovery from inactivation 
was studied with a 80 ms control pulse to -10 mV (giving Ic), return to -100 mV for a recovery 
interval ranging from 5 to 155 ms and then an identical test pulse to -10 mV (giving It). Holding 
potential was -100 mV and interpulse duration was 2 s. Recovered current (It /Ic) was plotted as a 
function of recovery interval and fitted with single exponential functions (n ≥ 6). There was no 
statistically significant difference (ANOVA) in any of the parameters between different treatment 
groups (Table 3.9). 
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Figure 3.27 Forskolin reversed the inhibitory effect of TTX on hypoxic increase in peak 
VGSC current density 
(A) VGSC peak current densities (in chronological order) of MDA-MB-231 cells pre-treated for 
24 h in: (1) normoxia (n = 31), (2) normoxia + 20 µM forskolin (n = 24), (3) normoxia + 20 µM 
forskolin + 10 µM TTX (n = 33), (4) normoxia + 20 µM forskolin + 20 µM Myr PKI14-22 (n = 
19), (5) hypoxia (2% O2) (n = 40), (6) hypoxia + 20 µM forskolin (n = 23), (7) hypoxia + 20 µM 
forskolin + 10 µM TTX (n = 22), and (8) hypoxia + 20 µM forskolin + 20 µM Myr PKI14-22 (n = 
21). Each bar represents a single cell. Currents were elicited by 60 ms pulses to between -80 mV 
and +45 mV from a holding potential of -100 mV; interpulse duration was 2 s. Normoxia / 
hypoxia ± 20 µM forskolin data were described earlier in Figure 3.25. (B) Average peak current 
density for each treatment group described in part A. Data (mean ± SEM) were compared using 
ANOVA followed by Newman-Keuls post hoc analysis. Right, table of multiple comparisons of 
significance (P < 0.05). 
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below the normoxic control levels (n = 31; treatment group 1) (Figure 3.27AB). This 
was consistent with the effect of forskolin on VGSC peak current density occurring via 
activation of PKA and not other intracellular cAMP targets, e.g. GTP-exchange protein 
Epac or cyclic nucleotide-gated ion channels (Fimia and Corsi, 2001; Murray, 2008). 
VGSC peak current density was similarly reduced in hypoxic cells pre-treated with 
forskolin + Myr PKI14-22 (n = 21; treatment group 8), as compared to cells pre-treated in 
hypoxia only (n = 40; treatment group 5) or hypoxia + forskolin (n = 23; treatment 
group 6) (Figure 3.27AB). This further substantiated the evidence that hypoxic increase 
in VGSC functional availability was mediated by PKA. 
 As described earlier (Section 5.2.3.1; Figure 3.19), 10 µM TTX inhibited the 
chronic hypoxic increase in peak VGSC current density, revealing the auto-regulatory 
nature of the hypoxic effect. Here, co-application of 20 µM forskolin with 10 µM TTX 
in hypoxic conditions (n = 22; treatment group 7 in Figure 3.27AB) did not affect 
VGSC peak current density compared to hypoxia alone (n = 40; treatment group 5), i.e. 
forskolin co-application counter-acted the inhibitory effect of TTX alone (Figure 
3.27AB). This suggested that PKA was downstream to VGSC activity in the auto-
regulatory upregulation of VGSC functional expression during chronic hypoxia. 
 
3.2.5.4 Lack of effect of chronic hypoxia on Nav1.4 
Unlike most VGSCαs, Nav1.4 functional expression or gating was reported not to be 
modulated by PKA (Zhou et al., 2000; Kim et al., 2006). Accordingly, Nav1.4-HEK 
cells were used as a negative control for the proposed role of PKA in hypoxic 
modulation of VGSC expression (Stea et al., 1995). In control recordings, Na+-free 
MPS abolished all inward currents in normoxic and hypoxic Nav1.4-HEK cells, 
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suggesting that INa was the only inward ionic conductance present (n = 4 each; 
Appendix 3).  
As predicted, hypoxia pre-treatment (2% O2, 24 h) had no significant effect on 
mean peak Nav1.4 current density (-197.2 ± 23.3 pA/pF in normoxia and -216.7 ± 22.3 
pA/pF in hypoxia; P = 0.76, n = 25-22) (Figure 3.28ABC and Table 3.10). Pre-
treatment with 20 µM Myr PKI14-22 also was without effect on peak Nav1.4 current 
density (-214.7 ± 13.8 pA/pF; n = 18), confirming Nav1.4 to be devoid of PKA 
modulation (Figure 3.28ABC and Table 3.10). Whole-cell capacitance was unchanged 
between cells pre-treated in normoxia, hypoxia, and normoxia + Myr PKI14-22 (P = 0.62; 
Figure 3.28A inset and Table 3.10). Chronic hypoxia and Myr PKI14-22 were also 
without effect on Nav1.4 gating characteristics. Thus, neither pre-treatment had any 
significant effect on Vthres, Vpeak, voltage-dependence of activation or steady-state 
inactivation, or the window current (Figure 3.28C and 3.29A). There was also no effect 
on kinetics of activation (Tpeak; Figure 3.29B) or inactivation (τfast, τslow and their 
fractional amplitudes; Figure 3.29D), or τrecovery (Figure 3.29C).  
The data from Nav1.4-HEK cells confirmed the specificity of the role of PKA 
and the treatments used to modulate it. Also, these findings suggested that PKA may be 
necessary for the chronic hypoxic upregulation of functional VGSC expression in 
general (Stea et al., 2005). This substantiated the evidence that positive autoregulation 
through PKA was the primary mechanism for the hypoxic increase in VGSC peak 
current density in MDA-MB-231 cells. 
 
3.2.5.5 Summary of effects 
Chronic hypoxic increase in functional VGSC expression in MDA-MB-231 cells was 
inhibited by 10 µM TTX. Thus, the hypoxic effect was VGSC-activity (i.e. Na+ influx)  
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Figure 3.28 Nav1.4 functional expression is not PKA-dependent and is insensitive to 
chronic hypoxia (2% O2)  
(A) Typical whole-cell VGSC currents in Nav1.4-HEK cells pre-treated (24 h) in (i) normoxia, 
(ii) hypoxia (2% O2), and (iii) normoxia + 20 µM Myr PKI14-22. Currents were elicited by 60 ms 
pulses to between -80 mV and +45 mV from a holding potential of -100 mV; interpulse duration 
was 2 s. Inset (part iii), whole-cell capacitance was unaffected by hypoxia or Myr PKI14-22 pre-
treatment (ANOVA: P = 0.62, n ≥ 18). (B) Average Nav1.4 peak current density in normoxia (n 
= 25), hypoxia (2% O2; n = 22) and normoxia + 20 µM Myr PKI14-22 (n = 18) (ANOVA: P = 
0.76). (C) Mean I-V relationships for Nav1.4-HEK cells pre-treated in normoxia, hypoxia and 
normoxia + Myr PKI14-22 (n ≥ 18). Data are mean ± SEM.   
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Table 3.10 Effect of chronic hypoxia (2% O2, 24 h) and Myr PKI14-22 (20 µM, 24 h) on Nav1.4 function in HEK-293 cells 
      
 
For abbreviations, see Table 3.5. Statistical significance was determined using ANOVA (P > 0.05 for each parameter). Data are mean ± SEM.
Parameter Normoxia Hypoxia  Nor + PKI n Significance 
Peak current density (pA/pF)  -197.2 ± 23.3  -216.7 ± 22.3  -214.7 ± 13.8  ≥ 18 -      (0.76) 
Capacitance (pF) 14.1 ± 0.5  13.5 ± 0.7  13.4 ± 0.6  ≥ 18  -      (0.62) 
Vthres (mV) -45.1 ± 0.8  -44.9 ± 0.8  -44.3 ± 0.8  ≥ 18 -      (0.79) 
Vpeak (mV)  -10.0 ± 1.6  -7.5 ± 1.9  -9.2 ± 2.0  ≥ 18 -      (0.60) 
Activation V1/2  (mV)  -23.9 ± 1.5  -21.9 ± 1.7  -22.4 ± 1.2  ≥ 18 -      (0.61) 
Activation k (mV) 5.3 ± 0.3  4.9 ± 0.7  5.1 ± 0.3  ≥ 18 -      (0.81) 
Inactivation V1/2 (mV)  -67.2 ± 0.9  -66.3 ± 0.8  -68.3 ± 0.8  ≥ 12 -      (0.43) 
Inactivation k (mV) -8.2 ± 0.3  -8.2 ± 0.5  -7.9 ± 0.3  ≥ 12 -      (0.74) 
V0 (mV)  22.1 ± 4.0  17.3 ± 2.5  21.6 ± 3.5  ≥ 18 -      (0.51) 
Tpeak at 0 mV (ms)  0.60 ± 0.02  0.60 ± 0.03  0.66 ± 0.04  ≥ 18 -      (0.36) 
τfast at 0 mV (ms) 0.34 ± 0.03  0.37 ± 0.05  0.40 ± 0.02  ≥ 10 -      (0.36) 
τslow at 0 mV (ms) 3.03 ± 0.30  3.31 ± 0.63  3.31 ± 0.27  ≥ 10 -      (0.84) 
Afast at 0 mV (%) 93.5 ± 1.0  91.9 ± 1.3  92.7 ± 0.7  ≥ 10 -      (0.53) 
τrecovery (ms)  26.1 ± 1.4  24.0 ± 1.3  25.6 ± 1.4  ≥ 13 -      (0.59) 
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Figure 3.29 Nav1.4 gating was unaffected by hypoxia or Myr PKI14-22 pre-treatment  
Data (mean ± SEM) were recorded from Nav1.4-HEK cells pre-treated (24 h) in normoxia, 
hypoxia (2% O2), and normoxia + 20 µM Myr PKI14-22. Values of the fitted parameters (obtained 
from cell-by-cell fits) are reported in Table 3.10. Pulse protocols and data analysis were as 
detailed in Figure 3.2. (A) Availability-voltage (squares; n ≥ 12) and G/Gmax-voltage relationships 
(circles; n ≥ 18) fitted with Boltzmann functions. The window current is magnified on the right. 
(B) Time to peak (Tpeak) as a function of voltage fitted with single exponential functions (n ≥ 18). 
(C) Time-course of recovery from inactivation fitted with single exponential functions (n ≥ 13). 
(D) τfast (i), τslow (ii), and their percentage amplitudes (iii) from double exponential fits to 
normalized INa decays at 0 mV (n ≥ 10). There was no statistically significant difference 
(ANOVA) in any of the parameters between different treatment groups (Table 3.9).  
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dependent, consistent with enhancement of INaP during hypoxia. PKA inhibitors 
KT5720 or Myr PKI14-22 each reversed the hypoxic augmentation of VGSC functional 
expression, indicating that this effect was also PKA-dependent. Consistently, AC/PKA 
activation by forskolin in normoxic conditions mimicked chronic hypoxia as regards the 
increase in VGSC peak current density, whilst forskolin application in hypoxic 
conditions did not induce further increase in current density. Also, forskolin counter-
acted the inhibitory effect of TTX pre-treatment on the hypoxic increase in VGSC 
current density, further indicating involvement of PKA. Nav1.4, which is devoid of 
PKA regulation, was unresponsive to chronic hypoxia, also consistent with PKA being 
a signalling intermediate in the chronic hypoxic upregulation of VGSC functional 
expression. Taken together, therefore, data agreed with the proposed hypothesis that 
chronic hypoxia upregulated functional VGSC expression in MDA-MB-231 cells via 
activation of AC/PKA signalling through enhanced VGSC activity / Na+ influx. 
Possible contributions of other hypoxic mechanisms to this pathway (e.g. enhanced 
NHE, reduced Na+/K+ ATPase) are discussed in Section 3.3.4.    
Next, the subcellular level (mRNA and/or protein) at which the hypoxic increase 
in VGSC functional expression occurred was investigated, focussing on nNav1.5, the 
predominant VGSCα expressed in MDA-MB-231 cells. 
 
3.2.6 Effect of chronic hypoxia on nNav1.5 and VGSCβ1-4 mRNA levels   
3.2.6.1 Initial observations and controls  
Initial real-time PCR (rt-PCR) experiments confirmed that the nNav1.5 mRNA level 
was > 1000-fold greater in highly metastatic MDA-MB-231 BCa cells vs. weakly 
metastatic MCF-7 cells (P < 0.01 with both β-actin and cytochrome-b5 reductase 
(Cytb5R) normalizations, n = 6 independent RNA extractions) (Figure 3.30A; Fraser et  
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Figure 3.30 nNav1.5 and VGSCβ1-4 expression in MDA-MB-231 and MCF-7 cell lines 
(A) Relative nNav1.5 mRNA expression in MDA-MB-231 vs. MCF-7 cells. nNav1.5 mRNA 
level was normalized to β-actin or cytochrome-b5 reductase (Cytb5R) by the 2-∆∆Ct method. 
Errors (SEM) are propagated through the 2-∆∆Ct analysis (n = 6). Significance: (**) P < 0.01 
(determined using both unpaired t-tests and Mann-Whitney rank sum tests). (B) (i) Fold 
differences in nNav1.5 and VGSCβ1-4 mRNA levels in MDA-MB-231 vs. MCF-7 cells. 
VGSCβ3 is not expressed in either cell line (Figure 3.31). Fold differences reported were from 
normalizations to Cytb5R (similar fold-differences were obtained with β-actin). Significance 
was determined using both unpaired t-tests (P-value reported in the table) and Mann-Whitney 
rank sum tests (n = 6). (ii) Fold differences in VGSCβ1, β2 and β4 mRNA levels within a given 
cell line (MDA-MB-231 or MCF-7). β-actin and Cytb5R normalizations result in identical 
outcomes in this case (n = 6). β4 and β2 mRNA expression was similar in MDA-MB-231 cells 
(unpaired t-test and Mann-Whitney rank sum test; P > 0.05). (C) VGSCβ1-4 mRNA levels in 
MDA-MB-231 vs. MCF-7 expressed relative to MCF-7 β1 levels. Data were normalized to 
Cytb5R, and compared with unpaired t-tests and Mann-Whitney rank sum tests (n = 6). 
Significance: (**) P < 0.01. (D) Same as part C but data were normalized to β-actin. 
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al., 2005). Both MDA-MB-231 and MCF-7 cells expressed mRNAs for VGSCβ1, β2 
and β4, whilst β3 subunit was not expressed in either cell line (Figure 3.30CD and 
Figure 3.31A) (Chioni et al., 2009). As a positive control for β3, a band with the 
expected size of 353 bp was amplified in PC-3M cells (Figure 3.31A) (Diss et al., 
2008).  
Consistent with earlier findings (Chioni et al., 2009), VGSCβ1 was the pre-
dominant β-subunit expressed in both MDA-MB-231 and MCF-7 cells; the relative 
mRNA levels were β1 >> β4 = β2 in MDA-MB-231 cells and β1 >> β4 > β2 in MCF-7 
cells (Figure 3.30BCD). Also, β-subunit expression was significantly greater in MCF-7 
vs. MDA-MB-231 cells; the difference in β1 mRNA level was 20-fold and β4 level 32-
fold (P < 0.01 for both with β-actin or Cytb5R normalizations, n = 6) (Figure 3.30B) 
(Chioni et al, 2009). Notably, VGSCβ4 was present in two molecular forms in MCF-7 
cells, with rt-PCR amplifying the full-length transcript (459 bp) and an exon 3-skipped 
isoform (305 bp) expressed at lower levels (Figure 3.31A) (Diss et al., 2008; Chioni et 
al., 2009). Only the full-length β4 transcript was expressed in MDA-MB-231 cells 
under normoxic conditions (Figure 3.31A).  
 Typical gel images of PCR products for β-actin, Cytb5R, nNav1.5 and 
VGSCβ1-4 confirmed the high-quality of the PCR products with the predicted band 
sizes (Figure 3.31A and Table 2.2); there was no amplification in no-template controls 
(NTC) or in control samples with Superscript reverse transcriptase (RT) omitted in the 
cDNA synthesis step.  
 
3.2.6.2 Effects of 24 h hypoxia 
MDA-MB-231 cells were incubated in normoxic or hypoxic (2% O2) conditions for 24 
h (3 h post-seeding) after which the mRNA levels of nNav1.5 and VGSCβ1-4 were  
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Figure 3.31 Effects of chronic hypoxia (2% O2, 24 h) on nNav1.5 and VGSCβ1-4 mRNA expression 
(A) Typical PCR products for β-actin, cytochrome-b5 reductase (Cytb5R), nNav1.5 and VGSCβ1-4. 
Lanes: 1, normoxic MDA-MB-231 cells; 2, hypoxic (2% O2, 24 h) MDA-MB-231 cells; 3, normoxic 
MCF-7 cells; 4, hypoxic (2% O2, 24 h) MCF-7 cells; 5, no template control (NTC); 6, normoxic PC-3M 
cells (positive control for VGSCβ3). Numbers at right indicate product sizes in base pairs (bp). For β4, 
shorter band (305 bp) corresponds to an exon 3-skipped splice variant (Diss et al., 2008). (B) Relative 
mRNA levels (vs. normoxia) of nNav1.5, VGSCβ1, VGSCβ2 and VGSCβ4 in chronically hypoxic (2% 
O2, 24 h) MDA-MB-231 cells. nNav1.5 and β-subunit mRNA levels were normalized to β-actin (white 
bars) and Cytb5R (black bars) by the 2-∆∆Ct method. Errors (SEM) are propagated through the 2-∆∆Ct 
analysis (n = 6). Significance: (X) P > 0.05, (*) P < 0.05 (both unpaired t-tests and Mann-Whitney rank 
sum tests vs. respective mRNA levels in normoxia). (C) Same as part B but for hypoxic (2% O2, 24 h) 
MCF-7 cells. Significance: (**) P < 0.01.  
1       2        3      4      5       6 
β-actin 
Cytb5R 
nNav1.5 
β1 
β2 
β3 
β4 
356 bp 
511 bp 
101 bp 
379 bp 
310 bp 
353 bp 
459 bp 
305 bp 
Normoxia nNav1.5 β1 β2 β4 
0.0 
0.5 
1.0 
1.5 
2.0 
m
R
N
A 
e
xp
re
ss
io
n
 
(vs
.
 
n
o
rm
o
xi
a
) 
Hypoxia (2% O2, 24 h) 
  β-actin 
  Cytb5R 
X 
X 
X X 
X 
X 
* 
* 
0 
1 
2 
3 
10 
20 
30 
m
R
N
A 
e
xp
re
ss
io
n
 
(vs
.
 
n
o
rm
o
xi
a
) 
  β-actin 
  Cytb5R 
Normoxia nNav1.5 β1 β2 β4 
Hypoxia (2% O2, 24 h) 
** ** 
** ** 
** 
** 
* 
* 
 Chapter 3                                                                        Modulation of VGSC activity by hypoxia 
 
 243 
assessed by rt-PCR. Hypoxia (24 h) did not affect the nNav1.5 mRNA level (P > 0.05 
vs. normoxia with β-actin or Cytb5R normalizations, n = 6) (Figure 3.31AB), whilst the 
VGSCβ1 mRNA level was significantly reduced by 26% (Cytb5R normalization; P < 
0.05, n = 6) (Figure 3.31AB). When data were normalized to β-actin, hypoxic reduction 
in VGSCβ1 was slightly smaller (17%) but still statistically significant (P < 0.05, n = 6) 
(Figure 3.31AB). mRNA levels of VGSCβ2 or VGSCβ4 were unaffected by chronic 
hypoxia (P > 0.05 vs. normoxia with both β-actin and Cytb5R normalizations, n = 6) 
(Figure 3.31AB). Notably, the exon 3-skipped variant of VGSCβ4 (305 bp), which was 
absent in normoxic MDA-MB-231 cells, was expressed after 24 h hypoxia, albeit at low 
levels (Figure 3.31A).  
 The effect of chronic hypoxia (2% O2, 24 h) on VGSC mRNA expression was 
also determined in the weakly metastatic MCF-7 cells. Unlike MDA-MB-231 cells, 
hypoxia pre-treatment reduced the nNav1.5 mRNA level by 75% in MCF-7 cells, whilst 
enhancing VGSCβ2 and β4 levels by 17-fold and 2-fold, respectively (β-actin 
normalization, P < 0.01 for all, n = 6) (Figure 3.31AC). The β1-subunit mRNA level 
was reduced by 48% in hypoxic vs. normoxic cells (β-actin normalization, P < 0.01, n = 
6), similar to the effect observed in MDA-MB-231 cells (Figure 3.31BC). For relative 
nNav1.5 and VGSCβ1-4 levels in hypoxia vs. normoxia, normalization to Cytb5R 
produced comparable results with β-actin normalization (Figure 3.31BC). Since β1 is 
the predominant VGSCβ expressed in MCF-7 cells (~ 5500-fold > β2 and ~ 400-fold > 
β4; Figure 3.30B), the net effect of hypoxia was ~ 48% reduction in the total VGSCβ 
mRNA level.  
 It was concluded (i) that the increased VGSC functional expression in 
chronically hypoxic MDA-MB-231 cells was not accompanied by an increase in the 
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nNav1.5 mRNA level at 24 h, and (ii) that VGSCβ1 mRNA expression was reduced by 
chronic hypoxia in both weakly and strongly metastatic BCa cells.  
 
3.2.6.3 Effects of shorter-term (3-12 h) hypoxia on the nNav1.5 mRNA level 
Hypoxia-induced transcriptional changes can have rapid onsets, consistent with 
activation of HIFα occurring via a post-translational mechanism (HIFα is the major 
transcription factor controlling expression of oxygen-sensitive genes) (Wenger et al., 
2005). Thus, despite the nNav1.5 mRNA level was unchanged by chronic hypoxia (24 
h), an increase in nNav1.5 mRNA expression may have occurred transiently within a 
shorter time-period. In fact, any increase in VGSC mRNA expression would be 
expected to occur in < 24 h, preceding the rise in functional channel expression 
observed at 24 h (Section 3.2.1). To test this possibility, MDA-MB-231 cells were 
incubated in normoxic or hypoxic (2% and 5% O2) conditions for 3, 6, 12 and 24 h (3 h 
post-seeding) after which nNav1.5 mRNA levels were determined.  
 The nNav1.5 mRNA level declined with increasing pre-incubation times (3-24 
h) in both normoxic and hypoxic conditions, as evident from the progressive rightward 
shift in amplification thresholds (Ct values) (Figure 3.32A). mRNA levels of the 
normalizing genes (β-actin and Cytb5R) remained unchanged (Figure 3.32A). 
Importantly, the time-dependent reduction in nNav1.5 mRNA was less pronounced in 
hypoxic vs. normoxic samples (e.g. Figure 3.32 part iii vs. part ii) indicating that the 
nNav1.5 mRNA level remained at a higher level in early hours (< 24 h) of chronic 
hypoxia. Consistently, when expressed relative to 3h-normoxic cells, the nNav1.5 
mRNA level was higher in hypoxic vs. normoxic cells pre-incubated for 3, 6 and 12 h 
(Figure 3.32BC). However, the hypoxic increase was statistically significant only at 12 
h; the difference was 2.2-fold with β-actin normalization and 2.9-fold with Cytb5R  
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Figure 3.32 Hypoxic increase in the nNav1.5 mRNA level occurred faster than 24 h 
(A) (i) rt-PCR setup for studying the effects of  3, 6, 12 and 24 h hypoxia on nNav1.5 mRNA levels in 
MDA-MB-231 cells (β-actin and Cytb5R were used as the normalizing genes). PCR shown was 
performed (in duplicates) for two separate RNA extractions from cells pre-treated for 3-24 h in normoxia 
(top half; Nor 1 and 2) or hypoxia (bottom half; Hyp 1 and 2). (ii) Fluorescence from incorporation of 
SYBR I Green to double-stranded DNA using nNav1.5, β-actin and Cytb5R specific primers in normoxic 
samples (colours as shown in part i; top half). (iii) Same as (ii) but for hypoxic (2% O2) samples. 
Amplification threshold (Ct) for β-actin and Cytb5R was unchanged by hypoxia or the pre-treatment 
period (3-24 h). Ct values for nNav1.5 progressively increased (i.e. expression decreased) with longer pre-
treatment periods; this effect was less pronounced in hypoxia vs. normoxia (red arrows). (B, C) Relative 
nNav1.5 mRNA expression in cells pre-treated for 3-24 in normoxia or hypoxia (2% O2). nNav1.5 mRNA 
levels were normalized to β-actin (B) or Cytb5R (C) by the 2-∆∆Ct method, and were expressed relative to 
the nNav1.5 level in 3h-normoxic cells (n = 6). (D, E) Same as parts B and C, respectively, but for 5% O2 
hypoxia (n = 6). Significance: (*) P < 0.05 (unpaired t-tests and Mann-Whitney rank sum tests comparing 
hypoxic vs. normoxic nNav1.5 mRNA levels at each time point). Data are mean ± SEM. 
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normalization (P < 0.05 with both normalizing genes, n = 6 each) (Figure 3.32BC). 
Similar time-series experiments were also performed for milder hypoxia (5% O2), and 
an ~ 2-fold significant increase in the nNav1.5 mRNA level was again observed at 12 h 
(P < 0.05 with both β-actin and Cytb5R normalizations, n = 5 each) (Figure 3.32DE). It 
was concluded that the hypoxic (2% and 5% O2) increase in VGSC functional 
expression could involve a transient (≤ 12 h) increase in the nNav1.5 mRNA level, 
which disappeared during later stages of chronic hypoxia (i.e. at 24 h). 
  
3.2.7 Effect of chronic hypoxia on VGSCα and VGSCβ1 protein levels 
3.2.7.1 VGSCα  
Western blot with a pan-VGSCα antibody was used to assess the effect of chronic 
hypoxia (2% O2, 24 h) on the total VGSCα protein level in MDA-MB-231 cells. A 
strong protein band was observed at the expected molecular weight of ~ 220 kDa; this 
nearly disappeared when the antibody was pre-absorbed with 5x excess immunizing 
peptide (Figure 3.33A). VGSCα band intensity was stronger in chronically hypoxic vs. 
normoxic samples (as shown for two repeat experiments in Figure 3.33A); densitometry 
using the corresponding actinin signal as loading control revealed that chronic hypoxia 
increased total VGSCα protein level by ~ 51% at 24 h (P < 0.05, n = 5) (Figure 3.33B).
 Consistent with this, confocal immunocytochemistry with the pan-VGSC 
antibody revealed that chronic hypoxia (2% O2, 24h) increased the VGSC α-subunit 
protein level in MDA-MB-231 cells. Control labelling experiments in normoxic and 
hypoxic cells confirmed that there was (i) no autofluorescence and (ii) no / minimal 
signal from samples incubated with non-specific rabbit IgG or pan-VGSC antibody pre-
absorbed with the immunizing peptide (Figure 3.34 and 3.35). The overall VGSCα 
immunoreactivity was stronger in chronically hypoxic vs. normoxic cells, as illustrated  
 Chapter 3                                                                        Modulation of VGSC activity by hypoxia 
 
 247 
 
 
 A  
 
 
 
 
 B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
0.0 
0.5 
1.0 
1.5 
2.0 
To
ta
l V
G
SC
α
 
pr
o
te
in
 
(re
la
tiv
e
) 
Normoxia Hypoxia 
* 
220 kDa 
100 kDa 
Nor Hyp 
VGSCα 
Actinin 
Repeat 1 
Nor Hyp 
Repeat 2 
Control 
Figure 3.33 Chronic hypoxia (2% O2, 24 h) increased the total VGSCα protein level 
(A) Western blot with 50 µg of total protein per lane, using a pan-VGSC antibody, and an 
actinin antibody as a control for loading. Nor, MDA-MB-231 cells pre-incubated for 24 h in 
normoxic conditions; hyp, MDA-MB-231 cells pre-incubated for 24 h in hypoxic (2% O2) 
conditions. Blots from two repeat experiments are shown. Control, pan-VGSC antibody was 
pre-absorbed with 5x excess immunizing peptide for 30 min at room temperature before 
application (hypoxic protein extract was used). (B) Relative total VGSCα protein level, 
quantified by densitometry, in normoxic and hypoxic cells. The VGSCα protein level was 
normalized to the actinin control. Data are presented as mean ± SEM (n = 5). Significance 
(unpaired t-test and Mann-Whitney rank sum test): (*) P < 0.05. 
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Figure 3.34 Controls for immunocytochemistry with pan-VGSC and VGSCβ1 antibodies in normoxic MDA-MB-231 cells 
Auto-fluorescence, cells were fixed, permeabilized and mounted without labelling; No primary antibody (Ab), cells were labelled with concanavalin A  plasma 
membrane marker (conA), and 5% BSA/PBS was used in the primary antibody step; Non-specific IgG, cells were labelled with conA, and non-specific healthy 
rabbit IgG fraction (Dako) was used in the primary antibody step either at the maximum working concentration for pan-VGSC antibody (0.01 µg/µl) or twice that 
concentration (0.02 µg/µl); Pre-absorbed (for pan-VGSC only), cells were labelled with conA and incubated with pan-VGSC antibody that had been pre-absorbed 
with 5x excess of the immunizing peptide for 30 min at room temperature. This could not be performed for VGSCβ1 antibody since the immunogenic peptide was 
not available. (A) Signal from conA staining (green). (B) Signal from autofluorescence, non-specific IgG or pre-absorbed pan-VGSC (red). (C) Bright field 
image. Scale bar (30 µm), applicable to all panels.  
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Figure 3.35 Controls for immunocytochemistry with pan-VGSC and VGSCβ1 antibodies in hypoxic (2% O2, 24 h) MDA-MB-231 cells 
Auto-fluorescence, cells were fixed, permeabilized and mounted without labelling; No primary antibody (Ab), cells were labelled with concanavalin A  plasma 
membrane marker (conA), and 5% BSA/PBS was used in the primary antibody step; Non-specific IgG, cells were labelled with conA, and non-specific healthy 
rabbit IgG fraction (Dako) was used in the primary antibody step either at the maximum working concentration for pan-VGSC antibody (0.01 µg/µl) or twice that 
concentration (0.02 µg/µl); Pre-absorbed (pan-VGSC only), cells were labelled with conA and incubated with pan-VGSC antibody that had been pre-absorbed 
with 5x excess of the immunizing peptide for 30 min at room temperature. This could not be performed for VGSCβ1 antibody since the immunogenic peptide was 
not available. (A) Signal from conA staining (green). (B) Signal from autoflourescence, non-specific IgG or pre-absorbed pan-VGSC (red). (C) Bright field 
image. Scale bar (30 µm), applicable to all panels.  
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with typical confocal images from cells co-labelled with concanavalin A and pan-VGSC 
antibody in Figure 3.36 and 3.37 (and also in Appendices 7 and 8). Three different 
quantification techniques were used to assess the effects of hypoxia on (i) peripheral 
VGSCα protein level, (ii) internal VGSCα protein level, and (iii) subcellular distribution 
of VGSCα protein (Figure 3.38 and 3.39) (image analysis was described in detail in 
Section 2.4.1):  
i. The plasma membrane (peripheral) VGSCα level was quantified using ‘freeform 
line profiles’ drawn around the cell edge, guided by concanavalin A staining 
(Figure 3.38BC and 3.39BC). Chronic hypoxia (2% O2, 24 h) caused a 44% 
increase in VGSCα immunoreactivity in the plasma membrane (P < 0.05, n = 160 
cells from four experiments) (Figure 3.40A). 
ii. Internal VGSCα protein level in 20 µm2 rectangular sections of cytoplasm, 
avoiding the nucleus, was quantified using the ‘area histogram’ analysis. As 
exemplified in Figure 3.38D vs. E and Figure3.39D vs. E, chronic hypoxia 
increased the internal VGSCα protein level by 42% (P < 0.01, n = 160 cells from 
four experiments) (Figure 3.40B). 
iii. Similar (~ 40%) increase in the peripheral and internal VGSCα protein levels 
suggested that subcellular distribution of VGSCα protein was unaffected by 
chronic hypoxia. This was ascertained by studying VGSCα immunoreactivity 
along cross-sections taken across immunofluorescent cells, avoiding the nucleus, 
as described previously (e.g. Figure 3.38A and 3.39A; Okuse et al., 2002; Shah et 
al., 2004). Concanavalin A labelling was used to identify the cell edge in cross-
sections. As illustrated in Figure 3.38F vs. G and Figure 3.39F vs. G, the pattern of 
VGSCα immunoreactivity along cytoplasmic cross-sections was not altered by 
chronic hypoxia, i.e. there was no disproportionate increase in  
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Figure 3.36 Chronic hypoxia increased VGSCα immunoreactivity 
Typical confocal images of fixed and permeabilized MDA-MB-231 cells pre-incubated in 
normoxic or hypoxic (2% O2) conditions for 24 h. (A) Signal from concanavalin A plasma 
membrane marker (green). (B) Signal from pan-VGSC antibody (red). (C) Overlay of 
concanavalin A and pan-VGSC labelling. (D) Bright field image. White lines in part C, 
typical cross-sections used for ‘straight-line’ subcellular distribution analysis (data shown in 
Figure 3.40C). Scale bar (15 µm), applicable to all panels. 
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Figure 3.37 Hypoxic increase in internal and peripheral VGSCα immunoreactivity 
(A) Confocal images from a normoxic and hypoxic (2% O2, 24 h) MDA-MB-231 cell. 
Concanavalin A (ConA) membrane labelling (green), pan-VGSC signal (red), and overlay of 
the two are shown. Scale bar (5 µm), applicable to all panels. Dotted square boxes are 
magnified in part B (scale bar applicable to all panels). Chronic hypoxia increased the level of 
internal and peripheral (i.e. plasma membrane) VGSCα immunoreactivity. 
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Figure 3.38 Hypoxic increase in VGSCα immunoreactivity: quantification example 1 
(A) Confocal images from a normoxic and a hypoxic (2% O2, 24 h) MDA-MB-231 cell. Concanavalin 
A (ConA) membrane labelling (green), pan-VGSC signal (red), and overlay of the two are shown. 
White lines are cross-sections used for analysis in parts F & G. (B, C) Cell surface (peripheral) VGSCα 
level in the normoxic (B) and the hypoxic (C) cell shown in part A, determined using ‘freeform line 
profile’ function drawn around the cell surface guided by ConA staining. Dotted lines indicate average 
pan-VGSC signal intensity, which was greater in the hypoxic cell. (D, E) Intracellular VGSCα level in 
the normoxic (D) and the hypoxic (E) cell shown in part A, quantified using the ‘area histogram’ 
function covering 20 µm2 rectangular sections of the cytoplasm (avoiding the nucleus). Rightward shift 
in frequency indicated a larger level internal VGSCα protein in the hypoxic cell. (F, G) Subcellular 
distribution of VGSCα protein was similar in the normoxic (F) and the hypoxic cell (G), determined 
using ‘straight-line’ analysis along the cross-sections indicated in part A. For further details of image 
analysis, see Section 2.4.1.  
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Figure 3.39 Hypoxic increase in VGSCα immunoreactivity: quantification example 2 
(A) Confocal images from a normoxic and a hypoxic (2% O2, 24 h) MDA-MB-231 cell. Concanavalin 
A (ConA) membrane labelling (green), pan-VGSC signal (red), and overlay of the two are shown. 
White lines are cross-sections used for analysis in parts F & G. (B, C) Cell surface (peripheral) VGSCα 
level in the normoxic (B) and the hypoxic (C) cell shown in part A, determined using ‘freeform line 
profile’ function drawn around the cell surface guided by ConA staining. Dotted lines indicate average 
pan-VGSC signal intensity, which was greater in the hypoxic cell. (D, E) Intracellular VGSCα level in 
the normoxic (D) and the hypoxic (E) cell shown in part A, quantified using the ‘area histogram’ 
function covering 20 µm2 rectangular sections of the cytoplasm (avoiding the nucleus). Rightward shift 
in frequency indicated a larger level internal VGSCα protein in the hypoxic cell. (F, G) Subcellular 
distribution of VGSCα protein was similar in the normoxic (F) and the hypoxic cell (G), determined 
using ‘straight-line’ analysis along the cross-sections indicated in part A. For further details of image 
analysis, see Section 2.4.1.  
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Figure 3.40 Chronic hypoxia enhanced the level of VGSCα protein without altering its 
subcellular distribution  
(A) Peripheral (plasma-membrane) VGSCα protein level (immunoreactivity), quantified by 
‘freeform line profiles’ drawn around the cell edge (as described in Figure 3.38BC and 3.39BC), 
in normoxic and hypoxic cells (n = 160 from 4 repeat experiments). (B) Internal VGSCα protein 
level (immunoreactivity), quantified by ‘area histogram’ digital analysis (as described in Figure 
3.38DE and 3.39DE), in normoxic and hypoxic (2% O2, 24 h) MDA-MB-231 cells (n = 160 from 
4 repeat experiments). (C) VGSCα protein distribution (immunoreactivity) along subcellular 
cross-sections (as illustrated in Figure 3.38AFG and 3.39AFG) in normoxic and hypoxic cells (n = 
120 from 4 repeat experiments). Left-hand bars, 1.5 µm sections measured inward from edge of 
concanavalin A staining, representing plasma membrane (PM) VGSCα level. Right-hand bars, 
middle 30% of the cross-section, representing internal (INT) VGSCα level. PM and INT VGSCα 
immunoreactivity was expressed as a percentage of total intensity along the cross-section. Data 
are presented as mean ± SEM (in parts A and B, data were expressed relative to normoxia). 
Significance (unpaired t-test and Mann-Whitney rank sum test): (*) P < 0.05, (**) P < 0.01, (X), P 
> 0.05 vs. normoxia. 
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immunofluorescence in intracellular regions vs. at the edges (plasma membrane). 
For quantification, the VGSCα immunoreactivity was measured in two regions 
along the cross-section: (1) ‘plasma membrane’, in a 1.5 µm section inward from 
the edge of concanavalin A staining (Okuse et al., 2002; Brackenbury and 
Djamgoz, 2006), and (2) ‘internal’, in the middle 30% of the cross-section. 
Expressed relative to total immunofluorescence along the cross-section, the levels 
of plasma membrane and internal VGSCα protein were respectively 8.5 ± 0.4% 
and 38.5 ± 0.5% in normoxic cells, and similarly 9.4 ± 0.4 % and 37.8 ± 0.4% in 
hypoxic cells (P > 0.05 for both, n = 120 from four experiments) (Figure 3.40C).  
Taken together, these results were consistent with chronic hypoxia inducing a ‘uniform’ 
global increase in the VGSCα protein level, such that the balance between intracellular 
and plasma membrane VGSCα levels remained unchanged (i.e. there was no net 
intracellular trafficking effect). Also, increase in the VGSCα protein level was possibly 
due to de novo protein synthesis since it was preceded by a rise in VGSCα (nNav1.5) 
mRNA level (Section 3.2.6.3). Importantly, ~ 44% hypoxic increase in the plasma 
membrane VGSCα level was comparable to the ~ 50% increase in peak current density 
observed in patch-clamp recordings (Section 3.2.1.2), i.e. the hypoxic increase in 
current density being was likely to be due to enhanced VGSCα expression in plasma 
membrane.  
 
3.2.7.2 VGSCβ1 
Effect of chronic hypoxia (2% O2, 24 h) on the VGSCβ1 protein level was assessed 
using confocal immunocytochemistry. The same three image analysis techniques, as for 
VGSCα, were used to determine the effect on the plasma membrane level, internal 
level, and subcellular distribution of VGSCβ1 protein.  
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The overall VGSCβ1 immunoreactivity was weaker in chronically hypoxic vs. 
normoxic cells, suggesting that hypoxia reduced the VGSCβ1 protein level (Figure 3.41 
and 3.42). Determined using ‘freeform line profile’ and ‘area histogram’ analyses, 
respectively (Section 2.4.1), the reduction in the plasma membrane VGSCβ1 level was 
24% and the internal VGSCβ1 level 16% (P < 0.05 for both vs. normoxia, n = 120 cells 
from three experiments) (Figure 3.43AB). In cross-sectional analysis, the relative level 
of VGSCβ1 in the ‘plasma membrane’ region was slightly but significantly reduced 
from 8.6 ± 0.4% in normoxia to 7.1 ± 0.4% in hypoxia (P < 0.05, n = 60 from three 
experiments) (Figure 3.43C, left-hand bars), whilst there was an opposite effect on the 
‘internal’ middle 30% of cross-sections: relative immunofluorescence was increased 
significantly from 33.4 ± 0.6% in normoxia to 35.6 ± 0.6% in hypoxia (P < 0.01, n = 60 
from three experiments) (Figure 3.43C, right-hand bars). 
Taken together, therefore, chronic hypoxia reduced both plasma membrane and 
internal levels of VGSCβ1 protein, consistent with a decline in total VGSCβ1 protein 
level. This possibly resulted from the concomitant reduction in the VGSCβ1 mRNA 
level (Section 3.2.6.2). In addition, hypoxic reduction in VGSCβ1 protein level was 
larger in the plasma membrane vs. in internal regions, such that subcellular distribution 
of VGSCβ1 protein was altered in favour of relative increased intracellular protein.  
 
3.2.8 Effect of chronic hypoxia on migration and invasion 
3.2.8.1 General observations and controls 
Migration through uncoated transwell filters (6 h) and invasion through Matrigel-coated 
transwell filters (24 h) were used as in vitro measures of metastatic potential (e.g. Fraser 
et al., 2005; Brackenbury and Djamgoz, 2006). The VGSC-dependent component of 
migration / invasion under normoxic and hypoxic (2% O2) conditions was assessed  
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Figure 3.41 Chronic hypoxia reduced VGSCβ1 immunoreactivity: example 1 
Typical confocal images of fixed and permeabilized MDA-MB-231 cells pre-incubated in 
normoxic or hypoxic (2% O2) conditions for 24 h. (A) Signal from concanavalin A plasma 
membrane marker (green). (B) Signal from VGSCβ1 antibody (red). (C) Overlay of 
concanavalin A and VGSCβ1 labelling. (D) Bright field image. White lines in part C, typical 
cross-sections used for ‘straight-line’ subcellular distribution analysis (data shown in Figure 
3.43C). Scale bar (15 µm), applicable to all panels. 
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Figure 3.42 Chronic hypoxia reduced VGSCβ1 immunoreactivity: example 2 
Typical confocal images of fixed and permeabilized MDA-MB-231 cells pre-incubated in 
normoxic or hypoxic (2% O2) conditions for 24 h. (A) Signal from concanavalin A plasma 
membrane marker (green). (B) Signal from VGSCβ1 antibody (red). (C) Overlay of 
concanavalin A and VGSCβ1 labelling. (D) Bright field image. White lines in part C, typical 
cross-sections used for ‘straight-line’ subcellular distribution analysis (data shown in Figure 
3.43C). Scale bar (15 µm), applicable to all panels. 
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Figure 3.43 Chronic hypoxia reduced the level of internal and peripheral VGSCβ1 protein, 
and reduced the relative proportion of peripheral VGSCβ1 protein  
(A) Peripheral (plasma-membrane) VGSCβ1 protein level (immunoreactivity), quantified by 
‘freeform line profiles’ drawn around the cell edge, in normoxic and hypoxic cells (n = 120 from 3 
repeat experiments). (B) Internal VGSCβ1 protein level (immunoreactivity), quantified by ‘area 
histogram’ digital analysis (20 µm2 cytoplasmic sections, avoiding the nucleus), in normoxic and 
hypoxic (2% O2, 24 h) MDA-MB-231 cells (n = 120 from 3 repeat experiments). (C) VGSCβ1 
protein distribution (immunoreactivity) along subcellular cross-sections (as illustrated in Figure 
3.41 and 3.42) in normoxic and hypoxic cells (n = 60 from 3 repeat experiments). Left-hand bars, 
1.5 µm sections measured inward from edge of concanavalin A staining, representing plasma 
membrane (PM) VGSCβ1 level. Right-hand bars, middle 30% of the cross-section, representing 
internal (INT) VGSCβ1 level. PM and INT VGSCβ1 immunoreactivity was expressed as a 
percentage of total intensity along the cross-section. Data are presented as mean ± SEM (in parts 
A and B, data were expressed relative to normoxia). Significance (unpaired t-test and Mann-
Whitney rank sum test): (*) P < 0.05, (**) P < 0.01. 
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using 10 µM TTX (which would almost completely block peak INa and INaP) or 20, 50 
and 300 µM ranolazine (to preferentially block INaP at 20 and 50 µM). Hypoxic and 
pharmacological treatments were applied only during the assays, i.e. there was no ‘pre-
treatment’. MTT assay was used to confirm that cell number was not affected by 
hypoxia, TTX or ranolazine treatments during the 24 h invasion assays in MDA-MB-
231 (Figure 3.44A) or MCF-7 cells (Figure 3.44B); cell viability was also unaffected by 
these treatments (Appendix 2). 
  
3.2.8.2 Transwell migration 
Migration of MDA-MB-231 cells through Transwell filters was not affected by hypoxic 
culture conditions (2% O2) (P = 0.31, n = 6; Figure 3.45AB). Also, 10 µM TTX applied 
in the presence of normoxia or hypoxia only insignificantly reduced cell migration by 
10-20% (P = 0.31, n = 6) (Figure 3.45AB). It was concluded therefore that migration 
through 8 µm-pore filters was insensitive to hypoxic stress and was not VGSC-
dependent (unlike migration through 12 µm-pore filters; Brackenbury et al., 2007). 
 
3.2.8.3 Matrigel invasion 
Consistent with earlier reports, invasiveness of MDA-MB-231 cells through Matrigel-
coated Transwell filters was ~ 2.5-fold larger in hypoxia vs. normoxia (P < 0.01, n = 9; 
Figure 3.46AB) (Yoon et al., 2005; Munoz-Najar et al., 2006). Invasiveness was 
significantly reduced by 45% when 10 µM TTX was applied in normoxic conditions (P 
< 0.01, n = 9; Figure 3.46AB); this confirmed VGSC-dependence of ‘basal-level’ 
invasion in MDA-MB-231 cells (Brackenbury et al., 2007; Gillet et al., 2009; Chioni et 
al., 2010). Importantly, when applied under hypoxic conditions, TTX effectively 
inhibited the potentiating effect of hypoxia on invasiveness (P < 0.05 vs. hypoxia alone,  
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Figure 3.44 Chronic hypoxia, TTX and ranolazine treatments did not affect cell number 
during functional assays in MDA-MB-231 or MCF-7 cells 
(A) Normalized cell number after 24 h normoxia / hypoxia (2% O2) ± pharmacological 
treatments in MDA-MB-231 cells, determined using the MTT assay. Data were normalized to 
‘zero hour recordings’, as described in Section 2.6. Hypoxia, TTX (10 µM) or ranolazine 
(Ran; 20-300 µM) did not affect cell number, i.e. in all treatment groups, cell number 
approximately doubled after 24 h similar to normoxia control (ANOVA: P = 0.51; n = 4). (B) 
Hypoxia and/or TTX (10 µM) treatment for 24 h did not affect MCF-7 cell number, 
determined using the MTT assay (ANOVA: P = 0.89; n = 4). Data were relative to the zero 
hour recordings as described in Section 2.6. Data are mean ± SEM. 
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Figure 3.45 Chronic hypoxia and/or TTX did not affect cell migration  
(A) Migrated MDA-MB-231 cells on the bottom surface of 8 µm-pore Transwell filters 
stained with crystal violet. Cells were allowed to migrate for 6 h under normoxic or hypoxic 
(2% O2) conditions in the absence (left-hand panels) or presence of 10 µM TTX (right-hand 
panels). A chemotactic gradient of 1-10% FBS was used. (B) Quantification of migrated cells 
relative to normoxia control. TTX alone, hypoxia alone or TTX + hypoxia were without 
effect on cell migration (ANOVA: P = 0.31; n = 6). Data are mean ± SEM. 
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Figure 3.46 Hypoxia-stimulated invasion involved VGSC activity 
(A) Invaded MDA-MB-231 (top panels) and MCF-7 cells (bottom panels) on the bottom surface of 8 
µm-pore Matrigel-coated Transwell filters (stained with crystal violet). Cells were allowed to invade 
for 24 h under normoxic or hypoxic (2% O2) conditions in the absence or presence of 10 µM TTX. (B) 
Quantification of invasive MDA-MB-231 cells relative to normoxia control (n = 9). (C) Quantification 
of invasive MCF-7 cells relative to normoxic MDA-MB-231 control (n = 4). In parts B and C, data 
(mean ± SEM) were compared using ANOVA (P < 0.01 for both) followed by Newman-Keuls post 
hoc analysis. Significance of pairwise comparisons between treatment groups are reported in tables on 
the right. 
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n = 9), reducing it by 62% and resulting in a rate of invasion comparable to that of 
normoxia alone and normoxia + TTX (P > 0.05 vs. both, n = 9; Figure 3.46AB). These 
findings suggested that upregulated VGSC activity under hypoxic conditions (i.e. 
increased functional channel expression and emergence of INaP) was critical for the 
hypoxic increase in invasiveness of MDA-MB-231 cells. This was consistent with the 
lack of effect of hypoxia on invasion of weakly metastatic MCF-7 cells, which do not 
express functional VGSCs (Figure 3.46AC). Relative to MDA-MB-231 cells, MCF-7 
cells exhibited ~ 100-fold lower invasive capability (P < 0.01 vs. MDA-MB-231 
normoxia control, n = 4), and their invasiveness was unaffected by hypoxic stress or 
VGSC inhibition by 10 µM TTX in normoxia / hypoxia (P > 0.05 for all vs. MCF-7 
normoxia control, n = 4; Figure 3.46AC). 
 As shown in Figure 3.16, ranolazine effectively blocked hypoxic INaP at low 
micromolar concentrations (≤  50 µM), which minimally affected peak INa 
(concentrations ≥ 500 µM were required to fully block peak INa). We therefore tested 20 
and 50 µM ranolazine on invasion of MDA-MB-231 cells to evaluate the specific role 
of INaP. 300 µM ranolazine was also tested as a positive control since it blocked most (~ 
70%) peak INa, together with INaP, and hence was analogous to 10 µM TTX in terms of 
current inhibition. The results were as follows: 
i. Under normoxic conditions, 300 µM ranolazine reduced invasion by 65% (P < 
0.01, n = 6), consistent with significant blockage of peak INa (Figure 3.47AB). 
20 and 50 µM ranolazine were without effect on invasion, consistent with 
absence of INaP in normoxic MDA-MB-231 cells (P > 0.05 vs. normoxia control, 
n = 6; Figure 3.47AB). This finding also indirectly suggested that other ionic 
conductances that are sensitive to ranolazine at low micromolar concentrations 
(i.e. delayed rectifier K+ currents, late Ca2+ currents; Antzelevitch et al., 2004)  
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Figure 3.47 Hypoxia-stimulated invasion involved INaP 
(A) Invaded MDA-MB-231 cells on the bottom surface of 8 µm-pore Matrigel-coated 
Transwell filters (stained with crystal violet). Cells were allowed to invade for 24 h under 
normoxic or hypoxic (2% O2) conditions in the absence or presence of 20-300 µM ranolazine 
(Ran). (B) Quantification of invasive MDA-MB-231 cells in normoxia / hypoxia ± ranolazine 
(20, 50 or 300 µM). Data (mean ± SEM) were expressed relative to normoxia control, and 
compared using ANOVA (P < 0.01, n = 6) followed by Newman-Keuls post hoc analysis. 
Significance of pairwise comparisons between treatments groups are reported in a table on the 
right. 
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did not contribute to invasion of MDA-MB-231 cells under normoxic control 
conditions.  
ii. Under hypoxic conditions, invasiveness was again enhanced by ~ 2-fold (P < 
0.05 vs. normoxia, n = 6); at all concentrations tested, ranolazine reversed the 
hypoxic effect on invasion, reducing invasiveness significantly by 67% at 20 
µM, 75% at 50 µM and 85% at 300 µM compared to hypoxia control (P < 0.01 
for all, n = 6) (Figure 3.47AB). Inhibition of invasion by 20 and 50 µM 
ranolazine in hypoxia but not in normoxia strongly suggested that INaP played a 
major role in hypoxia-stimulated invasion in MDA-MB-231 cells.  
 
3.3 Discussion 
The overall conclusion of this study is that chronic hypoxia upregulates functional 
VGSC expression in MDA-MB-231 BCa cells via a positive feedback mechanism 
consistent with enhanced Na+ influx and subsequent activation of PKA. The specific 
findings were as follows: (i) Chronic hypoxia (24 h) upregulated peak VGSC current 
density by ~ 50% in MDA-MB-231 cells, without affecting channel gating or TTX 
sensitivity. (ii) A similar hypoxic increase in current density was also observed in 
nNav1.5-transfectant EBNA-293 cells and Nav1.7-expressing Mat-LyLu PCa cells. (iii) 
Shorter term (90 min) hypoxia was without effect on peak VGSC current density in 
MDA-MB-231 cells. (iv) Acute hypoxia significantly enhanced INaP whilst minimally 
blocking peak INa in both MDA-MB-231 and nNav1.5-EBNA cells. (v) Long-term 
inhibition of VGSC or PKA activity inhibited the hypoxic increase in peak current 
density in MDA-MB-231 cells, whilst AC/PKA activation in normoxic conditions 
mimicked hypoxia as regards the increase in peak VGSC current density. (vi) Nav1.4, 
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which is devoid of PKA regulation, was unresponsive to chronic hypoxia. (vii) Chronic 
hypoxia upregulated the nNav1.5 mRNA level transiently (within 12 h) and resulted in 
increased expression of VGSC protein both in internal and plasma membrane regions of 
MDA-MB-231 cells. There was a concomitant decrease in the mRNA and protein levels 
of VGSCβ1, the predominant VGSCβ expressed in this cell line. (viii) Chronic hypoxia 
stimulated invasiveness in vitro; this effect was in part due to the hypoxic increase in 
VGSC activity (functional channel expression and INaP). 
 
3.3.1 Effect of chronic and acute hypoxia on VGSC activity 
A central finding of the present study is that chronic 24 h hypoxia (2 or 5% O2) 
enhanced VGSC peak current density by ~ 50% in MDA-MB-231. Importantly, this 
was not accompanied by any change in gating characteristics or TTX sensitivity, 
indicating unaltered proportion of functional VGSCαs expressed in MDA-MB-231 
cells, i.e. ~ 80% TTX-R nNav1.5 and ~ 20% TTX-S Nav1.7 (Fraser et al., 2005; 
Brackenbury et al., 2007). Consistently, when studied in isolation, chronic hypoxia 
enhanced current densities of nNav1.5 (in EBNA-293 cells) and Nav1.7 (in Mat-LyLu 
cells) similarly by ~ 50%. Overall, therefore, (i) hypoxic upregulation of VGSC activity 
occurred irrespective of the cellular background or the specific VGSCα isoform 
involved, and (ii) hypoxic control of VGSC expression may be a general mechanism 
applicable to multiple carcinomas including BCa and PCa. Consistent with point (i), 
previous reports showed that functional VGSC expression was enhanced by chronic 
hypoxia also in glomous cells of the carotid body and cortical and hippocampus central 
neurons, with no effect on voltage-dependence of channel gating (Stea et al., 1992, 
1995; Hempleman et al., 1995; Xia et al., 2000).  
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We also found that Cs+-sensitive outward current density (i.e. VGPC current 
density) was unchanged after 24 h hypoxia. Thus, increased VGSC activity with 
unchanged VGPC activity by chronic hypoxia possibly favoured ‘electrical excitability’ 
in MDA-MB-231 cells, consistent with the conclusion of earlier studies in glomous 
cells and central neurons (Hempleman et al., 1995; Xia et al., 2000). This finding also 
suggested that VGPC functional expression was not controlled by VGSC activity in 
MDA-MB-231 cells (i.e. increase in VGSC activity did not regulate VGPC functional 
expression), in agreement with earlier work on Mat-LyLu rat PCa cells (Brackenbury 
and Djamgoz, 2006). Therefore, the reciprocal relationship between increasing VGSC 
and decreasing VGPC expression in line with metastatic potential in BCa reported 
previously (Fraser et al., 2005; Onkal and Djamgoz, 2009) was not under the control of 
a single mechanism, such as VGSC activity. 
 Multiple lines of evidence suggested that the increase in peak VGSC current 
density in MDA-MB-231 was due to ‘long-term’ regulation of functional channel 
expression in the plasma membrane. First, the hypoxic increase in peak Na+ current 
density was not due to any change in VGSC gating via, for example, a biochemical 
modification such as phosphorylation. Second, hypoxic upregulation of VGSC current 
density remained stable for at least 75 min under normoxic conditions, suggesting that 
this effect was not rapidly reversible as would be expected in the case of modification of 
gating. Third, short-term (90 min) hypoxia did not induce any increase in VGSC current 
density. Thus, the suggested increase in the number of functional VGSCs in the plasma 
membrane was likely to involve de novo mRNA and/or protein synthesis and 
trafficking, rather than faster mechanism such as (i) trafficking of ‘mature’ channel 
protein docked in a cytoplasmic pool or (ii) unmasking of pre-existing but non-
functional VGSCs in plasma membrane (Stea et al., 1995; Zhou et al., 2000; 2002; 
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Yarbrough et al., 2002; Chioni et al., 2010). Overall, therefore, the chronic hypoxic 
effect was not a product of rapid regulatory processes but was due to long-term 
readjustment of functional VGSC expression. This conclusion was fully supported by 
the mRNA and protein expression studies, as discussed separately in Section 3.3.2. 
 Apart from the chronic hypoxic upregulation of VGSC functional expression, 
acute exposure to hypoxia exerted profound effects on VGSC gating in MDA-MB-231 
cells. Thus, peak INa was reduced by ~ 25%, whilst INaP was significantly enhanced. We 
were able to record similar effects of acute hypoxia on nNav1.5 currents in isolation 
(i.e. in EBNA-293 cells), which confirmed that nNav1.5, the predominant VGSCα in 
MDA-MB-231 cells, can alone generate INaP in response to acute hypoxic stress. In line 
with our findings in MDA-MB-231 and nNav1.5-EBNA cells, concomitant inhibition of 
INa and enhancement of INaP was observed earlier in acutely hypoxic Nav1.5-HEK-293 
cells (Fearon and Brown, 2004) and guinea pig ventricular cardiomyocytes (Wang et 
al., 2007). The precise mechanism of acute hypoxic increase in INaP is currently 
unknown but was suggested to involve altered inactivation of VGSCs via (i) ‘direct’ 
redox modulation of the channel protein or (ii) an ‘indirect’ effect from an O2-sensing, 
haem-containing membrane protein (Hammerstrom and Gage, 2002; Belardinelli et al., 
2006; Saint, 2006, 2008; Wang et al., 2007). Consistent with (i), ischemic/hypoxic and 
failing cardiomyocytes were reported to generate reactive oxygen/nitrogen species (e.g. 
H2O2 and NO) that can increase INaP in ventricular cardiomyocytes, hippocampal 
neurons and Nav1.5-expressing HEK-293 cells (Hammerstrom and Gage, 1999, 2002; 
Ahern et al., 2000; Song et al., 2006; Wang et al., 2007; Shryock and Belardinelli, 
2008). Indeed, when acutely applied to MDA-MB-231 cells, 300 µM H2O2 produced 
identical effects as acute hypoxia, slightly reducing peak INa and inducing significant 
INaP (Scott P. Fraser, unpublished observations). 
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Despite the slight hypoxic reduction in peak INa, since INaP is resistant to 
inactivation for seconds (Ju et al., 1996; Maltsev et al., 1998; Maltsev and Undrovinas, 
2006, 2008), the net outcome of acute hypoxic modulation of VGSC function in MDA-
MB-231 cells would be enhanced Na+ influx (Hammarstrom and Gage, 2002; Saint, 
2006, 2008). This was not directly measured in the present study; however, previous 
work showed that hypoxic INaP can induce significant Na+ loading into ventricular 
cardiomyocytes, especially during the first 30 min of hypoxia (Haigney et al., 1994; 
Eigel and Hadley, 1999; Xiao and Allen, 1999; O’Rourke and Maack, 2007). 
Importantly, such Na+ loading was found to be sufficient to prolong the cardiac AP 
duration, and result in early after depolarizations (EADs) and impaired mechanical 
function of the cardiac muscle (Maltsev et al., 1998, 2007; Ward and Giles, 1997; 
Antzelevitch et al., 1999; Undrovinas et al., 1999; Sakmann et al., 2000; Tian et al., 
2004; Belardinelli et al., 2006). Also, in central neurons, INaP was sufficient to modulate 
the subthreshold membrane potential, thereby regulating dendritic depolarizations, 
repetitive firing and synaptic transmission (Crill, 1996; Taddese and Bean, 2002; Huang 
and Trussell, 2008). 
Earlier studies in cardiomyocytes also showed that hypoxia can induce further 
intracellular Na+ loading through (i) reduced Na+/K+ ATPase activity (Hammarstrom 
and Gage, 2002; Saint, 2008), and (ii) enhanced Na+/H+ exchange (NHE) due to 
intracellular acidosis caused by the switch of energy metabolism to glycolysis and 
consequent lactic acid production (Ingwall, 1995; Xiao and Allen, 1999; Carmeliet, 
1999; Saint, 2006, 2008). Importantly, elevation of [Na+]i via INaP, enhanced NHE 
and/or reduced Na+/K+ ATPase was found to potentiate Ca2+ loading into ischemic / 
hypoxic cardiomyocytes through reduced or reversed Na+/Ca2+ exchange (NCX), 
further contributing to the progression of cardiac arrhythmias and mechanical 
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dysfunction (Friedman and Haddad, 1994; Haigney et al., 1994; Baartscheer et al., 
2003; Pieske and Houser, 2003; Bers et al., 2006; Maltsev and Undrovinas, 2008). 
Overall, therefore, hypoxia-induced changes in (i) INaP and/or (ii) transport mechanisms 
regulating Na+ influx/efflux can have significant physiological / pathophysiological 
consequences. The particular downstream effects of increased INaP on (i) Na+ and Ca2+ 
homeostasis and (ii) activity of Na+-dependent proteins (e.g. PKA, cathepsins) in MDA-
MB-231 cells are discussed separately in Sections 3.3.3 and 3.3.4. 
 
3.3.2 VGSC regulation at the mRNA and protein levels 
In MDA-MB-231 cells, hypoxia (2 or 5% O2) increased the nNav1.5 mRNA level 2- to 
3-fold after 12 h; this effect was transient and disappeared after 24 h. Importantly, there 
was also ~ 50% increase in the total VGSCα protein level; confocal 
immunocytochemistry revealed that hypoxic upregulation of VGSCα protein was 
similar in peripheral (i.e. plasma membrane) and intracellular regions, with no change in 
relative subcellular protein distribution (i.e. there was no net trafficking effect). Above 
all, these findings confirmed that the observed increase in peak VGSC current density 
could occur as a result of increased number of functional VGSCαs in plasma membrane.  
Although the hypoxic increase in the VGSCα protein level could be due to 
reduced degradation of channel protein (see Section 3.3.3; Abriel et al., 2000a; Herfst et 
al., 2004; Shao et al., 2009), the preceding rise at the mRNA level strongly suggested 
that de novo protein synthesis could be involved. This is in agreement with chronic 
hypoxic modulation of VGSCα expression in glomous cells and central neurons. For 
example, Stea et al. (1995) showed that the hypoxic increase in functional VGSC 
expression in glomous cells was abolished in the presence of protein synthesis inhibitor 
cycloheximide, suggesting that de novo protein synthesis was required for the effect. 
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Consistently, Caceres et al. (2007) found parallel increases in VGSCα mRNA and 
protein levels in chronically hypoxic whole rat carotid bodies; the total VGSCα protein 
level was upregulated by 60%, and VGSCα mRNA levels increased by 40-80%. Similar 
but reduced effects were seen in chronically hypoxic vs. normoxic dissociated glomous 
cells (Caceras et al., 2007). Furthermore, in rat cortical and hippocampal neurons, 
chronic hypoxia enhanced the VGSCα mRNA and protein levels similarly by ~ 80% 
(Xia et al., 2000), and in homogenized (whole) fetal rat brains, prolonged O2 
deprivation (9% O2, 4 weeks) upregulated the total VGSCα mRNA level by ~ 40% and 
protein level by ~ 75% (Xia and Haddad, 1999). Given that protein synthesis is 
generally reduced during prolonged hypoxia to limit energy consumption (Semenza, 
1999; Bertout et al., 2008), upregulation of VGSCα protein is indicative of a selective, 
adoptive response that may be physiologically / pathophysiologically relevant (as 
discussed in Section 3.3.5).  
The mechanism(s) by which chronic hypoxia could enhance VGSCα / nNav1.5 
mRNA levels is not known. Hypoxia inducible factor (HIFα) is the major transcription 
factor controlling expression of O2-sensitive genes (Wenger et al., 2005). Our finding 
that hypoxia enhanced nNav1.5 mRNA expression level in MDA-MB-231 cells within 
12 h is consistent with HIFα being activated ‘rapidly’ via a post-translational 
mechanism (Jaakkola et al., 2001; Bertout et al., 2008). Indeed, rapid changes in 
expression of O2-sensitive genes is common; some well-known examples include 
vascular endothelial growth factor (VEGF) involved in angiogenesis, glucose 
transporter (GLUT1) involved in glycolysis and carbonic anhydrase IX (CA9) involved 
in cellular pH regulation (Semenza, 1999; Seta et al., 2002; Wenger et al., 2005). After 
recruiting HIFβ and transcriptional co-activators, such as p300 and cAMP-response 
element binding protein (CREB), HIFα binds to hypoxia response elements (HREs) 
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present in target gene promoters, inducing transcription (Wenger et al., 2005). 
Importantly, 12 such consensus HRE sites are present in the promoter of SCN5A, the 
gene encoding Nav1.5 (Appendix 9; Yang et al., 2004). Thus, it is tempting to speculate 
that HIFα directly enhanced nNav1.5 transcription under hypoxic conditions. However, 
apart from HIFα, other transcriptional regulators including cAMP/PKA or Ca2+-
dependent transcription factors may also be involved in the upregulation of nNav1.5 
transcription, especially since hypoxic Na+ loading can alter cAMP and Ca2+ 
homeostasis, as discussed in Section 3.3.4 (Offord and Catterall, 1989; Berridge et al., 
2003; Herfst et al., 2004; Avila et al., 2007; Akl et al., 2009; Chioni et al., 2010). Also, 
alternative mechanisms including changes in mRNA stability or degradation may also 
be responsible for the observed hypoxic increase in the nNav1.5 mRNA level (Duff et 
al., 1992; Yanagita et al., 2003; Herfst et al., 2004; Wada et al., 2004). Interestingly, 
multiple hypoxia-regulated microRNAs (miRNAs) were recently identified, indicating 
that hypoxia can control target gene mRNA levels via post-transcriptional mechanisms 
(Bertout et al., 2008; Kulshreshtha et al., 2008).  
The auxiliary VGSC β-subunits (β1- β4) modulate the biophysical properties of 
VGSCαs, including channel gating, functional surface expression and cellular 
localization, in a VGSCα and VGSCβ subtype-dependent manner (Isom et al., 1992, 
1995; Morgan et al., 2000; Chen et al., 2002; Yu et al., 2003). Also, VGSCβs are 
unique among ion channel auxiliary subunits in that they function as immunoglobulin 
superfamily cell adhesion molecules (CAMs), participating in adhesion, as shown in 
vitro for MCF-7 BCa cells (Isom et al., 1994, 1995; Isom and Catterall, 1996; 
Brackenbury and Isom, 2008). In a previous study, Chioni et al. (2009) showed that the 
VGSCβ mRNA and protein levels were significantly greater in MCF-7 cells vs. the 
strongly metastatic MDA-MB-231 cells, in line with the pro-adhesive / anti-migratory 
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role played by VGSCβ1 in the weakly metastatic MCF-7 cells. Results presented here 
agree with Chioni et al. (2009) in that (i) VGSCβ mRNA levels were significantly 
greater in MCF-7 vs. MDA-MB-231 cells, and (ii) VGSCβ1 was the predominant β-
subunit expressed in both MCF-7 and MDA-MB-231 cells, whilst VGSCβ3 expression 
was absent in both cell lines. In addition, we observed that VGSCβ mRNA and protein 
levels were significantly but differentially altered by chronic hypoxia in both MCF-7 
and MDA-MB-231 cells. 
In MDA-MB-231 cells, chronic (24 hr) hypoxia reduced the level of VGSCβ1 
mRNA by ~ 20%, without affecting the expression of β2 and β4. Importantly, reduction 
in the β1 mRNA level was accompanied by a similar ~ 20% decrease in internal and 
plasma membrane protein levels. Earlier reports showed that VGSCβ1 minimally 
affects Nav1.5 gating (Nuss et al., 1995; Qu et al., 1995; Fahmi et al., 2001), and 
consistently, VGSCβ1 overexpression in MDA-MB-231 cells induced only a small 
effect on activation kinetics (Tpeak), without changing other VGSC gating characteristics 
(Chioni et al., 2009). This is in line with the unchanged gating of VGSCs in chronically 
hypoxic vs. normoxic MDA-MB-231 cells in the present study, despite the plasma 
membrane VGSCβ1 level being reduced in hypoxic cells.  
In MCF-7 cells, chronic hypoxia reduced the nNav1.5 mRNA level by 75%, 
opposite to the effect observed in the strongly metastatic MDA-MB-231 cells, whilst the 
VGSCβ1 mRNA level was reduced by 48%, similar to the effect in MDA-MB-231 
cells. There were also 17-fold and 2-fold hypoxic increases in VGSCβ2 and VGSCβ4 
mRNA levels. Thus, chronic hypoxia modulated nNav1.5, VGSCβ2 and VGSCβ4 
mRNA levels differently but VGSCβ1 mRNA level similarly in MCF-7 vs. MDA-MB-
231 cells. Notably, differential modulation of VGSC mRNA levels in cancer cell lines 
with differing metastatic potential has been documented earlier (Mycielska et al., 2005; 
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Chioni et al., 2010). Therefore, modulation of VGSC gene expression in weakly and 
strongly metastatic BCa cells may involve multiple differential regulatory pathways 
(Brackenbury and Djamgoz, 2006; Chioni et al., 2010). In particular, one major 
difference between the weakly metastatic MCF-7 cells and the strongly metastatic 
MDA-MB-231 cells is functional VGSC expression (Fraser et al., 2005; Onkal and 
Djamgoz, 2009). It is possible, therefore, that Na+ influx through VGSCs could activate 
intracellular enzymes that might regulate gene transcription (Page and Di Cera, 2006; 
House et al., 2010). As discussed in detail in Section 3.3.3, one such Na+-dependent 
protein is PKA, which has been shown to upregulate Nav1.7 and nNav1.5 mRNA levels 
in Mat-LyLu PCa cells and MDA-MB-231 BCa cells, respectively (Brackenbury and 
Djamgoz, 2006; Chioni et al., 2010).  
  
3.3.3 Hypoxic augmentation of VGSC auto-regulation via PKA  
Earlier studies showed that intracellular Na+ could directly increase PKA activity by 
activating AC, independent of Ca2+ (Reddy et al., 1995; Cooper et al., 1998; Murakami 
et al., 1998). Consistent with this, long-term treatment of MDA-MB-231 and Mat-LyLu 
cells with TTX significantly reduced the level of phosphorylated PKA, suggesting that 
Na+ influx through VGSCs did indeed activate PKA (Brackenbury and Djamgoz, 2006; 
Chioni et al., 2010). Moreover, in line with the well-evidenced enhancement of 
functional VGSC expression by PKA (Yuhi et al., 1996; Zhou et al., 2000, 2002; Hallaq 
et al., 2006), VGSC functional availability was found be positively auto-regulated 
through Na+ influx and subsequent activation of PKA in both MDA-MB-231 and Mat-
LyLu cells (Brackenbury and Djamgoz, 2006; Chioni et al., 2010). 
In the present study, we confirmed the activity-dependent auto-regulation of 
VGSC functional expression in MDA-MB-231 cells, and showed that hypoxic increase 
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in VGSC peak current density was simply due to upregulation of this positive feedback 
loop (Chioni et al., 2010). Thus, enhanced INaP (possibly together with increased NHE 
and/or reduced Na+/K+ ATPase activity) could induce excess Na+ loading into hypoxic 
MDA-MB-231 cells, thereby fuelling the auto-regulation of VGSC functional 
expression via PKA. In particular, we found that treatment with 10 µM TTX, but not 
100 nM TTX, abrogated the hypoxic increase in functional VGSC expression, which 
suggested that TTX-R (i.e. nNav1.5) channels were primarily responsible for the effect 
of hypoxia. PKA inhibitors KT5720 and Myr PKI14-22 both eliminated the hypoxic 
upregulation of VGSC expression, whilst treating normoxic cells with AC activator 
forskolin mimicked the hypoxic increase in functional VGSC expression. Importantly, 
forskolin reversed the inhibitory effect of TTX on peak current density in hypoxic cells, 
whereas Myr PKI14-22 inhibited the potentiating effect of forskolin in normoxic cells. 
The latter finding confirmed that the effect of forskolin on VGSC peak current density 
occurred due to activation of PKA and not other intracellular cAMP targets, e.g. GTP-
exchange protein Epac or cyclic nucleotide-gated ion channels (Murray, 2008). Taken 
together, these data provided compelling evidence that PKA was indeed a downstream 
signalling intermediate in the auto-regulatory upregulation of VGSC functional 
expression in chronically hypoxic MDA-MB-231 cells. Supporting evidence for this 
hypothesis came form studies with Nav1.4, which is devoid of PKA regulation 
(Frohnwieser et al., 1997; Zhou et al., 2000; Kim et al., 2006). Thus, Nav1.4 peak 
current density, which was confirmed to be insensitive to PKA inhibition, was unaltered 
by chronic hypoxia, suggesting that PKA activity may be necessary for the hypoxic 
augmentation of VGSC functional expression in general. This is in line with the 
conclusion of Stea et al. (1995) that hypoxic increase in VGSC peak current density 
involved PKA activity in glomous cells of the carotid body. 
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 There is evidence to suggest that PKA could be involved in (i) transcriptional, 
(ii) translational and (iii) intracellular trafficking processes responsible for the hypoxic 
upregulation of VGSC functional expression in MDA-MB-231 cells, as follows: 
i. mRNA level. cAMP-inducible genes contain cAMP-response elements (CRE) in 
their promoters (Appendix 9; Foulkes and Corsi, 1996). Activation of PKA leads to 
translocation of its catalytic subunits to the nucleus, where these phosphorylate and 
thereby activate transcriptional activators such as CRE-binding protein (CREB), 
CRE-modulator (CREM) and activating transcription factor (ATF) (Foulkes and 
Corsi, 1996; Don and Stelzer, 2002; Almeida et al., 2009). Previously, treatment of 
developing rat muscle with 8-Br-cyclic AMP for 8 days increased VGSCα mRNA 
expression (Offord and Catterall, 1989). Similar cAMP-dependent upregulation of 
the VGSCα mRNA level was also observed in denervated skeletal muscle, bovine 
adrenal chromaffin cells and spinal cord astrocytes (Sherman et al., 1985; Oh and 
Waxman, 1998; Wada et al., 2004). Importantly, in MDA-MB-231 cells, Chioni et 
al. (2010) showed that activation of AC/PKA (using forskolin) enhanced the 
nNav1.5 mRNA level, whilst inhibition of PKA (using KT5720) had the opposite 
effect. Inhibitory effect of KT5720 on the VGSCα (Nav1.7) mRNA level was also 
observed in Mat-LyLu rat PCa cells (Brackenbury and Djamgoz, 2006). Taken 
together, these findings imply that increase in cAMP/PKA levels stimulates VGSCα 
transcription. Thus, hypoxic Na+ loading in MDA-MB-231 cells could have 
increased the nNav1.5 mRNA level via upregulating PKA activity. Consistent with 
this, there exists a partial CRE site (75%) in the reported Nav1.5 promoter 
(Appendix 9; Yang et al., 2004). Alternatively, cAMP/PKA can regulate mRNA 
levels/stability of a given gene through post-transcriptional mechanisms via for 
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example modulating miRNA levels, e.g. in neonatal rat cortical neurones, the 
miRNA miR132 was upregulated by CREB (Vo et al., 2005).  
ii. Protein level. In both rat glomous and bovine adrenal chromaffin cells, protein 
synthesis inhibitor cycloheximide inhibited the cAMP-induced increase in 
functional VGSCα expression, suggesting that cAMP/PKA potentiated de novo 
synthesis of VGSCα protein (Stea et al., 1995; Yuhi et al., 1996). Thus, in MDA-
MB-231 cells, one possible mechanism for the observed hypoxic increase in the 
total VGSCα protein level is enhanced protein synthesis via PKA-mediated 
pathway(s). Alternatively, PKA can reduce degradation of VGSCαs via 
phosphorylating Nedd4 ubiquitin protein ligases (Shao et al., 2009). Nedd4 family 
of proteins bind to the C-terminal PY motifs of VGSCs (and other proteins), 
inducing targeted degradation via ubiquitination (Herfst et al., 2004; Ingham et al., 
2004). Previously, it was shown (i) that Nedd4-2 reduced the current amplitude of 
Xenopus oocytes expressing Nav1.2, Nav1.7 and Nav1.8 (Fotia et al., 2004), (ii) that 
over-expression of Nedd4-2 increased degradation of Nav1.2, Nav1.3 and Nav1.5 in 
HEK-293 cells (van Bemmelen et al., 2004; Rougier et al., 2005) and (iii) that co-
expression of Nedd4 with Nav1.5 in Xenopus oocytes reduced peak VGSC current 
amplitude, suggesting enhanced removal of functional VGSCs from the plasma 
membrane (Abriel et al., 2000a). Interestingly, MDA-MB-231 cells were found to 
have a higher level of Nedd4-2 mRNA compared to MCF-7 cells (Kuratomi et al., 
2005), and it was suggested by Shao et al. (2009) and Chioni et al. (2010) that 
phosphorylation of Nedd4-2 by PKA would inhibit its activity and thus decrease 
degradation of VGSC protein. Consistent with this, Nedd4-2 was shown to be a 
substrate for phosphorylation by PKA and serum and glucocorticoid inducible 
kinase (SGK) (Nagaki et al., 2006). Taken together, therefore, the observed hypoxic 
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increase in the VGSCα protein level may involve PKA-dependent inhibition of 
Nedd4 activity, resulting in reduced degradation of VGSCα protein.  
iii. Functional availability. VGSC expression in plasma membrane can be modulated 
post-translationally by protein trafficking via vesicular endo/exocytosis (Herfst et 
al., 2004). PKA activity has been shown to regulate budding of vesicles from the 
trans-Golgi network along the exocytic route to the cell surface (Muniz et al., 1996, 
1997). In agreement with this, a number of studies showed PKA-induced alteration 
of trafficking, resulting in upregulation of VGSCα functional expression. For 
instance, treatment with forskolin or dibutryl-cAMP for > 12 h was shown to 
increase functional VGSC availability in bovine adrenal chromaffin and rat muscle 
cells (Sherman et al., 1985; Yuhi et al., 1996; Wada et al., 2004). In Nav1.5-
expressing Xenopus oocytes, activation of PKA through cytosolic injection of 
cAMP or forskolin rapidly upregulated functional channel expression within 1 h 
(Frohnwieser et al., 1997); confocal immunomicroscopy of living HEK-293 cells 
confirmed PKA-induced externalization of Nav1.5 channels from intracellular 
storage pools, e.g. endoplasmic reticulum (Hallaq et al., 2006). Also, in Xenopus 
oocytes expressing Nav1.5, Zhou et al. (2000) showed that PKA-dependent 
upregulation of functional channel expression was abolished in the presence of 
monensin and chloroquine, disruptors of intracellular protein trafficking (Tietze et 
al., 1980; Tartakoff, 1983; Mollenhauer et al., 1990). Consistently, PKA-induced 
increase in VGSC peak current density in rat/canine cardiomyocytes and Xenopus 
oocytes expressing Nav1.8 was also suppressed by the choloroquine application 
(Baba et al., 2004; Vijayaragavan et al., 2004). Taken together, these results implied 
that PKA can alter trafficking of VGSCαs in favour of externalization from 
intracellular stores. In the present study, chronic hypoxia enhanced the total VGSCα 
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protein level with no change in subcellular protein distribution. Thus, the increase in 
intracellular protein level was accompanied by a parallel increase in plasma 
membrane VGSCα level, which required externalization of the de novo protein 
synthesized during the hypoxic treatment. Such enhanced VGSCα trafficking 
possibly involved PKA activity; Chioni et al. (2010) previously showed that 
treatment of MDA-MB-231 cells with PKA inhibitor KT5720 for 48 h reduced 
VGSC (nNav1.5) trafficking to plasma membrane, whilst forskolin application had 
the opposite effect, upregulating functional VGSC availability. Comparable results 
were also obtained in Nav1.7-expressing Mat-LyLu rat PCa cells (Brackenbury and 
Djamgoz, 2006). Thus, VGSC auto-regulation in BCa and PCa cell lines was 
suggested to involve promotion of VGSC protein externalization via Na+-dependent 
PKA activation (Shao et al., 2009; Chioni et al., 2010). We hypothesize that 
upregulation of this auto-regulatory mechanism due to enhanced Na+ influx during 
hypoxia contributes to the observed increase in functional VGSC expression in 
chronically hypoxic MDA-MB-231 cells.  
In addition to regulating VGSC expression at mRNA, protein and functional levels, 
phosphorylation by PKA is known to modulate VGSC gating, in a VGSCα subtype-
dependent manner (Cantrell and Catterall, 2001; Chahine et al., 2005). In the present 
study, long-term treatment with PKA inhibitors KT5720 and Myr PKI14-22 depolarized 
VGSC activation (Vthres) in both normoxic and hypoxic MDA-MB-231 cells. Also, the 
rate of activation was slowed and recovery from inactivation was accelerated by PKA 
inhibition. These data suggested that functional VGSCs in MDA-MB-231 cells are 
tonically phosphorylated by PKA in steady-state. Previously, PKA was shown to 
hyperpolarize voltage-dependence of activation in Nav1.5 and Nav1.8, similar to the 
effects we observed in MDA-MB-231 cells (England et al., 1996; Gold et al., 1998; 
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Zhou et al., 2000; Brackenbury and Djamgoz, 2006). Also, PKA has been shown to 
increase the rate of activation of Nav1.8 channels and slow the rate of recovery from 
inactivation of Nav1.5 channels, consistent with the findings of the present study (Gold 
et al., 1998; Fitzgerald et al., 1999; Zhou et al., 2000). Interestingly, we observed no 
effect on VGSC gating of forskolin or chronic hypoxia (suggested to increase PKA 
activity) in MDA-MB-231 cells. One possible explanation is that functional VGSCαs in 
MDA-MB-231 cells were maximally phosphorylated under steady-state control 
conditions such that further PKA activation (either by hypoxia or forskolin application) 
produced no effect on channel gating.  
It is noteworthy that forskolin increased whole-cell capacitance and altered 
morphology of MDA-MB-231 cells, suggesting an interaction with additional signalling 
pathways, e.g. regulating cell volume (Kunzelman, 2005; Chahine et al., 2005). 
However, since PKA inhibitors used in the present study had no effect on morphology 
or whole-cell capacitance, the forskolin effect on these parameters was independent of 
PKA activation and possibly involved other intracellular cAMP targets (Fimia and 
Corsi, 2001; Murray, 2008).   
 
3.3.4 A model for hypoxic upregulation of VGSC functional expression and 
metastatic cell behaviours  
Taking the present and published evidence together, a basic model of hypoxic VGSC 
regulation involving Na+ influx and PKA in MDA-MB-231 cells can be proposed 
(Figure 3.48). Accordingly, under normoxic control conditions, local Na+ influx through 
VGSCs potentiates PKA activity, which in turn may stimulate VGSCα transcription, 
translation and/or trafficking to the plasma membrane (Chioni et al., 2010). Under 
hypoxic conditions, such positive-feedback auto-regulation is enhanced due to increased  
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Figure 3.48 A basic model of hypoxic regulation of functional VGSC expression in 
MDA-MB-231 cells 
Excess Na+ loading (e.g. through INaP) during early-stages of hypoxia upregulates basal-level 
AC and PKA activity in MDA-MB-231 cells. In the long-term, PKA can have multiple 
effects on functional VGSC expression: (1) potentiation of de novo VGSC synthesis via 
transcription and translation; and (2) increased trafficking of VGSC protein from intracellular 
stores to the plasma membrane. Additionally, PKA can directly phosphorylate VGSCs at the 
plasma membrane, although this may be independent of Na+. This model is in principle a 
modified version of the VGSC auto-regulation model proposed earlier in MDA-MB-231 and 
Mat-LyLu cells under normoxic conditions (Brackenbury and Djamgoz, 2006; Chioni et al., 
2010). 
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Na+ influx, i.e. via INaP (and possibly due to enhanced NHE or reduced Na+/K+ ATPase 
activity). Thus, steady-state VGSC expression is elevated to a higher level during 
hypoxia via Na+-induced increase in PKA activity (Figure 3.48). Notably, earlier studies 
in various different cell types have consistently found enhanced cAMP levels under 
hypoxic conditions (whether this was Na+-dependent was not investigated) (Figure 
3.49) (e.g. Perez and Garcia et al., 1990; Delpiano and Acker et al., 1991; Wang et al., 
1991). This is consistent with the proposed cAMP/PKA-mediated upregulation of 
functional VGSC expression in hypoxic MDA-MB-231 cells. A similar conclusion for 
the involvement of PKA in hypoxic modulation of VGSC expression was reached 
earlier by others (Offord and Catterall, 1989; Stea et al., 1995). 
From a wider perspective, it should be noted that, at the mRNA level, hypoxic 
increase in VGSC (nNav1.5) expression may occur via PKA-independent pathways that 
involve HIFα (Wenger et al., 2005; Bertout et al., 2008) or Ca2+-dependent 
transcriptional regulators (Berridge et al., 2003; Berridge, 2006; Akl et al., 2009) 
(Figure 3.49). As regards functional protein expression, it is possible that the proposed 
positive feedback loop involves or interacts with other Na+-dependent protein kinases, 
e.g. mitogen-activated protein kinase (Chang et al., 2005; Jin and Gereau, 2006), 
Ca2+/calmodulin (Herzog et al., 2003; Kim et al., 2004), and Scr kinase (Hilborn et al., 
1998) (Figure 3.49). Furthermore, growth factors, e.g. nerve growth factors (NGF; 
Kalman et al., 1990; Klein et al., 2003), fibroblast growth factor (FGF; Pollock et al., 
1990) and epidermal growth factor (EGF; Ding et al., 2008), may also be involved in 
the hypoxic upregulation of VGSC functional expression (Figure 3.49) (Montano and 
Djamgoz, 2004; Brackenbury and Djamgoz, 2006). Consistent with this, in rat central 
neurons, hypoxia/ischemia was found to upregulate neurotrophic factors such as NGF 
and FGF (Isackson et al., 1991; Kiyota et al., 1991; Szaflarski et al., 1995), which are  
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Figure 3.49 A comprehensive model of hypoxic regulation of functional VGSC 
expression and metastatic cell behaviours in MDA-MB-231 cells 
Excess Na+ loading through VGSCs during hypoxia activates AC and PKA. This results in 
enhanced VGSC functional expression in the long term via de novo mRNA / protein synthesis 
and trafficking of mature VGSCs to the plasma membrane. Enhanced VGSC functional 
expression may further contribute to this positive feedback loop. Independent of VGSC 
activity, hypoxia can result in (i) Na+ loading via enhanced NHE or reduced Na+/K+ ATPase 
activity (X), (ii) enhanced cAMP levels (Y), (iii) enhanced VGSC transcription via pathways 
involving HIFα or growth factors (EGF, NGF, etc.) (Z), and (iv) upregulation of metastatic 
cell behaviours (MCBs) via HIFα- and/or growth factors-dependent pathways (Z). Apart from 
upregulating VGSC auto-regulation via PKA, hypoxic Na+ loading may affect other Na+-
dependent kinases (e.g. mitogen-activated protein kinase or cathepsins) or result in alteration 
of Ca2+ and pH homeostasis, further contributing to upregulation of MCBs (i.e. invasion) in 
MDA-MB-231 cells (W). 
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well-known to promote expression of VGSCs (Kalman et al., 1990; Islas-Suarez et al., 
1994; Lesser and Lo, 1995; Ding et al., 2008; Brackenbury and Djamgoz, 2007).  
Finally, the weakly metastatic MCF-7 BCa cells were previously shown to 
express VGSC mRNA and protein but no functional channel expression (Fraser et al., 
2005; Chioni et al., 2010). We observed that hypoxia pre-treatment did not induce 
functional VGSC expression in MCF-7 cells, consistent with earlier observations that 
MCF-7 cells resist functional VGSC expression due to unknown mechanism(s), e.g. no 
VGSC currents could be recorded from MCF-7 cells stably transfected with nNav1.5 
(Scott P. Fraser, unpublished observations). Importantly, given that the hypoxic increase 
in functional VGSC expression was triggered by Na+ influx in MDA-MB-231 cells, 
lack of induction of any such Na+ current in MCF-7 cells is consistent with the auto-
regulatory mechanism proposed for the hypoxic increase in VGSC functional 
availability. 
 
3.3.5 Pathophysiological implications 
Previously, under normoxic conditions, VGSC activity was shown to potentiate various 
in vitro metastatic cell behaviours (MCBs) in human and rat models of breast, prostate, 
lung and colon cancers (Bennett et al., 2004; Fraser et al., 2005; Onganer et al., 2005; 
Brackenbury and Djamgoz, 2006; Brackenbury et al., 2007; Gillet et al., 2009; 
Nakajima et al., 2009; House et al., 2010). This is the first study demonstrating hypoxic 
effects on VSGC expression/activity in a cancer cell line. We showed that functional 
VGSC expression in MDA-MB-231 cells is increased during long-term in vitro hypoxia 
via a positive feedback mechanism involving Na+ influx and PKA activity (Chioni et 
al., 2010). Such positive auto-regulation, which would ensure a high level of VGSC 
expression, would maximize sustained contribution of VGSCs to enhancement of 
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MCBs in hypoxic MDA-MB-231 BCa cells (Fraser et al., 2005; Brackenbury et al., 
2007; Gillet et al., 2009).  
 We observed that Matrigel invasion was enhanced by 2 to 3-fold in hypoxic 
conditions in MDA-MB-231 cells, consistent with earlier findings (Canning et al., 
2001; Yoon et al., 2005; Munoz-Najar et al., 2006; Erler et al., 2006; Subarsky and 
Hill, 2008). Also, under normoxic conditions, invasiveness was reduced by 45% by 10 
µM TTX, confirming VGSC-dependence of invasion in this BCa cell line (Brackenbury 
et al., 2007; Gillet et al., 2009). Importantly, 10 µM TTX suppressed the hypoxic 
increase in invasiveness, reducing invasion to a level similar to that in normoxic cells 
treated with 10 µM TTX, suggesting that a significant portion of the hypoxic effect 
occurred due to upregulation of VGSC activity (i.e. functional channel expression and 
INaP). Thus, breaking the VGSC positive-feedback loop by long-term application of 
TTX eliminated the VGSC-dependent component of cell invasiveness, suggesting that 
long-term inhibition of VGSC activity could result in long-term downregulation of its 
expression and contribution to MCBs (Brackenbury and Djamgoz, 2006; Chioni et al., 
2010). It may be possible to use such inherent characteristic of VGSC expression in the 
potential use of VGSC blockers as anti-metastatic BCa drugs (Roger et al., 2006; Onkal 
and Djamgoz, 2009). 
Pharmacological separation of INaP from peak INa using low doses of ranolazine 
was useful in determining the specific role played by INaP in VGSC-dependent 
metastatic cell behaviours in MDA-MB-231 cells. In earlier studies, ranolazine blocked 
INaP and peak INa with respective IC50s of 6-15 µM and 135-294 µM, depending on cell 
type, species and recording conditions used; block of INaP was complete at ~ 50 µM 
(Antzelevitch et al., 2004; Fredj et al., 2006; Undrovinas et al., 2006; Saint, 2008). 
Consistently, in the present study, ranolazine blocked peak Na+ currents in MDA-MB-
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231 cells (under normoxic conditions) with an IC50 of 180.6 ± 6.7 µM, whilst 50 µM 
ranolazine abolished hypoxic INaP. When we tested the effects of 20 and 50 µM 
ranolazine (selective for INaP) on invasion, there was no effect under normoxic 
conditions but significant suppression of invasiveness occurred under hypoxic 
conditions; 300 µM ranolazine suppressed invasion under both conditions. This finding 
confirmed that INaP, which is not detectable under normoxic conditions in MDA-MB-
231 cells, independently contributed to the hypoxic augmentation of invasiveness. 
Above all, this highlighted the importance of this ionic conductance despite its small 
amplitude; as discussed earlier, studies in cardiomyocytes and central neurons 
demonstrated that INaP is sufficient to increase intracellular [Na+], thereby resulting in a 
variety of mechanical and electrical pathologies (Crill, 1996; Antzelevitch et al., 1999; 
Undrovinas et al., 1999; Sakmann et al., 2000; Taddese and Bean, 2002; Tian et al., 
2004; Belardinelli et al., 2006; Huang and Trussell, 2008). 
Invasion of tumour cells involves degradation of the basement membrane and 
the extracellular matrix (ECM) by proteases, intregrin adhesion and cell motility 
(Chambers et al., 2002; Munoz-Najar et al., 2006; Nguyen and Massague, 2007). In 
MDA-MB-231 cells, multiple families of proteases including matrix metalloproteinases 
(MMPs), ADAMS (a disintegrin and metalloproteinase) and serine/aspartyl/cysteine 
cathepsins have been implicated in pro-invasive cascades (e.g. Munoz-Najar et al., 
2006; Pouyseggur et al., 2006; Subarsky and Hill, 2008; Gillet et al., 2009). 
Importantly, hypoxia, which is associated increased risk of metastatic dissemination in 
vivo (Pouyseggur et al., 2006; Bertout et al., 2008), was shown to enhance invasiveness 
of multiple cancer lines in vitro via upregulating expression / activity of various MMPs 
(e.g. MMP-2 and MMP-9) and cathepsins (e.g. cathepsin D) (Canning et al., 2001; 
Burke et al., 2003; Krishnamachary et al., 2003; Brat et al., 2004; Fahling et al., 2004; 
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Ridgway et al., 2005; Bertout et al., 2008). Of particular relevance, Gillet et al. (2009) 
showed that VGSC activity enhanced invasiveness of MDA-MB-231 cells by acidifying 
the perimembrane area, thereby enhancing the proteolytic activity of membrane-bound 
or soluble cathepsins B and S. Despite the precise mechanism through which VGSC 
activity induced perimembrane acidification was not revealed, involvement of Na+ 
influx was confirmed with experiments involving (i) selective VGSC-blocker TTX, (ii) 
VGSC-opener veratridine and (iii) cell culture with low-Na+ media. Thus, in the light of 
the findings of the present study, it can be speculated that hypoxia enhanced 
invasiveness of MDA-MB-231 cells in part by activating proteolytic cathepsin activity 
through enhanced Na+ influx via INaP (Gillet et al., 2009; Onkal and Djamgoz, 2009). 
In contrast to invasion, we observed that hypoxic conditions had no effect on 
Transwell migration in MDA-MB-231 cells. Interestingly, in contrast to earlier findings 
(Fraser et al., 2005; Chioni et al., 2010), TTX treatment was also without effect on cell 
migration. One possible explanation for this disparity is the diameter of the Transwell 
pores used. Previously, migration through 12 µm pores was shown to be VGSC-
dependent in MDA-MB-231 cells (Fraser et al., 2005; Chioni et al., 2010), whilst we 
and others (Roger et al., 2003; Gillet et al., 2009) observed that VGSC-dependence of 
migration is lost when 8 µm-pore Transwell filters were used. As regards the lack of 
effect of hypoxia on migration, it could be (i) that hypoxia did not modulate signalling 
pathways involved in migration or (ii) that the duration of the migration assay (6 h) was 
not long enough for hypoxia to modify expression/activity of proteins involved in 
migration. In fact, Subarsky and Hill (2008) demonstrated that, due to low-surface area 
to volume ratio, at least 14-16 hours were required to reduce the level of O2% to the 
desired hypoxic level in wells with Transwell filters (in contrast, 2-3 h incubation was 
sufficient for O2% to equilibrate at the desired level in normal Falcon tissue culture 
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dishes). Thus, a modified migration protocol with longer incubation periods may be 
required to further elucidate the possibility that hypoxia regulated migration of MDA-
MB-231 cells. 
 
3.3.6 Concluding remarks and evaluation of clinical potential 
In the present study, we showed that functional VGSC expression in MDA-MB-231 
BCa cells is preserved and even upregulated under hypoxic tissue culture conditions, 
which better mimic the in vivo status of tumour cells. Also, metastatic potential 
(represented in the present study by “invasiveness”) of MDA-MB-231 cells was 
enhanced by hypoxia, and this effect was partly VGSC-dependent. Therefore, our 
findings, taken together with published reports, would substantiate the evidence for 
VGSCs being a significant driving force for the metastatic progression of BCa (Fraser et 
al., 2005; Brackenbury et al., 2007; Gillet et al., 2009; Onkal and Djamgoz, 2009), as in 
other carcinomas (e.g. House et al., 2010). As regards the clinical potential of VGSC 
expression in metastatic disease two broad sets of possibilities can be considered. First, 
since hypoxia-induced INaP potentiated invasiveness in MDA-MB-231 cells, and this is 
likely to be a property of all VGSCs, INaP may be pharmacologically targeted as a means 
of suppressing cancer cell invasiveness and, hence, metastasis generally. Appropriate 
pharmacological blockers of INaP would be ranolazine and riluzole (Fredj et al., 2006; 
Weiss et al., 2010). Second, in the particular case of metastatic BCa, there are additional 
possibilities due to the specific subtype/splice variant of VGSC (nNav1.5) involved, as 
follows: 
i. Antibody. VGSC (nNav1.5) expression in metastatic BCa cells and tissues is 
oncofoetal, nNav1.5 being absent from healthy adult issues except for low levels in 
the brain (Chioni et al., 2005; Wang J. et al., 2008). This provides the channel with 
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significant advantages as a novel anti-BCa target (Onkal and Djamgoz, 2009). The 
closest relative of nNav1.5 is aNav1.5, which differs from it by 7 amino acids in the 
D1:S3/S4 region (Chioni et al., 2005; Onkal et al., 2008a). Chioni et al. (2005) 
generated a polyclonal antibody (NESOpAb), which recognized nNav1.5 
functionally with ~ 400-fold selectivity over aNav1.5. Also, Brackenbury et al. 
(2007) succeeded in suppressing migration and invasion of MDA-MB-231 cells by 
using a nNav1.5-specific siRNA. Thus, NESOpAb can form the basis of 
immunopharmacological targeting of nNav1.5 in metastatic BCa.  
ii. Small-molecule blockers. There is some evidence that small-molecule VGSC 
blockers including lidocaine and phenytoin may affect VGSC activity more in 
neonatal cardiomyocytes than adult (Xu et al., 1991, 1992). Thus, these compounds 
may confer some selectively for nNav1.5 over aNav1.5.  
iii. Peptide drug. Bosmans et al. (2008) showed that the D1:S3-S4 region of VGSCs are 
targeted directly by Protoxin-II (ProTx-II) and Hanatoxin (HaTx). Accordingly, a 
further possibility is to develop peptide drugs, based upon these toxins, in order to 
selectively block nNav1.5.   
In all these respects, studies were undertaken to determine the electrophysiological and 
pharmacological properties of nNav1.5 in comparison with aNav1.5, in Chapters 4 and 
5, respectively. 
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Electrophysiological comparison of Nav1.5 D1:S3 neonatal 
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4.1 Introduction 
Voltage-gated sodium channels (VGSCs) open briefly upon membrane depolarization, 
generating the transient Na+ current (INa) responsible for the initiation and propagation 
of action potentials in excitable tissues (Hille, 2001; Waxman, 2007). These large 
transmembrane proteins possess a central, pore-forming α-subunit (VGSCα), 
comprising four repeat domains (D1-D4), each composed of six membrane-spanning 
segments (S1-S6) (Catterall, 2000). Nine different VGSCα genes are found in higher 
vertebrates, each forming a channel with variable tetrodotoxin (TTX) sensitivity and 
electrophysiological properties (Ogatha and Ogishi, 2002; Catterall, 2010). TTX-
sensitive (TTX-S) VGSCαs (Nav1.1-1.4, 1.6, 1.7; IC50 ~ low nM) activate at around -40 
mV and have fast inactivation kinetics, whereas TTX-resistant (TTX-R) VGSCαs 
(Nav1.5, 1.8, 1.9; IC50 ~ µM) generally inactivate more slowly (Diss et al., 2004; Clare, 
2010). VGSCα properties can also be more finely modulated in a subtype specific 
manner by association with one or more smaller accessory β-subunits (VGSCβ1-4), 
typically altering voltage-dependence or kinetics of channel gating, and modifying the 
level of functional channel expression by promoting the intracellular trafficking of the 
mature VGSCα protein and/or by enhancing its cell surface stability via association with 
cytoskeletal elements such as ankyrin (Isom et al., 1992, 1995; Morgan et al., 2000; 
Catterall, 2000; Fahmi et al., 2001; Yu et al., 2003; Chahine et al., 2005). 
Further VGSCα diversity can be generated at transcriptional, pre-translational 
and post-translational levels (Herfst et al., 2004; Diss et al., 2004). In particular, 
alternative splicing has become an increasingly important mechanism for generating 
variation amongst VGSCαs (e.g. Gustafson et al., 1993; Schaller et al., 1995; Klugbauer 
et al., 1995; Dietrich et al., 1998; Raymond et al., 2004; Chatelier et al., 2008). A major 
type of alternative splicing of VGSCα genes in higher vertebrates involves usage of two 
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mutually exclusive alternative exons (exon 6: 5’ genomic and 3’ genomic) encoding 
part of D1:S3, most of D1:S4 and the D1:S3/S4 extracellular linker (Diss et al., 2004; 
Schroeter et al., 2010). These two exon 6 alternatives are distinguished by the presence 
(3’-exon) or absence (5’-exon) at position 7 of an aspartate residue. To date, D1:S3 
splicing has been shown to occur in six of the nine functional VGSCαs (Nav1.1, 1.2, 
1.3, 1.5, 1.6 and 1.7) (Diss et al., 2004). This splicing was first described for Nav1.2 
and Nav1.3 in rat brain and was deemed to be developmentally regulated since 
transcripts possessing the D1:S3 5’-exon were relatively abundant at birth but were 
quickly replaced by 3’-exon containing transcripts within a few days (Sarao et al., 1991; 
Gustafson et al., 1993). Consequently, the 5’-exon was termed ‘neonatal’ and the 3’-
exon ‘adult’.  
D1:S3 neonatal splice variant of Nav1.5 (nNav1.5) was identified in MDA-MB-
231 metastatic breast cancer (BCa) cells, where channel activity was found to potentiate 
various in vitro metastatic cell behaviours (MCBs) (Chioni et al., 2005, 2010; Fraser et 
al., 2005; Brackenbury et al., 2007; Gillet et al., 2009). The adult form of D1:S3 spliced 
Nav1.5 (aNav1.5) is the major current-carrying VGSCα expressed in mature cardiac 
muscle (Gellens et al., 1992). In most VGSCα genes, alternate D1:S3 exons differ at 19-
21 nucleotides but the subsequent proteins differ by only 1-3 amino acid. Nav1.5 D1:S3 
splicing is unusual in that the 5’-exon has 31 nucleotide differences from the 3’-exon 
form, resulting in 7 amino acid substitutions in D1:S3, S3/S4 linker and D1:S4 of the 
Nav1.5 protein (Figure 1.7B) (Gellens et al., 1992; Chioni et al., 2005). Importantly, 6 
of these changes are clustered in the extracellular D1:S3/S4 linker region, which 
enabled generation of a polyclonal antibody (NESOpAb) that recognized and blocked 
nNav1.5 activity with ~ 400x selectivity over aNav1.5, when tested on EBNA-293 cells 
stably expressing either Nav1.5 splice variant (Chioni et al., 2005). Using NESOpAb in 
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immunohistochemical studies, Chioni et al. (2005) also confirmed that D1:S3 splicing 
of Nav1.5 is developmentally regulated (as for Nav1.2 and Nav1.3) such that nNav1.5 
protein expression occurred significantly more abundantly in neonatal (1-day old) than 
adult heart and brain in mice, with minimal or no expression across other neonatal or 
adult tissues (Chioni et al., 2005). 
One of the amino acid changes between Nav1.5 D1:S3 splice variants involves 
replacement of the negatively charged aspartate at position 211 (Asp211) in aNav1.5 
with a positively charged lysine residue (Lys211) in nNav1.5, and not a non-charged 
amino acid as for the other D1:S3 spliced VGSCα genes (Diss et al., 2004; Schroeter et 
al., 2010). Current models of VGSCα architecture locate Lys/Asp211 residue in an 
extracellular position, towards the N-terminal border of the D1:S3/S4 linker (Figure 
1.7B) (Smith et al. 2007; Bosmans and Swartz, 2010). Thus, the positive charge-
reversal at this position could reduce the local negative surface potential sensed by the 
D1 voltage sensor in nNav1.5, electrostatically modifying voltage-dependence / kinetics 
of channel gating and/or altering channel interaction with positively charged molecules, 
including cations (Sheets and Hanck, 2002; Khan et al., 2006; McNulty et al., 2007). 
Such possible electrophysiological differences between nNav1.5 and aNav1.5 in turn 
may have important implications for pharmacological separation of nNav1.5 from 
aNav1.5 (Chapter 5), which could ultimately be clinically exploited against the 
proposed pro-metastatic activity of nNav1.5 in BCa (Fraser et al., 2005; Gillet et al., 
2009; Onkal and Djamgoz, 2009).  
In an earlier study, D1:S3 splice variants of human Nav1.7, which differ only by 
two amino acids (L201V and N206D; neonatal → adult), were found to have generally 
similar biophysical properties except that development of closed-state inactivation was 
slower in ‘adult’ vs. ‘neonatal’ Nav1.7, resulting in larger ramp currents in adult 
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(Chatelier et al., 2008; Jarecki et al., 2009). D1:S3 splicing in rat Nav1.2, which results 
in a single amino acid substitution (N209D; neonatal → adult), also produced 
functionally distinct isoforms; compared to the neonatal variant, adult Nav1.2 exhibited 
depolarized steady-state inactivation, slower activation kinetics and faster recovery from 
inactivation (Xu et al., 2007). As regards D1:S3 splice variants of Nav1.5, Ou et al. 
(2005) studied expression of nNav1.5, cloned from human neuroblastoma cells, but a 
direct electrophysiological comparison with aNav1.5 was not made.  
 
4.1.1 Aims and scope 
The main aim was to characterize and compare the electrophysiological properties of 
nNav1.5 and aNav1.5 channels heterologously expressed in EBNA-293 cells (Chioni et 
al., 2005). The specific aims were as follows: 
i. To elucidate the electrophysiological differences between nNav1.5 and aNav1.5. 
ii. To determine the extent to which the charge-reversing Asp211 to Lys211 switch in 
nNav1.5 contributed to any such functional difference. 
iii. To characterize the effects of monovalent (H+), divalent (Cd2+) and trivalent 
(Gd3+) cations on nNav1.5 and aNav1.5 activities in a comparative manner.  
Parts of the results presented in this Chapter have been published (Onkal et al., 2008a). 
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4.2 Results 
4.2.1 Electrophysiological comparison of nNav1.5 and aNav1.5  
4.2.1.1 Initial observations 
Non-transfected or empty vector-transfected EBNA-293 cells expressed endogenous 
inward currents of only small amplitude (~ 20 pA/pF) and only infrequently (~ 22%; n 
= 18) (Figure 4.1AB). Upon depolarization, EBNA-293 cells stably transfected with 
either nNav1.5 or aNav1.5 generated large (~ 300 pA/pF), rapidly-activating inward 
currents (Figure 4.1CD and Appendix 10). These currents were eliminated in a Na+-free 
mammalian physiological saline (MPS) perfusion solution, and substituting CaCl2 for 
BaCl2 in MPS had no effect, i.e. the currents were carried by Na+ (Figure 4.1CD and 
Appendix 10). Furthermore, consistent with expression of TTX-R Nav1.5 channels, the 
inward currents in both transfectant EBNA-293 cells were suppressed by micromolar 
TTX with similar IC50s of 3.9 ± 0.5 and 4.2 ± 0.3 µM for nNav1.5 and aNav1.5, 
respectively (P = 0.66, n ≥ 6) (Figure 4.2ABC and Table 4.1). Average peak current 
amplitudes, whole-cell capacitances and peak current densities were also similar in the 
studied nNav1.5-EBNA (n = 45) and aNav1.5-EBNA cells (n = 48) (Table 4.1).  
 
4.2.1.2 Voltage-dependence of steady-state activation 
Current-voltage (I-V) relationships revealed that nNav1.5 exhibited a more depolarized 
activation profile compared to aNav1.5. Thus, nNav1.5 and aNav1.5 channels activated 
(Vthres) at -58.3 ± 0.5 and -61.5 ± 0.4 mV (P < 0.001, n = 45-48) and peaked (Vpeak) at  
-12.2 ± 0.8 and -19.8 ± 0.8 mV, respectively (P < 0.001, n = 45-48) (Figure 4.3AB and 
Table 4.1). Consistently, Boltzmann fits to normalized conductance-voltage (G-V) 
relationships gave a depolarized average half-activation voltage (V1/2) for nNav1.5 (-
32.6 ± 0.6 mV; n = 45) vs. aNav1.5 (-39.0 ± 0.5 mV; n = 48) (P < 0.001); the values of  
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Figure 4.1 Control experiments for electrophysiological studies in EBNA-293 cells   
Endogenous VGSC currents in non-transfected EBNA-293 cells (A) and empty-vector EBNA-
293 cells (B) elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -100 mV; interpulse duration was 2 s. (C) Whole-cell Na+ currents in nNav1.5-EBNA cells 
were abolished in choline-substituted Na+-free MPS; superfusion with MPS in which Ba2+ was 
substituted for Ca2+ had no effect on peak current amplitude. Currents were elicited by 12 ms 
depolarizing pulses to 0 mV at 0.1 Hz from a holding potential of -100 mV. (D) Same as part C 
but for an aNav1.5-EBNA cell. 
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Figure 4.2 nNav1.5 and aNav1.5 exhibited similar sensitivity to TTX 
(A) Typical whole-cell Na+ currents in (i) nNav1.5-EBNA and (ii) aNav1.5-EBNA cells, before 
and after 0.5, 5 and 10 µM TTX. Currents were elicited by 12 ms depolarizing pulses to 0 mV at 
0.1 Hz from a holding potential of -100 mV. Dashed horizontal lines indicate zero current. (B) 
Time-course of 5 µM TTX block in nNav1.5 (open circles) and aNav1.5 (black circles). Arrow 
indicates TTX application. Data were normalized to peak current obtained by the first control 
pulse (n = 6-8 for nNav1.5 and aNav1.5, respectively). (C) Dose-response relationships for TTX 
block fitted with the Hill equation (nH = 1): nNav1.5 (n ≥ 6; open circles/dashed line) and 
aNav1.5 (n ≥ 8; black circles/solid line). Block was monitored until a steady-state maximum was 
reached (< 2 min) and data were normalized to first control current. IC50 estimates are reported in 
parentheses and also in Table 4.1. Data are presented as mean ± SEM. 
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Table 4.1 Summary of electrophysiological data obtained from EBNA-293 cells 
transfected with nNav1.5 or aNav1.5 
 
Parameter nNav1.5 aNav1.5 n P-value 
Peak current (pA) -2375.2 ± 212.5   -2835.9 ± 178.9  45-48 0.11 
Capacitance (pF) 8.9 ± 0.4 8.9 ± 0.4 45-48 0.88 
Peak current density (pA/pF) -278.9 ± 24.2 -344.8 ± 26.8 45-48 0.07 
Vthres (mV) -58.3 ± 0.5 -61.5 ± 0.4 45-48 < 0.001 ** 
Vpeak (mV) -12.2 ± 0.8 -19.8 ± 0.8 45-48 < 0.001 ** 
Activation V1/2 (mV) -32.6 ± 0.6 -39.0 ± 0.5  45-48 < 0.001 ** 
Activation k (mV) 7.0 ± 0.2 6.1 ± 0.2 45-48 0.002 ** 
Inactivation V1/2 (mV) -89.8 ± 0.9 -89.7 ± 1.0 38-43 0.96 
Inactivation k (mV) -6.2 ± 0.1 -6.2 ± 0.2 38-43 0.77 
V0 (mV) 20.2 ± 1.2  18.1 ± 0.7  45-48 0.14 
Tpeak at -20 mV (ms) 1.00 ± 0.02 0.86 ± 0.02 45-48 < 0.001 ** 
τfast at -20 mV (ms) 1.20 ± 0.04 1.02 ± 0.03 22-20 0.002 ** 
τslow at -20 mV (ms) 7.17 ± 0.38  5.70 ± 0.17  22-20 0.002 ** 
Afast at -20 mV (%) 83.5 ± 1.3 84.2 ± 1.0 22-20 0.66 
Aslow at -20 mV (%) 16.5 ± 1.3 15.8 ± 1.0 22-20 0.66 
τrecovery (ms)  35.5 ± 3.2 26.7 ± 1.5 31-37 0.01 * 
TTX IC50 (µM) 3.9 ± 0.5  4.2 ± 0.3  ≥ 6 0.66 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Vthres, threshold voltage for activation; Vpeak, voltage at current peak; V1/2, half-
(in)activation voltage; k, (in)activation slope factor; V0, coefficient describing voltage-
dependence of time to peak; Tpeak, time to peak; τfast, fast inactivation time constant; τslow, slow 
inactivation time constant; Afast, percentage amplitude of fast inactivation; Aslow, percentage 
amplitude of slow inactivation; τrecovery , recovery from inactivation time constant; IC50, 
concentration of tetrodotoxin (TTX) at which 50% of VGSC current is inhibited. Data are mean 
± SEM. Statistical significance was determined by unpaired t-tests: (*) P < 0.05, (**) P < 0.01. 
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Figure 4.3 Voltage-dependence of activation was depolarized in nNav1.5 vs. aNav1.5 
(A) Typical whole-cell Na+ currents in nNav1.5-EBNA and aNav1.5-EBNA cells, elicited by 60 
ms pulses to between -80 mV and +45 mV from a holding potential of -100 mV; interpulse 
duration was 2 s. (B) Normalized current-voltage (I-V) relationships for nNav1.5 (n = 45; open 
circles) and aNav1.5 (n = 48; black circles). (C) Normalized conductance-voltage (G-V) 
relationships fitted with Boltzmann functions for nNav1.5 (n = 45; open circles/dashed line) and 
aNav1.5 (n = 48; black circles/solid line). Average values of fitted parameters (V1/2 and k) are 
reported in Table 4.1. Data are mean ± SEM. Some error bars are smaller than symbols. 
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the slope factor k were 7.0 ± 0.2 and 6.1 ± 0.2 mV / e-fold, respectively (P < 0.01) 
(Figure 4.3C and Table 4.1). The reversal potential for INa (determined from linear 
interpolation of the I-V relationships between 0 mV and 45 mV) was unchanged at ~ 65 
mV (Figure 4.3AB). 
 
4.2.1.3 Kinetics of activation 
Latency of VGSC opening reflects the dwell time in multiple closed states in the 
activation pathway prior to channel opening (Chanda and Bezanilla, 2002). For both 
Nav1.5 variants, time to peak (Tpeak) decayed exponentially with membrane voltage in 
the range -40 mV to 10 mV (Figure 4.4B). However, over the voltage range tested, 
nNav1.5 reached peak current significantly more slowly as compared to aNav1.5 
(Figure 4.4.AB). For example, at -20 mV, average Tpeak for nNav1.5 and aNav1.5 were 
1.00 ± 0.02 and 0.86 ± 0.02 ms, respectively (P < 0.001, n = 45-48) (Figure 4.4B and 
Table 4.1). In contrast, the coefficient (V0) describing voltage-dependence of Tpeak 
(obtained from single exponential fits to Tpeak vs. test voltage) was similar in nNav1.5 
(20.2 ± 1.2 mV per e-fold decrease in Tpeak) and aNav1.5 (18.1 ± 0.7 mV per e-fold 
decrease in Tpeak) (P = 0.14, n = 45-48) (Table 4.1).  
 
4.2.1.4 Kinetics of inactivation  
Nav1.5 variants also differed significantly in their kinetics of inactivation, which was 
studied by fitting normalized INa decays with double exponential functions (Figure 4.4A 
and 4.5). In the voltage range tested (-30 mV to 0 mV), current decays were best-fit by 
the double exponential function in ~ 95% of both nNav1.5 (n = 154 traces from 22 
cells) and aNav1.5 cases (n = 140 traces from 20 cells). The average time constants for 
fast and slow components of inactivation (τfast and τslow, respectively) are shown as a  
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      B 
Figure 4.4 Time to peak was slower in nNav1.5 vs. aNav1.5 
(A) Traces of typical whole-cell Na+ currents (normalized for equal amplitude) in nNav1.5-
EBNA and aNav1.5-EBNA cells, elicited by a 60 ms pulse to -25 mV from a holding potential 
of -100 mV. (B) Time to peak (Tpeak), obtained from I-V recordings described in Figure 4.3, as a 
function of test potential and fitted with single exponential functions for nNav1.5 (n = 45; open 
circles/dashed line) and aNav1.5 (n = 48; black circles/solid line). Data were compared using 
unpaired t-tests: (*) P < 0.05, (**) P < 0.01. Average values of fitted parameters (V0) are 
reported in Table 4.1. Data are mean ± SEM. Some error bars are smaller than symbols. 
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Figure 4.5 Inactivation kinetics was slower in nNav1.5 vs. aNav1.5 
(A) (i) Time constant (τfast) and (ii) percentage amplitude (Afast) of fast inactivation (determined 
from double exponential fits to normalized Na+ current decays) plotted as a function of test 
potential for nNav1.5 (n = 22; open circles) and aNav1.5 (n = 20; black circles). Data were 
obtained from I-V recordings described in Figure 4.3. τfast data points are connected with dashed 
lines for nNav1.5 and solid lines for aNav1.5. For Afast (part ii), white and black bars represent 
nNav1.5 and aNav1.5, respectively. Data were compared using unpaired t-tests: (*) P < 0.05, 
(**) P < 0.01. Afast was similar for nNav1.5 and aNav1.5 at each voltage (P > 0.05). (B) Same 
as part A but for the slow component of inactivation (τslow and Afast). Note that Afast + Aslow = 
100% at each voltage. Data are presented as mean ± SEM.  
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function of test potential in Figure 4.5Ai and 4.5Bi, respectively. Values of τfast were 
significantly larger (i.e. channel inactivation was slower) for nNav1.5 compared with 
aNav1.5 for -30 mV to -5 mV, the bulk of the voltage range tested (P < 0.05, n = 22-20) 
(Figure 4.5Ai). For example, at -20 mV, τfast was 1.20 ± 0.04 ms for nNav1.5 and 1.02 ± 
0.03 ms for aNav1.5 (P < 0.01, n = 22-20) (Table 4.1). The average τslow values were 
also significantly larger for nNav1.5 vs. aNav1.5; at -20 mV, τslow was 7.17 ± 0.38 ms 
for nNav1.5 and 5.70 ± 0.17 ms for aNav1.5 (P < 0.01, n = 22-20) (Figure 4.5Bi and 
Table 4.1). On the other hand, the fractional contributions of fast and slow components 
of inactivation to the overall inactivation time-course were similar. Thus, percentage 
amplitudes of τfast (Afast) and τslow (Aslow) were unchanged between nNav1.5 and aNav1.5 
in the voltage-range tested (Figure 4.5Aii and 4.5Bii). For instance, at -20 mV, the 
fraction of inactivation described by the fast component (Afast) was 83.5 ± 1.3% in 
nNav1.5 and 84.2 ± 1.0% in aNav1.5 (P = 0.66, n = 22-20) (Table 4.1). 
 
4.2.1.5 Transient charge (Na+) entry  
Waveforms of the currents suggested that, compared to aNav1.5, nNav1.5 activity 
would be associated with greater transient Na+ influx, mainly due to its slower 
inactivation kinetics (i.e. area under macroscopic INa traces was greater for nNav1.5 vs. 
aNav1.5) (Figure 4.6A). Accordingly, we quantified the total transient charge entry into 
the cell (Qtotal, Coulomb x 10-15) at each test voltage by manually calculating the area 
under the recorded current trace, divided into 0.02 ms wide ‘columns’, for the period 0.5 
to 30 ms post onset of the command voltage (i.e. Qtotal = Σ (I x 0.02 ms), where I is 
current in pA). Since Qtotal comparisons would be biased by any difference in peak 
current amplitudes, for every recording used for this analysis (n = 6 each): (i) maximal 
peak currents were very similar, between 2340 and 2380 pA, and (ii) peak current  
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Figure 4.6 Slower kinetics of nNav1.5 gating resulted in larger transient charge entry 
(A) Whole-cell nNav1.5 (red traces) and aNav1.5 (black traces) currents in EBNA-293 cells, 
elicited by 60 ms pulses to between -80 mV and +45 mV (traces are shown for the range -20 mV 
to 20 mV) from a holding potential of -100 mV; interpulse duration was 2 s. Slower activation 
and inactivation of nNav1.5 vs. aNav1.5 was apparent at all activating test potentials (e.g. Figure 
4.4 and 4.5). (B) Total charge entry (Qtotal) during 0.5 ms to 30 ms post channel activation plotted 
as a function of test potential for nNav1.5 (n = 6; open circles) and aNav1.5 (n = 6; black 
circles). Data were from cells that had peak Na+ current amplitudes in the range 2340-2380 pA. 
(C) Percentage difference in Qtotal of nNav1.5 relative to aNav1.5 plotted as a function of test 
potential (data from part B). 
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amplitudes at in the voltage range -35 to +30 mV were similar to within ± 10% between 
different cells.  
As anticipated, compared to aNav1.5, nNav1.5 channels allowed substantially 
larger transient charge (Na+) influx, with an overall trend for the difference to increase 
in the voltage range -30 to +20 mV (Figure 4.6BC). For example, at -20 mV, nNav1.5 
channels allowed 45% more charge entry into the cell compared to aNav1.5, whilst this 
difference was 90% at 0 mV (i.e. nearly 2-fold larger charge influx in nNav1.5) (Figure 
4.6C). Notably, at more hyperpolarized test potentials near Vthres (e.g. -50 mV), aNav1.5 
channels allowed larger charge influx compared to nNav1.5 (Figure 4.6BC). This 
occurred due to bias from the larger peak currents at these potentials in aNav1.5-EBNA 
vs. nNav1.5-EBNA cells, resulting from relatively hyperpolarized activation of aNav1.5 
vs. nNav1.5. 
 
4.2.1.6 Voltage-dependence of steady-state inactivation  
Voltage-dependence of steady-state inactivation (availability) of the two Nav1.5 
variants was studied using 1 s long pre-pulses in the range -140 mV to -10 mV, 
followed immediately by a test pulse to -10 mV (Figure 4.7A). Average half-maximal 
inactivation voltage (V1/2), obtained from cell-by-cell Boltzmann fits to availability 
curves, was similar for nNav1.5 (-89.8 ± 0.9 mV) and aNav1.5 (-89.7 ± 1.0 mV) (P = 
0.96, n = 38-43) (Figure 4.7AB and Table 4.1). The values of the inactivation slope 
factor (k) were also similar (-6.2 ± 0.1 and -6.2 ± 0.2 mV / e-fold for nNav1.5 and 
aNav1.5, respectively; P = 0.77, n = 38-43) (Table 4.1). Using a modified protocol with 
shorter (250 ms) conditioning pre-pulses to reduce slow inactivation, again similar 
values for obtained, respectively, for nNav1.5 and aNav1.5: inactivation V1/2 (-84.9 ±  
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Figure 4.7 Voltage-dependence of inactivation was similar in nNav1.5 and aNav1.5 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, used for studying voltage-dependence of 
steady-state inactivation (availability). Currents were elicited by 80 ms test pulses to -10 mV 
after 1 s pre-pulses in the range -140 mV to -10 mV; holding potential was -100 mV and 
interpulse duration was 2 s. Trace generated following the pre-pulse at -90 mV is indicated for 
comparison. (B) Availability-voltage relationships fitted with Boltzmann functions for nNav1.5 
(n = 38; open circle/dashed line) and aNav1.5 (n = 43; black circles/solid line). Currents (I) were 
normalized to the maximum current (Imax) recorded following the most hyperpolarized pre-
pulse (-140 mV). Pulse protocol was as described in part A. Average values for inactivation V1/2 
and k are reported in parentheses and also in Table 4.1. (C) Same as part B but 250 ms-long pre-
pulses were used to inactivate channels (rather than 1 s-long pre-pulses); nNav1.5 (n = 20) and 
aNav1.5 (n = 24). Data are mean ± SEM; some error bars are smaller than symbols. 
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0.8 and -82.9 ± 1.5 mV; P = 0.25, n = 20-24), and inactivation k (-5.9 ± 0.2 and -6.0 ± 
0.3 mV / e-fold; P = 0.72, n = 20-24) (Figure 4.7C). 
 
4.2.1.7 Time-course of recovery from inactivation 
Recovery from inactivation was studied using a double-pulse protocol, and time-course 
of channel recovery was best fit with a single exponential function (Figure 4.8AB). 
Comparison of the overall fitted data revealed that the fraction of recovered channels 
was significantly lower for nNav1.5 vs. aNav1.5 at various recovery intervals ≤ 75 ms 
(P < 0.05, n = 31-37) (Figure 4.8B). Also, the average recovery time constant (τrecovery) 
was significantly larger (i.e. recovery was slower) for nNav1.5 vs. aNav1.5, with values 
of 35.5 ± 3.2 and 26.7 ± 1.5 ms, respectively (P < 0.05, n = 31-37) (Figure 4.8B and 
Table 4.1). Notably, at the maximum recovery period allowed (155 ms), channel 
recovery was near complete (but not 100%) for both nNav1.5 and aNav1.5 (Figure 
4.8AB); the small unrecovered fraction of current was possibly due to the presence of 
slow-inactivated channels that required longer intervals to recover from inactivation 
(Richmond et al., 1998; Chancey et al., 2007). 
 
4.2.1.8 Activity-dependent attenuation 
Activity-dependent attenuation (i.e. use-dependent run-down) of current was 
investigated with a train of 100 pulses applied at different frequencies (ranging from 10 
to 50 Hz). Figure 4.9A shows representative nNav1.5 and aNav1.5 current traces 
recorded at 20, 33 and 50 Hz. Frequencies ≤ 20 Hz induced similar use-dependent 
attenuation in Nav1.5 variants, whilst, at 33 and 50 Hz, this was significantly larger in 
nNav1.5 vs. aNav1.5 (n =17-16, Figure 4.9AB). For example, at 33 Hz, fraction of 
current remaining at the 100th pulse was 0.66 ± 0.02 in nNav1.5 and 0.74 ± 0.03 in  
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Figure 4.8 Recovery from inactivation was slower in nNav1.5 vs. aNav1.5 
(A) Superimposed whole-cell Na+ currents from (i) nNav1.5 and (ii) aNav1.5, used for studying 
kinetics of recovery from inactivation. Cells were treated with an 80 ms control pulse to -10 mV 
(giving current Ic), returned to -100 mV for a recovery interval ranging from 5 to 155 ms and 
then an identical test pulse to -10 mV was applied (giving current It). Holding potential was -100 
mV and interpulse duration was 2 s. Dashed horizontal lines indicate full recovery (i.e. It = Ic); 
arrows indicate slower recovery of nNav1.5 vs. aNav1.5. (B) Recovered current (It /Ic) plotted as 
a function of recovery interval and fitted with single exponential functions for nNav1.5 (n = 31; 
open circles/dashed line) and aNav1.5 (n = 37; black circles/solid line). Average recovery time 
constants (τrecovery) are reported in Table 4.1. Data (mean ± SEM) were compared using unpaired 
t-tests: (*) P < 0.05. Some error bars are smaller than symbols. 
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Figure 4.9 Activity-dependent attenuation was larger in nNav1.5 vs. aNav1.5 
(A) Typical whole-cell nNav1.5 (top) and aNav1.5 (bottom) currents, elicited by hundred 12 ms 
pulses to 0 mV at 20 Hz (left panels), 33 Hz (middle panels) or 50 Hz (right panels); holding 
potential was -100 mV. Dashed horizontal lines indicate zero current. (B) Development of use-
dependent current attenuation at 10, 20, 33 and 50 Hz (pulse protocol as in part A) for nNav1.5 
(n = 17; grey symbols) and aNav1.5 (n = 16; black symbols). Peak currents were normalized to 
the current of the first pulse and plotted against the pulse number. At 33 and 50 Hz, current at the 
100th pulse was smaller in nNav1.5 vs. aNav1.5 (unpaired t-tests: (*) P < 0.05); there was no 
difference at 10 and 20 Hz (unpaired t-tests: P > 0.05). Data are presented as mean ± SEM.   
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aNav1.5 (P < 0.05, n = 17-16); at 50 Hz, this was in 0.41 ± 0.02 nNav1.5 and 0.50 ± 
0.03 in aNav1.5 (P < 0.05, n = 17-16) (Figure 4.9AB). The greater activity-dependent 
attenuation in nNav1.5 vs. aNav1.5 channels was consistent with the relatively slower 
recovery from inactivation exhibited by nNav1.5 (Figure 4.8).  
 
4.2.1.9 Persistent activity 
Persistent Na+ current (INaP) expression in Nav1.5 variants was studied using the I-V 
protocol described in Section 4.2.1.2 but with longer (300 ms) pulse duration (Figure 
4.10A). Currents were first recorded in normal MPS and then in the presence of 30 µM 
TTX; the latter recording was used to subtract any background ionic or leak 
conductance. Using the subtracted (i.e. TTX-sensitive) I-V recordings, INaP was then 
measured and compared between nNav1.5 and aNav1.5 at three different time points: (i) 
25-50 ms, (ii) 100-125 ms and (iii) 200-225 ms (from onset of voltage command).  
 Although maximal peak INa densities were similar for nNav1.5-EBNA (285.3 ± 
39.8 pA/pF; n = 24) and aNav1.5-EBNA cells (318.0 ± 41.9 pA/pF; n = 17), INaP 
expression was significantly larger in nNav1.5 vs. aNav1.5 channels, as illustrated 
qualitatively in Figure 4.10A. To avoid any bias from variations in peak INa amplitude 
across cells, INaP at given time points was normalized to the maximal peak INa amplitude 
(Imaxpeak) for each cell and mean I/Imaxpeak values were plotted against voltage (Figure 
4.10CDE). At 25-50 ms, a TTX-sensitive inward current ‘limb’ was present in the I-V 
relationships for both Nav1.5 variants, signifying expression of INaP; this current 
activated at ~ -60 mV and peaked at ~ -25 mV for both nNav1.5 and aNav1.5 (Figure 
4.10C). For nNav1.5, INaP was also detectable at 100-125 ms and 200-225 ms (albeit 
with smaller amplitudes), whereas no such persistent activity was evident in aNav1.5 
channels at times ≥ 100 ms (Figure 4.10DE).  
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Figure 4.10 nNav1.5 expressed larger INaP compared to aNav1.5 
(A) Typical whole-cell Na+ currents in nNav1.5-EBNA and aNav1.5-EBNA cells, elicited by 
300 ms pulses to between -80 mV and +45 mV from a holding potential of -100 mV; interpulse 
duration was 2 s. Currents were leak-subtracted using recordings taken in the presence of 30 µM 
TTX. Traces shown are truncated (peak INa is not shown) for illustrative purposes. Arrows 
indicate the presence of larger INaP in nNav1.5 vs. aNav1.5. (B-E) Current-voltage (I-V) 
relationships normalized to maximal peak current for nNav1.5 (n = 24; open circles) and 
aNav1.5 (n = 17; black circles): (B) Peak INa; (C) INaP averaged between 25-50 ms post onset of 
voltage-pulse; (D) INaP averaged between 100-125 ms post onset of voltage pulse; and (E) INaP 
averaged between 200-225 post onset of voltage-pulse. Data are presented as mean ± SEM. 
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 The observed differences in INaP expression between nNav1.5 and aNav1.5 were 
compared using normalized (I/Imaxpeak) values at -25 mV, at which, (i) INaP was 
maximal (Figure 4.10CDE) and (ii) mean normalized peak INa amplitudes were 
statistically similar for nNav1.5 and aNav1.5 (P = 0.48, n = 24-17) (Figure 4.10B and 
4.11AB). At 25-50 ms, there was no significant difference in the values of INaP in 
nNav1.5 vs. aNav1.5 (P = 0.36, n = 24-17), whereas the differences at 100-125 ms and 
200-225 ms were statistically significant (P < 0.05, n = 24-17) (Figure 4.11AB). For 
example, at -25 mV, INaP density at 200-225 ms was -0.65 ± 0.13 pA/pF in nNav1.5 
(accounting for ~ 0.4% of maximal peak INa) and -0.04 ± 0.24 pA/pF in aNav1.5 
(accounting for < 0.01% of maximal peak INa) (P < 0.05 vs. nNav1.5, n = 24-17; Figure 
4.10E and 4.11AB).  
Notably, INaP recorded at 25-50 ms would, in part, be due to incomplete 
inactivation of ‘transient’ (peak) Nav1.5 channels, which would be completely 
inactivated during later stages of the 300-ms depolarizing pulses used (e.g. at 100-125 
ms and 200-225 ms; Maltsev et al., 1998, 2001). Thus, INaP recorded at 100-125 and 
200-225 ms but not at 25-50 ms represented true steady-state persistent channel activity. 
Also, the recorded INaP in Nav1.5 variants was not due to ‘window’ INa, since we were 
able to record INaP at relatively depolarized potentials (e.g. -10 mV) that lie well outside 
the ‘window’ voltage-range for Nav1.5 channels (e.g. Figure 3.8A inset). 
 
4.2.1.10 Summary 
Nav1.5 D1:S3 variants differed significantly in their electrophysiological 
characteristics. In particular, compared to aNav1.5, nNav1.5 channels (i) exhibited 
depolarized voltage-dependence of activation, (ii) had slower activation and inactivation 
kinetics, (iii) allowed significantly greater transient charge (Na+) influx, (iv) recovered  
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     A  
 
 
 
 
 
 
 
 
 
     B 
 I
-25mV / Imaxpeak (%) nNav1.5 aNav1.5 n P-value 
Peak INa 85.4 ± 3.6 89.6 ± 4.7 24-17 0.48 
INaP (25-50 ms) 1.0 ± 0.3 0.6 ± 0.3 24-17 0.36 
INaP (100-125 ms) 0.5 ± 0.1 0.0 ± 0.2 24-17 0.03 * 
INaP (200-225 ms) 0.4 ± 0.1 -0.1 ± 0.2 24-17 0.01 * 
Figure 4.11 INaP was larger in nNav1.5 vs. aNav1.5 
(A) Bar diagram comparing INaP expression in nNav1.5 (n = 24) vs. aNav1.5 (n = 17) at -25 mV. 
Data were from recordings described in Figure 4.10 and were compared using unpaired t-tests: 
(X) P > 0.05, (*) P < 0.05. Dashed line represents 1% of the maximal peak current. Results are 
summarized in a table in part B. Data are presented as mean ± SEM. 
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from inactivation significantly more slowly, (v) exhibited greater use-dependent 
attenuation, and (vi) expressed larger persistent Na+ currents (INaP). Next, we 
determined the extent to which the charge-reversing Asp211 to Lys211 switch in nNav1.5 
could contribute to these differences. 
 
4.2.2 Consequences of K211D mutagenesis on nNav1.5 function 
4.2.2.1 Initial observations 
Two different colonies of EBNA-293 cells transfected with the nNav1.5 K211D mutant 
were used for the electrophysiological studies: nNav1.5 K211D colony #13 (K211D#13) 
and nNav1.5 K211D colony #17 (K211D#17). Similar to nNav1.5 and aNav1.5 
expressing EBNA-293 cells, K211D#13 and K211D#17 transfectants generated large, 
rapidly-activating inward currents; these were eliminated in Na+-free MPS, whilst 
substituting CaCl2 for BaCl2 in MPS did not affect peak current amplitude, i.e. the 
currents were carried by Na+ (Figure 4.12A and Appendix 10). Compared to nNav1.5-
EBNA and aNav1.5-EBNA cells, average peak current amplitude was slightly yet 
significantly larger in K211D#13-EBNA but not K211D#17-EBNA cells; whole-cell 
capacitance was similar among nNav1.5, aNav1.5, K211D#13
 
and K211D#17 
transfectants (Table 4.2).  
 
4.2.2.2 Voltage-dependence of activation 
Activation characteristics of nNav1.5 K211D mutants were studied using the standard I-
V protocol as described before (Figure 4.12A). For both K211D#13 and K211D#17, we 
observed that the parameters (listed below) describing voltage-dependence of activation 
were shifted in the hyperpolarizing direction, towards aNav1.5-like values (see Table 
4.2 for statistics): 
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Figure 4.12 Lys211 was responsible for the depolarized activation of nNav1.5 vs. aNav1.5 
(A) Typical whole-cell Na+ currents in EBNA-293 cells transfected with nNav1.5, aNav1.5, 
nNav1.5 K211D (#13) or nNav1.5 K211D (#17), elicited by 60 ms pulses to between -80 mV 
and +45 mV from a holding potential of -100 mV; interpulse duration was 2 s. (B) Normalized I-
V relationships for nNav1.5 (n = 45; open circles), aNav1.5 (n = 48; black circles) and nNav1.5 
K211D #13 (n = 26; grey circles). (C) Same as part B but with nNav1.5 K211D #17 (n = 14; 
grey circles). For all parts, data for nNav1.5 and aNav1.5 were re-plotted from Figure 4.3 for 
comparison. Data are presented as mean ± SEM. Some error bars are smaller than symbols. 
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Table 4.2 Summary of electrophysiological data obtained from EBNA-293 cells transfected with Nav1.5 variants 
      
 
For abbreviations, see Table 4.1. Significance (ANOVA / Newman Keuls; P < 0.05): (a) nNav1.5 vs. aNav1.5; (b) nNav1.5 vs. K211D #13; (c) nNav1.5 vs. K211D 
#17; (d) aNav1.5 vs. K211D #13; (e) aNav1.5 vs. K211D #17; (f) K211D #13 vs. K211D #17. Data are mean ± SEM. nNav1.5 and aNav1.5 data are from Table 4.1.
Parameter nNav1.5 aNav1.5 nNav1.5 K211D (#13) nNav1.5 K211D (#17) n Significance 
Peak current (pA)  -2375.2 ± 212.5   -2835.9 ± 178.9  -3606.2 ± 231.7  -3147.2 ± 483.9  45-48-26-14 b, d 
Capacitance (pF) 8.9 ± 0.4 8.9 ± 0.4 8.2 ± 0.6 9.7 ± 0.7 45-48-26-14 - 
Vthres (mV) -58.3 ± 0.5 -61.5 ± 0.4 -62.6 ± 0.5 -60.9 ± 0.7 45-48-26-14 a, b, c 
Vpeak (mV)  -12.2 ± 0.8 -19.8 ± 0.8 -22.4 ± 1.0 -20.0 ± 1.7 45-48-26-14 a, b, c 
Activation V1/2  (mV)  -32.6 ± 0.6 -39.0 ± 0.5  -40.5 ± 0.7  -38.4 ± 1.0  45-48-26-14 a, b, c 
Activation k (mV) 7.0 ± 0.2 6.1 ± 0.2 5.6 ± 0.4 6.1 ± 0.4 45-48-26-14 a, b, c 
Inactivation V1/2 (mV)  -89.8 ± 0.9 -89.7 ± 1.0 -91.7 ± 0.6 -91.3 ± 0.9 38-43-19-13 - 
Inactivation k (mV) -6.2 ± 0.1 -6.2 ± 0.2 -6.2 ± 0.1 -6.0 ± 0.2 38-43-19-13 - 
V0 (mV)  20.2 ± 1.2  18.1 ± 0.7  17.4 ± 1.2  18.5 ± 1.4  45-48-26-14 - 
Tpeak at -20 mV (ms) 1.00 ± 0.02 0.86 ± 0.02 0.81 ± 0.02 0.90 ± 0.02 45-48-26-14 a, b, c, d, f 
τfast at -20 mV (ms) 1.20 ± 0.04 1.02 ± 0.03 0.91 ± 0.02 0.91 ± 0.03 22-20-26-14 a, b, c, d, e 
τslow at -20 mV (ms) 7.17 ± 0.38  5.70 ± 0.17  5.39 ± 0.14  6.02 ± 0.30  22-20-26-14 a, b, c 
Afast at -20 mV (%) 83.5 ± 1.3 84.2 ± 1.0 85.8 ± 1.2 85.9 ± 1.0 22-20-26-14 - 
Aslow at -20 mV (%) 16.5 ± 1.3 15.8 ± 1.0 14.2 ± 1.2 14.1 ± 1.0 22-20-26-14 - 
τrecovery (ms)  35.5 ± 3.2 26.7 ± 1.5 26.3 ± 1.6 25.3 ± 1.2 31-37-20-12 a, b, c 
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i. K211D#13 and K211D#17 mutants activated at -62.6 ± 0.5 mV (n = 26) and -60.9 
± 0.7 mV (n = 14), respectively, i.e. at significantly hyperpolarized potentials as 
compared to nNav1.5 (-58.3 ± 0.5 mV) but not to aNav1.5 (-61.5 ± 0.4 mV) 
(Figure 4.12BC and Table 4.2). 
ii. Values for Vpeak were -22.4 ± 1.0 mV for K211D#13 (n = 26) and -20.0 ± 1.7 mV 
for K211D#17 (n = 14), which were similar to aNav1.5 (-19.8 ± 0.8 mV) but 
significantly more negative than for nNav1.5 (-12.2 ± 0.8 mV) (Figure 4.12BC 
and Table 4.2). 
iii. Average half-activation voltages (V1/2) of K211D#13 (-40.5 ± 0.7 mV; n = 26) 
and K211D#17 (-38.4 ± 1.0 mV; n = 14) were similar to aNav1.5 (-39.0 ± 0.5 
mV) but significantly more hyperpolarized (~ 7 mV) than for nNav1.5 (-32.6 ± 
0.6 mV) (Figure 4.13AB and Table 4.2).  
iv. Activation slope factors (k) for K211D#13 (5.6 ± 0.4 mV / e-fold; n = 26) and 
K211D#17 (6.1 ± 0.4 mV / e-fold; n = 14) were significantly smaller than for 
nNav1.5 (7.0 ± 0.2 mV / e-fold) but not aNav1.5 (6.1 ± 0.2 mV / e-fold) (Figure 
4.13AB and Table 4.2). 
Overall, these results suggested that the positive charge-reversal in D1:S3/S4 of 
nNav1.5 (i.e. Asp211 → Lys211 switch) was primarily responsible for its depolarized 
activation profile, compared to aNav1.5.  
 
4.2.2.3 Kinetics of activation and inactivation 
nNav1.5 activation and inactivation kinetics were significantly accelerated by the 
K211D mutagenesis, i.e. Lys211 to Asp211 switch again resulted in a functional shift 
from nNav1.5 towards the aNav1.5 phenotype (Figure 4.14 and 4.15). Interestingly, in 
the case of the fast inactivation time constant (τfast), K211D#13 and K211D#17 values  
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  A 
 
 
 
 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Depolarized activation of nNav1.5 vs. aNav1.5 was due to Lys211  
(A) Normalized conductance-voltage (G-V) relationships fitted with Boltzmann functions for 
nNav1.5 (n = 45; open circles/solid line), aNav1.5 (n = 48; black circles/solid line) and nNav1.5 
K211D #13 (n = 26; grey circles/dashed line). Data for nNav1.5 and aNav1.5 were re-plotted 
from Figure 4.3; data for nNav1.5 K211D #13 were from recordings described in Figure 4.12. 
(B) Same as part A but with nNav1.5 K211D #17 (n = 14; grey circles/dashed line). Average 
values of fitted parameters (V1/2 and k) are reported in Table 4.2. Data are mean ± SEM. 
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       A  
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Figure 4.14 Lys211 was responsible for the slower activation kinetics of nNav1.5 vs. aNav1.5  
(A) Time to peak (Tpeak) as a function of test potential and fitted with single exponential functions 
for nNav1.5 (n = 45; open circles/solid line), aNav1.5 (n = 48; black circles/solid line) and 
nNav1.5 K211D #13 (n = 26; grey circles/dashed line). Data were obtained from I-V recordings 
described in Figure 4.3 and 4.12. Data for nNav1.5 and aNav1.5 were re-plotted from Figure 4.4 
for comparison. Data were compared using ANOVA / Newman-Keuls post-hoc analysis. For 
K211D #13 vs. nNav1.5: (*) P < 0.05, (**) P < 0.01; for K211D #13 vs. aNav1.5: (†) P < 0.05; 
(††) P < 0.01. Average values of fitted parameters (V0) are reported in Table 4.2. (B) Same as 
part A but with nNav1.5 K211D #17 (n = 14; grey circles/dashed line). Data are mean ± SEM. 
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A      B 
 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
E      F 
Figure 4.15 Lys211 was responsible for the slower inactivation kinetics of nNav1.5  
(A) Fast (τfast) and (B) slow (τslow) time constants of inactivation (determined from double 
exponential fits to normalized Na+ current decays) plotted as a function of test potential for 
nNav1.5 (n = 22; open circles/solid lines), aNav1.5 (n = 20; black circles/solid lines) and 
nNav1.5 K211D #13 (n = 26; grey circles/dashed lines). Data were obtained from I-V recordings 
described in Figure 4.3 and 4.12. Data for nNav1.5 and aNav1.5 were re-plotted from Figure 4.5. 
Data were compared using ANOVA / Newman-Keuls post-hoc analysis. For K211D #13 vs. 
nNav1.5: (*) P < 0.05, (**) P < 0.01; for K211D #13 vs. aNav1.5: (†) P < 0.05; (††) P < 0.01. 
(C, D) Same as part A (for τfast) and part B (for τslow), respectively, but with nNav1.5 K211D #17 
(n = 14; grey circles/dashed lines). (E, F) Percentage amplitudes of τfast (Afast) and τslow (Aslow) 
were similar in nNav1.5, aNav1.5, K211D #13 and K211D #17 (ANOVA: P > 0.05 at each 
voltage). Note that Afast + Aslow = 100% at each voltage. Data are presented as mean ± SEM. 
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were even smaller (i.e. faster) than aNav1.5 values, ‘overshooting’ beyond the aNav1.5 
phenotype (Figure 4.15AC and Table 4.2). Similar overshoot also occurred in the case 
of the slow inactivation time constant (τslow) but only at -10 mV for K211D#13 and 0 mV 
for K211D#17 (Figure 4.15BD and Table 4.2). For Tpeak, partial overshoot of aNav1.5 
values was observed in the case of K211D#13 but not K211D#17 (Figure 4.14AB and 
Table 4.2). These findings are exemplified, as follows (see Table 4.2 for statistics):  
i. At -20 mV, average Tpeak for K211D#13 (0.81 ± 0.02 ms; n = 26) was 
significantly faster than for nNav1.5 (1.00 ± 0.02 ms), and even aNav1.5 (0.86 ± 
0.02 ms) (Figure 4.14A and Table 4.2). For K211D#17, Tpeak at -20 mV (0.90 ± 
0.02 mV; n = 14) was significantly faster than for nNav1.5 but similar to 
aNav1.5 (i.e. there was no overshoot beyond the aNav1.5 phenotype) (Figure 
4.14B and Table 4.2). The coefficient describing voltage-dependence of Tpeak 
(V0), which was similar for nNav1.5 and aNav1.5, remained unchanged for 
K211D#13 and K211D#17 (Table 4.2). 
ii. At -20 mV, τfast and τslow for K211D#13 were 0.91 ± 0.02 and 5.39 ± 0.14 ms, 
respectively (n = 26) (Figure 4.15AB and Table 4.2). Both time constants were 
significantly smaller for K211D#13 as compared to nNav1.5, whilst τfast but not 
τslow was even smaller than the corresponding value for aNav1.5 (Figure 4.15AB 
and Table 4.2). Similar changes in τfast and τslow were also obtained in the case of 
K211D#17 (n = 14) (Figure 4.15CD and Table 4.2). Percentage amplitudes of τfast 
and τslow (Afast and Aslow, respectively), which were similar for nNav1.5 and 
aNav1.5 at any given voltage, remained unchanged in K211D#13 and K211D#17 
(Figure 4.15EF and Table 4.2). 
It was concluded that Asp211 to Lys211 switch, again, was primarily responsible for the 
slower kinetics of nNav1.5 compared to aNav1.5. 
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4.2.2.4 Steady-state inactivation  
The mean voltage for steady-state half-inactivation (V1/2) was -91.7 ± 0.6 mV for 
K211D#13 (n = 19) and -91.3 ± 0.9 mV for K211D#17 (n = 13), which were statistically 
similar to nNav1.5 (-89.8 ± 0.9 mV) and aNav1.5 (-89.7 ± 1.0 mV) (Figure 4.16AB and 
Table 4.2). The inactivation slope factor k of K211D#13 (-6.2 ± 0.1 mV / e-fold; n = 19) 
and K211D#17 (-6.0 ± 0.2 mV / e-fold; n = 13) were also similar to nNav1.5 (-6.2 ± 0.1 
mV / e-fold) and aNav1.5 (-6.2 ± 0.2 mV / e-fold) (Table 4.2). 
 
4.2.2.5 Recovery from inactivation 
Kinetics of recovery from inactivation was significantly faster in K211D mutants 
compared to nNav1.5 (Figure 4.16CD). In particular, τrecovery of K211D#13 (26.3 ± 1.6 
ms; n = 20) and K211D#17 (25.3 ± 1.2 ms; n = 12), which were similar to aNav1.5 (26.7 
± 1.5 ms), were significantly smaller than for nNav1.5 (35.5 ± 3.2 ms) (Figure 4.16CD 
and Table 4.2). In addition, at multiple recovery periods, the fraction of recovered 
current (It/Ic) was significantly larger in K211D#13 and K211D#17 compared to nNav1.5, 
whereas there was no difference between K211D#13 / K211D#17 and aNav1.5 values 
(Figure 4.16CD). These findings further supported the predominant role played by 
Lys/Asp211 residue in the electrophysiological differences observed between nNav1.5 
and aNav1.5. 
 
4.2.2.6 Summary of effects of K211D mutagenesis 
Mutating the positive Lys211 residue in nNav1.5 back to negative Asp resulted in a 
mutant phenotype similar to that of aNav1.5. Specifically, compared to nNav1.5, 
nNav1.5-K211D channels exhibited (i) hyperpolarized voltage-dependence of 
activation, (ii) faster activation and inactivation kinetics, and (iii) accelerated recovery  
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 325 
 
A      B 
  
 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Lys211 was responsible for the slower recovery from inactivation of nNav1.5  
(A) Availability-voltage relationships fitted with Boltzmann functions for nNav1.5 (n = 38; open 
circles/solid line), aNav1.5 (n = 43; black circles/solid line) and nNav1.5 K211D #13 (n = 19; 
grey circles/dashed line). Recording protocol was as described in Figure 4.7A; data for nNav1.5 
and aNav1.5 were re-plotted from Figure 4.7B. Currents (I) were normalized to the maximum 
current (Imax) recorded following the most hyperpolarized pre-pulse (-140 mV). Average values 
for inactivation V1/2 and k are reported in Table 4.2. (B) As in part A, but with nNav1.5 K211D 
#17 (n = 13; grey circles/dashed line). (C) Recovered current (It /Ic) plotted as a function of 
recovery interval and fitted with single exponential functions for nNav1.5 (n = 31; open 
circles/solid line), aNav1.5 (n = 37; black circles/solid line) and nNav1.5 K211D #13 (n = 20; 
grey circles/dashed line). Recording protocol and data analysis were as described in Figure 4.8; 
data for nNav1.5 and aNav1.5 were re-plotted from Figure 4.8B. Average recovery time 
constants (τrecovery) are reported in Table 4.2. Data were compared using ANOVA / Newman-
Keuls post-hoc analysis. For K211D #13 vs. nNav1.5: (*) P < 0.05, (**) P < 0.01; K211D #13 
and aNav1.5 data were similar (P > 0.05 at each time point). (D) Same as part C, but with 
nNav1.5 K211D #17 (n = 12; grey circles/dashed line). Data are mean ± SEM.  
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from inactivation. These findings strongly suggested that, whilst other amino acids may 
also contribute to the observed functional differences between the two Nav1.5 D1:S3 
variants, the Lys/Asp211 residue, located in the extracellular D1:S3/S4 linker of the 
channel protein, was predominantly responsible for shaping the nNav1.5 vs. aNav1.5 
phenotype. 
 
4.2.3 Endogenous VGSCβ expression in transfectant EBNA-293 cell lines 
Real-time PCR (rt-PCR) was employed to quantify the relative mRNA levels of 
VGSCβ1-4 in nNav1.5, aNav1.5, nNav1.5 K211D#13 and ‘empty-vector’ transfected 
EBNA-293 cell lines. In addition, confocal immunocytochemistry was performed to 
compare the plasma membrane protein level of VGSCβ1, one of the two most abundant 
VGSCβ mRNAs in EBNA-293 cells (see below). These experiments were designed 
ultimately to address one specific question: Could VGSCβ expression contribute to the 
functional differences observed between nNav1.5 vs. aNav1.5 or nNav1.5 vs. nNav1.5 
K211D?  
 
4.2.3.1 VGSCβ1-4 mRNA expression 
mRNAs for all four VGSCβs were present in EBNA-293 cells transfected with 
nNav1.5, aNav1.5, K211D#13 or the empty-vector plasmid (Figure 4.17A). Notably, β3 
and β4 were present in more than one molecular form, with rt-PCR amplifying the full 
length transcripts (353 bp for β3; 459 bp for β4) and exon-skipped variants expressed at 
lower levels (189 bp for exon 2-skipped β3; 305 bp for exon 3-skipped β4) (Figure 
4.17A) (Diss et al., 2008; Chioni et al., 2009). As controls for primer specificity, we 
used MCF-7 and PC-3M cells and confirmed that MCF-7 cells expressed mRNAs for  
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Figure 4.17 VGSCβ1-4 mRNA expression was similar in EBNA-293 cells transfected with 
nNav1.5, aNav1.5, nNav1.5 K211D (#13) or empty vector plasmid  
(A) Typical PCR products for β-actin and VGSCβ1-4. Lanes: 1, nNav1.5-EBNA cells; 2,  
aNav1.5-EBNA cells; 3, nNav1.5 K211D (#13)-EBNA cells; 4, empty vector-EBNA cells; 5, 
no template control (NTC); 6, MCF-7 cells (positive control for VGSCβ1, β2 and β4); 7, PC-3M 
cells (positive control for β3). Numbers at right indicate product sizes in base pairs (bp). For β3  
and β4, shorter bands (189 and 305 bp, respectively) correspond to exon-skipped splice variants 
(Diss et al., 2008). (B) Relative mRNA levels of VGSCβ1-4 (relative to the VGSCβ1 level in 
nNav1.5-EBNA cells) in EBNA-293 cells expressing nNav1.5, aNav1.5, nNav1.5 K211D (#13)  
or empty vector plasmid. Data were analyzed using the 2-∆∆Ct method with β-actin as the  
internal reference gene (n = 4). There was no difference in VGSCβ1-4 mRNA expression  
between the EBNA-293 cells lines tested (ANOVA: P > 0.05). (C) Same as part B but VGSC  
β1-4 levels were expressed relative to the corresponding VGSCβ subtype level in nNav1.5 cells.  
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β1, β2 and β4 but not β3, which was present in PC-3M cells (Diss et al., 2008; Chioni et 
al., 2009).  
In each of the EBNA-293 cell lines tested, the pattern of VGSCβ mRNA 
expression was similar; β1 and β4 were the most abundant β-subunits expressed, β3 was 
present at lower levels, and β2 expression was minimal (i.e. β1 ≈ β4 > β3 >> β2) 
(Figure 4.17B). Importantly, determined using the 2-∆∆Ct method with β-actin as the 
internal reference gene (Livak and Schmittgen, 2001), the mRNA levels of each of the 
four VGSCβ subtypes were similar between EBNA-293 cells lines transfected with 
nNav1.5, aNav1.5, K211D#13 or the empty-vector plasmid (P > 0.05 for each VGSCβ, n 
= 4) (Figure 4.17C). This confirmed that VGSCβ mRNA expression was uniform 
among the EBNA-293 cell lines used in electrophysiological recordings and also 
suggested that functional Nav1.5 expression did not affect VGSCβ mRNA expression in 
EBNA-293 cells (since VGSCβ mRNA levels were similar in empty-vector vs. Nav1.5-
expressing cells).  
 
4.2.3.2 VGSCβ1 plasma membrane protein expression 
Earlier studies have found that co-expression of Nav1.5 with VGSCβ1 in heterologous 
systems results in subtle but significant changes in Nav1.5 functional properties (Nuss 
et al., 1995; Qu et al., 1995; Xiao et al., 2000; Fahmi et al., 2001; Ko et al., 2005). On 
the other hand, in only study to date, co-expression on Nav1.5 with VGSCβ4 resulted in 
virtually no change in Nav1.5 electrophysiology (Yu et al., 2003). Thus, from the two 
most abundant VGSCβs expressed at the mRNA level in EBNA-293 cells (i.e. VGSCβ1 
and β4), we studied the plasma membrane protein level of VGSCβ1 using confocal 
immunocytochemistry. Control labelling experiments in nNav1.5-EBNA and aNav1.5-
EBNA cells confirmed (i) that there was no autofluorescence in EBNA-293 cells and 
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(ii) that there was no / minimal signal from samples incubated without the VGSCβ1 
antibody or with non-specific rabbit IgG (Figure 4.18AB).  
Confocal images from non-permeabilized cells co-labelled with concanavalin A 
and the VGSCβ1 antibody revealed that the plasma membrane VGSCβ1 
immunoreactivity was similar in EBNA-293 cells expressing nNav1.5, aNav1.5, 
K211D#13 or the empty vector plasmid (Figure 4.19AB). The plasma membrane 
VGSCβ1 level was quantified using ‘freeform line profiles’ drawn around the cell edge, 
guided by concanavalin A staining (as described in Section 2.4.1); no difference in 
surface expression of VGSCβ1 protein was found between the four EBNA-293 cell 
lines tested using pooled (P = 0.70, n ≥ 330 cells; Figure 4.20A) or non-pooled analysis 
(P = 0.57, n = 3 repeats; Figure 4.20B).  
 
 4.2.3.3 Summary 
VGSCβ1-4 mRNA levels and the plasma membrane protein level of VGSCβ1 were 
similar in EBNA-293 cell lines transfected with nNav1.5, aNav1.5, K211D#13 or the 
empty vector plasmid. It was thus concluded that VGSCβs were not likely to contribute 
to the electrophysiological differences observed between nNav1.5, aNav1.5 and 
nNav1.5 K211D mutant channels.  
 
4.2.4 Cationic modulation of nNav1.5 and aNav1.5 activity 
Cations can inhibit VGSCs by blocking Na+ conductance and depolarizing channel 
activation voltage; the latter effect is thought to occur mainly due to neutralization (i.e. 
by screening or binding) of negative charges of surface sialic acids and carboxylates, 
altering the electric field sensed by the channel voltage-sensors (Hanck and Sheets, 
1992a; Hille, 2001). The positive charge reversal in D1:S3/S4 voltage-sensing region of  
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Figure 4.18 Controls for immunocytochemistry with VGSCβ1 antibody in EBNA-293 cells 
Typical confocal images from fixed (non-permeabilized) nNav1.5-EBNA (A) and aNav1.5-
EBNA (B) cells: (i) Signal from concanavalin A (conA) plasma membrane marker (green); (ii) 
Signal from autofluorescence or non-specific IgG (red); (iii) Bright field image. Auto-
fluorescence, cells were fixed and mounted without labelling; No primary antibody (Ab), cells 
were labelled with concanavalin A plasma membrane marker (conA) and 5% BSA/PBS was used 
in the primary antibody step; Non-specific IgG, cells were labelled with conA and non-specific 
healthy rabbit IgG fraction (0.02 µg/µl; Dako) was used in the primary antibody step. Scale bar 
(10 µm), applicable to all panels. 
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Figure 4.19 VGSCβ1 immunoreactivity at the plasma membrane was similar in EBNA-293 
cells transfected with nNav1.5, aNav1.5, nNav1.5 K211D (#13) or empty vector plasmid  
(A, B) Two sets of example confocal images from fixed (non-permeabilized) EBNA-293 cells 
transfected with nNav1.5, aNav1.5, nNav1.5 K211D (#13) or empty vector plasmid: (i) Signal 
from concanavalin A (conA) plasma membrane marker (green); (ii) Signal from VGSCβ1 
antibody (red); (iii) Overlay of conA and VGSCβ1 labelling; (iv) Bright field image. Scale bar 
(10 µm), applicable to all panels. 
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Figure 4.20 Plasma membrane VGSCβ1 protein level was similar in EBNA-293 cells 
transfected with nNav1.5, aNav1.5, nNav1.5 K211D (#13) or empty vector plasmid  
(A) Peripheral (plasma-membrane) VGSCβ1 protein level in EBNA-293 cells transfected 
with nNav1.5 (n = 330), aNav1.5 (n = 340), nNav1.5 K211D (#13) (n = 346) or empty vector 
plasmid (n = 345), quantified by ‘freeform line profiles’ drawn around the cell edge guided 
by the concanavalin A labelling. Data (mean ± SEM from three repeat experiments) were 
compared using ANOVA (P = 0.70). (B) Same as part A but data were expressed relative to 
the plasma membrane VGSCβ1 level in nNav1.5-EBNA cells (n = 3; P = 0.57).  
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nNav1.5 could thus result in reduced effects of cations on nNav1.5 vs. aNav1.5, as if the 
negative surface charges were already partly shielded (i.e. by Lys211). To test this 
hypothesis, we next studied the effects of monovalent (H+), divalent (Cd2+) and trivalent 
(Gd3+) cations on nNav1.5 and nNav1.5 activity, in a comparative approach.  
Unless stated otherwise, when comparing a cationic effect on nNav1.5 vs. 
aNav1.5, paired t-tests were used to determine whether the effect was statistically 
significant vs. control, and an unpaired t-test was used to determine whether the effect 
was differential for nNav1.5 vs. aNav1.5.  
 
4.2.4.1 H+ 
4.2.4.1.1 Effects on peak conductance and voltage-dependence of activation 
Acidifying extracellular pH (pHo) (i.e. increasing [H+] in MPS) resulted in rapid 
inhibition of peak INa in both Nav1.5 variants; the time-courses of the effects on 
nNav1.5 and aNav1.5 were similar, and recovery from acid block was complete within 
< 20 seconds (Figure 4.21AB). The dose-response relationships for the effects of pHo on 
INa and Gmax were obtained from I-V relationships recorded at control pHo (pHo 7.25), 
and at five other pH points tested in random order (pHo 8.25, 6.75, 6.25, 5.75 and 5.25) 
(Figure 4.21CD and 4.22). The alkaline shift (pHo 8.25) had no effect on peak INa, Gmax, 
or gating characteristics of Nav1.5 variants (P > 0.05 vs. control for all comparisons, n = 
12-10) (Figure 4.21 CD and Table 4.3). 
Inhibition of INa in acid pHo is illustrated for nNav1.5 and aNav1.5 in Figure 
4.22A. The normalized I-V relationships demonstrated that the inhibition of INa by H+ 
occurred through at least two distinct mechanisms; Gmax was reduced and the voltage-
range over which the channels activated was depolarized (Figure 4.22BC). Control and 
washout data for each acid solution were superimposable, confirming (i) complete  
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Figure 4.21 Time-course of acid block and lack of effect of alkalinisation  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents in pHo 7.25 (control/wash), pHo 6.25 
and pHo 5.25, elicited by 12 ms depolarizing pulses to -20 mV at 0.1 Hz from a holding 
potential of -100 mV. Traces shown were recorded at times (a-e) indicated in part B. Acid 
block was fully reversible upon washout. Dashed horizontal lines indicate zero current. (B) 
Time-course of onset and offset of acid block in nNav1.5 (n = 5; protocol as in part A): a, pHo 
7.25 (control); b, pHo 6.25; c, pHo 7.25 (washout for pHo 6.25); d, pHo 5.25; e, pHo 7.25 
(washout for pHo 5.25). Similar time-course for acid block was also obtained for aNav1.5 (n = 
6; not shown). (C) Alkalinisation (pHo 8.25) had no effect on peak current amplitude in 
Nav1.5 variants. Traces shown are typical whole-cell nNav1.5 currents, before and after 
exposure to pHo 8.25, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding 
potential of -100 mV; interpulse duration was 2 s. (D) Normalized current-voltage (I-V) 
relationships in pHo 7.25 (control and washout) and pHo 8.25, showing that alkalinization did 
not alter voltage-dependence of activation in nNav1.5 (n = 12) or aNav1.5 (n = 10). Average 
values of fitted parameters (V1/2 and k) are reported in Table 4.3. Data are mean ± SEM. 
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Figure 4.22 Acid pHo suppressed peak Na+ conductance similarly in Nav1.5 variants but 
induced larger depolarization of activation voltage-dependence in aNav1.5 vs. nNav1.5  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, recorded in various pHo (pHo 7.25, 6.75, 
6.25, 5.75, 5.25) using 60 ms depolarizing pulses to between -80 mV and +45 mV from a holding 
potential of -100 mV; interpulse duration was 2 s. (B, C) Normalized I-V relationships for nNav1.5 
(B) and aNav1.5 (C) in control/washout pHo 7.25 and acid pHo 6.75-5.25 (n ≥ 10). Data were 
normalized relative to the maximal current recorded in control pHo (I/ImaxpH7.25). Insets, 
corresponding normalized conductance transforms (G/GmaxpH7.25). Note that all pre- and post-
treatment control data (pHo 7.25) were superimposable, indicating (i) full recovery from acidic 
effects and (ii) consistency of recordings / minimal time-dependent shifts. (D, E) Normalized G-V 
relationships (G/Gmax) in each pHo point tested, fitted with Boltzmann functions (solid red lines) for 
nNav1.5 (D) and aNav1.5 (E) (n ≥ 10). Average values of fitted parameters (V1/2 and k) are reported 
in Table 4.3. Data are mean ± SEM. Some error bars are smaller than symbols. 
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  Table 4.3 Effects of H+ on Nav1.5 D1:S3 splice variants 
 
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Unpaired t-tests were used to assess whether effects of H+ were differential 
for nNav1.5 vs. aNav1.5. Significance: (*) P < 0.05, (**) P < 0.01 (for n numbers, see text / figure legends). Control and wash data (pHo 7.25) are 
matched with pHo 6.25 data. Data are presented as mean ± SEM. 
   
Parameter Control pH 8.25 pHo 6.75 pHo 6.25 pHo 5.75 pHo 5.25 Wash  
        
Relative Gmax (%) 100.0 ± 0.0 100.0 ± 0.0 
99.3 ± 5.6 
100.2 ± 3.7 
87.8 ± 2.5 
85.9 ± 2.8 
69.5 ± 3.2 
70.3 ± 1.5 
45.3 ± 2.6 
42.7 ± 1.4 
21.4 ± 1.3 
20.2 ± 1.5 
99.3 ± 4.2 
104.9 ± 2.3 
Vthres (mV) -55.4 ± 0.9 
-60.8 ± 0.8 
-57.8 ± 0.9 
-62.5 ± 0.9 
-53.8 ± 1.0 
-59.8 ± 1.1 
-49.4 ± 1.2 
-55.8 ± 0.8 
-43.0 ± 1.8 
-47.0 ± 1.2 
-33.1 ± 2.0 
-35.0 ± 1.2 
-58.2 ± 1.0 
-62.3 ± 0.7 
Vpeak (mV) -7.3 ± 1.6 
-22.5 ± 1.9 
-10.0 ± 1.9 
-25 ± 1.8 
-6.5 ± 2.6 
-21.0 ± 2.4 
-1.9 ± 1.8 
-15.8 ± 2.0 
5.3 ± 3.0 
-2.7 ± 1.7 ** 
16.9 ± 2.5 
11.0 ± 2.9 * 
-9.1 ± 2.0 
-23.6 ± 1.7 
Activation V1/2  (mV) -27.3 ± 1.4 
-39.2 ± 1.2 
-30.7 ± 1.3 
-42.1 ± 0.8 
-26.0 ± 2.0 
-39.3 ± 1.6 
-21.7 ± 1.7 
-32.3 ± 1.3 
-15.1 ± 2.8 
-22.9 ± 1.5 ** 
-3.3 ± 2.5 
-7.5 ± 2.0 * 
-29.6 ± 1.6 
-41.4 ± 1.1 
Activation k  7.5 ± 0.4 5.2 ± 0.3 
7.4 ± 0.5 
5.1 ± 0.4 
8.3 ± 0.4 
5.2 ± 0.4 
8.5 ± 0.4 
6.2 ± 0.3 
9.5 ± 0.4 
7.6 ± 0.3 ** 
10.0 ± 0.6 
10.1 ± 0.6 ** 
8.0 ± 0.3 
5.0 ± 0.2 
Inactivation V1/2 (mV) -89.0 ± 1.6 
-91.0 ± 1.1 
- 
- 
- 
- 
-84.3 ± 1.3 
-86.1 ± 1.2 
- 
- 
-74.1 ± 1.4 
-77.1 ± 1.1 
-92.1 ± 1.5 
-93.0 ± 1.4 
Inactivation k -6.1 ± 0.2 
-5.8 ± 0.2 
- 
- 
- 
- 
-6.2 ± 0.2 
-6.0 ± 0.2 
- 
- 
-5.8 ± 0.3 
-6.2 ± 0.7 
-6.4 ± 0.2 
-6.1 ± 0.2 
V0 (mV) 19.8 ± 1.0 20.7 ± 1.6 
19.8 ± 1.6 
24.2 ± 2.4 
24.9 ± 2.1 
22.3 ± 1.0 
24.3 ± 2.1 
20.9 ± 1.7 
23.1 ± 1.8 
18.8 ± 1.1 
32.4 ± 9.4 
30.4 ± 8.0 
21.2 ± 1.9 
25.2 ± 1.4 
Tpeak at 0 mV (ms) 0.77 ± 0.03 0.58 ± 0.02 
0.71 ± 0.01 
0.55 ± 0.01 
0.79 ± 0.04 
0.61 ± 0.02 
0.92 ± 0.03 
0.70 ± 0.02 
1.10 ± 0.07 
0.87 ± 0.03 
1.44 ± 0.08 
1.16 ± 0.04 
0.69 ± 0.02 
0.57 ± 0.02 
τfast at 0 mV (ms) 0.91 ± 0.06 0.64 ± 0.02 
0.84 ± 0.02 
0.61 ± 0.04 
0.97 ± 0.08 
0.68 ± 0.03 
1.17 ± 0.10 
0.85 ± 0.07 
1.42 ± 0.14 
1.06 ± 0.07 
2.09 ± 0.25 
1.42 ± 0.06 
0.85 ± 0.06 
0.62 ± 0.03 
τslow at 0 mV (ms) 5.51 ± 0.24 5.10 ± 0.24 
5.14 ± 0.63 
5.07 ± 0.45 
6.41 ± 0.32 
5.60 ± 0.36 
7.28 ± 0.45 
6.38 ± 0.44 
8.18 ± 0.51 
8.53 ± 0.79 
10.31 ± 1.16 
12.68 ± 0.97 
5.80 ± 0.30 
5.92 ± 0.56 
τrecovery (ms) 22.9 ± 1.2 21.7 ± 1.1 
- 
- 
- 
- 
16.4 ± 1.1 
16.7 ± 0.8 
- 
- 
- 
- 
24.1 ± 1.7 
24.4 ± 1.2 
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recovery from acidic effects and (ii) minimal background time-dependent shifts in 
channel gating (Figure 4.22BC and Table 4.3). Gmax was suppressed to a statistically 
similar extent in nNav1.5 and aNav1.5 at each of the four acid pHo’s tested (Figure 
4.22BC insets and Table 4.3); the half-maximal conductance (pKa) values, determined 
from Hill equation fits to dose-response relationships for Gmax block, were 5.90 ± 0.14 
and 5.91 ± 0.14 for nNav1.5 and aNav1.5, respectively (P = 0.95, n ≥ 10) (Figure 4.23A 
and Table 4.4). Notably, the acid asymptotes (i.e. minimum asymptotes) of both Hill fits 
were statistically similar to zero (P > 0.05, n ≥ 10) (Table 4.4), i.e. there was no pHo-
independent fraction of Gmax in Nav1.5 variants, consistent with earlier findings on 
aNav1.5-expressing HEK-293 cells (Khan et al., 2006).  
To isolate the effects of H+ on voltage-dependence of activation, peak 
conductances were normalized to Gmax within each pHo, and data were fit with the 
Boltzmann equation on a cell-by-cell basis (Figure 4.22DE). With increasing H+ 
concentration, progressive depolarization of activation V1/2 and increase in slope factor k 
were observed; for both Nav1.5 variants, these effects were statistically significant for 
pHo ≤ 6.25 (P < 0.05 vs. control, n ≥ 10) (Figure 4.22DE and Table 4.3). Importantly, 
the increase in activation k was significantly smaller for nNav1.5 vs. aNav1.5 at pHo 
5.75 and 5.25 (P < 0.01, n ≥ 10) (Table 4.3). Similarly, acid-induced positive shifts in 
activation V1/2 were also significantly smaller for nNav1.5 vs. aNav1.5; there was 12.5 ± 
1.3 vs. 16.8 ± 0.7 mV shift at pHo 5.75 (P < 0.01, n = 10-11) and 25.1 ± 1.3 vs. 32.6 ± 
2.3 mV shift at pHo 5.25 (P < 0.05, n = 12-10) for nNav1.5 vs. aNav1.5, respectively 
(Figure 4.22DE and Table 4.3). Consistently, Hill equation fits to dose-response 
relationships for V1/2 shifts yielded ~ 14 mV larger maximum asymptote (i.e. maximum 
V1/2 shift) for aNav1.5 (54.69 ± 3.08 mV) compared to nNav1.5 (41.01 ± 4.75 mV; P < 
0.05, n ≥ 10) (Figure 4.23A and Table 4.4). In contrast, pKa values for V1/2 shifts were  
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B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Acid pHo induced larger depolarization of activation voltage-dependence in 
aNav1.5 vs. nNav1.5  
(A) Dose-response relationships (pHo 5.25-8.25) for H+ block of Gmax (squares) and H+-induced 
shift of activation V1/2 (circles) in nNav1.5 (open symbols) and aNav1.5 (black symbols). Data 
were from recordings described in Figure 4.21CD and 4.22. Gmax and activation V1/2 at each pHo 
were normalized / referenced to the corresponding control value recorded at pHo 7.25 (n ≥ 10). 
Dashed (nNav1.5) and solid (aNav1.5) lines represent Hill equation fits to Gmax and ∆V1/2 data. 
Values of fitted parameters are reported in Table 4.4. Unpaired t-tests were used to compare the 
effects of H+ on Gmax and V1/2 of nNav1.5 vs. aNav1.5 at each pHo. Significance: (*) P < 0.05, 
(**) P < 0.01 (for ∆V1/2). (B) Bar-diagram illustrating voltage-dependence of H+ block at pHo 
6.25; peak current block was plotted as a function of test potential for nNav1.5 (n = 13; grey 
bars) and aNav1.5 (n = 12; black bars). Data are presented as mean ± SEM. Some error bars are 
smaller than symbols. 
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Table 4.4 Summary of cationic effects on Nav1.5 D1:S3 splice variants 
 
      
 
1
 For each parameter, the fitted values obtained from the Hill equation fits are reported in red for nNav1.5 and black for aNav1.5. Data are presented as 
mean ± SEM. Unpaired t-tests were used to compare the cationic effects on nNav1.5 vs. aNav1.5. Significance: (*) P < 0.05, (**) P < 0.01.  
2
 pKa values (pH units) and IC50s (µM) apply to H+ and Cd2+/Gd3+ data, respectively.  
3
 The maximum asymptote for both fits was restricted at the maximal effect recorded at the most acidic pHo used (i.e. pHo 5.25). For these fixed values, 
SEM does not represent the error of the fit but the standard error obtained from raw data.  
 
Abbreviations: pKa; pHo giving half-maximum effect; IC50; concentration giving half-maximum block; Gmax, maximal Na+ conductance; V1/2, half-
activation voltage; Tpeak, time to peak; τfast, fast inactivation time constant; INa, Na+ current; R2, the correlation coefficient of the mean-least-squares fit.  
 
 
Cation Parameter1 n pKa / IC502 Maximum asymptote Minimum asymptote Hill coefficient (nH) R2 
        
H+ Relative Gmax (%) ≥ 10 
≥ 10 
 
5.90 ± 0.14 
5.91 ± 0.14 
101.69 ± 2.85 
102.07 ± 3.01 
2.73 ± 13.25 
1.01 ± 13.60 
0.96 ± 0.20 
0.95 ± 0.20 
0.99 
0.99 
 ∆ Activation V1/2 (mV) ≥ 10 
≥ 10 
 
5.46 ± 0.11 
5.43 ± 0.05 
41.01 ± 4.75  
54.69 ± 3.08 * 
-0.95 ± 0.59 
-1.07 ± 0.36 
-1.04 ± 0.22 
-1.01 ± 0.14 
0.99 
0.99 
 ∆ Tpeak at 0 mV (ms)3 ≥ 10 
≥ 10 
 
5.85 ± 0.10 
5.83 ± 0.07 
0.72 ± 0.07 
0.58 ± 0.03 
-0.00 ± 0.04 
-0.00 ± 0.03 
 
-1.05 ± 0.04 
-1.02 ± 0.06 
0.97 
0.98 
 ∆ τfast at 0 mV (ms) ≥ 10 
≥ 10 
 
5.55 ± 0.10 
5.48 ± 0.03 
1.38 ± 0.15 
1.48 ± 0.16 
-0.01 ± 0.01 
-0.00 ± 0.02 
-0.99 ± 0.10 
-0.98 ± 0.09 
1.00 
0.98 
Cd2+ Relative Gmax (%) ≥ 11 
≥ 11 
132.89 ± 13.01 
132.54 ± 17.81 
100.75 ± 3.14 
98.11 ± 4.23 
4.13 ± 4.36 
2.11 ± 6.22 
1.30 ± 0.17 
1.10 ± 0.19 
0.99 
0.99 
Gd3+ Relative INa at -20 mV ≥ 7 
≥ 8 
48.69 ± 4.93 
58.25 ± 9.10 
1.03 ± 0.03 
1.03 ± 0.04 
0.00 ± 0.03 
-0.01 ± 0.04 
1.05 ± 0.10 
0.92 ± 0.13 
0.99 
0.99 
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similar for nNav1.5 (5.46 ± 0.11) and aNav1.5 (5.43 ± 0.05; P = 0.84, n ≥ 10), possibly 
due to the larger maximal shift estimated by the aNav1.5 vs. nNav1.5 fit (Figure 4.23A 
and Table 4.4).  
Threshold voltage for activation (Vthres) and voltage at current peak (Vpeak), 
determined from the I-V relationships, were also depolarized in acid solutions (Figure 
4.22BC and Table 4.3). Shifts in Vthres were statistically significant for pHo ≤ 6.25 (P < 
0.05 vs. control, n ≥ 10), and were similar for nNav1.5 vs. aNav1.5 at all pHo values 
tested (Table 4.3). Shifts in Vpeak were also statistically significant for pHo ≤ 6.25 (P < 
0.05 vs. control, n ≥ 10); however, similar to the shifts in activation V1/2, depolarization 
of Vpeak was larger for aNav1.5 vs. nNav1.5 at pHo 5.75 and 5.25 (Figure 4.22BC and 
Table 4.3). For instance, at pHo 5.75, Vpeak of aNav1.5 was depolarized by 19.5 ± 1.6 
mV, whereas there was ~ 6 mV smaller shift Vpeak of nNav1.5 (13.3 ± 1.3 mV; P < 0.01, 
n = 10-11) (Table 4.3). This difference was even more pronounced at pHo 5.25, where 
there was ~ 8 mV larger shift in Vpeak of aNav1.5 vs. nNav1.5 (P < 0.05, n = 12-10) 
(Table 4.3).  
Finally, to investigate whether acid block was voltage-dependent, INa at pHo 6.25 
was normalized to control INa at corresponding voltages and block levels were plotted as 
a function of test voltage (Figure 4.23B). Inhibition of INa was significantly greater at 
negative potentials near Vthres for both nNav1.5 and aNav1.5 (n = 13-12), e.g. for 
aNav1.5, peak current block was 67% at -50 mV but only 29% at 0 mV (Figure 4.23B). 
This suggested that proton block of Nav1.5 INa was voltage-dependent; however, acid-
induced depolarization of activation gating (in particular Vthres) could have significantly 
contributed to this effect, i.e. proton block of Na+ conductance (pore-block) may not be 
voltage-dependent per se.  
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4.2.4.1.2 Effects on kinetics of activation and inactivation 
Nav1.5 kinetics were significantly slower in acid pHo, as illustrated for nNav1.5 in 
Figure 4.24A. For both nNav1.5 and aNav1.5, pHo-dependent slowing of time to peak 
(Tpeak) was significant at pHo ≤ 6.25 (Figure 4.24ABC and Table 4.3), whereas voltage-
dependence of Tpeak (V0) was not altered by acidosis (P > 0.05 vs. control, n ≥ 10) (Table 
4.3). Acidic effects on Tpeak were similar in Nav1.5 variants (Figure 4.24 part B vs. part 
C); Hill equation fits to shifts in Tpeak at 0 mV produced comparable pKa values of 5.85 
± 0.10 and 5.83 ± 0.07 for nNav1.5 and aNav1.5, respectively (P = 0.85, n ≥ 10) (Figure 
4.24D and Table 4.4). As regards inactivation kinetics, double-exponential fits to INa 
decays yielded significantly slower τfast and τslow values at pHo ≤ 6.25 (Figure 4.24AEF 
and Table 4.3). However, as for Tpeak, acid-induced slowing of inactivation kinetics was 
comparable for nNav1.5 and aNav1.5 (Figure 4.24 part E vs. part F), e.g. pKa for shifts 
in τfast at 0 mV was 5.55 ± 0.10 for nNav1.5 and 5.48 ± 0.03 for aNav1.5 (P = 0.51, n ≥ 
10) (Figure 4.24G and Table 4.4).  
Notably, acid-induced shifts in parameters describing kinetics of activation or 
inactivation did not saturate in the pHo range tested and this possibly interfered with 
accurate determination of pKa for these parameters (Figure 4.24DG and Table 4.4).  
 
4.2.4.1.3 Effects on steady-state inactivation and recovery from inactivation 
Acid pHo depolarized inactivation V1/2 similarly in Nav1.5 variants, whereas the 
inactivation slope factor (k) was unaffected (Figure 4.25ACE and Table 4.3).In 
particular, pHo 6.25 and 5.25 shifted inactivation V1/2 positively by 4.8 ± 0.6 and 14.9 ± 
0.7 mV for nNav1.5, and by 4.9 ± 0.4 and 13.9 ± 0.7 mV for aNav1.5, respectively (P < 
0.05 vs. control for all, P = 0.90 and 0.33 for nNav1.5 vs. aNav1.5, n ≥ 10) (Table 4.3).  
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  For parts BCEF
 Control
 pH 6.75
 pH 6.75 wash
 Control
 pH 6.25
 pH 6.25 wash
 Control
 pH 5.75 
 pH 5.75 wash
 Control
 pH 5.25
 pH 5.25 wash
pHo 5.75: τfast = 1.48 ms 
                  τslow = 8.97 ms 
  
1 nA 
1 ms 
pHo 6.25: τfast = 1.25 ms 
                  τslow = 6.80 ms 
  
pHo 7.25: τfast = 0.93 ms 
                  τslow = 5.56 ms 
  
pHo 5.75: Tpeak = 1.28 ms  
pHo 6.25: Tpeak = 0.92 ms  
pHo 7.25: Tpeak = 0.76 ms 
 
A  (i)              (ii) 
 
 
 
 
B     C    D 
 
 
 
 
 
 
 
E     F    G 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.24 Acid-induced slowing of gating kinetics was similar in nNav1.5 and aNav1.5 
(A) (i) Superimposed currents recorded at 0 mV from a nNav1.5-EBNA cell, in control pHo 7.25, 
pHo 6.25 and pHo 5.75, illustrating H+-induced slowing of inactivation kinetics (pulse protocol as 
in Figure 4.22). Fast (τfast) and slow (τslow) time constants of inactivation were obtained from 
double exponential fits to normalized current decays. (ii) Traces in part (i) were normalized to 
peak amplitude to demonstrate H+-induced slowing of time to peak (Tpeak). (B, C) Tpeak in pHo 
5.25-7.25 as a function of test potential and fitted to single exponential functions for nNav1.5 (B) 
and aNav1.5 (C). (D) Dose-response relationships for acid-induced slowing of Tpeak (at 0 mV) in 
Nav1.5 variants; solid lines represent Hill equation fits to data (with maxima restricted at the 
maximal effect occurring in pHo 5.25). (E, F) τfast and τslow, determined from double exponential 
fits to normalized Na+ current decays in pHo 5.25-7.25, plotted as a function of test potential for 
nNav1.5 (E) and aNav1.5 (F). Data points are connected with straight lines for clarity. (G) Dose-
response relationships for acid-induced slowing of τfast (at 0 mV) in Nav1.5 variants; solid lines 
represent Hill equation fits to data. In parts D and G, changes in nNav1.5 and aNav1.5 kinetics 
were similar at each pHo studied (unpaired t-tests: P > 0.05); values of fitted parameters are 
reported in Table 4.4. For all parts, data (mean ± SEM) were from recordings described in Figure 
4.22 (n ≥ 10). Some error bars are smaller than symbols. 
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Figure 4.25 Acid pHo depolarized steady-state inactivation and accelerated recovery from 
inactivation similarly in nNav1.5 and aNav1.5 
(A) Typical whole-cell nNav1.5 currents, used to assess voltage-dependence of steady-state 
inactivation, in pHo 7.25 (control) and pHo 6.25. Pulse protocol was as described in Figure 4.7A. 
(B) Superimposed whole-cell Na+ currents from nNav1.5, used to assess kinetics of recovery from 
inactivation, in pHo 7.25 (i) and pHo 6.25 (ii). Pulse protocol was as described in Figure 4.8A; 
arrows indicate acid-induced acceleration of channel recovery. (C, E) Availability-voltage 
relationships in pHo 7.25 (control/wash), pHo 6.25 and pHo 5.25 fitted with Boltzmann functions 
for nNav1.5 (C) and aNav1.5 (E) (n ≥ 10). Average values for inactivation V1/2 and k are reported 
in Table 4.3. (D, F) Recovered current (It /Ic) in pHo 7.25 (control/wash) and pHo 6.25, plotted as a 
function of recovery interval and fitted with single exponential functions for nNav1.5 (D; n = 19) 
and aNav1.5 (F; n = 18). Significance (paired t-tests vs. control): (*) P < 0.05, (**) P < 0.01. 
Average recovery time constants (τrecovery) are reported in Table 4.3. Data are mean ± SEM. 
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 Acid-induced acceleration of recovery from inactivation was also similar for 
Nav1.5 D1:S3 variants (Figure 4.25BDF and Table 4.3). For nNav1.5 and aNav1.5, 
τrecovery values were respectively 22.9 ± 1.2 and 21.7 ± 1.1 ms in control and 16.4 ± 1.1 
and 16.7 ± 0.8 ms in pHo 6.25 (P < 0.05 vs. control for both, P = 0.22 comparing the 
effects in nNav1.5 vs. aNav1.5, n = 19-18) (Table 4.3). 
 
4.2.4.1.4 Summary of effects of H+ 
Acid pHo inhibited peak INa by reducing Gmax and depolarizing the voltage-range of 
channel activation. Block of Gmax was similar in the Nav1.5 variants, whereas 
depolarization of activation (e.g. Vpeak and V1/2) was significantly greater for aNav1.5 vs. 
nNav1.5 at highly acidic pHo 5.75 and 5.25. This was consistent with the presence of an 
extra positive charge (i.e. Lys211) in the extracellular S3/S4 region of nNav1.5. 
Extracellular acidosis also (i) slowed activation and inactivation kinetics, (ii) 
depolarized steady-state inactivation (without affecting k) and (iii) accelerated recovery 
from inactivation; however, these effects were similar for nNav1.5 vs. aNav1.5.  
 
4.2.4.2 Cd2+ 
4.2.4.2.1 Effects on peak conductance and voltage-dependence of activation 
As with H+, Cd2+ block of INa reached steady-state within 10-20 s and recovery from 
block upon washout was complete within < 40 s at all concentrations tested (Figure 
4.26). I-V and G-V relationships described in Figure 4.27A-C revealed that Cd2+ was 
equally potent in blocking Gmax of nNav1.5 and aNav1.5 (Table 4.5), with respective 
half-inhibitory concentrations (IC50s) of 132.89 ± 13.01 µM and 132.54 ± 17.81 µM (P 
= 0.99, n ≥ 11) (Figure 4.28A and Table 4.4).  
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Figure 4.26 Time course of Cd2+ block in Nav1.5 variants 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 100-500 µM Cd2+ 
application, elicited by 12 ms depolarizing pulses to -20 mV at 0.1 Hz; holding potential was -
100 mV. Traces shown were recorded at times (a-e) indicated in parts B and C. Cd2+ block was 
fully reversible upon washout. Dashed horizontal lines indicate zero current. (B) Time-course 
of onset and offset of Cd2+ block in nNav1.5 channels (n = 6; protocol as in part A): a, control; 
b, 100 µM Cd2+; c, washout (for 100 µM Cd2+); d, 500 µM Cd2+; e, washout (for 500 µM 
Cd2+). (C) Same as part B but for aNav1.5 (n = 5). Data are presented as mean ± SEM. 
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Figure 4.27 Effect of Cd2+ on peak Na+ conductance and voltage-dependence of activation was 
similar in Nav1.5 variants  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, in control and 50-500 µM Cd2+, elicited by 60 
ms depolarizing pulses to between -80 mV and +45 mV from a holding potential of -100 mV; 
interpulse duration was 2 s. (B, C) Normalized I-V relationships for nNav1.5 (B) and aNav1.5 
(C) in control/washout and 50-500 µM Cd2+ (n ≥ 11). Data were normalized relative to the 
maximal control current (I/ImaxControl). Insets, corresponding normalized conductance 
transforms (G/GmaxControl). All control and washout data were included to show full recovery 
(i.e. within 10% of control) from effects induced by Cd2+. (D, E) Normalized G-V relationships 
(G/Gmax), in control/washout and 50-500 µM Cd2+, fitted with Boltzmann functions (solid red 
lines) for nNav1.5 (D) and aNav1.5 (E) (n ≥ 11). Average values of fitted parameters (V1/2 and k) are 
reported in Table 4.5. Data are mean ± SEM. Some error bars are smaller than symbols. 
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Table 4.5 Effects of Cd2+ on Nav1.5 D1:S3 splice variants 
 
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Unpaired t-tests were used to assess whether effects of Cd2+ were 
differential for nNav1.5 vs. aNav1.5 (P > 0.05 for all comparisons). For n numbers, see text / figure legends. Control and wash data are matched with 
250 µM Cd2+ data. Data are presented as mean ± SEM. 
   
Parameter Control 50 µM 100 µM  250 µM 500 µM Wash  
       
Relative Gmax (%) 100.0 ± 0.0 100.0 ± 0.0 
81.1 ± 3.6 
74.8 ± 3.2 
59.2 ± 1.2 
55.7 ± 2.2 
35.1 ± 2.0 
35.8 ± 1.4 
18.2 ± 0.9 
18.9 ± 1.1 
104.4 ± 4.7 
98.1 ± 6.4 
Vthres (mV) -55.4 ± 0.7 
-60.0 ± 1.0 
-53.6 ± 0.9 
-57.9 ± 0.9 
-53.8 ± 0.9 
-59.1 ± 1.4 
-48.8 ± 0.8 
-54.0 ± 1.2 
-44.8 ± 0.9 
-49.4 ± 1.4 
-56.3 ± 0.8 
-61.4 ± 1.3 
Vpeak (mV) -5.6 ± 1.6 
-18.1 ± 1.3 
 -3.2 ± 2.1 
-18.1 ± 1.3 
-5.8 ± 1.6 
-16.8 ± 1.4 
-0.4 ± 1.7 
-12.3 ± 0.9 
2.9 ± 2.5 
-5.4 ± 1.3 
-7.0 ± 2.4 
-21.1 ± 1.8 
Activation V1/2  (mV) -25.8 ± 1.3 
-37.3 ± 1.1 
-24.3 ± 1.9 
-34.9 ± 1.1 
-24.9 ± 1.5 
-37.4 ± 1.2 
-20.6 ± 1.8 
-30.9 ± 1.0 
-18.7 ± 2.0 
-27.2 ± 1.1 
-26.8 ± 1.7 
-39.8 ± 1.2 
Activation k  7.8 ± 0.3 6.1 ± 0.3 
8.1 ± 0.2 
6.8 ± 0.4 
8.1 ± 0.4 
6.7 ± 0.2 
8.9 ± 0.4 
7.9 ± 0.3 
9.3 ± 0.3 
8.6 ± 0.5 
7.5 ± 0.5 
6.5 ± 0.4 
Inactivation V1/2 (mV) -91.5 ± 1.5 
-90.5 ± 0.8 
- 
- 
- 
- 
-90.2 ± 1.2 
-91.2 ± 0.5 
- 
- 
-91.8 ± 2.0 
-90.8 ± 0.8 
Inactivation k -5.9 ± 0.2 
-6.3 ± 0.2 
- 
- 
- 
- 
-5.6 ± 0.2 
-6.2 ± 0.2 
- 
- 
-6.1 ± 0.3 
-6.2 ± 0.1 
V0 (mV) 21.2 ± 0.8 18.8 ± 1.7 
22.9 ± 3.7 
18.5 ± 3.8 
17.0 ± 1.6 
19.1 ± 1.9 
23.0 ± 3.0 
21.5 ± 4.0 
23.1 ± 5.0 
18.0 ± 3.9 
18.1 ± 0.7 
19.2 ± 1.7 
Tpeak at 0 mV (ms) 0.63 ± 0.04 0.51 ± 0.02 
0.65 ± 0.04 
0.55 ± 0.01 
0.67 ± 0.04 
0.48 ± 0.03 
0.69 ± 0.06 
0.56 ± 0.03 
0.72 ± 0.06 
0.58 ± 0.02 
0.65 ± 0.04 
0.49 ± 0.03 
τfast at 0 mV (ms) 0.72 ± 0.05 0.63 ± 0.02 
- 
- 
- 
- 
0.77 ± 0.02 
0.69 ± 0.03 
- 
- 
0.76 ± 0.04 
0.68 ± 0.02 
τslow at 0 mV (ms) 5.79 ± 0.35 5.21 ± 0.23 
- 
- 
- 
- 
6.06 ± 0.40 
5.79 ± 0.38 
- 
- 
5.88 ± 0.27 
5.16 ± 0.21 
τrecovery (ms) 21.3 ± 1.2 22.4 ± 0.9 
- 
- 
- 
- 
23.8 ± 1.3 
26.3 ± 1.3 
- 
- 
22.8 ± 1.8 
24.3 ± 1.1 
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Figure 4.28 Cd2+ blocked peak Na+ conductance similarly in nNav1.5 and aNav1.5  
(A) Dose-response relationships for Cd2+ block of maximal Na+ conductance (Gmax) in nNav1.5 
(open circles) and aNav1.5 (black circles). Data were from recordings described in Figure 4.27. 
Gmax after Cd2+ application was normalized relative to the corresponding control value (n ≥ 11). 
Dashed (nNav1.5) and solid (aNav1.5) lines represent Hill equation fits; values of fitted 
parameters are reported in Table 4.4 (IC50 values are reported in parentheses). At each 
concentration tested, Cd2+ block of Gmax was similar in nNav1.5 vs. aNav1.5 (unpaired t-tests: P 
> 0.05). (B) Bar-diagram illustrating voltage-independence of Cd2+ block at 100 µM (data from 
Figure 4.27); peak current block was plotted as a function of voltage for nNav1.5 (n = 12; grey 
bars) and aNav1.5 (n = 11; black bars). Data are presented as mean ± SEM. 
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As regards voltage-dependence of activation, Vthres, Vpeak and activation V1/2 were 
significantly depolarized, whilst activation k was significantly increased at [Cd2+] ≥ 250 
µM for both Nav1.5 variants (P < 0.05 vs. control, n ≥ 11) (Figure 4.27B-E and Table 
4.5). However, for all activation parameters described (Vthres, Vpeak, V1/2 and k), Cd2+ 
produced statistically similar effects in nNav1.5 and aNav1.5 in the concentration range 
tested (P > 0.05 for all comparisons, n ≥ 11) (Figure 4.27B-E and Table 4.5). The Cd2+-
induced effects on activating gating were fully reversible upon washout in both Nav1.5 
variants (Figure 4.27 and Table 4.5).   
Unlike H+, Cd2+ block of INa was not voltage-dependent (Figure 4.28B). This 
was consistent with Cd2+-induced depolarization of activation gating being considerably 
less pronounced than the corresponding effect of H+ (Figure 4.27DE vs. Figure 4.22DE).
 
For example, 500 µM Cd2+, which reduced Gmax by ~ 80%, depolarized activation V1/2 
by only 7.7 ± 1.3 mV in nNav1.5 and 10.3 ± 0.61 mV in aNav1.5 (P < 0.01 vs. control 
for both, P = 0.09 for nNav1.5 vs. aNav1.5, n = 12-12) (Figure 4.27DE and Table 4.5). 
In contrast, as noted earlier, pHo 5.25, which produced a similar (~ 80%) block of Gmax, 
induced a much greater shift in activation V1/2 of nNav1.5 and aNav1.5, by 25.1 ± 1.3 
and 32.6 ± 2.3 mV, respectively (Figure 4.22DE).  
 
4.2.4.2.2 Effects on kinetics of activation and inactivation 
In contrast to H+, Cd2+ had no/minimal effect on Tpeak of either Nav1.5 variant in the 
voltage-range tested (for all Cd2+ concentrations: P > 0.05 vs. control, n ≥ 11) (Figure 
4.29AB and Table 4.5). Inactivation τfast and τslow of Nav1.5 variants were also 
unaffected by Cd2+ (250 µM) (P > 0.05 vs. control, n = 12-13) (Figure 4.29CD and 
Table 4.5). 
 
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 350 
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Figure 4.29 Cd2+ did not affect activation or inactivation kinetics in Nav1.5 variants  
(A, B) Time to peak (Tpeak), plotted as a function of test potential and fitted to single exponential 
functions in control and 50-500 µM Cd2+, for nNav1.5 (A) and aNav1.5 (B) (n ≥ 11). Values of 
fitted parameters (V0) are reported in Table 4.5. Data were from I-V recordings described in 
Figure 4.27. (C, D) Inactivation τfast and τslow, determined from double exponential fits to 
normalized current decays in control and 250 µM Cd2+, plotted as a function of test potential for 
nNav1.5 (C; n = 12) and aNav1.5 (D; n = 13). Data were from I-V recordings described in Figure 
4.27. Data points are connected with straight lines for clarity. For both Nav1.5 variants, Cd2+ had 
no significant effect on Tpeak, τfast or τslow in the voltage range tested (paired t-tests vs. control: P > 
0.05). Data are presented as mean ± SEM; some error bars are smaller than symbols. 
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4.2.4.2.3 Effects on steady-state inactivation and recovery from inactivation 
Steady-state inactivation V1/2 and k were unaffected by 250 µM Cd2+ in either Nav1.5 
variant (P > 0.05 vs. control, n = 10-9) (Figure 4.30AB and Table 4.5). On the other 
hand, recovery from inactivation, was slightly and similarly slowed by 250 µM Cd2+ in 
nNav1.5 and aNav1.5; single exponential fits to recovery time-courses yielded average 
τrecovery values of 21.3 ± 1.2 and 22.4 ± 0.9 ms in control and 23.8 ± 1.3 and 26.3 ± 1.3 
ms in 250 µM Cd2+ for nNav1.5 and aNav1.5, respectively (P < 0.05 vs. control for 
both, P = 0.36 for comparing the effect for nNav1.5 vs. aNav1.5, n = 14-13) (Figure 
4.30CD and Table 4.5).  
 
4.2.4.2.4 Summary of effects of Cd2+ 
Similar to H+, Cd2+ inhibited Nav1.5 currents by reducing Gmax and depolarizing the 
voltage-range of channel activation, despite the latter effect was much smaller as 
compared to corresponding acidic effect. Cd2+ (i) did not modify kinetics of activation 
or inactivation, (ii) had no effect on steady-state inactivation and (iii) minimally slowed 
recovery from inactivation in Nav1.5 variants. The effects of Cd2+ on all recorded 
parameters were similar for nNav1.5 vs. aNav1.5. 
 
4.2.4.3 Gd3+ 
4.2.4.3.1 Dose-dependence of block and effects on voltage-dependence of activation 
Example traces illustrating the dose-dependent block of INa by Gd3+ are shown in Figure 
4.31A. At all concentrations tested, Gd3+ block stabilized rapidly, whereas recovery was 
slower and incomplete, reaching only ~ 80% after 4-5 min of washout (e.g. Figure 
4.31B for 50 µM). Incomplete recovery from Gd3+ block, which has been reported 
previously for VGSCs as well as L-type Ca2+ channels (Le Guennec et al., 1996; Li and  
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Figure 4.30 Cd2+ did not affect steady-state inactivation and minimally slowed recovery 
from inactivation in Nav1.5 variants 
(A, B) Availability-voltage relationships, in control/wash and 250 µM Cd2+, fitted with 
Boltzmann functions for nNav1.5 (A; n = 10) and aNav1.5 (B; n = 9). Average inactivation V1/2 
and k values are reported in Table 4.5. Recording protocol was as described in Figure 4.7A. (C, 
D) Recovered current (It /Ic), in control/wash and 250 µM Cd2+, plotted as a function of recovery 
interval and fitted with single exponential functions for nNav1.5 (C; n = 14) and aNav1.5 (D; n = 
13). Average recovery time constants (τrecovery) are reported in Table 4.5. Recording protocol was 
as described in Figure 4.8A. For both Nav1.5 variants, Cd2+ had no significant effect on current 
recovery (paired t-tests vs. control: P > 0.05). Data are presented as mean ± SEM; some error bars 
are smaller than symbols. 
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Figure 4.31 Gd3+ blocked peak Na+ current similarly in Nav1.5 variants: time-course and 
dose-dependence of block 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 20-500 µM Gd3+, 
elicited by 12 ms depolarizing pulses to -20 mV at 0.1 Hz; holding potential was -100 mV. 
Dashed horizontal lines indicate zero current. (B) Time-course of onset and offset of current 
block by 50 µM Gd3+ in nNav1.5 (n = 7; open circles) and aNav1.5 (n = 8; black circles); 
washout was incomplete (~ 80%) for both Nav1.5 variants. Pulse protocol was as described in 
part A. (C) Dose-dependence of Gd3+ block (1-10000 µM) of peak Na+ current at -20 mV (n ≥ 
7); block levels were similar in nNav1.5 vs. aNav1.5 at each Gd3+ concentration tested 
(unpaired t-tests; P > 0.05). Dashed (nNav1.5) and solid (aNav1.5) lines represent Hill 
equation fits to data; values of fitted parameters are reported in Table 4.4 (IC50 values are 
reported in parentheses). Data are mean ± SEM; some error bars are smaller than symbols.  
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Baumgarten, 2001), prevented the study of multiple Gd3+ concentrations on a given cell. 
Thus, rather than characterizing I-V and G-V relationships for a wide range of Gd3+ 
concentrations (as for H+ and Cd2+), we first obtained the IC50 for Gd3+ block of Nav1.5 
variants based on the inhibition of peak INa at -20 mV (Figure 4.31C), and then 
investigated the effects of Gd3+ on Gmax and activation gating at two concentrations near 
the IC50. 
Hill equation fits to dose-response relationships for block of INa by Gd3+ (in the 
range 1-5000 µM) yielded statistically similar IC50s for nNav1.5 (48.69 ± 4.93 µM) and 
aNav1.5 (58.25 ± 9.10 µM; P = 0.37, n ≥ 7) (Figure 4.31C and Table 4.4). Exemplar 
recordings used for constructing the I-V and G-V relationships in control and Gd3+ (50 
and 100 µM) are shown in Figure 4.32A. Similar to H+ and Cd2+, Gd3+ block of INa 
occurred through two major mechanisms; Gmax was suppressed and voltage-dependence 
of activation was depolarized (Figure 4.32CD). At 50 µM (~ IC50 for peak INa), Gd3+ 
blocked Gmax of nNav1.5 and aNav1.5 equally by 35.8 ± 4.0% and 33.0 ± 5.3%, 
respectively (P = 0.68, n = 9-8) (Figure 4.32CD insets and Table 4.6). At the same Gd3+ 
concentration, Vthres, Vpeak and activation V1/2 were similarly depolarized by 10-15 mV in 
both Nav1.5 variants (P < 0.05 vs. control, P > 0.05 for nNav1.5 vs. aNav1.5 for all 
comparisons, n = 9-8) (Figure 4.32C-F and Table 4.6). In addition, activation k was 
significantly increased by 50 µM Gd3+; this effect was also similar for nNav1.5 vs. 
aNav1.5 (P < 0.01 vs. control, P > 0.05 for nNav1.5 vs. aNav1.5, n = 9-8) (Table 4.6). 
At the higher concentration tested (100 µM), the effects of Gd3+ on Gmax and voltage-
dependence of activation were also similar for nNav1.5 and aNav1.5 (Figure 4.32C-F 
and Table 4.6). 
As in the case of H+, Gd3+ block of INa appeared to be voltage-dependent due to 
the strong positive shifts in activation gating: significantly larger suppression of INa was  
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Figure 4.32 Effect of Gd3+ on peak Na+ conductance and voltage-dependence of activation was 
similar in Nav1.5 variants  
(A) Typical whole-cell Na+ currents from nNav1.5 (i) and aNav1.5 (ii), in control and 50-100 µM 
Gd3+, elicited by 60 ms depolarizing pulses to between -80 mV and +45 mV from a holding 
potential of -100 mV; interpulse duration was 2 s. (B) Bar-diagram illustrating voltage-
dependence of Gd3+ block at 100 µM; peak current block was plotted as a function of voltage 
for nNav1.5 (n = 8; grey bars) and aNav1.5 (n = 8; black bars). (C, D) Normalized I-V 
relationships for nNav1.5 (C) and aNav1.5 (D) in control/washout and 50-100 µM Gd3+ (n ≥ 7). 
Data were normalized relative to the maximal control current (I/ImaxControl). Insets, 
corresponding normalized conductance transforms (G/GmaxControl). (E, F) Normalized G-V 
relationships (G/Gmax), in control/washout and 50-100 µM Gd3+, fitted with Boltzmann functions 
(solid red lines) for nNav1.5 (E) and aNav1.5 (F) (n ≥ 7). Average values of fitted parameters (V1/2 
and k) are reported in Table 4.6. Data are mean ± SEM. Some error bars are smaller than symbols. 
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Table 4.6 Effects of Gd3+ on Nav1.5 D1:S3 splice variants 
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Unpaired t-tests 
were used to assess whether effects of Gd3+ were differential for nNav1.5 vs. aNav1.5 (P > 0.05 
for all comparisons). For n numbers, see text / figure legends. Data are mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Control 50 µM 100 µM  Wash  
     
Relative Gmax (%) 100.0 ± 0.0 100.0 ± 0.0 
64.2 ± 4.0 
67.0 ± 5.3 
57.3 ± 3.2 
57.7 ± 7.7 
92.4 ± 10.0 
93.4 ± 9.8 
Vthres (mV) -53.3 ± 0.7 
-59.4 ± 1.1 
-42.2 ± 1.2 
-48.1 ± 1.4 
-36.6 ± 1.7 
-42.8 ± 1.1 
-51.1 ± 1.3 
-58.4 ± 1.4 
Vpeak (mV) -4.4 ± 2.1 
-20.0 ± 2.1 
9.4 ± 1.9 
-3.7 ± 1.6 
10.6 ± 2.2 
3.8 ± 2.5 
-0.7 ± 2.8 
-8.8 ± 4.1 
 
Activation V1/2  (mV) -24.7 ± 1.6 
-35.9 ± 1.8 
-11.4 ± 1.5 
-23.3 ± 1.6 
-8.1 ± 2.1 
-16.7 ± 1.7 
-21.4 ± 1.9 
-31.4 ± 2.7 
Activation k  7.7 ± 0.5 5.8 ± 0.5 
9.6 ± 0.5 
7.9 ± 0.4 
9.7 ± 0.5 
8.8 ± 0.5 
8.7 ± 0.6 
7.6 ± 0.7 
Inactivation V1/2 (mV) -87.0 ± 1.1 
-87.4 ± 1.8 
- 
- 
-77.4 ± 2.0 
-78.0 ± 2.3 
-83.0 ± 1.8 
-83.7 ± 0.8 
Inactivation k -5.5 ± 0.1 
-5.5 ± 0.2 
- 
- 
-6.4 ± 0.6 
-5.4 ± 0.3 
-6.1 ± 0.2 
-5.9 ± 0.2 
V0 (mV) 18.4 ± 1.8 17.6 ± 2.3 
19.7 ± 2.2 
19.9 ± 2.0 
21.8 ± 4.9 
19.6 ± 1.8 
20.0 ± 3.1 
19.7 ± 2.0 
Tpeak at 0 mV (ms) 0.86 ± 0.06 0.64 ± 0.03 
1.42 ± 0.15  
0.91 ± 0.04 
1.65 ± 0.23 
1.06 ± 0.08 
1.01 ± 0.13 
0.70 ± 0.04 
τfast at 0 mV (ms) 1.17 ± 0.15 0.75 ± 0.07 
1.83 ± 0.28 
1.19 ± 0.12 
1.78 ± 0.25 
1.38 ± 0.26 
1.03 ± 0.27 
0.81 ± 0.12 
τslow at 0 mV (ms) 7.44 ± 0.70 4.91 ± 0.27 
9.99 ± 1.18 
7.65 ± 0.51 
11.58 ± 1.52 
7.11 ± 1.71 
7.79 ± 0.66 
5.23 ± 0.31 
τrecovery (ms) 17.8 ± 1.3 16.5 ± 1.8 
- 
- 
12.0 ± 2.2 
11.5 ± 1.3 
17.5 ± 1.7 
12.5 ± 2.1 
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observed at hyperpolarized potentials near Vthres (Figure 4.32B). For example, 100 µM 
Gd3+ blocked peak nNav1.5 currents by 87% at -35 mV but only by 59% at 0 mV 
(Figure 4.32B). The IC50 for Gd3+ block of INa (~ 50 µM) determined earlier at -20 mV 
was thus possibly an over-estimate for more negative potentials and an under-estimate 
for more positive potentials. Accordingly, on the basis of block levels shown in Figure 
4.32B and respective Hill coefficients of 1.05 and 0.92 obtained at -20 mV for nNav1.5 
and aNav1.5 (Table 4.4), the re-estimated IC50s in the range -45 to -25 mV were < 25 
µM for both Nav1.5 variants. Conversely, the potency of Gd3+ was much lower at 
depolarized potentials > 10 mV, the estimated IC50 values being > 100 µM. Li and 
Baumgarten (2001) also described a similar voltage-dependency of IC50 estimations for 
Gd3+ block of INa in rabbit ventricular cardiomyocytes. 
 
4.2.4.3.2 Effects on kinetics of activation and inactivation 
Kinetics of activation was significantly slowed by 50 and 100 µM Gd3+; there was no 
differential effect on nNav1.5 vs. aNav1.5 (Figure 4.33AB). For instance, in the 
presence of 100 µM Gd3+, Tpeak at 0 mV roughly doubled from 0.86 ± 0.06 to 1.65 ± 
0.23 ms in nNav1.5 (P < 0.01, n = 9) and from 0.64 ± 0.03 to 1.06 ± 0.08 ms in aNav1.5 
(P < 0.01 vs. control, P = 0.11 vs. nNav1.5, n = 8) (Figure 4.33AB and Table 4.6). 
Voltage-dependence of Tpeak (V0) was not altered by Gd3+ in either Nav1.5 variant (P > 
0.05 vs. control, n = 9-8) (Table 4.6). As regards inactivation kinetics, 50 µM Gd3+ 
slowed τfast and τslow significantly and similarly in nNav1.5 and aNav1.5 (for voltages 
between -20 and 10 mV: P < 0.05 vs. control, P > 0.05 for nNav1.5 vs. aNav1.5, n = 9-
8) (Figure 4.33CD and Table 4.6). 
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Figure 4.33 Gd3+ slowed gating kinetics similarly in Nav1.5 variants 
(A, B) Time to peak (Tpeak), plotted as a function of test potential and fitted to single exponential 
functions in control and 50-100 µM Gd3+, for nNav1.5 (A) and aNav1.5 (B) (n ≥ 7). Values of 
fitted parameters (V0) are reported in Table 4.6. Data were from I-V recordings described in 
Figure 4.32. (C, D) Inactivation τfast and τslow, determined from double exponential fits to 
normalized current decays in control and 50 µM Gd3+, plotted as a function of test potential for 
nNav1.5 (C) and aNav1.5 (D) (n ≥ 7). Data were from I-V recordings described in Figure 4.32. 
Data points are connected with straight lines for clarity. Significance (paired t-tests vs. control): 
(*) P < 0.05, (**) P < 0.01. Data are mean ± SEM; some error bars are smaller than symbols. 
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4.2.4.3.3 Effects on steady-state inactivation and recovery from inactivation 
Gd3+ (100 µM) significantly depolarized inactivation V1/2 in Nav1.5 variants, without 
affecting the slope factor k (Figure 4.34ACE and Table 4.6). In particular, Gd3+ (100 
µM) shifted inactivation V1/2 equally by 9.6 ± 1.5 and 9.4 ± 1.3 mV in nNav1.5 and 
aNav1.5, respectively (P < 0.01 vs. control for both, P = 0.90 for nNav1.5 vs. aNav1.5, 
n = 6-7) (Table 4.6). In addition, Gd3+ (100 µM) significantly accelerated recovery from 
inactivation in both Nav1.5 variants (Figure 4.34BDF). For nNav1.5 and aNav1.5, 
τrecovery were 17.8 ± 1.3 and 16.5 ± 1.8 ms in control and 12.0 ± 2.2 and 11.5 ± 1.3 ms in 
100 µM Gd3+, respectively (P < 0.05 vs. control for both, P = 0.67 for comparing the 
effect for nNav1.5 vs. aNav1.5, n = 6-7) (Figure 4.34BDF and Table 4.6). 
 
4.2.4.3.4 Summary of effects of Gd3+ 
The effects of Gd3+ on the electrophysiology of Nav1.5 variants were (i) reduction of 
Gmax, (ii) depolarization of steady-state activation and inactivation, (iii) slowing of 
activation and inactivation kinetics and (iv) acceleration of recovery from inactivation. 
However, as for Cd2+, Gd3+ had no differential effect on nNav1.5 vs. aNav1.5. 
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Figure 4.34 Gd3+ depolarized steady-state inactivation and accelerated recovery from 
inactivation similarly in nNav1.5 and aNav1.5 
(A) Typical whole-cell nNav1.5 currents, used to assess voltage-dependence of steady-state 
inactivation, in control and 100 µM Gd3+. Pulse protocol was as described in Figure 4.7A. (B) 
Superimposed whole-cell Na+ currents from nNav1.5, used to assess kinetics of recovery from 
inactivation, in control (i) and 100 µM Gd3+ (ii). Pulse protocol was as described in Figure 4.8A; 
arrows indicate Gd3+-induced acceleration of channel recovery. (C, E) Availability-voltage 
relationships in control and 100 µM Gd3+ fitted with Boltzmann functions for nNav1.5 (C; n = 6) 
and aNav1.5 (E; n = 7). Average values for inactivation V1/2 and k are reported in Table 4.6.  
(D, F) Recovered current (It /Ic) plotted as a function of recovery interval and fitted with single 
exponential functions for nNav1.5 (E; n = 6) and aNav1.5 (F; n = 7) in control and 100 µM Gd3+. 
Significance (paired t-tests vs. control): (*) P < 0.05, (**) P < 0.01. Average recovery time 
constants (τrecovery) are reported in Table 4.6. Data are mean ± SEM. 
 
  
1 nA 
0 10 100 150 200 250 (ms) 
 
 
(i) 
(ii) 
Ic It 
0.5 nA 
2 ms 
 
Control 
 
100 µM Gd3+ 
-90 mV 
-80 mV 
-90 mV 
-80 mV 
R
e
la
tiv
e
 
a
va
ila
bi
lit
y 
 
Pre-pulse voltage (mV) 
R
e
co
ve
re
d 
cu
rr
e
n
t (I
t/I c
) 
Time (ms) 
R
e
la
tiv
e
 
a
va
ila
bi
lit
y 
 
Pre-pulse voltage (mV) 
R
e
co
ve
re
d 
cu
rr
e
n
t (I
t/I c
) 
Time (ms) 
** 
-140 -120 -100 -80 -60 -40 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
0 30 60 90 120 150 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
  
-140 -120 -100 -80 -60 -40 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2
0 30 60 90 120 150 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
  
 Control 
  
Gd3+ (100 µM) 
** 
** 
** 
** 
* * 
** 
** 
** 
** * * 
* 
 Control 
  
Gd3+ (100 µM) 
 Control 
  
Gd3+ (100 µM) 
 Control 
  
Gd3+ (100 µM) 
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 361 
4.3 Discussion 
The main finding of the present study is that developmental Nav1.5 D1:S3 splice 
variants differed significantly in their functional characteristics and that a particular 
amino acid change (Asp/Lys211) in the D1:S3/S4 linker was largely responsible for 
these differences. The specific findings were as follows:  
a. Compared to aNav1.5, nNav1.5 (i) activated and peaked at a voltage that was ~ 3 
mV and ~ 7 mV more positive, respectively; (ii) exhibited depolarized activation 
V1/2 and increased activation slope factor (k); (iii) had slower activation and open-
state inactivation kinetics; (iv) was associated with significantly greater transient 
charge (Na+) influx; (v) recovered from inactivation significantly more slowly; 
(vi) exhibited greater use-dependent attenuation at rapid (≥ 33 Hz) stimulation 
frequencies; and (vii) expressed larger INaP. On the other hand, TTX-sensitivity 
and voltage-dependence of steady-state inactivation were unchanged. 
b. The K211D mutagenesis in nNav1.5 resulted in a strong shift from the nNav1.5 
back to the aNav1.5 electrophysiological phenotype. This suggested that the 
charge-reversing Asp211 (aNav1.5) to Lys211 (nNav1.5) substitution was primarily 
responsible for the effects of D1:S3 splicing on Nav1.5 electrophysiology. 
c. The mRNA levels of VGSCβ1-4 and the plasma membrane protein level of 
VGSCβ1 were similar in EBNA-293 cell lines transfected with nNav1.5, aNav1.5 
or Nav1.5 K211D mutant. This indicated that the electrophysiological differences 
observed between Na+ currents from these EBNA-293 cell lines did not involve 
VGSCβs.  
d. Cationic (H+, Cd2+ and Gd3+) effects on channel activity were generally similar 
for nNav1.5 and aNav1.5; the only exception was that acid-induced 
depolarization of activation gating was significantly greater for aNav1.5 vs. 
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 362 
nNav1.5. Reduced acidic effect on nNav1.5 activation was consistent with the 
presence of positive Lys211 near the nNav1.5 D1 voltage sensor (i.e. the local 
negative surface potential was possibly already partly reduced by Lys211).  
 
4.3.1 D1:S3 splicing in Nav1.5: implications for cardiac development 
Alternative splicing can generate functionally diverse protein isoforms from a single 
genetic locus (Chen and Manley, 2009). Several VGSCαs have been shown to be 
alternatively spliced in different tissues and species; however, the electrophysiological 
consequences of most such splicing events have not yet been characterized (Gustafson 
et al., 1993; Schaller et al., 1995; Klugbauer et al., 1995; Diss et al., 2004). In the 
present study, we showed that the two developmentally regulated D1:S3 splice variants 
of Nav1.5 differ significantly in their biophysical properties, which may have a number 
of physiological (developmental) and pathophysiological consequences. 
We found that, compared to aNav1.5 (i.e. the wild-type Nav1.5 in adult heart), 
nNav1.5 channels activated at more depolarized potentials (~ 7 mV shift in activation 
V1/2) and exhibited significantly slower kinetics for activation (Tpeak), open-state 
inactivation (τfast and τslow) and recovery from inactivation (τrecovery). Overall, these 
changes were consistent with and comprised direct evidence for the general trend for 
ion channels expressed in immature cells (e.g. embryonic cardiomyocytes or neurons) 
having slower kinetics than those in the corresponding mature cells (Costa, 1996; 
Moody and Bosma, 2005). In particular, in full agreement with the results presented 
here, earlier studies have shown (i) that INa activates, inactivates and recovers from 
inactivation significantly more slowly in neonatal vs. adult rat ventricular 
cardiomyocytes and (ii) that the voltage-range of VGSC gating becomes more 
hyperpolarized during cardiac development (Zhang et al., 1992; Lipka et al., 1996; 
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Kupershmidt et al., 1998; Stocker and Bennett, 2006). Notably, comparable maturation 
of INa has also been reported to occur in AT-1 cells (derived from atrial tumours in 
transgenic mice), which exhibit similar biochemical, histological and 
electrophysiological properties with atrial cardiac myocytes (Delcarpio et al., 1991; 
Yang and Roden, 1996). Additionally, we showed that nNav1.5 channels expressed 
greater persistent Na+ currents (INaP) compared to their adult counterparts, and this 
finding was also consistent with the larger persistent VGSC activity recorded in fetal 
vs. mature rat ventricular cardiomyocytes and in neonatal vs. adult rabbit sinoatrial 
node (SAN) cells (Conforti et al., 1993; Baruscotti et al., 2000; Belardinelli et al., 
2006; Zaza et al., 2008). 
As regards the changes in VGSC gating that occur during cardiomyocyte 
development, earlier reports showed that differential VGSCα glycosylation (Stocker 
and Bennett, 2006; Montpetit et al., 2009), phosphorylation (Zhang et al., 1992; Yang 
and Roden, 1996) or association with VGSCβ subunits (Kupershmidt et al., 1998; 
Haufe et al., 2005) may play a role. Also, multiple VGSCα isoforms in addition to 
Nav1.5 (including Nav1.1-1.4 and Nav1.6) are functionally expressed in cardiac 
myocytes, and developmental changes in VGSCα expression patterns (i.e. increased 
expression of neuronal isoforms in mature heart muscle) was suggested to contribute to 
the differences in INa recorded from neonatal vs. adult cardiomyocytes (Maier et al., 
2004; Haufe et al., 2005, 2007; Kaufmann et al., 2010). However, apart from these 
mechanisms, results presented here reveal for the first time that maturation of cardiac 
INa may also involve developmentally-regulated alternative splicing of Nav1.5, the 
major VGSCα expressed in cardiac muscle. Thus, it is tempting to speculate that the 
slower kinetics and depolarized voltage-dependence of nNav1.5 vs. aNav1.5 may in 
part be responsible for the parallel differences observed in neonatal vs. adult 
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 364 
cardiomyocytes (Zhang et al., 1992; Lipka et al., 1996; Stocker and Bennett, 2006). 
This is consistent with significant expression of nNav1.5 protein (at a level similar to 
aNav1.5) in neonatal (1-day old) mouse ventricular cardiomyocytes but not in the 
corresponding adult cells (> 4-day old) (Chioni et al., 2005; Schroeter et al., 2010). 
Clearly, further studies are required to directly demonstrate the contribution of nNav1.5 
to the INa phenotype in neonatal cardiomyocytes; however, at a minimum, our results 
suggest that D1:S3 splicing can generate functionally distinct Nav1.5 variants that may 
play specific physiological roles at different times during cardiac development.  
To date, the only other developmentally-regulated alternative splicing in 
Nav1.5 involves deletion of exon 18, which encodes 53 amino acids of the interdomain 
D2-D3 (ID2-3) linker (Gersdorff Korsgaard et al., 2001; Zimmer et al., 2002b). The 
shorter Nav1.5 isoform (Nav1.5a or mH1-2), which has not yet been detected in human 
heart, was shown to be the pre-dominant VGSCα expressed in neonatal mouse 
cardiomyocytes but expressed at significantly lower levels in the adult mouse heart 
(Kerr et al., 2004; Haufe et al., 2005). As in the case of D1:S3 splicing, the 
developmental nature of ID2-3 splicing suggested a particular physiological role for the 
neonatal variant (Nav1.5a/mH1) during early ontogenic stages; however, Zimmer et al. 
(2002b) found that functional characteristics of Nav1.5a/mH1 were indistinguishable 
from the wild-type Nav1.5 channel when expressed heterologously in HEK-293 cells. 
This finding, together with the results presented here, would suggest that physiological 
significance of developmental Nav1.5 splicing may be splice-site-specific. Thus, whilst 
deletion of exon 18 (shortening the ID2-3 linker) has no detectable effect on Nav1.5 
function, developmental switch from 5’- to 3’ exon 6 (encoding D1:S3/S4) results in 
signification modulation of Nav1.5 electrophysiology and hence that must be 
advantageous for the adult cardiac muscle.  
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In addition to Nav1.5, earlier studies showed that D1:S3 splicing yields 
functionally distinct splice variants also for Nav1.2 and Nav1.7 (Xu et al., 2007; 
Chatelier et al., 2008; Jarecki et al., 2009). For instance, Nav1.2 channels derived from 
mRNAs possessing the ‘adult’ (3’-exon 6) variant were found to exhibit significantly 
more depolarized voltage dependence of steady-state inactivation, quicker recovery 
from inactivation and reduced use-dependent attenuation compared to ‘neonatal’ 
Nav1.2 channels (Xu et al., 2007). Thus, consistent with the effect of D1:S3 splicing 
on Nav1.5, the net outcome of the differences between Nav1.2 variants was that ‘adult’ 
channels were more excitable (i.e. more likely to fire, both in response to a given 
depolarizing stimulus and to repetitive stimuli) than ‘neonatal’ channels. Interestingly, 
this would also be consistent with the study of Chatelier et al. (2008) in which the only 
reported difference between Nav1.7 D1:S3 isoforms was the slower development of 
closed-state inactivation of ‘adult’ channels compared to ‘neonatal’ counterparts; the 
result of this being that ‘adult’ channels were again more excitable than ‘neonatal’ 
channels, since they were more likely to generate large ‘ramp’ currents in response to 
gradually increasing depolarizing stimuli that eventually reach threshold (Cummins et 
al., 1998; Chatelier et al., 2008; Jarecki et al., 2009). Taken together, therefore, D1:S3 
splicing may play a conserved role in ‘maturation’ of Nav1.2, Nav1.5 and Nav1.7 
function during development, i.e. by generating ‘adult’ VGSCα variants with a more 
excitable (gain-of-function) phenotype. Indeed, based on the published part of our 
findings (Onkal et al., 2008a), Schroeter et al. (2010) proposed that: “The developing 
mammalian heart may require a Na+ channel tuning, because aNav1.5 shows 
significant gain of function compared to nNav1.5, i.e. hyperpolarized steady-state 
activation, faster activation kinetics, and faster recovery from inactivation”. 
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4.3.2 D1:S3 splicing in Nav1.5: structural inferences and importance of Lys/Asp211 
Previous studies have found extracellular S3/S4 linkers to be important determinants of 
channel gating in VGSCs as well as in various other voltage-gated ion channels (e.g. 
voltage-gated K+ and Ca2+ channels and hyperpolarization-activated cyclic nucleotide-
modulated (HCN) channels; Gonzales et al., 2000, 2001; Sorensen et al., 2000; 
Henrikson et al., 2003; Tsujino et al., 2003; Chen et al., 2005; Jarecki et al., 2009). Six 
of the seven residues different between the Nav1.5 exon 6 variants (nNav1.5 and 
aNav1.5) are likely to be localized to the extracellular end of D1:S3 and the short 
D1:S3/S4 linker (Figure 1.7; Chioni et al., 2005; Onkal and Djamgoz, 2009). 
Importantly, the charge-reversing Asp211 (aNav1.5) to Lys211 (nNav1.5) switch is 
presumed to occur at an extracellular position (i.e. in the D1:S3/S4 linker), possibly 
altering the local transmembrane voltage gradient sensed by the D1:S4 voltage sensor 
(Gellens et al., 1992; Smith et al., 2007; Catterall, 2010). To determine the individual 
effect of this charge reversal on Nav1.5 function, we mutated the Lys211 residue in 
nNav1.5 back to Asp without altering the remaining amino acids different between 
nNav1.5 and aNav1.5. Remarkably, we found that Lys211 to Asp switch resulted in 
mutant nNav1.5 channels (nNav1.5 K211D) with virtually the aNav1.5 phenotype. In 
particular, voltage-dependence of activation and rate of recovery from inactivation 
were indistinguishable between the nNav1.5 K211D mutant and aNav1.5, whereas 
kinetics of activation and inactivation were even faster in nNav1.5 K211D vs. aNav1.5. 
It was thus concluded that, whilst other amino acid substitutions may also contribute to 
the functional differences between the Nav1.5 D1:S3 variants, the charge-reversing 
Lys/Asp211 switch was predominantly responsible for the distinct nNav1.5/aNav1.5 
phenotype.  
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Mechanistically, it is possible that the acidic Asp211 acts a negative surface 
charge in aNav1.5, contributing to the local negative surface potential near the D1 
voltage-sensor. Thus, Asp211 to Lys switch in nNav1.5 may positively bias the local 
electric field for D1:S4, as if a negative surface charge was ‘screened’. This would 
agree well with the depolarized activation of nNav1.5 compared to aNav1.5 (and 
nNav1.5 K211D), and the consequent slowing of activation and inactivation kinetics at 
a fixed membrane potential. Theoretically, however, change of a surface charge should 
produce concomitant shifts in the voltage-dependence of both steady-state activation 
and inactivation, which was not observed in the present study (also, Hanck and Sheets, 
1992a; Hille, 2001). Therefore, in addition to contributing to the surface charge, 
Lys/Asp211 residue may affect Nav1.5 function through a more complex mechanism, 
i.e. by directly participating in channel gating. For instance, earlier studies on voltage-
gated Na+ and K+ channels have shown that at least the two outermost arginine residues 
within S4 segments become extracellularly accessible upon membrane depolarization 
(Yang and Horn, 1995; Larsson et al., 1996; Yang et al., 1996; Tombola et al., 2006; 
Catterall, 2010). Thus, a negative charge on the extracellular D1:S3/S4 linker (i.e. 
Asp211 in aNav1.5) may electrostatically interact with these N-terminal S4 arginines 
(i.e. via ion pairings), thus favouring the outward translocation of D1:S4 during 
depolarization and thereby facilitating channel opening (Swartz, 2008; Catterall, 2010). 
This is in contrast to the nNav1.5 channel, where the positive Lys211 residue would be 
expected to electrostatically resist the outward movement of S4 arginines upon 
membrane depolarization (Tombola et al., 2006; Jarecki et al., 2009).  
Since we did not perform any charge-conserving mutations of Lys211 in 
nNav1.5, our data cannot rule out the possibility that ‘structure’ rather than the charge 
of the residue at position 211 was critical for its effect on Nav1.5 electrophysiology. 
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Nevertheless, results from previous studies suggested that charge of a S3-S4 linker 
residue may be a critical factor for its effect on channel functioning. For example, in 
HCN1 channels, charge-neutralizing and charge-reversing mutations of an acidic 
residue (Glu235) in S3/S4 linker were found to depolarize activation gating in a charge-
dependent fashion, indicating that Glu235 acted as a negative surface charge (Henrikson 
et al., 2003). Also, Tsujino et al. (2003) characterized the functional effect of Val1442 to 
Glu mutation in D4:S3/S4 of Nav1.4, concluding that introduction of a negative charge 
(i.e. Glu1442) potentiates the outward movement of the D4:S4 voltage-sensor, thereby 
enhancing activation-inactivation coupling. Clearly, additional experiments (e.g. 
neutralizing mutations of Asp/Lys211, gating current measurements) are necessary to 
reveal the precise way in which the charge-reversing Asp to Lys switch critically 
affects Nav1.5 electrophysiology. Also, despite our data suggesting a pre-dominant 
role for Asp/Lys211, it remains to be determined whether any of the other amino acid 
differences in the spliced region could contribute to the electrophysiological 
differences of nNav1.5 and aNav1.5. 
VGSC kinetics are known to be affected by association of the α-subunit with 
auxiliary β-subunit(s) (e.g. Isom et al., 1992, 1995; Morgan et al., 2000; Fahmi et al., 
2001). Accordingly, any differential (endogenous) VGSCβ expression in transfectant 
EBNA-293 cells could contribute to the electrophysiological differences observed 
between nNav1.5, aNav1.5 and nNav1.5 K211D. However, we found that VGSCβ1-4 
mRNA levels were similar among the transfectant EBNA-293 cell lines used, and also 
that β1 and β4 were the most abundant VGSCβ mRNAs expressed. Since earlier studies 
showed that co-expression with β1, but not β4, can modify Nav1.5 gating, we also 
determined the plasma membrane protein level of β1 and found that this was also 
similar in nNav1.5-, aNav1.5- or nNav1.5 K211D-expressing EBNA-293 cells (Nuss et 
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al., 1995; Qu et al., 1995; Fahmi et al., 2001; Yu et al., 2003). It was thus concluded 
that VGSCβs were not likely to contribute to the observed electrophysiological 
differences between the Nav1.5 variants characterized in the present study. This was 
consistent with the amino acid changes within the Nav1.5 α-subunit (in particular, 
K211D) being responsible for the distinct functional profiles of nNav1.5 and aNav1.5.  
 
4.3.3 Cationic modulation of Nav1.5 D1:S3 splice variants 
Cations can inhibit INa through (i) reducing maximal Na+ conductance, and (ii) 
depolarizing voltage-dependence of gating by neutralizing the negative surface charges 
(e.g. external sialic acids and negatively charged amino acids), thereby biasing the 
electric field sensed by the S4 voltage-sensors (Hanck and Sheets, 1992a; Hille, 2001). 
We hypothesized that cationic effects on channel gating would be smaller for nNav1.5 
vs. aNav1.5, since the negative surface potential near D1:S4 may already be partly 
reduced due to Asp211 to Lys charge reversal in nNav1.5. Studying the effects of H+, 
Cd2+ and Gd3+ on Nav1.5 D1:S3 splice variants, we found the following: (i) All 3 
cations inhibited peak INa through reducing Gmax and inducing a positive shift in voltage-
range of activation. (ii) Proton block of Gmax was similar in the Nav1.5 variants but 
depolarization of activation was significantly greater for aNav1.5 vs. nNav1.5. (iii) 
There was no splice-variant selective effect of Cd2+ or Gd3+ on any of the parameters 
tested. (iv) Effects of H+ and Gd3+ on channel gating were qualitatively similar, but 
distinct from Cd2+, i.e. Cd2+ was less potent in depolarizing the voltage-range of 
activation, and failed to depolarize voltage-dependence of inactivation, accelerate 
recovery from inactivation and slow kinetics of activation and inactivation.  
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4.3.3.1 Effects of protons on Gmax and voltage-dependence of activation: 
implications for functional architecture of VGSCs 
Acid block of INa has been studied in detail in native cardiomyocytes, neurons, skeletal 
muscle cells, and also in recombinant expression systems (Zhang and Siegelbaum, 
1991; Watson and Gold, 1995; Tombaugh and Somjen, 1996; Bénitah et al., 1997; 
Khan et al., 2002, 2006). Consistent with results presented here, two distinct effects of 
extracellular acidosis on VGSCs have been routinely observed: reduction of Gmax and 
depolarization of voltage-dependence of channel gating.  
The precise mechanism of acid block of Na+ conductance is not fully known but 
this was shown to involve titration of amino acid residues in Nav1.5 outer vestibule, 
including the four outer-ring carboxylates (i.e. ‘EEDD motif’) and the ‘TTX-sensitivity 
determining’ Cys373 located just above the selectivity-filter aspartate in D1 (Khan et al., 
2002, 2006). In contrast, selectivity-filter carboxylates were found to be protected from 
protonation because of their proximity to a lysine residue (i.e. ‘DEKA motif’; Khan et 
al., 2002, 2006). In all reported studies, proton inhibition of peak Na+ conductance was 
well represented by a single binding site model (e.g. Bénitah et al., 1997; Khan et al., 
2006), and in the present study, acid block of Gmax was also well-fit by a single-site Hill 
curve, yielding pKa of ~ 5.9 for both nNav1.5 and aNav1.5. Our pKa estimate for Gmax 
compare well with the corresponding pKa of 6.2 reported earlier for Nav1.5 expressed 
in HEK-293 cells (Khan et al., 2006). Also, for Nav1.4 expressed in Xenopus oocytes 
or HEK-293 cells, whole-cell and single-channel recordings revealed similar pKa 
values (5.9 - 6.1) for block of Na+ conductance, irrespective of β1 subunit co-
expression (Bénitah et al., 1997; Sun et al., 1997; Khan et al., 2002). In addition, Khan 
et al. (2006) showed that single-site dose-response curves for Gmax had an acid 
asymptote (i.e. pHo-independent fraction) of ~ 15% in Nav1.4 but not in Nav1.5; the 
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absence of a pHo-independent Na+ conductance in Nav1.5 was found to be due to 
Cys373 in D1 that may be protonated in acid solution to produce a positive charge that 
eliminates Na+ conductance completely (Khan et al., 2006). Consistently, in our dose-
response curves for Gmax, the acid asymptotes were not different from zero, confirming 
that no pHo-independent fraction of Na+ conductance exists in nNav1.5 or aNav1.5.  
The observed similar pKa values for Gmax of nNav.5 and aNav1.5 was 
anticipated since the spliced D1:S3/S4 region is located peripheral to the outer 
vestibule of the channel pore, as suggested by recent X-ray crystal structures of the 
mammalian voltage-gated K+ channels that share similar channel topology and S1-S4 
voltage sensing domains with VGSCs (Long et al., 2005a, 2007; Swartz, 2008). 
Consistent with this, French et al. (1996) showed that µ-conotoxin R13Q (containing 4-
5 net positive charges) shifted activation by ~ 6 mV when bound in the outer vestibule 
of Nav1.4, and they estimated from the µ-conotoxin effect that the channel vestibule 
and the S4 voltage sensors must be separated by more than 25 Å. Moreover, 
mutagenesis of the outer ring carboxylates in various VGSCα isoforms to neutral or 
positive residues had no detectable effect on voltage-dependence of activation, also 
suggesting that channel voltage sensors are distant from the outer vestibule residues 
(Terlau et al., 1991; Chiamvimonvat et al., 1996; Sun et al., 1997; Khan et al., 2002). 
Taken together, therefore, the spliced D1:S3/S4 region must be sufficiently far away 
from the channel outer vestibule that the amino acid changes between nNav1.5 and 
aNav1.5, including the charge-reversing Lys/Asp211 switch, do not structurally or 
electrostatically modify the acidic inhibition of Na+ permeation. 
As regards effects on channel gating, we found that acid pHo depolarized 
steady-state activation and inactivation, slowed activation and inactivation kinetics, and 
accelerated recovery from inactivation in both Nav1.5 D1:S3 variants. These effects 
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were qualitatively and quantitatively consistent with previous studies in 
cardiomyocytes and Nav1.5- or Nav1.4-expressing HEK-293 cells or Xenopus oocytes 
(Yatani et al., 1984; Zhang and Siegelbaum, 1991; Bénitah et al., 1997; Sun et al., 
1997; Khan et al., 2002, 2006). In general, protons are presumed to affect VGSC 
gating by screening or titrating the negatively charged sialic acids and carboxylates 
found on channel surface, the net effect being reduction of negative surface potential 
and positively biased S4 activation (Hille, 2001). However, our results support earlier 
suggestions that the effects of protons on channel gating cannot solely be explained by 
altered surface charge, whether by screening or titration (Bénitah et al., 1997; Hille, 
2001). For instance, for both nNav1.5 and aNav1.5, (i) acid pHo dose-dependently 
reduced activation slope factor (k), and (ii) the positive shifts in activation V1/2 were 
considerably larger than those in inactivation V1/2. As discussed earlier in Section 4.3.2, 
these findings argue against a pure surface charge effect (Hanck and Sheets, 1992a; 
Hille, 2001; Li and Baumgarten, 2001), and imply additional more complex 
interactions of protons with VGSCs (Zhang and Siegelbaum, 1991; Bénitah et al., 
1997; Khan et al., 2002). 
Importantly, the pHo-dependence of activation differed significantly between 
the two Nav1.5 D1:S3 variants. For instance, at pHo 5.75 and 5.25, activation V1/2, 
activation k and Vpeak were significantly more affected in aNav1.5; in particular, there 
were respectively 4.3 and 7.5 mV larger shifts in activation V1/2 at pHo 5.75 and 5.25, 
and single-site Hill fits estimated a significantly larger (14 mV) maximum V1/2 shift. 
These results were consistent with our initial hypothesis (i) that Asp211 acts as a 
negative surface charge in aNav1.5, and hence (ii) that its substitution for positive 
Lys211 in nNav1.5 should reduce the apparent acidic effect on voltage-dependence of 
activation. Thus, the D1:S4 voltage-sensor in nNav1.5 may already be partially 
 Chapter 4                                                                   Electrophysiology of Nav1.5 D1:S3 variants 
 
 373 
screened by Lys211 under control conditions, such that acid pHo produces a smaller 
additional effect as compared to the full-range effect on D1:S4 of aNav1.5. 
Nevertheless, since we did not study the effects of acid pHo on the nNav1.5 K211D 
mutant (due to limited time), it remains to be determined whether the differential acidic 
effects on Nav1.5 D1:S3 variants occurred specifically due to the charge-reversing 
Lys/Asp211 switch and/or involved one or more of the other amino acid substitutions in 
D1:S3/S4. Minimally, however, compared to nNav1.5, aNav1.5 activation was found 
to be more acid-sensitive, which was consistent with the presence of an additional 
‘titratable’ negative surface charge in the adult variant (i.e. Asp211). In agreement with 
this, a number of earlier studies reported that acidic residues in S3/S4 linkers are 
important determinants of cationic effects on channel gating. For example, Henrikson 
et al. (2003) showed in HCN channels that E235A and E235R mutations in the S3-S4 
linker significantly reduced the charge-screening effects of Mg2+, as if the surface 
charges in mutant channels were already partially screened by the charge-changing 
amino acid substitutions. Similarly, surface-charge shielding effects of protons were 
abolished in Shaker K+ channels, whose S3-S4 linker which includes four acidic 
residues Glu333, Glu334, Glu335 and Asp336 was deleted (Sorensen et al., 2000). 
 
4.3.3.2 Effects of Cd2+ and Gd3+ on Nav1.5 D1:S3 splice variants 
Both Cd2+ and Gd3+ had complex effects on Nav1.5 D1:S3 splice variants. For Gd3+, 
these included: (1) reduction of Gmax, (2) depolarization of activation and availability, 
(3) slowing of activation and inactivation kinetics, and (4) speeding of time-course of 
recovery from inactivation. Overall, Gd3+-induced effects were qualitatively very 
similar to those induced by protons, and combination of Gmax block with positive shifts 
in activation made Gd3+ a potent inhibitor of INa in Nav1.5 variants. Cd2+, on the other 
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hand, dose-dependently reduced Gmax but was significantly less potent in modifying 
channel gating, as compared to H+ and Gd3+. Thus, Cd2+ only minimally depolarized 
voltage-range of activation, whilst having no effect on voltage-dependence of 
inactivation and kinetics of activation, inactivation or recovery from inactivation. Such 
differences in cationic effects on channel gating suggested that changes in surface 
charge density via screening cannot solely explain all the observed effects, i.e. if that 
was the case, then divalent Cd2+ would be expected to induce greater shifts in 
activation than monovalent H+. Instead, binding to specific sites within proximity (i.e. 
Debye length) to the S4 voltage sensors can explain the differential effects of H+, Cd2+ 
and Gd3+ on channel gating (Li and Baumgarten, 2001). Thus, H+ and Gd3+, which 
induce substantial shifts in voltage-dependence of activation, may have such binding 
sites near S4 voltage-sensors, whereas Cd2+ does not (Hanck and Sheets, 1992a). In 
addition, this would similarly explain why H+, but not Cd2+ and Gd3+, induced 
differential effects on Nav1.5 D1:S3 variants. In this case, H+ may have a titratable site 
near the D1:S4 that differ between nNav1.5 and aNav1.5 (e.g. Asp211 in aNav1.5), 
whereas Cd2+ and Gd3+ do not have such differential binding site within this region, 
thereby inducing similar effects on nNav1.5 and aNav1.5. 
 It is worthwhile to compare our results with Gd3+ with those obtained in native 
cardiomyocytes, especially since effects of Gd3+ have not been tested on Nav1.5 in 
isolation earlier. To date, the only studies reporting on Gd3+-modulation of VGSCs 
were conducted in myelinated axons of Xenopus laevis (Elinder and Arhem, 1994) and 
native cardiomyoytes (Bustamante, 1987; Li and Baumgarten, 2001). Similar to H+, 
Gd3+ effects on VGSCs can be dissected into block of Na+ permeation and modification 
of channel gating (Hanck and Sheets, 1992a; Hille, 2001). Blocking efficacy of Gd3+ 
was similar in cardiomyocytes and Nav1.5 variants. For instance, Li and Baumgarten 
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(2001) reported 27% block of Gmax by 50 µM Gd3+ in rabbit ventricular 
cardiomyocytes, which is comparable to ~ 33% block of Gmax in Nav1.5 variants. IC50 
values for INa block were also similar in cardiomyocytes (48 µM, estimated at -35 mV; 
Li and Baumgarten, 2001) and Nav1.5 variants (49 and 58 µM, estimated at -20 mV). 
Moreover, Elinder and Arhem (1994) reported a similar IC50 of 69 µM for Gd3+ block 
of INa in myelinated Xenopus laevis axons, which is suggestive of a comparable Gd3+ 
sensitivity of Na+ permeation in different VGSCαs. 
On the other hand, Gd3+ modification of various aspects of VGSC gating was 
dissimilar in cardiomyocytes and Nav1.5 variants. For instance, 50 µM Gd3+ 
depolarized V1/2 by 7.9 mV in cardiomyocytes (Li and Baumgarten, 2001), this was 
considerably larger for nNav1.5 and aNav1.5 in the present study (13.3 and 12.6 mV, 
respectively). In addition, we detected a significant increase in activation slope factor 
upon 50 µM Gd3+ application but no such effect was reported in cardiomyocytes. 
Furthermore, 100 µM Gd3+ was found to markedly accelerate the rate of recovery from 
inactivation in Nav1.5 variants, whilst Li and Baumgarten (2001) reported no such 
effect of 50 µM Gd3+ on this parameter in cardiomyocytes. Although differences in 
species, recording techniques and/or solutions could account for the quantitative 
changes in Gd3+ effects, qualitative differences observed (e.g. effect vs. no effect on 
recovery from inactivation) strongly suggested intrinsic isoform-dependent effects of 
Gd3+.  
Taken together, Gd3+ block of Na+ conductance appears to be similar across 
different VGSCα isoforms, whereas the effects on channel gating may be isoform-
dependent. This is consistent with Elinder and Arhem (1994)’s conclusion that Gd3+ 
probably interacts with multiple sites on VGSCs, and distinct “blocking” and 
“modulatory” sites mediate particular actions of Gd3+ on VGSCs, i.e. block of 
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conductance vs. depolarization of activation. Similar to other cations, shielding of 
negative surface charges by Gd3+ can account for only some of the complex effects on 
channel gating, and thus there must exist unidentified binding sites on VGSCs 
mediating these effects. As regards block of Na+ conductance, the molecular identities 
of Gd3+-interacting sites within the pore are also not known, unlike in the case of the 
protons (Khan et al., 2002, 2006). Uniform block levels observed in different cell types 
strongly suggest that Gd3+ ions interact with residues that are highly conserved across 
VGSCα subtypes (Elinder and Arhem, 1994; Li and Baumgarten, 2001). Moreover, 
weak voltage-dependence of open-channel block by Gd3+ (assuming that shifts in 
activation gating is largely responsible for the apparent voltage-dependence of Gd3+ 
block of INa) indicates that the receptor site for Gd3+ is possibly located close to the 
external surface of the channel, e.g. outer ring carboxylates and nearby residues 
forming the outer vestibule. Interestingly, Elinder and Arhem (1994) reported a 
negative shift in Na+ reversal potential upon Gd3+ application in myelinated axons of 
Xenopus laevis, suggesting that selectivity filter residues may also be part of the 
receptor site for Gd3+. However, we and Li and Baumgarten (2001) did not find any 
changes in Na+ reversal potential in Nav1.5 variants or cardiomyocytes, and 
determination of whether Gd3+ alters Na+ selectivity in VGSCs requires further 
investigation.  
 
4.3.4 Pathophysiological implications of Nav1.5 D1:S3 splicing 
In Section 4.3.1, the possible consequences of Nav1.5 D1:S3 splicing were discussed 
from a strictly electrophysiological standpoint. Thus, the hyperpolarized activation and 
faster recovery kinetics of aNav1.5 (vs. nNav1.5) were considered as developmental 
‘gain-of-function’ changes. However, compared to aNav1.5, the nNav1.5 channel was 
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found to allow larger transient and persistent Na+ influx, which would correspond to a 
‘gain-of-function’ for nNav1.5 as regards the total Na+ entry. In embryonic/neonatal 
cardiomyocytes, such additional Na+ influx may be important for intracellular pH 
regulation, e.g. via Na+- H+ exchange (Karmazyn et al., 1999; Bers et al., 2003), activity 
of key enzymes such as Na+/K+-ATPase (Levi et al., 1997; Bers et al., 2003) and 
protein kinase A (PKA) (Cooper et al., 1998; Murakami et al., 1998; Brackenbury and 
Djamgoz, 2006; Chioni et al., 2010), and Ca2+ homeostatis, e.g. via Na+-Ca2+ exchange 
(Blaustein and Lederer, 1999; Pieske and Houser, 2003). Also, in mature 
cardiomyocytes, re-expression of nNav1.5 can occur under pathophysiological 
conditions such as cardiac hypertrophy and infarction, where there is a general shift to a 
phenotype characterized by the re-expression of ion channels usually restricted to foetal 
cardiac myocytes, e.g. ‘neonatal’ Nav1.1, HCN2, HCN4, T-type Ca2+ channel (Huang et 
al., 2001; Kuwahara et al., 2003). Such emergence of nNav1.5 could contribute to the 
larger persistent Na+ currents observed in failing and infarcted adult hearts, which 
merits further study (Maltsev et al., 1998; Undrovinas et al., 1999; Huang et al., 2001; 
Valdivia et al., 2005).  
We and others have reported upregulation of nNav1.5 in the human metastatic 
BCa cell line MDA-MB-231 and breast biopsy samples (Fraser et al., 2005; 
Brackenbury et al., 2007; Gillet et al., 2009). Similar nNav1.5 expression has also been 
detected in human neuroblastoma and colon cancer cells (Ou et al., 2005; House et al., 
2010). Importantly, the available in vivo and in vitro data, taken together, are consistent 
with nNav1.5 expression/activity being a significant driving force for the metastatic 
progression of BCa; however, the precise mechanism(s) through which nNav1.5 
enhances metastatic cell behaviours (MCBs) is not fully understood (Fraser et al., 2005; 
Brackenbury et al., 2007; Gillet et al., 2009; Onkal and Djamgoz, 2009). In this regard, 
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our findings suggest that persistent nNav1.5 activity may alter Na+, and hence Ca2+ 
and/or pH homeostasis in metastasizing BCa cells (Roger et al., 2003; Fraser et al., 
2005; Brackenbury et al., 2007). Consistent with this, it was recently shown using non-
invasive 23Na-MRI that Na+ concentration was elevated in malignant breast tissues 
(Ouwerkerk et al., 2007). Such alteration of cellular Na+ homeostasis can modify the 
activity of various Na+-dependent proteins (e.g. PKA, cathepsins) that may play a role 
in the enhancement of MCBs, including migration and invasion (Diss et al., 2004; 
Fraser et al., 2005; Roger et al., 2006; Brackenbury et al., 2007; Gillet et al., 2009; 
Chioni et al., 2010). Furthermore, given that functional VGSC expression in metastatic 
BCa cells is under control of positive auto-regulation via Na+ influx and PKA (Chapter 
3; Chioni et al., 2010), functional characteristics of nNav1.5 may be advantageous for 
maintaining a steady-state high-level VGSC activity in these cells. 
 
4.3.5 Concluding remarks: selective targeting of nNav1.5 in metastatic BCa 
A wealth of evidence suggests a significant role for nNav1.5 in metastatic progression 
(Onkal and Djamgoz, 2009). Importantly, nNav1.5 expression in BCa is an oncofoetal 
phenomenon (Ariel et al., 1997; Monk and Holding, 2001; Gillespie and Uversky, 
2000), and nNav1.5 mRNA is not expressed in healthy adults except at low levels in the 
brain (Wang J et al., 2008; Onkal et al., 2008b). Overall, therefore, nNav1.5 appears to 
have the hallmarks of an ideal target for specific anti-BCa treatment utilizing small-
interfering RNA (siRNA; Brackenbury et al., 2007), antibody (Chioni et al., 2005) or 
non-cytotoxic VGSC-blocker drugs/neurotoxins that selectively recognize nNav1.5 vs. 
aNav1.5 and other VGSCαs. In this regard, results presented here have important 
implications, as follows (these are discussed in more detail in Chapter 5, where 
pharmacological characteristics of Nav1.5 D1:S3 variants are characterized): 
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i. The electrophysiological differences observed between nNav1.5 and aNav1.5 are 
indicative of significant structural differences between these two channels in the 
spliced D1:S3/S4 region. Thus, ‘biological agents’ such as antibodies and 
neurotoxins that specifically interact with the extracellular D1:S3/S4 linker are 
likely to differentiate between nNav1.5 and aNav1.5. Indeed, Chioni et al. (2005) 
succeeded in generating a D1:S3/S4-targetting polyclonal antibody (NESOpAb), 
which blocked nNav1.5 currents with ~ 400-fold selectivity over aNav1.5 when 
tested on EBNA-293 transfectants used in the present study (Chioni et al., 2005). 
Also ‘gating-modifier’ neurotoxins are well-known to target extracellular S3/S4 
linkers of VGSCαs (e.g. α- and β-scorpion toxins target the S3/S4 linkers in D4 
and D2, respectively), and recently, two tarantula toxins (ProTx-II and HaTx) 
were shown to target the D1:S3/S4 linker in rat Nav1.2 (Bosmans et al., 2008; 
Bosmans and Swartz, 2010) (testing of ProTx-II and HaTx on Nav1.5 D1:S3 
variants are described in Chapter 5).  
ii. The electrophysiological differences between nNav1.5 and aNav1.5 may result in 
‘gating-dependent’ changes in block by small-molecule VGSC blockers (e.g. 
anticonvulsants, antiarrhythmics, and local anaesthetics), despite there being no 
intrinsic difference in the receptor sites for these drugs between nNav1.5 and 
aNav1.5 (Wright et al., 1997; Nuss et al., 2000). For instance, slower recovery 
from inactivation of nNav1.5 vs. aNav1.5 may favour use-dependent block by 
local anaesthetic and anticonvulsant drugs, since these agents preferentially target 
the inactivated vs. the resting channel state (i.e. “modulated receptor hypothesis”) 
(Ragsdale et al., 1994; Hille, 2001). In contrast, there was no difference in 
voltage-dependence of inactivation between nNav1.5 and aNav1.5, which would 
suggest that, at a given potential, the fraction of high-affinity inactivated states 
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would be equally prevalent in both channels, predicting similar tonic block by the 
small-molecule drugs (Ragsdale et al., 1994).  
iii. Previous studies showed that mutation of the S6 residues that modulate drug-
binding produced secondary effects on voltage-dependence of activation, 
suggesting that these inner-pore sites and the S4 voltage-sensors are functionally 
coupled (Yarov-Yarovoy et al., 2001; Browne et al., 2009). Thus, if ‘reverse’ 
coupling also exists, the amino acid changes between Nav1.5 variants (in 
D1:S3/S4) may allosterically modulate the small-molecule receptor site located 
within the channel’s inner-pore, thereby modifying its accessibility or affinity for 
VGSC blocker drugs (Lipkind and Fozzard, 2005; Clare, 2010).  
Consistent with (ii) and (iii) above, a number of studies on neonatal vs. adult 
cardiomyocytes (rat, canine or rabbit) found some differences in INa block by small-
molecule pharmaceuticals including lidocaine, mexiletine and phenytoin (Hering et al., 
1983; Jeck and Rosen, 1990; Xu et al., 1991, 1992; Wu et al., 1993). However, given 
the multiplicity of VGSCα expression in cardiomyocytes, as well as the developmental 
changes that occur in VGSCα phosphorylation, glycosylation and association with β-
subunits, a direct comparison of drug block between nNav1.5 vs. aNav1.5 requires 
isolated characterization (Yang and Roden, 1996; Haufe et al., 2005; Stocker and 
Bennett, 2006). This is the topic of the studies described in Chapter 5, where various 
agents, including NESOpAb, ProTx-II, HaTx and six small-molecule pharmaceuticals, 
were tested for selective block on Nav1.5 D1:S3 variants. 
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5.1 Introduction 
Domain 1: segment 3 (D1:S3) developmental splice variants of Nav1.5 differ by 7 
amino acids in the S3/S4 voltage-sensor region of D1 (Chioni et al., 2005). D1:S3 adult 
Nav1.5 (aNav1.5) is the major current-carrying voltage-gated sodium channel α-
subunit (VGSCα) expressed in mature cardiac muscle (Gellens et al., 1992), and the 
orchestrated functioning of this channel is vital for maintaining normal heart rhythm 
(Abriel, 2007). Thus, even slight changes in aNav1.5 electrophysiology have been 
associated with a wide range of cardiac conduction disorders including Brugada 
syndrome, long-QT syndrome, and arrhythmias resulting from ischemia or infarction 
(Bennett et al., 1995; Marbán, 2002; Remme et al., 2008; Ruan et al., 2009). 
D1:S3 neonatal Nav1.5 (nNav1.5) expression occurs significantly more 
abundantly in neonatal (1-day old) than adult heart and brain in mice, with minimal or 
no expression across other neonatal or adult tissues, as determined by 
immunohistochemistry with a polyclonal antibody specific for nNav1.5 (NESOpAb) 
(Chioni et al., 2005). Across healthy adult human tissues, nNav1.5 mRNA expression 
has been shown to be confined to brain, albeit at very low levels, with no report of 
corresponding protein expression to date (Wang J et al., 2008; Onkal et al., 2008b). 
Consistently, in preliminary immunohistochemical studies with NESOpAb, nNav1.5 
expression was not detected in a range of non-CNS human tissues (post-mortem or 
biopsy) including skeletal muscle, oesophagus, small intestine, colon, stomach, bladder 
and prostate (R. Fahrioglu, H. Kaya and M.B.A. Djamgoz, unpublished observations). 
On the other hand, re-expression of nNav1.5 can occur in mature cardiomyocytes under 
pathophysiological conditions such as cardiac hypertrophy and infarction, where there 
is a general shift to phenotypes characteristic of ‘foetal’ ion channels, including 
‘neonatal’ Nav1.1 (Huang et al., 2000, 2001; Kuwahara et al., 2003). Importantly, 
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nNav1.5 is the pre-dominant VGSCα expressed in human metastatic breast cancer 
(BCa) cells and tissues, where its activity potentiates various in vitro metastatic cell 
behaviours including transwell migration and invasion (Chapter 3; Fraser et al., 2005; 
Gillet et al., 2009). Similar nNav1.5 expression has also been described in a human 
neuroblastoma and colon cancer cell lines (Ou et al., 2005; House et al., 2010).  
As shown in Chapter 4, adult and neonatal Nav1.5 (expressed stably in EBNA-
293 cells) differed extensively in their electrophysiological profiles (Onkal et al., 
2008a). In particular, compared to aNav1.5, nNav1.5 channels exhibited more 
depolarized voltage-dependence of activation, slower recovery from inactivation, and 
slower activation and inactivation kinetics (Asp211 to Lys211 switch being 
predominantly responsible for the neonatal phenotype). Overall, these results were 
suggestive of significant conformational differences between nNav1.5 and aNav1.5 in 
the spliced D1:S3/S4 region; however, whether these would enable pharmacological 
distinction of Nav1.5 D1:S3 variants remained to be determined. An agent selective for 
nNav1.5 would be useful for determining the physiological / pathophysiological 
function of this protein, and can have clinical potential against metastatic BCa and/or 
cardiac disorders (e.g. hypertrophy or infarction) where nNav1.5 expression may occur 
(Roger et al., 2006; Onkal and Djamgoz, 2009). Various characteristics of nNav1.5 that 
would make it an ideal anti-BCa target were detailed previously in Section 1.3.9.1 
(summarized in Table 1.5). For selective targeting of nNav1.5, several different 
approaches as described in Section 1.4 were evaluated in the present study.  
 
5.1.1 Aims and scope 
The main aim was to determine the sensitivities of Nav1.5 D1:S3 splice variants to 
various VGSC blockers, in order (i) to better understand the molecular / structural 
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differences between nNav1.5 and aNav1.5, and (ii) to identify potential nNav1.5-
selective agents. Interactions of nNav1.5 and aNav1.5 (and nNav1.5 K211D where 
appropriate) with agents from the following three separate classes of VGSC inhibitors 
were characterized: 
i. Small-molecule pharmaceuticals lidocaine, phenytoin, mexiletine, procaine, 
ranolazine and riluzole (earlier studies showed these agents to confer differential 
blocking efficacy in neonatal vs. adult cardiomyocytes and/or CNS neurons); 
ii. Neurotoxins ProTx-II and HaTx (these peptide toxins were recently shown to 
target D1:S3/S4 linker in rNav1.2/Kv2.1 chimaeras (Bosmans et al., 2008) and 
hence were promising in generating differential effects on nNav1.5 vs. 
aNav1.5); and 
iii. Polyclonal antibody targeting nNav1.5 (NESOpAb). 
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5.2 Results 
The terms ‘nNav1.5’, ‘aNav1.5’ and ‘nNav1.5 K211D’ represent EBNA-293 cells 
stably expressing these isoforms. When comparing a drug-induced effect on nNav1.5 
vs. aNav1.5, paired t-tests were used to determine whether the effect was statistically 
significant vs. control, and an unpaired t-test was used to determine whether the effect 
was differential in nNav1.5 vs. aNav1.5. When nNav1.5 K211D mutant (colony#13) was 
also involved, ANOVA / Newman-Keuls analysis was used.  
 
5.2.1 Lidocaine  
5.2.1.1 Time-course and dose-dependence of tonic block 
Tonic block by lidocaine was assessed using low-frequency (0.1 Hz) stimulation with 
voltage pulses to 0 mV from two different holding potentials (Vh = -100 or -80 mV). 
Example traces illustrating dose-dependent inhibition of nNav1.5 and aNav1.5 currents 
are shown in Figure 5.1A. Lidocaine block of peak INa was rapid and fully reversible; at 
all concentrations tested, time-courses of the effects on nNav1.5 and aNav1.5 were 
similar, and recovery from block was complete within < 30 seconds (shown for 250 µM 
lidocaine at Vh = -100 mV in Figure 5.1B).  
Dose-response relationships were constructed by normalizing steady-state 
current amplitude after lidocaine application (5-5000 µM) to the first pre-control current 
(Figure 5.1C). Consistent with the higher affinity of lidocaine to inactivated vs. resting 
channels (Ragsdale et al., 1991; Hille, 2001), significantly larger block levels were 
obtained at the depolarized Vh of -80 mV vs. -100 mV for both Nav1.5 variants (Figure 
5.1C). However, Hill equation fits to dose-response curves yielded statistically similar 
IC50 values for nNav1.5 and aNav1.5 at both holding potentials, suggesting no 
differential tonic block by lidocaine (Table 5.1 and Figure 5.1C). IC50s for lidocaine  
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Figure 5.1 Lidocaine block of peak Na+ current was similar in nNav1.5 and aNav1.5 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 25-5000 µM lidocaine, 
elicited by 12 ms steps to 0 mV at 0.1 Hz from a holding potential of -100 mV. Insets, current 
block by 25 µM lidocaine in the same cells when the holding potential was -80 mV. Dashed 
horizontal lines indicate zero current. (B) Time-course of 250 µM lidocaine block / recovery at 
0.1 Hz for nNav1.5 (open circles) and aNav1.5 (black circles); holding potential was -100 mV. 
Solid and dashed arrows indicate drug application and washout, respectively. Data were 
normalized to peak current obtained by the first control pulse (n = 6 each). (C) Dose-response 
relationships for lidocaine block at two different holding potentials (-100 and -80 mV) fitted 
with the Hill equation (nH = 1); nNav1.5 (open symbols / dashed lines; n = 6-15) and aNav1.5 
(black symbols / solid lines; n = 6-15). Pulse protocol was as in part A; block was monitored 
until a steady-state maximum was reached (< 2 min), and data were normalized to first control 
current. IC50 estimates are reported in Table 5.1. Data are presented as mean ± SEM. 
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Table 5.1 Sensitivity (IC50) of Nav1.5 D1:S3 variants to various VGSC blockers 
 
Drug Parameter nNav1.5 (µM) aNav1.5 ( µM) P-value 
Lidocaine TB (-100 mV) TB (-80 mV) 
360.0 ± 31.2  
49.5 ± 3.0  
380.1 ± 20.8  
50.5 ± 3.4  
0.59 
0.51 
Phenytoin TB (-100 mV) TB (-80 mV) 
96.5 ± 3.5  
18.1 ± 1.6  
88.2 ± 3.8  
17.1 ± 1.3  
0.14 
0.61 
Mexiletine TB UDB 
111.6 ± 6.5 
33.1 ± 2.7 
105.0 ± 9.3 
35.8 ± 3.2 
0.57 
0.52 
Procaine TB UDB 
213.0 ± 12.6  
97.0 ± 10.3  
247.9 ± 17.0 
112.6 ± 6.3  
0.12 
0.21 
Ranolazine TB UDB 
141.8 ± 7.9  
37.7 ± 1.4 
142.8 ± 10.3  
35.0 ± 0.4  
0.94 
0.10 
Riluzole TB UDB 
11.1 ± 0.7  
6.9 ± 0.7  
10.6 ± 1.0  
5.3 ± 0.4  
0.71 
0.10 
 
 Abbreviations: TB, tonic block; UDB, use-dependent block. For lidocaine and phenytoin, 
holding potential at which TB was assessed is given in parentheses. No significant difference 
existed between IC50s estimated for nNav1.5 and aNav1.5 (unpaired t-tests; P > 0.05). n 
numbers are given in individual figure legends. Data are mean ± SEM. 
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block in nNav1.5 and aNav1.5 were 360.0 ± 31.2 µM and 380.1 ± 20.8 µM for Vh of -
100 mV (P = 0.59, n = 6-15), and 49.5 ± 3.0 µM and 50.5 ± 3.4 µM at Vh of -80 mV (P 
= 0.51, n = 6-15), respectively (Table 5.1). In all ‘preliminary’ Hill fits, estimated 
maxima, minima and the Hill coefficient (nH) were not statistically different from 100%, 
0% and 1, respectively (determined by unpaired t-test for slopes), and for consistency, 
these parameters were fixed at those values in the ‘final’ fitting of data (Figure 5.1C).  
 
5.2.1.2 Effects on steady-state activation and kinetics of gating 
Effects of lidocaine on Gmax, voltage-dependence of activation, and gating kinetics were 
studied at 300 µM, a concentration near IC50 for tonic block at Vh of -100 mV. Results 
are summarized in Table 5.2. Drug-free control recordings were consistent with the 
significantly depolarized activation and slower gating kinetics of nNav1.5 vs. aNav1.5, 
as described in Chapter 4 and by Onkal et al. 2008a (Figures 5.2, 5.3 and Table 5.2). 
Normalized I-V relationships (I/Imaxcontrol) and the corresponding conductance 
transforms (G/Gmaxcontrol) revealed that inhibition of INa by lidocaine occurred primarily 
due to block of Gmax, with no apparent change in the voltage-range of activation gating 
or INa reversal potential (Figure 5.2ABD). Gmax was suppressed similarly for nNav1.5 
(47.1 ± 6.3%) and aNav1.5 (52.6 ± 2.8%) (P = 0.47, n = 8 each; Figure 5.2BD insets). 
These effects were fully reversible upon washout (Table 5.2). There was no effect of 
lidocaine on activation V1/2 and k (Figure 5.2CE), Vthres or Vpeak in either Nav1.5 variant 
(Table 5.2). Voltage-dependence and kinetics of activation (V0 and Tpeak) and kinetics of 
inactivation from open-state (τfast, τslow and their fractional amplitudes at 0 mV) were 
also not modified by lidocaine (Figure 5.3 and Table 5.2), as clear from the current 
traces shown before and after lidocaine application in Figures 5.1A and 5.2A.  
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Table 5.2 Effects of lidocaine (300 µM) on Nav1.5 D1:S3 variants 
      
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Paired1 (lidocaine vs. control) or unpaired2 (comparing effects of 
lidocaine on nNav1.5 vs. aNav1.5) t-tests were used to determine statistical significance: (*) P < 0.05, (**) P < 0.01. Data are mean ± SEM. 
Parameter Control Lidocaine Wash n P-value (vs. 
control) 1 
P-value (nNav1.5 
vs. aNav1.5) 2 
       
Relative Gmax (%)  100.0 ± 0.0  100.0 ± 0.0  
52.9 ± 6.3  
47.4 ± 2.8  
91.8 ± 9.3  
91.2 ± 3.3  8-8 
< 0.001 ** 
 0.005 ** 0.47 
Vthres (mV) -52.8 ± 1.7  
-56.3 ± 0.8  
-53.4 ± 1.9  
-55.6 ± 0.6  
-55.4 ± 1.5  
-59.5 ± 1.5  8-8 
0.17  
0.35 - 
Vpeak (mV)  -16.9 ± 2.3  
-23.1 ± 2.3 
-16.3 ± 2.8  
-20.6 ± 2.6 
-21.0 ± 3.7  
-27.0 ± 1.2 8-8 
0.73  
0.31 - 
Activation V1/2  (mV)  -31.1 ± 1.7  
-38.2 ± 1.4  
-31.7 ± 2.0  
-37.5 ± 1.4  
-33.3 ± 3.8  
-41.1 ± 2.7  8-8 
0.67  
0.60 - 
Activation k (mV) 6.1 ± 0.3  5.8 ± 0.5 
5.9 ± 0.4  
5.8 ± 0.4 
5.6 ± 1.0  
5.8 ± 1.0 8-8 
0.49  
0.92 - 
Inactivation V1/2 (mV)  -83.1 ± 1.2 
-86.6 ± 1.1  
-98.8 ± 2.0  
-100.7 ± 1.5  
-87.3 ± 5.5    
-88.9 ± 1.9  11-9 
< 0.001 ** 
< 0.001 ** 0.42 
Inactivation k (mV) -5.6 ± 0.3  
-6.4 ± 0.4  
-7.6 ± 0.4  
-8.0 ± 0.3  
-5.7 ± 0.5  
-6.8 ± 0.5  11-9 
0.003 ** 
0.002 **  0.40 
V0 (mV)  17.8 ± 3.4  16.0 ± 2.0 
16.0 ± 2.1  
16.1 ± 2.3 
17.0 ± 2.3  
15.1 ± 1.7 8-8 
0.31  
0.96 - 
Tpeak at 0 mV (ms)  0.67 ± 0.03  0.56 ± 0.02  
0.70 ± 0.04  
0.61 ± 0.02  
0.76 ± 0.05  
0.63 ± 0.04  8-8 
0.21 
0.08 - 
τfast at 0 mV (ms)  0.54 ± 0.08  0.39 ± 0.03 
0.51 ± 0.10  
0.40 ± 0.04 
0.59 ± 0.12  
0.48 ± 0.07 8-8 
0.26  
0.75 - 
τslow at 0 mV (ms)  5.67 ± 1.28  4.39 ± 0.90  
5.46 ± 1.42  
4.42 ± 0.91  
5.70 ± 1.87  
4.61 ± 1.09  8-8 
0.49 
0.85 - 
Fast τrecovery (ms)  10.5 ± 0.9  12.0 ± 1.5 
48.2 ± 12.6  
64.5 ± 13.9 
16.2 ± 4.7 
14.1 ± 2.6 6-8 
0.03 * 
0.01 *  0.56 
Slow τrecovery (ms)  266.4 ± 55.3  225.1 ± 20.8 
476.6 ± 53.8  
455.3 ± 47.6 
293.0 ± 47.9  
261.7 ± 36.4 6-8 
0.02 * 
0.004 ** 0.33 
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Figure 5.2 Lidocaine did not modify voltage-dependence of activation and blocked peak 
conductance similarly in Nav1.5 variants 
(A) Typical whole-cell nNav1.5 (i) and aNav1.5 (ii) currents, before and after 300 µM 
lidocaine, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of -
100 mV; interpulse duration was 2 s. (B, D) Normalized I-V relationships in control (open 
circles) and 300 µM lidocaine (black circles) for nNav1.5 (B) and aNav1.5 (D). Currents after 
lidocaine application were normalized to the maximal Na+ current in control (I/Imaxcontrol). 
Insets, corresponding normalized conductance transforms (G/Gmaxcontrol) fitted with Boltzmann 
functions (solid red lines). (C, E) Normalized G-V relationships (G/Gmax) in control (open 
circles) and 300 µM lidocaine (black circles) fitted with Boltzmann functions (solid red lines) 
for nNav1.5 (C) and aNav1.5 (E). Data are presented as mean ± SEM (n = 8 each). 
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Figure 5.3 Lidocaine did not modify activation or inactivation kinetics in Nav1.5 variants 
Data were from recordings described in Figure 5.2 and are presented as mean ± SEM. (A, B) 
Time to peak (Tpeak) plotted as a function of test potential and fitted with single exponential 
functions (solid lines) in control (open circles) and 300 µM lidocaine (black circles) for nNav1.5 
(A; n = 8) and aNav1.5 (B; n = 8); some error bars are smaller than symbols. Tpeak was not 
affected by lidocaine in either nNav1.5 or aNav1.5 (paired t-test vs. control; P > 0.05 at all 
voltages). (C) Fast time constant of inactivation (τfast), determined from double exponential fits 
to Na+ current decays at 0 mV, in control (white bars) and 300 µM lidocaine (black bars) for 
nNav1.5 and aNav1.5 (n = 8 each). There was no effect of lidocaine on τfast (paired t-tests vs. 
control; P > 0.05). (D) As in part C, but for slow time constant of inactivation (τslow). 
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5.2.1.3 Effects on steady-state inactivation and recovery from inactivation 
Two ‘trademark’ effects of lidocaine on VGSCs are (i) hyperpolarization of steady-
state inactivation and (ii) slowing of recovery from inactivation, which respectively 
occur due to higher affinity binding to inactivated vs. resting channels and slow 
recovery of drug-bound channels (Nau and Wang, 2004). Lidocaine dose-dependently 
(50 and 300 µM) hyperpolarized inactivation V1/2 in Nav1.5 variants, with no 
differential effect on nNav1.5 vs. aNav1.5 (Figure 5.4 and Table 5.2). 50 and 300 µM 
lidocaine was found to shift inactivation V1/2 negatively by 4.9 ± 0.8 and 15.7 ± 1.5 mV 
in nNav1.5 and by 5.0 ± 0.6 and 14.1 ± 1.2 mV in aNav1.5, respectively (P < 0.01 vs. 
control, P = 0.94 and 0.42 for nNav1.5 vs. aNav1.5, n ≥ 8). These data are summarized 
in Figure 5.4C inset. Lidocaine (300 µM) also increased inactivation k from -5.6 ± 0.3 
to -7.6 ± 0.4 mV / e-fold in nNav1.5 and from -6.4 ± 0.4 to -8.0 ± 0.3 mV / e-fold in 
aNav1.5 (P < 0.01 vs. control for both, P = 0.40 for nNav1.5 vs. aNav1.5, n ≥ 9) (Table 
5.2); there was no effect of 50 µM lidocaine on inactivation k (Figure 5.4BC). 
 In Chapter 4, recovery from inactivation of Nav1.5 variants was monitored for a 
maximum period of 155 ms (at which channel recovery was near complete but not 
100%), and the time-course of channel recovery was best-fit with a single exponential 
function (see Figure 4.8). Small unrecovered fraction of current was possibly due to the 
presence of slow-inactivated channels that required longer intervals to recover from 
inactivation (Richmond et al., 1998; Chancey et al., 2007; Tikhonov and Zhorov, 
2007). Since lidocaine has been reported to drastically slow channel recovery 
(Ragsdale et al., 1991; Nuss et al., 2000), current recovery was studied over periods of 
up to 1750 ms (Figure 5.5). Under control conditions, the prolonged pulse protocol 
permitted complete current recovery, which was best-fit with a double exponential 
function in both Nav1.5 variants with a major fast component (‘fast τrecovery’; ~ 85%  
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Figure 5.4 Lidocaine hyperpolarized steady-state availability similarly in Nav1.5 variants  
(A) Typical whole-cell aNav1.5 currents, used to study voltage-dependence of steady-state 
inactivation, before and after 300 µM lidocaine. Currents were elicited by 80 ms test pulses to -
10 mV after 1 s pre-pulses in the range -140 mV to -10 mV; holding potential was -100 mV and 
interpulse duration was 2 s. The trace recorded after the pre-pulse to -100 mV is shown to 
illustrate hyperpolarization of availability by lidocaine. (B, C) Availability-voltage relationships 
fitted with Boltzmann functions (solid lines) in control (open circles; data combined from 
controls for 50 and 300 µM lidocaine), 50 µM lidocaine (black squares) and 300 µM lidocaine 
(black circles) for nNav1.5 (B; n ≥ 9) and aNav1.5 (C; n ≥ 8). Currents (I) were normalized to 
the maximum current (Imax) recorded following the most hyperpolarized pre-pulse (-140 mV). 
Effects of lidocaine were fully reversible (see Table 5.2). Inset (part C), lidocaine-induced 
hyperpolarization of inactivation V1/2 (∆ mV); shifts were similar in nNav1.5 (white bars) and 
aNav1.5 (black bars) (unpaired t-tests; P > 0.05). Data are presented as mean ± SEM. 
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Figure 5.5 Lidocaine slowed recovery from inactivation similarly in Nav1.5 variants   
(A) Superimposed whole-cell nNav1.5 currents, used to study kinetics of recovery from 
inactivation, before (i) and after (ii) 300 µM lidocaine. Cells were treated with a 80 ms control 
pulse to -10 mV (giving current Ic), returned to -100 mV for a recovery interval ranging from 5 
to 1750 ms and then an identical test pulse was applied (giving current It); data are from two 
separate protocols spanning recovery periods 5-155 ms (left, 10 ms increments) and 250-1750 
ms (right, 250 ms increments). Holding potential was -100 mV and interpulse duration was 2 s. 
For the traces on the right, Na+ currents appear as thin long lines due to the long time-range 
covered; shorter lines are uncorrected capacitative transients. Dashed horizontal lines indicate 
full recovery (i.e. It = Ic); arrows indicate slowed recovery in the presence of lidocaine. (B, C) 
Recovered current (It /Ic) plotted as a function of recovery interval and fitted with double 
exponential functions (solid lines) in control (open circles), 50 µM lidocaine (black squares) and 
300 µM lidocaine (black circles) for nNav1.5 (B; n ≥ 6) and aNav1.5 (C; n ≥ 8). Fast and slow 
time constants of recovery from inactivation are reported in Table 5.2. Data are presented as 
mean ± SEM; some error bars are smaller than symbols.  
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amplitude) and a minor slow component that possibly represented recovery from slow 
inactivated states (‘slow τrecovery’; ~ 15% amplitude) (Figure 5.5). In the presence of 
lidocaine (50 and 300 µM), the recovery time course was also bi-exponential but there 
were a dose-dependent (i) delay in both fast and slow τrecovery and (ii) a large 
‘amplitude’ shift towards slow τrecovery, due to slow-recovery of drug-bound channels 
(Figure 5.5BC and Table 5.2). However, at both lidocaine concentrations, the effects 
were similar in nNav1.5 vs. aNav1.5, illustrated for 300 µM lidocaine as follows: 
i. Fast τrecovery of nNav1.5 and aNav1.5 were 10.5 ± 0.9 and 12.0 ± 1.5 ms in 
control and 48.2 ± 12.6 and 64.5 ± 13.9 ms in lidocaine, respectively (P < 0.05 
vs. control for both, P = 0.56 for nNav1.5 vs. aNav1.5, n ≥ 6). Slow τrecovery of 
nNav1.5 and aNav1.5 were 266.4 ± 55.3 and 225.1 ± 20.8 ms in control and 
476.6 ± 53.8 and 455.3 ± 47.6 ms in lidocaine, respectively (P < 0.05 vs. 
control for both, P = 0.33 for nNav1.5 vs. aNav1.5, n ≥ 6) (Table 5.2). 
ii. Relative amplitudes of fast τrecovery in nNav1.5 and aNav1.5 were 82.5 ± 2.9% 
and 84.7 ± 1.4% in control and 16.6 ± 8.4% and 21.1 ± 9.8% in lidocaine, 
respectively (P < 0.05 vs. control for both, P = 0.86 for nNav1.5 vs. aNav1.5, n 
≥ 6). Thus, fast recovery was dominant under control conditions and slow 
recovery dominated in the presence of lidocaine; this shift was similar in 
nNav1.5 vs. aNav1.5 (~ 65% for both). 
Effects of lidocaine on steady-state inactivation and recovery from inactivation were 
fully reversible in both Nav1.5 variants; washout data are shown in Table 5.2.  
 
5.2.1.4 Use-dependent block 
Use-dependent block (UDB) by lidocaine during high-frequency stimulus results from 
accumulation of drug-bound channels due to drug dissociation/channel recovery 
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occurring slower than the interpulse period (Ragsdale et al., 1991; Hille, 2001). In the 
present study, effects of lidocaine on UDB of Nav1.5 variants were assessed using a 
train of fifty 12-ms pulses to 0 mV, applied at 2, 5 and 10 Hz (Figure 5.6); currents for 
given pulses were normalized to the current of the first pulse and plotted against pulse 
number (Figure 5.6BC). To isolate UDB from tonic block, lidocaine was applied for at 
least 2 min before the pulse trains were initiated; this ensured that tonic block had 
reached a steady-state (Figure 5.1B and 5.6A). In control conditions, 2 and 5 Hz 
stimulation caused minimal (< 5%) reductions in current amplitude by the 50th pulse; at 
10 Hz, a larger ~ 15% current attenuation occurred in both nNav1.5 and aNav1.5 (n ≥ 7; 
Figure 5.6). Upon lidocaine application (50 and 300 µM), there was an additional 
decline in Nav1.5 currents due to accumulation of UDB (n ≥ 7; Figure 5.6A); this effect 
was rapid, dose-dependent, and frequency-dependent, i.e. a larger block by the same 
lidocaine concentration was observed when the frequency of pulse trains was increased 
(Figure 5.6BCD). However, at all concentrations and frequencies tested, effects were 
similar for nNav1.5 and aNav1.5 (Figure 5.6D). Importantly, at the stimulation 
frequencies used, current attenuation under control conditions was also statistically 
similar in Nav1.5 variants, and thus, did not bias the comparison of lidocaine effects on 
nNav1.5 vs. aNav1.5 (Figure 5.6D).  
 
5.2.1.5 Summary of effects of lidocaine 
Tonic and use-dependent block by lidocaine was similar for aNav1.5 and nNav1.5. 
Lidocaine (i) suppressed Gmax without altering voltage-dependence of activation, (ii) did 
not modify kinetics of activation or inactivation, (iii) hyperpolarized voltage-
dependence of steady-state inactivation, and (iv) slowed recovery from inactivation; 
there was no differential effect on nNav1.5 vs. aNav1.5.  
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Figure 5.6 Use-dependent block (UDB) by lidocaine was similar in Nav1.5 variants   
(A) Typical whole-cell nNav1.5 (top) and aNav1.5 (bottom) currents, before and after 50 and 
300 µM lidocaine, elicited by fifty 12 ms steps to 0 mV at 10 Hz from a holding potential of -
100 mV. Dashed horizontal lines indicate zero current. (B, C) Development of UDB in control 
and 50-300 µM lidocaine at 2, 5 and 10 Hz for nNav1.5 (B; n ≥ 7) and aNav1.5 (C; n ≥ 7). Pulse 
protocol was as in part A but with different frequencies; first a control recording was taken, then 
lidocaine was applied for at least 2 min before the same protocol was repeated. Peak currents 
were normalized to the current of the first pulse and plotted against the pulse number. (D) 
Normalized current at the 50th pulse (at 2, 5 and 10 Hz) in control and 50-300 µM lidocaine for 
nNav1.5 (grey bars) and aNav1.5 (black bars). At 2, 5 and 10 Hz, 50 and 300 µM lidocaine 
induced significant UDB beyond the control level (paired t-tests vs. control; P < 0.05); however, 
these effects were similar in nNav1.5 vs. aNav1.5 (unpaired t-tests; P > 0.05). Data are 
presented as mean ± SEM; some error bars are smaller than symbols. 
 Chapter 5                                                                        Pharmacology of Nav1.5 D1:S3 variants 
 
 398 
5.2.2 Phenytoin  
At the maximum working concentration of phenytoin used (200 µM), the solution 
contained 0.2% DMSO. As shown in Appendices 11 and 12, this concentration of 
DMSO had no detectable effect on peak current amplitude, voltage-dependence and 
kinetics of activation/inactivation, recovery from inactivation and use-dependent 
attenuation in Nav1.5 variants. 
 
5.2.2.1 Time-course and dose-dependence of tonic block 
Tonic block by phenytoin was assessed using low-frequency (0.1 Hz) voltage-pulses to 
0 mV from two different holding potentials (Vh = -100 or -80 mV). Typical recordings 
illustrating dose-dependent inhibition of nNav1.5 and aNav1.5 currents are shown in 
Figure 5.7A. Phenytoin block of peak INa was rapid and fully reversible; at all 
concentrations tested, the time-courses of block on nNav1.5 and aNav1.5 were similar, 
and recovery from block was complete within 1 min (shown for 100 µM phenytoin at Vh 
= -100 mV in Figure 5.7B). Dose-response relationships fitted with the Hill equation 
yielded statistically similar IC50 values for nNav1.5 and aNav1.5 at both holding 
potentials, suggesting no differential tonic block by phenytoin (Figure 5.7C and Table 
5.1; for details of Hill fits, see Section 5.2.1.1). Estimated IC50s for phenytoin block in 
nNav1.5 and aNav1.5 were 96.5 ± 3.5 µM and 88.2 ± 3.8 µM at Vh of -100 mV (P = 
0.14, n = 3-15), and 18.1 ± 1.6 µM and 17.1 ± 1.3 µM at Vh of -80 mV (P = 0.61, n = 3-
15), respectively (Table 5.1).  
 
5.2.2.2 Effects on steady-state activation and gating kinetics 
Effects of phenytoin on Gmax, voltage-dependence of activation and gating kinetics of 
Nav1.5 variants were studied at 100 µM, a concentration near IC50 for tonic block at Vh  
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Figure 5.7 Phenytoin block of peak Na+ current was similar in nNav1.5 and aNav1.5 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 1-200 µM phenytoin, 
elicited by 12 ms steps to 0 mV at 0.1 Hz from a holding potential of -100 mV. Insets, current 
block by 10 µM phenytoin in the same cells when the holding potential was -80 mV. Dashed 
horizontal lines indicate zero current. (B) Time-course of 100 µM phenytoin block / recovery at 
0.1 Hz for nNav1.5 (open circles) and aNav1.5 (black circles); holding potential was -100 mV. 
Solid and dashed arrows indicate drug application and washout, respectively. Data were 
normalized to peak current obtained by the first control pulse (n = 5 each). (C) Dose-response 
relationships for phenytoin block at two different holding potentials (-100 and -80 mV) fitted 
with the Hill equation (nH = 1); nNav1.5 (open symbols / dashed lines; n = 3-14) and aNav1.5 
(black symbols / solid lines; n = 3-15). Pulse protocol as in part A; block was monitored until a 
steady-state maximum was reached (< 2 min) and data were normalized to first control current. 
IC50 estimates are reported in Table 5.1. Data are presented as mean ± SEM. 
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of -100 mV. Results are summarized in Table 5.3. Normalized I-V relationships 
(I/Imaxcontrol) and the corresponding conductance transforms (G/Gmaxcontrol) revealed 
that inhibition of INa by phenytoin occurred primarily due to block of Gmax, with no 
apparent change in the voltage-range of activation gating or INa reversal potential 
(Figure 5.8ABD). Gmax was suppressed similarly for nNav1.5 (53.1 ± 5.8%) and 
aNav1.5 (54.8 ± 4.0%) (P = 0.81, n = 10 each; Figure 5.8BD insets). These effects 
were fully reversible upon washout (Table 5.3). There was no effect of phenytoin on 
Vthres, Vpeak or activation V1/2 and k for either Nav1.5 variant (Figure 5.8CE and Table 
5.3). Voltage-dependence and kinetics of activation (V0 and Tpeak) and kinetics of 
inactivation (τfast, τslow and their fractional amplitudes at 0 mV) were also not modified 
by phenytoin (Figure 5.9 and Table 5.3).  
 
5.2.2.3 Effects on steady-state inactivation and recovery from inactivation 
Similar to lidocaine, phenytoin dose-dependently (25 and 100 µM) hyperpolarized V1/2 
of steady-state inactivation, with no differential effect on nNav1.5 vs. aNav1.5 (Figure 
5.10 and Table 5.3). Phenytoin (25 and 100 µM) shifted inactivation V1/2 negatively by 
3.9 ± 1.6 and 12.5 ± 1.7 mV in nNav1.5 and by 4.3 ± 1.3 and 11.9 ± 1.8 mV in 
aNav1.5, respectively (P < 0.05 vs. control, P = 0.84 and 0.79 for nNav1.5 vs. aNav1.5, 
n ≥ 9). These data are summarized in Figure 5.10C inset. Phenytoin (100 µM) also 
increased inactivation k from -6.0 ± 0.3 to -7.9 ± 0.3 mV / e-fold in nNav1.5 and from  
-5.7 ± 0.6 to -7.7 ± 0.4 mV / e-fold in aNav1.5 (P < 0.05 vs. control for both, P = 0.98 
for nNav1.5 vs. aNav1.5, n ≥ 10) (Table 5.3). There was no effect of 25 µM phenytoin 
on inactivation k (Figure 5.10BC). 
 Phenytoin delayed recovery from inactivation in a similar manner to lidocaine 
(see Section 5.2.1.3). Double exponential fits to recovery time-courses revealed that in
  
 
 
 
Chapter 5                                                                                                                                                                      Pharmacology of Nav1.5 D1:S3 variants 
 
 401 
 
Table 5.3 Effects of phenytoin (100 µM) on Nav1.5 D1:S3 variants 
      
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Paired1 (phenytoin vs. control) or unpaired2 (comparing effects of 
phenytoin on nNav1.5 vs. aNav1.5) t-tests were used to determine statistical significance: (*) P < 0.05, (**) P < 0.01. Data are mean ± SEM.
Parameter Control Phenytoin Wash n P-value (vs. 
control) 1 
P-value (nNav1.5 
vs. aNav1.5) 2 
       
Relative Gmax (%)  100.0 ± 0.0  100.0 ± 0.0  
46.9 ± 5.8  
45.2 ± 4.0  
93.8 ± 9.2  
90.1 ± 6.3  10-10 
< 0.001 ** 
< 0.001 ** 0.81 
Vthres (mV) -55.0 ± 1.4  
-59.7 ± 0.7  
-54.7 ± 1.2  
-58.9 ± 1.1  
-57.1 ± 1.5  
-61.3 ± 1.8  10-10 
0.81 
0.35 - 
Vpeak (mV)  -12.2 ± 1.7  
-23.3 ± 3.8 
-13.9 ± 2.3  
-23.3 ± 2.0  
-15.0 ± 1.7  
-27.5 ± 2.8  10-10 
0.54 
0.99 - 
Activation V1/2  (mV)  -34.6 ± 1.9  
-41.7 ± 2.6  
-32.9 ± 1.7  
-39.8 ± 1.5  
-38.4 ± 3.1 
-43.7 ± 2.9  10-10 
0.11 
0.45 - 
Activation k (mV) 6.2 ± 0.4  5.5 ± 0.7  
6.6 ± 0.4  
5.7 ± 0.7  
6.4 ± 0.7  
5.7 ± 0.9  10-10 
0.37 
0.75 - 
Inactivation V1/2 (mV)  -87.0 ± 1.3  
-88.1 ± 1.7  
-99.5 ± 1.8 
-99.9 ± 2.6  
-85.5 ± 1.7  
-89.0 ± 3.5  10-11 
< 0.001 ** 
< 0.001 ** 0.79 
Inactivation k (mV) -6.0 ± 0.3  
-5.7 ± 0.6  
-7.9 ± 0.3  
-7.7 ± 0.4  
-5.5 ± 0.3  
-6.4 ± 0.4  10-11 
< 0.001 ** 
0.03 * 0.98 
V0 (mV)  15.1 ± 2.2  16.2 ± 1.9  
15.0 ± 1.5  
17.2 ± 2.2  
16.4 ± 1.6  
16.9 ± 2.0  10-10 
0.96 
0.52 - 
Tpeak at 0 mV (ms)  0.63 ± 0.02  0.52 ± 0.02  
0.68 ± 0.03  
0.52 ± 0.02  
0.62 ± 0.03  
0.54 ± 0.04  10-10 
0.14 
0.61 - 
τfast at 0 mV (ms)  0.54 ± 0.06  0.48 ± 0.04  
0.52 ± 0.02  
0.48 ± 0.02  
0.58 ± 0.04  
0.44 ± 0.04  10-10 
0.76 
0.80 - 
τslow at 0 mV (ms)  6.12 ± 0.45  4.58 ± 0.56  
5.79 ± 0.56  
4.74 ± 0.62  
5.84 ± 0.70  
5.14 ± 0.81  10-10 
0.73 
0.75 - 
Fast τrecovery (ms)  8.3 ± 0.4  7.6 ± 1.3  
12.6 ± 1.7  
16.4 ± 2.6  
6.9 ± 1.1  
6.2 ± 1.8  8-8 
0.04 * 
0.04 * 0.76 
Slow τrecovery (ms)  70.7 ± 11.2  63.5 ± 14.2  
393.1 ± 30.5  
423.3 ± 96.6  
90.4 ± 17.4  
71.9 ± 13.0  8-8 
< 0.001 ** 
0.02 * 0.72 
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Figure 5.8 Phenytoin did not modify voltage-dependence of activation and blocked peak 
conductance similarly in Nav1.5 variants 
(A) Typical whole-cell nNav1.5 (i) and aNav1.5 (ii) currents, before and after 100 µM 
phenytoin, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential of 
-100 mV; interpulse duration was 2 s. (B, D) Normalized I-V relationships in control (open 
circles) and 100 µM phenytoin (black circles) for nNav1.5 (B) and aNav1.5 (D). Currents after 
phenytoin application were normalized to the maximal Na+ current in control (I/Imaxcontrol). 
Insets, corresponding normalized conductance transforms (G/Gmaxcontrol) fitted with Boltzmann 
functions (solid red lines). (C, E) Normalized G-V relationships (G/Gmax) in control (open 
circles) and 100 µM phenytoin (black circles) fitted with Boltzmann functions (solid red lines) 
for nNav1.5 (C) and aNav1.5 (E). Data are presented as mean ± SEM (n = 10 each). 
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Figure 5.9 Phenytoin did not modify activation or inactivation kinetics in Nav1.5 variants 
Data were from recordings described in Figure 5.8 and are presented as mean ± SEM. (A, B) 
Time to peak (Tpeak) plotted as a function of test potential and fitted with single exponential 
functions (solid lines) in control (open circles) and 100 µM phenytoin (black circles) for 
nNav1.5 (A; n = 10) and aNav1.5 (B; n = 10); some error bars are smaller than symbols. Tpeak 
was not affected by phenytoin in either nNav1.5 or aNav1.5 (paired t-test vs. control; P > 0.05 at 
all voltages). (C) Fast time constant of inactivation (τfast), determined from double exponential 
fits to Na+ current decays at 0 mV, in control (white bars) and 100 µM phenytoin (black bars) 
for nNav1.5 and aNav1.5 (n = 10 each). There was no effect of phenytoin on τfast (paired t-tests 
vs. control; P > 0.05). (D) As in part C, but for slow time constant of inactivation (τslow). 
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Figure 5.10 Phenytoin hyperpolarized steady-state availability similarly in Nav1.5 variants 
(A) Typical whole-cell aNav1.5 currents, used to study voltage-dependence of steady-state 
inactivation, before and after 100 µM phenytoin. Currents were elicited by 80 ms test pulses to -
10 mV after 1 s pre-pulses in the range -140 mV to -10 mV; holding potential was -100 mV and 
interpulse duration was 2 s. Trace recorded after the pre-pulse to -100 mV is shown to illustrate 
hyperpolarization of availability by phenytoin. (B, C) Availability-voltage relationships fitted 
with Boltzmann functions (solid lines) in control (open circles), 25 µM phenytoin (black 
squares) and 100 µM phenytoin (black circles) for nNav1.5 (B; n ≥ 9) and aNav1.5 (C; n ≥ 10). 
Currents (I) were normalized to the maximum current (Imax) recorded following the most 
hyperpolarized pre-pulse (-140 mV). Effects of phenytoin were fully reversible (see Table 5.3). 
Inset (part C), phenytoin-induced hyperpolarization of inactivation V1/2 (∆ mV); shifts were 
similar in nNav1.5 (white bars) and aNav1.5 (black bars) (unpaired t-tests; P > 0.05). Data are 
presented as mean ± SEM. 
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the presence of 100 and 200 µM phenytoin, (i) both fast and slow τrecovery were slower, 
and (ii) there was a significant ‘amplitude’ shift towards slow τrecovery (Figure 5.11 and 
Table 5.3). However, at both concentrations tested, the effect of phenytoin on recovery 
from inactivation was similar in both Nav1.5 variants, illustrated for 100 µM phenytoin 
as follows: 
i. Fast τrecovery of nNav1.5 and aNav1.5 were 8.3 ± 0.4 and 7.6 ± 1.3 ms in control 
and 12.6 ± 1.7 and 16.4 ± 2.6 ms in phenytoin, respectively (P < 0.05 vs. 
control for both, P = 0.76 for nNav1.5 vs. aNav1.5, n = 8 each). Slow τrecovery of 
nNav1.5 and aNav1.5 were 70.7 ± 11.2 and 63.5 ± 14.2 ms in control and 393.1 
± 30.5 and 423.3 ± 96.6 ms in phenytoin, respectively (P < 0.05 vs. control for 
both, P = 0.72 for nNav1.5 vs. aNav1.5, n = 8 each) (Table 5.3). 
ii. Amplitude of fast τrecovery in nNav1.5 and aNav1.5 was 88.9 ± 0.9 and 86.2 ± 
2.0% in control and 80.2 ± 0.9 and 74.6 ± 1.2% in phenytoin, respectively (P < 
0.05 vs. control for both, P = 0.10 for nNav1.5 vs. aNav1.5, n = 8 each). Thus, 
overall, phenytoin caused a significant shift from fast to slow recovery that was 
similar in nNav1.5 vs. aNav1.5 (~ 10% for both). 
Effects of phenytoin on steady-state inactivation and recovery from inactivation were 
fully reversible; washout data are shown in Table 5.3.  
 
5.2.2.4 Use-dependent block 
Under control conditions, trains of fifty 2, 5 and 10 Hz pulses to 0 mV caused use-
dependent current attenuation of ≤ 15% in Nav1.5 variants (n ≥ 7; Figure 5.12). Upon 
phenytoin application (100 µM), there was an additional decline in current amplitude (at 
5 and 10 Hz, but not 2 Hz) due to accumulation of UDB (n ≥ 7; Figure 5.12BC). At all 
frequencies tested, similar block levels (at the 50th pulse) were recorded in nNav1.5 and  
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Figure 5.11 Phenytoin slowed recovery from inactivation similarly in Nav1.5 variants   
(A) Superimposed whole-cell nNav1.5 currents, used to study kinetics of recovery from 
inactivation, before (i) and after (ii) 200 µM phenytoin. Cells were treated with a 80 ms control 
pulse to -10 mV (giving current Ic), returned to -100 mV for a recovery interval ranging from 5 
to 1750 ms and then an identical test pulse was applied (giving current It); data are from two 
separate protocols spanning recovery periods 5-155 ms (left, 10 ms increments) and 250-1750 
ms (right, 250 ms increments). Holding potential was -100 mV and interpulse duration was 2 s. 
For the traces on the right, Na+ currents appear as thin long lines due to the long time-range 
covered; shorter lines are uncorrected capacitative transients. Dashed horizontal lines indicate 
full recovery (i.e. It = Ic); arrows indicate slowed recovery in the presence of phenytoin. (B, C) 
Recovered current (It /Ic) plotted as a function of recovery interval and fitted with double 
exponential functions (solid lines) in control (open circles), 100 µM phenytoin (black circles) 
and 200 µM phenytoin (open squares) for nNav1.5 (B; n ≥ 8) and aNav1.5 (C; n ≥ 6); for 
clarity, data for only the first 1250 ms are shown. Fast and slow time constants of recovery from 
inactivation are reported in Table 5.3. Data are presented as mean ± SEM; some error bars are 
smaller than symbols.  
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Figure 5.12 Use-dependent block (UDB) by phenytoin was similar in Nav1.5 variants   
(A) Typical whole-cell nNav1.5 (top) and aNav1.5 (bottom) currents, before and after 100 µM 
phenytoin, elicited by fifty 12 ms steps to 0 mV at 10 Hz from a holding potential of -100 mV. 
Dashed horizontal lines indicate zero current. (B, C) Development of UDB in control and 100 
µM phenytoin at 2, 5 and 10 Hz for nNav1.5 (B; n ≥ 7) and aNav1.5 (C; n ≥ 7). Pulse protocol 
was as in part A but with different frequencies; first a control recording was taken, then 
phenytoin was applied for at least 2 min before the same protocol was repeated. Peak currents 
were normalized to the current of the first pulse and plotted against the pulse number. (D) 
Normalized current at the 50th pulse (at 2, 5 and 10 Hz) in control and 100 µM phenytoin for 
nNav1.5 (grey bars) and aNav1.5 (black bars). At 5 and 10 Hz, 100 µM phenytoin induced 
significant UDB beyond the control level (paired t-tests vs. control; P < 0.05); however, these 
effects were similar in nNav1.5 vs. aNav1.5 (unpaired t-tests; P > 0.05). Data are presented as 
mean ± SEM; some error bars are smaller than symbols. 
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aNav1.5, suggesting no differential UDB by phenytoin (Figure 5.12D). Current 
attenuation in control was statistically similar in Nav1.5 variants, and thus, did not bias 
the comparison of phenytoin effects (Figure 5.12D). 
 
5.2.2.5 Summary of effects of phenytoin 
Tonic and use-dependent block by phenytoin was similar in aNav1.5 and nNav1.5. 
Phenytoin (i) suppressed Gmax without altering voltage-dependence of activation, (ii) did 
not modify kinetics of activation or inactivation, (iii) hyperpolarized voltage-
dependence of steady-state inactivation, and (iv) slowed recovery from inactivation; all 
effects were similar in nNav1.5 and aNav1.5.  
 
5.2.3 Other small-molecule drugs 
Four other small-molecule VGSC inhibitors (mexiletine, procaine, ranolazine and 
riluzole) were tested for their potency on Nav1.5 variants. Tonic (0.2 Hz) and use-
dependent (10 Hz) block was assessed as described in Figure 5.13. However, 
previously, for lidocaine and phenytoin, UDB was defined as [current of the 50th pulse 
in drug / current of the 1st pulse in drug]; this isolated UDB from tonic block (e.g. 
Figure 5.6D). Here, UDB is defined as [current of the 50th pulse in drug / current of the 
50th pulse in control]. This represents ‘total’ drug-induced block at 10 Hz, including 
both tonic and use-dependent components. Normalizing to the 50th rather than the 1st 
control pulse eliminates the effect of use-dependent current attenuation (‘droop’) under 
drug-free conditions. 
Tonic inhibition of Nav1.5 variants by mexiletine, procaine, ranolazine and 
riluzole are illustrated in Figures 5.13-5.16A, respectively. Block of peak INa by each 
drug was rapid and fully reversible, with similar time-courses for nNav1.5 and aNav1.5  
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Figure 5.13 nNav1.5 and aNav1.5 exhibited similar sensitivity to mexiletine  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 10-5000 µM mexiletine, 
elicited by 12 ms depolarizing steps to 0 mV at 0.2 Hz from a holding potential of -100 mV. 
Dashed horizontal lines indicate zero current. (B) Time-course of 100 µM mexiletine block / 
recovery at 0.2 Hz; nNav1.5 (open circles) and aNav1.5 (black circles). Solid and dashed arrows 
indicate drug application and washout, respectively. Data were normalized to peak current 
obtained by the first control pulse (n = 6 each). (C) Concentration-response curves for tonic (0.2 
Hz) and use-dependent (10 Hz) block by mexiletine fitted with the Hill equation (nH = 1) for 
nNav1.5 (open symbols / dashed lines; n = 3-8) and aNav1.5 (black symbols / solid lines; n = 4-
11). For tonic block, pulse protocol as in part A; block was monitored until a steady-state 
maximum was reached (< 2 min) and data were normalized to first control current. For use-
dependent block (UDB), a control recording was taken with fifty 12 ms pulses to 0 mV at 10 Hz 
from a holding potential of -100 mV, and then mexiletine was applied for at least 2 min before 
the same protocol was repeated. The current generated by the 50th pulse in the presence of 
mexiletine was normalized to the current generated by the 50th pulse in control; this prevented 
contamination of results by the use-dependent attenuation of nNav1.5 and aNav1.5 activity at 10 
Hz under control conditions (see Figure 5.12). IC50 estimates are reported in Table 5.1. Data are 
presented as mean ± SEM. 
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Figure 5.14 nNav1.5 and aNav1.5 exhibited similar sensitivity to procaine  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 10-5000 µM procaine, 
elicited by 12 ms depolarizing steps to 0 mV at 0.2 Hz from a holding potential of -100 mV. 
Dashed horizontal lines indicate zero current. (B) Time-course of 100 µM procaine block / 
recovery at 0.2 Hz; nNav1.5 (open circles) and aNav1.5 (black circles). Solid and dashed arrows 
indicate drug application and washout, respectively. Data were normalized to peak current 
obtained by the first control pulse (n = 7-9 for nNav1.5 and aNav1.5, respectively). (C) 
Concentration-response curves for tonic (0.2 Hz) and use-dependent (10 Hz) block by procaine 
fitted with the Hill equation (nH = 1) for nNav1.5 (open symbols / dashed lines; n = 4-14) and 
aNav1.5 (black symbols / solid lines; n = 5-15). For tonic block, pulse protocol as in part A; 
block was monitored until a steady-state maximum was reached (< 2 min) and data were 
normalized to first control current. For use-dependent block (UDB), a control recording was 
taken with fifty 12 ms pulses to 0 mV at 10 Hz from a holding potential of -100 mV, and then 
procaine was applied for at least 2 min before the same protocol was repeated. The current 
generated by the 50th pulse in the presence of procaine was normalized to the current generated 
by the 50th pulse in control; this prevented contamination of results by the use-dependent 
attenuation of nNav1.5 and aNav1.5 activity at 10 Hz under control conditions (see Figure 
5.12). IC50 estimates are reported in Table 5.1. Data are presented as mean ± SEM. 
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Figure 5.15 nNav1.5 and aNav1.5 exhibited similar sensitivity to ranolazine  
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 10-5000 µM ranolazine, 
elicited by 12 ms depolarizing steps to 0 mV at 0.2 Hz from a holding potential of -100 mV. 
Dashed horizontal lines indicate zero current. (B) Time-course of 100 µM ranolazine block / 
recovery at 0.2 Hz; nNav1.5 (open circles) and aNav1.5 (black circles). Solid and dashed arrows 
indicate drug application and washout, respectively. Data were normalized to peak current 
obtained by the first control pulse (n = 5-6 for nNav1.5 and aNav1.5, respectively). (C) 
Concentration-response curves for tonic (0.2 Hz) and use-dependent (10 Hz) block by 
ranolazine fitted with the Hill equation (nH = 1) for nNav1.5 (open symbols / dashed lines; n = 
3-5) and aNav1.5 (black symbols / solid lines; n = 3-6). For tonic block, pulse protocol as in part 
A; block was monitored until a steady-state maximum was reached (< 2 min) and data were 
normalized to first control current. For use-dependent block (UDB), a control recording was 
taken with fifty 12 ms pulses to 0 mV at 10 Hz from a holding potential of -100 mV, and then 
ranolazine was applied for at least 2 min before the same protocol was repeated. The current 
generated by the 50th pulse in the presence of ranolazine was normalized to the current 
generated by the 50th pulse in control; this prevented contamination of results by the use-
dependent attenuation of nNav1.5 and aNav1.5 activity at 10 Hz under control conditions (see 
Figure 5.12). IC50 estimates are reported in Table 5.1. Data are presented as mean ± SEM. 
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Figure 5.16 nNav1.5 and aNav1.5 exhibited similar sensitivity to riluzole 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after 1-100 µM riluzole, 
elicited by 12 ms depolarizing steps to 0 mV at 0.2 Hz from a holding potential of -100 mV. 
Dashed horizontal lines indicate zero current. (B) Time-course of 10 µM riluzole block / 
recovery at 0.2 Hz; nNav1.5 (open circles) and aNav1.5 (black circles). Solid and dashed arrows 
indicate drug application and washout, respectively. Data were normalized to peak current 
obtained by the first control pulse (n = 5 each). (C) Concentration-response curves for tonic (0.2 
Hz) and use-dependent (10 Hz) block by riluzole fitted with the Hill equation (nH = 1) for 
nNav1.5 (open symbols / dashed lines; n = 3-5) and aNav1.5 (black symbols / solid lines; n = 3-
5). For tonic block, pulse protocol as in part A; block was monitored until a steady-state 
maximum was reached (< 2 min) and data were normalized to first control current. For use-
dependent block (UDB), a control recording was taken with fifty 12 ms pulses to 0 mV at 10 Hz 
from a holding potential of -100 mV, and then riluzole was applied for at least 2 min before the 
same protocol was repeated. The current generated by the 50th pulse in the presence of riluzole 
was normalized to the current generated by the 50th pulse in control; this prevented 
contamination of results by the use-dependent attenuation of nNav1.5 and aNav1.5 activity at 10 
Hz under control conditions (see Figure 5.12). IC50 estimates are reported in Table 5.1. Data are 
presented as mean ± SEM. 
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(Figures 5.13-5.16B). Dose-response relationships fitted with the Hill equation yielded 
statistically similar IC50 values in nNav1.5 and aNav1.5 for both tonic and use-
dependent block, suggesting no splice-variant-selective effect of these four inhibitors 
(Figures 5.13-5.16C and Table 5.1; for details of Hill fits, see Section 5.2.1.1). 
Estimated IC50 values for nNav1.5 and aNav1.5 respectively were as follows (Table 
5.1): 
i. Mexiletine: 111.6 ± 6.5 µM and 105.0 ± 9.3 µM for tonic block (P = 0.57), and 
33.1 ± 2.7 µM and 35.8 ± 3.2 µM for UDB (P = 0.52) (n = 3-11). 
ii. Procaine: 213.0 ± 12.6 µM and 247.9 ± 17.0 µM for tonic block (P = 0.12), and 
97.0 ± 10.3 µM and 112.6 ± 6.3 µM for UDB (P = 0.21) (n = 4-15). 
iii. Ranolazine: 141.8 ± 7.9 µM and 142.8 ± 10.3 µM for tonic block (P = 0.94), and 
37.7 ± 1.4 µM and 35.0 ± 0.4 µM for UDB (P = 0.10) (n = 3-6). 
iv. Riluzole: 11.1 ± 0.7 µM and 10.6 ± 1.0 µM for tonic block (P = 0.71), and 6.9 ± 
0.7 µM and 5.3 ± 0.4 µM for UDB (P = 0.10) (n = 3-5). 
Any differential drug-induced modulation of gating in nNav1.5 vs. aNav1.5 would have 
reflected as a difference in tonic or use-dependent block levels (e.g. a greater delay of 
recovery from inactivation would have induced larger UDB). Since this was not the 
case, effects of mexiletine, procaine, ranolazine and riluzole on Nav1.5 gating 
characteristics (e.g. voltage-dependence of activation, inactivation kinetics, etc.) were 
not characterized. 
 
5.2.4 Interaction of ProTx-II with Nav1.5 D1:S3 variants  
5.2.4.1 General observations and controls 
ProTx-II was applied using a micro-injector ‘puff’ pipette, while the cells were bathed 
with mammalian physiological saline (MPS) as normal. Puff-application (i) minimized 
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the quantities of toxin used, (ii) reduced toxin exposure to neighbouring cells, and (iii) 
ensured instant delivery / washout of toxin, resulting in fast onset and offset of effects, 
e.g. block of Nav1.5 currents by 1000 nM ProTx-II was stable within 10-15 s and fully 
reversible within ~ 40 s when studied with 0.2 Hz depolarisations to -15 mV (Figure 
5.17A; see Figure 5.18 for other concentrations). However, the onset of block was 
exceedingly rapid at micromolar toxin concentrations (i.e. inhibition was near-maximal 
in the first pulse after toxin application), which precluded accurate determination of 
onset time-constants (τ) for ProTx-II (e.g. Figure 5.18CD). Thus, kinetic comparison of 
toxin block between theNav1.5 variants was not performed. Other drawbacks of puff-
application were (i) only one concentration per cell could be studied resulting in low-
throughput, and (ii) slight changes in the positioning of the puff pipette may have 
enhanced cell-to-cell data variability. 
In control experiments, puff-application (of MPS only) slightly reduced peak 
Nav1.5 currents by 5-10%, possibly due to mechanosensitivity of channel function or 
changes in the pressure of fluid delivery (see Section 5.2.6.1; Tabarean et al., 1999; 
Morris and Juranka, 2007). Importantly, such ‘puff block’ was similar for nNav1.5, 
aNav1.5 and nNav1.5 K211D, and hence, did not bias any comparative analysis (see 
Figure 5.37). These control experiments were also applicable to other puff-delivered 
agents used in the present study (HaTx and NESOpAb), and quantitative data were 
chosen to be presented in Section 5.2.6.1 together with other controls for NESOpAb. 
All ProTx-II solutions were prepared in MPS supplied with 0.5 mg/ml BSA (i.e. peptide 
buffer) to prevent adsorption to tubing. Puff application of peptide buffer alone had no 
effect on peak current amplitude beyond ‘puff block’ (Figure 5.17B) and did not modify 
channel gating (Appendix 13).  
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Figure 5.17 Inhibition of Nav1.5 currents by ProTx-II was rapid and reversible  
(A) Representative whole-cell aNav1.5 currents, before and after ProTx-II (1000 nM) 
application, elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from a holding potential of 
-80 mV. ProTx-II trace shown (steady-state maximum block) was generated by the second pulse 
(10 s) after toxin application. Six grey traces represent progression of recovery during the first 
30 s of washout; trace for maximum recovery (at 35 ms) is shown in black. For full time-course 
of ProTx-II block/recovery, see Figure 5.18. (B) Lack of effect of peptide buffer (MPS with 0.5 
mg/ml BSA) on aNav1.5 currents under the same recording conditions used in part A; slight 
reduction in peak current was probably due to the mechanical side effects of ‘puffing’ (see 
Section 5.2.6.1). Dashed horizontal lines indicate zero current. 
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5.2.4.2 Dose-dependence of block: selectivity for aNav1.5 
The extent of channel modification by ProTx-II (10-10000 nM) was initially assessed 
with single pulses to -15 mV (0.2 Hz frequency, Vh = -80 mV). As shown in Figure 5.18 
(rightmost panels), ProTx-II inhibition of Nav1.5 variants was rapid, reversible, and 
dose-dependent. Importantly, compared to nNav1.5, aNav1.5 currents were markedly 
more sensitive to ProTx-II (Figure 5.18). In particular: (i) 10 and 100 nM ProTx-II 
reduced aNav1.5 currents respectively by ~ 20 and ~ 60%, with no detectable effect on 
nNav1.5 (n = 6-10; Figure 5.18AB), and (ii) block of aNav1.5 was near complete at 
1000 nM ProTx-II, where nNav1.5 currents were reduced only by 50-60% (n = 9; 
Figure 5.18C). Overall, therefore, low nanomolar concentrations of ProTx-II (10 and 
100 nM) were sufficient to block aNav1.5 currents, whilst inhibition of nNav1.5 
occurred in the high nanomolar to micromolar range (Figure 5.18). Blockage of Nav1.5 
variants were similar at 10000 nM ProTx-II, probably due to saturation of effects at this 
concentration (n = 4-6; Figure 5.18D).  
 Although these results suggested strong selectivity of ProTx-II for aNav1.5, only 
a single voltage pulse was used (from Vh of -80 mV to -15 mV). Since (i) ProTx-II 
inhibits INa in part by positively shifting activation gating (Sokolov et al., 2008), and (ii) 
nNav1.5 and aNav1.5 differ significantly in their activation voltage-dependence (Onkal 
et al., 2008a), comparative ProTx-II blockage of Nav1.5 variants may be voltage-
dependent (Edgerton et al., 2008; Schmalhofer et al., 2008). To remove any bias, we 
determined I-V relationships in the absence / presence of four ProTx-II concentrations 
(10-10000 nM), and used ‘test-voltage independent’ parameters such as Imax and Gmax to 
compare the extent of block in the Nav1.5 variants (Figure 5.19). For each Nav1.5 
variant, the four sets of control / washout data recorded were similar (as determined by  
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Figure 5.18 ProTx-II was selective for aNav1.5 over nNav1.5: time-course of block  
Typical whole-cell aNav1.5 and nNav1.5 currents, before (black) and after (color) ProTx-II 
application, elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from a holding potential of 
-80 mV: (A) 10 nM (magenta); (B) 100 nM (blue); (C) 1000 nM (red); (D) 10000 nM (green). 
First control current and trace for maximum ProTx-II block are shown; dashed horizontal lines 
indicate zero current. At each concentration, time-course of peak current block / recovery is 
shown in the rightmost panel; aNav1.5 (filled circles) and nNav1.5 (open circles). Solid and 
dashed arrows indicate ProTx-II application and washout, respectively. Currents were 
normalized to peak current obtained by the first control pulse. Data are presented as mean ± 
SEM (n = 4-10). 
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Figure 5.19 ProTx-II block of peak Na+ conductance was larger in aNav1.5 vs. nNav1.5 
(A) Typical whole-cell aNav1.5 and nNav1.5 currents, before and after ProTx-II (100 nM) 
application, elicited by 60 ms depolarizing pulses to between -80 mV and +45 mV from a 
holding potential of -80 mV; interpulse duration was 2 s. (B, C) Normalized I-V relationships in 
control / washout and ProTx-II (10-10000 nM) for aNav1.5 (B) and nNav1.5 (C). Data are 
presented as mean ± SEM (n = 3-11). Currents after ProTx-II application were normalized to 
the maximal Na+ current in control (I/Imaxcontrol). Insets, corresponding normalized conductance 
transforms (G/Gmaxcontrol) fitted with Boltzmann functions (solid red lines). Control / washout 
data shown are matched with 100 nM ProTx-II. Some error bars are smaller than symbols. 
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ANOVA comparing gating parameters listed in Table 5.4); typical data for 100 nM 
ProTx-II are shown in Figure 5.19BC.  
 Normalized I-V relationships (I/Imaxcontrol) and the corresponding conductance 
transforms (G/Gmaxcontrol) (Figure 5.19 and Table 5.4) revealed that ProTx-II inhibited 
Nav1.5 currents through (i) reducing Gmax and (ii) depolarizing the voltage-range over 
which the channels activated (discussed separately in Section 5.2.4.3). This was 
consistent with toxin-induced inhibition of the activation process (Smith et al., 2007; 
Edgerton et al., 2008). As regards splice-variant-selectivity, nanomolar ProTx-II (10 
and 100 nM) induced significant inhibition of Imax and Gmax in aNav1.5, whilst nNav1.5 
was responsive only to higher toxin concentrations (> 100 nM) (Figure 5.19). At all 
doses tested, block levels were significantly larger for aNav1.5 vs. nNav1.5; the most 
striking difference occurred at 100 nM, where there was no effect on nNav1.5 but  
> 50% Gmax block in aNav1.5 (Figure 5.19ABC and Table 5.4). To further characterize 
these differences, dose-response relationships were constructed for (i) peak INa at -15 
mV, (ii) Imax and (iii) Gmax (Figure 5.20 and Table 5.4). Since only one concentration per 
cell was studied, value from each cell was used as an independent observation, rather 
than averaged with other values obtained at the same toxin concentration (n = 3-11; 
Figure 5.20). This approach gave each cell an equal weight in the Hill fits, and hence 
was statistically more sound.  
Previous reports showed that ProTx-II inhibition of Nav1.2, Nav1.5 or Nav1.7 
currents were well-fit by a single binding site model (Middleton et al., 2002; Smith et 
al., 2007; Sokolov et al., 2008; Schmalhofer et al., 2008). Accordingly, dose-response 
here for ProTx-II were fit by a single-site Hill equation with nH = 1 (Figure 5.20). 
Minima of all fits were statistically similar to 0%, suggesting complete inhibition of 
Nav1.5 currents at saturating ProTx-II concentrations (Figure 5.20). Three sets of IC50 
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Table 5.4 Effects of ProTx-II (10-10000 nM) on Nav1.5 D1:S3 variants 
      
 
For abbreviations, see Table 4.1. Unpaired t-tests were used to compare the effects of ProTx-II on nNav1.5 (red) vs. aNav1.5 (black). Significance: (*) 
P < 0.05, (**) P < 0.01 (for n numbers, see text / figure legends). Control / wash data are matched with 100 nM1 and 1000 nM2. Data are mean ± SEM.
Parameter Control 10 nM 100 nM 1000 nM 10000 nM Wash 
       
Relative Imax (%) 1 100.0 ± 0.0  100.0 ± 0.0 
94.5 ± 2.7  
69.4 ± 3.3 ** 
92.0 ± 4.2  
37.7 ± 4.0 **  
54.8 ± 5.4  
19.3 ± 3.3 ** 
12.7 ± 1.5  
6.5 ± 1.1 * 
95.2 ± 8.3  
97.8 ± 6.8  
Relative Gmax (%) 1 100.0 ± 0.0 100.0 ± 0.0 
95.8 ± 2.7  
73.0 ± 3.9 ** 
94.9 ± 5.3  
44.0 ± 5.3 ** 
65.4 ± 4.7  
28.5 ± 4.9 ** 
19.9 ± 2.7   
11.4 ± 3.4   
93.2 ± 13.0  
94.6 ± 6.2  
Vthres (mV) 1 -51.5 ± 1.0  
-56.4 ± 0.7 
-51.0 ± 2.4  
-54.4 ± 1.5  
-51.0 ± 1.3  
-51.1 ± 1.1 * 
-46.0 ± 1.9  
-39.3 ± 1.5 ** 
-32.5 ± 1.4  
-13.3 ± 8.3  
-52.5 ± 1.1  
-57.0 ± 1.2  
Vpeak (mV) 1 -14.0 ± 4.3  
-17.9 ± 1.8 
-14.0 ± 3.7  
-18.8 ± 4.4  
-15.0 ± 4.5  
-4.3 ± 3.0 ** 
-4.3 ± 4.4  
10.5 ± 2.9 ** 
17.5 ± 4.3  
25.0 ± 7.6  
-15.0 ± 5.1  
-19.5 ± 2.7  
Activation V1/2  (mV) 1 -26.5 ± 2.6 
-34.3 ± 1.2  
-30.4 ± 3.0  
-36.3 ± 2.0  
-27.6 ± 3.1  
-23.3 ± 3.8 ** 
-20.6 ± 2.2  
-6.7 ± 2.4 ** 
6.3 ± 7.3  
8.7 ± 2.0  
-28.0 ± 3.3  
-36.7 ± 1.6  
Activation k (mV) 1 5.9 ± 1.2  5.7 ± 0.6  
6.0 ± 0.3  
6.4 ± 1.0  
5.9 ± 0.8  
7.0 ± 0.8  
7.7 ± 1.7  
10.0± 1.0  
13.9 ± 1.4  
15.9 ± 5.3  
5.4 ± 0.4  
5.6 ± 0.4  
Inactivation V1/2 (mV) 2 -81.8 ± 1.5  
-82.0 ± 1.8  
-  
-  
- 
-  
-81.6 ± 2.5  
-82.5 ± 2.2  
-  
-  
-80.1 ± 8.0  
-80.2 ± 3.7  
Inactivation k (mV)2 -6.4 ± 0.6  
-5.9 ± 0.9  
-  
-  
-  
-  
-5.9 ± 0.4  
-5.6 ± 0.5  
-  
-  
-5.7 ± 0.6  
-6.0 ± 0.5  
V0 (mV) 1 15.3 ± 0.9  16.6 ± 2.0  
16.3 ± 1.3  
16.6 ± 2.9  
16.3 ± 2.0  
17.4 ± 3.7  
16.2 ± 1.0  
15.5 ± 2.8  
-  
- 
19.8 ± 2.0  
20.6 ± 2.6  
Tpeak at 0 mV (ms) 1 0.67 ± 0.06  0.48 ± 0.04  
0.56 ± 0.02  
0.48 ± 0.01  
0.65 ± 0.07  
0.51 ± 0.03  
0.75 ± 0.05  
0.71 ± 0.04  
1.50 ± 0.44  
1.57 ± 0.47  
0.63 ± 0.02  
0.46 ± 0.04  
τfast at 0 mV (ms) 2 0.45 ± 0.04  0.43 ± 0.03  
-  
-  
-  
-  
0.56 ± 0.08  
0.46 ± 0.03  
-  
-  
0.73 ± 0.06  
0.56 ± 0.05  
τslow at 0 mV (ms) 2 5.40 ± 0.70   5.32 ± 0.43  
-  
-  
-  
-  
6.30 ± 1.00  
5.82 ± 0.56  
-  
-  
8.44 ± 1.19  
10.16 ± 0.75  
τrecovery (ms) 2 7.3 ± 1.0  5.7 ± 0.5 
-  
- 
-  
- 
7.0 ± 0.6  
5.6 ± 0.7 
-  
- 
7.9 ± 1.1  
7.7 ± 0.7 
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Figure 5.20 ProTx-II was selective for aNav1.5 over nNav1.5: dose-response relationships 
Concentration-response curves for ProTx-II block of aNav1.5 (squares) and nNav1.5 (circles) 
fitted with the Hill equation (smooth lines; nH = 1): (A) peak current measured at -15 mV; (B) 
maximal Na+ current (Imax); (C) maximal Na+ conductance (Gmax). Data were obtained from 
normalized I-V and G-V relationships described in Figure 5.19. Each data point represents a 
single cell; n = 3-11 for each concentration. Values reported in parentheses are IC50 estimates 
for ProTx-II block. 
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values generated revealed that ProTx-II was ~ 25-fold more selective for aNav1.5 over 
nNav1.5 (Figure 5.20): 
i. For normalized INa at -15 mV, the difference between IC50 for aNav1.5 (38.4 ± 
5.7 nM) and nNav1.5 (1181.1 ± 227.2 nM) was 31-fold (P < 0.001, n = 3-11). 
ii. For normalized Imax, the difference between IC50 for aNav1.5 (48.0 ± 10.2 nM) 
and nNav1.5 (1222.6 ± 169.6 nM) was 26-fold (P < 0.001, n = 3-11). 
iii. For normalized Gmax, the difference between IC50 for aNav1.5 (87.4 ± 24.1 nM) 
and nNav1.5 (1982.3 ± 313.4 nM) was 23-fold (P < 0.001, n = 3-11). 
For both Nav1.5 variants, IC50 estimates based on Gmax were somewhat larger than those 
based on the other two parameters; this difference was possibly due to the positive shift 
of activation gating by ProTx-II (see Section 5.2.4.3). Because INa was maximal at more 
positive potentials in the presence of ProTx-II, corresponding conductance transforms 
appeared larger than they would be under control conditions, i.e. lower driving force for 
Na+ at more positive potentials biased Gmax estimations in favour of ProTx-II vs. control 
values. Furthermore, Gmax-based estimation of IC50s yielded a slightly smaller fold-
difference between Nav1.5 variants, e.g. 23-fold vs. 26-fold for Imax. This was possibly 
due to the larger toxin-induced shift of activation gating in aNav1.5 vs. nNav1.5 (see 
Section 5.2.4.3). 
 Overall, the apparent selectivity of ProTx-II for aNav1.5 vs. nNav1.5 strongly 
suggested that D1:S3/S4 is among the targets for ProTx-II in Nav1.5, as reported earlier 
for rNav1.2 (Bosmans et al., 2008). 
 
5.2.4.3 Effects on steady-state activation and gating kinetics 
I/Imaxcontrol relationships shown in Figure 5.19BC revealed that ProTx-II shifted Nav1.5 
activation to more depolarized potentials, as noted earlier by others (Smith et al., 2007; 
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Edgerton et al., 2008). To study this effect in ‘isolation’, I-V and G-V relationships 
obtained from these recordings were normalized to maximal values within each 
treatment group (i.e. I/Imax and G/Gmax) (Figure 5.21A-D). G/Gmax data were fit by the 
Boltzmann equation on a cell-by-cell basis to determine activation V1/2 and k; these two 
parameters together with Vthres and Vpeak were used to compare the effects of ProTx-II on 
activation gating in aNav1.5 vs. nNav1.5 (Figure 5.21 and Table 5.4).  
At the lowest concentration tested (10 nM), ProTx-II showed no effect on 
channel activation, whilst higher toxin concentrations reversibly and dose-dependently 
increased activation k and depolarized Vthres, Vpeak and activation V1/2 in both Nav1.5 
variants (Figure 5.21 and Table 5.4). Consistent with its selectivity for aNav1.5, ProTx-
II was more potent in modifying activation parameters for aNav1.5 vs. nNav1.5, as 
apparent from the comparison of the data in parts A vs. C and B vs. D in Figure 5.21. 
For example, the larger toxin-induced depolarisation of activation V1/2 in aNav1.5 vs. 
nNav1.5 was clear from the greater rightward-shifts in blue (100 nM) and red (1000 
nM) conductance curves in Figure 5.21B vs. Figure 5.21D. Quantitatively, these 
differences can be summarized as follows (Figure 5.21E and Table 5.4):   
i. 100 nM ProTx-II depolarized activation V1/2 in aNav1.5 by 11.0 ± 3.3 mV (P < 
0.05 vs. control, n = 7), but had no effect on V1/2 in nNav1.5 (P = 0.41 vs. 
control, P < 0.001 vs. aNav1.5, n = 5) (Figure 5.21Ei). Corresponding shifts in 
Vthres and Vpeak for aNav1.5 were 5.4 ± 1.0 and 13.6 ± 2.4 mV (P < 0.05 vs. 
control for both); there was no effect on either parameter in nNav1.5 (P = 0.70 
and 0.37 vs. control, P < 0.05 and < 0.01 vs. aNav1.5, respectively) (Figure 
5.21Ei and Table 5.4).  
ii. 1000 nM ProTx-II depolarized activation Vthres, Vpeak and V1/2 substantially by 
18.0 ± 1.6, 30.0 ± 4.5 and 29.1 ± 3.2 mV in aNav1.5 (P < 0.001 vs. control for  
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Figure 5.21 ProTx-II induced larger depolarization of activation voltage-dependence in 
aNav1.5 vs. nNav1.5 
(A, C) Normalized I-V relationships in control (open circles), 100 nM ProTx-II (blue) and 1000 
nM ProTx-II (red) for aNav1.5 (A) and nNav1.5 (C). (B, D) Corresponding normalized G-V 
relationships fitted with Boltzmann functions (solid red lines) for aNav1.5 (B) and nNav1.5 (D). 
In A-D, control data shown are matched with 100 nM ProTx-II. Some error bars are smaller 
than symbols. (E) Shifts (∆ mV) in parameters describing voltage-dependence of activation 
induced by ProTx-II: (i) 100 nM and (ii) 1000 nM. Unpaired t-tests were used to compare the 
shifts in aNav1.5 vs. nNav1.5; significance: (*) P < 0.05, (**) P < 0.01. Data were from 
recordings described in Figure 5.19 and are presented as mean ± SEM (n = 5-11). Effects of 
ProTx-II were fully reversible (not shown for clarity; see Figure 5.19 and Table 5.4). 
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all, n = 11), but only by 7.1 ± 1.8, 10.0 ± 3.8 and 8.7 ± 2.5 mV in nNav1.5 (P < 
0.05 vs. control for all, P < 0.001 vs. aNav1.5 for all, n = 7) (Figure 5.21Eii). 
The differential between shifts in aNav1.5 vs. nNav1.5 was thus ~ 10 mV for 
Vthres and ~ 20 mV for Vpeak and V1/2.  
iii. At 10000 nM, ProTx-II also produced larger effects on activation of aNav1.5 vs. 
nNav1.5 (Table 5.4); however, statistical significance of these differences was 
not sought, since exceedingly small residual currents at this concentration may 
have precluded accurate determination of the activation parameters. Also, 
activation k was affected more in aNav1.5 vs. nNav1.5 at all concentrations 
tested; however, these differences were not statistically significant (Table 5.4). 
Taken together, ProTx-II concentration necessary for a 10-mV shift in activation V1/2 or 
Vpeak was < 100 nM in aNav1.5 (Figure 5.21Ei) but > 1000 nM in nNav1.5 (Figure 
5.21Eii). Thus, ProTx-II was at least 10-fold more potent in modifying activation gating 
in aNav1.5 vs. nNav1.5. This result was again consistent with ProTx-II binding to the 
D1:S3/S4 region in Nav1.5. 
Effects of ProTx-II on activation and inactivation kinetics were studied using the 
I-V recordings described in Figure 5.19 (Figure 5.22 and Table 5.4). Consistent with 
toxin-induced inhibition of the activation process, time-course of current development 
(i.e. Tpeak) was significantly delayed by ProTx-II in both Nav1.5 variants (Figure 
5.22AB and Table 5.4). This effect (i) occurred only at high toxin concentrations (≥ 
1000 nM) and (ii) was similar in aNav1.5 vs. nNav1.5. For instance, at -10 mV, 1000 
nM ProTx-II slowed Tpeak from 0.57 ± 0.04 ms to 0.77 ± 0.05 ms in aNav1.5 (~ 35% 
delay, P < 0.01 vs. control, n = 11) and from 0.66 ± 0.02 ms to 0.86 ± 0.06 ms in 
nNav1.5 (~ 31% delay; P < 0.01 vs. control, P = 0.96 vs. aNav1.5, n = 7) (Figure 
5.22AB). Consistent with these results, ProTx-II has been previously shown to slow  
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Figure 5.22 ProTx-II slowed time to peak similarly in Nav1.5 variants   
(A, B) Time to peak (Tpeak) plotted as a function of test potential and fitted with single 
exponential functions (solid lines) in control (open circles) and 1000 nM ProTx-II (black 
circles) for aNav1.5 (A; n = 11) and nNav1.5 (B; n = 7). Significance (paired t-tests vs. control): 
(*) P < 0.05, (**) P < 0.01. Slowing of time to peak was similar in aNav1.5 vs. nNav1.5 
(unpaired t-tests; P > 0.05 at all voltages). Effects of ProTx-II on Tpeak were fully reversible (not 
shown for clarity; see Table 5.4). (C, D) Inactivation time constants (τfast and τslow), determined 
from double exponential fits to Na+ current decays, plotted as a function of test potential in 
control (open circles) and 1000 nM ProTx-II (black circles) for aNav1.5 (C; n = 7) and nNav1.5 
(D; n = 7). Data points are connected with straight lines for clarity; some error bars are smaller 
than symbols. There was no effect of ProTx-II on τfast or τslow (paired t-tests vs. control; P > 
0.05). Data were from recordings described in Figure 5.19 and are presented as mean ± SEM. 
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Tpeak of aNav1.5 by ~ 30% at -30 mV (Smith et al., 2007; Edgerton et al., 2008). There 
was no effect of ProTx-II on voltage-dependence of Tpeak (V0) determined from single 
exponential fits to Tpeak plotted against test potential (Figure 5.22AB and Table 5.4). 
Toxin-induced effects on Tpeak were fully reversible upon washout (Table 5.4).  
Double exponential fits to normalized INa decays (i.e. current from peak to 30 
ms) at a range of test potentials revealed that fast (τfast) and slow (τslow) time constants of 
inactivation (and their relative amplitudes) were similar in the presence / absence of 
1000 nM ProTx-II (Figure 5.22CD and Table 5.4). This indicated that ProTx-II did not 
modify the rate of fast inactivation from open-state in Nav1.5 variants, in line with 
earlier findings for Nav1.2 and Nav1.5 (Smith et al., 2007; Sokolov et al., 2008). 
Overall, depolarization of activation gating and slowing of Tpeak by ProTx-II 
were consistent with the notion that toxin-bound channels can activate albeit with 
altered gating properties (i.e. requiring larger energy to activate) (e.g. Smith et al., 2007; 
Edgerton et al., 2008). This is because if toxin-bound channels did not activate, only 
toxin-free channels would contribute to the residual recorded current and hence the only 
observable toxin effect would be a reduction in Gmax with no change in gating 
parameters. The observed changes in gating may also be due toxin unbinding that 
occurs at more depolarized potentials, i.e. due to activation of newly toxin-liberated 
channels (Sokolov et al., 2008). Finally, effects of ProTx-II (which has a net +4 charge) 
on gating parameters may in part be due to ‘charge screening’ effects on toxin-free 
Nav1.5 channels (Edgerton et al., 2008). 
 
5.2.4.4 Effects on steady-state inactivation and recovery from inactivation 
ProTx-II did not modify voltage-dependence of steady-state inactivation or rate of 
recovery from inactivation in Nav1.5 variants, consistent with earlier reports (Smith et 
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al., 2007; Sokolov et al., 2008). Boltzmann fits to availability-voltage relationships 
revealed that inactivation V1/2 and k were not affected by 1000 nM ProTx-II in either 
Nav1.5 variant (Figure 5.23 and Table 5.4). Similarly, single exponential fits to 
recovery from inactivation time-courses yielded τrecovery values that were unchanged by 
1000 nM ProTx-II (Figure 5.24 and Table 5.4). Note that a modified protocol was used 
to study recovery from inactivation, i.e. twin-pulses were 10 ms-long rather than 80 ms, 
in order to minimize the depolarization-induced toxin unbinding that may occur after 
the first (control) pulse (Sokolov et al., 2008). Preliminary recordings with the 80-ms 
protocol resulted in test currents (It) that were larger than corresponding control currents 
(Ic) for recovery periods that allow near-complete channel recovery (data not shown). 
 
5.2.4.5 Interaction of ProTx-II with nNav1.5 K211D mutant  
ProTx-II has a net charge of +4 and its bioactive face has been shown to be constituted 
mainly by cationic and hydrophobic residues (Smith et al., 2007). Thus, the extra 
positive charge in D1:S3/S4 of nNav1.5 (Lys211) vs. aNav1.5 (Asp211) may be in part 
responsible for the lower potency of ProTx-II in nNav1.5 through an electrostatic effect.  
We tested this hypothesis by studying the interaction of ProTx-II with the 
nNav1.5 K211D mutant. Pulse protocols and data analysis were as before for aNav1.5 
and nNav1.5. The results were as follows: 
i. At -15 mV, the extent of ProTx-II inhibition was similar in nNav1.5 and K211D 
mutant, e.g. there was minimal effect at 100 nM and ~ 60% current block at 
1000 nM (Figure 5.25AB). I/Imaxcontrol and G/Gmaxcontrol relationships also 
revealed that ProTx-II blocked Imax and Gmax with similar potency in nNav1.5 
and K211D, e.g. there was minimal block at 100 nM and ~ 50% inhibition at 
1000 nM (Figure 5.19AC and 5.25CD).  
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Figure 5.23 ProTx-II did not modify steady-state inactivation in Nav1.5 variants   
(A) Example whole-cell Na+ currents (from aNav1.5), used to study voltage-dependence of 
steady-state inactivation (availability), shown before and after ProTx-II (1000 nM) application. 
Currents were elicited by 80 ms test pulses to -10 mV after 1 s pre-pulses in the range -140 mV 
to -10 mV; holding potential was -100 mV and interpulse duration was 2 s. Traces generated 
following pre-pulses at -90, -80 and -70 mV in control and -80 mV in ProTx-II are indicated for 
comparison. (B, C) Availability-voltage relationships fitted with Boltzmann functions (solid 
lines) in control (open circles) and 1000 nM ProTx-II (black circles) for aNav1.5 (B; n = 9) and 
nNav1.5 (C; n = 8). Currents (I) were normalized to the maximum current (Imax) recorded 
following the most hyperpolarized pre-pulse (-140 mV). Data are presented as mean ± SEM. 
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Figure 5.24 ProTx-II did not modify recovery from inactivation in Nav1.5 variants   
(A) Example superimposed whole-cell Na+ currents (from nNav1.5), used to study kinetics of 
recovery from inactivation, shown before (i) and after (ii) 1000 nM ProTx-II. Cells were treated 
with a 10 ms control pulse to -10 mV (giving current Ic), returned to -100 mV for a recovery 
interval ranging from 5 to 155 ms and then an identical test pulse was applied (giving current It). 
Holding potential was -100 mV and interpulse duration was 2 s. (B, C) Recovered current (It /Ic) 
plotted as a function of recovery interval and fitted with single exponential functions (solid 
lines) in control (open circles) and 1000 nM ProTx-II (black circles) for aNav1.5 (B; n = 6) and 
nNav1.5 (C; n = 6). Data are presented as mean ± SEM. Some error bars are smaller than 
symbols.  
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Figure 5.25 ProTx-II block of nNav1.5 and K211D were similar 
(A, B) Typical whole-cell nNav1.5 and K211D currents, before (black) and after (color) ProTx-
II application, elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from a holding potential 
of -80 mV: (A) 100 nM (blue) and (B) 1000 nM (red). nNav1.5 traces are re-plotted from Figure 
5.18 for comparison. Dashed horizontal lines indicate zero current. At each concentration, time-
course of peak current block / recovery is shown in the rightmost panel. For K211D (colored 
circles), n = 11-12 for 100-1000 nM, respectively. aNav1.5 (grey circles) and nNav1.5 (open 
circles) data are re-plotted from Figure 5.19 for comparison. Solid and dashed arrows indicate 
toxin application and washout, respectively. Currents were normalized to the peak current 
obtained by the first control pulse. (C) Typical whole-cell K211D currents, before and after 100 
nM ProTx-II, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -80 mV; interpulse duration was 2 s. (D) Mean ± SEM peak I-V relationships in control and 
ProTx-II (100-1000 nM) for K211D (n = 7-8). Currents after ProTx-II application were 
normalized to the maximal Na+ current in control (I/Imaxcontrol). Inset, corresponding normalized 
conductance transforms (G/Gmaxcontrol) fitted with Boltzmann functions (solid red lines).  
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ii. Hill equation fits to dose-response relationships (Figure 5.26) yielded the 
following statistically similar IC50 values for ProTx-II block for nNav1.5 and 
K211D: 
a. For normalized INa at -15 mV, IC50s were 1181.1 ± 227.2 nM for 
nNav1.5 and 728.7 ± 161.0 nM for K211D (P = 0.13).  
b. For normalized Imax, IC50s were 1222.6 ± 169.6 nM for nNav1.5 and 
1066.2 ± 233.3 nM for K211D (P = 0.60).  
c. For normalized Gmax, IC50s were 1982.3 ± 313.4 nM for nNav1.5 and 
1994.6 ± 501.3 nM for K211D (P = 0.98).  
iii. Modification of channel gating by ProTx-II was similar for nNav1.5 and 
K211D. Depolarization of I/Imax and G/Gmax curves by 100-1000 nM ProTx-II in 
K211D are shown in Figure 5.27AB. Toxin-induced shifts in Vthres, Vpeak and 
activation V1/2 were similar for K211D and nNav1.5 (Figure 5.27C). Delay in 
Tpeak of K211D by 1000 nM ProTx-II was 20-30% across the voltage-range 
tested (Figure 5.27D), which was similar to the delay observed for nNav1.5 
(Figure 5.22B). Finally, there was no effect of ProTx-II (1000 nM) on voltage-
dependence of inactivation or rate of recovery from inactivation for K211D 
(Figure 5.27EF), as also observed before for nNav1.5 (Figure 5.23 and 5.24).   
In conclusion, ProTx-II modification of the K211D mutant was not different from that 
of nNav1.5, i.e. the reduced potency of ProTx-II in nNav1.5 vs. aNav1.5 was not due to 
the presence of positive Lys211. 
 
5.2.4.6 Summary of effects of ProTx-II 
ProTx-II inhibited Nav1.5 activation thereby reducing Gmax, depolarizing voltage-range 
of activation and delaying onset of current activation (Tpeak). Reduction in Gmax (and  
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Figure 5.26 Lys211 was not responsible for the lower potency of ProTx-II in nNav1.5 
Concentration-response relationships for ProTx-II block of K211D (black diamonds) fitted with 
the Hill equation (dotted line; nH = 1): (A) peak current measured at -15 mV; (B) maximal Na+ 
current (Imax); (C) maximal Na+ conductance (Gmax). Data were obtained from normalized I-V 
and G-V relationships described in Figure 5.25. aNav1.5 (squares / solid line) and nNav1.5 
(circles / dashed line) data re-plotted from Figure 5.20 for comparison. Each data point 
represents a single cell; n = 7-8 for K211D in 100 and 1000 nM ProTx-II, respectively. In part 
C, the Hill curves for nNav1.5 and K211D overlap. IC50 estimates are reported in parentheses. 
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Figure 5.27 Modification of gating by ProTx-II was similar in nNav1.5 and K211D  
For A-D, data from recordings described in Figure 5.25 and analysis as before (Figure 5.21). 
(A) Normalized I-V relationships in control (open circles and squares), 100 nM ProTx-II (blue 
circles; n = 7) and 1000 nM ProTx-II (red circles; n = 8) for K211D. (B) Corresponding 
normalized G-V relationships (G/Gmax) fitted with Boltzmann functions (solid red lines). (C) 
Shifts (∆ mV) in parameters describing voltage-dependence of activation induced by 100 nM 
(blue) and 1000 nM ProTx-II (red) for aNav1.5, nNav1.5 and K211D; aNav1.5 and nNav1.5 
data re-plotted from Figure 5.21. Shifts in aNav1.5 were larger compared to nNav1.5 and 
K211D determined by ANOVA / Newman-Keuls post hoc; significance: (*) P < 0.05, (**) P < 
0.01. Shifts in nNav1.5 and K211D parameters were similar. (D) Time to peak, before (open 
circles) and after (black circles) 1000 nM ProTx-II plotted as a function of test potential and 
fitted with single-exponential functions (solid lines) for K211D (n = 8). Significance (paired t- 
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tests vs. control): (*) P < 0.05, (**) P < 0.01. (E) Availability-voltage relationships fitted with 
Boltzmann functions (solid lines) in control (open circles) and 1000 nM ProTx-II (black circles) 
for K211D (n = 7); pulse protocol and data analysis as before (Figure 5.23). (F) Recovered 
current (It /Ic) plotted as a function of recovery interval and fitted with single exponential 
functions (solid lines) in control (open circles) and 1000 nM ProTx-II (black circles) for K211D 
(n = 6); pulse protocol and data analysis as before (Figure 5.24). Data are presented as mean ± 
SEM. Some error bars are smaller than symbols.  
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Imax) was ~ 25-fold and shift of activation was ~ 10-fold selective for aNav1.5 vs. 
nNav1.5, suggesting toxin interaction with D1:S3/S4. Kinetics and voltage-dependence 
of inactivation or rate of recovery from inactivation were not modified by ProTx-II. 
Reduced potency of ProTx-II for nNav1.5 was not due to positive charge of Lys211.  
 
5.2.5 Interaction of HaTx with Nav1.5 D1:S3 variants  
5.2.5.1 Time-course and dose-dependence of block: selectivity for aNav1.5 
HaTx was puff-applied similar to ProTx-II. The extent of channel modification by HaTx 
(20-5000 nM) was assessed with single pulses to -15 mV (0.2 Hz frequency, Vh = -80 
mV). As shown in Figure 5.28 (rightmost panels), HaTx inhibited Nav1.5 currents 
rapidly and reversibly; at concentrations ≥ 200 nM, toxin block was stable within ~ 20 s 
and fully reversible within ~ 40 s of washout (Figure 5.28AB). As for ProTx-II, onset of 
HaTx block was exceedingly rapid at high toxin concentrations (i.e. near-maximal block 
in the first pulse after toxin application) preventing determination of onset τ (Figure 
5.28B). Interestingly, unlike ProTx-II, HaTx significantly slowed Nav1.5 inactivation 
kinetics in addition to blocking peak current, which was evident from the intersection of 
control and HaTx traces shown in Figure 5.28AB (e.g. at 200 nM for aNav1.5 and at 
1000 nM for nNav1.5); this is further discussed in Section 5.2.5.2. 
Compared to nNav1.5, aNav1.5 currents were markedly more sensitive to HaTx, 
as illustrated with the typical recordings in Figure 5.28. In particular, 200 nM HaTx 
reduced peak INa by > 50% and noticeably slowed inactivation kinetics in aNav1.5, 
whilst only minimally affecting nNav1.5 activity (n = 7-9; Figure 5.28A). Half-maximal 
inhibition and slowing of inactivation in nNav1.5 was observed only at micromolar 
HaTx (1000 nM), which produced near-maximal effects on aNav1.5 (n = 10-12; Figure 
5.28B). Dose-response relationships were constructed in the range 20-5000 nM for data  
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Figure 5.28 HaTx was selective for aNav1.5 over nNav1.5 
(A, B) Typical whole-cell aNav1.5 and nNav1.5 currents, before (black) and after (color) HaTx 
application, elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from a holding potential of 
-80 mV: (A) 200 nM (blue) and (B) 1000 nM (red). First control current and trace for maximum 
HaTx block are shown; dashed horizontal lines indicate zero current. At each concentration, 
time-course of peak current block / recovery is shown in the rightmost panel; aNav1.5 (black 
circles) and nNav1.5 (open circles). Solid and dashed arrows indicate HaTx application and 
washout, respectively. Currents were normalized to peak current obtained by the first control 
pulse; data are mean ± SEM (n = 7-12). (C) Concentration-response curve for HaTx inhibition 
of aNav1.5 (squares) and nNav1.5 (circles) fitted with the Hill equation (smooth lines; nH = 1). 
Data are normalized peak currents measured at -15 mV (protocol as in part A). Each data point 
represents a single cell (n = 4-12). Values reported in parentheses are IC50 estimates. 
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recorded at -15 mV (Figure 5.28C), since block at this potential was well-representative 
of Imax block (i.e. a ‘test-voltage independent’ parameter) in the case of ProTx-II (Figure 
5.20). Consistent with previous reports, dose-response curves for HaTx block of 
aNav1.5 and nNav1.5 were well-fit by a single-site Hill equation with nH = 1 (Figure 
5.28C) (Swartz and MacKinnon, 1995, 1997a). Minima of both fits were statistically 
similar to 0%, suggesting complete inhibition of both Nav1.5 variants at saturation 
(Figure 5.28C). IC50 estimates revealed that HaTx was ~ 5-fold selective for aNav1.5 
(198.8 ± 19.9 nM) over nNav1.5 (979.0 ± 103.0 nM; P < 0.001). This suggested that, 
similar to ProTx-II, HaTx interacted with the spliced D1:S3/S4 region in Nav1.5. 
 
5.2.5.2 Effects on steady-state activation and gating kinetics 
Studies on HaTx inhibition in Kv channels revealed that the toxin interacts and traps 
S3-S4 voltage-paddles in their resting states, thereby inhibiting channel activation 
(Swartz and MacKinnon, 1995, 1997a; Lee et al., 2003; Milescu et al., 2007). In order 
to gain an insight to the mechanism of HaTx block of the Nav1.5 variants, we recorded 
I-V relationships in the absence and presence of 1000 nM HaTx (Figure 5.29A and 
Table 5.5). Normalized I-V relationships (I/Imaxcontrol) and the corresponding 
conductance transforms (G/Gmaxcontrol) revealed that HaTx inhibited Nav1.5 currents 
through reducing Gmax and depolarizing activation voltage-dependence (Figure 
5.29BC), consistent with toxin-induced inhibition of channel activation as in Kv 
channels. As previously discussed for ProTx-II (see Section 5.2.4.3), positive shifts in 
activation gating indicated that HaTx-bound Nav1.5 channels can possibly activate but 
require larger energy to do so. This is also consistent with earlier findings indicating 
activation of toxin-bound Kv channels (Swartz and MacKinnon, 1995, 1997a; Lee et 
al., 2003). 
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Figure 5.29 HaTx block of peak Na+ conductance was larger in aNav1.5 vs. nNav1.5 
(A) Typical whole-cell aNav1.5 and nNav1.5 currents, before and after 1000 nM HaTx, elicited 
by 60 ms depolarizing pulses to between -80 mV and +45 mV from a holding potential of -80 
mV; interpulse duration was 2 s. (B, C) Normalized I-V relationships before and after 1000 nM 
HaTx for aNav1.5 (B; n = 8) and nNav1.5 (C; n = 5). Currents were normalized to the maximal 
Na+ current in control (I/Imaxcontrol). Corresponding normalized conductance transforms 
(G/Gmaxcontrol) are shown underneath the I-V relationships. Data are mean ± SEM. Some error 
bars are smaller than symbols. 
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Table 5.5 Effects of HaTx (1000 nM) on Nav1.5 D1:S3 variants 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For abbreviations, see Table 4.1; nNav1.5 data in red and aNav1.5 in black. Paired1 (comparing HaTx vs. control) and unpaired2 (comparing effects 
of HaTx on nNav1.5 vs. aNav1.5) t-tests were used to determine statistical significance: (*) P < 0.05, (**) P < 0.01. Data are mean ± SEM.
Parameter Control HaTx n P-value (vs. 
control) 1 
P-value (nNav1.5 
vs. aNav1.5) 2 
      
Relative Imax (%)  100.0 ± 0.0   100.0 ± 0.0  
50.0 ± 11.1  
13.1 ± 2.0  5-8 
0.002 ** 
< 0.001 ** 0.03 * 
Relative Gmax (%)  100.0 ± 0.0  100.0 ± 0.0  
51.2 ± 10.1  
19.9 ± 3.7  5-8 
0.007 ** 
< 0.001 ** 0.03 * 
Vthres (mV)  -52.5 ± 1.1  
-56.0 ± 1.5  
-51.0 ± 1.9  
-41.9 ± 3.0  5-8 
0.37 
< 0.001 ** < 0.001 ** 
Vpeak (mV)  -16.0 ± 2.9  
-21.9 ± 2.5  
-14.0 ± 3.7  
1.3 ± 3.5  5-8 
0.59 
< 0.001 ** 0.002 ** 
Activation V1/2  (mV)  -30.4 ± 2.7  
-36.1 ± 1.5  
-30.4 ± 2.4  
-12.4 ± 3.5  5-8 
0.97 
< 0.001 ** < 0.001 ** 
Activation k (mV)  6.2 ± 0.3  5.6 ± 0.3  
6.7 ± 0.2  
11.3 ± 1.0  5-8 
0.07 
< 0.001 ** < 0.001 ** 
Inactivation V1/2 (mV)  -78.5 ± 1.5  
-79.3 ± 1.5  
-81.0 ± 1.5  
-79.3 ± 1.6  4-5 
0.07 
0.99 - 
Inactivation k (mV) -5.5 ± 0.6  
-5.1 ± 0.3  
-5.3 ± 0.3  
-5.7 ± 1.4  4-5 
0.62 
0.63 - 
V0 (mV)  17.8 ± 1.8  19.0 ± 2.6  
16.5 ± 2.3  
17.5 ± 5.5  5-8 
0.49 
0.90 - 
Tpeak at 0 mV (ms)  0.49 ± 0.03  0.46 ± 0.02  
0.61 ± 0.02  
0.81 ± 0.08  5-8 
0.003 ** 
0.002 ** 0.01 * 
τfast at 0 mV (ms)  0.34 ± 0.01  0.33 ± 0.01 
0.42 ± 0.03  
2.18 ± 0.22 5-8 
0.01* 
0.001 ** 0.002 ** 
τslow at 0 mV (ms)  3.30 ± 0.44 4.24 ± 0.56  
3.95 ± 0.54  
8.23 ± 0.82  5-8 
0.18 
0.04 * 0.02 * 
τrecovery (ms)  8.1 ± 1.1  6.8 ± 0.7  
11.3 ± 2.0  
9.1 ± 1.0  5-8 
0.25 
0.09 - 
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As regards selectivity for aNav1.5 over nNav1.5, HaTx (1000 nM) blocked Gmax 
by 80.1 ± 3.7% in aNav1.5 but only 48.8 ± 10.1% in nNav1.5 (P < 0.05, n = 5-8) 
(Figure 5.29 and Table 5.5). Moreover, 1000 nM HaTx depolarized activation V1/2 in 
aNav1.5 by 23.8 ± 3.0 mV (P < 0.001 vs. control, n = 8), but had no significant effect 
on V1/2 in nNav1.5 (P = 0.97 vs. control, P < 0.001 vs. aNav1.5, n = 5) (Figure 5.30E 
and Table 5.5). Corresponding shifts in Vthres and Vpeak for aNav1.5 were 14.1 ± 2.1 and 
23.1 ± 4.1 mV (P < 0.001 vs. control for both); there was no effect on either parameter 
for nNav1.5 (P = 0.37 and 0.59 vs. control respectively, P < 0.001 vs. aNav1.5 for both) 
(Figure 5.30E and Table 5.5). Finally, 1000 nM HaTx nearly doubled the activation 
slope factor (k) from 5.6 ± 0.3 to 11.3 ± 1.0 mV / e-fold in aNav1.5 (P < 0.001 vs. 
control), whilst there was no such effect for nNav1.5 (P = 0.07 vs. control, P < 0.001 vs. 
aNav1.5) (Figure 5.30E and Table 5.5). These differences further indicated that HaTx 
interacted with the spliced D1:S3/S4 region in Nav1.5. 
Activation and inactivation kinetics of Nav1.5 variants were significantly slower 
in the presence of HaTx (Figure 5.31). As shown in Figure 5.31A, at -15 mV, 1000 nM 
HaTx induced a progressive delay of Tpeak and fast inactivation from open-state (τfast and 
τslow), both effects reaching steady-state within 1 min of toxin application. Importantly, 
slowing of channel kinetics was more pronounced for aNav1.5 vs. nNav1.5, in line with 
the apparent selectivity of HaTx for aNav1.5 (Figure 5.31BC). To quantify these 
differences at a range of voltages, effects of HaTx (1000 nM) on channel kinetics were 
studied using the I-V recordings described in Figure 5.29 and 5.30. The findings can be 
summarized as follows (Figure 5.32 and Table 5.5): 
i. Tpeak was significantly slowed by HaTx in both Nav1.5 variants; this delay was ~ 
3-fold larger in aNav1.5 (~ 75%) vs. nNav1.5 (~ 25%) across the voltage-range  
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Figure 5.30 HaTx induced larger depolarization of activation voltage-dependence in 
aNav1.5 vs. nNav1.5 
(A, C) Normalized I-V relationships in control (open circles) and 1000 nM HaTx (black circles) 
for aNav1.5 (A) and nNav1.5 (C). (B, D) Corresponding normalized G-V relationships fitted 
with Boltzmann functions (solid red lines) for aNav1.5 (B) and nNav1.5 (D). Some error bars 
are smaller than symbols. (E) Shifts (∆ mV) in parameters describing voltage-dependence of 
activation induced by 1000 nM HaTx. Unpaired t-tests were used to compare the shifts in 
aNav1.5 vs. nNav1.5; significance: (**) P < 0.01. Data were from recordings described in 
Figure 5.29 and are presented as mean ± SEM (n = 5-8).  
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Figure 5.31 HaTx slowed activation and inactivation kinetics in aNav1.5 and nNav1.5 
(A) Normalized nNav1.5 currents elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from 
a holding potential of -80 mV before and after 1000 nM HaTx. Progressive slowing of 
activation and inactivation kinetics was evident; these effects reached steady-state within 1 min 
of HaTx application. 4 traces (20 s) of control and 8 traces following HaTx application (40 s) 
are shown. (B, C) Normalized aNav1.5 (B) and nNav1.5 (C) currents recorded as in part A in 
control and 1000 nM HaTx. First control current and trace for maximum HaTx effect are 
shown. Slowing of activation (Tpeak) and inactivation kinetics (τfast and τslow) were more 
pronounced in aNav1.5 (B) vs. nNav1.5 (C); quantitative data are presented in Figure 5.32. 
Dashed horizontal lines indicate zero current.  
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Figure 5.32 HaTx slowed channel kinetics selectively in aNav1.5 vs. nNav1.5 
Data were from recordings described in Figure 5.29 and are presented as mean ± SEM. Some 
error bars are smaller than symbols. (A, B) Time to peak (Tpeak) plotted as a function of test 
potential and fitted with single exponential functions (solid lines) in control (open circles) and 
1000 nM HaTx (black circles) for aNav1.5 (A; n = 8) and nNav1.5 (B; n = 5). Statistical 
significance was determined by paired t-tests vs. control: (*) P < 0.05, (**) P < 0.01. Slowing of 
Tpeak was larger in aNav1.5 vs. nNav1.5 (unpaired t-tests: (#) P < 0.05).  (C, D) Inactivation time 
constants (τfast and τslow), determined from double exponential fits to Na+ current decays, plotted 
as a function of test potential in control (open circles) and 1000 nM HaTx (black circles) for 
aNav1.5 (C; n = 8) and nNav1.5 (D; n = 5). Data points are connected with straight lines for 
clarity. Statistical significance was determined by paired t-tests vs. control: (*) P < 0.05, (**) P 
< 0.01. Slowing of inactivation time constants was larger in aNav1.5 vs. nNav1.5 (unpaired t-
tests: (#) P < 0.05). 
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tested (n = 5-8; Figure 5.32AB and Table 5.5). Voltage-dependence of Tpeak (V0) 
was not altered in either Nav1.5 variant (Table 5.5). 
ii. τfast obtained from double exponential fits to normalized INa decays was slowed 
by HaTx in both Nav1.5 variants; this effect was significantly larger in aNav1.5 
(~ 5-fold slowing) vs. nNav1.5 (~ 20% slowing) (n = 5-8; Figure 5.32CD and 
Table 5.5). HaTx also delayed τslow in aNav1.5 (~ 2-fold) but not in nNav1.5 (n = 
5-8; Figure 5.32CD and Table 5.5). Note that substantial depolarisation of 
activation gating in aNav1.5 prevented the study of inactivation kinetics for test 
potentials more hyperpolarized than -15 mV (Figure 5.32CD). 
iii. Relative amplitudes of τfast and τslow were shifted by HaTx towards slow gating 
mode in both Nav1.5 variants; the magnitude of this percentage shift was similar 
in aNav1.5 and nNav1.5 (~ 25-35% across the voltage-range tested). For 
instance, at 0 mV, percentage amplitudes of τfast in aNav1.5 and nNav1.5 were 
94.5 ± 0.7  and 89.4 ± 2.3% in control and 64.4 ± 5.9 and 57.8 ± 3.6 % in HaTx, 
respectively (P < 0.01 vs. control for both, P = 0.78 for aNav1.5 vs. nNav1.5,  
n = 5-8).  
Taken together, (i) HaTx-induced changes in kinetics of activation and inactivation 
further suggested that toxin-bound Nav1.5 channels are capable of activation albeit with 
altered gating properties, and (ii) differential modification of channel kinetics in 
aNav1.5 vs. nNav1.5 further validated D1:S3/S4 as a HaTx binding site in Nav1.5. 
 
5.2.5.3 Effects on steady-state inactivation and recovery from inactivation 
Similar to ProTx-II, HaTx did not modify voltage-dependence of steady-state 
inactivation in Nav1.5 variants. Boltzmann fits to availability-voltage relationships 
revealed that inactivation V1/2 and k were unchanged by 1000 nM HaTx in either Nav1.5 
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variant (Figure 5.33AB and Table 5.5). On the other hand, rate of recovery from 
inactivation was slightly and similarly slowed by 1000 nM HaTx in Nav1.5 variants 
(Figure 5.33CD). Slowing of channel recovery was apparent only after short recovery 
intervals (< 25 s), and single exponential fits to recovery time-courses yielded τrecovery 
values that were similar in the presence / absence of HaTx for both Nav1.5 variants 
(Figure 5.33CD and Table 5.5). For instance, τrecovery in aNav1.5 and nNav1.5 were 8.1 ± 
1.1 ms and 6.8 ± 0.7 ms in control and 11.3 ± 2.0 ms and 9.1 ± 1.0 ms in HaTx, 
respectively (P = 0.25 and 0.09 vs. control, respectively, n = 5-8).  
 
5.2.5.4 Interaction of HaTx with nNav1.5 K211D mutant  
Similar to ProTx-II, HaTx is positively charged (+2 or +3 depending on protonation of 
His18; Figure 1.14) and its bioactive surface is thought to be constituted mainly by 
hydrophobic and cationic residues (Swartz, 2007). Thus, as for ProTx-II, we anticipated 
that Asp211 to Lys211 switch in nNav1.5 may, at least in part, be responsible for the 
reduced sensitivity of nNav1.5 to HaTx through an electrostatic effect.  
We tested this hypothesis by studying the interaction of HaTx with the nNav1.5 
K211D mutant, using pulse protocols and data analysis as before for nNav1.5 / aNav1.5. 
The results were as follows: 
i. At -15 mV, the extent of HaTx inhibition was similar in nNav1.5 and K211D, 
e.g. there was minimal effect at 200 nM and 50-60% current block at 1000 nM 
(Figure 5.34AB). Dose-response relationships (Figure 5.34C) yielded 
statistically similar IC50 values for HaTx block for nNav1.5 (979.0 ± 103.0 nM) 
and K211D (859.7 ± 129.0) (P = 0.49). Consistently, I/Imaxcontrol and 
G/Gmaxcontrol relationships revealed that that 1000 nM HaTx blocked Imax and 
Gmax similarly by ~ 50% in nNav1.5 and K211D (Figure 5.29AC and 5.35AB).  
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Figure 5.33 HaTx did not modify steady-state inactivation and slowed recovery from 
inactivation slightly in Nav1.5 variants   
(A, B) Availability-voltage relationships fitted with Boltzmann functions (solid lines) in control 
(open circles) and 1000 nM HaTx (black circles) for aNav1.5 (A; n = 5) and nNav1.5 (B; n = 4). 
Data were recorded by 80 ms test pulses to -10 mV after 1 s pre-pulses in the range -140 mV to 
-10 mV; holding potential was -100 mV and interpulse duration was 2 s. Currents (I) were 
normalized to the maximum current (Imax) recorded following the most hyperpolarized pre-
pulse (-140 mV). (C, D) Recovered current (It /Ic) plotted as a function of recovery interval and 
fitted with single exponential functions (solid lines) in control (open circles) and 1000 nM HaTx 
(black circles) for aNav1.5 (B; n = 8) and nNav1.5 (C; n = 5). Cells were treated with a 10 ms 
control pulse to -10 mV (giving current Ic), returned to -100 mV for a recovery interval ranging 
from 5 to 155 ms and then an identical test pulse was applied (giving current It). Holding 
potential was -100 mV and interpulse duration was 2 s. Statistical significance was determined 
by paired t-tests: (*) P < 0.05, (**) P < 0.01. There was no differential effect on aNav1.5 vs. 
nNav1.5 (unpaired t-tests, P > 0.05). Data are presented as mean ± SEM. Some error bars are 
smaller than symbols.  
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Figure 5.34 HaTx block of peak Na+ current in nNav1.5 and K211D were similar 
(A, B) Typical whole-cell nNav1.5 and K211D currents, before (black) and after (color) HaTx 
application, elicited by 12 ms depolarizing steps to -15 mV at 0.2 Hz from a holding potential of 
-80 mV: (A) 200 nM (blue) and (B) 1000 nM (red). nNav1.5 traces are re-plotted from Figure 
5.28 for comparison. Dashed horizontal lines indicate zero current. At each concentration, time-
course of peak current block / recovery is shown in the rightmost panel. For K211D (colored 
circles), n = 6-7 for 200-1000 nM, respectively. aNav1.5 (grey circles) and nNav1.5 (open 
circles) data are re-plotted from Figure 5.28 for comparison. Solid and dashed arrows indicate 
toxin application and washout, respectively. Currents were normalized to the peak current 
obtained by the first control pulse. (C) Concentration-response curve for HaTx in K211D (black 
diamonds) fitted with the Hill equation (dotted line; nH = 1). Each data point represents a single 
cell (n = 6-7 for K211D). aNav1.5 (squares / solid line) and nNav1.5 (circles / dashed line) data 
re-plotted from Figure 5.28 for comparison. Data are normalized peak currents measured at -15 
mV (protocol as in part A). Values reported in parentheses are IC50 estimates. 
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Figure 5.35 HaTx-modification of voltage-dependence of activation was greater in K211D 
vs. nNav1.5 
(A) Typical whole-cell K211D currents, before and after 1000 nM HaTx, elicited by 60 ms 
pulses to between -80 mV and +45 mV from a holding potential of -80 mV; interpulse duration 
was 2 s. (B) Mean ± SEM peak I-V relationships in control and 1000 nM HaTx for K211D (n = 
5). Currents were normalized to the maximal Na+ current in control (I/Imaxcontrol). Inset, 
corresponding normalized conductance transforms (G/Gmaxcontrol). (C) Normalized G-V 
relationships (normalized to maximal current within each treatment group; G/Gmax) fitted with 
Boltzmann functions (solid red lines) in control and 1000 nM HaTx for K211D (n = 5). (D) 
Shifts (∆ mV) in parameters describing voltage-dependence of activation induced by 1000 nM 
HaTx for aNav1.5, nNav1.5 and K211D; aNav1.5 and nNav1.5 data re-plotted from Figure 
5.30. Shifts in Nav1.5 variants / mutant were compared using ANOVA / Newman-Keuls post 
hoc. Significance: (i) For aNav1.5 vs. nNav1.5: (*) P < 0.05, (**) P < 0.01. (ii) For aNav1.5 vs. 
K211D: (#) P < 0.05, (##) P < 0.01. (iii) For K211D vs. nNav1.5: ($$) P < 0.01. 
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ii. 1000 nM HaTx depolarized activation V1/2 by 9.1 ± 1.0 mV in K211D (Figure 
5.35CD), whilst having no effect on nNav1.5 (Figure 5.30CD and 5.35D). The 
corresponding shift in aNav1.5 was 23.8 ± 3.0 mV (Figure 5.30AB and 5.35D). 
ANOVA followed by Newman-Keuls post hoc analysis revealed that toxin-
induced shift in activation V1/2 was significantly greater in aNav1.5 vs. K211D 
(P < 0.001) and K211D vs. nNav1.5 (P < 0.001). There was a tendency for other 
parameters describing activation voltage-dependence (Vthres, Vpeak and activation 
k) to be affected more in K211D vs. nNav1.5; however, these differences were 
not statistically significant (P > 0.05 for all) (Figure 5.35D).  
iii. HaTx (1000 nM) slowed Tpeak in K211D by 20-30% across the voltage-range 
tested (Figure 5.36A), which was similar to the delay observed in nNav1.5 
(Figure 5.32B). Modification of inactivation from open-state was also the same 
in K211D and nNav1.5, i.e. τfast was delayed 20-25 % across the voltage-range 
tested, τslow was not altered, and percentage amplitude shift towards τslow was 
similar at ~ 30% (Figure 5.32 CD and 5.36 BC).  
iv. 1000 nM HaTx did not modify voltage-dependence of steady-state inactivation 
and slightly slowed recovery from inactivation in K211D (Figure 5.36DE), as 
observed before in nNav1.5 (Figure 5.33 BD).   
Thus, HaTx modified nNav1.5 and the K211D mutant similarly, except for positively 
shifting activation gating in K211D but not in nNav1.5. 
 
5.2.5.5 Summary of effects of HaTx 
HaTx inhibited Nav1.5 activation thereby reducing Gmax, positively shifting voltage-
range of activation and delaying activation kinetics (Tpeak). Additionally, inactivation 
kinetics and rate of recovery from inactivation were slowed, whilst there was no effect  
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Figure 5.36 HaTx-modification of channel kinetics, voltage-dependence of inactivation, 
and recovery from inactivation were similar in nNav1.5 and K211D 
For A-C, data were from recordings described in Figure 5.35. (A) Time to peak (Tpeak) as a 
function of test potential fitted with single-exponential functions (solid lines) before (open 
circles) and after (black circles) 1000 nM HaTx for K211D (n = 5). (B, C) Inactivation time 
constants τfast (B) and τslow (C) as a function of test potential in control (open circles) and 1000 
nM HaTx (black circles) for K211D (n = 5); data points are connected with straight lines for 
clarity. (D) Availability-voltage relationships fitted with Boltzmann functions (solid lines) in 
control (open circles) and 1000 nM HaTx (black circles) for K211D (n = 6); pulse protocol and 
data analysis as before (Figure 5.33). (E) Recovered current (It /Ic) plotted as a function of 
recovery interval and fitted with single exponential functions (solid lines) in control (open 
circles) and 1000 nM HaTx (black circles) for K211D (n = 3); pulse protocol and data analysis 
as before (Figure 5.33). Statistical significance was determined by paired t-tests vs. control: (*) 
P < 0.05. Slowing of Tpeak, τfast, and channel recovery was similar in K211D and nNav1.5 (see 
Figure 5.32 and 5.33) as determined with unpaired t-tests. Data are presented as mean ± SEM. 
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on steady-state inactivation. HaTx was 5-fold more potent in blocking aNav1.5 vs. 
nNav1.5, and induced substantial depolarization of activation voltage-range in aNav1.5 
but not in nNav1.5. Slowing of activation and inactivation kinetics was also 
significantly larger in aNav1.5 vs. nNav1.5. These results suggested binding of HaTx to 
the D1:S3/S4 linker in Nav1.5. The key Asp211 (aNav1.5) to Lys211 (nNav1.5) switch in 
nNav1.5 was only partly responsible for the reduced toxin effect on voltage-dependence 
of activation, and did not mediate differential modification of other aspects of channel 
function by HaTx. 
 
5.2.6 Inhibition of Nav1.5 D1:S3 variants by NESOpAb 
5.2.6.1 General observations and controls 
Similar to ProTx-II and HaTx, NESOpAb was puff-applied in patch-clamp experiments. 
In control recordings, ‘background’ effects of puff-application on Nav1.5 variants were 
studied with single pulses to 0 mV at 0.1 Hz frequency. Upon puff-application of 
control MPS, there was no apparent change in kinetics of channel gating (Figure 
5.37A), whilst peak current amplitude was reduced slightly by 7.7 ± 1.0% in nNav1.5 
(P < 0.05 vs. control, n = 12), 8.9 ± 1.4% in aNav1.5 (P < 0.05 vs. control, n = 8) and 
6.7 ± 2.5% in K211D (P < 0.05 vs. control, n = 6) (Figure 5.37AB). Such ‘puff block’ 
possibly occurred due to mechanical stress brought onto the plasma membrane by the 
local high-pressure application of solutions. Indeed, Nav1.5 (and other VGSCα) activity 
has been shown to be mechanosensitive, i.e. responsive to physical bilayer deformations 
(e.g. Tabarean et al., 1999; Morris and Juranka, 2007). Alternatively, puff-application 
may have interfered with the mechanics of ion flow in / around channel pore, thereby 
slightly altering channel conductance. 
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Figure 5.37 Puffing resulted in small but significant block of Nav1.5 currents  
Effects of puffing (MPS only) on Na+ currents recorded from EBNA-293 cells expressing 
nNav1.5 (n = 12), aNav1.5 (n = 8) and K211D (n = 6). (A) Whole-cell Na+ currents, before and 
after puff application of MPS, elicited by 12 ms depolarizing steps to 0 mV at 0.1 Hz from a 
holding potential of -100 mV; traces are from a nNav1.5 cell that showed the largest sensitivity 
to puffing among the 26 cells studied. ‘Puff block’ was rapid (stable within < 20 sec; the trace 
shown was recorded on the second pulse following application) and fully reversible. Dashed 
horizontal line indicates zero current. (B) Average ‘puff block’ of peak current in nNav1.5 (7.7 
± 1.0%), aNav1.5 (8.9 ± 1.4%) and K211D (6.7 ± 2.5%); these were statistically significant 
(paired t-test vs. control; P < 0.05). Block levels were similar among Nav1.5 variants (ANOVA; 
P = 0.62); combined percentage block was 7.8 ± 0.8%. Data are presented as mean ± SEM. 
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Importantly, the ‘puff block’ was similar among the Nav1.5 variants (ANOVA, 
P = 0.62) (Figure 5.37B), and hence, did not bias any comparative analysis. 
Accordingly, we did not previously attempt to compensate for this error while 
comparing the effects of ProTx-II and HaTx on Nav1.5 variants. However, in the case 
of NESOpAb, one of the aims was to characterize the ‘threshold’ concentration for 
current block, for which, compensation of ‘background’ effects of puffing was 
necessary. Since ‘puff-block’ was not differential among Nav1.5 variants, data from 
nNav1.5, aNav1.5 and K211D were combined to give an overall ‘puff block’ of 7.8 ± 
0.8% (n = 26) (Figure 5.37B). This value was subtracted from the time-course and dose-
response data presented in Figure 5.39-5.41. Also, since ‘puff block’ was fully and 
rapidly reversible (Figure 5.37A), it was not subtracted from the recovery data points 
shown in Figure 5.39C. For the rest of the results described, effects of puffing were 
compensated only when the pulse protocol for a given recording was identical to the 
one used to determine ‘puff block’ (e.g. Figure 5.46).  
In preliminary recordings, when studied with 0.1 Hz depolarisations to 0 mV, 
1000 ng/ml NESOpAb (maximum antibody concentration used in the present study) 
inhibited peak nNav1.5 currents by > 70% (n = 8; ‘puff block’ not compensated) 
(Figure 5.38). To ensure that this block was due to specific binding of NESOpAb to its 
target sequence in D1:S3/S4, the following control experiments were performed using 
the same pulse protocol as above: (Figure 5.38): (i) Antibody storage buffer equivalent 
to 1000 ng/ml antibody (n = 4); (ii) 1000 ng/ml NESOpAb pre-absorbed with 5-fold (by 
weight) excess of the immunizing peptide (n = 6), and (iii) 1000 ng/ml non-specific 
healthy rabbit IgG fraction (Dako, n = 5). Compared with the ‘puff block’, none of the 3 
treatments was effective (ANOVA, P = 0.27), confirming specificity of NESOpAb.  
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Figure 5.38 Controls for NESOpAb had no effect beyond ‘puff block’ 
Experiments were performed in EBNA-293 cells expressing nNav1.5; data for NESOpAb (‘puff 
block’ not compensated) and MPS (from Figure 5.37) are included for comparison. (A) 
Representative whole-cell Na+ currents, elicited by 12 ms depolarizing steps to 0 mV at 0.1 Hz 
from a holding potential of -100 mV, before (black) and after (red) puff application of: (i) 1000 
ng/ml NESOpAb (n = 8), (ii) MPS (n = 12); (iii) antibody storage buffer (equivalent to 1000 
ng/ml NESOpAb; n = 4); (iv) 1000 ng/ml NESOpAb pre-absorbed with 5x excess immunizing 
peptide (n = 6); (v) healthy rabbit IgG fraction (1000 ng/ml; n = 5). First control trace and trace 
for maximum current block are shown; dashed horizontal lines indicate zero current. (B) 
Average inhibition of peak nNav1.5 current in solutions described in part A. Block induced by 
control solutions (ii-v) were statistically significant (paired t-test vs. control; P < 0.05) and 
similar (ANOVA; P = 0.27). Data are presented as mean ± SEM. 
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5.2.6.2 Time-course of NESOpAb block  
Kinetics of current block by NESOpAb was characterized using low-frequency (0.1 Hz) 
voltage-pulses to 0 mV (Vh = -100 mV). At 1000 ng/ml, inhibition of each Nav1.5 
variant occurred at the first pulse following application (< 10 s) and reached a steady-
state after ~ 2 minutes (n = 7-8; Figure 5.39AB). Block was slower in the presence of 
lower antibody concentrations, e.g. at 10 ng/ml, stable block levels were achieved only 
after ~ 5 minutes (data not shown). The onset time constants (τ) for block determined 
from single exponential fits were similar (~ 30 s) in all three Nav1.5 variants (Figure 
5.39B). However, slight changes in puff-application times or cell-to cell variability in 
the positioning of the puff-pipette may have affected accurate determination of onset 
time-constants, as discussed earlier (see Section 5.2.4.1).  
Recovery of Nav1.5 currents from NESOpAb (1000 ng/ml) block was slow and 
incomplete during the monitored recovery period (Figure 5.39C). Importantly, nNav1.5 
recovery was less complete and occurred with a slightly slower offset τ (~ 95 s) 
compared to aNav1.5 and K211D (τ ~ 65 s) (Figure 5.39C). This indicated higher 
selectivity of NESOpAb for D1:S3/S4 in nNav1.5 vs. aNav1.5 and K211D. Recovery of 
Nav1.5 variants was more complete at concentrations < 1000 ng/ml, and recovery 
within 10% of control was observed at 10 ng/ml (Figure 5.39D).  
 
5.2.6.3 Dose-dependence of block: importance of Lys211 for selectivity in nNav1.5 
Recordings shown in Figure 5.39 were consistent with earlier findings by Chioni et al. 
(2005) that NESOpAb block is greater for nNav1.5 vs. aNav1.5. Furthermore, the 
apparent reduced potency of NESOpAb for the K211D mutant (Figure 5.39B) 
suggested that Lys211 may be critical for selectivity of antibody-channel interaction in 
nNav1.5. To formalize these observations, we characterized dose-dependence (in the  
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Figure 5.39 NESOpAb was selective for nNav1.5: kinetics of inhibition and reversibility 
(A) Representative whole-cell nNav1.5 currents, before and after puff application of 1000 ng/ml 
NESOpAb, elicited by 12 ms depolarizing steps to 0 mV at 0.1 Hz from a holding potential of -
100 mV. First control current and every other trace in NESOpAb (until maximum block) are 
shown; pulse numbering starts after NESOpAb application. Dashed horizontal line indicates 
zero current. (B) Time-course of peak current block by 1000 ng/ml NESOpAb (‘puff block’ was 
compensated) for nNav1.5 (n = 7), aNav1.5 (n = 8) and K211D (n = 8). (C) Time course of 
recovery from NESOpAb (1000 ng/ml) block in the same cells. For parts B and C, solid lines 
represent single-exponential fits to data; estimated time constants are reported in parentheses. 
Solid and dashed arrows indicate NESOpAb application (part B) and washout (part C), 
respectively. (D) Maximal recovered current during washout at different NESOpAb 
concentrations for nNav1.5, aNav1.5 and K211D (n = 5-8). For B-D, data were normalized to 
peak current obtained by the first control pulse and are presented as mean ± SEM.  
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range 0.05-1000 ng/ml) of NESOpAb block for all three Nav1.5 variants (Figure 5.40). 
Block was monitored using single-pulses to 0 mV at 0.1 Hz frequency (Vh = -100 mV). 
Normalized currents remaining after antibody application are shown in Figure 5.40B. 
As suggested by the following quantitative evaluations, NESOpAb block was selective 
for nNav1.5 vs. aNav1.5, whilst Lys/Asp211 was critical for this selectivity: 
i. Threshold of block. This was the lowest antibody concentration inducing current 
inhibition in more than 50% of the cells tested after compensating for ‘puff-
block’. At 1 ng/ml, NESOpAb blocked all nNav1.5 cells tested on average by 
12.6 ± 2.5% (n = 10), whilst there was no detectable effect beyond ‘puff-block’ 
in 12 out of 14 aNav1.5 cells (Figure 5.40AB and Table 5.6). In K211D, 6 out of 
11 cells were responsive, but on average antibody inhibition was only 1.1 ± 1.2 
% beyond ‘puff-block’ (P < 0.001 vs. nNav1.5, n = 11). At a lower 
concentration of 0.05 ng/ml, there was no effect of NESOpAb on any K211D 
cell tested (n = 13), whilst currents in 7 out 10 nNav1.5 cells were inhibited by 
2.6 ± 1.4% beyond ‘puff-block’ (n = 10) (Figure 5.40B and Table 5.6). Overall, 
therefore, the threshold for antibody block in nNav1.5 (0.05 ng/ml) was 
respectively ~ 20-fold and ~ 200-fold lower compared to K211D (1 ng/ml) and 
aNav1.5 (10 ng/ml) (Figure 5.40C). Testing of more ‘intermediate’ antibody 
concentrations, which would have yielded more accurate estimates for threshold 
of antibody block, was not performed due to low-throughput data collection 
imposed by puff-application of the antibody, i.e. only one concentration per cell 
could be studied.  
ii. Maximal block. Maximal antibody block (at 1000 ng/ml) in nNav1.5 (67.3 ± 
3.0%, n = 8) was significantly larger than that in K211D (46.2 ± 3.4%; P < 0.01, 
n = 10) and aNav1.5 (42.0 ± 4.9%; P < 0.01 vs. nNav1.5, P = 0.49 vs. K211D, n  
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Parameter nNav1.5 aNav1.5 K211D 
Threshold (ng/ml)  ~ 0.05 ~ 10 ~ 1 
Half-max. block (ng/ml) ~ 23 ~ 90 ~ 54 
Maximal block (%) 67.3 ± 3.0 42.0 ± 4.9 46.2 ± 3.4 
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Figure 5.40 Lys211 was critical for the selectivity of NESOpAb to nNav1.5  
(A) Representative whole-cell nNav1.5, aNav1.5 and K211D currents, elicited by 12 ms 
depolarizing steps to 0 mV at 0.1 Hz from a holding potential of -100 mV, before (black) and 
after (red) NESOpAb application: (i) 1 ng/ml and (ii) 1000 ng/ml. First control current and trace 
for maximum NESOpAb block are shown. Dashed horizontal lines indicate zero current; arrows 
in (i) illustrate the larger NESOpAb (1 ng/ml) block in nNav1.5. (B) Normalized current (‘puff 
block’ was compensated) as a function of NESOpAb concentration for nNav1.5, aNav1.5 and 
K211D; each point represents data from a single cell (n = 7-12, see Table 5.6). (C) Summary of 
several key aspects of NESOpAb block. Threshold is the lowest concentration of NESOpAb 
inducing current block in more than half the cells tested; half-maximal block represents the 
estimated antibody concentration giving half the maximum block produced by 1000 ng/ml 
(which, in turn, is reported as maximal block; mean ± SEM). 
 
K211D  aNav1.5  nNav1.5  
0.5 nA 
0.5 ms 
0.5 nA 
0.5 ms 
0.5 nA 
0.5 ms 
0.3 nA 
0.5 ms 
0.2 nA 
0.5 ms 
0.2 nA 
0.5 ms 
 Chapter 5                                                                         Pharmacology of Nav1.5 D1:S3 variants 
 
 460 
 
Table 5.6 NESOpAb (0.05-1000 ng/ml) block of Nav1.5 variants 
 
 
NESOpAb (ng/ml) nNav1.5 (%) aNav1.5 (%) K211D (%) n P-value  
1000 67.3 ± 3.0 42.0 ± 4.9 46.2 ± 3.4 8-8-10 < 0.001 1,2 
100 45.2 ± 1.6 23.4 ± 2.3 31.7 ± 3.3 7-9-9 < 0.001 1,2 
10 22.7 ± 3.2 3.2 ± 1.7 5.3 ± 1.6 12-10-9 < 0.001 1,2 
1 12.6 ± 2.5 - 1.1 ± 1.2 10-11 < 0.001 2 
0.05 2.6 ± 1.4 - - 10 - 
      
 
Reported values represent peak current block (%) induced by NESOpAb after compensating for 
‘puff block’. Statistical significance (P-value) was determined by ANOVA followed by 
Newman-Keuls post hoc analysis: 1 larger nNav1.5 block vs. aNav1.5; 2 larger nNav1.5 block 
vs. K211D. Block levels for aNav1.5 and K211D were similar at each concentration tested. n 
values are reported sequentially for nNav1.5, aNav1.5 and K211D. Data are mean ± SEM. 
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= 8) (Figure 5.40 and Table 5.6). These differences are illustrated with typical 
traces in Figure 5.40Aii. Limited availability of NESOpAb restricted the 
maximum working concentration to 1000 ng/ml; thus, we could not determine 
whether NESOpAb can induce complete inhibition of Nav1.5 currents. 
Previously, block of nNav1.5 currents by NESOpAb was found to saturate (~ 
50-60%) at 1000 ng/ml (Chioni et al., 2005). Also, to our knowledge, no 
previous study reported complete current inhibition by an ion-channel blocker 
antibody (e.g. Morton et al., 1988; Zhou B et al., 1998; Liao et al., 2008).  
iii. Half-maximal block. At every NESOpAb concentration tested (0.05-1000 
ng/ml), block of nNav1.5 was superior to that of K211D and aNav1.5 (P < 0.01 
for all comparisons, n ≥ 7) (Table 5.6). Assuming that block by NESOpAb was 
maximal at 1000 ng/ml for all Nav1.5 variants, concentration for half-maximal 
block in nNav1.5 (~ 23 ng/ml) was respectively ~ 2-fold and ~ 4-fold lower 
compared to that of K211D (~ 54 ng/ml) and aNav1.5 (~ 90 ng/ml) (Figure 
5.40BC).  
iv. IC50 estimations. Accurate estimation of IC50 values using the Hill-equation 
requires the maximal block level at saturation to be known. Despite this was not 
the case with NESOpAb, we used the Hill-equation to gain more insight into the 
differences that existed between the antibody block of the three Nav1.5 variants. 
Thus, various parameters of the Hill equation (maximum, minimum, nH) were 
alternatively constrained, and the estimated IC50 and minima values were used to 
compare NESOpAb block in nNav1.5, aNav1.5 and K211D (Figure 5.41). Dose-
response data shown throughout Figure 5.41 are the means ± SEMs of the 
individual data points shown in Figure 5.40B. Starting with minimal parameter  
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Parameter nNav1.5 aNav1.5 K211D 
Max. (%) 100.0±0.0 100.0±0.0 100.0±0.0 
Min. (%) 0.0±0.0 0.0±0.0 0.0±0.0 
IC50 (ng/ml) 148.2±78.7 1143.1±505 833.2±415.4 
nH 1.0±0.0 1.0±0.0 1.0±0.0 
R^2 0.69 0.65 0.62 
  
 
 
 
 
 
 
 
 
 
 
 
Parameter nNav1.5 aNav1.5 K211D 
Max. (%) 100.0±0.0 100.0±0.0 100.0±0.0 
Min. (%) -0.3±15.0 55.3±0.0 52.2±1.0 
IC50 (ng/ml) 171.8±12.6 92.1±0.0 56.6±4.1 
nH 0.41±0.05 1.15±0.00 1.19±0.08 
R^2 0.99 1.00 0.99 
Parameter nNav1.5 aNav1.5 K211D 
Max. (%) 100.0±0.0 100.0±0.0 100.0±0.0 
Min. (%) 0.0±0.0 0.0±0.0 0.0±0.0 
IC50 (ng/ml) 169.1±14.8 1753.0±94.3 1094.6±62.4 
nH 0.41±0.02 0.49±0.14 0.46±0.12 
R^2 0.99 0.95 0.94 
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Figure 5.41 Lys211 was critical for NESOpAb selectivity: dose-response relationships  
Concentration-response curves for NESOpAb block of nNav1.5 (black circles / dotted line), 
aNav1.5 (open squares / dashed line) and K211D (open diamonds / solid line) fitted with the 
Hill equation. Mean ± SEM data (same for A-D) are from individual points shown in Figure 
5.40 (n = 7-12). In parts A-D, various parameters of the Hill curves are alternatively 
constrained: (A) maxima (100%) fixed; (B) maxima (100%) and minima (0%) fixed; (C) 
maxima (100%) and nH (1) fixed; (D) maxima (100%), minima (0%) and nH (1) fixed. For each 
part, estimated / constrained parameters from Hill fits (± SEM) are reported in a table together 
with parameters describing goodness-of-fit. Constrained parameters are shaded.  
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constraining in Figure 5.41A and progressing to maximal constraining in Figure 
5.41D, the following results were obtained: 
a. The maxima of the Hill fits were fixed at 100% (i.e. assuming no block 
at infinitely low antibody concentrations), while rest of the parameters 
were set free (Figure 5.41A). The estimated minimum for nNav1.5 was 
0%, suggesting complete current block at saturation. In contrast, for 
K211D and aNav1.5, minima were at 52.2% and 55.3%, respectively. 
This suggested that the block levels observed at 1000 ng/ml in these 
variants, in fact, were near-maximal. Also, similar maximal block in 
K211D and aNav1.5 indicated that the maximal block attainable by 
NESOpAb may be determined by the Lys/Asp211 residue. Given 
different saturation levels, IC50 values were not compared amongst the 
Nav1.5 variants. Consistent with a single binding site for NESOpAb, nH 
in aNav1.5 and K211D fits were close to 1; however, for nNav1.5, nH 
was considerably smaller than 1 (0.41). The reason for this was not 
clear. However, Hill coefficients smaller than 1 have been reported in 
earlier studies involving ion channel antibodies (e.g. Zhou B et al., 
1998; Liao et al., 2008).  
b. The maxima were fixed at 100% and minima at 0% (i.e. complete block 
at saturation was assumed) (Figure 5.41B). Under these conditions, the 
fit to the nNav1.5 data was essentially unchanged from before; aNav1.5 
and K211D fits were considerably different, e.g. the values of nH were 
smaller than 1, and IC50 estimates were much larger than those in Figure 
5.41A. R2 values for all fits were ≥ 0.94, suggesting significant 
goodness-of-fit. The main purpose of fixing minima at 0% was to 
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facilitate comparison of IC50 values amongst the Nav1.5 variants. Thus, 
IC50 for nNav1.5 (169.1 ± 14.8 ng/ml) was 6.5-fold and 10-fold lower 
than those for K211D (1094.6 ± 62.4 ng/ml; P < 0.001) and aNav1.5 
(1753.0 ± 94.3 ng/ml; P < 0.001). The IC50 value for K211D was 
significantly lower than that for aNav1.5 (P < 0.001), suggesting that the 
Lys211 to Asp211 switch reduced but did not completely abolish the 
selectivity of NESOpAb for nNav1.5. 
c. The maxima were fixed at 100% and nH were constrained at unity 
(Figure 5.41C). Fits for the aNav1.5 and K211D data were not changed 
much from Figure 5.41A, but the nNav1.5 fit was considerably different, 
e.g. minimum was non-zero and IC50 was much reduced. R2 for all fits 
were ≥ 0.93, suggesting sufficient goodness-of-fit. Estimated minimum 
for nNav1.5 (36.3 ± 7.4 %) was significantly smaller than the minima 
estimated for K211D (50.6 ± 1.7 %; P < 0.05) and aNav1.5 (53.6 ± 1.4 
%; P < 0.05). Minima were again similar for K211D and aNav1.5 (P = 
0.19). Given that saturation levels (minima) were non-zero and different, 
IC50 values were not compared amongst the Nav1.5 variants.  
d. The maxima, minima, and nH were fixed at 100%, 0% and 1, respectively 
(Figure 5.41D). Under these conditions, data were not fit well by the Hill 
equation, as suggested by the low R2 values (0.62-0.69). The IC50 
estimate for nNav1.5 (148.2 ng/ml) was lower that those for K211D 
(833.2 ng/ml) and aNav1.5 (1143.1 ng/ml); however, the large SEM of 
the IC50 estimates prevented statistical significance of these differences.  
In summary, the threshold concentration for NESOpAb block was ~ 200-fold lower in 
nNav1.5 vs. aNav1.5, whilst K211D mutation diminished this selectivity to ~ 10 fold. 
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The maximal antibody block was more than 20% larger in nNav1.5 vs. aNav1.5, whilst 
K211D mutagenesis completely abolished this difference. Consistently, in Hill-plots, 
block at saturation was estimated to be more than 50% larger in nNav1.5 vs. aNav1.5, 
and K211D mutagenesis again abolished this difference. In half-maximal block and IC50 
estimations, NESOpAb was found to be 4 to 10-fold selective for nNav1.5 vs. aNav1.5, 
whilst K211D mutagenesis reduced this selectivity by ~ 2-fold (i.e. difference between 
nNav1.5 and K211D was 2 to 6.5-fold). Taken together, therefore, NESOpAb was 
selective for the D1:S3/S4 sequence in nNav1.5 vs. aNav1.5, and Lys211 was critical for 
this selectivity. 
 
5.2.6.4 Effects on endogenous nNav1.5 currents 
We next tested NESOpAb on nNav1.5 currents expressed endogenously in MDA-MB-
231 BCa cells (Figure 5.42). The purpose was to compare antibody potency for 
endogenous vs. heterologously expressed nNav1.5 currents. In MDA-MB-231 
(shortened as ‘MDA’) cells, only ~ 80% of the total INa is carried by TTX-R channels 
(predominantly nNav1.5), whilst the remaining 20% TTX-S fraction is thought to be 
due to the D1:S3 neonatal splice variant of Nav1.7 (nNav1.7) (since this is the only 
VGSCα mRNA expressed other than Nav1.5 that would form a ‘functional’ channel) 
(Fraser et al., 2005; Brackenbury et al., 2007). For comparison, we also tested 
NESOpAb on Na+ currents expressed in Mat-LyLu PCa cells, where nNav1.7 is the 
predominant VGSCα expressed (Brackenbury and Djamgoz, 2006) (Figure 5.42). 
NESOpAb block was monitored with 0.1 Hz pulses to 0 mV, as before. Puffing 
of MPS alone inhibited MDA currents by 6.5 ± 0.7% (P < 0.01 vs. control, n = 10; 
Figure 5.42B); accordingly, the antibody dose-response data (Figure 5.42DE) were 
compensated for ‘puff block’. Surprisingly, puff-application had no significant effect on  
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Parameter nNav1.5 MDA MLL 
Max. (%) 100.0±0.0 100.0±0.0 100.0±0.0 
Min. (%) -0.3±15.0 18.2±26.0 78.8±0.0 
IC50 (ng/ml) 171.8±12.6 99.1±18.2 32.4±0.0 
nH 0.41±0.05 0.40±0.13 1.17±0.0 
R^2 0.99 0.99 1.00 
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[NESOpAb] (ng/ml) nNav1.5 (%) MDA-MB-231 (%) n P-value 
1000 67.3 ± 3.0 58.2 ± 3.3  8-10 0.07 
100 45.2 ± 1.6 42.4 ± 6.2  7-6 0.65 
10 22.7 ± 3.2 21.0 ± 4.0  12-6 0.74 
1 12.6 ± 2.5 12.9 ± 3.3  10-6 0.94 
   
NESOpAb 
 
nNav1.5         205 YVSENIKLGNLSALRTFRVLRALKTISVIP 234 
aNav1.5         205 YTTEFVDLGNVSALRTFRVLRALKTISVIS 234 
nNav1.7         200 YLTEFVNLGNVSALRTFRVLRALKTISVIP 229 
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Figure 5.42 NESOpAb block was similar in recombinant and endogenous nNav1.5  
(A) Typical whole-cell Na+ currents from MDA-MB-231 (MDA) and Mat-LyLu (MLL) cells, 
elicited by 12 ms depolarizing steps to 0 mV at 0.1 Hz from a holding potential of -100 mV, 
before (black) and after (red) 1000 ng/ml NESOpAb. First control trace and trace for 
maximum block are shown; dashed horizontal lines indicate zero current. (B) Mean ± SEM 
‘puff block’ of peak Na+ current in MDA (6.5 ± 0.7%; paired t-test vs. control: P < 0.01, n = 
10) and MLL (1.1 ± 0.8%; paired t-test vs. control: P = 0.19, n = 14). (C) Amino acid 
sequence of D1:S3/S4 region of nNav1.5, aNav1.5 and nNav1.7. Bold / underlined residues 
in nNav1.5 are the seven residues different from aNav1.5. Sequence targeted by NESOpAb is 
boxed / shaded. (D) Dose-response curves for NESOpAb block in nNav1.5 EBNA-293 (open 
circles/dotted line, re-plotted from Figure 5.41 for comparison), MDA (black circles / solid 
line) and MLL (black squares / dashed line) fitted to the Hill equation with maxima fixed at 
100% (n ≥ 5). Estimated parameters (± SEM) are reported in a table. (E) Summary table 
comparing NESOpAb block of nNav1.5 and MDA currents. Reported values represent 
percentage peak current block by NESOpAb. Statistical significance (P-value) was 
determined by unpaired t-tests. In parts D and E, ‘puff block’ was compensated. 
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nNav1.7 currents in Mat-LyLu cells (1.1 ± 0.8%, P = 0.19 vs. control, n = 14) (Figure 
5.42B). One possibility is that mechanosensitivity of channel function may be isoform-
dependent among VGSCαs (Morris and Juranka, 2007). 
NESOpAb showed minimal effect on nNav1.7 currents in Mat-LyLu cells 
(Figure 5.42AD). Maximal block obtained at 1000 ng/ml was 20.9 ± 2.1% (n = 10), and 
the Hill equation fit to nNav1.7 dose-response data yielded 78.8% residual current at 
saturation, which indicated that the observed block at 1000 ng/ml was near-maximal 
(Figure 5.42D). Threshold for antibody block was ~ 10 ng/ml (n = 5; Figure 5.42D), 
which was ~ 200-fold higher than that of nNav1.5. The observed limited potency of 
NESOpAb for nNav1.7 currents was not unanticipated since 6 of the 14 amino acids 
targeted by the antibody were different in nNav1.7 from nNav1.5 (Figure 5.42C). 
Overall, these results suggested that NESOpAb block in MDA cells would be largely 
due to the block of nNav1.5 currents, and hence, a direct comparison of antibody 
potency for endogenous and recombinant nNav1.5 channels could be made.  
Current block by 1000 ng/ml NESOpAb in MDA cells is illustrated in Figure 
5.42A; ~ 60% inhibition observed indicated that NESOpAb was a potent blocker of 
endogenous nNav1.5 as well as the recombinant nNav1.5. Time-course of NESOpAb 
block in MDA cells was also similar to that in nNav1.5-expressing EBNA-293 cells, 
reaching a steady-state within 2-3 minutes of application (data not shown). Dose-
response curve (range: 1-1000 ng/ml; n ≥ 6) for antibody block in MDA cells is shown 
in Figure 5.42D; for comparison, data for recombinant nNav1.5 were re-plotted from 
Figure 5.41. Potency of NESOpAb for MDA currents was similar to that for 
recombinant nNav1.5 currents, as suggested by the statistically similar block levels at 
each concentration tested (Figure 5.42DE). Only at 1000 ng/ml, NESOpAb block 
appeared slightly (but not significantly) larger in recombinant nNav1.5 vs. MDA 
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currents; this was probably due to the contribution of nNav1.7 to the latter current. The 
Hill fits to dose-response data yielded 18.2% residual current at saturation in MDA 
cells, whilst complete block was estimated for recombinant nNav1.5 currents (Figure 
5.42D); again, the reported ~ 20% contribution of nNav1.7 to MDA currents was 
probably responsible for this difference (Brackenbury et al., 2007). Comparison of IC50 
estimates between recombinant nNav1.5 and MDA currents was not performed, given 
the different minima estimated in the two cell lines (Figure 5.42D).  
Previously, NESOpAb was shown to suppress VGSC-dependent enhancement 
of various MCBs in MDA-MB-231 cells (Brackenbury et al., 2007). Results presented 
here were the first demonstration of direct NESOpAb block of nNav1.5 activity in 
MDA-MB-231 cells. Our findings also confirmed (i) that recombinant and endogenous 
Nav1.5 currents exhibit similar sensitivity to NESOpAb, and (ii) that NESOpAb is 
highly selective for D1:S3/S4 in nNav1.5 vs. other VGSCαs (i.e. nNav1.7). 
 
5.2.6.5 Effects on steady-state activation and gating kinetics 
The majority of earlier studies on ion channel blocker antibodies focused on 
determining antibody potency, selectivity and specificity, with minimal evaluation of 
the mechanism of antibody action in terms of channel blockade (e.g. Morton et al., 
1988; Zhou B et al., 1998; Chioni et al., 2005; Xu et al., 2005; Pardo and Stuhmer, 
2008). In the remainder of the present study, we aimed to gain more insight into the 
ways in which NESOpAb could modify / block Nav1.5 activity. All experiments were 
performed on nNav1.5-EBNA cells and NESOpAb concentration was 1000 ng/ml 
unless stated otherwise. 
Effects of NESOpAb on Gmax, voltage-dependence and kinetics of activation, 
and rate of inactivation from open-state in nNav1.5 were studied with the standard I-V 
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protocol described in Figure 5.43. Results are summarized in Table 5.7 (n = 7). 
Normalized I-V relationships (I/Imaxcontrol) and the corresponding conductance 
transforms (G/Gmaxcontrol) revealed that 1000 ng/ml NESOpAb suppressed Gmax by 63.3 
± 2.0% (Figure 5.43AB), consistent with the level of peak current block at 0 mV at this 
concentration observed earlier (Figure 5.40). There was no apparent change in the 
voltage-range of activation (Figure 5.43B). Accordingly, current inhibition was not 
voltage-dependent, i.e. block levels did not vary with the test potential used (Figure 
5.43C). There was no effect on Vthres, Vpeak and activation V1/2 or k (Figure 5.43BD and 
Table 5.7). Kinetics of activation (V0 and Tpeak) and kinetics of inactivation (i.e. τfast, τslow 
and their fractional amplitudes, derived from double exponential fits to INa decays) were 
also not modified (Figure 5.43EF and Table 5.7). That channel kinetics were unaltered 
were clear from the current traces recorded before and after antibody application (Figure 
5.40A and 5.43A). 
Taken together, residual nNav1.5 currents in the presence of NESOpAb 
exhibited virtually identical gating properties to control currents in the absence of the 
antibody. This suggested that NESOpAb acts as a simple pore blocker in the manner of 
TTX, with the distinction that it blocks ion permeation not by binding to a site within 
the pore region, but by interacting with the D1:S3/S4 region whilst physically occluding 
the extracellular mouth of the pore due to its bulky size. Such physical blockage and 
alternative mechanisms of current inhibition are discussed in Section 5.3.3.4. 
 
5.2.6.6 Effects on steady-state inactivation  
We next determined whether 1000 ng/ml NESOpAb would have any effect on voltage-
dependence of steady-state inactivation (availability) (Figure 5.44A). Under control 
conditions, nNav1.5 inactivation was half-maximal at ~ -90 mV (Figure 5.44A left).  
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Figure 5.43 NESOpAb reduced peak conductance without modifying channel gating  
Data were recorded from nNav1.5; NESOpAb concentration was 1000 ng/ml. (A) Typical 
whole-cell nNav1.5 currents, before and after NESOpAb application, elicited by 60 ms pulses to 
between -80 mV and +45 mV from a holding potential of -100 mV; interpulse duration was 2 s. 
(B) Normalized I-V relationships; currents after NESOpAb application were normalized to the 
maximal Na+ current in control (I/Imaxcontrol). Inset, corresponding conductance transforms 
(G/Gmaxcontrol) fitted with Boltzmann functions (solid lines). (C) NESOpAb block of peak 
current (%) plotted as a function of test potential; block level was similar across the voltage-
range tested (ANOVA; P = 0.30). (D) Normalized G-V relationships (G/Gmax) fitted with 
Boltzmann functions (solid lines). (E) Time to peak as a function of test potential and fitted with 
single-exponential functions (solid lines). (F) Inactivation time constants (τfast and τslow 
determined from double exponential fits to Na+ current decays) as a function of test potential. 
Data points are connected with straight lines for clarity. For parts B-F, data are presented as 
mean ± SEM (n = 7); control (open circles) and 1000 ng/ml NESOpAb (black circles). 
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Table 5.7 Effects of NESOpAb (1000 ng/ml) on nNav1.5 characteristics 
 
 
Parameter Control NESOpAb P-value 
Relative Gmax (%) 100 ± 0.0 36.7 ± 2.0 0.002 ** 
Vthres (mV) -55.0 ± 1.5 -56.4 ± 0.9 0.46 
Vpeak (mV) -12.1 ± 4.2 -12.9 ± 3.6 0.60 
Activation V1/2 (mV) -30.5 ± 3.0 -31.8 ± 3.5 0.19 
Activation k (mV) 6.6 ± 0.7 6.7 ± 0.4 0.86 
Inactivation V1/2 (mV) -89.5 ± 1.9 -98.8 ± 1.7 < 0.001 ** 
Inactivation k (mV) -6.7 ± 0.5 -7.0 ± 0.2 0.56 
V0 (mV) 19.2 ± 1.6 20.5 ± 1.8 0.63 
Tpeak at 0 mV (ms) 0.81 ± 0.05 0.81 ± 0.06 0.85 
τfast at 0 mV (ms) 0.87 ± 0.05 0.80 ± 0.10 0.40 
τslow at 0 mV (ms) 5.35 ± 0.53 5.15 ± 0.85 0.79 
 
 
Abbreviations: Gmax, maximal Na+ conductance; Vthres, threshold voltage for activation; Vpeak, 
voltage at current peak; V1/2, half-(in)activation voltage; k, (in)activation slope factor; V0, 
coefficient describing voltage-dependence of time to peak; Tpeak, time to peak; τfast, fast 
inactivation time constant; τslow, slow inactivation time constant. Data are presented as mean ± 
SEM (n ≥ 6). Statistical significance (P-value) was determined by paired t-tests: (**) P < 0.01. 
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Figure 5.44 NESOpAb hyperpolarized steady-state availability 
(A) Typical whole-cell nNav1.5 currents, used to study voltage-dependence of steady-state 
inactivation, shown before and after 1000 ng/ml NESOpAb. Currents were elicited by 80 ms 
test pulses to -10 mV after 1 s pre-pulses in the range -140 mV to -10 mV; holding potential was 
-100 mV and interpulse duration was 2 s. Traces generated following pre-pulses at -120 and -90 
mV are indicated to illustrate the larger NESOpAb block at more depolarized pre-pulse 
potentials (see part C). (B) Availability-voltage relationships fitted with Boltzmann functions 
(solid lines) in control (open circles) and 1000 ng/ml NESOpAb (black circles) for nNav1.5; 
effects of NESOpAb on availability were partially reversible (grey circles). Currents (I) were 
normalized to the maximum current (Imax) recorded following the most hyperpolarized pre-
pulse (-140 mV). (C) Same as part B, but NESOpAb data were normalized to the maximum 
current in control (I/Imaxcontrol). Inset, percentage current inhibition plotted as a function of pre-
pulse potential. For parts B and C, data are presented as mean ± SEM (n = 6). 
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Upon NESOpAb application, currents elicited after a -90 mV pre-pulse were much 
smaller than half-maximal, suggesting that channel availability was significantly 
hyperpolarized (Figure 5.44A right). Consistently, cell-by-cell Boltzmann fits to 
normalized availability (I/Imax) curves revealed that NESOpAb shifted inactivation V1/2 
negatively by ~ 10 mV, from -89.5 ± 1.9 mV in control to -98.8 ± 1.7 mV (P < 0.001, n 
= 6) (Figure 5.44B and Table 5.7). This effect was ~ 50% reversible after 4-5 min 
washout (Figure 5.44B). Inactivation k (-6.7 ± 0.5 mV / e-fold in control) was not 
affected by NESOpAb (-7.0 ± 0.2 mV / e-fold; P = 0.56) (Table 5.7).  
  
5.2.6.7 State-dependence of block  
Hyperpolarisation of the availability curve indicated that inhibition by NESOpAb may 
be ‘state-dependent’ such that block was selective for open/inactivated vs. resting- 
channels (as in the case of local anaesthetics and other small-molecule VGSC 
inhibitors; Section 5.2.1 and 5.2.2). In accordance with this, a closer study of the 
current traces shown in Figure 5.44A revealed that NESOpAb block was considerably 
larger at relatively more depolarized conditioning (pre-pulse) potentials. For instance, 
currents elicited after a pre-pulse to -120 mV were only ~ 20% smaller in NESOpAb 
vs. control, suggesting that antibody block was minimal when most channels resided in 
their resting states (Figure 5.44A). In contrast, conditioning at -90 mV, which would 
inactivate half the channels, resulted in a markedly larger block by NESOpAb (~ 70%), 
confirming selective antibody binding to inactivated nNav1.5 channels (Figure 5.44A).  
To better illustrate the voltage / state-dependence of NESOpAb block, 
availability-voltage relationships were normalized to the control maximal current 
(Figure 5.44C), and percentage current inhibition at each conditioning potential was 
plotted against voltage (Figure 5.44C inset). At a pre-pulse potential of -140 mV, 
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where nearly all channels would exist in their resting states, NESOpAb inhibited 
nNav1.5 currents by only 17.1 ± 3.1% (n = 6). Block was substantially larger at more 
depolarized pre-pulse potentials, e.g. 49.2 ± 4.1% at -100 mV (P > 0.001 vs. -140 mV) 
and 82.9 ± 2.7% at -80 mV (P > 0.001 vs. -140 mV and -100 mV) (Figure 5.44C inset).  
This result strongly suggested that NESOpAb selectively interacted with the inactivated 
state of nNav1.5 channels. 
The simplest way to confirm the state-dependence of NESOpAb block was to 
determine antibody potency at two different values of Vh, where relative proportions of 
resting vs. inactivated channels would be different. Thus, we tested NESOpAb at Vh of -
120 mV vs. -100 mV, with the anticipation that inhibition of nNav1.5 currents would be 
lower at the more hyperpolarized Vh of -120 mV (Figure 5.45). At 10 and 100 ng/ml, 
NESOpAb could be tested at both Vh on the same cell, provided complete recovery from 
block after the first antibody application (Figure 5.45AC); such paired study was not 
possible for 1000 ng/ml since recovery at this concentration was always partial (e.g. 
Figure 5.39C). Block was monitored with 0.1 Hz pulses to 0 mV as before. 
Indeed, at all concentrations tested (10, 100 and 1000 ng/ml), antibody block 
was significantly lower at the Vh of -120 mV vs. -100 mV (P < 0.01 for all comparisons; 
Figure 5.45CD). At Vh = -120 mV, NESOpAb block was < 20% even at the maximum 
antibody concentration used, suggesting limited antibody binding to resting channels 
(Figure 5.45BC). In contrast, when the Vh was -100 mV, NESOpAb block was 25.5 ± 
2.9, 46.4 ± 3.2 and 60.5 ± 2.6% at 10, 100 and 1000 ng/ml, respectively (Figure 
5.45CD), which confirmed that NESOpAb preferentially targeted inactivated nNav1.5 
channels. Such state-dependence of NESOpAb block is illustrated for an example cell in 
Figure 5.45A. Block was first studied at Vh of -120 mV, where 100 ng/ml NESOpAb 
inhibited peak INa by < 20% (Figure 5.45A left). After antibody block was fully washed  
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Figure 5.45 NESOpAb block was voltage-dependent: state-dependence 
(A) Whole-cell Na+ currents from a nNav1.5 cell, before (black) and after (red) 100 ng/ml 
NESOpAb, elicited by 12 ms depolarizing steps to 0 mV at 0.1 Hz from a holding potential of -
120 mV (left) or -100 mV (right); block was first investigated with holding potential at -120 
mV, then effects were washed off (full recovery) before antibody block with holding potential at 
-100 mV was deduced. For both recordings, first control trace and trace for maximum block are 
shown; dashed horizontal lines indicate zero current. (B) Mean ± SEM peak current block 
induced by 10-1000 ng/ml NESOpAb in nNav1.5 at two different holding potentials, -120 mV 
(white bars) and -100 mV (grey bars); ‘puff block’ was not compensated. Statistical significance 
(P-value) was determined by unpaired t-tests: (**) P < 0.01. (C) Quantitative summary of the 
data presented in part B; n numbers are given respectively for -120 mV and -100 mV. The 
number of cases where -120 mV and -100 mV data were recorded from the same cell is given in 
parentheses; this was possible only when complete recovery occurred after first antibody 
application (either while holding at -100 mV or -120 mV). Such paired study was not possible 
for 1000 ng/ml since antibody block at this concentration was weakly reversible (Figure 5.39).  
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off, Vh was switched to -100 mV and NESOpAb was re-applied. At this more 
depolarized Vh, 100 ng/ml antibody reduced peak INa by ~ 50%, which was ~ 3-fold 
larger than the block observed at Vh of -120 mV (Figure 5.45A right).  
In the final experiment to test state-dependence, we compared antibody block 
when (i) the channels were activated at a frequency of 0.1 Hz for 100 s, vs. (ii) no 
stimulation during 100 s antibody application. We anticipated that if NESOpAb was 
selective for inactivated channels, cycling of nNav1.5 between closed, open and 
inactivated state upon repeated stimulation would improve NESOpAb block. For (i), the 
data were used from experiments performed earlier to study time-course of block at 
1000 ng/ml (e.g. Figure 5.39). For (ii), after recording current amplitude under control 
conditions, we applied NESOpAb (1000 ng/ml) for 100 s with no stimulation of 
channels, and 0.1 Hz pulses were initiated after this period in the continual application 
of the antibody (Figure 5.46).  
NESOpAb inhibited nNav1.5 currents by 60-70%, 100 s after antibody 
application, with ongoing 0.1 Hz pulses (Figure 5.46AB). In contrast, NESOpAb block 
was only ~ 35% after 100 s of antibody application, without pulses during this period 
(Figure 5.46AB). However, with the initiation of the pulses, NESOpAb block 
progressively improved to its normal level of 60-70% (Figure 5.46AB). This suggested 
that cycling of nNav1.5 channels through their inactivated conformation was necessary 
for maximal NESOpAb block. We concluded that NESOpAb block is state-dependent 
and consequently use-dependent (at 0.1 Hz).  
 
5.2.6.8 Summary of effects of NESOpAb 
NESOpAb induced preferential block of nNav1.5 vs. aNav1.5. Selectivity was ~ 200-
fold at threshold and 4 to 10-fold at half-maximal block. Lys211 was critical for the  
 Chapter 5                                                                         Pharmacology of Nav1.5 D1:S3 variants 
 
 477 
 
A     
 
 
 
 
  
 
 
    
  B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 s / 10th pulse 
0.5 nA 
1 ms 
0.4 nA 
 1 ms 
100 s / 1st pulse 
(i) 0.1 Hz pulsing for 100 s (ii) No pulsing for 100 s 
Control Control 
0 30 60 90 120 150 180 210 240 
0.2 
0.4 
0.6 
0.8 
N
o
rm
a
liz
e
d 
cu
rr
e
n
t 
Time (s) 
Pulses start at: 
 10 s 
 100 s 
NESOpAb 
1st pulse after 100 s 
1.0 
Figure 5.46 NESOpAb block was use-dependent at 0.1 Hz 
(A) Whole-cell nNav1.5 currents, before and after 1000 ng/ml NESOpAb, elicited by 12 ms 
depolarizing steps to 0 mV from a holding potential of -100 mV: (i) Pulsing (0.1 Hz) started 
with NESOpAb application (i.e. 1st pulse after 10 s antibody application); first control current 
and current remaining after 100 s antibody application (10th pulse) are shown. (ii) Pulsing (0.1 
Hz) started 100 s after NESOpAb application. First control current and current remaining after 
100 s antibody application (1st pulse) are shown together with traces representing progressive 
current block upon further pulsing at 0.1 Hz. Dashed horizontal lines indicate zero current. (B) 
Time-course of peak current block in nNav1.5 by 1000 ng/ml NESOpAb (‘puff block’ was 
compensated) in the presence of conditions described in part Ai (open circles; n = 7, data re-
plotted from Figure 5.39) and Aii (black circles; n = 8). Data were normalized to peak current 
obtained by the first control pulse and are presented as mean ± SEM.  
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preference of the antibody for nNav1.5. Potency of NESOpAb to block endogenous and 
recombinant nNav1.5 currents was similar. NESOpAb acted as a simple pore blocker, 
with no effect on voltage-range of activation and kinetics of activation and inactivation. 
Steady-state inactivation was hyperpolarized in the presence of the antibody, suggestive 
of antibody binding being state-dependent. NESOpAb inhibition (i) was larger at Vh of -
100 mV vs. -120 mV, and (ii) reached maximal level only if the channels were 
repeatedly stimulated, i.e. cycled through their inactivated states. In overall conclusion, 
NESOpAb block of nNav1.5 was state-dependent, with preferential binding to the 
inactivated configuration of the D1:S3/S4 region.  
 
5.3 Discussion 
The main findings of the present study are as follows: (1) Small-molecule VGSC 
blockers lidocaine, phenytoin, mexiletine, procaine, ranolazine and riluzole failed to 
induce any differential effect on the two Nav1.5 D1:S3 splice variants. (2) Neurotoxins 
ProTx-II and HaTx selectively inhibited aNav1.5 vs. nNav1.5, suggesting toxin 
interaction with the D1:S3/S4 region. Charge-reversing Asp211 to Lys switch was not 
responsible for the reduced potency of ProTx-II in nNav1.5, but could partly account for 
the differential HaTx effects. (iii) NESOpAb, a polyclonal antibody targeting nNav1.5, 
produced selective block of nNav1.5 vs. aNav1.5, and Lys211 was critical for this 
selectivity. NESOpAb inhibition was similar for endogenous and recombinant nNav1.5, 
and current block was state-dependent with preferential binding of antibody to 
inactivated vs. resting channels.  
The overall conclusion, therefore, is that the structural difference between 
nNav1.5 and aNav1.5 in the spliced D1:S3/S4 region is targetable by ‘biological agents’ 
such as neurotoxins and antibodies that specifically interact with this region. On the 
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other hand, mainstream small-molecule VGSC inhibitors, which bind to an inner-pore 
site distant from the spliced region, are not likely to discriminate between nNav1.5 and 
aNav1.5 channels.  
 
5.3.1 Mainstream VGSC blockers were not selective for the Nav1.5 variants 
In this study, we tested six small-molecule VGSC inhibitors with diverse therapeutic 
applications and widely-differing chemical structures (Figure 1.13), and found that 
these drugs have no differential effect on the two Nav1.5 D1:S3 variants studied.  
 In terms of drug potency (i.e. IC50) and modification of channel gating, the 
present results are qualitatively and quantitatively consistent with earlier reports. For 
instance, in the present study, lidocaine induced tonic block of the Nav1.5 variants with 
an IC50 of ~ 370 µM (Vh = -100 mV), whilst the corresponding IC50 was 318 µM or 440 
µM for Nav1.5 expressed in HEK-293 cells (Wright et al., 1997; Abriel et al., 2000b), 
450 µM for Nav1.8 expressed in Xenopus oocytes (Chevrier et al., 2004), 319 µM for 
Nav1.8 expressed in ND7/23 cells (Leffler et al., 2007), and 491 µM for Nav1.4 
expressed in HEK-293 cells (Wright et al., 1997). We observed that 300 µM lidocaine 
hyperpolarized Nav1.5 inactivation (V1/2) by ~15 mV and drastically slowed recovery 
from inactivation with an ~ 65% amplitude shift from fast to slow channel recovery. At 
this concentration, Nuss et al. (2000) observed nearly identical effects of lidocaine on 
Nav1.5 and Nav1.4 currents expressed in Xenopus oocytes. Studies on Nav1.2 
expressed in CHO cells (Ragsdale et al., 1991) and on Nav1.7 in Xenopus oocytes 
(Chevrier et al., 2004) also yielded quantitatively similar effects of lidocaine on 
inactivation and recovery from inactivation gating. Finally, we recorded no effect of 
lidocaine on voltage-dependence and kinetics of activation, and rate of inactivation from 
open-state in Nav1.5 D1:S3 variants, which was similar to earlier results with Nav1.2, 
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Nav1.4, Nav1.5, Nav1.7 and Nav1.8 (Ragsdale et al., 1991; 1994; Xu et al., 1992; Nuss 
et al., 2000; Ribeiro and Costa, 2003; Chevrier et al., 2004). Similarly, Our results also 
agree with previous studies for phenytoin (Ragsdale et al., 1991; Xu et al., 1991; Kuo et 
al., 1997; 2000; Yang et al., 2009), mexiletine (Desaphy et al., 2001; Takahashi and 
Cannon, 2001; Wang GK et al., 2004; Ruan et al., 2007), procaine (Brau et al., 1998; 
Ribeiro and Costa, 2003), ranolazine (Fredj et al., 2006; Rajamani et al., 2008; Wang 
GK et al., 2008), and riluzole (Hebert et al., 1994; Wang YJ et al., 2008). 
As regards non-differential action on nNav1.5 vs. aNav1.5, common small-
molecule VGSC inhibitors bind to an inner-pore site constituted by various S6 residues 
in D1, D2 and D4 (Figure 1.12; Lipkind and Fozzard, 2005). X-ray crystal structure of 
the mammalian Kv1.2 channel and molecular modelling of VGSCs generally locate 
D1:S3/S4 distant from this drug ‘binding pocket’ (Long et al, 2005a; 2007; Swartz, 
2008; Bosmans and Swartz, 2010; Catterall, 2010). Thus, differential action of small-
molecule VGSC inhibitors on nNav1.5 vs. aNav1.5 was only a remote possibility. 
Nevertheless, previous reports showed that mutation of the S6 residues that modulate 
drug-binding induced secondary effects on voltage-dependence of activation gating, 
suggesting that these inner-pore sites and the S4 voltage-sensor residues are functionally 
coupled (Yarov-Yarovoy et al., 2001; Browne et al., 2009). We hypothesized that if 
‘reverse’ coupling also existed such that the changes in the activation apparatus (i.e. 
D1:S3/S4) affects the drug receptor, then the amino acid differences between the 
Nav1.5 variants in D1:S3/S4 could result in differential drug binding. Also, aNav1.5 
and nNav1.5 exhibited different electrophysiological characteristics (e.g. slowed 
recovery from inactivation of nNav1.5 vs. aNav1.5; Chapter 4 and Onkal et al., 2008a), 
which initially looked promising for ‘gating-dependent’ changes in small-molecule drug 
action (e.g. Wright et al., 1997; Nuss et al., 2000). 
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However, we observed no differential modification of Nav1.5 D1:S3 variants by 
the small-molecule drugs tested, which suggested (i) that residues in D1:S3/S4 linker do 
not ‘allosterically’ modulate the configuration of the drug binding site (e.g. its 
accessibility or affinity) in Nav1.5 channels, and (ii) that the electrophysiological 
differences between nNav1.5 and aNav1.5 are not sufficient to produce ‘gating-
dependent’ differences in drug block. As regards (ii), previous reports showed that 
‘gating-dependent’ differences in drug block among VGSCαs generally involve changes 
in voltage-dependence of inactivation or rate of recovery from inactivation (e.g. Xu et 
al., 1991; Nuss et al., 2000; Leffler et al., 2007). This is consistent with the “modulated 
receptor hypothesis” of drug block, which proposes that a high-affinity interaction 
between a VGSC and a small-molecule drug occurs only when the channel is in the 
open, inactivated or slow-inactivated states (as opposed to the resting state) (Hille, 
1977; 2001). Thus, a VGSCα isoform with a relatively hyperpolarized availability (e.g. 
Nav1.5 vs. Nav1.4) or a greater tendency to occupy a slow-inactivated state (e.g. Nav1.8 
vs. Nav1.7) would be more vulnerable to block by small-molecule inhibitors (Wright et 
al., 1997; Nuss et al., 2000; Leffler et al., 2007).  
However, as shown in Chapter 4, whilst Nav1.5 D1:S3 variants differed 
extensively in their kinetics and voltage-dependence of activation, and rate of 
inactivation from open-state, there was no change in voltage-dependence of inactivation 
and only small differences in recovery from inactivation kinetics (Onkal et al., 2008a). 
Thus, at a given holding potential, the fraction of high-affinity inactivated states would 
be equally prevalent in nNav1.5 and aNav1.5, consistent with the observed similar tonic 
block of these Nav1.5 variants by the small-molecule drugs at Vh -80 or -100 mV. As 
regards UDB, slightly slower rate of recovery from inactivation in nNav1.5 vs. aNav1.5 
was insufficient to induce differential inhibition at any of the stimulation frequencies 
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tested. This was probably because drug dissociation occurred considerably more slowly 
than drug-free channel recovery, thereby masking any differences in recovery kinetics 
of the Nav1.5 variants, i.e. rate-limiting step in recovery from [drug-bound inactivated 
state] → [drug-free resting state] was dissociation of the drug molecule (Ragsdale et al., 
1991; Nuss et al., 2000). In Chapter 4, we did not characterize the rate of entry into 
slow inactivated states in the Nav1.5 variants; although, at rapid stimulation rates (e.g. 
50 Hz), which may enhance slow-inactivation of VGSCs (Rudy, 1978; Nuss et al., 
2000), use-dependent current attenuation was significantly larger in nNav1.5 vs. 
aNav1.5. This difference may correspond to a greater tendency of nNav1.5 channels to 
enter high-affinity slow-inactivated states; however, it was insufficient to produce 
differential drug block between the Nav1.5 variants at the maximum stimulation 
frequency (10 Hz) tested here. 
A number of studies on neonatal vs. adult cardiomyocytes (rat, canine or rabbit) 
found some differences in INa block by small-molecule pharmaceuticals including 
lidocaine, mexiletine and phenytoin (Hering et al., 1983; Jeck and Rosen, 1990; Xu et 
al., 1991, 1992; Wu et al., 1993). A number of factors may account for the differences 
in these results and the present study. First, multiple VGSCα isoforms other than 
Nav1.5 (including Nav1.1-1.4 and Nav1.6) are functionally expressed in cardiac 
myocytes, albeit at levels lower compared to Nav1.5, and hence, differential block 
observed in neonatal vs. adult cardiomyocytes may be due to developmental changes in 
the proportional expression of VGSCα isoforms present (Maier et al., 2004; Haufe et 
al., 2005, 2007; Kaufmann et al., 2010). Second, the reported electrophysiological and 
pharmacological differences in cardiomyocytes may have resulted from developmental 
changes in VGSCα phosphorylation (Zhang et al., 1992; Yang and Roden, 1996; 
Chatelier et al., 2008), glycosylation (Tyrrell et al., 2001; Bennett, 2002; Stocker and 
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Bennett, 2006; Montpetit et al., 2009) and/or interaction with VGSCβs (Makielski et al., 
1996; 1999; Xiao et al., 2000; Fahmi et al., 2001; Meadows and Isom, 2005; David et 
al., 2008; Uebachs et al., 2010). Third, the abovementioned studies on cardiac tissue 
involved rat (Hering et al., 1983; Xu et al., 1991, 1992), canine (Jeck and Rosen, 1990) 
or rabbit (Wu et al., 1993). In these species, aNav1.5 was the predominant VGSCα 
responsible for INa recorded from adult cardiomyocytes; however, it is not known 
whether nNav1.5 was functionally present in the corresponding neonatal cardiomyoctes 
since mice was the only species where nNav1.5 was shown to be expressed at protein 
level during the neonatal period (Chioni et al., 2005).  
 
5.3.1.1 Future applications 
The results presented here suggested that standard small-molecule pharmaceuticals fail 
to discriminate between nNav1.5 and aNav1.5. Consequently, this class of VGSC 
inhibitors may not be well-suited for the selective targeting of nNav1.5 in an 
experimental or a clinical setup (e.g. against metastatic BCa or cardiac pathologies 
where nNav1.5 may be functionally relevant) (Onkal and Djamgoz, 2009).  
Currently, the search for VGCS subtype-specific drugs is being facilitated by 
two interdisciplinary approaches: (i) high-throughput screening of libraries, e.g. using 
membrane potential dyes or ion flux assays, coupled with secondary 
electrophysiological analysis of any ‘hit’ (Drizin et al., 2008; Kort et al., 2008; Clare, 
2010) and (ii) ‘templating’, where the chemical structure of an established VGSC 
blocker can be adopted and modified whereupon some specificity may be achieved 
(England, 2008; Wang et al., 2009). Such approaches have yielded VGSCα-subtype 
specific small-molecule drugs, e.g. 1-benzazepin-2 for Nav1.7 and A-803467 for 
Nav1.8 (Jarvis et al., 2007; Williams et al., 2007), and may generate Nav1.5- or even 
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nNav1.5-selective agents in the future. However, even if nNav1.5-selective agents are 
developed, a number of other issues need to be addressed before small-molecule drugs 
can be adopted in an anti-nNav1.5 therapy for metastatic BCa (Onkal and Djamgoz, 
2009). In particular, by design, some small-molecule blockers of VGSCs 
(anticonvulsants and anti-depressants) can readily penetrate the blood-brain barrier 
(England, 2008), and given albeit low-level expression of nNav1.5 in adult CNS 
(Chioni et al., 2005; Wang J et al., 2008), systemic application of such drugs could have 
serious side-effects. 
 
5.3.2 Selectivity of ProTx-II and HaTx for aNav1.5  
Our results with ProTx-II and HaTx revealed for the first time that neurotoxins can have 
‘splice-variant-selective’ effects on VGSCs. Differences observed in toxin block of 
aNav1.5 vs. nNav1.5 also indicated (i) that ProTx-II and HaTx share an overlapping 
binding site in D1:S3/S4, a region only recently implicated as a toxin receptor site in 
rNav1.2 (Bosmans et al., 2008), and (ii) that the structural (amino acid) differences 
between the Nav1.5 D1:S3 variants are targetable using polypeptides. 
 
5.3.2.1 Inhibition of Nav1.5 by ProTx-II and HaTx: comparison with earlier studies  
ProTx-II and HaTx inhibition were characterized earlier extensively for VGSCs and 
voltage-gated potassium channels (VGPCs) (Swartz and MacKinnon, 1995, 1997ab; 
Smith et al., 2007; Edgerton et al., 2008; Sokolov et al., 2008). Consistent with these 
earlier studies, our results on Nav1.5 showed that ProTx-II and HaTx produce similar 
effects, inhibiting channel activation and reducing peak conductance possibly via 
trapping S4 voltage-sensors in their inward (resting) conformations (Bosmans and 
Swartz, 2010).  
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We found that ProTx-II blocked Gmax of aNav1.5 with an IC50 of 87 nM, a value 
comparable to previous estimates of 93 nM and 79 nM for Nav1.5 expressed in HEK-
293 cells (Smith et al., 2007; Schmalhofer et al., 2008). In the only earlier study on 
HaTx block of VGSCs (Bosmans et al., 2008), 50 nM HaTx reduced peak rNav1.2 
currents by ~ 25% at -15 mV, which also agrees with the IC50 of 199 nM obtained at -15 
mV for aNav1.5 here. We showed that the inhibition of Nav1.5 currents by ProTx-II 
and HaTx reached a steady-state within 10-15 s, and were fully reversible within ~ 40 s 
(except at saturating toxin concentrations, where incomplete recovery was observed). 
For ProTx-II, similar time-courses for block onset / offset were obtained earlier in 
Nav1.5 as well as other VGSCαs (Smith et al., 2007; Edgerton et al., 2008). For HaTx, 
kinetics of current inhibition / recovery has not been studied for any VGSC before but 
was reported to occur significantly more slowly for Kv2.1 (τ > 100 s) compared to 
Nav1.5 here (Swartz and MacKinnon, 1995, 1997a). This difference may be due to (i) 
differential kinetics of toxin binding / unbinding in VGPCs (i.e. Kv2.1) vs. VGSCs, 
and/or (ii) alternative methods used for toxin delivery, i.e. puff application here vs. bath 
application in Kv2.1 studies. 
Consistent with inhibition of channel activation, both ProTx-II and HaTx 
depolarized voltage-dependence of activation, slowed time-course of current 
development (i.e. Tpeak) and reduced peak Na+ conductance for Nav1.5. These findings 
are qualitatively and quantitatively similar to those from earlier studies, as noted 
throughout Sections 5.2.4 and 5.2.5 (Swartz and MacKinnon, 1995; Smith et al., 2007; 
Bosmans et al., 2008; Edgerton et al., 2008; Sokolov et al., 2008). For ProTx-II, Gmax 
block occurred at low toxin concentrations (e.g. 10 nM for aNav1.5), at which, no 
change in activation V1/2 or Tpeak was recorded. Such differences in dose-dependencies 
of individual effects suggested that there are multiple Nav1.5 binding sites with 
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different affinities for ProTx-II, as shown earlier in rNav1.2 (Bosmans et al., 2008). It 
was not possible to deduce whether a similar ‘multifaceted’ interaction also occurred in 
the case of HaTx, since I-V relationships were not characterized at multiple 
concentrations for this toxin. Nonetheless, earlier experiments on Kv2.1 / rNav1.2 
chimaeras indicated that HaTx, like ProTx-II, binds to multiple S3/S4 voltage-sensors in 
D1, D2 and D4 (Bosmans et al., 2008).  
Despite having similar effects on activation, ProTx-II and HaTx differed in their 
modification of other aspects of Nav1.5 gating. In particular, ProTx-II effects were 
highly selective for activation, with no apparent modification of fast inactivation from 
open-state, steady-state availability or recovery from inactivation kinetics; these results 
were consistent with earlier studies on Nav1.5 and Nav1.2 (Smith et al., 2007; Bosmans 
et al., 2008; Sokolov et al., 2008; but see Xiao et al. (2010), who reported that ProTx-II 
also altered inactivation kinetics for Nav1.7). On the other hand, HaTx was less specific 
for channel activation, also modifying kinetics of fast inactivation and recovery from 
inactivation of Nav1.5. Dissimilar effects of HaTx and ProTx-II on Nav1.5 inactivation 
would indicate (i) that these two toxins may have differing affinities for particular 
voltage-sensors, and/or (ii) that the functional outcome of their interaction with a given 
voltage-sensor may be different. This is illustrated in Figure 5.47 with a simple 
conceptual model that makes two assumptions: (i) HaTx and ProTx-II interact with 
S3/S4 voltage-sensors (paddles) of D1, D2 and D4 in Nav1.5, as observed earlier in 
rNav1.2 (Bosmans et al., 2008), and (ii) toxin-targeting of voltage-sensors in D1, D2 
and D3 impedes activation, whilst targeting of D4 sensor impedes inactivation (see 
below; Bosmans et al., 2008). Parallel effect of HaTx and ProTx-II on Nav1.5 
activation can thus be explained by similar affinities and functional effects of these 
toxins on voltage-sensors in D1 and D2 (Figure 5.47). As regards slowing of Nav1.5  
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HaTx >> ProTx-II 
 
HaTx ≈ ProTx-II 
 
HaTx ≈ ProTx-II 
 
Similar effect on activation Differential effect on inactivation 
Nav1.5: S3/S4 linkers 
 
ProTx-II or HaTx 
 
ProTx-II or HaTx 
 
ProTx-II or HaTx 
 
Figure 5.47 A conceptual model comparing HaTx and ProTx-II inhibition of Nav1.5. 
The model assumes (i) that HaTx and ProTx-II interact with S3/S4 in D1, D2 and D4 of 
Nav1.5, as in rNav1.2 (Bosmans et al., 2008) and (ii) that targeting of voltage-sensors in D1, 
D2 and D3 affect activation (green), whilst targeting of D4 voltage sensor (red) alters 
inactivation (Bosmans et al., 2008). Similar effects of HaTx and ProTx-II on Nav1.5 activation 
suggest that interactions of these toxins with S3/S4 in D1 and D2 result in similar functional 
outcomes. On the other hand, slowing of inactivation by HaTx but not ProTx-II indicates (i) 
that HaTx may have higher affinity for D4:S3/S4 compared to ProTx-II, and/or (ii) that toxin 
binding to D4:S3/S4 results in differential modification of inactivation in the case of HaTx 
(slowing of inactivation) vs. ProTx-II (no effect).  
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inactivation by HaTx but not ProTx-II, it may be (i) that HaTx has significantly higher 
affinity to the D4 voltage-sensor compared to ProTx-II, and/or (ii) that the functional 
outcome of toxin binding to the D4 voltage-sensor is different for HaTx (slowing of 
inactivation) vs. ProTx-II (no / minimal effect) (Figure 5.47). Notably, however, it was 
recently shown by Xiao et al. (2010) that ProTx-II slowed inactivation kinetics for 
Nav1.7. Thus, interaction of ProTx-II with the D4 voltage-sensor may be weak (or 
functionally ineffectual) for Nav1.5 and Nav1.2 but not for Nav1.7 (Smith et al., 2007; 
Bosmans et al., Xiao et al., 2010).  
One principle that emerged form the paddle transfer studies of Bosmans et al. 
(2008) was that toxins targeting the voltage-sensors in D1, D2 and D3 of rNav1.2 
(irrespective of whether D4 sensor is also targeted) were those which influenced the 
activation properties of VGSCs (e.g. ProTx-II, β-toxin TsVII), whereas only the toxins 
that exclusively interacted with the rNav1.2 D4 voltage-sensor could modify channel 
inactivation (e.g. α-toxin AaHII, SGTx1). Interestingly, our results with HaTx 
suggested that this modus operandi may not apply to Nav1.5 (and possibly other 
VGSCαs). This is because HaTx induced a profound effect of Nav1.5 inactivation 
despite it interacted with at least one non-D4 voltage-sensor (i.e. D1 voltage-sensor, as 
evident from the differential effects of HaTx on aNav1.5 vs. nNav1.5; see Section 
5.3.2.2). Strictly, this was inconsistent with the suggestion that inactivation is modified 
only if the D4 voltage-sensor is exclusively targeted; instead, targeting of D4 voltage-
sensor in a ‘non-exclusive’ manner may be sufficient for a neurotoxin to impede 
inactivation. Consistent with this, Xiao et al. (2010) recently showed that ProTx-II 
interacted with multiple voltage-sensors (D2 and D4) in Nav1.7 but still induced 
slowing of channel inactivation.  
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The focus on D4 voltage-sensor regarding inactivation is due to the critical role 
played by this sensor in activation-inactivation coupling of VGSC gating (Chanda and 
Bezanilla, 2002; Armstrong, 2006). Intriguingly, however, HaTx produced differential 
effects on inactivation of aNav1.5 vs. nNav1.5, which suggested that D1:S3/S4 may 
also play a role in channel inactivation. Alternatively, the binding of HaTx to D4:S3/S4 
was augmented by simultaneous toxin binding to D1, resulting in larger slowing of 
inactivation in aNav1.5 vs. nNav1.5 (given the larger affinity of HaTx for D1:S3/S4 in 
aNav1.5 vs. nNav1.5; see Section 5.3.2.2).  
 
5.3.2.2 D1:S3/S4 as a novel neurotoxin receptor site in VGSCs 
We found that ProTx-II and HaTx are selective inhibitors of aNav1.5 vs. nNav1.5. In 
the case of ProTx-II, inhibition of Gmax was ~ 25-fold and shift of activation V1/2 was ~ 
10-fold greater for aNav1.5 vs. nNav1.5. HaTx was 5-fold more potent in blocking peak 
INa in aNav1.5 vs. nNav1.5, induced substantial depolarization of activation voltage-
range in aNav1.5 but not in nNav1.5, and slowed channel kinetics significantly more in 
aNav1.5 vs. nNav1.5. These findings would suggest that ProTx-II and HaTx interact 
with a receptor site located at least partially within the spliced D1:S3/S4 region of 
aNav1.5, whilst one or more of the six amino acids different in nNav1.5 significantly 
disrupt toxin interaction with this receptor site. The net result is reduced inhibitory 
effects of both neurotoxins on channel activation in nNav1.5, i.e. activation of toxin-
bound channels (and/or toxin-unbinding) requires less energy in nNav1.5, reflected as a 
smaller depolarising shift in activation V1/2 and a smaller block of Gmax (Swartz and 
MacKinnon, 1995, 1997a; Sokolov et al., 2008). 
S3/S4 voltage-sensors (paddles) in D4 and D2 are well-established receptor sites 
for gating-modifier α- and β-scorpion toxins, respectively. On the other hand, the only 
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evidence for S3/S4 targeting in D1 is from the more recent paddle transfer studies of 
Bosmans et al. (2008), who showed that both HaTx and ProTx-II interact with the D1 
voltage-paddle in rNav1.2 / Kv2.1 chimaeras. Our results with Nav1.5 variants here 
demonstrate, for first time, that toxin binding to D1:S3/S4 also occurs in ‘native’ 
VGSCαs. This validates D1:S3/S4 as a novel ‘conserved’ neurotoxin site, which has 
now been shown to interact with at least two different toxins (i.e. HaTx and ProTx-II) in 
two different VGSCαs (i.e. Nav1.2, Nav1.5) (Bosmans et al., 2008).  
The reasons why the D1:S3/S4 linker has not been addressed as a toxin site 
earlier was possibly due to (i) the failure of conventional electrophysiological analyses 
to detect toxin binding to multiple receptors (i.e. S3/S4 linkers), and (ii) the common 
conviction that a given neurotoxin interacts with a single site on VGSCs, e.g. D2:S3/S4 
for β-scorpion toxins and D4:S3/S4 for α-scorpion toxins (Catterall et al., 2007). 
However, the paddle-transfer studies of Bosmans et al. (2008) challenged the single 
receptor idea, revealing that even β-scorpion toxins, which are universally accepted to 
target a single site in D2:S3/S4, can bind to multiple receptors on VGSCαs, e.g. TsVII 
was found to interact with S3/S4 paddles of D2, D3 and D4 of rNav1.2. Subsequent 
studies thus started to evaluate the possibility of a multi-faceted interaction between 
neurotoxins and VGSCs, revealing previously overlooked neurotoxin binding sites for 
different neurotoxins (e.g. ProTx-II and HwTx were recently found to target multiple 
S3/S4 linkers in D2 and D4 of Nav1.7) (Xiao et al., 2010). Accordingly, it is possible 
that future studies will identify new or existing neurotoxins that target D1:S3/S4, and 
thus give rise to a novel group of gating-modifier neurotoxins classified by their 
interaction with the D1 receptor site. 
At this stage, the particular amino acids that constitute the D1:S3/S4 receptor 
site remain controversial, and may not be identical for different VGSCαs or for different 
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neurotoxins, as follows (scheme shown below is from Section 1.4.2; amino acids 
different between aNav1.5 and nNav1.5 are in red, and shaded rNav1.2 and Kv2.1 
residues are those implicated in ProTx-II and HaTx binding, respectively): 
 
 
 
 
 
i. Larger ProTx-II and HaTx inhibition of aNav1.5 vs. nNav1.5 indicates that one 
or several of the five amino acids different between the Nav1.5 D1:S3 variants 
(i.e. excluding Asp/Lys211) must be critical for toxin-channel interaction. These 
residues are Thr/Val206, Thr/Ser207, Phe/Asn209, Val/Ile210 and Val/Leu215 
(aNav1.5 residues first).  
ii. In native and chimaeric rNav1.2 channels, Glu208 and Phe209 (Nav1.5 
numbering) were critical for the interaction between ProTx-II and D1:S3/S4, 
whilst Val210, Asp211 and Leu212 also influenced toxin-channel interaction but to 
a lesser degree (Bosmans et al., 2008). For HaTx, mutagenesis has not been 
preformed in VGSCs but the most important residues for toxin binding in Kv2.1 
channel (Phe274 and Glu277) correspond to Phe209 and Leu212 in D1 of aNav1.5 
(scheme above). Significantly, all these residues are either acidic or 
hydrophobic, consistent with the bioactive face of ProTx-II and HaTx being 
constituted mainly by basic and hydrophobic residues (Smith et al., 2007)  
iii. In contrast to its critical role in rNav1.2, Glu208 did not contribute to the 
D1:S3/S4 binding site in Nav1.5 or Nav1.7; mutation of this acidic residue to 
neutral Gln (in Nav1.5) or positive Lys (in Nav1.7) had no effect on inhibition 
 
nNav1.5         205 YVSENIKLGNLSALRTFRVLRALKTISVIP 234 
aNav1.5         205 YTTEFVDLGNVSALRTFRVLRALKTISVIS 234 
rNav1.2         203 YVTEFVDLGNVSALRTFRVLRALKTISVIP 232 
Kv2.1           270 YVTIFLTESNKSVLQFQNVRRVVQIFRIMR 299 
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of channel activity by ProTx-II (Smith et al., 2007; Xiao et al., 2010). Also, 
Glu208 is conserved between aNav1.5 and nNav1.5, so it could not directly 
contribute to the differential ProTx-II effects on Nav1.5 D1:S3 variants in the 
present study. Different roles played by Glu208 in rNav1.2 vs. Nav1.5 / Nav1.7 
indicate that the constituents of the D1:S3/S4 toxin receptor may not be identical 
in different VGSCα isoforms (Smith et al., 2007; Bosmans et al., 2008).  
iv. Phe209 remains a strong candidate for modulating the interaction of both ProTx-
II and HaTx with D1:S3/S4 in Nav1.5, given its conserved role for ProTx-II 
block in rNav1.2 and HaTx block in Kv2.1 (Li-Smerin and Swartz, 2000; 
Swartz, 2007; Bosmans et al., 2008). Nevertheless, Xiao et al. (2010) recently 
found that mutation of Phe209 (Phe204 in Nav1.7 numbering) to Ala does not 
affect the interaction of ProTx-II with D1:S3/S4 of Nav1.7. Mutagenesis data 
are not yet available in Nav1.5; however, hydrophobic Phe209 in aNav1.5 is 
changed to polar Asn209 in nNav1.5, and given the hydrophobicity of the active 
surface of ProTx-II (Smith et al., 2007), introduction of a polar residue at this 
position is consistent with significant disruption of toxin affinity to D1:S3/S4 in 
nNav1.5.  
v. Cationic residues found on the active faces of ProTx-II and HaTx are thought to 
interact with acidic residues on S3/S4 linkers (Smith et al., 2007; Bosmans and 
Swartz, 2010). Accordingly, Asp211 would be expected to be important for toxin 
binding to D1:S3/S4, as shown in the case of ProTx-II interaction with rNav1.2 
D1 paddle (Bosmans et al., 2008). In contrast, Smith et al. (2007) reported that 
mutation of Asp211 to neutral Ala did not alter ProTx-II binding to Nav1.5. 
Consistently, our mutation of the positive Lys211 back to Asp211 in nNav1.5 (i.e. 
nNav1.5 K211D mutant) did not enhance ProTx-II inhibition of nNav1.5, 
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suggesting that ProTx-II does not interact with Asp/Lys211 in Nav1.5. Taken 
together, this further suggests that D1:S3/S4 toxin receptor may not be identical 
in different VGSCαs (i.e. rNav1.2 vs. Nav1.5).  
vi. For HaTx, Lys211 to Asp211 mutagenesis in nNav1.5 (i.e. K211D) partly reduced 
the difference between nNav1.5 and aNav1.5 in the magnitude of the shift in 
activation V1/2, consistent with Asp/Lys211 being part of the HaTx receptor site in 
D1:S3/S4. This is in contrast to the lack of effect of this residue for ProTx-II 
binding to Nav1.5, and suggests that the D1:S3/S4 toxin receptor may be 
overlapping but not identical for different neurotoxins (i.e. HaTx and ProTx-II).  
Taken together, earlier and present evidence designate D1:S3/S4 linker (paddle) as a 
novel neurotoxin receptor on VGSCαs. However, future work is necessary to identify 
the precise molecular determinants for toxin binding to this D1 region. Future studies 
will reveal (i) whether neurotoxins interact with D1:S3/S4 of all VGSCαs, and (ii) 
whether the D1:S3/S4 site is identical, overlapping or non-overlapping for different 
neurotoxins or VGSCα subtypes. 
 
5.3.2.3 Multifaceted interaction of ProTx-II with VGSCs 
Apart from D1:S3/S4, ProTx-II targets D2:S3/S4 and D4:S3/S4 in rNav1.2 and Nav1.7 
(Bosmans et al., 2008; Xiao et al., 2010). Multiple toxin binding also occurs in Nav1.5 
(and possibly in all VGSCαs), since we and others have observed ProTx-II to modify 
different aspects of Nav1.5 gating with differing dose-dependencies (Smith et al., 2007; 
Edgerton et al., 2008). Furthermore, qualitatively parallel effects of ProTx-II on 
rNav1.2, Nav1.5 and other VGSCαs suggest that the same set of voltage-sensors are 
being targeted by ProTx-II in all VGSCαs (i.e. those in D1, D2 and D4). On the other 
hand, it remains uncertain which S3/S4 linker is most influential (i.e. has the highest 
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affinity) for ProTx-II binding, or alternatively, whether multiple S3/S4 linkers with 
similar affinities exist.  
Scanning mutagenesis of S3/S4 paddles in rNav1.2 revealed that ProTx-II 
interacts most strongly with S3/S4 in D1, e.g. point mutations in D1:S3/S4 reduced 
ProTx-II potency by up to 32-fold, whilst this was only ~ 10 to 15-fold in D2 and D4 
(Bosmans et al., 2008). Similarly, we found that one or several amino acid changes in 
D1:S3/S4 of Nav1.5 could reduce toxin potency by ~ 25-fold. In contrast, ProTx-II was 
shown to be ~ 100-fold selective for human Nav1.7 over other VGSCαs due to a single 
amino acid change in D2:S3/S4 (Phe813 in Nav1.7 vs. Gly/Ser in other VGSCαs), 
implying that D2 rather than D1 may be most critical for ProTx-II block (Schmalhofer 
et al., 2008; Xiao et al., 2010). Intriguingly, however, mutating the equivalent Gly813 
residue in Nav1.2 to Phe (as in Nav1.7) failed to increase ProTx-II efficacy, suggesting 
that the residue at position 813 is necessary but not sufficient for conferring the higher 
sensitivity to ProTx-II (Schmalhofer et al., 2008). Possibly, therefore, D2:S3/S4 is a 
‘low-affinity’ ProTx-II receptor in most VGSCαs, whilst the presence of Phe813 in 
Nav1.7 turns this receptor into a ‘high affinity’ state in Nav1.7. Consistent with this, 
replacement of D2:S3/S4 linker with D4:S3/S4, or vice versa, had no effect on 
interaction of ProTx-II with Nav1.5, suggesting that S3/S4 linkers in D2 and D4 are 
equally important for ProTx-II binding (i.e. Nav1.5 channels with two D2:S3/S4 linkers 
or two D4:S3/S4 linkers have toxin sensitivity similar to the wild-type channel) (Smith 
et al., 2007). Thus, given the equal importance of D2 and D4 linkers for ProTx-II 
binding, and the well-evidenced role of D4:S3/S4 in channel inactivation (Armstrong, 
2006), the lack of effect of ProTx-II on inactivation of VGSCαs (except Nav1.7) 
indicates that D4:S3/S4, and thus D2:S3/S4, are both ‘low-affinity’ ProTx-II sites on 
most VGSCαs with the exception of Nav1.7 (Sokolov et al., 2008).  
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Based on the abovementioned findings, we created a simple conceptual model of 
the multifaceted interaction of ProTx-II with VGSCs (Figure 5.48). To simplify 
analysis, we discretely classified the S3/S4 linker in each domain as either a ‘high-
affinity’ or a ‘low-affinity’ site for ProTx-II. Accordingly, D1:S3/S4 is suggested to be 
a high-affinity site in all VGSCαs (Bosmans et al., 2008), whereas D2:S3/S4 and 
D4:S3/S4 are high-affinity sites in Nav1.7 but low-affinity otherwise (Bosmans et al., 
2008; Schmalhofer et al., 2008; Xiao et al., 2010) (Figure 5.48). Thus, VGSCαs except 
Nav1.7 have one high-affinity (D1) and two low-affinity (D2, D4) receptors for ProTx-
II, which result in IC50 for current inhibition of ~ 100 nM, as observed in the present 
study for aNav1.5 and in earlier studies for other VGSCαs (Schmalhofer et al., 2008). 
Nav1.7, on the other hand, has three high-affinity (D1, D2, D4), exhibiting much higher 
sensitivity to ProTx-II (IC50 ~ 1 nM). Finally, nNav1.5, which loses its only high-
affinity receptor in D1:S3/S4 due to 6 amino acid changes, has three low-affinity sites 
(D1, D2, D4), exhibiting significantly lower ProTx-II sensitivity (IC50 > 1000 nM) 
(Figure 5.48). 
This conceptual model is by no means a conclusive account of the complex 
interaction of ProTx-II with VGSCs; however, it is the first portrayal of ProTx-II-
channel interaction that is consistent with the present and published evidence, providing 
a framework for future studies. It will be exciting to find out whether the assumptions as 
well as conclusions of this model can be backed up with further experimental data. In 
particular, future paddle / linker transfer studies in which the high-affinity D1 receptor 
is removed in Nav1.7 (leaving D2 and D4 as the only high affinity receptors) will be 
useful to determine the relative importance of D1 vs. D2 and D4 S3/S4 linkers for 
ProTx-II binding in this VGSCα isoform. Furthermore, it remains to be tested whether 
transfer of the suggested low-affinity D2 or D4 linkers to D1 would create mutant  
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Channel High affinity S3/S4 Low affinity S3/S4 IC50 (nM) 
nNav1.5 None D1, D2, D4 > 1000 
Most VGSCαs (aNav1.5) D1 D2, D4 ~ 100 
Nav1.7 D1, D2, D4 - ~ 1 
D1 D2 D3 D4 
LOW affinity site 
for all VGSCαs 
except Nav1.7 
 
LOW affinity site 
for all VGSCαs  
except Nav1.7 
 
HIGH affinity site 
for all VGSCαs 
except nNav1.5 
 
VGSCα: S3/S4 linkers 
 
ProTx-II 
 
ProTx-II 
 
ProTx-II 
 
Figure 5.48 Conceptual model for high- and low-affinity ProTx-II binding sites. 
This model assumes that ProTx-II interacts with S3/S4 in D1, D2 and D4 (but not D3) of all 
VGSCαs (Bosmans et al., 2008; Xiao et al., 2010). Based on published evidence, the S3/S4 
linker in each domain is discreetly classified as either a ‘high-affinity’ (solid red arch) or a 
‘low-affinity’ site (dashed red arch) for ProTx-II. It is suggested that D1:S3/S4 is the canonical 
high-affinity ProTx-II site in most VGSCαs, resulting in IC50s of ~ 100 nM, whereas D2:S3/S4 
and D4:S3/S4 are assumed to be a low-affinity receptors given the mutagenesis data and the 
lack of effect of ProTx-II on channel inactivation, respectively (Bosmans et al., 2008; Sokolov 
et al., 2008). In Nav1.7, in addition to D1:S3/S4, D2:S3/S4 and D4:S3/S4 are also high-affinity 
sites, significantly increasing ProTx-II potency (IC50 ~ 1 nM) (Schmalhofer et al., 2008; Xiao et 
al., 2010). In nNav1.5, six amino acid changes in D1:S3/S4 turns the normally high-affinity D1 
site into a low affinity site, leaving no high-affinity site for ProTx-II binding and resulting in an 
IC50 > 1000 nM.  
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channels with three low-affinity sites for VGSCαs (other than Nav1.7), resulting in IC50 
for ProTx-II block of > 1000 nM.  
 
5.3.2.4 Implications for selective targeting of nNav1.5 and future applications 
In the present study, we identified two gating-modifier neurotoxins (ProTx-II and 
HaTx) that can confer selectivity between aNav1.5 and nNav.5. Principally, this 
confirms that the structural differences between Nav1.5 D1:S3 variants are targetable, 
consistent with the results obtained with NESOpAb.  
Our initial motive for testing neurotoxins was to identify nNav1.5-selective 
agents that can be exploited in ‘proof-of concept’ experiments for the pro-metastatic 
role of nNav1.5 in metastatic BCa models (e.g. MDA-MB-231). However, aNav.1.5-
selective toxins identified in the present study (ProTx-II and HaTx) can still be useful in 
this regard. First, these toxins are valuable tools for characterizing the structural 
differences between Nav1.5 D1:S3 variants, which, in turn, may provide the 
groundwork for generating nNav1.5-selective synthetic peptides in the future (Onkal 
and Djamgoz, 2009; Bosmans and Swartz, 2010). Second, aNav1.5-selective (and thus 
nNav1.5-unselective) toxins are experimentally useful to determine the specific role 
played by nNav1.5 in VGSC-dependent upregulation of in vitro metastatic cell 
behaviours. For instance, at its ~ IC50 for aNav1.5 and most other VGSCαs, ProTx-II 
(100 nM) would induce negligible block of nNav1.5 activity in MDA-MB-231 cells, 
whilst abolishing the remaining ~ 20% TTX-S / Nav1.7 current (Fraser et al., 2005; 
Brackenbury et al., 2007). Thus, long-term treatment of MDA-MB-231 cells with 100 
nM ProTx-II would be expected to have no effect on the VGSC-dependent component 
of migration or invasion, if nNav1.5 channels are solely responsible for the total 
contribution of VGSCs to these metastatic cell behaviours, as suggested by RNA-
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interference and NESOpAb studies earlier (Brackenbury et al., 2007; Gillet et al., 2009) 
(note that promiscuity of ProTx-II is not likely to complicate data interpretation since 
functional VGPC expression is negligible and voltage-gated calcium channel (VGCC) 
expression absent in MDA-MB-231 cells; Chapter 3 and Fraser et al., 2005). 
D1:S3/S4 is only beginning to be treated as a neurotoxin target (Bosmans et al., 
2008), and further studies involving site-directed mutagenesis and chimaeric voltage-
sensor swapping experiments will most likely identify novel or existing neurotoxins 
other than ProTx-II and HaTx, that interact with this D1 linker (Bosmans et al., 2008). 
Any D1:S3/S4-targetting neurotoxin is likely to differentiate between aNav1.5 and 
nNav1.5, and it will be interesting to see whether in addition to aNav1.5-selective 
neurotoxins, nNav1.5-selective ones also exist. Importantly, as regards amino acid 
sequence, D1:S3/S4 region of nNav1.5 is unique among all known subtypes and splice 
variants of VGSCs (and other ion channel families) (Appendix 14; Chioni et al., 2005). 
Thus, any neurotoxin that is selective for the D1:S3/S4 of nNav1.5 is likely to have (i) 
a superior selectivity profile compared to existing neurotoxins, and (ii) exhibit minimal 
target promiscuity unlike most other gating modifier neurotoxins (e.g. ProTx-II and 
HaTx; Bosmans and Swartz, 2010).  
Finally, natural neurotoxins, when used at appropriate concentrations, have been 
shown to be medically useful in a variety of disorders, including cancer, e.g. (i) local 
injections of botulinium toxin type A (‘Botox’) is used extensively for relieving a 
variety of bladder outlet (including urethral sphincter) obstructions, thus restoring 
continence (Leippold et al., 2003; Kostrzewa and Segura-Aguilar, 2007), (ii) the viper 
venom toxin (SVT from Vipera lebetina turanica) inhibited human hormone-refractory 
PCa cell growth by inducing programmed cell death (Son et al., 2007), and (iii) there is 
preliminary evidence that α-scorpion toxin BmK and chloride channel blocker 
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chlorotoxin may be effective against malignant gliomas (Soroceanu et al., 1998; Wang 
and Ji, 2005). Accordingly, discovery of a nNav1.5-selective neurotoxin (or synthetic 
peptide) may have clinical implications regarding nNav1.5 expression in BCa (Fraser et 
al., 2005; Roger et al., 2006; Onkal and Djamgoz, 2009). Apart from selectivity and 
promiscuity issues, one important challenge that remains in the way of clinical 
applicability of gating modifier toxins is their inherent biochemical instability (Bosmans 
and Swartz, 2010). Nevertheless, chemical modifications including cyclization and use 
of diselenide or fluorous bridges have been proposed for increasing the stability of short 
peptides, and this may extend the in vivo usage of VGSC blocker neurotoxins in the 
near future (Craik and Adams, 2007; Bulaj, 2008; Bosmans and Swartz, 2010). 
 
 
5.3.3 Selectivity of NESOpAb for nNav1.5  
5.3.3.1 Comparison of results with earlier findings 
In the present study, we have confirmed earlier findings by Chioni et al. (2005) that 
NESOpAb is a blocking polyclonal antibody specific and selective for its target epitope 
in D1:S3/S4 (E2) of nNav1.5. As regards specificity, application of non-specific rabbit 
IgG or NESOpAb pre-absorbed with excess immunizing peptide showed no effect 
beyond ‘puff block’ in nNav1.5, confirming that the NESOpAb block was due to 
binding of the antibody to its target epitope in D1:S3/S4. Regarding selectivity, Chioni 
et al. (2005) found that the threshold of NESOpAb block was ~ 400-fold lower in 
nNav1.5 vs. its nearest relative (aNav1.5), which is on the same order of magnitude 
with the difference observed in the present study (~ 200-fold). Also, in our half-
maximal block and IC50 estimations, NESOpAb was 4 to 10-fold selective for nNav1.5 
vs. aNav1.5, similar to the fold-difference observed in these parameters by Chioni et al. 
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(2005). Finally, maximal NESOpAb block was 25% larger in nNav1.5 (67%) vs. 
aNav1.5 (42%), consistent with ~30 % larger maximal block in nNav1.5 reported by 
Chioni et al. (2005). Overall, therefore, data presented here and by Chioni et al. (2005) 
are consistent in that NESOpAb is selective for nNav1.5 vs. aNav1.5, supporting our 
earlier conclusion with neurotoxins that the difference between the D1:S3/S4 (E2) 
region of nNav1.5 and aNav1.5 is ‘pharmacologically’ distinguishable.  
 Potency, specificity and selectivity of NESOpAb compares well with the 
previously reported ion channel blocking antibodies. For instance, S5/S6 (E3) targeting 
antibodies exhibited IC50 or half-maximal block at 50-1600 nM (Table 1.7), whilst 
NESOpAb was significantly more potent, producing half-maximal block at 23 ng/ml (< 
5 nM). Notably, such efficacy of NESOpAb was even better than that of most existing 
VGSC blocker neurotoxins, including TTX (Catterall et al., 2007; Clare, 2010). In the 
only study that characterized selectivity (i.e. threshold concentration) with respect to 
the nearest relative, Kv1.2 antibody was found to be ~ 400-fold selective for Kv1.2 vs. 
Kv1.3 (Zhou B et al., 1998). This compares well with the corresponding ~200-fold 
selectivity of NESOpAb for nNav1.5 vs. aNav1.5, especially since the Kv1.2 antibody 
was only ‘subtype-selective’ and not ‘splice-variant selective’ as NESOpAb. Finally, 
NESOpAb blocked nNav1.5 currents by a maximum of 67%, which is comparable or 
better than the maximal block attained by previously reported ion channel antibodies 
(Table 1.7; Zhou B et al., 1998; Xu et al., 2005; Liao et al., 2008; Naylor et al., 2008). 
Due to limited availability, we could not test NESOpAb concentrations higher than 
1000 ng/ml, and hence, whether complete current block can be achieved at higher 
antibody concentrations is not known. Previously, NESOpAb block was shown to 
saturate at ~1000 ng/ml (~ 60% block), suggesting that antibody block would be 
incomplete (Chioni et al., 2005). In general, incomplete current inhibition is an 
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intriguing property shared by ion channel antibodies (including the ones that directly 
target the outer vestibule of the channel pore structure, i.e. E3; Figure 1.15) and is 
further discussed in Section 5.3.3.4. 
Interestingly, comparison of time-course and reversibility of NESOpAb block 
with that of previously reported ion channel antibodies revealed that the generally 
observed slow onset and offset of antibody block may not be due to the slow kinetics of 
antibody-epitope interaction but rather due to the slow diffusion of the large antibody 
molecule to its target site. Thus, when the antibody was puff-applied (present study and 
Liao et al., 2008), ensuring fast target-delivery of the antibody, current block reached 
stable levels rapidly within 2-3 min and was reversible especially at lower antibody 
concentrations (Table 1.7). On the other hand, upon bath-application, antibody block 
occurred more slowly (5-20 min) and was relatively irreversible (Table 1.7; Zhou B et 
al., 1998; Xu et al., 2005). Overall, therefore, the limiting factor for the slow onset / 
offset of antibody block may be the dialysis of the antibody and not the kinetics of the 
antibody-channel interaction. 
 
5.3.3.2 Importance of Lys211 for NESOpAb selectivity 
Meiri et al. (1989) stated that accessibility, mobility (i.e. conformational change during 
channel activation and inactivation) and valency of the target epitope are the three 
major determinants of a successful blocking ion channel antibody. High efficacy of 
NESOpAb to block nNav1.5 currents indicated that the short D1:S3/S4 linker is 
extracellularly accessible (see Section 5.3.3.1), whilst the mobility of this S3/S4 linker 
upon depolarization was critical for antibody block (see Section 5.3.3.5).  
 As regards valency, our results indicate that the positive charge of Lys211 in 
nNav1.5 is essential for the selectivity of NESOpAb for nNav1.5 vs. aNav1.5. Residue 
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at this position was the only one with a net charge-difference between the two Nav1.5 
variants, and mutating Lys211 in nNav1.5 to Asp (as in aNav1.5) drastically reduced the 
selectivity of NESOpAb for nNav1.5 over aNav1.5. For instance, the 200-fold 
threshold selectivity of NESOpAb for nNav1.5 vs. aNav1.5 was diminished to ~ 10 
fold for K211D mutant vs. aNav1.5. Moreover, 25% larger maximal antibody block in 
nNav1.5 vs. aNav1.5 was completely abolished by the K211D mutagenesis in nNav1.5. 
Consistently, in Hill-fits, the 50% larger estimated block at saturation in nNav1.5 vs. 
aNav1.5 was eliminated by K211D mutagenesis. Finally, concentration for half-
maximal block and IC50 for NESOpAb block was 4 and 10-fold lower for nNav1.5 vs. 
aNav1.5, respectively, whilst K211D mutagenesis reduced this selectivity to ~ 2-fold 
(i.e. difference between K211D and aNav1.5 was ~ 2-fold).  
Overall, therefore, independent of the other amino acid changes within the 
target epitope, NESOpAb’s selectivity for nNav1.5 over aNav1.5 was critically 
dependent on the Lys/Asp211 residue. Possibly, the positive charge of Lys211 was 
electrostatically involved in the intimate antibody-D1:E2 interaction in nNav1.5, which 
was disturbed in the K211D mutant and the aNav1.5 variant by the negative charge 
introduced by Asp211. Nevertheless, our data do not rule out the possibility that the 
structure rather than the charge of the residue at position 211 is critical for NESOpAb 
selectivity. Further mutagenesis experiments involving a switch from Lys211 to a 
neutral or a positive amino acid in nNav1.5 would help resolve this issue.  
Previously, we found Lys/Asp211 also to be predominantly responsible for the 
electrophysiological differences between Nav1.5 D1:S3 variants, including the 
depolarized activation of nNav1.5 relative to aNav1.5 (see Chapter 4; Onkal et al. 
2008a). Current models of VGSCαs locate Lys/Asp211 towards the N-terminal border 
of the D1:S3/S4 linker (Figure 1.7; Gellens et al., 1992; Smith et al. 2007). We 
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postulated, therefore, that the positive charge-reversal at this position would reduce the 
local negative surface potential in nNav1.5, electrostatically resisting the outward 
displacement of D1 voltage-sensor and depolarizing activation voltage-dependence 
(Onkal et al. 2008a; Onkal and Djamgoz, 2009). This conclusion assumed an 
extracellular position for the Lys211 residue, which was confirmed in the present study 
since the extracellular accessibility of Lys/Asp211 was a prerequisite for the observed 
critical role played by this residue for selectivity of NESOpAb in nNav1.5 vs. aNav1.5. 
 
5.3.3.3 NESOpAb block of endogenous nNav1.5 currents in MDA-MB-231 
In MDA-MB-231 cells, ~ 80% of the VGSC current is TTX-R carried predominantly by 
nNav1.5, whilst the ~ 20% TTX-S fraction is probably due to nNav1.7, the only other 
full-length VGSCα mRNA expressed (Fraser et al., 2005; Brackenbury et al., 2007).  
To facilitate direct comparison of NESOpAb block in endogenous vs. 
recombinant nNav1.5 (i.e. stably expressed in EBNA-293), we first tested NESOpAb on 
VGSC currents expressed in Mat-LyLu PCa cells, where nNav1.7 is the predominant 
VGSCα expressed (Brackenbury and Djamgoz, 2006). We found that NESOpAb 
exerted minimal effects on nNav1.7 currents, with ~ 20% maximal block and a 
threshold concentration for block that was ~ 200-fold greater compared to nNav1.5. 
Among the 14 amino acids targeted by NESOpAb, six were different between nNav1.5 
and nNav1.7, which, together with intrinsic structural differences between Nav1.5 and 
Nav1.7, could explain the observed limited potency of NESOpAb for nNav1.7. Overall, 
our findings with nNav1.7 indicated (i) that NESOpAb block of VGSC activity in 
MDA-MB-231 cells would be largely due to block of nNav1.5 channels, and more 
importantly (ii) that selectivity of NESOpAb for nNav1.5 vs. other VGSCαs is likely to 
be even superior to its selectivity for nNav1.5 vs. aNav1.5.  
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Previously, NESOpAb was shown to suppress VGSC-dependent enhancement 
of various MCBs (e.g. transwell migration, invasion) in MDA-MB-231 BCa cells 
(Fraser et al., 2005; Brackenbury et al., 2007). Here, we provide the first 
electrophysiological evidence for direct NESOpAb block of endogenous nNav1.5 
currents in MDA-MB-231 cells. Importantly, we showed that the sensitivity of 
endogenous nNav1.5 channels to NESOpAb was comparable to that of recombinant 
nNav1.5 channels expressed in EBNA-293 cells, as evident from the statistically 
similar block levels at each antibody concentration tested. Zhou B et al. (1998) also 
found that their Kv1.2-E3 antibody exhibits similar efficacy in recombinant and 
endogenous Kv1.2 currents expressed in HEK-293 and neuronal NG108-15 cells, 
respectively. With NESOpAb, the only observed difference between recombinant and 
endogenous nNav1.5 currents was that the Hill equation fits to dose-response curves 
yielded a non-zero (18.2%) residual current at saturation for endogenous MDA-MB-
231 currents, whilst estimating complete block for recombinant EBNA-293 currents. 
This was probably not due to any differential interaction of NESOpAb with 
recombinant and endogenous nNav1.5, and can simply be explained by the fact that ~ 
20% of total INa in MDA-MB-231 cells is carried by ‘low-affinity’ nNav1.7 channels 
(Brackenbury et al., 2007).  
 
5.3.3.4 Mechanism of NESOpAb block 
The majority of earlier studies on ion channel antibodies did not evaluate the 
mechanism of channel inhibition; however, several hypotheses have been proposed in 
this regard, as follows: (i) Steric (physical) pore block. The large size of the antibody 
molecule (i.e. 150 kDa with ~ 140 Å overall diameter) would block the ion channel 
pore (Colman et al. 1987; Meiri et al., 1986, 1989; Zhou B et al., 1998). (ii) Allosteric 
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(conformational) modulation. Modification of channel structure upon antibody binding 
would favour non-conducting vs. open channel states (Meiri et al., 1989; Naylor et al., 
2008). (iii) Internalization of channel protein. Upon antibody binding, the channel 
protein could be subject to endocytosis, effectively reducing the number of functional 
ion channels in the plasma membrane (Kim and Neher, 1988; Zhou B et al., 1998). 
 The ‘internalization’ hypothesis was first introduced by Kim and Neher (1988), 
who found by single-channel recordings that autoantibodies from Lambert-Eaton 
myasthenic syndrome (LEMS) patients block VGCCs in an all-or-none fashion with no 
effect on unitary conductance, open probability and mean open time, suggestive of 
current block being due to reduced number of functional channels. However, 
subsequent work with other antibodies revealed that current block was at least partially 
reversible, which is incompatible with an internalization effect (e.g. Zhou B et al., 
1998; Liao et al., 2008). Our results with NESOpAb also show full or partial 
reversibility of current inhibition depending on the antibody concentration, further 
suggesting that channel internalization is not the likely mechanism of antibody block. 
Consistently, Wyatt et al. (1997) recorded ~ 50% inhibition of peak VGCC currents 
after 2 h incubation with an anti Cav1.3 antibody, whilst (non-permeabilized) 
immunostaining of the cells after the 2 hr incubation period showed no reduction in 
fluorescence, i.e. there was no decrease in the number of membrane-bound channels.  
 As regards ‘steric’ or ‘allosteric’ block, electrophysiological studies with most 
ion channel antibodies, including NESOpAb here, are compatible with both 
hypotheses. We report that NESOpAb suppresses peak nNav1.5 currents with no 
apparent effect on activation I-V relationships or kinetics of channel gating, similar to 
earlier findings with other ion channel blocking antibodies (Meiri et al., 1986, 1989; 
Wyatt et al., 1997; Xu et al., 2005). This is consistent with inhibition of nNav1.5 
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channels occurring in an all-or-none fashion (Kim and Neher, 1988), i.e. antibody-
bound channels become electrically ‘silent’, whilst the remaining drug-unbound 
channels continue to function normally. However, our data do not clarify whether 
channel inhibition occurred via a simple steric pore block and/or an allosteric 
mechanism through which antibody-bound channels become non-conducting. In the 
latter scenario, given that the outward movement of D1:S3/S4 linker is essential for 
channel activation (Swartz, 2008), binding of NESOpAb may ‘lock’ this voltage-sensor 
linker in a non-conducting resting or inactivated conformation, thereby inhibiting 
channel activation (e.g. similar to ProTx-II except that antibody-bound channels never 
activate). As regards steric block, an antibody generated against the pore-region of D4 
of rNav1.2 channels was shown to effectively reduce α-scorpion toxin binding to 
D4:S3/S4, indicating that an antibody molecule is large enough to occupy a S3/S4 
linker while interacting with the outer vestibule (S5/S6 linkers) of the channel protein 
(Thomsen and Catterall, 1989). Conversely, NESOpAb, which interacts with the 
D1:S3/S4 linker, may occupy the external entrance (S5/S6 linker) to the channel pore, 
sterically inhibiting ion flow.  
 As mentioned earlier, one interesting property of ion channel blocking 
antibodies, including NESOpAb, is that current inhibition is not complete (e.g. Zhou B 
et al., 1998; Xu et al., 2005; Liao et al., 2008). If antibody inhibition occurs in an all-
or-none fashion, as suggested by Kim and Neher (1988), then how do we explain the 
incomplete channel block at saturation? It could be that single-channel recordings by 
Kim and Neher (1988) only concern the LEMS autoantibody that these authors tested 
on VGCCs, whereas single-channel block by NESOpAb and other ion channel 
antibodies is in fact partial. In this case, since the target epitope of NESOpAb is not in 
the pore forming E3 region, antibody binding may not result in ‘tight’ occlusion of the 
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channel pore, resulting only partial reduction of Na+ conductance (Xu et al., 2005). On 
the other hand, if we assume an all-or-none block by NESOpAb, incomplete current 
inhibition at saturation is harder to explain. One possibility is that the antibody 
molecule, which is almost as large as the VGSCα subunit itself, may not efficiently 
diffuse and orient itself in membrane regions with closely packed channel protein, such 
that NESOpAb binding to a nNav1.5 channel becomes antagonistic to antibody binding 
to adjacent nNav1.5 channels. Thus, even at saturating concentrations, a fraction of 
channels always remain antibody-unbound, explaining the partial antibody block 
observed.  
Regardless of the mechanism, however, an antibody molecule first needs to 
recognize and bind to its target epitope before exerting its effects on channel function. 
Our data strongly suggest that NESOpAb binding occurs preferentially when nNav1.5 
channels are in their inactivated vs. resting (closed) states. In particular, NESOpAb 
application significantly hyperpolarized (~ 10 mV) nNav1.5 availability, consistent 
with selective antibody binding to the open / inactivated states of the channel as for 
small-molecule VGSC blockers (Ragsdale et al., 1991; Nau and Wang, 2004). Notably, 
hyperpolarization of availability occurred mainly across a voltage-range that would not 
allow for channel opening (e.g. < -70 mV), implying that NESOpAb was selective for 
inactivated rather than open-state channels. This was illustrated by the study of 
percentage current block at different conditioning pre-pulse voltages, which revealed 
that NESOpAb (1000 ng/ml) blocked only ~ 25% of nNav1.5 current at a pre-pulse 
potential of -120 mV, whilst blocking ~ 70% of nNav1.5 current at -90 mV. At either 
of these hyperpolarized potentials, channels may occupy partially activated states but 
probability of reaching open configuration is very small, suggesting that the observed 
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difference in block levels was due to higher affinity antibody binding to inactivated 
channels.  
State (voltage)-dependence of NESOpAb block was further demonstrated by 
experiments in which the extent of current inhibition was determined at two different 
holding potentials (Vh = -100 vs. -120 mV). Consistent with the proposed low affinity 
of NESOpAb for resting channels, antibody block was minimal at Vh = -120 mV, 
where almost all channels occupy their resting (closed) states. At Vh = -100 mV, where 
~ 25% of the channel population would be in inactivated state, the block level appeared 
higher, as predicted. Furthermore, we observed that channel activity was necessary for 
NESOpAb to achieve maximal efficacy. At 0.1 Hz stimulation, NESOpAb (1000 
ng/ml) block improved progressively at each depolarizing stimulus, reaching 60-70% 
after ~ 100 s. However, when NESOpAb was applied in the absence of depolarizing 
pulses, block appeared much smaller (~ 30%) at the first pulse after 100 s, whilst 
progressing to the typical 60-70% level only when the 0.1 Hz depolarizing pulses were 
initiated. This is consistent with NESOpAb interacting preferentially with the 
inactivated nNav1.5 channels and achieving maximal efficacy only if all channels 
cycled through their ‘high-affinity’ inactivated conformations. Notably, this suggests 
that efficacy of NESOpAb could be much higher at physiological resting membrane 
potentials, which would be more depolarized than the experimental Vh used here 
(Fraser et al., 2005; Onkal and Djamgoz, 2009).  
State (voltage)-dependence of NESOpAb block is consistent with the 
configuration of D1:S3/S4 linker being significantly different in resting vs. inactivated 
states of nNav1.5 channels (Catterall, 2000; Swartz, 2008). In particular, the ‘paddle-
model’ of activation, which is based on the recent X-ray crystal structures of VGPCs 
(Jiang et al., 2003; Long et al., 2005a; Ruta et al., 2005), proposes that the voltage-
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sensor paddles (S3b / S4 region) are positioned largely within the core of the lipid 
membrane at negative membrane potentials (i.e. resting channel states), translocating to 
the extracellular surface upon membrane depolarization (Swartz, 2008). Thus, 
extracellular accessibility of the antibody epitope may be limited in the resting channel 
conformation, whilst the outward movement of the D1:S4 voltage-sensor (i.e. 
conventional sliding helix model of activation) or D1:S3/S4 paddle (i.e. paddle model 
of activation) upon depolarization may expose the antibody epitope in a position that 
favours NESOpAb binding (Figure 5.49). Interestingly, multiple examples of voltage-
dependence of antibody inhibition have been reported earlier. In particular, Gomez-
Varela et al. (2007) found that 10-min application of the Eag1-E3 antibody was 
without effect in the absence of depolarizing pulses, concluding that the antibody block 
was voltage- and use-dependent. Similarly, Wyatt et al. (1997) generated a D4:S6 
targeting Cav1.3 antibody that was more potent in KCl-depolarized vs. normal rat DRG 
neurons and cardiac myocytes. Finally, Meiri et al. (1989) described a D1:S4 targeting 
VGSC antibody that produced a substantial 20-30 mV hyperpolarizing shift of channel 
availability in eel electroplax. This also suggested state-dependent antibody binding 
with preference to the inactivated channel state.  
In all these examples, including NESOpAb, a partially membrane-buried epitope 
(e.g. in E2 or E3) may become accessible to the antibody only in the presence of 
depolarized holding potentials. This is analogous to the state-dependent interaction of 
β-scorpion toxins with VGSCs, which occurs mainly when the toxin-receptor in D2:S4 
becomes exposed to the extracellular space upon membrane depolarization / channel 
activation (Catterall et al., 2007; Bosmans and Swartz, 2010). Thus, the conformational 
changes that nNav1.5 channels undergo upon depolarization may relocate the antibody 
recognition site from an inaccessible location near the external border of D1:S3/S4 to  
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A  Conventional (helical-screw) model 
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Figure 5.49 Schematic presentation of state (voltage)-dependence of NESOpAb block 
(A) Cartoon illustrates the six-transmembrane D1 of nNav1.5 at hyperpolarized potentials (i.e. 
resting conformation) on the left and at depolarized potentials (i.e. open / inactivated) on the 
right. Pore-forming S5-S6 segments are shown in purple and positively charged S4 voltage-
sensor is in yellow. Upon depolarization, conformational changes that drive the transition from 
resting to open / inactivated states (e.g. outward ‘helical screw’ movement of the S4 segment) 
relocates the extracellular D1:S3/S4 linker in a position more favourable for NESOpAb 
interaction. (B) In the recent paddle-model of activation, D1:S3/S4 linker is intracellular in the 
resting conformation, whilst outward translocation of the S3b-S4 paddles (S4 in yellow) upon 
depolarization relocates D1:S3/S4 linker in a solvent-exposed position reachable by NESOpAb. 
Channel and antibody structures are not drawn to scale; antibody molecule is larger than a six-
transmembrane VGSC domain in reality. 
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an ‘exofacial’ position, facilitating NESOpAb interaction (Figure 5.49). Notably, this 
implies that both open and inactivated states of nNav1.5 (i.e. ‘depolarized’ 
conformations) favour antibody binding; however, given the brief open-time for 
VGSCs (few milliseconds), larger NESOpAb block observed in the presence more 
depolarized Vh or repeated channel activity is probably due to preferential binding to 
inactivated rather than open channels. Also, as discussed earlier, NESOpAb-induced 
negative shift in nNav1.5 availability occurred at a hyperpolarized voltage-range that 
would not allow channel opening, consistent with the notion that inactivated rather than 
open-states mediated enhanced antibody binding. 
   
5.3.3.5 Future applications 
nNav1.5 has been extensively studied in relation to its pro-metastatic role in BCa 
progression (Fraser et al., 2005; Brackenbury et al., 2007; Gillet et al., 2009). A major 
class of clinically used anti-cancer agents are monoclonal antibodies (mAbs; Carter, 
2001; Zangemeister-Wittke, 2005; Baker, 2005b). Familiar examples include Herceptin, 
Rituxan, Avastin and Erbitux, most of which act by blocking receptors for hormones or 
growth factors that are important for cancer development and progression (e.g. Bedard 
and Piccart-Gebhart, 2008; Ademuyiwa and Miller, 2008). The therapeutic value of 
such antibodies comes from their specificity and interaction with extracellularly 
accessible targets. The same principle is thus applicable to ion channels, and this has 
been shown earlier for Eag1 expression in cancer (Gomez-Varela et al., 2007; Pardo 
and Stuhmer, 2008). In conjunction with this anti-Eag1 antibody, results presented with 
NESOpAb here and earlier by Chioni et al. (2005) provide a proof-of-principle that 
‘blocking’ ion channel antibodies can serve as selective diagnostic and/or therapeutic 
agents against oncogenic / pro-metastatic activity of ion channels.  
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Our results indicate that, at the very least, NESOpAb can serve as an 
experimental tool for probing/validating the specific role played by nNav1.5 in the 
development and progression of metastatic BCa (Brackenbury et al., 2007). As regards 
possible future clinical use, the following characteristics of NESOpAb block and 
nNav1.5 expression in BCa are particularly pertinent: (i) When applied extracellularly, 
NESOpAb recognizes and blocks nNav1.5 activity (at nanomolar concentrations) with 
at least ~ 200-fold threshold-selectivity over its nearest neighbour, aNav1.5 and a more 
distant nNav1.7. (ii) The antibody blocks in vitro migration and invasion of the strongly 
metastatic MDA-MB-231 cells, without any effect on PCa cells (Brackenbury et al., 
2007). (iii) In vitro, using NESOpAb, it was confirmed that nNav1.5 was more highly 
expressed in the highly metastatic MDA-MB-231 BCa cells compared to weakly 
metastatic MCF-7 cells (Chioni et al., 2005; Fraser et al., 2005). (iv) As a neonatal 
gene/protein, nNav1.5 expression is absent from normal adult tissues (except possibly at 
low levels in CNS; Chioni et al., 2005; Wang J et al., 2008).  
Accordingly, a humanized monoclonal form of NESOpAb may serve as a 
specific indicator and/or suppressor of metastatic BCa. In addition, the therapeutic 
efficiency of anti-cancer mAbs can be enhanced by combination with mainstream 
chemo- or hormone-therapies, other mAbs and/or biological agents which activate the 
immune system (Mellstedt, 2003; Newsome and Ernstoff, 2008). Thus, an anti-nNav1.5 
mAb may be used together with existing conventional treatments, providing a ‘tailor-
made’ anti-BCa treatment. Alternatively, the antibody may be modified to induce 
selective cancer cell cytotoxicity by chaperoning cytotoxic molecules, i.e. 
immunoconjugates such as chemotherapy drugs, radio-nuclides, toxins or biological 
agents such as interferons (Newsome and Ernstoff, 2008).  
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5.3.4 Conclusions  
The conclusions of the present study are as follows: 
i. Mainstream small-molecule VGSC blocker drugs failed to distinguish between 
nNav1.5 and aNav1.5. Thus, despite these agents are currently in clinical use 
against VGSC-involving pathophysiologies (e.g. arrhythmias, neuropathic pain), 
their lack of subtype-selectivity (or splice-variant selectivity in the case of 
Nav1.5 D1:S3 variants) may be problematic as regards the possibility of adverse 
side-effects upon clinical use against nNav1.5 expression in metastatic BCa. 
ii. Neurotoxins, ProTx-II and HaTx, were found to be selective for aNav1.5 vs. 
nNav1.5, which suggested that the structural difference in D1:S3/S4 of these two 
Nav1.5 splice variants is targetable. Nav1.5 splice-variant selective neurotoxins 
can be employed in in vitro proof-of-concept studies for determining the specific 
role played by nNav1.5 in metastatic BCa. Also, neurotoxins that exhibit 
selectivity for nNav1.5 vs. aNav1.5 could be exploited clinically against the pro-
metastatic nNav1.5 expression in BCa. Currently, however, biochemical 
instability and target promiscuity remain the major challenges in the way of 
clinical applicability of natural neurotoxins. 
iii. NESOpAb was confirmed to be a blocking antibody selective for nNav1.5 vs. 
aNav1.5 (and possibly other VGSCs such as Nav1.7). We also found NESOpAb 
to exhibit similar potency for recombinant and endogenous nNav1.5 in EBNA-
293 and MDA-MB-231 cells, respectively. Thus, a monoclonal form of 
NESOpAb, which exhibits a similar selectivity profile for nNav1.5 vs. aNav1.5, 
would presently be the best candidate for selective targeting of nNav1.5 in 
metastatic BCa.  
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At present, there is a significant need to identify  novel anti-metastatic ‘targets’ and 
corresponding agents to control metastasis in various major cancers, including breast 
cancer (BCa) (Jemal et al., 2010). In this regard, an emerging and promising new field 
of investigation is centered around functional expression of voltage-sensitive ion 
channels (Fraser and Pardo, 2008; Arcangeli et al., 2009; Onkal and Djamgoz, 2009). In 
particular, voltage-gated sodium channels (VGSCs) appear to be strongly associated 
with metastatic potential, as evinced by their high level expression in aggressive 
carcinomas and role in controlling (potentiating) various steps of the metastatic cascade 
(Fraser et al., 2005; Brackenbury et al., 2007; Gillet et al., 2009). Accordingly, VGSCs 
are becoming an exciting new class of targets for selective evaluation of metastatic 
potential and/or blockage of its progression (Onkal and Djamgoz, 2009). To this end, 
the main aims of the present study were (i) to investigate the effect of long- and short-
term hypoxia (a major micro-environmental stress condition experienced by tumour 
cells in vivo) on VGSC (mainly ‘neonatal’ Nav1.5) expression and function in the 
strongly metastatic MDA-MB-231 BCa cells, and (ii) to characterize the 
pharmacological properties of the ‘neonatal’ Nav1.5 (nNav1.5) channel, with respect to 
its nearest counterpart – ‘adult’ Nav1.5 (aNav1.5), using various small-molecule VGSC 
blockers, neurotoxins and a nNav1.5-selective blocking antibody. 
 
6.1 Summary of key findings 
The main findings of this PhD are as follows: 
i. Steady-state functional VGSC expression in the strongly metastatic MDA-MB-231 
BCa cell line was upregulated by long-term (24 h) hypoxia via a positive feedback 
mechanism consistent with enhanced Na+ influx (i.e. via hypoxia-induced 
persistent Na+ current – INaP) and subsequent activation of PKA. 
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ii. Long-term hypoxia increased invasiveness of MDA-MB-231 cell in vitro, and this 
effect was in part due to the hypoxic increase in VGSC activity (i.e. functional 
channel expression and INaP). 
iii. nNav1.5 and aNav1.5 differed significantly in their electrophysiological 
characteristics and a particular amino acid change (Asp/Lys211) in the domain 1: 
segment 3-4 (D1:S3/S4) linker of the channel protein was largely responsible for 
these differences. 
iv. Small-molecule VGSC blockers lidocaine, phenytoin, mexiletine, procaine, 
ranolazine and riluzole failed to induce any differential effect on the transient 
current component of D1:S3 aNav1.5 vs. nNav1.5 splice variants.  
v. Neurotoxins ProTx-II and HaTx selectively inhibited aNav1.5 vs. nNav1.5, 
suggesting toxin interaction with the D1:S3/S4 region. Charge-reversing Asp211 to 
Lys switch was not responsible for the reduced potency of ProTx-II in nNav1.5, 
but could partly account for the differential HaTx effects.  
vi. NESOpAb, a polyclonal antibody targeting nNav1.5, produced selective block of 
nNav1.5 vs. aNav1.5, and Lys211 was critical for this selectivity. NESOpAb 
inhibition was similar for endogenous and recombinant nNav1.5, and current block 
was state-dependent with preferential binding of antibody to inactivated vs. resting 
channels. 
 
6.2 Hypoxic regulation of VGSC expression and activity in BCa 
Previously, under normoxic conditions, VGSC activity was shown to potentiate various 
in vitro metastatic cell behaviours (MCBs) in human and rat models of breast, prostate, 
lung and colon cancers (Bennett et al., 2004; Fraser et al., 2005; Onganer et al., 2005; 
Brackenbury and Djamgoz, 2006; Brackenbury et al., 2007; Gillet et al., 2009; 
 Chapter 6                                                                                                           General Discussion 
 
 517 
Nakajima et al., 2009; House et al., 2010). This is the first study demonstrating hypoxic 
effects on VGSC expression/activity in a cancer cell line. We showed that functional 
VGSC expression in MDA-MB-231 BCa cells is increased during long-term in vitro 
hypoxia (which mimic the in vivo status of tumour cells) via a positive feedback 
mechanism involving Na+ influx and PKA activity (Chioni et al., 2010). Such positive 
auto-regulation, which would ensure a high level of VGSC expression, would maximize 
sustained contribution of VGSCs to enhancement of MCBs in hypoxic MDA-MB-231 
BCa cells (Fraser et al., 2005; Brackenbury et al., 2007; Gillet et al., 2009).  
In addition, metastatic potential of MDA-MB-231 cells, evaluated in the present study 
using in vitro Matrigel invasion assays, was enhanced by hypoxia, and this effect was 
partly VGSC-dependent. Overall, therefore, our findings, taken together with published 
reports, would substantiate the evidence for VGSCs being a significant driving force for 
the metastatic progression of BCa (Fraser et al., 2005; Gillet et al., 2009; Onkal and 
Djamgoz, 2009), as in other carcinomas (e.g. House et al., 2010).  
 As regards the clinical potential (diagnostic and/or therapeutic) of VGSC 
expression in metastatic disease two broad sets of possibilities can be considered. First, 
since hypoxia-induced INaP potentiated invasiveness in MDA-MB-231 cells, and this is 
likely to be a property of all VGSCs, INaP may be pharmacologically targeted as a means 
of suppressing cancer cell invasiveness and, hence, metastasis generally (i.e. INaP may 
be considered as an individual drug target against BCa metastasis). To this end, 
appropriate pharmacological blockers of INaP would be ranolazine and riluzole, which 
are in clinical use against cardiac angina and amyotrophic lateral scelerosis, respectively 
(Fredj et al., 2006; Weiss et al., 2010). Second, in the particular case of metastatic BCa, 
VGSC expression is ‘oncofoetal’ and this provides the channel with significant 
advantages as a novel anti-BCa target, discussed as follows.  
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6.3 Pharmacology of nNav1.5: clinical implications for BCa metastasis 
D1:S3 developmental splice variants of Nav1.5 differ by 7 amino acids in the S3/S4 
voltage-sensor region of D1 (Chioni et al., 2005). The ‘culprit’ VGSC expressed in BCa 
is the D1:S3 ‘neonatal’ Nav1.5, whose expression is developmentally down-regulated in 
cardiac muscle and is absent in non-CNS healthy adult tissues (Chioni et al., 2005; 
Wang J et al., 2008). Therefore, given the blood-brain barrier, the only reachable target 
for a fully nNav1.5-selective drug or antibody could be the metastatic BCa cell in the 
adult patient’s body. In this regard, we determined the sensitivity of nNav1.5 to various 
different classes of VGSC inhibitors, in a comparative approach also including aNav1.5, 
with the view to identify nNav1.5-selective channel blockers. The overall conclusion of 
these pharmacological studies was that the structural difference between nNav1.5 and 
aNav1.5 in the spliced D1:S3/S4 region is targetable by ‘biological agents’ such as 
neurotoxins and antibodies that specifically interact with this D1 region. On the other 
hand, mainstream small-molecule VGSC inhibitors, which bind to an inner-pore site 
distant from the spliced region, are not likely to discriminate between nNav1.5 and 
aNav1.5 channels. Therefore, it must be stressed that the previously reported differential 
efficacies of these VGSC-blocker drugs in neonatal vs. adult cardiomyocytes (i.e. our 
rationale to test these agents in the first place) did not involve D1:S3 splice variants of 
Nav1.5 and possibly involved other developmental changes, e.g. change in expression 
of different VGSC α- and/or β-subunits, glycosylation, phosphorylation (Maier et al., 
2004; Stocker and Bennett, 2006; Kaufmann et al., 2010). 
Our results with two peptide toxins, ProTx-II and HaTx, revealed for the first 
time that neurotoxins can have ‘splice-variant-selective’ effects on VGSCs. Differences 
observed in toxin block of aNav1.5 vs. nNav1.5 also indicated (i) that ProTx-II and 
HaTx share an overlapping binding site in D1:S3/S4, validating this region as a novel 
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neurotoxin site (Bosmans et al., 2008), and (ii) that the structural (amino acid) 
differences between the Nav1.5 D1:S3 variants are targetable using polypeptides. As 
regards (i), it is likely that future studies will identify new or existing neurotoxins that 
target D1:S3/S4, and thus give rise to a novel group of gating-modifier neurotoxins 
classified by their interaction with the D1 receptor site. Importantly, any D1:S3/S4-
targetting neurotoxin is likely to differentiate between aNav1.5 and nNav1.5, and it will 
be interesting to see whether in addition to aNav1.5-selective neurotoxins, nNav1.5-
selective ones also exist. Importantly, as regards amino acid sequence, D1:S3/S4 region 
of nNav1.5 is unique among all known subtypes and splice variants of VGSCs (and 
other ion channel families) (Chioni et al., 2005). Thus, any neurotoxin that is selective 
for the D1:S3/S4 of nNav1.5 is likely to have (i) a superior selectivity profile compared 
to existing neurotoxins, and (ii) exhibit minimal target promiscuity unlike most other 
gating modifier neurotoxins (e.g. ProTx-II and HaTx; Bosmans and Swartz, 2010). 
Importantly, natural neurotoxins, when used at appropriate concentrations, have been 
shown to be medically useful in a variety of disorders, including cancer (Leippold et al., 
2003; Son et al., 2007). Accordingly, discovery of a nNav1.5-selective neurotoxin (or 
synthetic peptide) may have clinical implications regarding nNav1.5 expression in BCa 
(Fraser et al., 2005; Roger et al., 2006; Onkal and Djamgoz, 2009).  
A major class of clinically used anti-cancer agents are monoclonal antibodies 
(mAbs; Carter, 2001; Zangemeister-Wittke, 2005; Baker, 2005b). Familiar examples 
include Herceptin, Rituxan, Avastin and Erbitux, most of which act by blocking 
receptors for hormones or growth factors that are important for cancer development and 
progression (e.g. Bedard and Piccart-Gebhart, 2008; Ademuyiwa and Miller, 2008). The 
therapeutic value of such antibodies comes from their specificity and interaction with 
extracellularly accessible targets. The same principle is thus applicable to ion channels, 
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and this has been shown earlier for Eag1 expression in cancer (Gomez-Varela et al., 
2007; Pardo and Stuhmer, 2008). In conjunction with this anti-Eag1 antibody, results 
presented with NESOpAb here and earlier by Chioni et al. (2005) provide a proof-of-
principle that ‘blocking’ ion channel antibodies can serve as selective diagnostic and/or 
therapeutic agents against oncogenic / pro-metastatic activity of ion channels. Our 
results indicate that, at the very least, NESOpAb can serve as an experimental tool for 
probing/validating the specific role played by nNav1.5 in the development and 
progression of metastatic BCa (Brackenbury et al., 2007). As regards possible future 
clinical use, a humanized monoclonal form of NESOpAb may serve as a specific 
indicator and/or suppressor of metastatic BCa. Such anti-nNav1.5 mAb may be used 
together with existing conventional treatments, providing a ‘tailor-made’ anti-BCa 
treatment. Alternatively, the antibody may be modified to induce selective cancer cell 
cytotoxicity by chaperoning cytotoxic molecules, i.e. immunoconjugates such as 
chemotherapy drugs, radio-nuclides, toxins or biological agents such as interferons 
(Newsome and Ernstoff, 2008).  
 
6.4 Future perspectives 
Following on from this project, the following directions for further work on VGSC 
expression and activity in BCa can be envisaged: 
i. Upstream. Elucidation of the mechanism(s) responsible for the upregulation of 
VGSC activity in metastatic BCa. It would be useful to study weakly metastatic 
MCF-7 cells MDA-MB-268 cells to ascertain what genes/proteins/signalling 
pathways are involved in functional VGSC expression in strongly metastatic BCa 
(i.e. MDA-MB-231 cells). Given that VGSC (nNav1.5) protein is present in 
internal compartments of MCF-7 cells (Chioni et al., 2010), it would be 
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worthwhile to investigate the molecular mechanism(s)/signature(s) underlying the 
trafficking of the channel protein to the plasma membrane. 
ii. Downstream. Elucidation of the mechanisms by which VGSC activity potentiates 
metastatic cell behaviour in BCa cells. A microarray approach could be used to 
identify the genes/proteins controlled by VGSC activity in MDA-MB-231 cells 
(House et al., 2010). In addition, the potential involvement of VGSC activity in 
controlling the resting membrane potential (Vm) and [Na+]i, [Ca2+]i and pH 
homeostasis in BCa cells could be investigated using a combination of 
electrophysiological and live cell Na+/Ca2+/Vm imaging techniques. Given the 
strong evidence on the pro-invasive effect of VGSC activity in BCa, it would be 
worthwhile to study the functional interaction between VGSCs and proteins 
involved in invasive cascades (e.g. matrix metalloproteinases, cathepsins). 
iii. Pharmacology. Testing of efficacy/selectivity/specificity of (1) a functional 
monoclonal antibody raised against nNav1.5, and (2) a library of VGSC-blocker 
natural neurotoxins and small-molecule-pharmaceuticals, with the view to identify 
nNav1.5-selective agents. In addition, INaP was shown in the present study to 
individually contribute to BCa cell invasiveness, and thus, studies directed towards 
identification of novel INaP selective agents would be worthwhile. These proposed 
pharmacological studies could be performed in collaboration with commercial drug 
companies for high-throughout screening of the agents. 
iv. In vivo. Transfer of the presented in vitro studies to in vivo models of BCa with a 
view to potential clinical applications. To this end, application of small-molecule 
VGSC blockers as well as nNav1.5-selective antibodies could be used to test the 
contribution of VGSC activity to metastatic spread of BCa in vivo.  
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In overall conclusion, the results of this PhD, taken together with the published 
evidence, could have important clinical implications, whereby targeting the functional 
expression of VGSCs (nNav1.5) in BCa may form the basis of novel methods for 
clinical management of cancer. 
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Appendix 1 Hypoxia did not change morphology of any of the cell lines used 
MDA-MB-231 (A), MCF-7 (B), nNav1.5-EBNA (C), and Mat-LyLu (D) cells were cultured in 
normoxic (left) or hypoxic (2% O2) conditions (right) for 24 h before being photographed. Scale 
bar, 15 µm. 
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Appendix 2 Chronic hypoxia and long-term pharmacological treatments (24 h) did not 
affect cell viability 
(A) Cell viability as determined using the Trypan blue toxicity assay was not affected by the 
hypoxic treatment (2% O2, 24 h) in MDA-MB-231, MCF-7 and nNav1.5-EBNA cells. Data 
are mean ± SEM from three separate experiments (n = 30 each), and were compared using 
unpaired t-tests (P > 0.05). (B) Long-term (24 h) pharmacologic treatments tested in Chapter 
3 did not affect viability of normoxic / hypoxic MDA-MB-231 cells. Nor, normoxia; hyp, 
hypoxia; TTX, tetrodotoxin; Ran, ranolazine; Fors, forskolin. Data are mean ± SEM from at 
least three separate experiments (n = 30 each), and were compared using ANOVA (P = 0.96).  
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Appendix 3 Na+-free MPS abolished inward currents expressed in MDA-MB-231, 
nNav1.5-EBNA, Mat-LyLu and Nav1.4-HEK cells  
Typical whole-cell inward currents in (A) MDA-MB-231, (B) nNav1.5-EBNA, (C) Mat-
LyLu, and (D) Nav1.4-HEK cells before (i) and after (ii) perfusion with Na+-free MPS 
(equimolar choline was substituted for Na+). Currents were elicited by 60 ms depolarizing 
pulses to between -80 mV and +45 mV from a holding potential of -100 mV; interpulse 
duration was 2 s. In the absence of Na+, all inward currents were abolished. 
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Trace # Time Application Notes
1 0 Control
2 10 Control
3 20 Na+ free
4 30 Na+ free
5 40 Control  Time-course plots start here (e.g. Figure 3.14) 
6 50 Control
7 60 Control
8 70 Control  Hypoxic MPS applied right after this pulse
9 80 Hypoxia
10 90 Hypoxia
11 100 Hypoxia
12 110 Hypoxia
13 120 Hypoxia
14 130 Hypoxia
15 140 Hypoxia
16 150 Hypoxia
17 160 Hypoxia
18 170 Hypoxia
19 180 Hypoxia
20 190 Hypoxia
21 200 Hypoxia
22 210 Hypoxia
23 220 Hypoxia  5 min hypoxia
24 230 Hypoxia
25 240 Hypoxia
26 250 Hypoxia
27 260 Hypoxia
28 270 Hypoxia
29 280 Hypoxia
30 290 Hypoxia
31 300 Hypoxia
32 310 Hypoxia
33 320 Hypoxia
34 330 Hypoxia
35 340 Hypoxia
36 350 Hypoxia
37 360 Hypoxia
38 370 Hypoxia
Followed by either:
(i) Control for 2-3 min (for reversibility)
Na+free 3 pulses to check for leak
OR
(ii) Ranolazine or TTX for 1-2 min until effects are stable
Na+ free 3 pulses to check for leak
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 Protocol for acute hypoxia studies in MDA-MB-231 and nNav1.5-EBNA 
cells 
Voltage pulses were 300 ms long and applied at 0.1 Hz to -20 mV from a holding potential of 
-100 mV. Initially, 2 pulses were applied under control (normoxic) conditions to check for 
Na+ current expression. This was followed by the first Na+ free application for 20 seconds (2 
pulses). Next, 4 pulses were applied under control conditions, followed by 30 pulses in the 
presence of acute hypoxia (5 min / 300 sec). Finally, (i) the cells were re-perfused with 
normoxic MPS (typically 1-2 min) to check reversibility of the hypoxic effects, followed by 
the second Na+-free application, or (ii) ranolazine or TTX (in hypoxic MPS) were applied 
until inhibition of Na+ currents became stable (< 1 min), followed by the second Na+-free 
application. 
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Appendix 5 Effect of long-term (24 h) TTX, KT5720, Myr PKI14-22 and forskolin 
treatment on cell morphology 
MDA-MB-231 cells were photographed after 24 h incubation in: (A) control conditions 
(normoxia or hypoxia (2% O2), (B) 10 µM TTX, (C) 500 nM KT5720, (D) 20 µM Myr PKI14-
22, and (E) 20 µM forskolin. Scale bar shown in part A (30 µm) applies to all photos. 
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Appendix 6 DMSO pre-treatment (0.025%, 24 h) had no effect on VGSC characteristics  
Data were recorded from MDA-MB-231 cells pre-treated (24 h) in normoxia, hypoxia (2% O2), 
normoxia + DMSO (0.025%), and hypoxia + DMSO (0.025%). Normoxia and hypoxia data were 
re-plotted from Figures 3.21, 3.22 and 3.23. For pulse protocols, see Figure 3.1A (for parts A, B, 
C and E), Figure 3.2A (for part D), and Figure 3.2C (for part F). (A) Mean current density I-V 
relationships for normoxia / hypoxia ± DMSO (n ≥ 19). (B) Average VGSC peak current density 
in normoxia / hypoxia ± DMSO (n ≥ 19); DMSO was without effect (unpaired t-test vs. normoxia 
or hypoxia; P > 0.05). Inset, whole-cell capacitance was unchanged by DMSO pre-treatment 
(unpaired t-test vs. normoxia or hypoxia; P > 0.05). (C) Normalized G-V relationships (G/Gmax) 
fitted with Boltzmann functions (n ≥ 19). (D) Normalized availability-voltage relationships fitted 
with Boltzmann functions (n ≥ 17); currents (I) were normalized to the maximum current (Imax) 
recorded following the most hyperpolarized pre-pulse (-140 mV). (E) Time to peak (Tpeak) plotted 
as a function of test potential and fitted with single exponential functions (n ≥ 19). (F) Recovered 
current (It /Ic) plotted as a function of recovery interval and fitted with single exponential functions 
(n ≥ 7). Data are presented as mean ± SEM.  
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Appendix 7 Chronic hypoxia increased VGSCα immunoreactivity 
Typical confocal images of fixed and permeabilized MDA-MB-231 cells pre-incubated in 
normoxic or hypoxic (2% O2) conditions for 24 h. (A) Signal from concanavalin A plasma 
membrane marker (green). (B) Signal from pan-VGSC antibody (red). (C) Overlay of 
concanavalin A and pan-VGSC labelling. (D) Bright field image. White lines in part C, 
typical cross-sections used for ‘straight-line’ subcellular distribution analysis (data shown in 
Figure 3.40C). Scale bar (15 µm) is applicable to all panels. 
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Appendix 8 Hypoxic increase in internal and peripheral VGSCα immunoreactivity 
(A) Confocal images from a normoxic and a hypoxic (2% O2, 24 h) MDA-MB-231 cell. 
Concanavalin A (ConA) membrane labelling (green), pan-VGSC signal (red), and overlay of 
the two are shown. Scale bar (5 µm), applicable to all panels. Dotted square boxes are 
magnified in part B (scale bar applicable to all panels). Chronic hypoxia increased the level of 
both internal and peripheral VGSCα immunoreactivity. 
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        1 taggaagtgc ctgtctccag acacctgttg cctgtctctg cactctgagg cctctctagg 
       61 accacaaggt gtgcttttat ggatgaactt ctacaggttc agagctctgg ttccccatcc 
      121 cctgggcttc tctccccctg tttaaattca gggtgcatgt agacttacca ggctcagccc 
      181 acctctcctg ctggcaacat ccagttgccc aatactaaac aggagagtga aaaccccact 
      241 tctgctacat atggacggaa gggaggcagg tatccacccc tactcccagc agcttctatc 
      301 ctagccttgt ctcctgcttg acccaatgtc agtttgcaag tagaagcttc attctgaggc 
      361 cgagaagccc gtgatggaag ttcttagggg aggtaggacc ttcctgctac tgtactctcc 
      421 tgcctggtag gtgtgactct gggaaggcgg ctgcacgtgg gttgaaacgt tgacactgcc 
      481 tgcacttccc cttctggccg atagtgggag ctgctagcca acctgaggct cgtcaggcgc 
      541 taaaggctgg cagccgacct gtgtggtcca tccgtctgta ccccagacac cccactcaac 
      601 tcggggccgg agaggcccat gtcctgaact ttcctgtgga ctgactttcc tactgatccc 
      661 ctcctgcaag cagagcagcc cctccgtatg tacctaaggc gtccaacgaa gccccacacc 
      721 caggtcgcaa acggacgctg tcccccaccc ccctctttgc cctcccacct cttcaagatc 
      781 cccatcatgg aggagcaggt cccagcctct gggctcccaa acccagcacc tctgtgccct 
      841 ctgagaccct ggcacccatt tggctctcta agagcggttc ttgcttttgg gagccctgaa 
      901 aatgtggcag aaaagtgtac catcccttcc aatgactgta cttttttcgt gggcaaaagc 
      961 tgatggcctg ttttttgttg ttgttttgtt ttgtttttgt ttttgttttt agaagcgcaa 
     1021 gatttattgt gaagagggaa agaacaaagc ttccacagcg tggaagggga cccaagcggg 
     1081 ttgccctgat ggcctgtttt gtttaaacaa gaagtgtgtc cccataggtc ctgggcatgg 
     1141 gcatgggagc aactgtttgt cagcgtatgt ctccgtgtgt gtgtgcctgt gaccatgtct 
     1201 ctgagtgaga aacagtgggt gtgtaagtat gtgactccag gctctgcatg tgtcaaggtg 
     1261 aaggttgtat gtggctcaag agggtggaag tatatatata aagaggtata tacatgtata 
     1321 tatatgtatg tgtgtgtgtg tgtttgcgcg cgcgcgtgtg tgggtgtctc tgtgttggtt 
     1381 gcctgcttgc ttctgggtct gggtgtgtgt ttggttctgt cagcatgtgc gtccgtgtgt 
     1441 tcaggtagat gtgtaccatt gtgcagattt ctgtggcatc actaagtgtg tctccaggaa 
     1501 agtgtggttc gagtgagtgt gtgtgtctct gtgtcagtgt gtcagtggat gtgtgtctaa 
     1561 gtcatgtggg tgtctaagtt tgtcagagtg tcttcctcag tgtcagtgtg tgtcaatgat 
     1621 gtgtctgtct gtgtctgtgt gggtgtgtgg gggtgtgtat ctgtctcagg gtgcatgtgt 
     1681 gtgtctgtgt cagtgcaggt atgcctatgg cagcgtgtgt ctgtctcggc atgagtgtca 
     1741 gtgtatgccc gtgtccacgt gggtgggtgg gtgtctggta gccttcccaa gtcagcaagg 
     1801 ttgcgtgtgt gtgtgtgtat actctggcgg gtgctggtgt gtatgccagt gtttgttaat 
     1861 gtgagcctgt ccgcgtccgc gtgggtggcc atctgtggtg aagcgtcgcc gggtcgccgt 
     1921 gtgtgtaccc ccgcctatgt ctgtctgtcc gcggccgcgt gtgcggctgt ctgtggctgt 
     1981 gagcccccgg gtcagtgtgg gagtgtgcgc cccggcgggc gctggtgtgt cccccctccg 
     2041 agcgggcgga gcaccacgtg cggagccctg ggcgcgtcgc tctggggcgg agccagcccg 
     2101 gggccccaag ccccaggccg aacccaggcg gggcccgccc cgaccccgcc cccgaccccg 
     2161 cccccagccc gagcccgcgc cgcctgccca (Promoter ends) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9 Hypoxia and cAMP response elements in the Nav1.5 promoter 
Nav1.5 promoter sequence was from Yang et al., 2004 (NCBI accession code: AY313163). 
The consensus hypoxia-responsive element (HRE) site is constituted by (A/G)CGTG (this 
site is targetted by hypoxia-inducible transcription factor – HIF; Wenger et al., 2005). The 
reverse compliment of the HRE sequence is CACG(T/C). There exist 12 consensus HRE sites 
in the Nav1.5 promoter: 9 forward (shaded in yellow) and 3 reverse (underlined by black 
lines). Consensus cAMP-responsive element (CRE) site (targetted by cAMP / PKA activated 
transcriptional activators such as CREB, CREM and ATF; Foulkes and Corsi, 1996) is 
constituted by an 8 bp palindromic sequence (TGACGTCA). There exists one partial CRE 
site in the Nav1.5 promoter (shaded in green). This site shares 75% (6 out of 8 nucleotides) 
homology with the consensus CRE sequence. 
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Appendix 10 Inward currents were carried by Na+ in EBNA-293 cells transfected with 
nNav1.5, aNav1.5, nNav1.5 K211D (#13) and nNav1.5 K211D (#17) 
Typical whole-cell Na+ currents recorded in EBNA-293 cells transfected with nNav1.5 (A), 
aNav1.5 (B), nNav1.5 K211D #13 (C) or nNav1.5 K211D #17 (D), during superfusion with 
control MPS (left panels), MPS in which Ca2+ was substituted for Ba2+ (middle panels) and 
MPS in which Na+ was substituted for choline (right panels). Currents were elicited by 60 ms 
pulses to between -80 mV and +45 mV from a holding potential of -100 mV; interpulse 
duration was 2 s. For each transfectant EBNA-293 cell line, Ba2+ substitution had no noticeable 
effect on peak inward current, whereas Na+-free MPS abolished all inward currents (n ≥ 4), i.e. 
currents were carried by Na+. 
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Appendix 11 DMSO (0.2%) had no significant effect on peak Na+ current 
(A) Typical whole-cell nNav1.5 and aNav1.5 currents, before and after DMSO (0.2%), elicited 
by 12 ms steps to 0 mV at 0.1 Hz from a holding potential of -100 mV. Dashed horizontal lines 
indicate zero current. (B) Time-course of DMSO (0.2%) effects on nNav1.5 peak current at 0.2 
Hz; control (open circles) and DMSO (black circles). Data were normalized to the peak current 
obtained from the first pulse and are presented as mean ± SEM (n = 3). Similar data were also 
recorded from aNav1.5 (n = 3). (C, E) Typical whole-cell nNav1.5 (C) and aNav1.5 (E) 
currents, before and after 0.2% DMSO, elicited by 60 ms pulses to between -80 mV and +45 
mV from a holding potential of -100 mV; interpulse duration was 2 s. (D) Peak I-V relationships 
for the nNav1.5 cell shown in part C; control (open circles) and 0.2% DMSO (black circles). (F) 
Peak I-V relationships for the aNav1.5 cell shown in part E; control (open circles) and 0.2% 
DMSO (black circles).  
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Appendix 12 DMSO (0.2%) did not modify channel gating  
Data shown were recorded from aNav1.5 and are presented as mean ± SEM (n ≥ 5). Similar 
data were also recorded from nNav1.5 (n ≥ 5, not shown). For pulse protocols, see Figure 5.8 
(for parts A, B and C), Figure 5.10 (for part D), Figure 5.11 (for part E) and Figure 5.12 (for 
part F). In parts A-E, control (open circles) and 0.2% DMSO (black circles); some error bars are 
smaller than symbols. (A) Normalized I-V relationships; currents after DMSO application were 
normalized to the maximal Na+ current in control (I/Imaxcontrol). (B) Normalized G-V 
relationships (G/Gmax) fitted with Boltzmann functions (solid red lines). (C) Time to peak 
plotted as a function of test potential and fitted with single exponential functions (solid lines). 
(D) Availability-voltage relationships fitted with Boltzmann functions (solid lines); currents (I) 
were normalized to the maximum current (Imax) recorded following the most hyperpolarized 
pre-pulse (-140 mV). (E) Recovered current (It /Ic) plotted as a function of recovery interval and 
fitted with double exponential functions (solid lines). Inset, the first 100 ms of the recovery 
period re-plotted for better illustration of data. (F) Use-dependent block (UDB) at 2, 5 and 10 
Hz; data were normalized to the current of the first pulse and plotted against the pulse number. 
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Appendix 13 Peptide buffer had no detectable effect on Nav1.5 gating 
Data were recorded from K211D before (open circles) and after peptide buffer (MPS with 0.5 
mg/ml BSA; black circles). (A) Typical whole-cell Na+ currents, before and after peptide buffer 
application, elicited by 60 ms pulses to between -80 mV and +45 mV from a holding potential 
of -80 mV; interpulse duration was 2 s. (B) Normalized I-V relationships; currents after peptide 
buffer application were normalized to the maximal Na+ current in control (I/Imaxcontrol). (C) 
Normalized G-V relationships (G/Gmax) fitted with Boltzmann functions (solid red lines). (D) 
Time to peak plotted as a function of test potential and fitted with single-exponential functions 
(solid lines). For A-D, n = 8. (E) Availability-voltage relationships fitted with Boltzmann 
functions (solid lines; n = 5); for pulse protocol and data analysis, see Figure 5.23. (F) 
Recovered current (It /Ic) plotted as a function of recovery interval and fitted with single 
exponential functions (solid lines; n = 5); for pulse protocol and data analysis, see Figure 5.24. 
Data are mean ± SEM; some data points overlap and some error bars are smaller than symbols.  
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D1:S3/S4          S3                         S4 
 
Nav1.1    PWNWLDFTVITFAYVTEFVDLGN-VSALRTFRVLRALKTISVIPGLK 234 
Nav1.2    PWNWLDFTVITFAYVTEFVDLGN-VSALRTFRVLRALKTISVIPGLK 235 
Nav1.3    PWNWLDFSVIVMAYVTEFVDLGN-VSALRTFRVLRALKTISVIPGLK 234 
Nav1.4    PWNWLDFSVIMMAYLTEFVDLGN-ISALRTFRVLRALKTITVIPGLK 237 
Nav1.5    PWNWLDFSVIIMAYTTEFVDLGN-VSALRTFRVLRALKTISVISGLK 237 
Nav1.6    PWNWLDFSVIMMAYITEFVNLGN-VSALRTFRVLRALKTISVIPGLK 238 
Nav1.7    PWNWLDFVVIVFAYLTEFVNLGN-VSALRTFRVLRALKTISVIPGLK 232 
Nav1.8    PWNWLDFSVITLAYVGTAIDLRG-ISGLRTFRVLRALKTVSVIPGLK 233 
Nav1.9    PWNWLDSIVIGIAIVSYIPGITIKLLPLRTFRVFRALKAISVVSRLK 240 
 
 
D2:S3/S4           S3                         S4 
 
Nav1.1    WNIFDGFIVTLSLVELG--LANVEGLSVLRSFRLLRVFKLAKSWPTL 876 
Nav1.2    WNIFDGFIVSLSLMELG--LANVEGLSVLRSFRLLRVFKLAKSWPTL 867 
Nav1.3    WNIFDGIIVSLSLMELG--LSNVEGLSVLRSFRLLRVFKLAKSWPTL 868 
Nav1.4    WNIFDSIIVTLSLVELG--LANVQGLSVLRSFRLLRVFKLAKSWPTL 686 
Nav1.5    WNIFDSIIVILSLMELG--LSRMSNLSVLRSFRLLRVFKLAKSWPTL 825 
Nav1.6    WNIFDGFIVSLSLMELS--LADVEGLSVLRSFRLLRVFKLAKSWPTL 861 
Nav1.7    WNIFDSLIVTLSLVELF--LADVEGLSVLRSFRLLRVFKLAKSWPTL 841 
Nav1.8    WNIFDCIIVTVSLLELG--VAKKGSLSVLRSFRLLRVFKLAKSWPTL 773 
Nav1.9    WNIFDSIVALLSFADVMNCVLQKRSWPFLRSFRVLRVFKLAKSWPTL 687 
 
 
D3:S3/S4            S3                           S4 
 
Nav1.1    NAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFE 1331 
Nav1.2    NAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFE 1321 
Nav1.3    NAWCWLDFLIVDVSLVSLVANALGYSELGAIKSLRTLRALRPLRALSRFE 1319 
Nav1.4    NAWCWLDFLIVDVSIISLVANWLGYSELGPIKSLRTLRALRPLRALSRFE 1144 
Nav1.5    NAWCWLDFLIVDVSLVSLVANTLGFAEMGPIKSLRTLRALRPLRALSRFE 1318 
Nav1.6    NAWCWLDFLIVAVSLVSLIANALGYSELGAIKSLRTLRALRPLRALSRFE 1311 
Nav1.7    NAWCWLDFLIVDVSLVTLVANTLGYSDLGPIKSLRTLRALRPLRALSRFE 1294 
Nav1.8    NAWCWLDFLIVNISLISLTAKILEYSEVAPIKALRTLRALRPLRALSRFE 1265 
Nav1.9    SAWCCLDFIIVIVSVTTLIN-------LMELKSFRTLRALRPLRALSQFE 1162 
 
 
D4:S3/S4             S3                                  S4 
 
Nav1.1    IGWNIFDFVVVILSIVGMFLAELIEKY--FVSPTLFRVIRLARIGRILRLIKGAKGIRTL 1659 
Nav1.2    IGWNIFDFVVVILSIVGMFLAELIEKY--FVSPTLFRVIRLARIGRILRLIKGAKGIRTL 1649 
Nav1.3    IGWNIFDFVVVILSIVGMFLAEMIEKY--FVSPTLFRVIRLARIGRILRLIKGAKGIRTL 1644 
Nav1.4    VGWNIFDFVVVILSIVGLALSDLIQKY--FVSPTLFRVIRLARIGRVLRLIRGAKGIRTL 1471 
Nav1.5    NSWNIFDFVVVILSIVGTVLSDIIQKY--FFSPTLFRVIRLARIGRILRLIRGAKGIRTL 1646 
Nav1.6    IGWNIFDFVVVILSIVGMFLADIIEKY--FVSPTLFRVIRLARIGRILRLIKGAKGIRTL 1640 
Nav1.7    VGWNIFDFVVVIISIVGMFLADLIETY--FVSPTLFRVIRLARIGRILRLVKGAKGIRTL 1622 
Nav1.8    NGWNVFDFIVVVLSIASLIFSAILKSLQSYFSPTLFRVIRLARIGRILRLIRAAKGIRTL 1596 
Nav1.9    NGWNLFDCVVVLLSIVSTMISTLENQEHIPFPPTLFRIVRLARIGRILRLVRAARGIRTL 1486 
 
 
 
 
 
 
 
 
 
Appendix 14 Amino acid sequence comparison of S3/S4 segments of human VGSCαs 
Locations for transmembrane S3 and S4 segments are designated by horizontal lines according 
to Gellens et al. (1992). Non-conserved residues are boxed in grey. NCBI accession codes for 
each VGSCα sequence: Nav1.1 (NP_001159435), Nav1.2 (NP_001035232), Nav1.3 
(NP_008853), Nav1.4 (NP_000325), Nav1.5 (NP_932173), Nav1.6 (NP_055006), Nav1.7 
(NP_002968), Nav1.8 (NP_006505) and Nav1.9 (NP_054858). Sequences were aligned using 
ClustelW software. 
 
